In O O
the O O
absence O O
of O O
histological O O
criteria O O
, O O
which O O
it O O
is O O
difficult O O
to O O
demand O O
in O O
view O O
of O O
the O O
variability O O
of O O
results O O
and O O
potential O O
dangers O O
of O O
endomyocardial O O
biopsy O O
involving O O
such O O
thin O O
and O O
fragile O O
ventricular O O
walls O O
, O O
the O O
diagnosis O O
of O O
ACRV O O
is O O
based O O
upon O O
the O O
concomitant O O
existence O O
of O O
: O O
( O O
0 O O
) O O
electrophysiological O O
criteria O O
: O O
ventricular O O
arrhythmias O O
, O O
in O O
particular O O
sustained O O
monomorphous O O
VT O O
, O O
with O O
the O O
particular O O
feature O O
of O O
a O O
very O O
high O O
degree O O
of O O
sensitivity O O
to O O
adrenergic O O
stimulation O O
( O O
exercise O O
) O O
, O O
the O O
existence O O
of O O
late O O
potentials O O
on O O
the O O
high O O
amplification O O
ECG O O
, O O
a O O
highly O O
specific O O
sign O O
, O O
though O O
unfortunately O O
of O O
poor O O
sensitivity O O
in O O
localized O O
froms O O
, O O
those O O
which O O
are O O
most O O
difficult O O
to O O
identify O O
( O O
0 O O
) O O
; O O
segmentary O O
morphological O O
and O O
kinetic O O
RV O O
abnormalities O O
, O O
most O O
often O O
resulting O O
in O O
localized O O
akinetic O O
or O O
dyskinetic O O
parietal O O
vaulting O O
, O O
with O O
stasis O O
" O O
in O O
situ O O
" O O
. O O

Consequently O O
, O O
significant O O
differences O O
between O O
the O O
measured O O
and O O
calculated O O
methods O O
were O O
noted O O
in O O
oxygen O O
uptake O O
( O O
000 O O
+ O O
/ O O
- O O
00 O O
ml O O
/ O O
min O O
vs O O
000 O O
+ O O
/ O O
- O O
00 O O
ml O O
/ O O
min O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
, O O
oxygen O O
delivery O O
( O O
000 O O
+ O O
/ O O
- O O
000 O O
ml O O
/ O O
min O O
vs O O
000 O O
+ O O
/ O O
- O O
000 O O
ml O O
/ O O
min O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
, O O
and O O
cardiac O O
output O O
( O O
0 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
L O O
/ O O
min O O
vs O O
0 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
L O O
/ O O
min O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
. O O

To O O
determine O O
whether O O
vanadate O O
could O O
inhibit O B-GENE
PEPCK B-GENE I-GENE
gene I-GENE I-GENE
transcription O O
, O O
a O O
series O O
of O O
chimeric O O
genes O O
containing O O
several O O
deletions O O
in O O
the O O
P B-GENE O
- I-GENE O
enolypyruvate I-GENE O
carboxykinase I-GENE O
promoter I-GENE O
between O O
- O O
000 O O
and O O
- O O
00 O O
was O O
linked O O
to O O
the O O
structural O O
genes O O
for O O
either O O
amino B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
glycosyl I-GENE I-GENE
phosphotransferase I-GENE I-GENE
( O O
neo B-GENE O
) O O
or O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
and O O
introduced O O
into O O
hepatoma O O
cells O O
using O O
three O O
methods O O
: O O
( O O
a O O
) O O
infection O O
with O O
a O O
Moloney O O
murine O O
leukemia O O
virus O O
- O O
based O O
retrovirus O O
, O O
( O O
b O O
) O O
transfection O O
and O O
stable O O
selection O O
for O O
neo B-GENE O
expression O O
, O O
or O O
( O O
c O O
) O O
transient O O
expression O O
of O O
chloroamphenicol B-GENE O
acetyltransferase I-GENE O
. O O

In O O
the O O
normal O O
, O O
basal O O
( O O
unstimulated O O
) O O
condition O O
there O O
were O O
no O O
significant O O
correlations O O
( O O
p O O
greater O O
than O O
0 O O
. O O
00 O O
) O O
between O O
the O O
systolic O O
blood O O
pressure O O
and O O
dopamine O O
( O O
r O O
= O O
0 O O
. O O
00 O O
) O O
, O O
norepinephrine O O
( O O
r O O
= O O
0 O O
. O O
00 O O
) O O
, O O
or O O
epinephrine O O
( O O
r O O
= O O
0 O O
. O O
00 O O
) O O
, O O
nor O O
were O O
there O O
significant O O
correlations O O
between O O
melatonin O O
and O O
dopamine O O
( O O
r O O
= O O
- O O
0 O O
. O O
00 O O
) O O
, O O
norepinephrine O O
( O O
r O O
= O O
- O O
0 O O
. O O
00 O O
) O O
, O O
or O O
growth B-GENE O
hormone I-GENE O
( O O
r O O
= O O
0 O O
. O O
00 O O
) O O
. O O

Diltiazem O O
decreased O O
the O O
total O O
body O O
clearance O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
mL O O
/ O O
min O O
( O O
P O O
less O O
than O O
. O O
00 O O
) O O
, O O
and O O
prolonged O O
the O O
elimination O O
half O O
- O O
life O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
hours O O
( O O
P O O
less O O
than O O
. O O
00 O O
) O O
of O O
antipyrine O O
without O O
any O O
changes O O
in O O
volume O O
of O O
distribution O O
. O O

Behaviorally O O
, O O
a O O
pain O O
- O O
tolerant O O
group O O
( O O
PT O O
= O O
00 O O
Ss O O
) O O
tolerated O O
the O O
entire O O
0 O O
- O O
min O O
test O O
( O O
means O O
= O O
000 O O
+ O O
/ O O
- O O
0 O O
sec O O
) O O
, O O
while O O
a O O
pain O O
- O O
sensitive O O
group O O
( O O
PS O O
= O O
00 O O
Ss O O
) O O
averaged O O
only O O
00 O O
. O O
00 O O
+ O O
/ O O
- O O
00 O O
. O O
00 O O
sec O O
of O O
the O O
cold O O
- O O
pressor O O
test O O
( O O
t O O
= O O
00 O O
. O O
00 O O
, O O
P O O
less O O
than O O
0 O O
. O O
0000 O O
) O O
, O O
replicating O O
our O O
earlier O O
studies O O
. O O

A O O
comparison O O
of O O
the O O
amino O O
acid O O
sequence O O
of O O
the O O
T O O
. O O
thermophilus O O
enzyme O O
with O O
that O O
of O O
the O O
Escherichia O O
coli O O
enzyme O O
showed O O
( O O
i O O
) O O
a O O
00 O O
% O O
overall O O
similarity O O
; O O
( O O
ii O O
) O O
the O O
conservation O O
of O O
the O O
Ser O O
residue O O
, O O
which O O
is O O
known O O
to O O
be O O
phosphorylated O O
in O O
the O O
E O O
. O O
coli O O
enzyme O O
, O O
and O O
of O O
the O O
surrounding O O
sequence O O
; O O
and O O
( O O
iii O O
) O O
the O O
presence O O
of O O
000 O O
extra O O
residues O O
at O O
the O O
C O O
terminus O O
of O O
the O O
T O O
. O O
thermophilus O O
enzyme O O
. O O

We O O
conclude O O
that O O
( O O
a O O
) O O
the O O
likelihood O O
of O O
detecting O O
carcinoma O O
or O O
atypical O O
hyperplasia O O
exclusively O O
in O O
the O O
adipose O O
tissue O O
component O O
of O O
grossly O O
benign O O
breast O O
biopsies O O
is O O
extremely O O
low O O
, O O
and O O
( O O
b O O
) O O
a O O
possible O O
cost O O
- O O
effective O O
method O O
of O O
sampling O O
grossly O O
benign O O
breast O O
biopsies O O
consists O O
of O O
initially O O
submitting O O
a O O
maximum O O
of O O
00 O O
blocks O O
of O O
fibrous O O
parenchyma O O
for O O
each O O
case O O
, O O
then O O
examining O O
the O O
remaining O O
tissue O O
histologically O O
only O O
if O O
carcinoma O O
or O O
atypical O O
hyperplasia O O
is O O
found O O
among O O
these O O
blocks O O
. O O

In O O
order O O
to O O
study O O
the O O
influence O O
of O O
iron O O
overload O O
on O O
the O O
polymorphonuclear O O
leucocyte O O
( O O
PMN O O
) O O
metabolism O O
of O O
patients O O
on O O
chronic O O
hemodialysis O O
, O O
generation O O
of O O
superoxide O O
anion O O
( O O
O0 O O
- O O
) O O
by O O
PMN O O
in O O
whole O O
blood O O
was O O
compared O O
in O O
two O O
groups O O
of O O
hemodialyzed O O
patients O O
: O O
group O O
A O O
consisted O O
of O O
twenty O O
- O O
one O O
individuals O O
with O O
serum O O
ferritin B-GENE O
levels O O
above O O
0000 O O
ng O O
/ O O
ml O O
and O O
group O O
B O O
of O O
nineteen O O
individuals O O
with O O
serum O O
ferritin B-GENE O
levels O O
below O O
0000 O O
ng O O
/ O O
ml O O
. O O

The O O
patients O O
were O O
divided O O
into O O
0 O O
subgroups O O
: O O
0 O O
) O O
00 O O
N O O
+ O O
patients O O
with O O
multiple O O
hot O O
spots O O
( O O
greater O O
than O O
0 O O
) O O
( O O
N O O
+ O O
IM O O
) O O
; O O
0 O O
) O O
00 O O
N O O
+ O O
patients O O
with O O
single O O
hot O O
spots O O
( O O
less O O
than O O
or O O
equal O O
to O O
0 O O
) O O
( O O
N O O
+ O O
IS O O
) O O
; O O
0 O O
) O O
00 O O
N O O
- O O
patients O O
with O O
single O O
hot O O
spots O O
( O O
less O O
than O O
or O O
equal O O
to O O
0 O O
) O O
( O O
N O O
- O O
IS O O
) O O
. O O

The O O
mean O O
( O O
+ O O
/ O O
- O O
SD O O
) O O
PaO0 O O
increased O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
00 O O
. O O
0 O O
mmHg O O
before O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
00 O O
. O O
0 O O
mmHg O O
after O O
the O O
infusion O O
( O O
P O O
< O O
0 O O
. O O
00 O O
) O O
and O O
the O O
PaCO0 O O
decreased O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
mmHg O O
( O O
P O O
< O O
0 O O
. O O
00 O O
) O O
. O O

The O O
bactericidal O O
activity O O
of O O
six O O
new O O
rifamycin O O
derivatives O O
- O O
- O O
rifabutin O O
( O O
RBU O O
) O O
, O O
FCE O O
00000 O O
( O O
F00 O O
) O O
, O O
rifapentine O O
( O O
RPE O O
) O O
, O O
CGP O O
00000 O O
( O O
C00 O O
) O O
, O O
CGP O O
0000 O O
( O O
C00 O O
) O O
and O O
CGP O O
00000 O O
( O O
C00 O O
) O O
and O O
rifampicin O O
( O O
RMP O O
) O O
- O O
- O O
have O O
been O O
measured O O
against O O
log O O
phase O O
and O O
, O O
as O O
a O O
better O O
test O O
of O O
sterilising O O
activity O O
, O O
against O O
stationary O O
phase O O
cultures O O
of O O
Mycobacterium O O
tuberculosis O O
, O O
H00Rv O O
. O O

Two O O
points O O
are O O
indicated O O
: O O
first O O
, O O
the O O
photosensitized O O
damage O O
of O O
YHPD O O
is O O
interrelated O O
to O O
not O O
only O O
0O0 O O
, O O
but O O
also O O
free O O
radicals O O
( O O
O0 O O
- O O
. O O
. O O
OH O O
and O O
YHPD O O
- O O
. O O
) O O
; O O
second O O
, O O
although O O
the O O
photosensitized O O
damage O O
of O O
YHPD O O
is O O
stronger O O
than O O
that O O
of O O
BHPD O O
, O O
yet O O
the O O
photosensitized O O
damage O O
is O O
negatively O O
correlated O O
to O O
the O O
yield O O
of O O
0O0 O O
but O O
positively O O
correlated O O
to O O
those O O
of O O
O0 O O
- O O
. O O
and O O
OH O O
. O O

The O O
SSB B-GENE O
- O O
poly O O
( O O
dT O O
) O O
affinity O O
is O O
too O O
high O O
to O O
measure O O
in O O
buffers O O
containing O O
even O O
0 O O
M O O
NaCl O O
; O O
however O O
, O O
in O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
M O O
NaBr O O
, O O
we O O
measure O O
alpha O O
log O O
Kobsd O O
/ O O
alpha O O
log O O
[ O O
NaBr O O
] O O
= O O
- O O
0 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
, O O
with O O
a O O
lower O O
value O O
of O O
omega O O
T O O
/ O O
O O O
= O O
000 O O
+ O O
/ O O
- O O
00 O O
. O O

Higher O O
fasting O O
serum O O
gastrin B-GENE O
concentration O O
( O O
000 O O
. O O
0 O O
+ O O
/ O O
- O O
00 O O
. O O
0 O O
vs O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
ng O O
. O O
l O O
- O O
0 O O
) O O
, O O
and O O
greater O O
postprandial O O
gastrin B-GENE O
release O O
( O O
AUC0 O O
- O O
000 O O
: O O
00000 O O
+ O O
/ O O
- O O
0000 O O
vs O O
00000 O O
+ O O
/ O O
- O O
0000 O O
ng O O
. O O
l O O
- O O
0 O O
min O O
) O O
were O O
observed O O
after O O
VTP O O
- O O
HM O O
than O O
after O O
VTP O O
- O O
Cas O O
. O O

In O O
addition O O
a O O
greater O O
proportion O O
of O O
women O O
in O O
the O O
sweeping O O
group O O
had O O
a O O
cervical O O
dilatation O O
of O O
0 O O
cm O O
or O O
more O O
at O O
the O O
first O O
vaginal O O
examination O O
in O O
the O O
labour O O
ward O O
( O O
00 O O
/ O O
00 O O
( O O
00 O O
% O O
) O O
vs O O
0 O O
/ O O
00 O O
( O O
00 O O
% O O
) O O
; O O
OR O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
0 O O
. O O
00 O O
to O O
00 O O
. O O
00 O O
; O O
P O O
= O O
0 O O
. O O
000 O O
) O O
. O O

The O O
imino O O
proton O O
of O O
T0 O O
in O O
the O O
O0meG O O
. O O
T O O
00 O O
- O O
mer O O
and O O
G0 O O
in O O
the O O
O0meG O O
. O O
N O O
00 O O
- O O
mer O O
helix O O
, O O
which O O
are O O
associated O O
with O O
the O O
modification O O
site O O
, O O
resonate O O
at O O
unusually O O
high O O
field O O
( O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
ppm O O
) O O
compared O O
to O O
imino O O
protons O O
in O O
Watson O O
- O O
Crick O O
base O O
pairs O O
( O O
00 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
ppm O O
) O O
. O O

The O O
experiment O O
results O O
showed O O
: O O
( O O
i O O
) O O
not O O
only O O
0O0 O O
, O O
but O O
also O O
free O O
radicals O O
( O O
O0 O O
- O O
. O O
. O O
OH O O
and O O
YHPD O O
- O O
. O O
) O O
can O O
be O O
formed O O
by O O
the O O
aid O O
of O O
YHPD O O
; O O
and O O
( O O
ii O O
) O O
as O O
to O O
the O O
ability O O
of O O
producing O O
0O0 O O
, O O
YHPD O O
less O O
than O O
BHPD O O
, O O
while O O
for O O
generating O O
O0 O O
- O O
. O O
and O O
. O O
OH O O
, O O
YHPD O O
greater O O
than O O
BHPD O O
. O O

Because O O
single O O
- O O
chamber O O
rate O O
- O O
adaptive O O
atrial O O
pacing O O
leaves O O
the O O
patient O O
exposed O O
to O O
the O O
risk O O
of O O
future O O
development O O
of O O
AV O O
block O O
and O O
DDD O O
pacing O O
does O O
not O O
provide O O
chronotropic O O
support O O
, O O
it O O
is O O
likely O O
that O O
the O O
new O O
rate O O
- O O
adaptive O O
dual O O
- O O
chamber O O
( O O
DDDR O O
) O O
devices O O
will O O
be O O
used O O
in O O
a O O
significant O O
number O O
of O O
these O O
patients O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

Dissolution O O
of O O
the O O
Pt O O
- O O
00 O O
% O O
Ir O O
microelectrode O O
tip O O
was O O
observed O O
by O O
scanning O O
electron O O
microscopy O O
at O O
charge O O
densities O O
as O O
low O O
as O O
000 O O
microC O O
/ O O
cm0 O O
X O O
ph O O
( O O
0 O O
A O O
/ O O
cm0 O O
) O O
, O O
whereas O O
erosion O O
of O O
activated O O
iridium O O
microelectrodes O O
occurred O O
only O O
at O O
the O O
highest O O
charge O O
and O O
current O O
densities O O
( O O
0000 O O
microC O O
/ O O
cm0 O O
X O O
ph O O
, O O
00 O O
A O O
/ O O
cm0 O O
) O O
. O O

Metformin O O
plasma O O
concentrations O O
remained O O
unchanged O O
except O O
for O O
patients O O
transferred O O
from O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
g O O
daily O O
to O O
000 O O
mg O O
twice O O
daily O O
; O O
in O O
these O O
patients O O
plasma O O
concentrations O O
increased O O
from O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
micrograms O O
/ O O
l O O
( O O
p O O
less O O
than O O
0 O O
. O O
00 O O
) O O
. O O

The O O
previously O O
described O O
four O O
sets O O
of O O
00 O O
- O O
to O O
00 O O
- O O
base O O
- O O
pair O O
interspersed O O
repeat O O
elements O O
between O O
- O O
00 O O
and O O
- O O
000 O O
provide O O
most O O
of O O
the O O
high O O
basal O O
transcriptional O O
strength O O
, O O
whereas O O
the O O
arrangement O O
of O O
further O O
upstream O O
tandemly O O
repeated O O
NF0 B-GENE O
- I-GENE O
binding I-GENE O
sites I-GENE O
may O O
contribute O O
significantly O O
to O O
the O O
expanded O O
biological O O
host O O
range O O
for O O
expression O O
of O O
SCMV B-GENE O
IE00 I-GENE O
compared O O
with O O
HCMV B-GENE O
IE00 I-GENE O
. O O

During O O
the O O
observation O O
period O O
of O O
0 O O
. O O
0 O O
- O O
00 O O
weeks O O
, O O
cardiac O O
white O O
spots O O
on O O
the O O
right O O
ventricle O O
of O O
BALB O O
/ O O
c O O
mice O O
were O O
first O O
detected O O
at O O
three O O
weeks O O
( O O
0 O O
of O O
00 O O
mice O O
; O O
00 O O
% O O
) O O
, O O
and O O
the O O
maximal O O
incidence O O
of O O
cardiac O O
white O O
spots O O
was O O
obtained O O
at O O
nine O O
weeks O O
( O O
00 O O
of O O
00 O O
mice O O
; O O
00 O O
% O O
) O O
. O O

The O O
absolute O O
concentrations O O
of O O
alpha B-GENE O
0 I-GENE O
- I-GENE O
plasmin I-GENE O
inhibitor O O
, O O
alpha B-GENE O
0 I-GENE O
- I-GENE O
macroglobulin I-GENE O
, O O
and O O
antithrombin B-GENE O
III I-GENE O
increased O O
with O O
exercise O O
( O O
all O O
P O O
less O O
than O O
0 O O
. O O
000 O O
) O O
, O O
but O O
when O O
concentrations O O
were O O
corrected O O
for O O
acute O O
shifts O O
of O O
plasma O O
water O O
during O O
exercise O O
, O O
the O O
quantity O O
of O O
these O O
inhibitors O O
actually O O
decreased O O
( O O
all O O
P O O
less O O
than O O
0 O O
. O O
000 O O
) O O
. O O

Trial O O
0 O O
broiler O O
chickens O O
were O O
maintained O O
on O O
control O O
feed O O
until O O
they O O
reached O O
0 O O
weeks O O
of O O
age O O
at O O
which O O
time O O
they O O
were O O
taken O O
off O O
of O O
feed O O
for O O
0 O O
. O O
0 O O
hr O O
and O O
then O O
placed O O
on O O
either O O
control O O
feed O O
or O O
feed O O
containing O O
0 O O
. O O
0 O O
ppm O O
ochratoxin O O
A O O
, O O
and O O
heart O O
rate O O
and O O
blood O O
pressure O O
were O O
measured O O
every O O
half O O
hour O O
through O O
0 O O
hr O O
. O O

The O O
concept O O
of O O
" O O
structural O O
identifiability O O
" O O
is O O
employed O O
in O O
this O O
analysis O O
to O O
determine O O
which O O
model O O
parameters O O
can O O
be O O
and O O
which O O
cannot O O
be O O
determined O O
" O O
uniquely O O
" O O
from O O
given O O
input O O
- O O
output O O
data O O
; O O
a O O
step O O
- O O
by O O
- O O
step O O
procedure O O
based O O
on O O
an O O
extension O O
of O O
this O O
concept O O
is O O
presented O O
for O O
adapting O O
the O O
overall O O
approach O O
to O O
the O O
experimental O O
design O O
problem O O
. O O

Buflomedil O O
( O O
i O O
. O O
v O O
. O O
) O O
induced O O
a O O
dose O O
- O O
dependent O O
increase O O
of O O
cardiac O O
output O O
at O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
mg O O
/ O O
kg O O
, O O
biphasic O O
changes O O
at O O
0 O O
. O O
00 O O
and O O
0 O O
. O O
00 O O
mg O O
/ O O
kg O O
and O O
a O O
marked O O
decrease O O
and O O
subsequent O O
slight O O
increase O O
at O O
a O O
large O O
dose O O
of O O
0 O O
. O O
00 O O
mg O O
/ O O
kg O O
. O O

Data O O
from O O
000 O O
men O O
and O O
00 O O
women O O
undergoing O O
coronary O O
angiography O O
provide O O
an O O
opportunity O O
to O O
compare O O
these O O
associations O O
in O O
relation O O
to O O
a O O
direct O O
and O O
continuous O O
measure O O
of O O
atherosclerosis O O
while O O
controlling O O
for O O
age O O
, O O
sex O O
, O O
income O O
, O O
hypertension O O
, O O
serum O O
cholesterol O O
, O O
smoking O O
, O O
angina O O
, O O
diabetes O O
, O O
family O O
history O O
of O O
heart O O
disease O O
, O O
Type O O
A O O
behavior O O
pattern O O
, O O
and O O
hostility O O
. O O

The O O
mean O O
transfer O O
ratios O O
of O O
the O O
drug O O
into O O
the O O
genital O O
tissues O O
to O O
the O O
concentration O O
in O O
the O O
uterine O O
arterial O O
blood O O
were O O
such O O
that O O
the O O
transfer O O
ratio O O
into O O
the O O
portio O O
vaginalis O O
was O O
the O O
highest O O
, O O
followed O O
by O O
the O O
uterine O O
cervix O O
and O O
the O O
myometrium O O
, O O
and O O
that O O
into O O
the O O
oviduct O O
was O O
the O O
lowest O O
with O O
about O O
0 O O
/ O O
0 O O
that O O
into O O
the O O
portio O O
vaginalis O O
. O O

A O O
one O O
- O O
way O O
analysis O O
of O O
variance O O
, O O
performed O O
separately O O
for O O
men O O
and O O
women O O
for O O
differences O O
among O O
the O O
three O O
phobic O O
groups O O
on O O
field O O
dependence O O
, O O
showed O O
significance O O
( O O
rho O O
less O O
than O O
. O O
00 O O
) O O
for O O
the O O
females O O
, O O
with O O
the O O
famale O O
agoraphobic O O
being O O
more O O
field O O
dependent O O
than O O
the O O
female O O
simple O O
phobic O O
groups O O
, O O
but O O
not O O
for O O
the O O
males O O
. O O

When O O
considered O O
with O O
the O O
known O O
neurotoxic O O
effects O O
on O O
children O O
of O O
" O O
low O O
levels O O
" O O
of O O
exposure O O
to O O
lead O O
, O O
these O O
results O O
also O O
suggest O O
that O O
either O O
an O O
excessively O O
narrow O O
margin O O
of O O
safety O O
or O O
insufficient O O
safety O O
is O O
provided O O
by O O
present O O
U O O
. O O
S O O
. O O
guidelines O O
, O O
which O O
classify O O
an O O
elevated O O
blood O O
lead O O
concentration O O
as O O
00 O O
micrograms O O
/ O O
dl O O
or O O
greater O O
. O O

Prolonged O O
heavy O O
work O O
effected O O
an O O
increase O O
of O O
00 O O
. O O
0 O O
plus O O
or O O
minus O O
0 O O
. O O
0 O O
mmHg O O
in O O
in O O
vivo O O
P00 O O
( O O
0 O O
. O O
00 O O
PH O O
- O O
v O O
, O O
00 O O
degrees O O
C O O
- O O
v O O
, O O
and O O
00 O O
Pv O O
- O O
CO0 O O
) O O
; O O
due O O
entirely O O
to O O
the O O
additive O O
effects O O
of O O
increased O O
venous O O
temperature O O
and O O
[ O O
H O O
+ O O
] O O
. O O

Three O O
of O O
the O O
short O O
ORFs O O
in O O
the O O
central O O
region O O
of O O
BIV O O
have O O
been O O
identified O O
by O O
location O O
and O O
structural O O
similarity O O
to O O
the O O
nonstructural O B-GENE
/ O O
regulatory O O
genes O O
( O O
vif B-GENE O
, O O
tat B-GENE O
, O O
and O O
rev B-GENE O
) O O
of O O
other O O
lentiviruses O O
; O O
we O O
also O O
discovered O O
two O O
unique O O
ORFs O O
, O O
termed O O
W O O
and O O
Y O O
, O O
which O O
may O O
serve O O
as O O
exons O O
for O O
novel O O
genes O O
. O O

In O O
the O O
00 O O
patients O O
with O O
a O O
more O O
severe O O
degree O O
of O O
steatorrhea O O
the O O
decrease O O
in O O
fat O O
loss O O
approached O O
00 O O
% O O
and O O
a O O
close O O
relationship O O
was O O
found O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
p O O
less O O
than O O
0 O O
. O O
00 O O
) O O
between O O
the O O
extent O O
of O O
the O O
fatty O O
acid O O
loss O O
on O O
placebo O O
and O O
the O O
decrease O O
of O O
this O O
loss O O
on O O
taurine O O
. O O

Since O O
the O O
UfAP B-GENE O
and O O
UTMP B-GENE O
share O O
many O O
biosynthetic O O
and O O
structural O O
features O O
that O O
include O O
site O O
of O O
biosynthesis O O
in O O
the O O
endometrium O O
, O O
P0 O B-GENE
- O O
responsiveness O O
, O O
the O O
presence O O
of O O
the O O
mannose O B-GENE
0 O I-GENE
- O I-GENE
phosphate O I-GENE
lysosomal O O
recognition O O
marker O O
, O O
and O O
considerable O O
sequence O O
similarity O O
, O O
the O O
UfAP B-GENE O
and O O
the O O
UTMP B-GENE O
may O O
have O O
homologous O O
function O O
which O O
for O O
both O O
still O O
remains O O
obscure O O
. O O

The O O
galactose B-GENE O
transporter I-GENE O
shows O O
both O O
sequence O O
and O O
structural O O
homology O O
with O O
a O O
superfamily O O
of O O
sugar B-GENE O
transporters I-GENE O
which O O
includes O O
the O O
human B-GENE O
HepG0 I-GENE O
- I-GENE O
erythrocyte I-GENE O
and I-GENE O
fetal I-GENE O
muscle I-GENE O
glucose I-GENE O
transporters I-GENE O
, O O
the O O
rat B-GENE O
brain I-GENE O
and I-GENE O
liver I-GENE O
glucose I-GENE O
transporters I-GENE O
, O O
the O O
Escherichia B-GENE O
coli I-GENE O
xylose I-GENE O
and I-GENE O
arabinose I-GENE O
permeases I-GENE O
, O O
and O O
the O O
S B-GENE O
. I-GENE O
cerevisiae I-GENE O
glucose I-GENE O
, I-GENE O
maltose I-GENE O
, I-GENE O
and I-GENE O
galactose I-GENE O
transporters I-GENE O
. O O

During O O
a O O
00 O O
- O O
week O O
promotion O O
bioassay O O
, O O
groups O O
of O O
00 O O
male O O
CD O O
- O O
0 O O
mice O O
were O O
treated O O
once O O
with O O
00 O O
microliter O O
of O O
either O O
DMBA O O
( O O
0 O O
. O O
0 O O
mg O O
/ O O
ml O O
) O O
or O O
acetone O O
, O O
rested O O
for O O
0 O O
weeks O O
, O O
and O O
then O O
treated O O
twice O O
per O O
week O O
with O O
test O O
material O O
for O O
the O O
remaining O O
00 O O
weeks O O
. O O

Heat O O
- O O
labile O O
- O O
like O O
enterotoxin O O
( O O
LT B-GENE O
) O O
was O O
produced O O
by O O
00 O O
of O O
00 O O
stool O O
isolates O O
( O O
00 O O
% O O
) O O
, O O
while O O
only O O
0 O O
of O O
the O O
00 O O
isolates O O
( O O
0 O O
% O O
) O O
produced O O
enterotoxinlike O O
activity O O
in O O
suckling O O
mice O O
; O O
00 O O
% O O
of O O
the O O
cytotoxin O O
- O O
producing O O
strains O O
also O O
produced O O
an O O
LT B-GENE O
- I-GENE O
like I-GENE O
material O O
. O O

The O O
0 O O
patients O O
receiving O O
Ir000 O O
implant O O
in O O
addition O O
to O O
external O O
radiation O O
showed O O
improved O O
( O O
p O O
= O O
0 O O
. O O
00 O O
) O O
survival O O
compared O O
to O O
the O O
0 O O
receiving O O
external O O
only O O
: O O
median O O
00 O O
months O O
( O O
range O O
0 O O
. O O
0 O O
- O O
00 O O
+ O O
months O O
) O O
versus O O
0 O O
months O O
( O O
range O O
0 O O
. O O
0 O O
- O O
00 O O
months O O
) O O
. O O

The O O
results O O
indicate O O
that O O
increased O O
pulmonary O O
blood O O
flow O O
and O O
decreased O O
pulmonary O O
vascular O O
resistance O O
with O O
advancing O O
gestation O O
are O O
due O O
to O O
an O O
increase O O
in O O
the O O
total O O
number O O
of O O
vessels O O
and O O
increased O O
vasomotor O O
reactivity O O
is O O
related O O
to O O
an O O
increase O O
in O O
the O O
total O O
amount O O
of O O
smooth O O
muscle O O
while O O
the O O
thickness O O
of O O
muscle O O
in O O
individual O O
vessels O O
remains O O
constant O O
. O O

A O O
synthetic O O
oligonucleotide O O
containing O O
the O O
SRE O O
sequence O O
from O O
the O O
mouse B-GENE B-GENE
c I-GENE I-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
gene I-GENE I-GENE
promoter I-GENE I-GENE
( O O
- O O
000 O O
to O O
- O O
000 O O
) O O
was O O
radioactively O O
labeled O O
, O O
used O O
as O O
a O O
probe O O
for O O
the O O
mobility O O
shift O O
assay O O
and O O
Southwestern O O
( O O
DNA O B-GENE
- O I-GENE
protein O I-GENE
) O O
blotting O O
, O O
and O O
also O O
used O O
for O O
sequence O O
- O O
specific O O
affinity O O
chromatography O O
. O O

We O O
have O O
previously O O
identified O O
, O O
by O O
screening O O
a O O
lambda O O
gt00 O O
expression O O
library O O
, O O
murine B-GENE B-GENE
protein I-GENE I-GENE
mXBP I-GENE O
, O O
which O O
binds O O
to O O
a O O
sequence O O
which O O
overlaps O O
the O O
0 O O
' O O
end O O
of O O
the O O
murine B-GENE B-GENE
class I-GENE I-GENE
II I-GENE I-GENE
major I-GENE I-GENE
histocompatibility I-GENE I-GENE
complex I-GENE I-GENE
A I-GENE I-GENE
alpha I-GENE I-GENE
gene I-GENE I-GENE
X I-GENE I-GENE
box I-GENE I-GENE
, O O
a O O
conserved O O
transcription O O
element O O
found O O
upstream O O
of O O
all O O
class O O
II O O
genes O O
. O O

The O O
dichloromethane O O
is O O
removed O O
, O O
mobile O O
phase O O
solvent O O
is O O
added O O
, O O
and O O
aliquots O O
are O O
injected O O
onto O O
a O O
PRP O O
- O O
0 O O
liquid O O
chromatographic O O
column O O
; O O
fluazifop O O
acid O O
is O O
separated O O
from O O
coextracted O O
compounds O O
and O O
detected O O
at O O
an O O
applied O O
potential O O
of O O
+ O O
0 O O
. O O
00 O O
V O O
, O O
using O O
an O O
amperometric O O
electrochemical O O
detector O O
in O O
the O O
oxidation O O
mode O O
. O O

Basing O O
on O O
experimental O O
toxicity O O
research O O
it O O
was O O
established O O
that O O
, O O
out O O
of O O
00 O O
atmosphere O O
metal O O
corrosion O O
inhibitors O O
, O O
some O O
00 O O
per O O
cent O O
were O O
found O O
extremely O O
hazardous O O
, O O
00 O O
per O O
cent O O
- O O
- O O
of O O
high O O
level O O
hazardous O O
, O O
00 O O
percent O O
- O O
- O O
of O O
moderate O O
and O O
00 O O
per O O
cent O O
- O O
- O O
of O O
low O O
hazardous O O
. O O

Improved O O
cosmesis O O
, O O
extension O O
of O O
the O O
scope O O
of O O
the O O
problems O O
that O O
can O O
be O O
addressed O O
with O O
this O O
repair O O
( O O
including O O
treatment O O
of O O
a O O
distal O O
urethrocutaneous O O
fistula O O
) O O
and O O
the O O
ease O O
with O O
which O O
the O O
Arap O O
procedure O O
can O O
be O O
performed O O
are O O
the O O
advantages O O
that O O
this O O
operation O O
has O O
over O O
other O O
0 O O
- O O
stage O O
distal O O
hypospadias O O
repairs O O
. O O

Codon O O
usage O O
in O O
C O O
. O O
reinhardtii O O
mitochondria O O
is O O
highly O O
biased O O
, O O
with O O
eight O O
codons O O
entirely O O
absent O O
from O O
all O O
protein O O
- O O
coding O O
genes O O
; O O
however O O
, O O
even O O
though O O
codon O O
usage O O
is O O
restricted O O
, O O
it O O
appears O O
that O O
C O O
. O O
reinhardtii O O
mtDNA O O
cannot O O
encode O O
the O O
minimum O O
number O O
of O O
tRNAs O O
needed O O
to O O
support O O
mitochondrial O O
protein O O
synthesis O O
. O O

Cephradine O O
000 O O
mg O O
at O O
night O O
for O O
00 O O
months O O
was O O
given O O
as O O
a O O
prophylactic O O
measure O O
to O O
00 O O
female O O
patients O O
of O O
mean O O
age O O
00 O O
. O O
0 O O
years O O
, O O
who O O
had O O
a O O
history O O
in O O
the O O
preceding O O
00 O O
months O O
of O O
between O O
three O O
and O O
00 O O
( O O
median O O
= O O
0 O O
) O O
episodes O O
of O O
frequency O O
and O O
/ O O
or O O
dysuria O O
. O O

E O O
. O O
, O O
Hession O O
, O O
C O O
. O O
, O O
Goff O O
, O O
D O O
. O O
, O O
Griffiths O O
, O O
B O O
. O O
, O O
Tizard O O
, O O
R O O
. O O
, O O
Newman O O
, O O
B O O
. O O
, O O
Chi O O
- O O
Rosso O O
, O O
G O O
. O O
, O O
and O O
Lobb O O
, O O
R O O
. O O
, O O
( O O
0000 O O
) O O
Cell O O
00 O O
, O O
0000 O O
- O O
0000 O O
) O O
. O O

Urine O O
specimens O O
containing O O
either O O
phencyclidine O O
( O O
PCP O O
) O O
or O O
00 O O
- O O
nor O O
- O O
delta O O
0 O O
- O O
tetrahydrocannabinol O O
- O O
0 O O
- O O
carboxylic O O
acid O O
( O O
0 O O
- O O
THC O O
- O O
COOH O O
) O O
were O O
adulterated O O
with O O
sodium O O
chloride O O
, O O
bleach O O
, O O
vinegar O O
, O O
potassium O O
hydroxide O O
, O O
liquid O O
soap O O
, O O
0 O O
- O O
propanol O O
, O O
and O O
ammonia O O
. O O

This O O
generalization O O
of O O
MFP O O
involves O O
defining O O
an O O
appropriate O O
high O O
- O O
resolution O O
cost O O
function O O
, O O
parametrizing O O
the O O
search O O
space O O
of O O
the O O
environment O O
and O O
source O O
, O O
constructing O O
solutions O O
of O O
the O O
wave O O
equation O O
, O O
and O O
utilizing O O
a O O
nonlinear O O
optimization O O
method O O
to O O
search O O
the O O
parameter O O
landscape O O
for O O
the O O
global O O
minimum O O
of O O
the O O
cost O O
function O O
. O O

The O O
specific O O
interaction O O
between O O
a O O
defined O O
structural O O
element O O
of O O
the O O
human O B-GENE
immunodeficiency O I-GENE
virus O I-GENE
mRNA O I-GENE
( O O
RRE B-GENE O
, O O
the O O
Rev B-GENE O
response I-GENE O
element I-GENE O
) O O
and O O
the O O
virus B-GENE B-GENE
- I-GENE I-GENE
encoded I-GENE I-GENE
protein I-GENE I-GENE
Rev I-GENE O
has O O
been O O
implicated O O
in O O
the O O
regulation O O
of O O
the O O
export O O
of O O
unspliced O O
or O O
singly O O
spliced O O
mRNA O O
from O O
the O O
nucleus O O
to O O
the O O
cytoplasm O O
. O O

We O O
have O O
determined O O
the O O
nucleotide O O
( O O
nt O O
) O O
sequence O O
of O O
the O O
0 B-GENE O
. I-GENE O
0 I-GENE I-GENE
- I-GENE I-GENE
kb I-GENE I-GENE
COR I-GENE O
segment I-GENE O
that O O
encompasses O O
a O O
cluster O O
of O O
six O B-GENE
genes O I-GENE
( O O
CYC0 B-GENE B-GENE
, O O
UTR0 B-GENE O
, O O
UTR0 B-GENE O
, O O
OSM0 B-GENE B-GENE
, O O
tRNA B-GENE B-GENE
( I-GENE O
Gly I-GENE B-GENE
) I-GENE O
and O O
RAD0 B-GENE O
) O O
located O O
on O O
chromosome O O
X O O
of O O
the O O
yeast O O
Saccharomyces O O
cerevisiae O O
. O O

Two O O
separate O O
NF0 B-GENE O
- I-GENE O
binding I-GENE O
loci I-GENE O
were O O
also O O
found O O
in O O
the O O
equivalent O O
IE00 B-GENE O
gene I-GENE O
of O O
HCMV O B-GENE
( O O
Towne O O
) O O
DNA O O
, O O
but O O
in O O
this O O
case O O
the O O
DNA O O
sequence O O
and O O
competition O O
filter O O
binding O O
experiments O O
indicated O O
a O O
maximum O O
of O O
only O O
four O O
to O O
five O O
consensus O O
binding O O
sites O O
encompassing O O
the O O
promoter O O
- O O
enhancer O O
region O O
. O O

WR O O
- O O
0000 O O
( O O
S O O
- O O
0 O O
- O O
( O O
0 O O
aminopropylamino O O
) O O
ethylphosphorothioic O O
acid O O
) O O
has O O
been O O
investigated O O
for O O
its O O
ability O O
to O O
protect O O
gut O O
, O O
lung O O
, O O
and O O
testis O O
, O O
as O O
well O O
as O O
fibrosarcoma O O
( O O
FSa O O
) O O
tumor O O
nodules O O
, O O
in O O
the O O
lungs O O
of O O
mice O O
from O O
gamma O O
- O O
radiation O O
injury O O
. O O

The O O
present O O
study O O
examined O O
the O O
dependence O O
of O O
difference O O
tone O O
level O O
[ O O
L O O
( O O
f0 O O
- O O
f0 O O
) O O
] O O
on O O
the O O
following O O
parameters O O
of O O
the O O
two O O
- O O
tone O O
input O O
: O O
f0 O O
, O O
f0 O O
/ O O
f0 O O
( O O
f0 O O
greater O O
than O O
f0 O O
) O O
, O O
L0 O O
, O O
L0 O O
, O O
and O O
L0 O O
= O O
L0 O O
. O O

At O O
the O O
C O O
- O O
terminus O O
of O O
the O O
protein O O
is O O
a O O
domain O O
that O O
contains O O
sequences O O
very O O
similar O O
to O O
those O O
found O O
in O O
the O O
breakpoint O B-GENE
cluster O I-GENE
region O I-GENE
gene O I-GENE
product O O
, O O
n B-GENE B-GENE
- I-GENE I-GENE
chimerin I-GENE I-GENE
, O O
and O O
rho B-GENE O
GAP I-GENE O
, O O
all O O
of O O
which O O
have O O
been O O
shown O O
to O O
possess O O
intrinsic O O
GAP B-GENE O
activity O O
on O O
small B-GENE O
GTPases I-GENE O
. O O

UDP B-GENE O
- I-GENE O
Gal I-GENE O
: I-GENE O
Gal I-GENE O
beta I-GENE O
0 I-GENE O
- I-GENE O
- I-GENE I-GENE
- I-GENE I-GENE
- I-GENE I-GENE
0GlcNAc I-GENE I-GENE
alpha I-GENE I-GENE
0 I-GENE O
- I-GENE O
- I-GENE O
- I-GENE O
- I-GENE O
0 I-GENE O
- I-GENE O
galactosyltransferase I-GENE O
is O O
a O O
terminal B-GENE O
glycosyltransferase I-GENE O
that O O
is O O
widely O O
expressed O O
in O O
a O O
variety O O
of O O
mammalian O O
species O O
, O O
with O O
the O O
notable O O
exception O O
of O O
man O O
, O O
apes O O
, O O
and O O
Old O O
World O O
monkeys O O
. O O

A O O
0 O O
. O O
0 O O
- O O
kilobase O O
BamHI B-GENE O
- O O
HindIII B-GENE O
fragment O O
encoding O O
the O O
entire B-GENE O
Neurospora I-GENE O
crassa I-GENE O
CuZn I-GENE I-GENE
superoxide I-GENE I-GENE
dismutase I-GENE I-GENE
gene I-GENE I-GENE
( O O
herein O O
designated O O
sod B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
was O O
isolated O O
from O O
a O O
genomic O O
library O O
using O O
two O O
00 O O
- O O
base O O
deoxyoligonucleotide O O
probes O O
corresponding O O
to O O
the O O
published O O
N O O
. O O
crassa O O
amino O O
acid O O
sequence O O
. O O

Analysis O O
with O O
additional O O
anti O O
- O O
peptide O O
antibodies O O
specific O O
for O O
alpha B-GENE B-GENE
, I-GENE O
beta I-GENE O
, I-GENE O
or I-GENE O
gamma I-GENE O
PKC I-GENE O
indicated O O
that O O
all O O
three O O
types O O
of O O
PKC B-GENE O
are O O
expressed O O
in O O
JK O O
cells O O
; O O
however O O
, O O
JKPE O O
cells O O
lost O O
a O O
major O O
approximately O O
00 O O
kDa O O
immunoreactive O O
cytosolic O O
protein O O
detectable O O
with O O
anti B-GENE B-GENE
- I-GENE I-GENE
PKC I-GENE I-GENE
alpha I-GENE I-GENE
antibody I-GENE I-GENE
. O O

The O O
serum O O
erythropoietin B-GENE O
( O O
EPO B-GENE O
) O O
concentrations O O
of O O
00 O O
male O O
triathletes O O
( O O
00 O O
. O O
0 O O
U O O
. O O
ml O O
- O O
0 O O
) O O
were O O
significantly O O
lower O O
than O O
those O O
of O O
00 O O
male O O
distance O O
runners O O
( O O
00 O O
. O O
0 O O
U O O
. O O
ml O O
- O O
0 O O
; O O
P O O
less O O
than O O
0 O O
. O O
00 O O
) O O
. O O

Formalin O O
activated O O
both O O
SNO O O
NS O O
and O O
NnS O O
neurones O O
, O O
but O O
, O O
when O O
they O O
responded O O
, O O
NS O O
neurones O O
( O O
n O O
= O O
0 O O
) O O
showed O O
only O O
the O O
first O O
phase O O
of O O
activity O O
while O O
NnS O O
neurones O O
showed O O
either O O
one O O
( O O
n O O
= O O
00 O O
) O O
or O O
two O O
phases O O
( O O
n O O
= O O
0 O O
) O O
. O O

After O O
base O O
- O O
line O O
CBF O O
was O O
established O O
, O O
hexamethonium O O
bromide O O
( O O
0 O O
mg O O
/ O O
kg O O
iv O O
) O O
, O O
ipratropium O O
bromide O O
( O O
0 O O
. O O
0 O O
microgram O O
/ O O
kg O O
iv O O
) O O
, O O
indomethacin O O
( O O
0 O O
mg O O
/ O O
kg O O
iv O O
) O O
, O O
or O O
intravenous O O
0 O O
. O O
0 O O
% O O
saline O O
was O O
administered O O
. O O

When O O
two O O
- O O
dimensional O O
polyacrylamide O O
gel O O
electrophoretic O O
patterns O O
of O O
[ O O
00S O O
] O O
methionine O O
- O O
labeled O O
proteins O O
secreted O O
from O O
cells O O
infected O O
with O O
parental O O
and O O
recombinant O O
viruses O O
were O O
compared O O
, O O
a O O
spot O O
missing O O
from O O
the O O
latter O O
corresponded O O
in O O
molecular O O
weigh O O
and O O
isoelectric O O
point O O
with O O
that O O
predicted O O
from O O
the O O
N0L B-GENE O
ORF I-GENE O
. O O

Quantitative O O
analysis O O
of O O
the O O
coronary O O
stenosis O O
was O O
assessed O O
before O O
and O O
after O O
PTCA O O
, O O
and O O
the O O
dilatation O O
resulted O O
in O O
an O O
increase O O
in O O
minimal O O
luminal O O
cross O O
- O O
sectional O O
area O O
from O O
0 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
mm0 O O
. O O

Comparison O O
of O O
the O O
amino O O
acid O O
sequence O O
of O O
the O O
M B-GENE O
RNA I-GENE O
product I-GENE O
of I-GENE O
Uukuniemi I-GENE O
virus I-GENE O
with O O
that O O
of O O
Punta O O
Toro O O
and O O
Rift O O
Valley O O
fever O O
viruses O O
showed O O
in O O
both O O
cases O O
a O O
weak O O
homology O O
that O O
was O O
more O O
pronounced O O
for O O
the O O
proteins O O
located O O
at O O
the O O
COOH O O
- O O
terminal O O
end O O
of O O
the O O
precursor O O
. O O

Comparison O O
with O O
the O O
sequence O O
databanks O O
show O O
that O O
Tactile B-GENE O
is O O
a O O
member O O
of O O
the O O
immunoglobulin B-GENE B-GENE
gene I-GENE I-GENE
superfamily I-GENE I-GENE
, O O
with O O
similarity O O
to O O
Drosophila B-GENE O
amalgam I-GENE O
, O O
the O O
melanoma B-GENE O
Ag I-GENE O
MUC I-GENE O
- I-GENE O
00 I-GENE O
, O O
members O O
of O O
the O O
carcinoembryonic B-GENE B-GENE
Ag I-GENE I-GENE
family I-GENE I-GENE
, O O
the O O
poliovirus B-GENE B-GENE
receptor I-GENE I-GENE
, O O
and O O
the O O
neural B-GENE O
cell I-GENE O
adhesion I-GENE O
molecule I-GENE O
. O O

Seven O O
clones O O
encoding O O
interferon B-GENE O
response I-GENE O
element I-GENE O
binding I-GENE O
factors I-GENE O
have O O
been O O
isolated O O
from O O
a O O
mouse O O
fibroblast O O
lambda O O
gt00 O O
cDNA O O
library O O
by O O
using O O
a O O
00P O O
end O O
- O O
labeled O O
tandem O O
trimer O O
of O O
the O O
mouse B-GENE B-GENE
( I-GENE I-GENE
0 I-GENE I-GENE
' I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
' I-GENE O
) I-GENE O
oligoadenylate I-GENE O
synthetase I-GENE O
gene I-GENE O
interferon O O
response O O
element O O
as O O
a O O
probe O O
. O O

The O O
00 B-GENE O
. I-GENE O
0C I-GENE O
mAb I-GENE O
recognizes O O
a O O
site O O
on O O
IgE B-GENE O
which O O
is O O
identical O O
or O O
very O O
close O O
to O O
the O O
Fc B-GENE O
epsilon I-GENE O
R I-GENE O
binding I-GENE O
site I-GENE O
, O O
and O O
00 O O
. O O
0 O O
recognizes O O
a O O
site O O
on O O
IgE B-GENE O
which O O
is O O
related O O
, O O
but O O
not O O
identical O O
to O O
the O O
Fc B-GENE O
epsilon I-GENE O
R I-GENE O
binding I-GENE O
site I-GENE O
. O O

With O O
both O O
wild O O
- O O
type O O
and O O
the O O
mutant O O
enzymes O O
, O O
ATP O O
activates O O
both O O
[ O O
00C O O
] O O
Asp O O
in O O
equilibrium O O
N O O
- O O
carbamyl O O
- O O
L O O
- O O
aspartate O O
( O O
C O O
- O O
Asp O O
) O O
and O O
the O O
[ O O
00P O O
] O O
carbamyl O O
phosphate O O
( O O
C O B-GENE
- O I-GENE
P O I-GENE
) O O
in O O
equilibrium O O
Pi O O
exchanges O O
. O O

Like O O
scrotal O O
testes O O
, O O
undescended O O
testes O O
were O O
hypointense O O
to O O
fat O O
on O O
sequences O O
with O O
a O O
short O O
repetition O O
time O O
( O O
TR O O
) O O
and O O
echo O O
time O O
( O O
TE O O
) O O
in O O
all O O
cases O O
, O O
and O O
hyperintense O O
or O O
isointense O O
to O O
fat O O
on O O
long O O
TR O O
/ O O
TE O O
sequences O O
in O O
all O O
but O O
two O O
cases O O
. O O

The O O
p000 B-GENE B-GENE
and O O
p00 B-GENE B-GENE
tyrosine O I-GENE
- O I-GENE
phosphorylated O I-GENE
proteins O O
that O O
complexed O B-GENE
v B-GENE I-GENE
- I-GENE I-GENE
Src I-GENE I-GENE
SH0 B-GENE I-GENE
in O O
vitro O O
also O O
associated O O
with O O
v B-GENE B-GENE
- I-GENE I-GENE
Src I-GENE I-GENE
in O O
v B-GENE B-GENE
- I-GENE I-GENE
src I-GENE I-GENE
- O O
transformed O O
Rat O O
- O O
0 O O
cells O O
; O O
this O O
in O O
vivo O O
binding O O
was O O
dependent O O
on O O
the O O
v B-GENE B-GENE
- I-GENE I-GENE
Src I-GENE I-GENE
SH0 B-GENE O
domain O O
. O O

UF O O
- O O
000 O O
ophthalmic O O
solution O O
( O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
% O O
) O O
, O O
when O O
topically O O
applied O O
to O O
the O O
eyes O O
of O O
rabbits O O
, O O
caused O O
dose O O
- O O
dependent O O
IOP O O
reduction O O
( O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
mmHg O O
) O O
, O O
without O O
transient O O
IOP O O
rise O O
. O O

Interspecific O O
backcross O O
analysis O O
using O O
progeny O O
derived O O
from O O
matings O O
of O O
( O O
C00BL O B-GENE
/ O O
0J O B-GENE
x O I-GENE
Mus O I-GENE
spretus O I-GENE
) O I-GENE
F0 O I-GENE
x O I-GENE
C00BL O I-GENE
/ O O
0J O O
mice O O
indicates O O
that O O
the O O
thrombospondin B-GENE B-GENE
gene I-GENE I-GENE
is O O
tightly O O
linked O O
to O O
the O O
Fshb B-GENE O
, O O
Actcl B-GENE O
, O O
Ltk B-GENE O
, O O
and O O
B0M B-GENE O
loci I-GENE O
on O O
murine O O
chromosome O O
0 O O
. O O

Results O O
of O O
this O O
study O O
indicate O O
that O O
GLC O O
of O O
short O O
chain O O
fatty O O
acids O O
produced O O
on O O
agar O O
medium O O
by O O
anaerobes O O
, O O
combined O O
with O O
simple O O
tests O O
such O O
as O O
Gram O O
' O O
s O O
stain O O
and O O
colonial O O
morphology O O
, O O
may O O
allow O O
fir O O
direct O O
presumptive O O
genus O O
identification O O
from O O
an O O
initial O O
pure O O
agar O O
culture O O
. O O

Oxygen O O
tension O O
of O O
the O O
small O O
lymph O O
vessels O O
( O O
PLO0 O O
) O O
of O O
the O O
rabbit O O
hind O O
limb O O
was O O
measured O O
with O O
both O O
a O O
flow O O
- O O
through O O
micro O O
chamber O O
and O O
a O O
polarographic O O
catheter O O
- O O
tip O O
oxygen O O
electrode O O
to O O
obtain O O
experimental O O
data O O
on O O
the O O
source O O
of O O
oxygen O O
in O O
the O O
lymph O O
. O O

The O O
findings O O
suggest O O
that O O
, O O
although O O
iodine O O
deficiency O O
is O O
the O O
most O O
probable O O
cause O O
of O O
goiter O O
among O O
immigrants O O
of O O
the O O
0000 O O
cohort O O
, O O
where O O
the O O
native O O
population O O
is O O
concerned O O
( O O
both O O
men O O
and O O
women O O
) O O
, O O
some O O
other O O
goitrogenic O O
factor O O
( O O
s O O
) O O
must O O
be O O
involved O O
. O O

Gastric O O
CO0 O O
/ O O
HCO0 O O
was O O
determined O O
in O O
absence O O
of O O
simultaneous O O
inhibition O O
of O O
acid O O
secretion O O
by O O
intra O O
- O O
and O O
extragastric O O
pCO0 O O
/ O O
pH O O
measurements O O
in O O
00 O O
persons O O
and O O
calculated O O
using O O
the O O
equation O O
of O O
Henderson O O
- O O
Hasselbalch O O
. O O
pCO0 O O
was O O
measured O O
with O O
use O O
of O O
a O O
new O O
electrode O O
. O O

This O O
TC B-GENE O
- I-GENE O
II I-GENE O
enhanson I-GENE O
, O O
which O O
is O O
identical O O
to O O
the O O
kappa B-GENE O
B I-GENE O
motif I-GENE O
from O O
the O O
kappa B-GENE B-GENE
chain I-GENE I-GENE
enhancer I-GENE I-GENE
, O O
was O O
active O O
in O O
both O O
lymphoid O O
and O O
non O O
- O O
lymphoid O O
cells O O
, O O
which O O
contrasts O O
with O O
the O O
previously O O
reported O O
lymphoid O O
cell O O
specificity O O
of O O
the O O
kappa B-GENE B-GENE
B I-GENE I-GENE
motif I-GENE I-GENE
. O O

Polysorbate O O
00 O O
did O O
not O O
have O O
a O O
direct O O
stimulant O O
or O O
relaxant O O
effect O O
on O O
either O O
guinea O O
pig O O
ileum O O
or O O
rat O O
uterus O O
, O O
however O O
, O O
it O O
antagonised O O
the O O
contractions O O
induced O O
by O O
acetylcholine O O
, O O
histamine O O
, O O
barium O O
, O O
0 O O
- O O
hydroxytryptamine O O
and O O
carbachol O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

Finally O O
, O O
some O O
point O O
mutations O O
in O O
the O O
Gag B-GENE O
- O O
Pol B-GENE O
PR O O
domain O O
inhibited O O
activation O O
of O O
RT B-GENE O
in O O
trans O O
by O O
a O O
wild O O
- O O
type O O
PR B-GENE O
, O O
suggesting O O
that O O
the O O
correct O O
conformation O O
of O O
the O O
PR B-GENE O
domain O O
in O O
Gag B-GENE O
- O O
Pol B-GENE O
is O O
prerequisite O O
for O O
activation O O
of O O
RT B-GENE O
. O O

Young O O
CD O O
- O O
0 O O
mice O O
, O O
0 O O
days O O
old O O
, O O
exposed O O
to O O
0 O O
. O O
0 O O
% O O
nicotine O O
sulfate O O
on O O
gestational O O
days O O
0 O O
- O O
00 O O
were O O
compared O O
with O O
untreated O O
pups O O
of O O
the O O
same O O
age O O
to O O
determine O O
its O O
effect O O
on O O
the O O
development O O
of O O
mandibular O O
first O O
molars O O
. O O

The O O
gene O O
is O O
contained O O
within O O
a O O
0 O O
. O O
0 O O
- O O
kilobase O O
AccI B-GENE O
- O O
EcoRI B-GENE O
restriction O O
fragment O O
mapping O O
at O O
map O O
coordinates O O
0 O O
. O O
000 O O
to O O
0 O O
. O O
000 O O
in O O
the O O
UL O O
region O O
of O O
the O O
EHV O B-GENE
- O I-GENE
0 O I-GENE
genome O I-GENE
and O O
is O O
transcribed O O
from O O
right O O
to O O
left O O
. O O

Significant O O
clinical O O
differences O O
between O O
the O O
patients O O
treated O O
with O O
and O O
without O O
AMB O O
were O O
longer O O
survival O O
time O O
following O O
diagnosis O O
of O O
illness O O
( O O
P O O
less O O
than O O
0 O O
. O O
00 O O
) O O
and O O
more O O
frequent O O
cranial O O
nerve O O
signs O O
in O O
the O O
treated O O
patients O O
( O O
P O O
= O O
0 O O
. O O
000 O O
) O O
. O O

A O O
five O O
- O O
phase O O
experiment O O
was O O
designed O O
to O O
investigate O O
( O O
a O O
) O O
whether O O
contingent O O
music O O
- O O
listening O O
would O O
act O O
as O O
a O O
reinforcer O O
to O O
increase O O
arithmetic O O
performance O O
of O O
EMR O O
children O O
and O O
( O O
b O O
) O O
whether O O
this O O
contingent O O
reinforcement O O
would O O
affect O O
preference O O
for O O
that O O
reinforcer O O
. O O

At O O
the O O
very O O
high O O
dose O O
levels O O
used O O
, O O
sodium O O
saccharin O O
and O O
sodium O O
cyclamate O O
were O O
weak O O
solitary O O
carcinogens O O
producing O O
0 O O
/ O O
000 O O
and O O
0 O O
/ O O
000 O O
bladder O O
tumours O O
respectively O O
, O O
and O O
the O O
first O O
of O O
these O O
tumours O O
did O O
not O O
appear O O
for O O
more O O
than O O
00 O O
weeks O O
. O O

The O O
phenotypes O O
of O O
the O O
ICP0 B-GENE O
nonsense O O
mutants O O
were O O
intermediate O O
between O O
those O O
of O O
the O O
wild O O
- O O
type O O
virus O O
and O O
0000 O O
in O O
that O O
the O O
more O O
ICP0 B-GENE O
- I-GENE O
coding I-GENE O
sequence I-GENE O
expressed O O
by O O
a O O
given O O
nonsense O O
mutant O O
, O O
the O O
more O O
wild O O
type O O
- O O
like O O
was O O
its O O
phenotype O O
. O O

Here O O
, O O
we O O
present O O
evidence O O
for O O
a O O
model O O
in O O
which O O
mRNA O O
sequences O O
up O O
to O O
around O O
000 O O
nucleotides O O
downstream O O
from O O
the O O
start O O
codon O O
of O O
00K O O
fold O O
back O O
and O O
base O O
- O O
pair O O
to O O
the O O
00K O O
translation O O
initiation O O
region O O
, O O
thereby O O
decreasing O O
the O O
translation O O
initiation O O
frequency O O
. O O

Patients O O
with O O
an O O
enzymatic O O
activity O O
below O O
X O O
- O O
- O O
0 O O
manifested O O
a O O
decrease O O
of O O
the O O
content O O
of O O
IgA B-GENE O
, O O
IgG B-GENE O
, O O
IgM B-GENE O
, O O
T O O
and O O
B O O
lymphocytes O O
, O O
and O O
of O O
phagocytic O O
activity O O
of O O
neutrophils O O
as O O
compared O O
to O O
patients O O
exhibiting O O
a O O
high O O
enzymatic O O
activity O O
. O O

Surprisingly O O
, O O
there O O
is O O
no O O
sequence O O
homology O O
between O O
this O O
region O O
of O O
Ly B-GENE B-GENE
- I-GENE I-GENE
0E I-GENE I-GENE
and O O
the O O
established O O
consensus O O
for O O
the O O
interferon B-GENE O
- I-GENE O
stimulated I-GENE O
response I-GENE O
element I-GENE O
, O O
which O O
has O O
been O O
shown O O
functionally O O
important O O
to O O
all O O
previously O O
characterized O B-GENE
alpha B-GENE I-GENE
/ I-GENE I-GENE
beta I-GENE I-GENE
interferon I-GENE I-GENE
- O I-GENE
inducible O I-GENE
promoters O O
. O O

DNA O O
- O O
protein O O
UV O O
cross O O
- O O
linking O O
studies O O
indicated O O
that O O
UHF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
has O O
an O O
electrophoretic O O
mobility O O
on O O
sodium O O
dodecyl O O
sulfate O O
- O O
acrylamide O O
gels O O
of O O
approximately O O
00 O O
kDa O O
and O O
suggested O O
that O O
additional O O
proteins O O
, O O
specific O O
to O O
each O O
promoter O O
, O O
bind O O
to O O
each O O
site O O
. O O

The O O
major O O
promoter O O
responds O O
strongly O O
to O O
virus O O
- O O
encoded O O
trans O O
activators O O
EIA B-GENE O
and O O
EIV B-GENE O
and O O
contains O O
four O O
elements O O
: O O
a O O
TAGA O O
motif O O
analogous O O
to O O
the O O
TATA O O
box O O
, O O
two O O
EIIF B-GENE O
sites I-GENE O
present O O
in O O
an O O
inverted O O
orientation O O
, O O
and O O
an O O
ATF B-GENE O
/ O O
CREB B-GENE O
site O O
. O O

This O O
, O O
together O O
with O O
the O O
data O O
obtained O O
with O O
haloperidol O O
, O O
suggests O O
that O O
a O O
minimal O O
increase O O
in O O
the O O
firing O O
rate O O
of O O
LC O O
cells O O
( O O
+ O O
000 O O
% O O
) O O
is O O
required O O
before O O
it O O
could O O
influence O O
the O O
turnover O O
of O O
NA O O
, O O
as O O
measured O O
by O O
DOPAC O O
changes O O
. O O

Erythrocyte O O
protoporphyrin O O
concentration O O
increased O O
significantly O O
( O O
P O O
less O O
than O O
0 O O
. O O
00 O O
) O O
by O O
00 O O
days O O
in O O
dogs O O
fed O O
the O O
basal O O
diet O O
, O O
and O O
remained O O
significantly O O
high O O
relative O O
to O O
that O O
in O O
dogs O O
of O O
the O O
other O O
dietary O O
groups O O
for O O
the O O
remainder O O
of O O
the O O
study O O
. O O

Methods O O
used O O
include O O
Cobb O O
angle O O
and O O
a O O
segmental O O
evaluation O O
( O O
T0 O O
- O O
T00 O O
) O O
of O O
each O O
of O O
convex O O
and O O
concave O O
rib O O
- O O
vertebra O O
angles O O
( O O
RVAs O O
) O O
, O O
rib O O
- O O
vertebra O O
angle O O
differences O O
( O O
RVADs O O
) O O
, O O
vertebral O O
rotation O O
, O O
tilt O O
and O O
displacement O O
. O O

A O O
significant O O
relationship O O
existed O O
during O O
the O O
evolution O O
of O O
the O O
disease O O
between O O
CRS O O
/ O O
BW O O
and O O
gas O O
exchange O O
parameters O O
( O O
FIO0 O O
and O O
a O O
/ O O
AO0 O O
ratio O O
) O O
( O O
P O O
less O O
than O O
0 O O
. O O
00 O O
) O O
, O O
but O O
gas O O
exchange O O
improved O O
earlier O O
than O O
lung O O
mechanics O O
. O O

The O O
primary O O
structure O O
and O O
cotranscription O O
of O O
the O O
petCA B-GENE O
genes I-GENE O
encoding O O
the O O
Rieske B-GENE B-GENE
- I-GENE I-GENE
FeS I-GENE I-GENE
( O O
nuclear B-GENE O
encoded I-GENE O
in I-GENE O
plants I-GENE O
) O O
and O O
apocytochrome B-GENE O
f I-GENE O
proteins I-GENE O
has O O
been O O
described O O
previously O O
( O O
Kallas O O
, O O
T O O
. O O
, O O
Spiller O O
, O O
S O O
. O O
, O O
and O O
Malkin O O
, O O
R O O
. O O

The O O
number O O
of O O
fecal O O
pellets O O
ingested O O
peaked O O
at O O
0 O O
to O O
0 O O
weeks O O
old O O
( O O
00 O O
pellets O O
/ O O
day O O
) O O
and O O
gradually O O
decreased O O
, O O
thereafter O O
( O O
0 O O
. O O
0 O O
pellets O O
at O O
00 O O
weeks O O
old O O
, O O
0 O O
. O O
0 O O
pellets O O
at O O
000 O O
weeks O O
old O O
) O O
. O O

The O O
results O O
from O O
the O O
first O O
five O O
years O O
of O O
follow O O
up O O
in O O
0000 O O
showed O O
a O O
0 O O
. O O
0 O O
- O O
fold O O
excess O O
mortality O O
for O O
ischaemic O O
and O O
other O O
heart O O
diseases O O
( O O
ICD O O
A00 O O
- O O
A00 O O
) O O
compared O O
with O O
a O O
comparable O O
reference O O
cohort O O
of O O
paper O O
mill O O
workers O O
. O O

The O O
difficulties O O
to O O
analyse O O
prostaglandins O O
( O O
PG O O
) O O
by O O
gas O O
- O O
liquid O O
chromatography O O
are O O
mainly O O
due O O
to O O
the O O
lack O O
of O O
sensitivity O O
of O O
the O O
gas O O
- O O
chromatograph O O
itself O O
( O O
higher O O
than O O
000 O O
ng O O
) O O
and O O
to O O
the O O
poor O O
resolution O O
of O O
the O O
packed O O
columns O O
. O O

Saccharomyces O O
cerevisiae O O
has O O
been O O
used O O
widely O O
both O O
as O O
a O O
model O O
system O O
for O O
unraveling O O
the O O
biochemical O O
, O O
genetic O O
, O O
and O O
molecular O O
details O O
of O O
gene O O
expression O O
and O O
the O O
secretion O O
process O O
, O O
and O O
as O O
a O O
host O O
for O O
the O O
production O O
of O O
heterologous O O
proteins O O
of O O
biotechnological O O
interest O O
. O O

The O O
antinociceptive O O
properties O O
, O O
as O O
measured O O
by O O
the O O
tail O O
- O O
flick O O
and O O
hot O O
- O O
plate O O
tests O O
, O O
and O O
the O O
motor O O
effects O O
of O O
an O O
intrathecally O O
- O O
administered O O
benzodiazepine O O
agonist O O
midazolam O O
, O O
alone O O
, O O
and O O
in O O
combination O O
with O O
morphine O O
, O O
was O O
examined O O
in O O
rats O O
. O O

An O O
FP B-GENE O
mutant I-GENE O
, O O
AcFP000 B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
had O O
a O O
0 O O
. O O
0 O O
- O O
kbp O O
insertion O O
of O O
S O O
. O O
frugiperda O O
DNA O O
near O O
the O O
0 O O
' O O
end O O
of O O
these O O
transcripts O O
which O O
by O O
S0 B-GENE O
analysis O O
were O O
shown O O
to O O
initiate O O
within O O
the O O
host O O
cell O O
sequence O O
. O O

A O O
centromere O O
in O O
S O O
. O O
cerevisiae O O
consists O O
of O O
a O O
region O O
of O O
DNA O O
, O O
approximately O O
000 O O
bp O O
in O O
length O O
, O O
containing O O
three O O
important O O
sequence O O
elements O O
, O O
which O O
are O O
folded O O
with O O
proteins O O
into O O
a O O
specific O O
conformation O O
in O O
the O O
chromatin O O
( O O
the O O
yeast O O
kinetochore O O
) O O
. O O

To O O
evaluate O O
the O O
relative O O
accuracy O O
of O O
continuous O O
wave O O
( O O
CW O O
) O O
and O O
high O O
pulse O O
repetition O O
frequency O O
( O O
HPRF O O
) O O
Doppler O O
for O O
estimating O O
aortic O O
transvalvular O O
pressure O O
gradients O O
, O O
Doppler O O
examinations O O
with O O
both O O
devices O O
were O O
obtained O O
in O O
00 O O
consecutive O O
patients O O
with O O
aortic O O
valve O O
disease O O
. O O

Patients O O
were O O
subclassified O O
into O O
age O O
- O O
matched O O
groups O O
of O O
primary O O
untreated O O
cancer O O
( O O
00 O O
) O O
, O O
recurrent O O
cancer O O
( O O
00 O O
) O O
, O O
and O O
" O O
cured O O
" O O
patients O O
who O O
had O O
been O O
free O O
of O O
disease O O
for O O
at O O
least O O
0 O O
months O O
( O O
00 O O
) O O
. O O

When O O
transiently O O
transfected O O
into O O
K000 O O
cells O O
, O O
this O O
Lg B-GENE O
genomic O O
clone O O
is O O
actively O O
transcribed O O
, O O
suggesting O O
that O O
, O O
although O O
it O O
possesses O O
the O O
characteristics O O
of O O
a O O
processed O O
pseudogene O O
, O O
it O O
is O O
likely O O
to O O
correspond O O
to O O
the O O
gene O O
encoding O O
this O O
new O O
ferritin B-GENE O
subunit I-GENE O
. O O

AgMNPV O O
and O O
Orgyia O O
pseudotsugata O O
MNPV O O
( O O
OpMNPV O O
) O O
are O O
similar O O
in O O
terms O O
of O O
promoter O O
structure O O
and O O
polyhedrin B-GENE O
primary I-GENE O
sequence I-GENE O
, O O
and O O
the O O
polyhedrin B-GENE O
gene I-GENE O
of O O
both O O
viruses O O
is O O
transcribed O O
in O O
the O O
anti O B-GENE
- O I-GENE
clockwise O I-GENE
direction O O
in O O
relation O O
to O O
their O O
physical O O
maps O O
. O O

The O O
relation O O
between O O
myocardial B-GENE O
beta I-GENE O
- I-GENE O
adrenergic I-GENE O
receptor I-GENE O
and O O
left O O
ventricular O O
( O O
LV O O
) O O
function O O
was O O
studied O O
in O O
00 O O
patients O O
, O O
aged O O
00 O O
to O O
00 O O
years O O
( O O
average O O
00 O O
) O O
, O O
with O O
LV O O
volume O O
overload O O
mainly O O
due O O
to O O
chronic O O
mitral O O
regurgitation O O
. O O

No O O
causal O O
relations O O
may O O
be O O
inferred O O
from O O
the O O
correlation O O
between O O
the O O
level O O
of O O
trapezius O O
activity O O
and O O
complaints O O
, O O
though O O
it O O
indicates O O
that O O
individual O O
, O O
inexpedient O O
muscle O O
activity O O
patterns O O
may O O
constitute O O
an O O
important O O
risk O O
factor O O
for O O
development O O
of O O
musculo O O
- O O
skeletal O O
complaints O O
. O O

In O O
contrast O O
, O O
0 O O
, O O
000 O O
( O O
00 O O
% O O
) O O
had O O
one O O
or O O
more O O
risk O O
factors O O
( O O
not O O
low O O
risk O O
) O O
; O O
of O O
these O O
, O O
0 O O
. O O
0 O O
% O O
died O O
in O O
0 O O
weeks O O
( O O
p O O
less O O
than O O
0 O O
. O O
000 O O
) O O
. O O

We O O
evaluated O O
the O O
likelihood O O
of O O
tissues O O
to O O
be O O
positive O O
for O O
carcinoembryonic B-GENE O
antigen I-GENE O
and O O
the O O
intensity O O
of O O
carcinoembryonic B-GENE O
antigen I-GENE O
staining O O
in O O
specimens O O
of O O
villous O O
adenomas O O
, O O
mixed O O
polypoid O O
villous O O
adenomas O O
, O O
polypoid O O
adenomas O O
, O O
and O O
diverticulitis O O
using O O
the O O
peroxidase B-GENE O
- O O
antiperoxidase B-GENE O
technique O O
. O O

Spontaneous O O
sensitization O O
to O O
cross O O
- O O
reacting O O
chemicals O O
in O O
a O O
proportion O O
of O O
control O O
animals O O
is O O
strongly O O
suggested O O
, O O
somewhat O O
akin O O
to O O
spontaneous O O
sensitization O O
in O O
patients O O
with O O
anaphylactoid O O
reactions O O
to O O
neuromuscular O O
blockers O O
on O O
first O O
exposure O O
, O O
and O O
in O O
whom O O
IgE B-GENE O
antibodies I-GENE O
are O O
detected O O
. O O

Evidence O O
from O O
the O O
structure O O
of O O
a O O
number O O
of O O
cDNA O O
clones O O
, O O
as O O
well O O
as O O
S0 B-GENE O
nuclease I-GENE O
and O O
primer O O
extension O O
studies O O
supports O O
the O O
hypothesis O O
that O O
the O O
PTHrP B-GENE B-GENE
gene I-GENE I-GENE
contains O O
at O O
least O O
two O O
mRNA O O
transcription O O
start O O
points O O
that O O
define O O
two O O
putative O O
regulatory O O
domains O O
. O O

In O O
cases O O
of O O
0 O O
degrees O O
HPT O O
, O O
the O O
plasma O O
0 O O
, O O
00 O O
- O O
( O O
OH O O
) O O
0D O O
level O O
rose O O
significantly O O
in O O
all O O
cases O O
( O O
P O O
less O O
than O O
0 O O
. O O
00 O O
) O O
, O O
although O O
the O O
pattern O O
of O O
the O O
increase O O
was O O
not O O
uniform O O
. O O

Either O O
a O O
UV O O
detector O O
set O O
at O O
000 O O
nm O O
or O O
an O O
electrochemical O O
( O O
EC O O
) O O
detector O O
set O O
at O O
a O O
potential O O
of O O
+ O O
0 O O
. O O
0 O O
V O O
( O O
versus O O
Ag O O
/ O O
AgCl O O
/ O O
0 O O
M O O
NaCl O O
) O O
was O O
used O O
to O O
monitor O O
the O O
drug O O
. O O

These O O
results O O
were O O
compared O O
with O O
those O O
obtained O O
in O O
- O O
D O O
mothers O O
and O O
pups O O
, O O
after O O
giving O O
the O O
mothers O O
an O O
oral O O
supplement O O
( O O
00 O O
i O O
. O O
u O O
. O O
vitamin O O
D0 O O
/ O O
day O O
) O O
during O O
the O O
period O O
of O O
lactation O O
( O O
00 O O
days O O
) O O
. O O

The O O
statistical O O
analysis O O
of O O
data O O
of O O
TRH B-GENE O
test O O
on O O
a O O
sample O O
of O O
00 O O
healthy O O
volunteers O O
has O O
permitted O O
an O O
evaluation O O
of O O
the O O
upper O O
limits O O
of O O
the O O
normal O O
thyrotropin B-GENE O
response O O
; O O
the O O
secretory O O
area O O
( O O
As O O
) O O
was O O
shown O O
to O O
be O O
more O O
discriminating O O
. O O

Three O O
experiments O O
contrasted O O
the O O
effects O O
of O O
0 O O
- O O
hydroxydopamine O O
- O O
induced O O
lesions O O
of O O
the O O
ventral O O
noradrenergic O O
and O O
dorsal O O
noradrenergic O O
projections O O
, O O
predominantly O O
to O O
hypothalamus O O
and O O
cortex O O
, O O
respectively O O
, O O
upon O O
body O O
weight O O
changes O O
and O O
food O O
- O O
related O O
behaviour O O
in O O
the O O
rat O O
. O O

A O O
000 O O
- O O
bp O O
segment O O
of O O
the O O
0 O O
' O O
- O O
flanking O O
region O O
consisting O O
of O O
the O O
proximal O O
E O O
- O O
box O O
flanked O O
upstream O O
by O O
a O O
mammalian O O
- O O
specific O O
000 O O
- O O
bp O O
region O O
was O O
sufficient O O
for O O
maximal O O
transcriptional O O
activation O O
in O O
postconfluent O O
BC0H0 O O
myoblasts O O
. O O

Sequence O O
analysis O O
of O O
the O O
sMtCK B-GENE O
genomic I-GENE O
upstream I-GENE O
sequences I-GENE O
reveals O O
a O O
typical O O
TATAA O O
box O O
within O O
the O O
00 O O
base O O
pairs O O
( O O
bp O O
) O O
that O O
, O O
by O O
transfection O O
experiments O O
, O O
are O O
sufficient O O
to O O
promote O O
expression O O
of O O
chimeric O O
plasmids O O
with O O
the O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
reporter I-GENE O
. O O

Sequence O O
analysis O O
of O O
the O O
sMtCK B-GENE O
genomic I-GENE O
upstream I-GENE O
sequences I-GENE O
reveals O O
a O O
typical O O
TATAA O O
box O O
within O O
the O O
00 O O
base O O
pairs O O
( O O
bp O O
) O O
that O O
, O O
by O O
transfection O O
experiments O O
, O O
are O O
sufficient O O
to O O
promote O O
expression O O
of O O
chimeric O O
plasmids O O
with O O
the O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
reporter I-GENE O
. O O

Regulation O O
of O O
irgA B-GENE O
by O O
iron O O
in O O
V O O
. O O
cholerae O O
occurs O O
at O O
the O O
transcriptional O O
level O O
, O O
and O O
there O O
is O O
an O O
interrupted O O
dyad O O
symmetric O O
sequence O O
in O O
the O O
vicinity O O
of O O
the O O
promoter O O
that O O
is O O
homologous O O
to O O
Fur B-GENE O
binding I-GENE O
sites I-GENE O
of O O
E O O
. O O
coli O O
. O O

Expression O O
of O O
the O O
human O B-GENE
T B-GENE I-GENE
cell I-GENE I-GENE
receptor I-GENE I-GENE
( I-GENE O
TCR I-GENE B-GENE
) I-GENE I-GENE
alpha I-GENE I-GENE
gene I-GENE I-GENE
is O O
regulated O O
by O O
a O O
T O O
cell O O
- O O
specific O O
transcriptional O O
enhancer O O
that O O
is O O
located O O
0 O O
. O O
0 O O
kilobases O O
( O O
kb O O
) O O
0 O O
' O O
to O O
the O O
C B-GENE B-GENE
alpha I-GENE I-GENE
gene I-GENE I-GENE
segment I-GENE O
. O O

Human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV O B-GENE
- O I-GENE
I O I-GENE
) O O
encodes O O
a O O
00 O O
- O O
kDa O O
nuclear O O
protein O O
, O O
Tax B-GENE O
, O O
which O O
stimulates O O
transcription O O
from O O
three O O
00 O O
- O O
base O O
pair O O
( O O
bp O O
) O O
repeats O O
in O O
its O O
U0 O O
region O O
. O O

The O O
purpose O O
of O O
this O O
study O O
is O O
twofold O O
: O O
( O O
0 O O
) O O
to O O
present O O
a O O
parallel O O
form O O
of O O
the O O
Gudjonsson O O
Suggestibility O O
Scale O O
( O O
GSS O O
, O O
Form O O
0 O O
) O O
; O O
( O O
0 O O
) O O
to O O
study O O
test O O
- O O
retest O O
reliabilities O O
of O O
interrogative O O
suggestibility O O
. O O

In O O
three O O
of O O
the O O
seven O O
, O O
inhalation O O
of O O
0 O O
ml O O
normal O O
saline O O
produced O O
FEV0 O O
falls O O
of O O
00 O O
% O O
to O O
00 O O
% O O
, O O
but O O
these O O
falls O O
were O O
not O O
as O O
great O O
as O O
each O O
subject O O
' O O
s O O
reactions O O
to O O
the O O
test O O
solutions O O
. O O

These O O
data O O
support O O
a O O
possible O O
biological O O
significance O O
of O O
the O O
frameshift O O
to O O
occur O O
at O O
this O O
position O O
of O O
the O O
large O O
overlap O O
by O O
including O O
the O O
putative O O
RNA O O
template O O
- O O
binding O O
site O O
of O O
the O O
PLRV B-GENE O
replicase I-GENE O
in O O
the O O
ORF0a B-GENE B-GENE
/ I-GENE I-GENE
ORF0b I-GENE I-GENE
transframe I-GENE I-GENE
protein I-GENE I-GENE
. O O

An O O
0 O O
- O O
h O O
exposure O O
to O O
00 O O
mg O O
DMEA O O
/ O O
m0 O O
corresponds O O
to O O
a O O
postexposure O O
plasma O O
concentration O O
and O O
0 O O
- O O
h O O
postexposure O O
urinary O O
excretion O O
of O O
0 O O
. O O
0 O O
mumol O O
/ O O
l O O
and O O
00 O O
mmol O O
/ O O
mol O O
creatinine O O
, O O
respectively O O
. O O

The O O
present O O
study O O
reports O O
visual O O
evoked O O
potential O O
responses O O
to O O
pattern O O
reversal O O
( O O
VEP O O
- O O
P O O
) O O
in O O
ten O O
third O O
trimester O O
pregnant O O
women O O
and O O
changes O O
in O O
latency O O
of O O
NPN O O
complex O O
when O O
compared O O
with O O
these O O
responses O O
in O O
the O O
non O O
pregnant O O
state O O
. O O

Along O O
with O O
previously O O
mapped O O
genes O O
including O O
Ly B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
CD00 B-GENE O
, O O
OSBP B-GENE O
defines O O
a O O
new O O
conserved O O
syntenic O O
group O O
on O O
the O O
long O O
arm O O
of O O
chromosome O O
00 O O
in O O
the O O
human O O
and O O
the O O
proximal O O
end O O
of O O
chromosome O O
00 O O
in O O
the O O
mouse O O
. O O

Examination O O
of O O
immediate B-GENE O
- I-GENE O
early I-GENE O
transcription I-GENE O
factor I-GENE O
expression O O
during O O
the O O
MDI O O
regimen O O
revealed O O
that O O
RA O O
mediated O O
an O O
elevated O O
, O O
prolonged O O
expression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
mRNA I-GENE O
accompanied O O
by O O
diminished O O
expression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
and O O
Jun B-GENE B-GENE
- I-GENE I-GENE
B I-GENE I-GENE
mRNAs I-GENE O
. O O

This O O
led O O
to O O
the O O
conclusion O O
that O O
the O O
metatarsal O O
artery O O
should O O
be O O
used O O
for O O
toe O O
MP O O
joint O O
grafts O O
, O O
while O O
the O O
unilateral O O
proper O O
digital O O
artery O O
is O O
suitable O O
for O O
toe O O
PIP O O
joint O O
grafts O O
, O O
together O O
with O O
concomitant O O
or O O
dorsal O O
cutaneous O O
vein O O
. O O

If O O
delay O O
has O O
occurred O O
between O O
centrifugation O O
and O O
the O O
measurement O O
, O O
causing O O
substantial O O
loss O O
of O O
CO0 O O
, O O
equilibration O O
of O O
the O O
sample O O
with O O
a O O
gas O O
mixture O O
corresponding O O
to O O
PCO0 O O
= O O
0 O O
. O O
0 O O
kPa O O
prior O O
to O O
the O O
measurement O O
is O O
recommended O O
. O O

Linear O O
regression O O
analysis O O
was O O
performed O O
and O O
the O O
following O O
result O O
was O O
obtained O O
: O O
clearance O O
( O O
HMPAO O O
) O O
= O O
0 O O
. O O
00 O O
+ O O
0 O O
. O O
00 O O
. O O
rCBF O O
with O O
a O O
high O O
significance O O
( O O
p O O
less O O
than O O
0 O O
. O O
000 O O
) O O
. O O

A O O
portion O O
of O O
Region O O
II O O
also O O
resembles O O
part O O
of O O
the O O
human O O
c B-GENE O
- I-GENE O
jun I-GENE O
oncoprotein O O
' O O
s O O
leucine O O
zipper O O
, O O
which O O
in O O
turn O O
, O O
has O O
been O O
demonstrated O O
to O O
be O O
the O O
heterodimerization O O
site O O
between O O
the O O
jun B-GENE O
and O O
fos B-GENE O
oncoproteins I-GENE O
. O O

At O O
temperatures O O
permissive O O
for O O
transformation O O
, O O
0m0 O O
cells O O
contain O O
P00gag B-GENE O
produced O O
from O O
the O O
0 O O
. O O
0 O O
- O O
kilobase O O
( O O
kb O O
) O O
viral O O
RNA O O
genome O O
and O O
P00gag B-GENE O
- O O
mos B-GENE O
translated O O
from O O
a O O
0 O O
. O O
0 O O
- O O
kb O O
spliced O O
mRNA O O
. O O

As O O
a O O
last O O
resort O O
, O O
it O O
may O O
be O O
possible O O
to O O
maintain O O
a O O
patient O O
on O O
dialysis O O
in O O
reasonable O O
health O O
with O O
a O O
DiaTAP O O
button O O
graft O O
complex O O
infected O O
with O O
Staphylococcus O O
epidermidis O O
and O O
intermittent O O
positive O O
blood O O
cultures O O
using O O
long O O
term O O
vancomycin O O
therapy O O
. O O

The O O
risk O O
for O O
these O O
complications O O
is O O
increased O O
by O O
the O O
following O O
factors O O
: O O
multiple O O
gestation O O
, O O
the O O
combination O O
of O O
magnesium O O
sulfate O O
and O O
beta O O
- O O
adrenergic O O
agonist O O
, O O
and O O
the O O
use O O
of O O
adrenocortico O O
- O O
steroids O O
to O O
hasten O O
fetal O O
pulmonary O O
maturity O O
. O O

At O O
Cabras O O
( O O
Oristano O O
) O O
, O O
a O O
town O O
characterized O O
by O O
a O O
high O O
incidence O O
of O O
thalassaemia O O
and O O
G0PD B-GENE O
deficiency O O
less O O
than O O
half O O
the O O
people O O
between O O
00 O O
and O O
00 O O
have O O
a O O
fair O O
knowledge O O
of O O
genetic O O
diseases O O
and O O
of O O
their O O
prevention O O
. O O

In O O
conclusion O O
, O O
these O O
studies O O
indicate O O
that O O
LiCl O B-GENE
( O O
0 O O
) O O
decreases O O
histamine O O
- O O
stimulated O O
gastric O O
acid O O
secretion O O
, O O
and O O
( O O
0 O O
) O O
diminishes O O
bile O O
- O O
induced O O
disruption O O
of O O
the O O
gastric O O
mucosal O O
barrier O O
in O O
the O O
canine O O
Heidenhain O O
pouch O O
. O O

Negatively O O
supercoiled O O
plasmid O O
pUC00 O O
did O O
not O O
compete O O
, O O
whereas O O
an O O
otherwise O O
identical O O
plasmid O O
pUC00 O O
( O O
CG O O
) O O
, O O
which O O
contained O O
a O O
( O O
dG O O
- O O
dC O O
) O O
0 O O
segment O O
in O O
the O O
Z O O
- O O
form O O
was O O
an O O
excellent O O
competitor O O
. O O

From O O
this O O
library O O
, O O
LEU0 B-GENE O
and O O
HIS0 B-GENE O
cDNAs O O
were O O
recovered O O
at O O
a O O
frequency O O
of O O
about O O
0 O O
in O O
00 O O
( O O
0 O O
) O O
and O O
in O O
00 O O
out O O
of O O
00 O O
cases O O
these O O
were O O
expressed O O
in O O
a O O
galactose O O
- O O
dependent O O
manner O O
. O O

Relatively O O
large O O
DNA O O
rearrangements O O
spanning O O
the O O
region O O
with O O
tandem O O
direct O O
repeats O O
encoding O O
the O O
carboxy O O
- O O
terminal O O
histone B-GENE O
H0 I-GENE O
- I-GENE O
like I-GENE O
structure O O
of O O
AlgP B-GENE O
were O O
detected O O
in O O
several O O
strains O O
upon O O
conversion O O
from O O
the O O
mucoid O O
to O O
the O O
nonmucoid O O
phenotype O O
. O O

The O O
cDNA O O
segment O O
is O O
flanked O O
by O O
the O O
immunoglobulin B-GENE B-GENE
gene I-GENE I-GENE
recombination I-GENE O
signal I-GENE O
sequences I-GENE O
so O O
that O O
the O O
cDNA O O
segment O O
can O O
invert O O
and O O
the O O
human B-GENE B-GENE
IL I-GENE I-GENE
- I-GENE I-GENE
0R I-GENE I-GENE
L I-GENE O
chain I-GENE O
is O O
subsequently O O
expressed O O
under O O
the O O
control O O
of O O
the O O
SV00 B-GENE B-GENE
promoter I-GENE I-GENE
. O O

However O O
, O O
primary O O
transcripts O O
of O O
a O O
variant B-GENE O
tRNA I-GENE O
( I-GENE O
Val I-GENE O
) I-GENE O
( I-GENE O
UAC I-GENE O
) I-GENE O
gene I-GENE O
are O O
processing O O
deficient O O
under O O
standard O O
growth O O
conditions O O
( O O
00 O O
degrees O O
C O O
) O O
, O O
due O O
to O O
a O O
slightly O O
altered O O
0 O O
' O O
flanking O O
region O O
. O O

Nonvascular O O
ophthalmic O O
and O O
neurologic O O
disorders O O
that O O
can O O
be O O
confused O O
with O O
amaurosis O O
fugax O O
are O O
listed O O
, O O
and O O
an O O
algorithm O O
for O O
evaluation O O
( O O
which O O
includes O O
ophthalmic O O
examination O O
, O O
laboratory O O
studies O O
, O O
and O O
noninvasive O O
carotid O O
artery O O
studies O O
) O O
is O O
given O O
. O O

A O O
0 O O
. O O
0 O O
rating O O
was O O
intended O O
to O O
characterize O O
subjects O O
in O O
whom O O
mild O O
cognitive O O
impairment O O
due O O
to O O
senile O O
dementia O O
of O O
the O O
Alzheimer O O
type O O
was O O
suspected O O
but O O
was O O
insufficient O O
in O O
degree O O
to O O
warrant O O
a O O
diagnosis O O
of O O
definite O O
dementia O O
. O O

Mo O O
+ O O
SV O O
M O O
- O O
MuLV O O
- O O
inoculated O O
animals O O
became O O
moribund O O
at O O
0 O O
to O O
00 O O
months O O
postinoculation O O
, O O
whereas O O
delta O O
Mo O O
+ O O
SV O O
M O O
- O O
MuLV O O
- O O
inoculated O O
animals O O
became O O
moribund O O
at O O
0 O O
to O O
00 O O
months O O
postinoculation O O
. O O

Its O O
predicted O O
amino O O
acid O O
sequence O O
shows O O
extensive O O
homology O O
to O O
those O O
of O O
Drosophila B-GENE O
hsp00 I-GENE O
, O O
trout B-GENE O
hsp00 I-GENE O
, O O
Xenopus B-GENE O
hsp00 I-GENE O
, O O
yeast B-GENE O
hsp00 I-GENE O
, O O
and O O
some O O
homology O O
to O O
the O O
heat B-GENE B-GENE
- I-GENE I-GENE
inducible I-GENE I-GENE
dnaK I-GENE I-GENE
gene I-GENE I-GENE
product I-GENE O
of O O
Escherichia O O
coli O O
. O O

Because O O
the O O
human B-GENE B-GENE
Antp I-GENE I-GENE
TATAA I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
is O O
expressed O O
in O O
both O O
lymphoid O O
and O O
non O O
- O O
lymphoid O O
cells O O
, O O
we O O
suggest O O
that O O
this O O
homeobox B-GENE B-GENE
gene I-GENE I-GENE
has O O
evolved O O
a O O
more O O
general O O
transcriptional O O
regulatory O O
function O O
in O O
higher O O
eukaryotic O O
cells O O
. O O

Testosterone O O
, O O
free O O
testosterone O O
, O O
non B-GENE O
- I-GENE O
sex I-GENE O
hormone I-GENE O
- I-GENE O
binding I-GENE O
globulin I-GENE O
- O O
bound O O
testosterone O O
, O O
and O O
free O O
androgen O O
index O O
: O O
which O O
testosterone O O
measurement O O
is O O
most O O
relevant O O
to O O
reproductive O O
and O O
sexual O O
function O O
in O O
men O O
with O O
epilepsy O O
? O O

Moreover O O
, O O
promoters O O
containing O O
a O O
TATA O O
box O O
in O O
the O O
absence O O
of O O
Sp0 B-GENE O
sites I-GENE O
or O O
Sp0 B-GENE O
sites I-GENE O
in O O
the O O
absence O O
of O O
a O O
TATA O O
box O O
were O O
equally O O
inducible O O
in O O
vitro O O
, O O
as O O
was O O
an O O
RNA B-GENE O
polymerase I-GENE O
III I-GENE O
promoter I-GENE O
. O O

The O O
muscles O O
from O O
the O O
ischemic O O
group O O
had O O
significantly O O
lower O O
( O O
P O O
less O O
than O O
. O O
00 O O
) O O
values O O
for O O
capillary O O
density O O
and O O
capillary O O
to O O
fiber O O
ratio O O
and O O
significantly O O
higher O O
intercapillary O O
distance O O
than O O
those O O
from O O
the O O
normal O O
group O O
. O O

Co O O
- O O
administration O O
of O O
0FU O O
, O O
angiotensin B-GENE O
II I-GENE O
and O O
microspheres O O
via O O
the O O
hepatic O O
artery O O
may O O
reduce O O
drug O O
exposure O O
in O O
the O O
systemic O O
compartment O O
and O O
therefore O O
may O O
increase O O
the O O
therapeutic O O
ratio O O
of O O
0FU O O
administration O O
via O O
the O O
hepatic O O
artery O O
. O O

RNA O O
blot O O
hybridizations O O
identified O O
an O O
0 O O
. O O
0 O O
- O O
kb O O
mRNA O O
common O O
to O O
cytochrome B-GENE O
b0 I-GENE O
and O O
subunit O O
IV O O
, O O
and O O
an O O
intensely O O
hybridizing O O
0 O O
. O O
0 O O
- O O
kb O O
mRNA O O
specific O O
to O O
the O O
subunit O O
IV O O
gene O O
probe O O
. O O

Which O O
cineangiographically O O
assessed O O
anatomic O O
variable O O
correlates O O
best O O
with O O
functional O O
measurements O O
of O O
stenosis O O
severity O O
? O O
A O O
comparison O O
of O O
quantitative O O
analysis O O
of O O
the O O
coronary O O
cineangiogram O O
with O O
measured O O
coronary O O
flow O O
reserve O O
and O O
exercise O O
/ O O
redistribution O O
thallium O O
- O O
000 O O
scintigraphy O O
. O O

Although O O
not O O
common O O
, O O
the O O
disorder O O
is O O
the O O
most O O
frequently O O
diagnosed O O
disturbance O O
of O O
porphyrin O O
metabolism O O
in O O
many O O
countries O O
, O O
and O O
further O O
insight O O
into O O
its O O
unusual O O
pathogenesis O O
may O O
clarify O O
the O O
hepatotoxic O O
effects O O
of O O
the O O
0 O O
etiologic O O
agents O O
. O O

Two O O
of O O
these O O
six O O
cases O O
showed O O
mucosal O O
spread O O
without O O
stromal O O
invasion O O
( O O
type O O
A O O
) O O
; O O
the O O
remaining O O
four O O
cases O O
presented O O
a O O
direct O O
extension O O
( O O
type O O
B O O
) O O
from O O
muscle O O
- O O
invasive O O
carcinomas O O
of O O
the O O
bladder O O
. O O

Such O O
studied O O
acquired O O
with O O
low O O
energy O O
or O O
medium O O
energy O O
collimation O O
and O O
a O O
window O O
centered O O
on O O
the O O
000 O O
keV O O
000I O O
photopeak O O
contain O O
appreciable O O
septal O O
breakthrough O O
signals O O
originating O O
from O O
Compton O O
scatter O O
of O O
high O O
energy O O
photons O O
primarily O O
from O O
000I O O
. O O

The O O
susceptibility O O
of O O
the O O
PPNG O O
strains O O
to O O
clinically O O
relevant O O
antibiotics O O
varied O O
with O O
the O O
plasmid O O
pattern O O
; O O
this O O
stresses O O
the O O
necessity O O
of O O
permanent O O
surveillance O O
of O O
gonococcal O O
infections O O
and O O
of O O
regular O O
evaluation O O
of O O
the O O
recommendations O O
for O O
antimicrobial O O
treatment O O
. O O

Resistance O O
to O O
the O O
simulated O O
physiologic O O
environment O O
was O O
tested O O
by O O
measured O O
retention O O
of O O
mechanical O O
properties O O
after O O
immersion O O
times O O
in O O
pseudo O O
- O O
extracellular O O
fluid O O
( O O
PECF O O
) O O
at O O
00 O O
degrees O O
C O O
for O O
as O O
long O O
as O O
three O O
years O O
. O O

One O O
- O O
third O O
of O O
the O O
men O O
with O O
azoospermia O O
and O O
with O O
sperm O O
density O O
of O O
less O O
than O O
00 O O
million O O
had O O
marked O O
FSH B-GENE O
elevation O O
and O O
our O O
experience O O
confirms O O
the O O
work O O
of O O
others O O
that O O
this O O
indicates O O
a O O
poor O O
prognosis O O
. O O

Control O O
Tmuscle O O
was O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
degrees O O
C O O
, O O
with O O
control O O
Wi O O
, O O
max O O
being O O
00 O O
. O O
0 O O
( O O
SD O O
0 O O
. O O
0 O O
) O O
W O O
. O O
kg O O
- O O
0 O O
. O O

Limits O O
of O O
energy O O
turnover O O
in O O
relation O O
to O O
physical O O
performance O O
were O O
addressed O O
in O O
terms O O
of O O
upper O O
and O O
lower O O
limit O O
, O O
changes O O
during O O
a O O
training O O
programme O O
and O O
how O O
to O O
regulate O O
energy O O
balance O O
at O O
a O O
changing O O
energy O O
turnover O O
. O O

The O O
N O O
- O O
terminal O O
000 O O
amino O O
acids O O
correspond O O
to O O
a O O
putative O O
DNA O O
- O O
binding O O
domain O O
and O O
show O O
significant O O
sequence O O
similarity O O
with O O
other O O
cloned O B-GENE
IFN B-GENE I-GENE
response I-GENE I-GENE
factors I-GENE I-GENE
( O O
IRF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
IRF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
. O O

A O O
contiguous O O
and O O
sequentially O O
occupied O O
secondary O O
Fur B-GENE O
- I-GENE O
binding I-GENE O
site I-GENE O
in O O
entC B-GENE O
was O O
protected O O
at O O
higher O O
Fur B-GENE O
concentrations O O
, O O
extending O O
the O O
protected O O
region O O
to O O
+ O O
00 O O
, O O
and O O
sequestering O O
the O O
putative O O
Shine O O
- O O
Dalgarno O O
sequence O O
. O O

In O O
transient O O
cotransfection O O
assays O O
using O O
Chang O O
liver O O
cells O O
( O O
CCL O O
00 O O
) O O
, O O
pM0 O O
DNA O O
exerts O O
a O O
0 O O
- O O
to O O
00 O O
- O O
fold O O
trans O O
- O O
activating O O
effect O O
on O O
the O O
expression O O
of O O
the O O
pSV0CAT O O
reporter O O
plasmid O O
. O O

The O O
Mauriceville O O
and O O
Varkud O O
mitochondrial O O
plasmids O O
are O O
closely O O
related O O
, O O
closed O O
- O O
circular O O
DNAs O O
( O O
0 O O
. O O
0 O O
and O O
0 O O
. O O
0 O O
kb O O
, O O
respectively O O
) O O
that O O
have O O
characteristics O O
of O O
mtDNA O O
introns O O
and O O
retroid O O
elements O O
. O O

The O O
circadian O O
rhythm O O
, O O
however O O
, O O
was O O
not O O
affected O O
and O O
the O O
difference O O
between O O
minimum O O
( O O
00 O O
. O O
00 O O
h O O
) O O
and O O
maximum O O
( O O
00 O O
. O O
00 O O
h O O
) O O
serum O O
concentrations O O
was O O
00 O O
. O O
0 O O
% O O
. O O

In O O
resting O O
0T0 O O
cells O O
, O O
jun B-GENE O
- I-GENE O
D I-GENE O
is O O
expressed O O
at O O
a O O
higher O O
level O O
compared O O
to O O
c B-GENE B-GENE
- I-GENE I-GENE
jun I-GENE I-GENE
and O O
jun B-GENE B-GENE
- I-GENE I-GENE
B I-GENE I-GENE
, O O
and O O
its O O
transcription O O
is O O
stimulated O O
only O O
slightly O O
by O O
serum O O
growth O O
factors O O
. O O

According O O
to O O
the O O
published O O
sequence O O
of O O
the O O
CHS0 B-GENE B-GENE
gene I-GENE I-GENE
, O O
this O O
fragment O O
contains O O
four O O
repeats O O
of O O
a O O
TGAAACA O O
consensus O O
sequence O O
previously O O
identified O O
in O O
the O O
alpha B-GENE B-GENE
- I-GENE I-GENE
factor I-GENE I-GENE
- O I-GENE
inducible O I-GENE
BAR0 B-GENE I-GENE
promoter I-GENE I-GENE
[ O O
Kronstad O O
, O O
J O O
. O O

A O O
000 O O
- O O
bp O O
sequence O O
of O O
the O O
0 O O
' O O
flanking O O
region O O
adjacent O O
to O O
the O O
cap O O
site O O
of O O
the O O
human B-GENE B-GENE
AFP I-GENE I-GENE
gene I-GENE I-GENE
shows O O
a O O
00 O O
% O O
similarity O O
with O O
the O O
corresponding O O
region O O
of O O
the O O
mouse B-GENE B-GENE
AFP I-GENE I-GENE
gene I-GENE I-GENE
. O O

A O O
raised O O
amplitude O O
of O O
the O O
aggregation O O
of O O
plates O O
and O O
a O O
decrease O O
in O O
the O O
threshold O O
of O O
their O O
sensitivity O O
to O O
ADP O O
were O O
established O O
in O O
the O O
persons O O
with O O
types O O
IIa O O
and O O
IIb O O
HLP O O
and O O
in O O
CHD O O
without O O
HLP O O
. O O

The O O
000 O O
kDa O O
precursor O O
is O O
converted O O
slowly O O
( O O
t O O
0 O O
/ O O
0 O O
= O O
0 O O
h O O
) O O
by O O
proteolytic O O
processing O O
into O O
a O O
000 O O
kDa O O
( O O
alpha O O
' O O
) O O
and O O
00 O O
kDa O O
( O O
beta O O
' O O
) O O
species O O
. O O

The O O
spermicide O O
nonoxynol O B-GENE
- O I-GENE
0 O I-GENE
is O O
a O O
member O O
of O O
a O O
homologous O O
series O O
of O O
alkylphenol O B-GENE
- O I-GENE
ethoxylates O I-GENE
( O O
polyethoxyethanols O O
) O O
of O O
general O O
formula O O
C0H00 O O
- O O
C0H0 O B-GENE
- O I-GENE
O O I-GENE
- O I-GENE
( O O
CH0CH0O O O
) O O
n O O
- O O
0 O O
CH0CH0OH O O
. O O

Significant O O
increases O O
in O O
mean O O
serum O O
E0 O O
concentration O O
( O O
000 O O
to O O
000 O O
pg O O
/ O O
ml O O
) O O
were O O
noted O O
at O O
0 O O
and O O
0 O O
hours O O
after O O
administration O O
on O O
day O O
0 O O
and O O
at O O
0 O O
hours O O
on O O
day O O
0 O O
. O O

The O O
recently O O
developed O O
gamma B-GENE O
- I-GENE O
interferon I-GENE O
( O O
IFN B-GENE O
- I-GENE O
gamma I-GENE O
) O O
assay O O
system O O
for O O
the O O
diagnosis O O
of O O
bovine O O
tuberculosis O O
in O O
cattle O O
has O O
been O O
accredited O O
by O O
the O O
Standing O O
Committee O O
on O O
Agriculture O O
for O O
use O O
in O O
Australia O O
. O O

These O O
results O O
support O O
the O O
diagnostic O O
validity O O
of O O
NFPD O O
in O O
CP O O
/ O O
NCA O O
patients O O
, O O
because O O
such O O
patients O O
had O O
a O O
family O O
history O O
of O O
panic O O
disorder O O
similar O O
to O O
patients O O
with O O
a O O
more O O
classical O O
panic O O
disorder O O
presentation O O
. O O

There O O
occurred O O
a O O
linear O O
relationship O O
between O O
the O O
drop O O
in O O
glucose B-GENE O
- I-GENE O
0 I-GENE O
- I-GENE O
phosphatase I-GENE O
dehydrogenase I-GENE O
activity O O
and O O
in O O
vitamin O O
E O O
level O O
, O O
on O O
one O O
hand O O
, O O
and O O
the O O
duration O O
of O O
poisoning O O
with O O
sodium O O
nitrite O O
. O O

The O O
currently O O
proposed O O
extended O O
arch O O
repair O O
should O O
be O O
reserved O O
for O O
the O O
small O O
group O O
of O O
infants O O
with O O
transverse O O
aortic O O
arch O O
to O O
ascending O O
aorta O O
diameter O O
ratios O O
( O O
arch O O
indices O O
) O O
of O O
less O O
than O O
0 O O
. O O
00 O O
. O O

We O O
report O O
two O O
patients O O
receiving O O
maintenance O O
valproate O O
, O O
one O O
with O O
resolving O O
acute O O
hepatitis O O
C O O
and O O
the O O
other O O
with O O
chronic O O
persistent O O
hepatitis O O
C O O
, O O
with O O
incidental O O
microvesicular O O
steatosis O O
demonstrated O O
on O O
oil O O
- O O
red O O
O O O
stains O O
. O O

In O O
this O O
article O O
we O O
propose O O
to O O
find O O
out O O
the O O
percentage O O
of O O
normal O O
occlusion O O
and O O
the O O
distribution O O
of O O
maloclusions O O
, O O
according O O
to O O
the O O
anteroposterior O O
relationship O O
between O O
the O O
dental O O
archs O O
( O O
following O O
the O O
ANGLE0 O O
classification O O
) O O
. O O

Both O O
strains O O
grew O O
very O O
poorly O O
, O O
or O O
not O O
at O O
all O O
, O O
on O O
nonfermentable O O
carbon O O
sources O O
and O O
exhibited O O
, O O
at O O
most O O
, O O
only O O
0 O O
% O O
of O O
wild B-GENE O
- I-GENE O
type I-GENE O
ubiquinol I-GENE O
- I-GENE O
cytochrome I-GENE O
c I-GENE O
oxidoreductase I-GENE O
activity O O
. O O

The O O
coding O O
sequences O O
of O O
the O O
Crry B-GENE B-GENE
gene I-GENE I-GENE
encompass O O
over O O
00 O O
kb O O
of O O
DNA O O
, O O
whereas O O
the O O
Crry B-GENE B-GENE
- O I-GENE
ps B-GENE I-GENE
sequences O O
are O O
included O O
within O O
a O O
single O O
0 B-GENE O
. I-GENE O
0 I-GENE O
- I-GENE O
kb I-GENE O
Eco I-GENE O
- I-GENE O
R0 I-GENE O
fragment I-GENE O
. O O

The O O
Nostoc O B-GENE
petBD B-GENE I-GENE
genes I-GENE I-GENE
are O O
not O O
closely O O
linked O O
to O O
the O O
psbB B-GENE B-GENE
gene I-GENE I-GENE
( O O
encoding O O
the O O
00 O O
- O O
kDa O O
photosystem B-GENE O
II I-GENE O
polypeptide I-GENE O
) O O
and O O
do O O
not O O
contain O O
introns O O
as O O
do O O
the O O
closely O O
related O O
chloroplast O O
genes O O
. O O

Two O O
polyadenylation O O
sites O O
were O O
used O O
, O O
one O O
at O O
the O O
end O O
of O O
the O O
early B-GENE O
( I-GENE O
E I-GENE O
) I-GENE O
region I-GENE O
of O O
the O O
viral O O
DNA O O
, O O
the O O
other O O
at O O
the O O
end O O
of O O
the O O
late B-GENE O
( I-GENE O
L I-GENE O
) I-GENE O
region I-GENE O
. O O

Diazepam O O
( O O
0 O O
mg O O
/ O O
kg O O
) O O
generalized O O
to O O
Ro O O
00 O O
- O O
0000 O O
whereas O O
the O O
structurally O O
related O O
Ro O O
0 O O
- O O
0000 O O
( O O
0 O O
mg O O
/ O O
kg O O
and O O
00 O O
mg O O
/ O O
kg O O
) O O
did O O
not O O
. O O

The O O
selenium O O
level O O
and O O
glutathione B-GENE O
peroxidase I-GENE O
activity O O
in O O
the O O
blood O O
, O O
liver O O
, O O
and O O
stomach O O
mucosa O O
were O O
significantly O O
higher O O
in O O
the O O
high O O
- O O
selenium O O
diet O O
group O O
than O O
in O O
the O O
low O O
- O O
selenium O O
diet O O
group O O
. O O

Entry O O
of O O
yeast O O
cells O O
into O O
the O O
mitotic O O
cell O O
cycle O O
( O O
Start O O
) O O
involves O O
a O O
form O O
of O O
the O O
CDC00 B-GENE B-GENE
kinase I-GENE I-GENE
that O O
associates O O
with O O
G0 O O
- O O
specific O O
cyclins B-GENE O
encoded O O
by O O
CLN0 B-GENE O
and O O
CLN0 B-GENE O
( O O
ref O O
. O O

The O O
sequence O O
data O O
now O O
permit O O
a O O
detailed O O
interpretation O O
of O O
the O O
X O O
- O O
ray O O
crystallographic O O
structure O O
of O O
the O O
enzyme O O
and O O
the O O
cloning O O
and O O
expression O O
of O O
the O O
clostridial O B-GENE
gene O I-GENE
will O O
facilitate O O
site O O
- O O
directed O O
mutagenesis O O
. O O

Stable O O
expression O O
of O O
the O O
chimeric O B-GENE
alpha B-GENE I-GENE
i I-GENE I-GENE
( I-GENE O
00 I-GENE O
) I-GENE O
/ I-GENE O
s I-GENE O
polypeptide O O
in O O
Chinese O O
hamster O O
ovary O O
( O O
CHO O O
) O O
cells O O
constitutively O O
increased O O
both O O
cAMP O O
synthesis O O
and O O
cAMP B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
activity O O
. O O

Although O O
the O O
N00 O O
- O O
N00 O O
interpeak O O
interval O O
remained O O
stable O O
because O O
of O O
the O O
parallel O O
shift O O
of O O
the O O
0 O O
peaks O O
, O O
the O O
central O O
conduction O O
time O O
measured O O
from O O
onset O O
latencies O O
of O O
N00 O O
and O O
N00 O O
significantly O O
increased O O
. O O

The O O
Thr000Val O O
mutation O O
causes O O
a O O
lethal O O
phenotype O O
in O O
the O O
fission O O
yeast O O
Schizosaccharomyces O O
pombe O O
, O O
while O O
replacement O O
of O O
Thr000 O O
with O O
glutamic O O
acid O O
, O O
potentially O O
mimicking O O
phosphorylation O O
, O O
causes O O
uncoordination O O
of O O
mitosis O O
and O O
multiple O O
cytokinesis O O
. O O

The O O
original O O
technique O O
was O O
developed O O
in O O
the O O
0000 O O
' O O
s O O
to O O
analyze O O
the O O
inner O O
ear O O
fluid O O
as O O
a O O
diagnostic O O
procedure O O
( O O
i O O
. O O
e O O
. O O
, O O
diagnostic O O
labyrinthotomy O O
) O O
in O O
acoustic O O
neuroma O O
suspects O O
. O O

Nodular O O
involvement O O
of O O
the O O
left O O
lung O O
and O O
infiltration O O
of O O
the O O
mucosa O O
of O O
the O O
left O O
lower O O
lobe O O
bronchus O O
followed O O
very O O
gradually O O
and O O
a O O
monoclonal O O
gammopathy O O
( O O
IgA B-GENE O
- I-GENE O
- I-GENE O
Type I-GENE O
Kappa I-GENE O
) O O
was O O
demonstrated O O
. O O

Kidney O O
weight O O
and O O
kidney O O
- O O
to O O
- O O
body O O
weight O O
ratio O O
were O O
significantly O O
elevated O O
at O O
the O O
highest O O
dose O O
level O O
after O O
00 O O
weeks O O
and O O
at O O
the O O
two O O
higher O O
dose O O
levels O O
after O O
00 O O
weeks O O
of O O
exposure O O
. O O

One O O
group O O
( O O
n O O
= O O
0 O O
) O O
was O O
premedicated O O
with O O
midazolam O O
, O O
0 O O
. O O
0 O O
mg O O
kg O O
- O O
0 O O
, O O
and O O
atropine O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
mg O O
i O O
. O O
m O O
. O O

The O O
distribution O O
phase O O
is O O
followed O O
by O O
an O O
elimination O O
phase O O
with O O
a O O
much O O
longer O O
half O O
- O O
life O O
( O O
mean O O
value O O
000 O O
min O O
) O O
and O O
a O O
volume O O
of O O
distribution O O
of O O
approximately O O
000 O O
- O O
000 O O
l O O
. O O

In O O
the O O
0 O O
patients O O
the O O
difference O O
betweent O O
he O O
mean O O
diastolic O O
values O O
of O O
delta O O
PU O O
and O O
delta O O
PM O O
was O O
- O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
( O O
SD O O
) O O
mmHg O O
. O O

It O O
was O O
concluded O O
that O O
both O O
of O O
these O O
surgical O O
procedures O O
were O O
as O O
effective O O
as O O
pinealectomy O O
in O O
reversing O O
the O O
pineal O O
- O O
induced O O
alterations O O
in O O
the O O
reproductive O O
physiology O O
of O O
the O O
blind O O
- O O
anosmic O O
female O O
rat O O
. O O

We O O
found O O
that O O
both O O
the O O
E00 O O
virus O O
- O O
encoded O O
v B-GENE O
- I-GENE O
ets I-GENE O
and O O
the O O
myeloid B-GENE B-GENE
/ I-GENE O
B I-GENE B-GENE
- I-GENE I-GENE
cell I-GENE I-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
factor I-GENE I-GENE
PU I-GENE I-GENE
. I-GENE O
0 I-GENE O
bind O O
efficiently O O
to O O
this O O
site O O
in O O
vitro O O
. O O

The O O
gene O O
is O O
0 O O
, O O
000 O O
base O O
pairs O O
( O O
bp O O
) O O
long O O
, O O
and O O
, O O
like O O
other O O
members O O
of O O
the O O
SIG B-GENE O
family I-GENE O
, O O
the O O
beta B-GENE B-GENE
TG I-GENE I-GENE
gene I-GENE I-GENE
is O O
divided O O
into O O
0 O O
exons O O
. O O

The O O
first O O
follow O O
- O O
up O O
was O O
at O O
a O O
nearly O O
constant O O
interval O O
of O O
0 O O
. O O
0 O O
years O O
in O O
Caerphilly O O
and O O
0 O O
. O O
0 O O
years O O
in O O
Speedwell O O
; O O
000 O O
major O O
IHD O O
events O O
had O O
occurred O O
. O O

A O O
gene O O
in O O
Drosophila O O
melanogaster O O
that O O
maps O O
cytologically O O
to O O
0C0 O B-GENE
- O I-GENE
0 O I-GENE
on O O
the O O
distal O O
portion O O
of O O
the O O
X O B-GENE
- O I-GENE
chromosome O I-GENE
encodes O O
a O O
member O O
of O O
the O O
steroid B-GENE B-GENE
/ I-GENE I-GENE
thyroid I-GENE I-GENE
hormone I-GENE I-GENE
receptor I-GENE I-GENE
superfamily I-GENE O
. O O

Significant O O
correlations O O
were O O
obtained O O
between O O
changes O O
in O O
SSEP O O
in O O
response O O
to O O
AS O O
and O O
the O O
presence O O
of O O
not O O
deep O O
residual O O
- O O
organic O O
disturbances O O
, O O
so O O
- O O
called O O
" O O
ground O O
" O O
in O O
psychogenic O O
disorders O O
. O O

An O O
implant O O
may O O
release O O
a O O
drug O O
either O O
by O O
diffusion O O
concurrent O O
with O O
dissolution O O
of O O
the O O
polymeric O O
implant O O
material O O
without O O
depolymerization O O
( O O
Type O O
A O O
) O O
or O O
by O O
bioerosion O O
involving O O
depolymerization O O
( O O
Type O O
B O O
) O O
. O O

Liquid O O
chromatography O O
with O O
amperometric O O
detection O O
( O O
LC O O
/ O O
AD O O
) O O
is O O
used O O
to O O
determine O O
fluazifop O O
acid O O
produced O O
from O O
the O O
metabolism O O
or O O
base O O
hydrolysis O O
of O O
fluazifop O O
- O O
butyl O O
in O O
soybeans O O
and O O
soybean O O
oil O O
. O O

In O O
Experiment O O
0 O O
, O O
we O O
again O O
used O O
classification O O
, O O
but O O
the O O
fixed O O
standard O O
00 O O
was O O
not O O
at O O
the O O
center O O
of O O
the O O
range O O
of O O
target O O
numbers O O
( O O
00 O O
, O O
00 O O
, O O
. O O
. O O
. O O

The O O
biosynthesis O O
and O O
stability O O
of O O
the O O
three O O
mutant O O
proteins O O
were O O
similar O O
to O O
those O O
of O O
the O O
wild B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
erbB I-GENE I-GENE
protein I-GENE I-GENE
, O O
and O O
all O O
three O O
retained O O
the O O
ability O O
to O O
transform O O
chicken O O
embryo O O
fibroblasts O O
. O O

The O O
seco O B-GENE
- O I-GENE
steroid O I-GENE
hormone O I-GENE
0 O I-GENE
, O O
00 O O
- O O
dihydroxyvitamin O O
D0 O O
is O O
known O O
to O O
induce O O
the O O
expression O O
of O O
a O O
calcium O O
binding O O
protein O O
termed O O
calbindin B-GENE O
- I-GENE O
D00K I-GENE O
in O O
a O O
variety O O
of O O
target O O
tissues O O
. O O

Mature O O
mRNA O O
for O O
cytosolic B-GENE O
phosphoenolpyruvate I-GENE O
carboxykinase I-GENE O
of I-GENE O
the I-GENE O
chicken I-GENE O
is O O
0 O O
. O O
0 O O
kilobases O O
in O O
length O O
, O O
similar O O
to O O
that O O
previously O O
noted O O
for O O
mRNA O O
coding O O
for O O
the O O
same O O
enzyme O O
in O O
the O O
rat O O
. O O

This O O
generally O O
means O O
an O O
energy O O
intake O O
of O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
times O O
the O O
energy O O
expenditure O O
, O O
with O O
a O O
N O O
intake O O
of O O
000 O O
to O O
000 O O
mg O O
/ O O
kg O O
/ O O
day O O
. O O

The O O
responsiveness O O
of O O
visual O O
cortex O O
( O O
VC O O
) O O
and O O
superior O O
colliculus O O
( O O
SC O O
) O O
was O O
simultaneously O O
compared O O
following O O
conditioning O O
" O O
ON O O
" O O
or O O
" O O
OFF O O
" O O
stimulation O O
, O O
in O O
the O O
rabbit O O
. O O

It O O
was O O
concluded O O
that O O
patients O O
with O O
acute O O
respiratory O O
failure O O
requiring O O
artificial O O
ventilation O O
have O O
two O O
componenents O O
of O O
the O O
pulmonary O O
shunt O O
, O O
one O O
parallel O O
with O O
and O O
the O O
other O O
inversely O O
related O O
with O O
the O O
PAO0 O O
. O O

Since O O
0000 O O
, O O
a O O
steep O O
decrease O O
in O O
the O O
number O O
of O O
strains O O
resistant O O
to O O
three O O
or O O
more O O
antibiotics O O
( O O
multiple O O
- O O
resistant O O
) O O
and O O
in O O
strains O O
of O O
the O O
00A O O
complex O O
was O O
noticed O O
. O O

The O O
- O O
00 O O
/ O O
- O O
00 O O
region O O
interacted O O
with O O
purified O O
Sp0 B-GENE O
and O O
an O O
unidentified O O
protein O O
( O O
s O O
) O O
, O O
proximal B-GENE O
regulatory I-GENE O
factor I-GENE O
( I-GENE O
s I-GENE O
) I-GENE O
I I-GENE O
( O O
PRF B-GENE O
- I-GENE O
I I-GENE O
) O O
. O O

Comparable O O
amounts O O
of O O
alpha B-GENE B-GENE
0 I-GENE I-GENE
beta I-GENE I-GENE
0 I-GENE I-GENE
integrin I-GENE I-GENE
were O O
isolated O O
from O O
these O O
cells O O
by O O
chromatography O O
of O O
detergent O O
extracts O O
on O O
a O O
fibronectin B-GENE O
cell O O
- O O
binding O O
fragment O O
affinity O O
column O O
and O O
elution O O
with O O
EDTA O O
. O O

Thus O O
, O O
the O O
positive O O
effect O O
of O O
NS0 B-GENE O
on O O
the O O
steady O O
- O O
state O O
levels O O
of O O
P0 B-GENE O
transcripts I-GENE O
depends O O
on O O
the O O
amplification O O
of O O
gene O O
copy O O
number O O
and O O
the O O
integrity O O
of O O
the O O
terminal O O
repeats O O
. O O

Once O O
the O O
proliferation O O
of O O
fibroblasts O O
and O O
collagen B-GENE O
synthesis O O
had O O
led O O
to O O
an O O
increase O O
of O O
mechanical O O
strength O O
, O O
no O O
negative O O
effect O O
on O O
wound O O
healing O O
could O O
be O O
detected O O
applying O O
the O O
same O O
chemotherapeutic O O
agents O O
. O O

In O O
Denmark O O
only O O
0 O O
- O O
0 O O
cases O O
of O O
transfusion O O
- O O
associated O O
hepatitis O O
NANB O O
( O O
TAH O O
- O O
NANB O O
) O O
are O O
registered O O
annually O O
or O O
about O O
0 O O
case O O
per O O
000 O O
, O O
000 O O
units O O
transfused O O
. O O

The O O
protein O O
product O O
of O O
orfD B-GENE O
, O O
which O O
is O O
probably O O
a O O
new O O
tra B-GENE O
gene I-GENE O
( O O
named O O
traX B-GENE O
) O O
, O O
contains O O
00 O O
% O O
hydrophobic O O
amino O O
acids O O
, O O
especially O O
rich O O
in O O
alanine O O
and O O
leucine O O
. O O

The O O
effects O O
on O O
reflex O O
latencies O O
but O O
not O O
on O O
paCO0 O O
or O O
pHa O O
were O O
blocked O O
by O O
naloxone O O
( O O
0 O O
mg O O
/ O O
kg O O
) O O
, O O
and O O
were O O
not O O
present O O
in O O
morphine O O
- O O
tolerant O O
animals O O
. O O

Lithium O O
delays O O
the O O
circadian O O
rhythm O O
of O O
wheel O O
- O O
running O O
in O O
Syrian O O
hamsters O O
at O O
plasma O O
concentrations O O
( O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
mM O O
) O O
that O O
also O O
cause O O
toxic O O
weight O O
loss O O
. O O

The O O
predicted O O
L B-GENE O
mRNA I-GENE O
was O O
0000 O O
nucleotides O O
long O O
and O O
contained O O
a O O
single O O
open O O
reading O O
frame O O
corresponding O O
to O O
an O O
L B-GENE O
protein I-GENE O
encompassing I-GENE O
0000 I-GENE O
amino I-GENE O
acids I-GENE O
with O O
a O O
MW O O
of O O
000 O O
, O O
000 O O
. O O

We O O
propose O O
that O O
the O O
technique O O
of O O
low O O
- O O
frequency O O
kindling O O
is O O
a O O
useful O O
experimental O O
model O O
in O O
assessing O O
the O O
effects O O
of O O
antipsychotic O O
or O O
antiepileptic O O
drugs O O
on O O
the O O
excitability O O
of O O
the O O
limbic O O
regions O O
. O O

Functional O O
flow O O
was O O
evaluated O O
using O O
laser O O
Doppler O O
flowmetry O O
( O O
LDF O O
) O O
, O O
for O O
which O O
the O O
output O O
signal O O
, O O
blood O O
cell O O
flux O O
( O O
BCF O O
) O O
, O O
is O O
expressed O O
in O O
terms O O
of O O
volts O O
. O O

PATIENTS O O
and O O
METHODS O O
: O O
Thallium O O
- O O
000 O O
myocardial O O
scintigraphy O O
was O O
performed O O
at O O
rest O O
and O O
after O O
0 O O
. O O
00 O O
mg O O
/ O O
kg O O
intravenous O O
dipyridamole O O
during O O
four O O
minutes O O
in O O
00 O O
patients O O
with O O
sarcoidosis O O
. O O

The O O
average O O
deviations O O
in O O
the O O
X O O
- O O
ray O O
counts O O
of O O
the O O
constant O O
elements O O
from O O
the O O
series O O
means O O
were O O
used O O
to O O
correct O O
the O O
recorded O O
count O O
of O O
the O O
variable O O
element O O
in O O
each O O
block O O
. O O

The O O
fast O O
real O O
- O O
time O O
digital O O
processing O O
of O O
the O O
N0 O O
and O O
flow O O
signals O O
incorporated O O
filtering O O
, O O
delay O O
compensation O O
, O O
and O O
corrections O O
for O O
the O O
effects O O
of O O
changes O O
in O O
gas O O
composition O O
and O O
temperature O O
. O O

The O O
customary O O
coupling O O
reagent O O
sulfanilic O O
acid O O
has O O
been O O
replaced O O
by O O
0 O O
, O O
0 O O
- O O
dimethylbarbituric O O
acid O O
; O O
CNCl O O
is O O
produced O O
in O O
the O O
flow O O
through O O
system O O
directly O O
from O O
KCN O O
and O O
chloramine O O
T O O
. O O

Among O O
six O O
different O O
library O O
isolates O O
containing O O
0 B-GENE O
. I-GENE O
0 I-GENE O
- I-GENE O
to I-GENE O
0 I-GENE O
- I-GENE O
kb I-GENE O
IAP I-GENE O
units I-GENE O
, O O
some O O
restriction O O
sites O O
were O O
highly O O
conserved O O
whereas O O
others O O
varied O O
in O O
both O O
occurrence O O
and O O
position O O
. O O

The O O
present O O
paper O O
elucidates O O
the O O
existing O O
discrepancies O O
, O O
and O O
offers O O
a O O
consistent O O
terminology O O
incorporating O O
also O O
such O O
terms O O
as O O
" O O
additivity O O
" O O
, O O
" O O
potentiation O O
" O O
, O O
and O O
" O O
simple O O
similarity O O
" O O
. O O

A O O
00 O O
year O O
- O O
old O O
woman O O
was O O
given O O
Ergotamine O O
Tartrate O O
0 O O
. O O
0 O O
mg O O
p O O
. O O
d O O
. O O
during O O
seven O O
days O O
, O O
after O O
an O O
abortion O O
( O O
a O O
still O O
birth O O
) O O
. O O

Infants O O
who O O
died O O
in O O
the O O
first O O
00 O O
hours O O
from O O
' O O
IVH O O
only O O
' O O
had O O
suffered O O
severe O O
birth O O
asphyxia O O
but O O
in O O
those O O
who O O
died O O
later O O
the O O
main O O
symptom O O
was O O
recurrent O O
apnoea O O
. O O

Nerve O O
stimulation O O
( O O
0 O O
. O O
0 O O
- O O
00 O O
cycles O O
/ O O
s O O
) O O
produced O O
frequency O O
- O O
dependent O O
reductions O O
in O O
CBF O O
, O O
a O O
decrease O O
of O O
00 O O
percent O O
occurring O O
with O O
the O O
highest O O
frequency O O
. O O

The O O
second O O
method O O
, O O
the O O
" O O
macro O O
" O O
assay O O
, O O
has O O
a O O
sensitivity O O
range O O
of O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
0 O O
micrograms O O
phosphorus O O
with O O
000 O O
- O O
000 O O
microliters O O
HClO0 O O
. O O

ME0a0 B-GENE O
, O O
a O O
00 O O
- O O
base O O
- O O
pair O O
nuclear O O
factor O O
binding O O
site O O
residing O O
between O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
MYC I-GENE I-GENE
P0 I-GENE I-GENE
and I-GENE O
P0 I-GENE O
transcription I-GENE O
initiation I-GENE O
sites I-GENE O
, O O
is O O
required O O
for O O
P0 O O
activity O O
. O O

A O O
control O O
group O O
of O O
nine O O
women O O
( O O
age O O
00 O O
- O O
00 O O
years O O
) O O
on O O
oral O O
contraceptives O O
( O O
Nordette O O
- O O
00 O O
) O O
was O O
also O O
studied O O
four O O
times O O
during O O
a O O
pill O O
cycle O O
. O O

It O O
is O O
, O O
however O O
, O O
extremely O O
homologous O O
to O O
a O O
third O O
' O O
non O O
- O O
classical O O
' O O
gene O O
, O O
HLA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. I-GENE O
0 I-GENE O
, O O
and O O
to O O
the O O
chimpanzee O O
gene O O
, O O
Ch00 B-GENE O
. O O

The O O
above O O
results O O
mean O O
that O O
the O O
increase O O
in O O
alpha B-GENE O
- I-GENE O
adrenergic I-GENE O
receptors I-GENE O
makes O O
the O O
prostate O O
, O O
which O O
has O O
been O O
already O O
hypertrophied O O
, O O
less O O
elastic O O
, O O
inhibiting O O
external O O
urinary O O
sphincter O O
function O O
. O O

A O O
mouse B-GENE O
brain I-GENE O
beta I-GENE O
- I-GENE O
spectrin I-GENE O
of O O
cDNA O O
was O O
identified O O
within O O
a O O
lambda O O
Gt00 O O
expression O O
library O O
using O O
an O O
antibody O O
which O O
specifically O O
binds O O
with O O
the O O
000 B-GENE O
kDa I-GENE O
spectrin I-GENE O
beta I-GENE O
- I-GENE O
subunit I-GENE O
. O O

Marked O O
thrombocytopenia O O
, O O
depletion O O
of O O
serum B-GENE O
fibrinogen I-GENE O
and O O
prolonged O O
prothrombin B-GENE O
and O O
activated O O
partial O O
thromboplastin B-GENE O
time O O
, O O
were O O
recorded O O
at O O
0 O O
to O O
00 O O
and O O
00 O O
to O O
00 O O
minutes O O
after O O
intravenous O O
envenomation O O
. O O

Auditory O O
threshold O O
shifts O O
, O O
as O O
measured O O
by O O
the O O
auditory O O
evoked O O
brainstem O O
response O O
, O O
were O O
measured O O
at O O
0 O O
, O O
0 O O
, O O
0 O O
, O O
00 O O
, O O
00 O O
, O O
00 O O
and O O
00 O O
kHz O O
. O O

A O O
deletion O O
series O O
of O O
the O O
0 O O
' O O
flanking O O
region O O
was O O
created O O
from O O
position O O
- O O
0000 O O
to O O
- O O
00 O O
relative O O
to O O
the O O
transcriptional O O
initiation O O
site O O
and O O
similarly O O
examined O O
in O O
transgenic O O
tobacco O O
. O O

Further O O
, O O
they O O
are O O
consistent O O
with O O
the O O
suggestion O O
that O O
sites O O
homologous O O
to O O
the O O
CAR0 B-GENE O
URS I-GENE O
may O O
be O O
situated O O
in O O
the O O
0 O O
' O O
- O O
flanking O O
regions O O
of O O
multiple O O
unrelated O O
yeast O O
genes O O
. O O

Hence O O
, O O
the O O
replacement O O
of O O
Phe O O
- O O
00 O O
with O O
Ser O O
specifically O O
affects O O
a O O
determinant O O
on O O
the O O
lambda B-GENE O
I I-GENE O
light I-GENE O
chain I-GENE O
that O O
is O O
necessary O O
for O O
the O O
intracellular O O
transport O O
of O O
this O O
molecule O O
. O O

PAO O O
blocks O O
turnover O O
of O O
the O O
phosphoryl O O
group O O
of O O
pp00 B-GENE O
, O O
causing O O
its O O
accumulation O O
, O O
and O O
thereby O O
appears O O
to O O
interrupt O O
signal O O
transmission O O
from O O
the O O
receptor O O
to O O
the O O
glucose O O
- O O
transport O O
system O O
. O O

These O O
results O O
support O O
the O O
view O O
that O O
clonidine O O
and O O
0 O O
- O O
OHDA O O
, O O
but O O
not O O
alpha O O
- O O
MD O O
, O O
have O O
central O O
pressor O O
actions O O
in O O
the O O
rat O O
that O O
oppose O O
their O O
antihypertensive O O
action O O
. O O

In O O
00 O O
% O O
of O O
00 O O
lead O O
- O O
toxic O O
children O O
, O O
bone O O
lead O O
values O O
measured O O
by O O
LXRF O O
were O O
equal O O
to O O
or O O
greater O O
than O O
those O O
measured O O
in O O
normal O O
and O O
industrially O O
exposed O O
adults O O
. O O

These O O
data O O
locate O O
the O O
aniridia B-GENE B-GENE
gene I-GENE I-GENE
( O O
AN0 B-GENE B-GENE
) O O
and O O
a O O
recurrent O O
T B-GENE O
- I-GENE O
cell I-GENE O
leukemia I-GENE O
breakpoint I-GENE O
( O O
TCL0 B-GENE O
) O O
in O O
the O O
marker O O
sequence O O
, O O
on O O
opposite O O
sides O O
of O O
MIC0 B-GENE O
. O O

Thus O O
, O O
multiple O O
myogenic O O
factors O O
that O O
vary O O
qualitatively O O
and O O
quantitatively O O
may O O
be O O
responsible O O
for O O
the O O
different O O
and O O
complex O O
modulatory O O
programs O O
of O O
actin B-GENE B-GENE
gene I-GENE I-GENE
expression O O
observed O O
during O O
in O O
vivo O O
muscle O O
differentiation O O
. O O

A O O
family O O
of O O
RNA O O
molecules O O
in O O
the O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
- O O
kilobase O O
range O O
identified O O
with O O
a O O
probe O O
from O O
this O O
gene O O
was O O
overexpressed O O
in O O
the O O
resistant O O
cells O O
. O O

The O O
development O O
and O O
distribution O O
of O O
Trypanosoma O O
congolense O O
, O O
T O O
vivax O O
and O O
T O O
brucei O O
in O O
the O O
skin O O
of O O
goats O O
was O O
examined O O
after O O
the O O
animals O O
were O O
bitten O O
by O O
infected O O
Glossina O O
morsitans O O
centralis O O
. O O

These O O
data O O
should O O
be O O
useful O O
in O O
developing O O
reagents O O
for O O
heterozygote O O
detection O O
and O O
prenatal O O
diagnosis O O
of O O
00 B-GENE O
beta I-GENE O
- I-GENE O
hydroxylase I-GENE O
deficiency O O
, O O
the O O
second O O
most O O
frequent O O
cause O O
of O O
congenital O O
adrenal O O
hyperplasia O O
. O O

Tissue O O
pressure O O
, O O
rCBF O O
, O O
and O O
water O O
content O O
were O O
measured O O
from O O
gray O O
matter O O
in O O
the O O
central O O
core O O
and O O
the O O
peripheral O O
margin O O
of O O
the O O
MCA O O
territory O O
over O O
0 O O
h O O
after O O
MCAO O O
. O O

Value O O
of O O
the O O
method O O
of O O
passive O O
hemagglutination O O
with O O
polysaccharide O O
C O O
in O O
detecting O O
C B-GENE B-GENE
- I-GENE I-GENE
reactive I-GENE I-GENE
protein I-GENE I-GENE
as O O
compared O O
to O O
precipitation O O
in O O
capillaries O O
and O O
slide O O
latex O O
test O O
with O O
anti B-GENE B-GENE
- I-GENE I-GENE
CRP I-GENE I-GENE
serum O I-GENE

Eight O O
recombinant O O
DNA O O
clones O O
of O O
endogenous O O
murine O O
leukemia O O
virus O O
( O O
MuLV O O
) O O
- O O
related O O
DNA O O
sequences O O
have O O
been O O
isolated O O
from O O
a O O
lambdaphage O O
genomic O O
library O O
of O O
Balb O B-GENE
/ O O
c O O
mouse O O
DNA O O
. O O

While O O
these O O
findings O O
may O O
reflect O O
the O O
sensitivity O O
of O O
a O O
thick O O
myocardial O O
wall O O
to O O
ischaemia O O
during O O
surgery O O
, O O
the O O
postoperative O O
recovery O O
was O O
not O O
related O O
to O O
the O O
serum B-GENE O
CK I-GENE O
- I-GENE O
MB I-GENE O
level O O
. O O

In O O
contrast O O
, O O
gel O O
mobility O O
shift O O
experiments O O
have O O
failed O O
to O O
reveal O O
that O O
HAP0 B-GENE O
or O O
HAP0 B-GENE O
binds O O
to O O
domain O O
0 O O
or O O
that O O
hap0 B-GENE O
mutations O O
affect O O
the O O
complexes O O
bound O O
to O O
it O O
. O O

Fructokinase B-GENE O
activity O O
is O O
elevated O O
up O O
to O O
twofold O O
when O O
Z O O
. O O
mobilis O O
was O O
grown O O
on O O
fructose O O
instead O O
of O O
glucose O O
, O O
and O O
there O O
was O O
a O O
parallel O O
increase O O
in O O
frk B-GENE O
mRNA I-GENE O
levels O O
. O O

We O O
obtained O O
quantitative O O
evidence O O
on O O
the O O
coding O O
of O O
interaural O O
time O O
differences O O
( O O
ITDs O O
) O O
of O O
click O O
stimuli O O
by O O
00 O O
single O O
neurons O O
in O O
the O O
auditory O O
cortex O O
of O O
anesthetized O O
albino O O
rats O O
. O O

In O O
all O O
instances O O
the O O
apparent O O
alcohol O O
responses O O
were O O
very O O
small O O
and O O
never O O
exceeded O O
a O O
reading O O
of O O
0 O O
microgram O O
/ O O
000ml O O
for O O
breath O O
samples O O
more O O
than O O
00min O O
post O O
- O O
exposure O O
. O O

Although O O
there O O
are O O
no O O
octamer O O
elements O O
in O O
the O O
adenovirus O O
genome O O
that O O
are O O
known O O
to O O
be O O
important O O
for O O
transcription O O
, O O
there O O
are O O
octamer O O
elements O O
in O O
the O O
viral O O
terminal O O
repeat O O
sequences O O
. O O

Using O O
appropriate O O
synthetic O O
HSE O O
oligonucleotides O O
, O O
three O O
types O O
of O O
clones O O
with O O
potential O O
HSE O O
binding O O
domains O O
were O O
isolated O O
from O O
a O O
tomato O O
lambda O O
gt00 O O
expression O O
library O O
by O O
DNA O O
- O O
ligand O O
screening O O
. O O

Patients O O
with O O
detectable O O
serum O O
TNF B-GENE O
levels O O
had O O
significantly O O
lower O O
serum O O
T0 O O
concentrations O O
compared O O
to O O
those O O
with O O
undetectable O O
levels O O
[ O O
0 O O
. O O
000 O O
+ O O
/ O O
- O O
0 O O
. O O
000 O O
vs O O
. O O

Taste O O
reactivity O O
tests O O
were O O
used O O
to O O
examine O O
the O O
orofacial O O
responses O O
of O O
alcohol O O
preferring O O
( O O
P O O
) O O
rats O O
and O O
alcohol O O
nonpreferring O O
( O O
NP O O
) O O
rats O O
to O O
the O O
taste O O
of O O
alcohol O O
. O O

Accumulations O O
of O O
Tl O O
+ O O
0 O O
( O O
000Tl O O
label O O
) O O
were O O
0 O O
times O O
those O O
for O O
Ga O O
or O O
In O O
in O O
the O O
brain O O
and O O
muscles O O
, O O
and O O
. O O
0 O O
times O O
in O O
plasma O O
. O O

We O O
have O O
therefore O O
evaluated O O
the O O
efficacy O O
and O O
safety O O
of O O
doxazosin O O
, O O
a O O
new O O
orally O O
active O O
selective O B-GENE
alpha B-GENE I-GENE
0 I-GENE I-GENE
blocker O I-GENE
, O O
in O O
patients O O
with O O
systemic O O
hypertension O O
with O O
concomitant O O
airflow O O
limitation O O
. O O

The O O
differential O O
diagnosis O O
of O O
both O O
affections O O
is O O
based O O
on O O
the O O
clinical O O
course O O
, O O
sialography O O
and O O
CT O O
examination O O
which O O
along O O
with O O
modern O O
ATB O O
treatment O O
significantly O O
modify O O
hitherto O O
used O O
surgical O O
therapy O O
. O O

The O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
( I-GENE O
EGF I-GENE B-GENE
) I-GENE I-GENE
receptor I-GENE I-GENE
, O O
which O O
exhibits O B-GENE
intrinsic O I-GENE
protein B-GENE I-GENE
tyrosine I-GENE I-GENE
kinase I-GENE I-GENE
activity O O
, O O
undergoes O O
a O O
rapid O O
, O O
intramolecular O O
self O O
- O O
phosphorylation O O
reaction O O
following O O
EGF B-GENE O
activation O O
. O O

The O O
0 O O
degrees O O
stimuli O O
were O O
found O O
to O O
elicit O O
scalp O O
distributions O O
for O O
the O O
pattern O O
reversal O O
P000 O O
and O O
the O O
pattern O O
onset O O
C0 O O
consistent O O
with O O
striate O O
and O O
extrastriate O O
visual O O
cortical O O
origins O O
respectively O O
. O O

In O O
addition O O
, O O
marked O O
hypertension O O
accompanied O O
this O O
disorder O O
and O O
all O O
abnormalities O O
, O O
including O O
the O O
hypertension O O
, O O
responded O O
to O O
0 B-GENE O
- I-GENE O
desamino I-GENE O
- I-GENE O
0 I-GENE O
- I-GENE O
D I-GENE O
- I-GENE O
arginine I-GENE O
vasopressin I-GENE O
therapy O O
. O O

In O O
00 O O
patients O O
vagotomy O O
not O O
only O O
curbed O O
the O O
bleeding O O
but O O
provided O O
definitive O O
therapy O O
( O O
Visick O O
I O O
- O O
II O O
) O O
; O O
0 O O
patients O O
died O O
( O O
mortality O O
rate O O
00 O O
% O O
) O O
. O O

We O O
have O O
investigated O O
the O O
requirements O O
of O O
the O O
CH B-GENE B-GENE
gene I-GENE I-GENE
switch O O
by O O
characterizing O O
two O O
rearranged B-GENE O
gamma I-GENE O
0b I-GENE O
genes I-GENE O
from O O
a O O
gamma B-GENE O
0b I-GENE O
producing O O
mouse O O
myeloma O O
( O O
MPC O O
- O O
00 O O
) O O
. O O

Bepridil O O
, O O
a O O
calcium O O
antagonist O O
with O O
a O O
half O O
- O O
life O O
of O O
approximately O O
00 O O
hours O O
, O O
was O O
compared O O
with O O
placebo O O
in O O
a O O
double O O
- O O
blind O O
, O O
randomized O O
, O O
crossover O O
trial O O
. O O

Hydrocortisone O O
seems O O
to O O
be O O
unable O O
to O O
hinder O O
the O O
postdenervation O O
changes O O
in O O
the O O
muscle O O
membrane O O
whereas O O
high O O
doses O O
of O O
the O O
hormone O O
are O O
able O O
to O O
induce O O
changes O O
in O O
the O O
muscle O O
membrane O O
. O O

Two O O
splice O O
variants O O
of O O
ALF0 B-GENE O
cDNA I-GENE O
have O O
been O O
found O O
, O O
differing O O
by O O
a O O
00 O O
- O O
bp O O
insertion O O
, O O
coding O O
for O O
putative O O
proteins O O
of O O
000 O O
and O O
000 O O
amino O O
acids O O
. O O

Also O O
, O O
the O O
human B-GENE B-GENE
glycoprotein I-GENE I-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
subunit I-GENE I-GENE
promoter I-GENE I-GENE
was O O
induced O O
00 O O
- O O
fold O O
by O O
FSK B-GENE O
in O O
GH0 O O
rat O O
pituitary O O
cells O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

Anti B-GENE O
- I-GENE O
CRK I-GENE O
antibodies I-GENE O
detect O O
a O O
00kDa O O
protein O O
in O O
extracts O O
of O O
C O O
. O O
fasciculata O O
in O O
agreement O O
with O O
the O O
size O O
predicted O O
from O O
the O O
nucleotide O O
sequence O O
of O O
the O O
cloned O B-GENE
gene O I-GENE
. O O

These O O
characteristics O O
of O O
N00 O B-GENE
/ O O
P00 O O
indicate O O
that O O
it O O
is O O
a O O
localized O O
synaptically O O
dependent O O
event O O
conforming O O
to O O
a O O
transverse O O
dipole O O
with O O
dorsal O O
negativity O O
and O O
a O O
simultaneous O O
anterior O O
positivity O O
. O O

The O O
ORF0 O B-GENE
product O I-GENE
was O O
required O O
for O O
competence O O
, O O
while O O
ORF0 O O
, O O
which O O
was O O
cotranscribed O O
with O O
ORF0 O O
and O O
encoded O O
a O O
predicted O O
protein O O
of O O
000 O O
amino O O
acids O O
, O O
was O O
not O O
. O O

Recently O O
, O O
an O O
alternatively O O
spliced O O
form O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
myb I-GENE I-GENE
- I-GENE I-GENE
encoded I-GENE I-GENE
mRNA I-GENE I-GENE
has O O
been O O
identified O O
in O O
murine O O
cells O O
containing O O
either O O
normal O O
or O O
rearranged O B-GENE
c B-GENE I-GENE
- I-GENE I-GENE
myb I-GENE I-GENE
genes I-GENE I-GENE
. O O

Studies O O
were O O
performed O O
on O O
several O O
superficial O O
veins O O
from O O
the O O
rabbit O O
face O O
to O O
examine O O
the O O
relationship O O
between O O
beta B-GENE O
adrenoceptor I-GENE O
subtype I-GENE O
distribution O O
, O O
intrinsic O O
myogenic O O
tone O O
and O O
sympathetic O O
nerve O O
innervation O O
. O O

Minor O O
differences O O
were O O
noted O O
with O O
latamoxef O O
producing O O
mild O O
persistant O O
elevation O O
of O O
prothrombin B-GENE O
time O O
( O O
0 O O
. O O
0 O O
second O O
) O O
associated O O
with O O
depression O O
of O O
factor B-GENE O
II I-GENE O
and O O
factor B-GENE O
VII I-GENE O
. O O

The O O
poly O O
( O O
A O O
) O O
segment O O
of O O
the O O
RNA O O
was O O
selectively O O
cross O O
- O O
linked O O
to O O
the O O
00 O O
, O O
000 O O
- O O
molecular O I-GENE
- O I-GENE
weight O I-GENE
protein O I-GENE
( O O
00K O B-GENE
protein O I-GENE
) O O
. O O

Due O O
to O O
its O O
relatively O O
soluble O O
chemical O O
form O O
, O O
00Sr O O
was O O
rapidly O O
translocated O O
from O O
lung O O
to O O
bone O O
where O O
a O O
substantial O O
portion O O
was O O
retained O O
for O O
a O O
long O O
period O O
of O O
time O O
. O O

This O O
expression O O
assumes O O
: O O
( O O
0 O O
) O O
a O O
laminar O O
flow O O
regimen O O
during O O
expiration O O
, O O
and O O
( O O
0 O O
) O O
a O O
constant O O
CT O O
value O O
over O O
the O O
range O O
of O O
VT O O
. O O

We O O
cloned O O
the O O
third O O
human O O
gene O O
for O O
the O O
LD00 B-GENE O
, O O
termed O O
LD00 B-GENE O
gamma I-GENE O
and O O
the O O
sequence O O
analysis O O
showed O O
that O O
it O O
is O O
a O O
0 O O
' O O
- O O
truncated O O
pseudogene O O
. O O

The O O
RNase B-GENE B-GENE
MRP I-GENE I-GENE
RNA I-GENE I-GENE
gene I-GENE I-GENE
was O O
deleted O O
by O O
insertional O O
replacement O O
and O O
found O O
to O O
be O O
essential O O
for O O
cellular O O
viability O O
, O O
indicating O O
a O O
critical O O
nuclear O O
role O O
for O O
RNase B-GENE O
MRP I-GENE O
. O O

Computer O O
- O O
aided O O
" O O
FRAME O O
" O O
analysis O O
revealed O O
four O O
possible O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
, O O
three O O
in O O
one O O
direction O O
and O O
one O O
in O O
the O O
opposite O O
direction O O
. O O

However O O
, O O
alterations O O
in O O
electrostatic O O
and O O
hydrophobic O O
interactions O O
created O O
by O O
the O O
three O O
amino O O
acid O O
substitutions O O
prevent O O
the O O
conformational O O
change O O
in O O
the O O
enzyme O O
usually O O
produced O O
by O O
calmodulin B-GENE O
binding O O
. O O

The O O
human O O
cDNA O O
was O O
used O O
to O O
demonstrate O O
that O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
could O O
rapidly O O
stimulate O O
MARCKS B-GENE O
gene I-GENE O
transcription O O
in O O
the O O
human O O
promyelocytic O O
leukemia O O
cell O O
line O O
HL00 O O
. O O

This O O
study O O
indicates O O
that O O
this O O
dose O O
- O O
intense O O
regimen O O
can O O
be O O
safely O O
administered O O
, O O
even O O
with O O
the O O
use O O
of O O
purged O O
marrow O O
, O O
with O O
an O O
acceptable O O
toxicity O O
profile O O
. O O

HeLa O O
and O O
Jurkat O O
cell O O
lines O O
carrying O O
the O O
nef B-GENE B-GENE
gene I-GENE I-GENE
linked O O
to O O
the O O
CMV O O
promoter O O
or O O
the O O
HIV B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
LTR I-GENE O
were O O
isolated O O
by O O
coselection O O
for O O
neomycin O O
resistance O O
. O O

Conclusion O O
: O O
inlet O O
type O O
VSD O O
and O O
perimembranous O O
type O O
TOF O O
have O O
anatomic O O
features O O
in O O
which O O
the O O
proximal O O
His O O
bundle O O
tends O O
to O O
be O O
jeopardized O O
by O O
suturing O O
for O O
VSD O O
closure O O
. O O

Luteinizing B-GENE O
hormone I-GENE O
- I-GENE O
releasing I-GENE O
hormone I-GENE O
analog O O
therapy O O
of O O
uterine O O
fibroid O O
: O O
analysis O O
of O O
results O O
obtained O O
with O O
buserelin O O
administered O O
intranasally O O
and O O
goserelin O O
administered O O
subcutaneously O O
as O O
a O O
monthly O O
depot O O
. O O

These O O
genes O O
are O O
expressed O O
within O O
a O O
few O O
hours O O
of O O
the O O
initiation O O
of O O
development O O
; O O
their O O
mRNAs O O
accumulate O O
to O O
a O O
peak O O
at O O
00 O O
hr O O
and O O
persist O O
until O O
culmination O O
. O O

It O O
is O O
likely O O
that O O
the O O
sequence O O
similarities O O
reflect O O
a O O
common O O
molecular O O
architecture O O
of O O
the O O
two O O
heme O O
binding O O
sites O O
and O O
of O O
a O O
copper O O
binding O O
site O O
in O O
these O O
enzymes O O
. O O

The O O
Ets B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
binding I-GENE O
site I-GENE O
was O O
localized O O
to O O
a O O
00 O O
- O O
base O O
pair O O
( O O
bp O O
) O O
region O O
from O O
the O O
0 O O
' O O
end O O
of O O
T B-GENE O
alpha I-GENE O
0 I-GENE O
. O O

In O O
addition O O
, O O
the O O
calbindin B-GENE B-GENE
- I-GENE I-GENE
D00K I-GENE I-GENE
promoter I-GENE I-GENE
is O O
composed O O
of O O
a O O
variety O O
of O O
simple O O
repeated O O
sequences O O
, O O
some O O
of O O
which O O
are O O
components O O
of O O
putative O O
regulatory O O
signals O O
. O O

In O O
00 O O
% O O
a O O
small O O
cardiac O O
vein O O
does O O
not O O
exist O O
, O O
but O O
its O O
origin O O
, O O
the O O
right O O
marginal O O
vein O O
, O O
joins O O
the O O
system O O
of O O
anterior O O
cardiac O O
veins O O
. O O

The O O
activity O O
of O O
the O O
EGF B-GENE B-GENE
receptor I-GENE I-GENE
promoter I-GENE I-GENE
can O O
be O O
modulated O O
by O O
E0A B-GENE O
protein I-GENE O
and O O
receptor O O
RNA O O
levels O O
increased O O
by O O
stimulation O O
with O O
phorbol O O
ester O O
or O O
fetal O O
calf O O
serum O O
. O O

Ischemic O O
heart O O
disease O O
, O O
age O O
of O O
more O O
than O O
00 O O
years O O
, O O
and O O
the O O
fact O O
that O O
the O O
patient O O
was O O
a O O
woman O O
were O O
independent O O
predictors O O
of O O
poor O O
cardiac O O
function O O
. O O

Artificial O O
ventilation O O
was O O
conducted O O
using O O
a O O
tidal O O
volume O O
of O O
00 O O
ml O O
X O O
kg O O
- O O
0 O O
and O O
a O O
rate O O
of O O
00 O O
to O O
00 O O
c O O
X O O
min O O
- O O
0 O O
. O O

Findings O O
of O O
positive O O
potentials O O
showed O O
that O O
N0 O O
originated O O
in O O
the O O
area O O
of O O
ventral O O
gray O O
matter O O
through O O
the O O
ventro O O
- O O
lateral O O
column O O
and O O
N0 O O
through O O
the O O
dorsal O O
column O O
. O O

Plasma O O
and O O
erthrocyte O O
lipid O O
profile O O
and O O
lipoprotein B-GENE O
lipase I-GENE O
activity O O
in O O
postheparin O O
plasma O O
on O O
vasectomized O O
rabbits O O
were O O
studied O O
and O O
also O O
the O O
incidence O O
of O O
atherosclerosis O O
in O O
different O O
arterial O O
beds O O
. O O

Toxicity O O
was O O
significant O O
in O O
selected O O
cases O O
; O O
three O O
patients O O
developed O O
WBC O O
counts O O
less O O
than O O
0 O O
, O O
000 O O
/ O O
mm0 O O
and O O
one O O
of O O
these O O
patients O O
died O O
with O O
sepsis O O
. O O

Iodine O O
- O O
000 O O
was O O
satisfactorily O O
imaged O O
only O O
with O O
the O O
MEC O O
and O O
pinhole O O
collimators O O
, O O
which O O
in O O
turn O O
yielded O O
MTF O O
values O O
comparable O O
to O O
those O O
measured O O
for O O
00mTc O O
. O O

Reduction O O
in O O
dosage O O
restored O O
normal O O
taste O O
sense O O
in O O
all O O
three O O
, O O
but O O
in O O
two O O
the O O
drug O O
had O O
to O O
be O O
discontinued O O
because O O
of O O
persisting O O
high O O
transaminase O O
levels O O
. O O

Possibly O O
, O O
the O O
scr0 B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
mutation I-GENE O
does O O
not O O
affect O O
signal O O
recognition O O
or O O
translational O O
arrest O O
but O O
instead O O
results O O
in O O
maintenance O O
of O O
translational O O
arrest O O
of O O
AEP B-GENE O
synthesis O O
. O O

A O O
patient O O
suffering O O
from O O
heparin O O
- O O
associated O O
thrombocytopenia O O
( O O
HAT O O
) O O
, O O
recurrent O O
arteriothromboses O O
, O O
and O O
acute O O
renal O O
failure O O
after O O
treatment O O
with O O
standard O O
heparin O O
is O O
described O O
. O O

DESIGN O O
: O O
Serum O O
aldosterone O O
and O O
plasma B-GENE O
renin I-GENE O
activity O O
were O O
measured O O
supine O O
prior O O
to O O
and O O
00 O O
, O O
00 O O
, O O
000 O O
minutes O O
after O O
oral O O
captopril O O
, O O
00 O O
mg O O
. O O

Transfer O O
RNA O O
genes O O
from O O
Dictyostelium O O
discoideum O O
are O O
frequently O O
associated O O
with O O
repetitive O O
elements O O
and O O
contain O O
consensus O O
boxes O O
in O O
their O O
0 O O
' O O
and O O
0 O O
' O O
- O O
flanking O O
regions O O
. O O

Complex O O
repetitive O O
discharges O O
were O O
observed O O
in O O
muscles O O
of O O
mdx O O
mice O O
but O O
no O O
complex O O
repetitive O O
discharges O O
or O O
other O O
abnormalities O O
were O O
observed O O
in O O
muscles O O
of O O
normal O O
control O O
mice O O
. O O

Previous O O
analysis O O
of O O
the O O
00 O B-GENE
- O I-GENE
bp O I-GENE
sequence O I-GENE
has O O
delineated O O
several O O
protein O O
- O O
binding O O
domains O O
that O O
are O O
recognized O O
by O O
nuclear O O
factors O O
present O O
in O O
human O O
brain O O
cells O O
. O O

Although O O
heart O O
rate O O
and O O
diastolic O O
pressure O O
rose O O
in O O
some O O
degree O O
0 O O
min O O
after O O
intubation O O
, O O
free O O
and O O
total O O
CA O O
concentrations O O
did O O
not O O
increase O O
during O O
study O O
period O O
. O O

We O O
have O O
now O O
identified O O
, O O
after O O
00 O O
serial O O
undiluted O O
passages O O
of O O
MHV O O
, O O
a O O
small B-GENE O
DI I-GENE O
RNA I-GENE O
, O O
DIssF B-GENE O
, O O
which O O
is O O
efficiently O O
packaged O O
into O O
virions O O
. O O

Of O O
the O O
remaining O O
seven O O
, O O
five O O
reacted O O
either O O
with O O
immediate O O
and O O
strong O O
symptoms O O
or O O
had O O
spontaneously O O
reduced O O
gluten B-GENE O
intake O O
, O O
or O O
had O O
an O O
acquired O O
IgA B-GENE O
deficiency O O
. O O

Intracellular O O
activity O O
studies O O
indicated O O
that O O
, O O
at O O
ten O O
times O O
MBC O O
, O O
only O O
penicillin O O
had O O
any O O
significant O O
activity O O
against O O
intracellular O O
staphylococci O O
, O O
reducing O O
survival O O
by O O
00 O O
% O O
. O O

The O O
effect O O
of O O
acetazolamide O O
( O O
ACZ O O
) O O
on O O
HCO0 O O
- O O
and O O
Cl O O
- O O
activities O O
in O O
inner O O
ear O O
fluid O O
was O O
investigated O O
by O O
ion O O
- O O
selective O O
microelectrode O O
methods O O
. O O

Computer O O
analysis O O
included O O
digital O O
averaging O O
, O O
followed O O
by O O
digital O O
filtering O O
in O O
different O O
frequency O O
bands O O
in O O
order O O
to O O
determine O O
the O O
frequency O O
range O O
corresponding O O
to O O
notches O O
and O O
slurs O O
. O O

Bacteriologic O O
culture O O
of O O
pancreatic O O
tissue O O
was O O
positive O O
in O O
0 O O
/ O O
0 O O
IB O O
and O O
0 O O
/ O O
00 O O
NIB O O
rats O O
( O O
p O O
less O O
than O O
0 O O
. O O
00 O O
) O O
. O O

An O O
00 O O
- O O
month O O
- O O
old O O
girl O O
suffering O O
from O O
Dandy O O
- O O
Walker O O
malformation O O
( O O
DWM O O
) O O
associated O O
with O O
tetralogy O O
of O O
Fallot O O
( O O
TOF O O
) O O
is O O
presented O O
. O O

Significantly O O
lower O O
heart O O
rate O O
reactivity O O
and O O
significantly O O
less O O
pronounced O O
left O O
temporal O O
artery O O
pulse O O
amplitude O O
responses O O
were O O
found O O
in O O
non O O
- O O
medicated O O
TH O O
subjects O O
than O O
in O O
controls O O
. O O

The O O
development O O
of O O
a O O
data O O
base O O
is O O
described O O
which O O
can O O
be O O
used O O
as O O
common O O
reference O O
for O O
ECG O O
computer O O
programs O O
analyzing O O
00 O O
or O O
00 O O
simultaneously O O
recorded O O
leads O O
. O O

Effect O O
of O O
variations O O
in O O
time O O
interval O O
between O O
treatment O O
with O O
BCG O O
and O O
quartz O O
dust O O
on O O
translocation O O
of O O
quartz O O
dust O O
from O O
the O O
lungs O O
to O O
their O O
regional O O
lymph O O
nodes O O
. O O

During O O
the O O
period O O
from O O
May O O
to O O
August O O
, O O
0000 O O
, O O
an O O
epidemic O O
of O O
hand O O
, O O
foot O O
and O O
mouth O O
disease O O
( O O
HFMD O O
) O O
occurred O O
in O O
Gifu O O
prefecture O O
. O O

The O O
major O O
urinary O O
metabolites O O
were O O
0 O O
- O O
( O O
0 O O
- O O
carboxyphenyl O O
) O O
- O O
0 O O
- O O
hydroxymethyl O O
- O O
0 O O
- O O
oxazolidinone O O
and O O
a O O
glucuronide O O
of O O
toloxatone O O
. O O

In O O
both O O
cases O O
, O O
at O O
the O O
end O O
of O O
exposure O O
the O O
same O O
level O O
of O O
blood B-GENE O
carboxyhemoglobin I-GENE O
( O O
COHb B-GENE O
) O O
( O O
about O O
00 O O
% O O
) O O
was O O
reached O O
. O O

This O O
soluble O O
form O O
of O O
the O O
HGFr B-GENE O
( O O
sHGFr B-GENE O
) O O
bound O O
HGF B-GENE O
with O O
an O O
affinity O O
similar O O
to O O
that O O
of O O
the O O
authentic O O
, O O
membrane O O
- O O
associated O O
receptor O O
. O O

These O O
results O O
are O O
consistent O O
with O O
the O O
roles O O
that O O
CCK B-GENE O
and O O
trypsin B-GENE O
inhibitors O O
are O O
believed O O
to O O
play O O
in O O
the O O
negative O O
feedback O O
control O O
of O O
pancreatic O O
exocrine O O
function O O
. O O

The O O
model O O
is O O
able O O
to O O
anticipate O O
why O O
the O O
effect O O
of O O
water O O
fluoridation O O
on O O
caries O O
prevalence O O
is O O
most O O
pronounced O O
when O O
caries O O
is O O
diagnosed O O
at O O
cavity O O
level O O
. O O

DNA O O
hybridization O O
analysis O O
revealed O O
that O O
both O O
pigmented O O
and O O
nonpigmented O O
cells O O
of O O
Y O O
. O O
pestis O O
possess O O
a O O
DNA O O
locus O O
homologous O O
to O O
the O O
Escherichia B-GENE B-GENE
coli I-GENE I-GENE
fur I-GENE I-GENE
gene I-GENE I-GENE
. O O

The O O
TraD B-GENE B-GENE
protein I-GENE I-GENE
( I-GENE O
00 I-GENE O
, I-GENE O
000 I-GENE O
Da I-GENE O
) I-GENE O
contains O O
three O O
hydrophobic O O
regions O O
, O O
of O O
which O O
two O O
are O O
located O O
near O O
the O O
amino O O
- O O
terminal O O
region O O
. O O

Experiments O O
showed O O
that O O
temporary O O
arrest O O
of O O
pulmonary O O
circulation O O
under O O
conditions O O
of O O
extracorporeal O O
circulation O O
is O O
attended O O
by O O
the O O
development O O
of O O
ischemia O O
of O O
the O O
respiratory O O
pulmonary O O
tissue O O
. O O

Our O O
data O O
, O O
however O O
, O O
did O O
not O O
suggest O O
the O O
existence O O
of O O
a O O
conversion O O
factor O O
for O O
LDF O O
signal O O
to O O
absolute O O
flow O O
values O O
from O O
experiment O O
to O O
experiment O O
. O O

Influence O O
of O O
cyclo B-GENE B-GENE
- I-GENE O
oxygenase I-GENE O
inhibition O O
and O O
of O O
leukotriene B-GENE O
receptor I-GENE O
blockade O O
on O O
pulmonary O O
vascular O O
pressure O O
/ O O
cardiac O O
index O O
relationships O O
in O O
hyperoxic O O
and O O
in O O
hypoxic O O
dogs O O
. O O

The O O
nucleotide O O
sequences O O
of O O
the O O
human B-GENE O
and I-GENE O
murine I-GENE O
ornithine I-GENE O
decarboxylase I-GENE O
mRNAs I-GENE O
share O O
an O O
00 O O
% O O
homology O O
, O O
even O O
in O O
their O O
0 O O
' O O
- O O
noncoding O O
regions O O
. O O

Nickel O O
is O O
the O O
most O O
common O O
cause O O
of O O
allergic O O
contact O O
dermatitis O O
in O O
Singapore O O
, O O
resulting O O
in O O
positive O O
reactions O O
in O O
patch O O
tests O O
between O O
0 O O
and O O
00 O O
% O O
. O O

The O O
possibility O O
of O O
a O O
hereditary O O
disorder O O
leading O O
to O O
a O O
minor O O
defect O O
in O O
elastic O O
fibre O O
structure O O
which O O
could O O
be O O
responsible O O
for O O
the O O
spontaneous O O
lesions O O
is O O
discussed O O
. O O

Under O O
the O O
same O O
hematocrit O O
and O O
flow O O
conditions O O
, O O
the O O
rate O O
of O O
oxygen O O
saturation O O
decrease O O
was O O
significantly O O
higher O O
for O O
the O O
sickle O O
cells O O
than O O
for O O
normal O O
cells O O
. O O

For O O
this O O
purpose O O
, O O
a O O
simple O O
respiration O O
- O O
control O O
device O O
has O O
been O O
developed O O
that O O
enables O O
the O O
patient O O
to O O
monitor O O
breath O O
- O O
holding O O
during O O
successive O O
scans O O
. O O

Upstream O O
activation O O
sites O O
of O O
the O O
CYC0 B-GENE B-GENE
gene I-GENE I-GENE
of O O
Saccharomyces O O
cerevisiae O O
are O O
active O O
when O O
inverted O O
but O O
not O O
when O O
placed O O
downstream O O
of O O
the O O
" O O
TATA O O
box O O
" O O
. O O

The O O
ensembles O O
are O O
considered O O
to O O
be O O
one O O
of O O
the O O
forms O O
of O O
activity O O
of O O
the O O
structured O O
morphofunctional O O
cortical O O
units O O
, O O
i O O
. O O
e O O
. O O
the O O
columns O O
. O O

Catch O O
- O O
up O O
growth O O
was O O
observed O O
only O O
for O O
a O O
00 O O
- O O
month O O
period O O
in O O
0 O O
children O O
with O O
a O O
bone O O
age O O
of O O
0 O O
to O O
0 O O
years O O
. O O

The O O
salient O O
clinical O O
features O O
, O O
the O O
problems O O
of O O
management O O
and O O
the O O
modern O O
approaches O O
to O O
the O O
reconstruction O O
of O O
facial O O
deformities O O
seen O O
in O O
this O O
disease O O
are O O
described O O
. O O

The O O
authors O O
report O O
the O O
clinicopathologic O O
findings O O
in O O
four O O
cases O O
of O O
adult O O
women O O
with O O
rhabdomyosarcomas O O
that O O
originated O O
in O O
the O O
endometrium O O
or O O
cervix O O
, O O
or O O
both O O
. O O

Near O O
term O O
, O O
under O O
experimental O O
conditions O O
, O O
maternal O O
and O O
fetal O O
blood O O
gases O O
, O O
pH O O
, O O
uterine O O
and O O
umbilical O O
blood O O
flows O O
were O O
measured O O
or O O
calculated O O
. O O

Also O O
, O O
samples O O
of O O
serum O O
were O O
absorbed O O
with O O
the O O
various O O
solid O O
- O O
phase O O
allergens O O
and O O
the O O
reactivity O O
of O O
the O O
remaining O O
IgE B-GENE O
antibodies I-GENE O
was O O
determined O O
. O O

In O O
contrast O O
, O O
the O O
lumenal O O
domains O O
of O O
Sec00p B-GENE O
, O O
Stl0p B-GENE O
and O O
Stl0p B-GENE O
are O O
very O O
different O O
in O O
size O O
and O O
do O O
not O O
show O O
any O O
appreciable O O
homology O O
. O O

The O O
promoter O O
was O O
stimulated O O
0 O O
- O O
00 O O
- O O
fold O O
by O O
phorbol O O
esters O O
accounting O O
for O O
the O O
previously O O
observed O O
transcriptional O O
activation O O
of O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C I-GENE I-GENE
beta I-GENE I-GENE
. O O

In O O
the O O
eight O O
patients O O
with O O
persistent O O
generalized O O
lymph O O
- O O
adenopathy O O
( O O
PGL O O
) O O
and O O
nontender O O
, O O
nonenlarging O O
nodes O O
, O O
pathologic O O
analysis O O
revealed O O
lymphoid O O
hyperplasia O O
. O O

The O O
MET0 B-GENE B-GENE
gene O I-GENE
was O O
cloned O O
, O O
and O O
its O O
sequence O O
reveals O O
that O O
it O O
encodes O O
a O O
protein O O
related O O
to O O
the O O
family O O
of O O
the O O
bZIP B-GENE O
transcriptional I-GENE O
activators I-GENE O
. O O

This O O
is O O
in O O
contrast O O
with O O
the O O
classical O O
' O O
oxygen O O
debt O O
hypothesis O O
' O O
, O O
which O O
states O O
that O O
the O O
oxygen O O
debt O O
and O O
lactate O O
clearance O O
are O O
linked O O
. O O

No O O
such O O
benefits O O
were O O
seen O O
for O O
children O O
with O O
CD0 B-GENE O
+ I-GENE O
counts O O
below O O
0 O O
. O O
0 O O
x O O
00 O O
( O O
0 O O
) O O
per O O
liter O O
at O O
entry O O
. O O

In O O
some O O
early O O
B O O
cells O O
and O O
Abelson O O
murine O O
leukemia O O
virus O O
- O O
transformed O O
pre O O
- O O
B O O
- O O
cell O O
lines O O
, O O
LT B-GENE O
mRNA I-GENE O
is O O
constitutively O O
expressed O O
. O O

It O O
is O O
transparent O O
, O O
cheap O O
to O O
be O O
made O O
, O O
and O O
easy O O
to O O
empty O O
and O O
was O O
tested O O
in O O
000 O O
animals O O
for O O
two O O
and O O
four O O
weeks O O
. O O

A O O
vector O O
containing O O
a O O
transcriptionally O O
inactive O O
neomycin B-GENE I-GENE
phosphotransferase I-GENE I-GENE
II I-GENE I-GENE
gene I-GENE I-GENE
was O O
used O O
to O O
select O O
promoter O O
sequences O O
from O O
a O O
pool O O
of O O
random O O
genomic O O
DNA O O
fragments O O
. O O

Toxicity O O
was O O
very O O
mild O O
with O O
both O O
regimens O O
, O O
although O O
sedation O O
was O O
significantly O O
higher O O
in O O
arm O O
B O O
( O O
p O O
less O O
than O O
0 O O
. O O
000 O O
) O O
. O O

Southern O O
blot O O
analyses O O
demonstrated O O
a O O
low O O
, O O
if O O
not O O
single O O
, O O
copy O O
number O O
for O O
this O O
gene O O
and O O
conservation O O
of O O
this O O
domain O O
in O O
other O O
vertebrates O O
. O O

The O O
titer O O
of O O
anti B-GENE O
HSV I-GENE O
type I-GENE O
0 I-GENE O
and O O
anti B-GENE O
HSV I-GENE O
type I-GENE O
0 I-GENE O
antibodies I-GENE O
in O O
the O O
mothers O O
' O O
and O O
cord O O
blood O O
was O O
determined O O
and O O
compared O O
. O O

A O O
larval B-GENE O
albumin I-GENE O
- I-GENE O
like I-GENE O
protein I-GENE O
was O O
not O O
detectable O O
by O O
silver O O
staining O O
in O O
serum O O
of O O
tadpoles O O
before O O
the O O
beginning O O
of O O
metamorphosis O O
at O O
stage O O
00 O O
. O O

RVEF O O
and O O
LVEF O O
both O O
increased O O
by O O
about O O
00 O O
% O O
( O O
p O O
less O O
than O O
0 O O
. O O
00 O O
and O O
p O O
less O O
than O O
0 O O
. O O
00 O O
) O O
. O O

The O O
number O O
of O O
polymerases O O
active O O
in O O
vitro O O
at O O
the O O
E O O
strand O O
promoter O O
was O O
similar O O
to O O
the O O
number O O
of O O
polymerases O O
at O O
the O O
L O O
strand O O
promoter O O
. O O

Clinical O O
findings O O
were O O
: O O
height O O
000 O O
cm O O
, O O
weight O O
00 O O
kg O O
, O O
increased O O
length O O
of O O
lower O O
limbs O O
, O O
P0 O O
- O O
A0 O O
pilosity O O
and O O
micropenis O O
. O O

Factors O O
involved O O
in O O
specific O O
transcription O O
by O O
mammalian O O
RNA B-GENE O
polymerase I-GENE O
II I-GENE O
: O O
purification O O
, O O
genetic O O
specificity O O
, O O
and O O
TATA O O
box O O
- O O
promoter O O
interactions O O
of O O
TFIID B-GENE O
. O O

The O O
results O O
presented O O
suggest O O
that O O
TIQ O O
reduces O O
the O O
turnover O O
rate O O
of O O
the O O
nigrostriatal O O
dopamine O O
neurons O O
after O O
repeated O O
administration O O
for O O
a O O
long O O
period O O
in O O
mice O O
. O O

Increasing O O
the O O
RH O O
beyond O O
00 O O
% O O
resulted O O
in O O
solvation O O
of O O
the O O
peroxy O O
radical O O
, O O
sterically O O
hindering O O
the O O
radical O O
from O O
entering O O
the O O
propagation O O
transition O O
state O O
. O O

A O O
yeast O O
DNA O O
fragment O O
carrying O O
the O O
gene B-GENE O
CP I-GENE O
A0 I-GENE O
encoding O O
the O O
small O O
subunit O O
of O O
the O O
arginine O B-GENE
pathway O I-GENE
carbamoyl B-GENE I-GENE
- I-GENE I-GENE
phosphate I-GENE I-GENE
synthetase I-GENE O
has O O
been O O
sequenced O O
. O O

The O O
immuno O B-GENE
- O I-GENE
purified O I-GENE
mRNA O O
in O O
the O O
polysome O O
complex O O
was O O
used O O
to O O
prepare O O
cDNA O O
with O O
which O O
to O O
probe O O
a O O
D O O
. O O
melanogaster O O
genomic O O
library O O
. O O

Thromboplastic O O
and O O
fibrynolytic O O
activity O O
of O O
the O O
blood O O
after O O
administration O O
of O O
intralipid O O
in O O
men O O
with O O
history O O
of O O
myocardial O O
infarction O O
up O O
to O O
00 O O
year O O
of O O
life O O

00mTc O O
phytate O O
, O O
000Au O O
colloid O O
, O O
and O O
00mTc O O
antimony O O
sulfide O O
have O O
been O O
used O O
; O O
the O O
last O O
appears O O
to O O
have O O
been O O
the O O
most O O
satisfactory O O
. O O

Thus O O
, O O
the O O
human B-GENE B-GENE
D0A I-GENE I-GENE
gene I-GENE I-GENE
belongs O O
to O O
the O O
category O O
of O O
tissue O O
- O O
specific O O
, O O
regulated O O
genes O O
that O O
have O O
housekeeping O O
- O O
type O O
promoters O O
. O O

The O O
single O O
most O O
important O O
element O O
, O O
by O O
linker O O
- O O
scanning O O
analysis O O
, O O
is O O
a O O
00 O O
- O O
bp O O
region O O
that O O
contains O O
a O O
CCAAT O O
motif O O
. O O

Capnography O O
curves O O
of O O
00 O O
HVS O O
patients O O
, O O
00 O O
non O O
- O O
HVS O O
patients O O
with O O
psycho O O
- O O
somatic O O
complaints O O
and O O
00 O O
healthy O O
controls O O
were O O
analyzed O O
. O O

Here O O
we O O
show O O
that O O
these O O
synthetic O O
binding O O
sites O O
have O O
a O O
more O O
restricted O O
and O O
specific O O
ability O O
to O O
enhance O O
transcription O O
when O O
assayed O O
in O O
transformed O O
embryos O O
. O O

This O O
study O O
suggests O O
that O O
BSPMs O O
are O O
useful O O
in O O
the O O
assessment O O
of O O
AMI O O
in O O
terms O O
of O O
diagnosis O O
, O O
location O O
and O O
extent O O
of O O
myocardial O O
infarct O O
. O O

Processing O O
, O O
secretion O O
, O O
and O O
immunoreactivity O O
of O O
carboxy B-GENE O
terminally I-GENE O
truncated I-GENE O
dengue I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
virus I-GENE O
envelope I-GENE O
proteins I-GENE O
expressed O O
in O O
insect O O
cells O O
by O O
recombinant O O
baculoviruses O O
. O O

To O O
identify O O
these O O
sites O O
, O O
the O O
deduced O O
amino O O
acid O O
sequence O O
of O O
the O O
0T0 O B-GENE
- O I-GENE
L0 O I-GENE
adipocyte B-GENE O
insulin I-GENE O
receptor I-GENE O
of O O
the O O
mouse O O
was O O
determined O O
. O O

Most O O
strains O O
( O O
00 O O
% O O
) O O
of O O
S O O
. O O
lugdunensis O O
produced O O
a O O
delta B-GENE O
hemolysin I-GENE O
like O O
that O O
seen O O
with O O
nine O O
other O O
species O O
of O O
CNS O O
. O O

The O O
discussion O O
focuses O O
primarily O O
on O O
the O O
newer O O
drugs O O
like O O
angiotensin B-GENE O
converting I-GENE O
enzyme I-GENE O
inhibitors O O
, O O
alpha B-GENE B-GENE
- I-GENE I-GENE
adrenergic I-GENE I-GENE
receptor I-GENE I-GENE
blockers O O
, O O
and O O
calcium O O
antagonists O O
. O O

On O O
the O O
other O O
hand O O
, O O
if O O
the O O
measured O O
angle O O
ANB O O
is O O
smaller O O
than O O
the O O
calculated O O
angle O O
, O O
the O O
skeletal O O
relation O O
is O O
Class O O
III O O
. O O

Samples O O
from O O
0000 O O
neurological O O
patients O O
were O O
used O O
to O O
study O O
the O O
diagnostic O O
value O O
of O O
acid B-GENE O
alpha I-GENE O
0 I-GENE O
- I-GENE O
glycoprotein I-GENE O
in O O
the O O
lumbar O O
cerebrospinal O O
fluid O O
. O O

The O O
concentrations O O
of O O
apo B-GENE O
A I-GENE O
- I-GENE O
I I-GENE O
and O O
apo B-GENE O
A I-GENE O
- I-GENE O
II I-GENE O
of O O
abstainers O O
decreased O O
significantly O O
compared O O
with O O
the O O
corresponding O O
changes O O
in O O
controls O O
. O O

Results O O
of O O
the O O
official O O
inspection O O
of O O
the O O
commercial O O
anti O O
- O O
inflammatory O O
enzyme O O
preparations O O
containing O O
chymotrypsin B-GENE O
and O O
trypsin B-GENE O
by O O
means O O
of O O
modified O O
NF O O
00 O O
methods O O

The O O
dnaQ B-GENE B-GENE
- O O
lacZ B-GENE O
and O O
the O O
rnh B-GENE B-GENE
- O I-GENE
lacZ B-GENE I-GENE
fused O I-GENE
genes O I-GENE
were O O
constructed O O
and O O
hybrid O O
proteins O O
with O O
beta B-GENE B-GENE
- I-GENE O
galactosidase I-GENE O
activity O O
were O O
produced O O
. O O

It O O
is O O
concluded O O
that O O
axillo O O
- O O
axillary O O
by O O
- O O
pass O O
is O O
a O O
simple O O
solution O O
for O O
a O O
complex O O
haemodynamic O O
, O O
clinical O O
and O O
therapeutic O O
problem O O
. O O

Endothelium O O
of O O
the O O
central O O
ear O O
artery O O
of O O
an O O
anesthetized O O
rabbit O O
is O O
damaged O O
by O O
placing O O
artery O O
forceps O O
on O O
the O O
ear O O
directly O O
over O O
the O O
vessel O O
. O O

Brainstem O O
auditory O O
evoked O O
responses O O
( O O
BAERs O O
) O O
and O O
quantitative O O
saccadic O O
eye O O
movement O O
studies O O
provide O O
information O O
on O O
the O O
integrity O O
of O O
pathways O O
traversing O O
the O O
brainstem O O
. O O

Female O O
Wistar O O
rats O O
were O O
fed O O
a O O
liquid O O
diet O O
, O O
Sustacal O O
, O O
which O O
contained O O
ethanol O O
( O O
00 O O
% O O
of O O
calories O O
) O O
or O O
isocaloric O O
sucrose O O
. O O

The O O
study O O
of O O
calcium O O
metabolism O O
in O O
ten O O
thalassaemic O O
children O O
comperatively O O
with O O
controls O O
after O O
oral O O
administration O O
of O O
00Ca O O
has O O
shown O O
diminished O O
intestinal O O
absorption O O
. O O

It O O
is O O
believed O O
that O O
these O O
domains O O
are O O
important O O
for O O
directing O O
specific O O
protein O I-GENE
- O I-GENE
protein O I-GENE
interactions O O
necessary O O
for O O
the O O
proper O O
functioning O O
of O O
Src B-GENE O
. O O

USF B-GENE O
synthesized O O
in O O
an O O
in O O
vitro O O
transcription O O
and O O
translation O O
system O O
also O O
binds O O
to O O
the O O
ADH B-GENE O
promoter I-GENE O
as O O
well O O
as O O
to O O
the O O
MLP O O
. O O

Radiation O O
- O O
induced O O
changes O O
in O O
the O O
area O O
of O O
alveoli O O
and O O
septa O O
as O O
well O O
as O O
collagen B-GENE O
content O O
were O O
seen O O
00 O O
weeks O O
after O O
irradiation O O
. O O

During O O
the O O
years O O
0000 O O
- O O
00 O O
a O O
total O O
of O O
000 O O
persons O O
received O O
disability O O
pensions O O
in O O
the O O
municipality O O
of O O
Nordreisa O O
in O O
northern O O
Norway O O
. O O

Two O O
patients O O
had O O
immediate O O
adverse O O
effects O O
from O O
NMF O O
; O O
one O O
had O O
a O O
grand O O
mal O O
seizure O O
and O O
the O O
other O O
developed O O
severe O O
abdominal O O
pain O O
. O O

This O O
result O O
indicates O O
that O O
separate O O
complexes O O
exist O O
containing O O
ankyrin B-GENE O
and O O
fodrin B-GENE O
with O O
either O O
uvomorulin B-GENE O
or O O
Na B-GENE O
+ I-GENE O
, I-GENE O
K I-GENE O
+ I-GENE O
- I-GENE O
ATPase I-GENE O
. O O

The O O
recombinant O O
contains O O
the O O
normal O B-GENE
beta B-GENE I-GENE
A I-GENE I-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
gene I-GENE I-GENE
, O O
the O O
mutant O B-GENE
gene O I-GENE
and O O
Ylp O O
vector O O
sequences O O
between O O
the O O
two O O
copies O O
. O O

The O O
characterized O O
Y B-GENE O
' I-GENE O
repeated I-GENE O
sequence I-GENE O
families I-GENE O
provide O O
an O O
experimental O O
system O O
in O O
which O O
repeated O O
sequence O O
interactions O O
and O O
subsequent O O
evolution O O
can O O
be O O
studied O O
. O O

The O O
contribution O O
that O O
alternative O O
splicing O O
events O O
in O O
c B-GENE O
- I-GENE O
myb I-GENE O
expression O O
may O O
make O O
on O O
c B-GENE O
- I-GENE O
myb I-GENE O
function O O
remains O O
to O O
be O O
elucidated O O
. O O

IgG B-GENE O
and O O
IgM B-GENE O
antibody O O
activity O O
was O O
determined O O
by O O
adding O O
a O O
0 O O
: O O
000 O O
dilution O O
of O O
serum O O
to O O
plates O O
coated O O
with O O
A00 B-GENE O
antigen I-GENE O
. O O

The O O
study O O
included O O
000 O O
eyes O O
with O O
presumed O O
ocular O O
histoplasmosis O O
syndrome O O
( O O
POHS O O
) O O
and O O
age O O
- O O
related O O
macular O O
degeneration O O
( O O
AMD O O
) O O
. O O

Endocrine O O
cells O O
were O O
studied O O
by O O
means O O
of O O
Grimelius O O
' O O
silver O O
staining O O
and O O
immunostaining O O
for O O
chromogranin B-GENE O
, O O
a O O
general O O
marker O O
of O O
endocrine O O
cells O O
. O O

In O O
all O O
sessions O O
under O O
IFN B-GENE O
, O O
the O O
latency O O
of O O
the O O
P000 O O
component O O
of O O
the O O
VEP O O
was O O
shortened O O
as O O
compared O O
to O O
baseline O O
conditions O O
. O O

This O O
means O O
that O O
the O O
loss O O
of O O
recessives O O
must O O
be O O
calculated O O
by O O
using O O
a O O
hypergeometric O O
and O O
not O O
a O O
binomial O O
model O O
as O O
Fisher O O
did O O
. O O

The O O
growing O O
drug O O
problem O O
is O O
also O O
reflected O O
in O O
the O O
increasing O O
number O O
of O O
cases O O
of O O
hepatitis O O
B O O
and O O
of O O
drug O O
- O O
related O O
deaths O O
. O O

Deep O O
tans O O
were O O
induced O O
over O O
the O O
backs O O
of O O
volunteers O O
with O O
repeated O O
exposure O O
to O O
longwave O O
ultraviolet O O
radiation O O
( O O
UV O O
- O O
A O O
) O O
. O O

The O O
effect O O
of O O
hydrostatic O O
pressure O O
on O O
the O O
swimming O O
activity O O
of O O
three O O
hyponeustonic O O
crustacea O O
, O O
Anomalocera O O
patersoni O O
, O O
Pontella O O
mediterranea O O
, O O
Labidocera O O
wollastoni O O

However O O
, O O
a O O
00 O O
- O O
- O O
00 O O
% O O
lengthening O O
of O O
the O O
partial O O
thromboplastin B-GENE O
time O O
is O O
evident O O
after O O
00 O O
hours O O
of O O
storage O O
. O O

A O O
late O O
diagnosis O O
of O O
retinoblastoma O O
is O O
an O O
unquestionable O O
fact O O
that O O
allows O O
its O O
growth O O
and O O
leads O O
to O O
a O O
deterioration O O
in O O
the O O
outlook O O
. O O

AP O O
was O O
induced O O
by O O
intraductal O O
infusion O O
of O O
two O O
different O O
concentrations O O
of O O
glycodeoxycholic O O
acid O O
( O O
GDOC O O
00 O O
mmol O O
and O O
00 O O
mmol O O
) O O
. O O

Tissue B-GENE O
plasminogen I-GENE O
activator I-GENE O
, O O
its O O
inhibitor O O
and O O
other O O
parameters O O
of O O
fibrinolysis O O
in O O
blood O O
of O O
patients O O
operated O O
for O O
mild O O
hypertrophy O O
of O O
the O O
prostate O O

The O O
chick O O
axon O O
- O O
associated O O
surface O O
glycoprotein O O
neurofascin B-GENE O
is O O
implicated O O
in O O
axonal O O
growth O O
and O O
fasciculation O O
as O O
revealed O O
by O O
antibody O O
perturbation O O
experiments O O
. O O

From O O
all O O
clinically O O
important O O
yeasts O O
species O O
, O O
a O O
total O O
of O O
00 O O
% O O
were O O
identified O O
by O O
ATB O O
method O O
according O O
to O O
conventional O O
methods O O
. O O

The O O
gene O O
sequence O O
also O O
identified O O
a O O
000 O O
- O O
nucleotide O O
RNA O O
in O O
total O O
yeast O O
RNA O O
and O O
in O O
purified O O
RNase B-GENE O
MRP I-GENE O
enzyme I-GENE O
preparations O O
. O O

Localization O O
of O O
the O O
brachial O O
plexus O O
with O O
the O O
nerve O O
stimulator O O
is O O
equally O O
effective O O
at O O
the O O
interscalene O O
, O O
supraclavicular O O
, O O
and O O
axillary O O
sites O O
. O O

As O O
a O O
part O O
of O O
a O O
large O O
examination O O
, O O
total O O
and O O
free O O
serum O O
cholesterol O O
, O O
total O O
lipid O O
and O O
triglyceride O O
levels O O
were O O
determined O O
. O O

The O O
gene O O
encoding O O
TRP B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
maps O I-GENE
to O O
mouse O O
chromosome O O
00 O O
, O O
in O O
the O O
region O O
of O O
the O O
coat B-GENE O
colour I-GENE O
mutation I-GENE O
slaty I-GENE O
. O O

Domain O O
II O O
is O O
highly O O
homologous O O
to O O
the O O
LDL B-GENE O
receptor I-GENE O
and O O
contains O O
four O O
repeats O O
with O O
perfect O O
conservation O O
of O O
all O O
0 O O
consecutive O O
cysteines O O
. O O

These O O
results O O
indicate O O
that O O
baculovirus O B-GENE
- O O
expressed O O
TR B-GENE O
mediates O O
transcriptional O O
activation O O
and O O
repression O O
in O O
a O O
promoter O O
- O O
specific O O
manner O O
in O O
vitro O O
. O O

This O O
report O O
substantiates O O
that O O
at O O
least O O
two O O
of O O
the O O
00 O O
kDa O O
hsps B-GENE O
in O O
maize O O
are O O
products O O
of O O
different O O
but O O
related O O
genes O O
. O O

The O O
EPO B-GENE O
levels O O
were O O
distinctly O O
increased O O
before O O
transfusion O O
; O O
they O O
did O O
not O O
significantly O O
change O O
just O O
after O O
transfusion O O
, O O
but O O
subsequently O O
decreased O O
. O O

Felodipine O O
did O O
not O O
alter O O
the O O
baseline O O
FEV0 O O
, O O
but O O
showed O O
a O O
small O O
significant O O
inhibitory O O
effect O O
upon O O
histamine O O
and O O
AMP O O
induced O O
bronchoconstriction O O
. O O

RNA O O
gel O O
retardation O O
and O O
competition O O
analyses O O
indicate O O
that O O
TRP B-GENE B-GENE
- I-GENE I-GENE
000 I-GENE I-GENE
binding O O
is O O
strongly O O
dependent O O
on O O
the O O
TAR O O
RNA O O
loop O O
sequences O O
. O O

Grossly O O
, O O
the O O
experimental O O
vulvitis O O
was O O
identical O O
to O O
the O O
field O O
condition O O
, O O
and O O
bacteria O O
indistinguishable O O
from O O
the O O
inoculated O O
strains O O
were O O
reisolated O O
. O O

Functional O O
rearranged O O
antibody O O
genes O O
were O O
detected O O
with O O
JH B-GENE O
and O O
VH B-GENE O
heavy I-GENE O
chain I-GENE O
probes O O
and O O
with O O
Jk B-GENE O
and O O
Vk B-GENE O
light I-GENE O
chain I-GENE O
probes O O
. O O

The O O
DNA O O
sequences O O
predict O O
proteins O O
for O O
SRP00sc B-GENE O
and O O
SRP00sp B-GENE O
that O O
are O O
00 O O
% O O
and O O
00 O O
% O O
identical O O
to O O
SRP00mam B-GENE O
, O O
respectively O O
. O O

Mapping O O
results O O
suggested O O
that O O
the O O
complementation O O
group O O
identified O O
by O O
these O O
mutants O O
is O O
allelic O O
to O O
the O O
ag B-GENE B-GENE
alpha I-GENE I-GENE
0 I-GENE I-GENE
mutation O O
identified O O
previously O O
. O O

Among O O
booked O O
patients O O
the O O
maternal O O
mortality O O
rate O O
was O O
0 O O
. O O
00 O O
and O O
among O O
unbooked O O
patients O O
00 O O
. O O
00 O O
per O O
0000 O O
deliveries O O
. O O

We O O
use O O
the O O
term O O
corticosteroid O O
- O O
dependent O O
IA O O
to O O
refer O O
to O O
the O O
serious O O
problem O O
of O O
chronic O O
IA O O
requiring O O
maintenance O O
prednisone O O
therapy O O
. O O

The O O
two O O
IL0 B-GENE O
mRNA I-GENE O
species O O
are O O
generated O O
by O O
alternative O O
polyadenylation O O
at O O
sites O O
separated O O
by O O
a O O
distance O O
of O O
0 O O
. O O
0 O O
kilobases O O
. O O

In O O
contrast O O
, O O
the O O
PPSF O O
+ O O
DBP O O
side O O
showed O O
large O O
amounts O O
of O O
bone O O
formation O O
, O O
and O O
bone O O
almost O O
covered O O
the O O
implant O O
. O O

Efficacy O O
and O O
field O O
evaluation O O
of O O
Bacillus O O
thuringiensis O O
( O O
H O O
- O O
00 O O
) O O
and O O
B O O
. O O
sphaericus O O
against O O
floodwater O O
mosquitoes O O
in O O
California O O
. O O

A O O
000 O O
- O O
base O O
pair O O
sequence O O
of O O
predominantly O O
repeating O O
purine O O
- O O
pyrimidine O O
nucleotides O O
separates O O
these O O
two O O
d O O
( O O
AC O O
) O O
repeats O O
. O O

The O O
PSS B-GENE B-GENE
gene I-GENE I-GENE
was O O
subcloned O O
into O O
a O O
0 O O
. O O
0 O O
- O O
kb O O
fragment O O
of O O
the O O
yeast O O
DNA O O
on O O
the O O
YEp00 O O
vector O O
. O O

The O O
results O O
of O O
these O O
experiments O O
indicate O O
that O O
at O O
least O O
two O O
upstream O O
activator O O
sequences O O
( O O
UAS O O
) O O
mediate O O
maximum O O
induction O O
by O O
galactose O O
. O O

Depending O O
on O O
the O O
location O O
and O O
size O O
of O O
the O O
mass O O
, O O
a O O
wide O O
range O O
of O O
clinical O O
presentations O O
is O O
associated O O
with O O
the O O
lesion O O
. O O

It O O
is O O
largely O O
predicted O O
by O O
lupus O O
anticoagulant O O
( O O
estimated O O
by O O
activated O O
partial O O
thromboplastin B-GENE O
time O O
) O O
and O O
/ O O
or O O
antibody O O
to O O
cardiolipin O O
. O O

The O O
strong O O
conservation O O
of O O
the O O
inverted O O
terminal O O
repeat O O
sequence O O
may O O
reflect O O
a O O
common O O
integration O O
mechanism O O
for O O
VL00 B-GENE O
elements I-GENE O
and O O
MuLV O O
proviruses O O
. O O

The O O
recovered O O
calves O O
were O O
tested O O
for O O
immunity O O
to O O
homologous O O
severe O O
challenge O O
, O O
00 O O
or O O
00 O O
days O O
after O O
the O O
first O O
infection O O
. O O

RNA B-GENE O
polymerase I-GENE O
IIA I-GENE O
was O O
recovered O O
in O O
transcriptionally O O
active O O
complexes O O
in O O
reactions O O
in O O
which O O
the O O
input O O
enzyme O O
was O O
RNA B-GENE O
polymerase I-GENE O
IIA I-GENE O
. O O

Amino O O
acid O O
sequence O O
comparison O O
revealed O O
significant O O
homology O O
between O O
the O O
yeast B-GENE O
and I-GENE O
Escherichia I-GENE O
coli I-GENE O
gamma I-GENE O
- I-GENE O
glutamyl I-GENE O
kinases I-GENE O
throughout O O
their O O
lengths O O
. O O

In O O
the O O
last O O
00 O O
years O O
, O O
the O O
therapeutic O O
uses O O
of O O
botulinum B-GENE O
toxin I-GENE O
, O O
a O O
potent O O
neurotoxin O O
, O O
have O O
been O O
investigated O O
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
has O O
the O O
greatest O O
homology O O
( O O
00 O O
% O O
) O O
to O O
the O O
green B-GENE O
alga I-GENE O
Scenedemus I-GENE O
obliquus I-GENE O
plastocyanin I-GENE O
. O O

We O O
conclude O O
that O O
Hansel O O
' O O
s O O
stain O O
substantially O O
improves O O
the O O
recognition O O
of O O
eosinophiluria O O
as O O
compared O O
with O O
Wright O O
' O O
s O O
stain O O
. O O

This O O
paper O O
presents O O
the O O
reasons O O
why O O
countries O O
to O O
which O O
Chagas O O
disease O O
is O O
endemic O O
should O O
carry O O
out O O
the O O
relevant O O
research O O
themselves O O
. O O

The O O
levels O O
of O O
NPY B-GENE O
- O O
ir O O
in O O
the O O
rat O O
vas O O
deferens O O
were O O
not O O
affected O O
by O O
either O O
surgical O O
or O O
pharmacological O O
treatment O O
. O O

This O O
loss O O
was O O
independent O O
of O O
drug O O
concentration O O
and O O
a O O
correction O O
factor O O
was O O
employed O O
to O O
calculate O O
the O O
true O O
free O O
diazepam O O
concentration O O
. O O

We O O
also O O
examined O O
the O O
relationship O O
between O O
the O O
side O O
of O O
sinusitis O O
and O O
the O O
cleft O O
side O O
in O O
patients O O
with O O
unilateral O O
cleft O O
palate O O
. O O

Evidence O O
for O O
a O O
role O O
of O O
endogenous B-GENE O
corticotropin I-GENE O
- I-GENE O
releasing I-GENE O
factor I-GENE O
in O O
cold O O
, O O
ether O O
, O O
immobilization O O
, O O
and O O
traumatic O O
stress O O
. O O

Reversal O O
of O O
the O O
increase O O
in O O
apomorphine O O
- O O
induced O O
stereotypy O O
and O O
aggression O O
in O O
REM O O
sleep O O
deprived O O
rats O O
by O O
dopamine O O
agonist O O
pretreatments O O
. O O

Inhibition O O
of O O
histalog O B-GENE
- O O
stimulated O O
gastric O O
secretion O O
by O O
00 O O
000 O O
RP O O
, O O
a O O
new O O
long O O
- O O
acting O O
gastric O O
antisecretory O O
agent O O
. O O

The O O
bearing O O
of O O
season O O
and O O
sequence O O
of O O
calving O O
on O O
frequency O O
of O O
male O O
, O O
female O O
and O O
total O O
calvings O O
in O O
Hariana O O
cows O O
. O O

The O O
primary O O
structure O O
of O O
the O O
GAL0 B-GENE O
0 I-GENE O
' I-GENE O
flanking I-GENE O
region I-GENE O
has O O
many O O
features O O
common O O
to O O
those O O
of O O
multicellular O O
eukaryotic O O
genes O O
. O O

Their O O
conduction O O
velocity O O
ranged O O
from O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
m O O
/ O O
sec O O
( O O
group O O
C O O
) O O
. O O

A O O
suspected O O
hypothalamic O O
dysfunction O O
and O O
a O O
slightly O O
impaired O O
pituitary O O
function O O
manifested O O
as O O
GH B-GENE O
deficiency O O
were O O
their O O
common O O
endocrinological O O
features O O
. O O

Mutational O O
analysis O O
of O O
essential O O
IncP O O
alpha O O
plasmid O O
transfer O O
genes O O
traF B-GENE O
and O O
traG B-GENE O
and O O
involvement O O
of O O
traF B-GENE O
in O O
phage O O
sensitivity O O
. O O

DIBA O O
was O O
more O O
sensitive O O
and O O
had O O
a O O
better O O
negative O O
predictive O O
value O O
and O O
a O O
lower O O
false O O
negative O O
percentage O O
than O O
DFAT O O
. O O

The O O
cDNA O O
has O O
an O O
open O O
reading O O
frame O O
of O O
000 O O
amino O O
acids O O
capable O O
of O O
encoding O O
a O O
00 O O
- O O
kDa O O
protein O O
. O O

axl O O
, O O
a O O
transforming O O
gene O O
isolated O O
from O O
primary O O
human O O
myeloid O O
leukemia O O
cells O O
, O O
encodes O O
a O O
novel O O
receptor B-GENE O
tyrosine I-GENE O
kinase I-GENE O
. O O

Cloning O O
of O O
a O O
human O O
cDNA O O
encoding O O
a O O
CDC0 B-GENE O
- I-GENE O
related I-GENE O
kinase I-GENE O
by O O
complementation O O
of O O
a O O
budding B-GENE O
yeast I-GENE O
cdc00 I-GENE O
mutation O O
. O O

Pulmonary O O
hypertension O O
, O O
with O O
or O O
without O O
coronary O O
arterial O O
narrowing O O
, O O
is O O
the O O
major O O
condition O O
leading O O
to O O
isolated O O
atrial O O
infarction O O
. O O

Fifteen O O
light O O
for O O
dates O O
infants O O
and O O
their O O
placentae O O
were O O
compared O O
to O O
00 O O
well O O
- O O
grown O O
infants O O
and O O
their O O
placentae O O
. O O

ATP O O
gamma O O
S O O
inhibition O O
can O O
be O O
overcome O O
by O O
high O O
concentrations O O
of O O
ATP O O
, O O
dATP O O
, O O
araATP O O
, O O
or O O
ddATP O O
. O O

In O O
contrast O O
, O O
a O O
similar O O
fragment O O
lacking O O
the O O
00 O O
- O O
base O O
- O O
pair O O
region O O
had O O
no O O
such O O
stabilizing O O
effect O O
. O O

Multistep O O
transformation O O
by O O
defined O O
fragments O O
of O O
herpes O O
simplex O O
virus O O
type O O
0 O O
DNA O O
: O O
oncogenic O O
region O O
and O O
its O O
gene O O
product O O
. O O

Active O O
lambda B-GENE O
and I-GENE O
kappa I-GENE B-GENE
antibody I-GENE I-GENE
gene I-GENE I-GENE
rearrangement O O
in O O
Abelson O O
murine O O
leukemia O O
virus O O
- O O
transformed O O
pre O O
- O O
B O O
cell O O
lines O O
. O O

The O O
incidence O O
of O O
cryptosporidiosis O O
in O O
young O O
children O O
was O O
determined O O
by O O
staining O O
of O O
faecal O O
specimens O O
with O O
a O O
modified O O
Kinyoun O O
stain O O
. O O

The O O
presence O O
in O O
such O O
patients O O
of O O
antibodies O O
to O O
adrenaline O O
and O O
noradrenaline O O
is O O
indicative O O
of O O
considerable O O
disruption O O
of O O
catecholamine O O
biotransformation O O
. O O

The O O
rats O O
were O O
used O O
for O O
the O O
study O O
of O O
the O O
effects O O
of O O
sepsis O O
on O O
the O O
utilization O O
of O O
exogenous O O
fat O O
emulsion O O
. O O

However O O
, O O
kidneys O O
perfused O O
for O O
00 O O
hr O O
demonstrated O O
more O O
similar O O
renal O O
functions O O
when O O
tested O O
by O O
either O O
IMPK O O
or O O
IBPK O O
. O O

We O O
also O O
observed O O
that O O
the O O
predictive O O
ability O O
of O O
the O O
selected O O
attitudes O O
and O O
orientations O O
increased O O
considerably O O
from O O
0000 O O
to O O
0000 O O
. O O

A O O
study O O
in O O
vivo O O
of O O
adrenergic B-GENE O
receptors I-GENE O
in O O
the O O
rectum O O
and O O
in O O
the O O
internal O O
and O O
sphincter O O
of O O
the O O
cat O O
. O O

The O O
effect O O
of O O
osmotic O O
flow O O
on O O
the O O
distribution O O
of O O
horseradish B-GENE O
peroxidase I-GENE O
within O O
the O O
intercellular O O
spaces O O
of O O
toad O O
bladder O O
epithelium O O
. O O

The O O
rational O O
for O O
the O O
prophylactic O O
treatment O O
, O O
the O O
therapy O O
of O O
the O O
meningopathy O O
and O O
AIL O O
- O O
AIEOP O O
protocols O O
are O O
exposed O O
. O O

The O O
unphosphorylated O O
form O O
of O O
RNA B-GENE O
polymerase I-GENE O
II I-GENE O
is O O
designated O O
IIA O O
, O O
whereas O O
the O O
phosphorylated O O
form O O
is O O
designated O O
IIO O O
. O O

Some O O
research O O
studies O O
have O O
related O O
this O O
kind O O
of O O
tumors O O
with O O
prolonged O O
ingestion O O
of O O
H0 O O
inhibitors O O
and O O
others O O
antacid O O
. O O

Isolation O O
and O O
characterization O O
of O O
the O O
rat O B-GENE
chromosomal O I-GENE
gene O I-GENE
for O O
a O O
polypeptide O O
( O O
pS0 B-GENE O
) O O
antigenically O O
related O O
to O O
statin B-GENE O
. O O

Relatively O O
little O O
is O O
known O O
regarding O O
the O O
role O O
of O O
0 B-GENE O
- I-GENE O
HT0 I-GENE I-GENE
receptor I-GENE I-GENE
activity O O
in O O
male O O
rat O O
sexual O O
behavior O O
. O O

Dd B-GENE O
PK0 I-GENE O
RNA I-GENE O
decreases O O
after O O
0 O O
h O O
of O O
starvation O O
to O O
re O O
- O O
accumulate O O
once O O
the O O
cells O O
have O O
aggregated O O
. O O

Ivermectin O O
uptake O O
and O O
distribution O O
in O O
the O O
plasma O O
and O O
tissue O O
of O O
Sudanese O O
and O O
Mexican O O
patients O O
infected O O
with O O
Onchocerca O O
volvulus O O
. O O

Evolution O O
of O O
lesions O O
did O O
not O O
necessarily O O
follow O O
a O O
regular O O
progression O O
through O O
the O O
later O O
stages O O
of O O
the O O
vitelliform O O
classification O O
. O O

Enhancer O O
and O O
promoter O O
elements O O
directing O O
activation O O
and O O
glucocorticoid O O
repression O O
of O O
the O O
alpha B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
fetoprotein I-GENE I-GENE
gene I-GENE I-GENE
in O O
hepatocytes O O
. O O

Isolated O O
proteinuria O O
( O O
i O O
. O O
e O O
. O O
without O O
hematuria O O
and O O
/ O O
or O O
pyuria O O
) O O
is O O
a O O
frequent O O
finding O O
. O O

All O O
of O O
the O O
indigo O O
- O O
producing O O
bacteria O O
had O O
an O O
indoxyl B-GENE O
phosphatase I-GENE O
with O O
a O O
pI O O
of O O
0 O O
. O O
0 O O
. O O

The O O
median O O
survival O O
is O O
not O O
reached O O
with O O
a O O
median O O
follow O O
- O O
up O O
time O O
of O O
0 O O
. O O
0 O O
years O O
. O O

Fourteen O O
patients O O
were O O
in O O
the O O
multifocal O O
disease O O
group O O
; O O
00 O O
were O O
detected O O
by O O
SPECT O O
and O O
00 O O
by O O
TCT O O
. O O

An O O
epidemiological O O
survey O O
of O O
rheumatic O O
valve O O
disease O O
and O O
rheumatic O O
fever O O
in O O
primary O O
and O O
secondary O O
school O O
students O O
in O O
Jiangxi O O
Province O O

Clinical O O
course O O
and O O
nursing O O
care O O
of O O
patients O O
with O O
decubitus O O
ulcer O O
- O O
- O O
use O O
of O O
pillows O O
stuffed O O
with O O
buckwheat O O
chaff O O

A O O
possible O O
role O O
for O O
the O O
mixed O O
function O O
oxidase B-GENE O
enzyme O O
system O O
in O O
the O O
requirement O O
for O O
selenium O O
in O O
the O O
rat O O
. O O

We O O
have O O
followed O O
00 O O
phenytoin O O
- O O
treated O O
patients O O
with O O
reduced O O
serum B-GENE O
IgA I-GENE O
concentrations O O
for O O
0 O O
- O O
0 O O
years O O
. O O

If O O
facilities O O
for O O
measurements O O
of O O
O0 O O
consumption O O
and O O
hence O O
metabolic O O
rate O O
are O O
available O O
, O O
these O O
should O O
be O O
utilized O O
. O O

This O O
implies O O
that O O
the O O
groups O O
do O O
not O O
just O O
differ O O
along O O
one O O
dimension O O
, O O
but O O
along O O
three O O
dimensions O O
. O O

As O O
expected O O
, O O
the O O
heparin O O
did O O
produce O O
increased O O
recalcification O O
times O O
and O O
the O O
development O O
of O O
occasional O O
subcutaneous O O
hematomas O O
. O O

The O O
most O O
common O O
cause O O
of O O
renal O O
deterioration O O
in O O
the O O
spinal O O
cord O O
injured O O
patient O O
is O O
irreversible O O
vesicoureteral O O
reflux O O
. O O

The O O
contraceptive O O
pattern O O
of O O
000 O O
women O O
was O O
analysed O O
and O O
00 O O
. O O
0 O O
percent O O
were O O
using O O
inefficient O O
methods O O
. O O

Study O O
of O O
the O O
physico O O
- O O
chemical O O
state O O
of O O
plutonium O B-GENE
- O I-GENE
000 O I-GENE
in O O
a O O
citrate O O
solution O O
- O O
blood O O
system O O

Both O O
Rep00 B-GENE O
and O O
Rep00 B-GENE O
cut O O
the O O
terminal O O
AAV O O
sequence O O
at O O
the O O
same O O
site O O
( O O
nucleotide O O
000 O O
) O O
. O O

Cloning O O
and O O
primary O O
structure O O
of O O
neurocan O O
, O O
a O O
developmentally O O
regulated O O
, O O
aggregating O O
chondroitin O O
sulfate O O
proteoglycan O O
of O O
brain O O
. O O

One O O
patients O O
had O O
plasma B-GENE O
C I-GENE O
- I-GENE O
peptide I-GENE O
greater O O
than O O
0 O O
pM O O
and O O
was O O
therefore O O
excluded O O
from O O
analysis O O
. O O

Serum B-GENE O
TNF I-GENE O
concentrations O O
were O O
elevated O O
at O O
diagnosis O O
and O O
gradually O O
decreased O O
toward O O
the O O
reference O O
limits O O
by O O
week O O
00 O O
. O O

The O O
remainder O O
( O O
00 O O
. O O
0 O O
% O O
) O O
was O O
with O O
IgA B-GENE O
nephropathy O O
, O O
which O O
was O O
histologically O O
mild O O
. O O

Rarely O O
, O O
patients O O
with O O
locally O O
advanced O O
, O O
uncontrollable O O
, O O
non O O
- O O
metastatic O O
prostatic O O
cancer O O
enjoy O O
prolonged O O
survival O O
. O O

We O O
have O O
identified O O
and O O
characterized O O
the O O
structure O O
of O O
the O O
Spec0 B-GENE B-GENE
gene I-GENE I-GENE
in O O
the O O
sea O O
urchin O O
Strongylocentrotus O O
purpuratus O O
. O O

Northern O O
analyses O O
of O O
RNAs O O
from O O
mouse O O
tissues O O
and O O
cell O O
lines O O
indicated O O
that O O
p00 B-GENE B-GENE
mRNA I-GENE O
levels O O
vary O O
widely O O
. O O

The O O
mean O O
weight O O
and O O
height O O
velocities O O
were O O
000 O O
% O O
and O O
000 O O
% O O
of O O
the O O
standard O O
, O O
respectively O O
. O O

Potentiation O O
of O O
the O O
thrombolytic O O
efficacy O O
of O O
single B-GENE B-GENE
- I-GENE I-GENE
chain I-GENE I-GENE
urokinase I-GENE I-GENE
( O O
Pro B-GENE O
- I-GENE O
urokinase I-GENE O
) O O
by O O
heparin O O
. O O

The O O
variability O O
is O O
most O O
likely O O
a O O
result O O
of O O
alternative O O
splicing O O
of O O
exons O O
from O O
the O O
primary O O
elastin B-GENE O
transcripts I-GENE O
. O O

The O O
temporal O O
and O O
static O O
plasma O O
concentration O O
- O O
effect O O
relationships O O
were O O
evaluated O O
by O O
pharmacodynamic O O
modeling O O
and O O
linear O O
regression O O
. O O

Duration O O
of O O
remission O O
in O O
advanced O O
gastric O O
cancer O O
patients O O
responding O O
to O O
sequential O O
dose O O
of O O
MTX O O
and O O
0 O O
- O O
FU O O

Delayed O O
mortality O O
of O O
mice O O
following O O
inhalation O O
of O O
acute O O
doses O O
of O O
CH0O O O
, O O
SO0Cl0 O O
, O O
and O O
Br0 O O
. O O

We O O
remain O O
convinced O O
that O O
antilymphocyte B-GENE B-GENE
globulin I-GENE I-GENE
( O O
ALG B-GENE O
) O O
is O O
a O O
potent O O
immunosuppressive O O
agent O O
in O O
humans O O
. O O

Wherever O O
the O O
site O O
of O O
the O O
conditioning O O
stimulation O O
, O O
these O O
modifications O O
disappeared O O
after O O
ischaemia O O
of O O
the O O
leg O O
. O O

Nucleotide O O
sequence O O
analysis O O
revealed O O
that O O
TAR B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
is O O
very O O
similar O O
to O O
the O O
CREB0 B-GENE B-GENE
protein I-GENE I-GENE
. O O

The O O
next O O
twenty O O
years O O
of O O
prevention O O
in O O
Indian O O
country O O
: O O
visionary O O
, O O
complex O O
, O O
and O O
practical O O
. O O

A O O
third O O
is O O
a O O
partial O O
element O O
terminating O O
at O O
a O O
probable O O
internal O O
restriction O O
site O O
used O O
for O O
cloning O O
. O O

In O O
conclusion O O
, O O
we O O
observed O O
a O O
great O O
regeneration O O
ability O O
following O O
mechanical O O
injury O O
in O O
the O O
nasal O O
mucosa O O
. O O

The O O
suppression O O
was O O
also O O
demonstrated O O
in O O
a O O
transient O O
expression O O
assay O O
in O O
vivo O O
using O O
isolated O O
barley O O
endosperms O O
. O O

In O O
adulthood O O
these O O
rats O O
were O O
hyperactive O O
and O O
learned O O
the O O
active O O
avoidance O O
response O O
later O O
than O O
the O O
controls O O
. O O

Uses O O
of O O
orthoclone O O
OKT0 B-GENE O
for O O
prophylaxis O O
of O O
rejection O O
and O O
induction O O
in O O
initial O O
nonfunction O O
in O O
kidney O O
transplantation O O
. O O

Uses O O
of O O
orthoclone O O
OKT0 O O
for O O
prophylaxis O O
of O O
rejection O O
and O O
induction O O
in O O
initial O O
nonfunction O O
in O O
kidney O O
transplantation O O
. O O

A O O
potential O O
TATA O O
box O O
is O O
located O O
00 O O
base O O
pairs O O
upstream O O
of O O
the O O
first O O
transcription O O
initiation O O
site O O
. O O

The O O
PETCO0 O O
measurement O O
during O O
precordial O O
compression O O
predicted O O
the O O
success O O
of O O
defibrillation O O
with O O
return O O
of O O
spontaneous O O
circulation O O
. O O

A O O
fine O O
- O O
structure O O
deletion O O
map O O
of O O
human O O
chromosome O O
00p O O
: O O
analysis O O
of O O
J0 O O
series O O
hybrids O O
. O O

The O O
seventh O O
cysteine O O
residue O O
of O O
CTSE B-GENE O
is O O
located O O
within O O
the O O
activation O O
peptide O O
region O O
of O O
the O O
proenzyme O O
. O O

A O O
second O O
promoter O O
activity O O
was O O
identified O O
in O O
the O O
region O O
between O O
the O O
two O O
major O O
transcriptional O O
start O O
sites O O
. O O

Translation O O
of O O
specific O O
cellular O O
genes O O
from O O
the O O
chimeric O O
viral O O
- O O
cellular O O
transcripts O O
seems O O
to O O
be O O
unlikely O O
. O O

The O O
genetic O O
basis O O
for O O
the O O
expression O O
of O O
a O O
latent O O
VH B-GENE O
allotype I-GENE O
in O O
the O O
rabbit O O
was O O
investigated O O
. O O

Reward O O
value O O
of O O
prosodic O O
features O O
of O O
language O O
for O O
autistic O O
, O O
mentally O O
retarded O O
, O O
and O O
normal O O
children O O
. O O

Amikacin O O
was O O
the O O
most O O
stable O O
and O O
tobramycin O O
was O O
the O O
least O O
stable O O
aminoglycoside O O
under O O
the O O
conditions O O
tested O O
. O O

This O O
may O O
explain O O
in O O
part O O
a O O
secular O O
trend O O
towards O O
reduced O O
birthweight O O
for O O
gestation O O
in O O
preterm O O
infants O O
. O O

It O O
has O O
been O O
reported O O
that O O
rat O O
blood O O
chloroform O O
levels O O
were O O
significantly O O
decreased O O
after O O
treatment O O
with O O
ClO0 O O
. O O

Pre B-GENE O
- I-GENE O
beta I-GENE O
- I-GENE O
0 I-GENE O
lipoprotein I-GENE O
and O O
early O O
detection O O
of O O
risk O O
factors O O
for O O
coronary O O
heart O O
disease O O
. O O

Effects O O
of O O
ionizing O O
radiation O O
in O O
the O O
human O O
oral O O
cavity O O
and O O
oropharynx O O
: O O
results O O
of O O
a O O
survey O O
. O O

The O O
non O O
- O O
role O O
of O O
fluoride O O
in O O
the O O
control O O
of O O
plasma O O
calcium O O
in O O
the O O
parathyroidectomized O O
rat O O
. O O

The O O
effect O O
of O O
low O O
dosage O O
radiation O O
on O O
metabolism O O
and O O
function O O
of O O
the O O
rat O O
kidney O O
damaged O O
by O O
ischemia O O

Effect O O
of O O
heparin O O
on O O
the O O
inactivation O O
of O O
serum B-GENE O
lipoprotein I-GENE O
lipase I-GENE O
by O O
the O O
liver O O
in O O
unanesthetized O O
dogs O O
. O O

The O O
abluminal O O
surface O O
is O O
often O O
almost O O
entirely O O
encircled O O
by O O
a O O
thick O O
layer O O
of O O
fibrillary O O
connective O O
tissue O O
. O O

Sweet O O
oranges O O
, O O
mandarin O O
, O O
grapefruit O O
, O O
lemon O O
, O O
and O O
lime O O
are O O
generally O O
used O O
for O O
processing O O
. O O

The O O
Sarns O O
00F O O
cavoatrial O O
cannula O O
decompressed O O
the O O
venous O O
system O O
as O O
efficiently O O
as O O
the O O
double O O
caval O O
cannulas O O
. O O

The O O
overall O O
incidence O O
of O O
SIDS O O
was O O
0 O O
. O O
00 O O
per O O
0 O O
, O O
000 O O
live O O
births O O
. O O

Estimation O O
of O O
L O O
- O O
alanine O O
in O O
serum O O
or O O
plasma O O
using O O
the O O
LKB O O
reaction O O
rate O O
analyser O O
. O O

This O O
sequence O O
is O O
almost O O
identical O O
with O O
that O O
of O O
human B-GENE B-GENE
luteinizing I-GENE I-GENE
hormone I-GENE I-GENE
( O O
Sairam O O
, O O
M O O
. O O

This O O
computation O O
is O O
performed O O
by O O
a O O
parallel O O
network O O
of O O
locally O O
connected O O
neuron O O
- O O
like O O
elements O O
. O O

Deregulation O O
of O O
their O O
expression O O
may O O
contribute O O
to O O
malignant O O
transformation O O
associated O O
with O O
HTLV O B-GENE
- O I-GENE
0 O I-GENE
infection O O
. O O

Nucleotide O O
sequences O O
between O O
the O O
env B-GENE B-GENE
gene I-GENE I-GENE
and O O
the O O
LTR B-GENE O
of I-GENE O
SFV I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
were O O
determined O O
. O O

Arterial O O
radioactivity O O
content O O
after O O
the O O
intravenous O O
administration O O
of O O
HMPAO O O
in O O
seven O O
human O O
subjects O O
was O O
analyzed O O
. O O

In O O
all O O
cases O O
, O O
high O O
- O O
level O O
expression O O
of O O
the O O
truncated B-GENE O
avian I-GENE O
integrins I-GENE O
was O O
obtained O O
. O O

0 O O
, O O
among O O
which O O
nine O O
have O O
been O O
cloned O O
and O O
two O O
( O O
potentially O O
functional O O
) O O
sequenced O O
. O O

The O O
urinary O O
protein O O
, O O
serum O O
albumin B-GENE O
, O O
BUN O O
and O O
SCr O O
all O O
had O O
very O O
significant O O
improvement O O
. O O

A O O
poor O O
correlation O O
was O O
also O O
observed O O
between O O
PbB O O
and O O
ALAD B-GENE O
activity O O
of O O
the O O
stearate O O
workers O O
. O O

Xenopus B-GENE O
homolog I-GENE O
of I-GENE O
the I-GENE O
mos I-GENE O
protooncogene I-GENE O
transforms O O
mammalian O O
fibroblasts O O
and O O
induces O O
maturation O O
of O O
Xenopus O O
oocytes O O
. O O

Erythrocytic O O
stages O O
of O O
mammalian O O
malarial O O
parasites O O
contain O O
acristate O O
mitochondria O O
whose O O
functions O O
are O O
not O O
well O O
understood O O
. O O

Restriction O O
maps O O
of O O
the O O
cloned O O
plasmids O O
revealed O O
that O O
their O O
chromosomal O O
inserts O O
consisted O O
of O O
overlapping O O
fragments O O
. O O

The O O
antigen B-GENE B-GENE
- I-GENE O
specific I-GENE O
IgG0 I-GENE O
antibody I-GENE O
seems O O
to O O
be O O
an O O
index O O
in O O
evaluating O O
immunotherapy O O
objectively O O
. O O

In O O
one O O
acromegalic O O
patient O O
visual O O
improvement O O
was O O
obtained O O
while O O
the O O
abnormal O O
GH B-GENE O
secretion O O
remained O O
unaltered O O
. O O

In O O
00 O O
evaluable O O
patients O O
the O O
response O O
rate O O
was O O
00 O O
% O O
, O O
with O O
one O O
complete O O
response O O
. O O

The O O
East O O
African O O
dik O O
- O O
dik O O
antelope O O
represents O O
a O O
miniature O O
model O O
ruminant O O
for O O
comparative O O
studies O O
. O O

Two O O
mutants O O
, O O
each O O
representative O O
of O O
a O O
separate O O
pet B-GENE O
complementation O O
group O O
, O O
have O O
been O O
analyzed O O
. O O

A O O
case O O
of O O
AIDS O O
- O O
related O O
complex O O
( O O
ARC O O
/ O O
LAS O O
) O O
in O O
a O O
health O O
worker O O

The O O
H0 B-GENE O
receptor I-GENE O
antagonists O O
and O O
sucralfate O O
cost O O
about O O
the O O
same O O
and O O
have O O
few O O
side O O
effects O O
. O O

Effect O O
of O O
castration O O
on O O
pituitary B-GENE O
and I-GENE O
serum I-GENE O
LH I-GENE O
and O O
FSH B-GENE O
in O O
testosterone O O
- O O
sterilized O O
rats O O
. O O

The O O
significance O O
of O O
the O O
phenolphthalein B-GENE O
sulphatase I-GENE O
test O O
for O O
the O O
differentiation O O
and O O
identification O O
of O O
Nocardia O O
species O O
. O O

Plasma B-GENE O
secretin I-GENE O
, O O
pancreozymin B-GENE O
, O O
and O O
somatostatin B-GENE B-GENE
- I-GENE O
like I-GENE O
hormone I-GENE O
in O O
chronic O O
renal O O
failure O O
patients O O
. O O

Transitory O O
subclinical O O
and O O
permanent O O
hypothyroidism O O
in O O
the O O
course O O
of O O
subacute O O
thyroiditis O O
( O O
de O O
Quervain O O
) O O
. O O

During O O
the O O
following O O
0 O O
0 O O
/ O O
0 O O
years O O
three O O
sequential O O
liver O O
biopsies O O
were O O
performed O O
. O O

Neither O O
gene O O
possesses O O
a O O
distinct O O
transcriptional O O
start O O
site O O
as O O
shown O O
by O O
nuclease B-GENE O
S0 I-GENE O
analysis O O
. O O

Gene O O
and O O
pseudogene O O
of O O
the O O
mouse O O
cation O O
- O O
dependent O O
mannose B-GENE I-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
phosphate I-GENE I-GENE
receptor I-GENE I-GENE
. O O

Cold O O
cardioplegia O O
was O O
administered O O
at O O
00 O O
mm O O
Hg O O
every O O
00 O O
minutes O O
for O O
0 O O
hours O O
. O O

An O O
approximately O O
0 B-GENE O
- I-GENE O
kilobase I-GENE O
B0 I-GENE O
transcript I-GENE O
was O O
expressed O O
in O O
all O O
alfalfa O O
organs O O
tested O O
. O O

Insulin B-GENE O
- I-GENE O
like I-GENE O
growth I-GENE O
factor I-GENE O
0 I-GENE O
( O O
IGF B-GENE O
- I-GENE O
0 I-GENE O
) O O
in O O
burn O O
patients O O
. O O

Subjects O O
were O O
00 O O
male O O
chronic O O
schizophrenics O O
consisting O O
of O O
0 O O
DST O O
suppressors O O
and O O
0 O O
nonsuppressors O O
. O O

Rats O O
with O O
one O O
olfactory O O
bulb O O
removed O O
and O O
the O O
contralateral O O
naris O O
closed O O
can O O
detect O O
odors O O
. O O

Isolation O O
of O O
Weeksella O O
virosa O O
( O O
formerly O O
CDC O O
group O O
IIf O O
) O O
from O O
a O O
vaginal O O
sample O O
. O O

The O O
lowest O O
detectable O O
concentration O O
was O O
0 O O
. O O
0 O O
ng O O
/ O O
ml O O
in O O
the O O
serum O O
. O O

Aplastic O O
crisis O O
in O O
sickle O O
cell O O
disorders O O
: O O
bone O O
marrow O O
necrosis O O
and O O
human O O
parvovirus O O
infection O O
. O O

Factors O O
influencing O O
the O O
bond O O
strength O O
between O O
glass O O
polyalkenoate O O
( O O
ionomer O O
) O O
cements O O
and O O
dentine O O
. O O

Neither O O
ethanol O O
nor O O
estrogen O O
has O O
been O O
shown O O
to O O
cause O O
UROD B-GENE O
- O O
deficiency O O
in O O
animals O O
. O O

Possible O O
pathogenetic O O
mechanisms O O
of O O
hemopoietic O O
changes O O
in O O
response O O
to O O
space O O
flight O O
effects O O
are O O
described O O
. O O

Effects O O
of O O
a O O
low O O
- O O
energy O O
laser O O
beam O O
on O O
the O O
cells O O
of O O
the O O
newt O O
embryo O O

The O O
primary O O
CT O O
findings O O
were O O
misinterpreted O O
as O O
a O O
brain O O
infarct O O
or O O
possibly O O
a O O
tumour O O
. O O

Lower O O
extremity O O
weight O O
bearing O O
under O O
various O O
standing O O
conditions O O
in O O
independently O O
ambulatory O O
patients O O
with O O
hemiparesis O O
. O O

Early O O
disagnosis O O
of O O
cancer O O
- O O
- O O
00 O O
per O O
cent O O
of O O
all O O
patients O O
could O O
be O O
cured O O

With O O
certain O O
exceptions O O
the O O
method O O
was O O
considered O O
suitable O O
in O O
the O O
routine O O
intravenous O O
cholangiography O O
. O O

0 O O
) O O
The O O
time O O
- O O
sharing O O
principle O O
was O O
applied O O
to O O
gain O O
high O O
stability O O
. O O

The O O
histochemistry O O
and O O
ultrastructure O O
of O O
calcified O O
cerebellar O O
deposits O O
described O O
by O O
Tonge O O
et O O
al O O
. O O

The O O
enhancer O O
region O O
of O O
Akv O O
murine O O
leukemia O O
virus O O
contains O O
the O O
sequence O O
motif O O
ACAGATGG O O
. O O

The O O
rationale O O
for O O
continuous O O
dopaminergic O O
stimulation O O
in O O
patients O O
with O O
Parkinson O O
' O O
s O O
disease O O
. O O

Among O O
these O O
, O O
ACT0 B-GENE O
was O O
isolated O O
four O O
times O O
, O O
and O O
NSR0 B-GENE O
three O O
times O O
. O O

Caries O O
and O O
parodontitis O O
have O O
been O O
one O O
of O O
the O O
most O O
spread O O
diseases O O
of O O
mankind O O
. O O

The O O
experimental O O
group O O
consisted O O
of O O
00 O O
examinees O O
class O O
II O O
/ O O
0 O O
orthodontic O O
anomalies O O
. O O

The O O
genomic O O
and O O
transcriptional O O
complexity O O
of O O
the O O
Crry B-GENE B-GENE
and O O
Crry B-GENE B-GENE
- O I-GENE
ps B-GENE I-GENE
genes O I-GENE
. O O

Lars O O
has O O
AIDS O O
- O O
- O O
a O O
more O O
dignified O O
life O O
with O O
care O O
at O O
home O O
. O O

Five O O
patients O O
developed O O
metastatic O O
spread O O
, O O
and O O
all O O
of O O
them O O
died O O
of O O
tumor O O
. O O

Histological O O
examination O O
revealed O O
a O O
small O O
simple O O
renal O O
cyst O O
associated O O
with O O
renal O O
cell O O
carcinoma O O
. O O

Critical O O
evaluation O O
of O O
various O O
methods O O
of O O
determining O O
markers O O
of O O
fetal O O
maturity O O
in O O
amniotic O O
fluid O O

Neuromyelitis O O
optica O O
( O O
Devic O O
' O O
s O O
syndrome O O
) O O
: O O
not O O
always O O
multiple O O
sclerosis O O
. O O

Effect O O
of O O
the O O
methods O O
of O O
cutaneous O O
administration O O
of O O
methyl O O
isobutyl O O
ketone O O
on O O
its O O
toxicity O O

Contraction O O
of O O
the O O
tracheal O O
muscle O O
and O O
the O O
activity O O
of O O
stretch O O
receptors O O
in O O
the O O
trachea O O

N O O
- O O
Substituted O O
trimethylsilylcarbamates O O
were O O
tested O O
as O O
derivatizing O O
reagents O O
for O O
gas O O
chromatographic O O
analysis O O
. O O

Five O O
- O O
year O O
prospective O O
study O O
of O O
peripheral O O
white O O
blood O O
cells O O
in O O
infectious O O
mononucleosis O O
. O O

Treatment O O
with O O
oxyphenylbutazone O O
and O O
hydrocortisone O O
failed O O
to O O
inhibit O O
the O O
raised O O
serum B-GENE O
CPN I-GENE O
levels O O
. O O

Re O O
- O O
examining O O
methylbenzene O O
( O O
toluene O O
) O O
as O O
a O O
treatment O O
for O O
Ancylostomum O O
caninum O O
. O O

Modification O O
of O O
the O O
growth O O
of O O
Tetrahymena O O
by O O
compounds O O
which O O
affect O O
the O O
adrenergic O O
mechanism O O
. O O

Morphogenesis O O
of O O
the O O
trochanter O O
produced O O
by O O
femoral O O
regeneration O O
in O O
the O O
phasmid O O
Carausius O O
morosus O O
Br O O

Combination O O
of O O
a O O
Shwachman O O
syndrome O O
and O O
a O O
complex O O
granulocyte O O
function O O
disorder O O
in O O
a O O
girl O O

Measurement O O
of O O
magnesium O O
absorption O O
in O O
man O O
using O O
stable O O
00Mg O O
as O O
a O O
tracer O O
. O O

Naturally O O
acquired O O
antibodies O O
were O O
demonstrated O O
in O O
some O O
rabbits O O
kept O O
on O O
commercial O O
farms O O
. O O

INTERVENTIONS O O
: O O
Patients O O
received O O
rt B-GENE O
- I-GENE O
PA I-GENE O
, O O
heparin O O
, O O
and O O
aspirin O O
. O O

Habituation O O
of O O
completely O O
isolated O O
neurons O O
of O O
the O O
edible O O
snail O O
to O O
electrical O O
stimulation O O
. O O

No O O
recombination O O
signal O O
sequences O O
have O O
been O O
found O O
contiguous O O
to O O
the O O
recombination O O
point O O
. O O

Determination O O
of O O
three O O
- O O
dimensional O O
imaging O O
properties O O
of O O
a O O
light O O
microscope O O
system O O
. O O

A O O
brief O O
account O O
of O O
the O O
0000 O O
seminar O O
in O O
Shanghai O O
on O O
viral O O
hepatitis O O
A O O

Most O O
of O O
them O O
were O O
situated O O
at O O
Sylvius O O
fissure O O
( O O
00 O O
cases O O
) O O
. O O

Effects O O
of O O
a O O
perfluorochemical O O
blood O O
substitute O O
on O O
diazepam O O
binding O O
by O O
human B-GENE O
albumin I-GENE O
. O O

These O O
similarities O O
suggest O O
that O O
these O O
E0 B-GENE O
proteins I-GENE O
are O O
structurally O O
and O O
evolutionarily O O
related O O
. O O

Thus O O
, O O
prostacyclin O O
enhanced O O
the O O
autoregulative O O
property O O
of O O
the O O
inner O O
ear O O
vessels O O
. O O

Effects O O
of O O
long O O
- O O
term O O
parenteral O O
nutrition O O
on O O
gastrin B-GENE O
release O O
in O O
dogs O O
. O O

Conservative O O
treatment O O
of O O
bladder O O
carcinoma O O
by O O
partial O O
cystectomy O O
and O O
interstitial O O
iridium O O
000 O O
. O O

Thyrotropin B-GENE O
- I-GENE O
releasing I-GENE O
hormone I-GENE O
- O O
induced O O
contraction O O
of O O
urethral O O
and O O
vaginal O O
muscle O O
. O O

Estral O O
cycle O O
in O O
white O O
rats O O
in O O
the O O
low O O
and O O
high O O
mountains O O
of O O
Kirghizia O O

Sensitization O O
to O O
hyperlactatemia O O
induced O O
by O O
phenformin O O
after O O
subtotal O O
ablation O O
of O O
the O O
pancreas O O
. O O

00th O O
birthday O O
of O O
colonel O O
prof O O
. O O
e O O
. O O
cerny O O
m O O
. O O
d O O
. O O

Effect O O
of O O
a O O
high O O
- O O
intensity O O
SHF O O
field O O
on O O
the O O
blood O O
coagulation O O
system O O

The O O
distribution O O
of O O
body O O
fluids O O
following O O
hemorrhage O O
and O O
resuscitation O O
in O O
combat O O
casualties O O
. O O

Propagation O O
and O O
hormone O O
production O O
by O O
human O O
normal O O
and O O
malignant O O
trophoblast O O
in O O
rats O O
. O O

The O O
effect O O
of O O
a O O
constant O O
magnetic O O
field O O
on O O
the O O
phagocytic O O
activity O O
of O O
Paramecia O O

On O O
the O O
amount O O
and O O
significance O O
of O O
the O O
effective O O
glucose O O
level O O
in O O
tumors O O
. O O

Potency O O
of O O
enflurane O O
in O O
dogs O O
: O O
comparison O O
with O O
halothane O O
and O O
isoflurane O O
. O O

Petrous O O
meningioma O O
en O O
plaque O O
presenting O O
as O O
a O O
right O O
middle O O
ear O O
tumor O O
. O O

A O O
study O O
of O O
chromosomes O O
of O O
lymphocytes O O
from O O
patients O O
treated O O
with O O
hycanthone O O
. O O

BiP000 B-GENE O
retains O O
basal O O
and O O
Ca0 O O
+ O O
ionophore O O
A00000 O O
- O O
inducible O O
activities O O
. O O

However O O
, O O
other O O
regions O O
of O O
the O O
plasmid O O
are O O
also O O
efficiently O O
repaired O O
. O O

A O O
method O O
for O O
establishing O O
stimulus O O
control O O
of O O
ethanol O O
responding O O
was O O
developed O O
. O O

0 O O
( O O
" O O
long O O
method O O
" O O
) O O
and O O
the O O
HML O O
method O O
. O O

Comparison O O
of O O
propofol O O
and O O
thiopentone O O
as O O
anaesthetic O O
agents O O
for O O
electroconvulsive O O
therapy O O
. O O

Swim O O
- O O
over O O
: O O
an O O
alternative O O
method O O
for O O
harvesting O O
motile O O
spermatozoa O O
. O O

0 O O
cases O O
of O O
type O O
II O O
tyrosinosis O O
( O O
Richner O O
- O O
Hanhart O O
syndrome O O
) O O

The O O
method O O
is O O
accurate O O
, O O
with O O
good O O
precision O O
and O O
adequate O O
sensitivity O O
. O O

Plasma B-GENE O
renin I-GENE O
activity O O
does O O
not O O
predict O O
the O O
antihypertensive O O
efficacy O O
of O O
chlorthalidone O O
. O O

Liquid O O
chromatographic O O
method O O
for O O
determination O O
of O O
citreoviridin O O
in O O
corn O O
and O O
rice O O
. O O

A O O
Golgi O O
study O O
of O O
the O O
sixth O O
layer O O
of O O
the O O
cerebral O O
cortex O O
. O O

Some O O
reflexions O O
apropos O O
of O O
a O O
personal O O
statistical O O
study O O
of O O
000 O O
arterial O O
embolisms O O

Factors O O
influencing O O
in O O
vitro O O
skin B-GENE O
permeability I-GENE O
factor I-GENE O
production O O
by O O
Vibrio O O
cholerae O O
. O O

Quantitation O O
of O O
exocrine B-GENE O
IgA I-GENE O
in O O
human O O
serum O O
in O O
health O O
and O O
disease O O
. O O

These O O
differences O O
are O O
smaller O O
than O O
those O O
described O O
in O O
standard O O
textbooks O O
. O O

Female O O
mice O O
were O O
significantly O O
more O O
resistant O O
to O O
infection O O
than O O
males O O
. O O

Urine O O
antibodies O O
could O O
not O O
be O O
demonstrated O O
in O O
any O O
other O O
cases O O
. O O

Bacteriostatic O O
and O O
bacteriacidal O O
activity O O
of O O
hydroxy O B-GENE
- O I-GENE
0 O I-GENE
ellipticine O O
in O O
vitro O O

Personal O O
satisfaction O O
in O O
nursing O O
: O O
an O O
encounter O O
with O O
extremely O O
hostile O O
patients O O

No O O
evidence O O
of O O
either O O
positive O O
or O O
negative O O
chemography O O
was O O
found O O
. O O

The O O
two O O
drugs O O
increase O O
the O O
rate O O
of O O
early O O
diastolic O O
filling O O
. O O

Rice B-GENE O
dwarf I-GENE O
phytoreovirus I-GENE O
segment I-GENE O
S00 I-GENE O
transcript I-GENE O
is O O
tricistronic O O
in O O
vitro O O
. O O

The O O
calcium O O
requirement O O
for O O
hypothermic O O
storage O O
of O O
the O O
cardiac O O
explant O O
. O O

The O O
transcription O O
initiation O O
site O O
was O O
determined O O
by O O
S0 B-GENE O
nuclease I-GENE O
mapping O O
. O O

Successful O O
use O O
of O O
transureteroureterostomy O O
to O O
salvage O O
ureterosigmoidostomy O O
after O O
anastomotic O O
failure O O
. O O

There O O
were O O
no O O
interfering O O
peaks O O
in O O
the O O
quantitation O O
of O O
sulbactam O O
. O O

Morphine O O
produced O O
a O O
dose O O
- O O
dependent O O
bradycardia O O
followed O O
by O O
tachycardia O O
. O O

Vimentin B-GENE O
positivity O O
was O O
noted O O
in O O
the O O
undifferentiated O O
and O O
fibroblastic O O
components O O
. O O

Intensification O O
of O O
human O O
myocardial O O
contractile O O
activity O O
as O O
affected O O
by O O
blood O O
serum O O

The O O
M O B-GENE
- O I-GENE
0 O I-GENE
subtype O I-GENE
was O O
an O O
adverse O O
prognostic O O
factor O O
. O O

Postnatal O O
volumetric O O
development O O
of O O
the O O
prefrontal O O
cortex O O
in O O
the O O
rat O O
. O O

Analysis O O
of O O
clearance O O
curve O O
of O O
rose O O
bengal O O
- O O
I O O
- O O
000 O O

Plastic O O
solution O O
of O O
elbow O O
joint O O
ankylosis O O
with O O
a O O
decorticated O O
cylindrical O O
flap O O

Working O O
session O O
report O O
: O O
in O O
vivo O O
- O O
in O O
vitro O O
screening O O
. O O

The O O
absolute O O
configuration O O
at O O
C O B-GENE
- O I-GENE
0 O I-GENE
in O O
monocrotalic O O
acid O O
. O O

Story O O
of O O
a O O
hospital O O
that O O
filmed O O
its O O
employee O O
orientation O O
program O O
. O O

The O O
biochemistry O O
of O O
amniotic O O
fluid O O
with O O
poor O O
fetal O O
growth O O
. O O

The O O
ventilation O O
did O O
not O O
increase O O
when O O
PACO0 O O
was O O
increased O O
. O O

Changes O O
of O O
thirtynine O O
serum O O
protein O O
components O O
following O O
surgical O O
stress O O
. O O

Guinea O O
pigs O O
weighing O O
000 O O
approximately O O
000 O O
g O O
were O O
used O O
. O O

Elimination O O
of O O
bagassosis O O
in O O
Louisiana O O
paper O O
manufacturing O O
plant O O
workers O O
. O O

Respiratory O O
interaction O O
after O O
spinal O O
anesthesia O O
and O O
sedation O O
with O O
midazolam O O
. O O

Hemorrhagic O O
shock O O
and O O
bacterial O O
translocation O O
in O O
a O O
swine O O
model O O
. O O

In O O
addition O O
serum B-GENE O
IgE I-GENE O
concentrations O O
were O O
not O O
statistically O O
different O O
. O O

Water O O
content O O
and O O
equilibrium O O
water O O
partition O O
in O O
immature O O
cartilage O O
. O O

Development O O
of O O
a O O
yeast O O
system O O
to O O
assay O O
mutational O O
specificity O O
. O O

Splenectomized O O
patients O O
are O O
predisposed O O
toward O O
developing O O
overwhelming O O
bacterial O O
infections O O
. O O

Study O O
of O O
antinuclear O O
autoantibodies O O
by O O
immunofluorescence O O
technic O O
in O O
collagen B-GENE O
diseases O O

Gel O O
route O O
preparation O O
of O O
low O O
fusing O O
dental O O
porcelain O O
frit O O
. O O

None O O
of O O
the O O
cystometrograms O O
showed O O
uninhibited O O
detrusor O O
contractions O O
. O O

Allergic O O
reaction O O
to O O
Patent O O
Blue O O
Violet O O
during O O
lymphography O O
. O O

Evaluation O O
of O O
the O O
Du O O
Pont O O
aca O O
ammonia O O
procedure O O
. O O

Residues O O
removed O O
from O O
transcripts O O
by O O
splicing O O
were O O
identified O O
. O O

During O O
activity O O
III O O
, O O
one O O
patient O O
developed O O
angina O O
. O O

Acquired O O
factor B-GENE O
VIII I-GENE O
inhibitor O O
in O O
non O O
- O O
hemophilic O O
patients O O

00 O O
: O O
000 O O
- O O
000 O O
, O O
0000 O O
) O O
. O O

FDA O O
regulations O O
for O O
growth O O
factors O O
and O O
related O O
products O O
. O O

In O O
a O O
previous O O
study O O
( O O
Brandl O O
, O O
C O O
. O O

The O O
gene O O
is O O
essential O O
for O O
yeast O O
vegetative O O
growth O O
. O O

Man O O
and O O
insect O O
, O O
past O O
, O O
present O O
, O O
future O O

Mean O O
fluorosis O O
scores O O
, O O
however O O
, O O
were O O
similar O O
. O O

Novel O O
multigene O O
families O O
encoding O O
highly O O
repetitive O O
peptide O O
sequences O O
. O O

National O O
Institutes O O
of O O
Health O O
Consensus O O
Development O O
Conference O O
Statement O O
. O O

Studies O O
on O O
the O O
organic O O
matrix O O
of O O
human O O
ear O O
ossicles O O

The O O
Twentieth O O
Anniversary O O
of O O
the O O
Pomeranian O O
Medical O O
Academy O O
. O O

Nitrogen O O
- O O
hydrogen O O
tautomerism O O
in O O
porphyrins O O
and O O
chlorins O O
. O O

CO0 O O
assimilation O O
by O O
chloroplasts O O
illuminated O O
on O O
filter O O
paper O O
. O O

Experience O O
with O O
the O O
tensor O O
fasciae O O
latae O O
free O O
flap O O
. O O

Risk O O
of O O
infection O O
in O O
the O O
treatment O O
of O O
fractures O O

The O O
circadian O O
rhythmicity O O
of O O
sleep O O
was O O
pronounced O O
. O O

Both O O
parents O O
are O O
clinically O O
normal O O
and O O
unrelated O O
. O O

Treating O O
renal O O
anaemia O O
with O O
recombinant O O
human O O
erythropoietin B-GENE O
. O O

Postcoital O O
contraception O O
: O O
a O O
family O O
planning O O
study O O
. O O

No O O
effect O O
was O O
found O O
on O O
grooming O O
behavior O O
. O O

Clinical O O
and O O
biological O O
correlates O O
of O O
panic O O
states O O
. O O

Autonomic O O
dysfunctions O O
were O O
restricted O O
to O O
tonic O O
pupils O O
. O O

Metastasis O O
of O O
colon O O
carcinoma O O
to O O
the O O
lip O O
. O O

Reactivities O O
to O O
horse B-GENE O
anti I-GENE O
- I-GENE O
lymphocyte I-GENE O
globulin I-GENE O
. O O

Periodic O O
breathing O O
and O O
apnea O O
in O O
preterm O O
infants O O
. O O

Dynamics O O
of O O
hospital O O
stay O O
in O O
peptic O O
ulcer O O
patients O O

The O O
content O O
of O O
glucosamine O O
and O O
galactosamine O O
in O O
tartar O O

Tolerance O O
test O O
of O O
HB O O
000 O O
in O O
animal O O
experiments O O

Once O O
more O O
Hong O O
Kong O O
influenza O O
in O O
the O O
Netherlands O O

Antimicrobial O O
substance O O
isolated O O
from O O
an O O
acorn O O
extract O O
. O O

Propranolol O O
also O O
effectively O O
controlled O O
her O O
familial O O
tremor O O
. O O

Abnormal O O
calcium O O
metabolism O O
in O O
normocalcaemic O O
sarcoidosis O O
. O O

Circulatory O O
arrest O O
in O O
the O O
operating O O
room O O
. O O

Use O O
of O O
free O O
- O O
access O O
minerals O O
. O O

Growth O O
of O O
tracheal O O
anastomoses O O
in O O
growing O O
animals O O

Inefficacy O O
of O O
phosphine O O
fumigation O O
against O O
ticks O O
. O O

They O O
also O O
discuss O O
the O O
existing O O
nomenclature O O
. O O

Teratological O O
studies O O
on O O
SF O O
- O O
000 O O
. O O

Morphology O O
of O O
bacteriophages O O
of O O
Klebsiella O O
bacilli O O
. O O

Methyl O O
mercury O O
intoxication O O
in O O
rat O O
kidneys O O
. O O

Difficulties O O
bound O O
to O O
measuring O O
of O O
sputum O O
viscosity O O

Evaluation O O
of O O
automatic O O
blood O O
cell O O
counters O O
. O O

Relations O O
between O O
adrenergic O O
mechanisms O O
and O O
analgesic O O
effects O O

The O O
need O O
in O O
the O O
small O O
hospital O O
. O O

Climatic O O
treatment O O
of O O
children O O
with O O
respiratory O O
allergy O O

Treatment O O
of O O
Graves O O
' O O
disease O O
. O O

Extramedullary O O
plasmacytoma O O
of O O
the O O
parotid O O
gland O O

Histamine O B-GENE
- O I-GENE
0 O O
blockade O O
in O O
psoriasis O O

Uptake O O
of O O
ofloxacin O O
by O O
Escherichia O O
coli O O

Van O O
der O O
Ende O O
, O O
R O O
. O O

By O O
Felix O O
Lagrange O O
, O O
0000 O O
. O O

Diagnosis O O
: O O
progressive O O
multifocal O O
leukoencephalopathy O O
. O O

Problems O O
common O O
to O O
pediatrics O O
and O O
anesthesiology O O

Benign O O
intramural O O
tumors O O
of O O
the O O
esophagus O B-GENE

Disability O O
insurance O O
under O O
social O O
security O O
. O O

Midge O O
control O O
in O O
flood O O
channels O O
. O O

Iodine O O
metabolism O O
in O O
chronic O O
thyroiditis O O
. O O

Statistics O O
of O O
the O O
past O O
0 O O
years O O

Naphthalene O O
and O O
paradichlorobenzene O O
in O O
clinical O O
toxicology O O

Venkatesan O O
, O O
and O O
D O O
. O O

Organ O O
transplantation O O
in O O
Denmark O O
. O O

You O O
make O O
the O O
diagnosis O O
. O O

00 O O
, O O
000 O O
) O O
. O O

A O O
case O O
of O O
M O O
hemoglobinosis O O

Unusual O O
course O O
of O O
plasmocytosis O O
. O O

W O O
. O O
G O O
. O O

Antihistamines O O
in O O
asthma O O
. O O

Polycythemia O O
- O O
0000 O O
. O O

Nephrectomy O O
applied O O
to O O
cattle O O

Experimental O O
chlorpromazine O O
cataracts O O
. O O

Intravesical O O
chemotherapy O O
. O O

Hepatitis O O
B O O
vaccine O O

Introductory O O
remarks O O
. O O

I O O
. O O

I O O
. O O

Maternal O O
lactation O O

V O O
. O O

Chem O O
. O O

Biol O O
. O O

0 O O
. O O

I O O
. O O

VII O O
. O O

0 O O
. O O

Repeated O O
administration O O
of O O
GRg0 O O
00 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
significantly O O
improved O O
the O O
CYP O O
- O O
induced O O
recognitional O O
deficits O O
by O O
increasing O O
the O O
CYP O O
- O O
decreased O O
rate O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
in O O
d O O
0 O O
learning O O
acquisition O O
( O O
F O O
( O O
0 O O
, O O
00 O O
) O O
= O O
0 O O
. O O
0 O O
, O O
p O O
< O O
0 O O
. O O
00 O O
) O O
, O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
in O O
00 O O
h O O
memory O O
acquisition O O
( O O
F O O
( O O
0 O O
, O O
00 O O
) O O
= O O
0 O O
. O O
0 O O
, O O
p O O
< O O
0 O O
. O O
00 O O
) O O
and O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
in O O
00 O O
h O O
memory O O
retention O O
( O O
F O O
( O O
0 O O
, O O
00 O O
) O O
00 O O
. O O
0 O O
, O O
p O O
< O O
0 O O
. O O
00 O O
) O O
as O O
well O O
as O O
from O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
in O O
00 O O
h O O
memory O O
retrieval O O
( O O
F O O
( O O
0 O O
, O O
00 O O
) O O
= O O
0 O O
. O O
0 O O
, O O
p O O
< O O
0 O O
. O O
00 O O
) O O
, O O
respectively O O
. O O

Despite O O
significant O O
lethality O O
and O O
cardiovascular O O
dysfunction O O
, O O
in O O
the O O
septic O O
group O O
on O O
Days O O
0 O O
and O O
0 O O
, O O
septic O O
versus O O
control O O
animals O O
had O O
no O O
significant O O
differences O O
in O O
mean O O
metabolic O O
cart O O
measured O O
( O O
Vo0DIR O O
, O O
ml O O
/ O O
kg O O
/ O O
min O O
; O O
Day O O
0 O O
: O O
00 O O
. O O
0 O O
versus O O
00 O O
. O O
0 O O
, O O
p O O
= O O
0 O O
. O O
00 O O
; O O
Day O O
0 O O
: O O
00 O O
. O O
0 O O
versus O O
00 O O
. O O
0 O O
, O O
p O O
= O O
0 O O
. O O
00 O O
, O O
respectively O O
) O O
and O O
intravascular O O
catheter O O
calculated O O
( O O
Vo0INDIR O O
, O O
ml O O
/ O O
kg O O
/ O O
min O O
; O O
Day O O
0 O O
: O O
00 O O
. O O
0 O O
versus O O
00 O O
. O O
0 O O
, O O
p O O
= O O
0 O O
. O O
00 O O
; O O
Day O O
0 O O
: O O
00 O O
. O O
0 O O
versus O O
00 O O
. O O
0 O O
, O O
p O O
= O O
0 O O
. O O
00 O O
, O O
respectively O O
) O O
. O O

Left O O
atrial O O
volumes O O
were O O
greater O O
in O O
old O O
compared O O
with O O
young O O
subjects O O
( O O
maximal O O
: O O
00 O O
+ O O
/ O O
- O O
00 O O
cm0 O O
/ O O
m0 O O
vs O O
00 O O
+ O O
/ O O
- O O
0 O O
cm0 O O
/ O O
m0 O O
, O O
p O O
= O O
0 O O
. O O
00 O O
; O O
at O O
onset O O
of O O
atrial O O
systole O O
: O O
00 O O
+ O O
/ O O
- O O
0 O O
cm0 O O
/ O O
m0 O O
vs O O
00 O O
+ O O
/ O O
- O O
0 O O
cm0 O O
/ O O
m0 O O
, O O
p O O
= O O
0 O O
. O O
0000 O O
; O O
minimal O O
: O O
00 O O
+ O O
/ O O
- O O
0 O O
cm0 O O
/ O O
m0 O O
vs O O
0 O O
+ O O
/ O O
- O O
0 O O
cm0 O O
/ O O
m0 O O
, O O
p O O
= O O
0 O O
. O O
000 O O
) O O
. O O

The O O
monoexponential O O
rate O O
of O O
clearance O O
of O O
tracer O O
- O O
- O O
obtained O O
from O O
the O O
portion O O
of O O
the O O
residue O O
- O O
detection O O
curve O O
reflecting O O
metabolism O O
of O O
fatty O O
acid O O
incorporated O O
into O O
neutral O O
lipids O O
- O O
- O O
correlated O O
directly O O
with O O
induced O O
changes O O
in O O
tension O O
- O O
time O O
index O O
after O O
injections O O
into O O
the O O
left O O
atrium O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
n O O
= O O
00 O O
) O O
, O O
right O O
atrium O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
n O O
= O O
00 O O
) O O
, O O
and O O
ear O O
vein O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
n O O
= O O
00 O O
) O O
. O O

The O O
evidence O O
in O O
support O O
of O O
this O O
was O O
derived O O
from O O
the O O
fact O O
that O O
the O O
affinity O O
or O O
interaction O O
between O O
the O O
two O O
subunits O O
was O O
impaired O O
as O O
indicated O O
by O O
the O O
first O O
order O O
rate O O
constant O O
of O O
hCG B-GENE O
alpha I-GENE O
0 I-GENE O
beta I-GENE O
( O O
km O O
= O O
0 O O
. O O
0 O O
x O O
00 O O
( O O
- O O
0 O O
) O O
min O O
- O O
0 O O
) O O
at O O
pH O O
0 O O
. O O
0 O O
at O O
00 O O
degrees O O
C O O
which O O
is O O
one O O
order O O
of O O
magnitude O O
greater O O
relative O O
to O O
rehCG B-GENE O
( O O
kw O O
= O O
0 O O
. O O
0 O O
x O O
00 O O
( O O
- O O
0 O O
) O O
min O O
- O O
0 O O
) O O
. O O

Dilutions O O
of O O
H B-GENE O
- I-GENE O
0b I-GENE O
or I-GENE O
H I-GENE B-GENE
- I-GENE I-GENE
0d I-GENE I-GENE
NP I-GENE O
peptides I-GENE O
indicated O O
that O O
0 O O
- O O
0 O O
logs O O
less O O
H B-GENE O
- I-GENE O
0b I-GENE O
NP I-GENE O
peptide I-GENE O
was O O
required O O
to O O
sensitize O O
syngeneic O O
target O O
cells O O
for O O
CTL O O
- O O
specific O O
lysis O O
, O O
suggesting O O
that O O
the O O
differing O O
affinities O O
of O O
H O B-GENE
- O I-GENE
0b O I-GENE
and O O
H O B-GENE
- O I-GENE
0d O I-GENE
major B-GENE O
histocompatibility I-GENE O
complex I-GENE O
molecules I-GENE O
for O O
their O O
peptides O O
likely O O
account O O
for O O
the O O
total O O
removal O O
of O O
NP O O
CTL O O
in O O
the O O
H O O
- O O
0b O O
mice O O
but O O
only O O
partial O O
removal O O
in O O
H O O
- O O
0d O O
mice O O
made O O
to O O
express O O
thymic O O
NP O O
. O O

A O O
comparison O O
of O O
the O O
promoters O O
for O O
muMIP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
beta I-GENE I-GENE
and O O
muMIP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
alpha I-GENE I-GENE
reveals O I-GENE
a O O
conserved O O
CK O O
- O O
0 O O
element O O
, O O
but O O
transient O O
expression O O
studies O O
in O O
RAW O O
000 O O
. O O
0 O O
macrophages O O
with O O
proximal O O
fragments O O
of O O
either O O
the O O
muMIP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
beta I-GENE I-GENE
or O O
the O O
muMIP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
alpha I-GENE I-GENE
0 I-GENE I-GENE
' I-GENE O
promoter I-GENE O
fused O O
to O O
a O O
human B-GENE O
growth I-GENE O
hormone I-GENE I-GENE
reporter I-GENE I-GENE
gene I-GENE I-GENE
link O O
LPS O O
- O O
inducibility O O
in O O
both O O
to O O
promoter O O
segments O O
near O O
to O O
, O O
but O O
not O O
identical O O
with O O
, O O
the O O
consensus O O
CK O O
- O O
0 O O
sequence O O
. O O

Basal O O
components O O
of O O
the O O
transcription O O
apparatus O O
( O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II I-GENE I-GENE
, O O
TATA B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
) O O
contain O O
activation O O
domains O O
: O O
is O O
the O O
repetitive O B-GENE
C O I-GENE
- O I-GENE
terminal O I-GENE
domain O I-GENE
( O O
CTD O O
) O O
of O O
RNA B-GENE O
polymerase I-GENE O
II I-GENE O
a O O
" O O
portable O O
enhancer O O
domain O O
" O O
? O O
Regions O O
rich O O
in O O
serine O O
, O O
threonine O O
, O O
and O O
proline O O
residues O O
can O O
be O O
found O O
in O O
transcriptional O O
activation O O
domains O O
, O O
as O O
well O O
as O O
in O O
the O O
N O O
- O O
terminal O O
parts O O
of O O
mammalian B-GENE B-GENE
TATA I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins I-GENE I-GENE
, O O
where O O
they O O
are O O
interrupted O O
by O O
polyglutamine O O
stretches O O
. O O

However O O
, O O
artificially O O
ventilated O O
rats O O
, O O
pretreated O O
with O O
MK O O
- O O
000 O O
, O O
were O O
more O O
sensitive O O
( O O
lethal O O
cocaine O O
dose O O
, O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
mg O O
/ O O
kg O O
, O O
n O O
= O O
0 O O
) O O
than O O
vehicle O O
pretreated O O
rats O O
( O O
000 O O
. O O
0 O O
+ O O
/ O O
- O O
00 O O
. O O
0 O O
mg O O
/ O O
kg O O
, O O
n O O
= O O
0 O O
) O O
, O O
indicating O O
that O O
MK O O
- O O
000 O O
may O O
increase O O
both O O
the O O
respiratory O O
and O O
the O O
cardiac O O
toxicity O O
of O O
cocaine O O
in O O
urethane O O
anesthetized O O
rats O O
. O O

Pregnancy O O
screening O O
by O O
uterine O O
artery O O
Doppler O O
velocimetry O O
- O O
- O O
which O O
criterion O O
performs O O
best O O
? O O
OBJECTIVE O O
: O O
To O O
test O O
whether O O
repeating O O
Doppler O O
studies O O
of O O
the O O
uteroplacental O O
circulation O O
late O O
in O O
gestation O O
will O O
improve O O
the O O
test O O
' O O
s O O
power O O
for O O
predicting O O
pregnancy O O
- O O
induced O O
hypertension O O
and O O
fetal O O
growth O O
restriction O O
( O O
FGR O O
) O O
, O O
and O O
whether O O
analysis O O
based O O
on O O
a O O
combination O O
of O O
quantitative O O
and O O
qualitative O O
assessments O O
of O O
the O O
uterine O O
arterial O O
waveforms O O
will O O
yield O O
better O O
results O O
than O O
analysis O O
based O O
on O O
either O O
alone O O
. O O

The O O
RI B-GENE B-GENE
alpha I-GENE I-GENE
gene I-GENE I-GENE
is O O
composed O O
of O O
nine O O
coding O O
exons O O
of O O
varying O O
lengths O O
, O O
separated O O
by O O
introns O O
, O O
giving O O
the O O
gene O O
a O O
total O O
length O O
of O O
at O O
least O O
00 O O
kb O O
. O O
our O O
recent O O
cloning O O
of O O
a O O
processed O O
RI B-GENE O
alpha I-GENE O
pseudogene I-GENE O
with O O
a O O
0 O O
' O O
- O O
noncoding O O
region O O
different O O
from O O
the O O
previously O O
reported O O
RI B-GENE O
alpha I-GENE O
complementary I-GENE O
RNA I-GENE O
indicated O O
that O O
the O O
RI B-GENE B-GENE
alpha I-GENE I-GENE
gene I-GENE I-GENE
may O O
have O O
multiple O O
leader O O
exons O O
giving O O
rise O O
to O O
alternately O O
spliced O O
messenger O O
RNAs O O
( O O
mRNAs O O
) O O
. O O

To O O
determine O O
which O O
sequences O O
in O O
the O O
rat B-GENE O
P000c00 I-GENE O
promoter I-GENE O
may O O
be O O
responsible O O
for O O
basal O O
and O O
cAMP O B-GENE
- O I-GENE
stimulated O I-GENE
gene O I-GENE
transcription O O
, O O
deletion O O
constructs O O
containing O O
between O O
- O I-GENE
0 O I-GENE
, O O
000 O O
and O O
- O O
00 O O
base O O
pairs O O
of O O
0 O O
' O O
- O O
flanking O O
DNA O O
from O O
the O O
rat B-GENE B-GENE
P000c00 I-GENE I-GENE
gene I-GENE I-GENE
were O O
ligated O O
to O O
plasmids O O
expressing O O
the O O
reporter O B-GENE
gene O I-GENE
luciferase B-GENE O
and O O
transfected O O
into O O
two O O
mouse O O
cell O O
lines O O
, O O
adrenal O O
Y O O
- O O
0 O O
cells O O
, O O
and O O
testicular O O
Leydig O O
MA O O
- O O
00 O O
cells O O
. O O

In O O
00 O O
patients O O
with O O
Horton O O
' O O
s O O
headache O O
morphological O O
investigations O O
( O O
differential O O
white O O
blood O O
cell O O
count O O
) O O
, O O
cytoenzymatic O O
determinations O O
( O O
alkaline B-GENE O
and I-GENE O
acid I-GENE O
phosphatase I-GENE O
, O O
non B-GENE O
- I-GENE O
specific I-GENE O
esterase I-GENE O
) O O
and O O
cytoimmunological O O
tests O O
( O O
IgM B-GENE O
and O O
IgG B-GENE O
binding O O
) O O
were O O
carried O O
out O O
on O O
capillary O O
blood O O
neutrophils O O
obtained O O
from O O
the O O
area O O
of O O
pain O O
, O O
non O O
- O O
painful O O
area O O
of O O
the O O
skin O O
on O O
the O O
head O O
on O O
the O O
contralateral O O
side O O
, O O
and O O
from O O
the O O
finger O O
. O O

Apart O O
from O O
two O O
proline O O
- O O
rich O O
regions O O
( O O
amino O O
acids O O
0 O O
- O O
000 O O
and O O
000 O O
- O O
000 O O
) O O
, O O
p000 B-GENE O
contains O O
a O O
very O O
high O O
frequency O O
of O O
heptad O O
repeats O O
, O O
characteristic O O
of O O
alpha O B-GENE
- O O
helices O O
that O O
form O O
dimeric O O
coiled O O
- O O
coil O O
structures O O
. O O
p000 B-GENE O
also O O
includes O O
the O O
sequence O O
ESLALEELEL O O
( O O
amino O O
acids O O
000 O O
- O O
000 O O
) O O
, O O
a O O
motif O O
found O O
in O O
the O O
granin B-GENE O
family I-GENE O
of O O
acidic O O
proteins O O
present O O
in O O
secretory O O
granules O O
of O O
neuroendocrine O O
cells O O
. O O

The O O
first O O
group O O
of O O
sequential O O
BMB O O
showed O O
a O O
significant O O
progress O O
to O O
myelofibrosis O O
in O O
so O O
- O O
called O O
" O O
Chronic O O
Megakaryocytic O O
- O O
Granulocytic O O
Myelosis O O
" O O
- O O
- O O
CMGM O O
- O O
, O O
which O O
corresponds O O
to O O
Agnogenic O O
Myeloid O O
Metaplasia O O
- O O
AMM O O
- O O
in O O
00 O O
. O O
0 O O
% O O
( O O
00 O O
/ O O
00 O O
patients O O
) O O
, O O
as O O
well O O
as O O
in O O
CML O O
with O O
megakaryocytic O O
increase O O
- O O
CML O O
. O O
MI O O
- O O
in O O
00 O O
. O O
0 O O
% O O
( O O
00 O O
/ O O
00 O O
) O O
. O O

Subjects O O
with O O
a O O
short O O
postexposure O O
time O O
and O O
a O O
dioxin O O
burden O O
> O O
0 O O
. O O
0 O O
pg O O
/ O O
m0 O O
had O O
a O O
significantly O O
higher O O
risk O O
of O O
hypoergy O O
than O O
unexposed O O
subjects O O
( O O
hypoergy O O
I O O
: O O
OR O O
= O O
0 O O
. O O
00 O O
, O O
00 O O
% O O
CI O O
= O O
0 O O
. O O
00 O O
- O O
00 O O
. O O
00 O O
; O O
hypoergy O O
II O O
: O O
OR O O
= O O
0 O O
. O O
00 O O
, O O
00 O O
% O O
CI O O
= O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
0 O O
) O O
. O O

In O O
the O O
ultramarathon O O
runner O O
the O O
testosterone O O
levels O O
sharply O O
rose O O
at O O
the O O
beginning O O
of O O
the O O
training O O
session O O
( O O
from O O
the O O
0 O O
, O O
00 O O
ng O O
/ O O
ml O O
to O O
00 O O
, O O
00 O O
ng O O
/ O O
ml O O
after O O
00 O O
' O O
training O O
) O O
, O O
and O O
subsequently O O
decrease O O
after O O
0 O O
hours O O
( O O
0 O O
, O O
00 O O
ng O O
/ O O
ml O O
) O O
and O O
at O O
the O O
end O O
of O O
the O O
0 O O
hours O O
training O O
( O O
0 O O
, O O
00 O O
ng O O
/ O O
ml O O
) O O
. O O

The O O
binding O O
of O O
transcription O B-GENE
factor O I-GENE
AP B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
vitamin B-GENE B-GENE
D I-GENE I-GENE
receptor I-GENE I-GENE
( O O
VDR B-GENE O
) O O
to O O
the O O
composite O B-GENE
AP B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
plus I-GENE O
vitamin I-GENE O
- I-GENE O
D I-GENE O
- I-GENE O
responsive I-GENE O
promoter I-GENE O
region O O
( O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
+ I-GENE O
VDRE I-GENE O
) O O
of O O
the O O
human B-GENE B-GENE
osteocalcin I-GENE I-GENE
gene I-GENE I-GENE
was O O
characterized O O
in O O
osteocalcin B-GENE O
- O O
producing O O
( O O
MG O B-GENE
- O I-GENE
00 O I-GENE
) O O
and O O
non O O
- O O
producing O O
( O O
U0 O B-GENE
- O I-GENE
Os O I-GENE
, O O
SaOs O B-GENE
- O I-GENE
0 O I-GENE
) O O
human O O
osteosarcoma O O
cell O O
lines O O
. O O

We O O
found O O
that O O
T0 O O
( O O
00 O O
( O O
- O O
0 O O
) O O
M O O
) O O
selectively O O
stimulates O O
transcription O O
from O O
rGH B-GENE O
- O O
TRE O O
- O O
and O O
TREpal O O
- O O
, O O
but O O
not O O
ME O O
- O O
TRE O O
- O O
and O O
F0 O O
- O O
TRE O O
- O O
, O O
containing O O
templates O O
in O O
which O O
these O O
TREs O O
are O O
linked O O
in O O
front O O
of O O
the O O
rGH B-GENE O
minimal I-GENE O
promoter I-GENE O
containing O O
only O O
the O O
TATA B-GENE B-GENE
box I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
, O O
but O O
not O O
any O O
other O O
proximal O O
binding O O
protein O O
, O O
sequence O O
. O O

Three O O
classes O O
of O O
test O O
objects O O
were O O
considered O O
: O O
( O O
0 O O
) O O
a O O
multicompartment O O
test O O
object O O
for O O
00P O O
MRS O O
measurements O O
performed O O
with O O
slice O O
- O O
selective O O
sequences O O
; O O
( O O
0 O O
) O O
a O O
two O O
- O O
compartment O O
test O O
object O O
for O O
volume O O
- O O
selection O O
0H O O
MRS O O
; O O
and O O
( O O
0 O O
) O O
two O O
- O O
compartment O O
test O O
objects O O
for O O
assessing O O
the O O
performance O O
of O O
experimental O O
systems O O
using O O
ISIS O O
as O O
volume O O
localization O O
sequence O O
in O O
00P O O
MRS O O
. O O

Total O O
cholesterol O O
was O O
also O O
reduced O O
at O O
week O O
00 O O
by O O
00 O O
. O O
0 O O
% O O
( O O
00 O O
mg O O
/ O O
day O O
) O O
and O O
00 O O
. O O
0 O O
% O O
( O O
00 O O
- O O
00 O O
mg O O
/ O O
day O O
) O O
, O O
and O O
at O O
week O O
00 O O
by O O
00 O O
. O O
0 O O
% O O
( O O
< O O
or O O
= O O
00 O O
mg O O
/ O O
day O O
) O O
and O O
00 O O
. O O
0 O O
% O O
( O O
> O O
or O O
= O O
00 O O
mg O O
/ O O
day O O
) O O
. O O

However O O
, O O
as O O
determined O O
by O O
PCR O O
with O O
primers O O
specific O O
for O O
the O O
00 O O
- O O
kDa O O
product O O
, O O
the O O
majority O O
of O O
cats O O
at O O
0 O O
and O O
0 O O
weeks O O
p O O
. O O
t O O
. O O
had O O
gastric O O
fluid O O
samples O O
which O O
were O O
positive O O
for O O
H O O
. O O
pylori O O
and O O
three O O
of O O
three O O
cats O O
at O O
0 O O
weeks O O
p O O
. O O
t O O
. O O
had O O
dental O O
plaque O O
which O O
was O O
positive O O
for O O
H O O
. O O
pylori O O
. O O

A O O
method O O
for O O
the O O
simultaneous O O
determination O O
of O O
de O O
( O O
N O O
- O O
methyl O O
) O O
- O O
N O O
- O O
ethyl O O
- O O
0 O O
, O O
0 O O
- O O
anhydroerythromycin O O
A O O
0 O O
, O O
0 O O
- O O
hemiacetal O O
( O O
EM000 O O
, O O
I O O
) O O
and O O
its O O
three O O
metabolites O O
in O O
human O O
plasma O O
and O O
urine O O
has O O
been O O
developed O O
using O O
high O O
- O O
performance O O
liquid O O
chromatography O O
( O O
HPLC O O
) O O
with O O
chemiluminescence O O
( O O
CL O O
) O O
detection O O
. O O

Expression O O
of O O
h0 O O
. O O
0 O O
in O O
COS O O
- O O
0 O O
cells O O
led O O
to O O
the O O
production O O
of O O
a O O
typical O O
type B-GENE O
IV I-GENE O
PDE I-GENE O
activity O O
in O O
that O O
cAMP O O
, O O
but O O
not O O
cGMP O O
, O O
served O O
as O O
substrate O O
and O O
its O O
activity O O
was O O
insensitive O O
to O O
either O O
Ca0 O O
+ O O
/ O O
CaM B-GENE O
or O O
cGMP O O
but O O
was O O
inhibited O O
by O O
low O O
concentrations O O
of O O
rolipram O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

00mTc O O
- O O
HMPAO O O
was O O
distributed O O
in O O
the O O
territories O O
of O O
the O O
ACA O O
and O O
MCA O O
in O O
the O O
two O O
patients O O
who O O
were O O
treated O O
with O O
intraarterial O O
infusion O O
of O O
papaverine O O
from O O
the O O
C0 O O
segment O O
, O O
but O O
was O O
distributed O O
only O O
to O O
the O O
territory O O
of O O
the O O
ACA O O
in O O
four O O
patients O O
who O O
were O O
treated O O
with O O
intraarterial O O
infusion O O
of O O
papaverine O O
from O O
the O O
C0 O O
segment O O
at O O
0 O O
ml O O
/ O O
min O O
. O O

This O O
study O O
indicates O O
that O O
the O O
phenotype O O
of O O
myofibrillar O O
disarray O O
seen O O
in O O
HCM O O
patients O O
which O O
harbor O O
either O O
of O O
these O O
two O O
mutations O O
may O O
not O O
be O O
directly O O
due O O
to O O
the O O
failure O O
of O O
the O O
mutant B-GENE O
myosin I-GENE O
heavy I-GENE O
chain I-GENE O
protein I-GENE O
to O O
assemble O O
and O O
form O O
normal O O
sarcomeres O O
, O O
but O O
may O O
rather O O
be O O
a O O
secondary O O
effect O O
possibly O O
resulting O O
from O O
the O O
chronic O O
stress O O
of O O
decreased O O
beta B-GENE O
MHC I-GENE O
function O O
. O O

Volume O O
of O O
distribution O O
of O O
total O O
DMDZ O O
( O O
range O O
, O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
l O O
/ O O
kg O O
) O O
and O O
of O O
unbound O O
DMDZ O O
after O O
correction O O
for O O
protein O O
binding O O
( O O
range O O
, O O
00 O O
to O O
000 O O
l O O
/ O O
kg O O
) O O
was O O
larger O O
in O O
women O O
than O O
in O O
men O O
of O O
all O O
ages O O
, O O
and O O
in O O
the O O
elderly O O
as O O
opposed O O
to O O
the O O
young O O
. O O

The O O
promoter O O
region O O
( O O
P0 O O
) O O
corresponding O O
to O O
the O O
main O O
group O O
of O O
transcription O O
initiation O O
sites O O
is O O
devoid O O
of O O
TATA O O
and O O
CAAT O O
boxes O O
but O O
has O O
putative O O
binding O O
sites O O
for O O
the O O
transcription B-GENE O
factor I-GENE O
SP0 I-GENE O
and O O
is O O
embedded O O
in O O
a O O
large O O
G O O
+ O O
C O O
- O O
rich O O
domain O O
of O O
a O O
CpG O O
island O O
, O O
features O O
shared O O
by O O
the O O
promoters O O
of O O
constitutively O O
expressed O O
housekeeping O O
genes O O
. O O

Ten O O
volunteers O O
were O O
tested O O
at O O
00 O O
, O O
000 O O
ft O O
( O O
0 O O
, O O
000 O O
m O O
) O O
, O O
and O O
through O O
00 O O
, O O
000 O O
, O O
0 O O
, O O
000 O O
, O O
and O O
0 O O
, O O
000 O O
ft O O
( O O
0 O O
, O O
000 O O
, O O
0 O O
, O O
000 O O
, O O
and O O
0 O O
, O O
000 O O
m O O
) O O
with O O
directional O O
sounds O O
recorded O O
via O O
a O O
dummy O O
head O O
microphone O O
and O O
presented O O
binaurally O O
. O O

We O O
then O O
demonstrated O O
that O O
0 O O
) O O
GAL0 B-GENE O
- O O
REV B-GENE O
- O O
erbA B-GENE O
alpha I-GENE O
chimeras O O
that O O
contain O O
the O O
' O O
AB O O
' O O
region O O
and O O
lack O O
the O O
' O O
E O O
' O O
region O O
activated O O
transcription O O
of O O
GAL0 B-GENE O
response I-GENE O
elements I-GENE O
in O O
the O O
presence O O
of O O
0 O O
- O O
Br O O
- O O
cAMP O O
and O O
0 O O
) O O
the O O
ligand O O
- O O
binding O O
domain O O
( O O
LBD O O
) O O
contains O O
an O O
active O O
transcriptional O O
silencer O O
. O O

The O O
Cdk0 B-GENE B-GENE
- O I-GENE
cyclin B-GENE I-GENE
- I-GENE I-GENE
D0 I-GENE I-GENE
complex O O
did O O
not O O
phosphorylate O O
any O O
tested O O
substrates O O
, O O
such O O
as O O
H0 B-GENE O
histone I-GENE O
, O O
pRB B-GENE O
, O O
SV00 B-GENE O
large I-GENE O
T I-GENE O
antigen I-GENE O
, O O
p00 B-GENE B-GENE
, O O
E0F B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
or O O
a O O
preparation O O
of O O
nuclear O O
proteins O O
from O O
HeLa O O
cells O O
; O O
in O O
contrast O O
, O O
Cdk0 B-GENE O
- O O
cyclin B-GENE O
- I-GENE O
E I-GENE O
and O O
Cdk0 B-GENE O
- O O
cyclin B-GENE O
- I-GENE O
A I-GENE O
phosphorylated O O
these O O
proteins O O
. O O

In O O
Experiment O O
0 O O
, O O
pups O O
that O O
had O O
received O O
an O O
injection O O
of O O
the O O
noncompetitive O O
N B-GENE O
- I-GENE O
methyl I-GENE O
- I-GENE O
D I-GENE O
- I-GENE O
aspartate I-GENE O
receptor I-GENE O
antagonist O O
MK O O
- O O
000 O O
( O O
0 O O
. O O
0 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
either O O
00 O O
min O O
before O O
or O O
immediately O O
after O O
conditioning O O
spent O O
less O O
time O O
over O O
the O O
conditioned O O
odor O O
than O O
saline O O
- O O
treated O O
controls O O
. O O

We O O
have O O
attempted O O
to O O
clone O O
two O O
recessive O O
extragenic O O
suppressors O O
of O O
such O O
ts O O
mutants O O
( O O
sdp0 B-GENE O
for O O
mutation B-GENE O
pol0 I-GENE O
- I-GENE O
00 I-GENE O
and O O
sdp0 B-GENE O
- I-GENE O
0 I-GENE O
for O O
mutation B-GENE O
pol0 I-GENE O
- I-GENE O
00 I-GENE O
) O O
by O O
transforming O O
thermoresistant O O
haploid O O
strains O O
pol0 B-GENE O
- I-GENE O
00 I-GENE O
sdp0 I-GENE O
and O O
pol0 B-GENE O
- I-GENE O
00 I-GENE O
sdp0 I-GENE O
- I-GENE O
0 I-GENE O
with O O
wild O O
- O O
type O O
genomic O O
libraries O O
in O O
singlecopy O O
or O O
multicopy O O
vectors O O
. O O

When O O
ligated O O
to O O
the O O
proIL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
beta I-GENE I-GENE
cap I-GENE O
site I-GENE O
- I-GENE O
proximal I-GENE O
region I-GENE O
( O O
located O O
between O O
- O O
000 O O
to O O
+ O O
00 O O
) O O
, O O
both O O
the O O
proIL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
beta I-GENE I-GENE
and O O
the O O
simian B-GENE O
virus I-GENE O
00 I-GENE O
enhancer I-GENE O
elements I-GENE O
functioned O O
more O O
efficiently O O
in O O
monocytes O O
than O O
in O O
HeLa O O
cells O O
, O O
which O O
are O O
not O O
normally O O
competent O O
for O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
beta I-GENE I-GENE
expression O O
. O O

The O O
role O O
of O O
HIV B-GENE O
tat I-GENE O
, O O
which O O
is O O
the O O
main O O
enhancing O O
factor O O
for O O
viral B-GENE O
LTR I-GENE O
, O O
in O O
the O O
regulation O O
of O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
transcription O I-GENE
has O O
been O O
studied O O
following O O
transient O O
expression O O
of O O
the O O
tat B-GENE B-GENE
gene I-GENE I-GENE
in O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
- O O
activated O O
Jurkat O O
cells O O
transfected O O
with O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter O I-GENE
- O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
reporter O O
constructs O O
. O O

Because O O
L B-GENE O
- I-GENE O
plastin I-GENE O
expression O O
in O O
tissue O O
- O O
specifically O O
regulated O O
in O O
both O O
humans O O
and O O
rodents O O
, O O
it O O
is O O
likely O O
that O O
similar O O
mechanisms O O
regulate O O
L B-GENE B-GENE
- I-GENE I-GENE
plastin I-GENE I-GENE
gene I-GENE I-GENE
expression O O
in O O
human O O
and O O
rodent O O
cells O O
and O O
that O O
they O O
could O O
be O O
identified O O
by O O
comparing O O
the O O
function O O
and O O
nucleotide O O
sequences O O
of O O
the O O
human O O
and O O
murine O B-GENE
L B-GENE I-GENE
- I-GENE I-GENE
plastin I-GENE I-GENE
gene O I-GENE
promoters O O
. O O

Thirty O O
- O O
one O O
age O O
- O O
matched O O
, O O
conscious O O
, O O
virgin O O
, O O
male O O
Sprague O O
- O O
Dawley O O
rats O O
and O O
spontaneously O O
hypertensive O O
rats O O
( O O
SHRs O O
) O O
were O O
individually O O
injected O O
with O O
a O O
single O O
subcutaneous O O
dose O O
of O O
00 O O
mg O O
/ O O
kg O O
dl O O
- O O
isoproterenol O O
to O O
determine O O
the O O
degree O O
and O O
time O O
course O O
of O O
drug O O
- O O
induced O O
cardiac O O
failure O O
and O O
functional O O
recovery O O
. O O

We O O
have O O
cloned O O
and O O
sequenced O O
the O O
mouse B-GENE O
NMO0 I-GENE O
cDNA I-GENE O
, O O
which O O
encodes O O
the O O
NAD B-GENE O
( I-GENE O
P I-GENE O
) I-GENE O
H I-GENE O
: I-GENE O
menadione I-GENE O
oxidoreductase I-GENE O
[ O O
also O O
called O O
NAD B-GENE O
( I-GENE O
P I-GENE O
) I-GENE O
H I-GENE O
: I-GENE O
( I-GENE O
quinone I-GENE O
acceptor I-GENE O
) I-GENE O
oxidoreductase I-GENE O
; O O
quinone B-GENE O
reductase I-GENE O
; O O
azo B-GENE O
dye I-GENE O
reductase I-GENE O
; O O
DT B-GENE O
diaphorase I-GENE O
; O O
EC B-GENE O
0 I-GENE O
. I-GENE O
0 I-GENE O
. I-GENE O
00 I-GENE O
. I-GENE O
0 I-GENE O
] O O
. O O

A O O
polypeptide O O
encoded O O
by O O
the O O
NTS O O
00 O O
open O O
reading O O
frame O O
has O O
sequence O O
similarity O O
to O O
the O O
catalytic O O
domain O O
of O O
several O O
receptor B-GENE O
protein I-GENE O
kinases I-GENE O
from I-GENE O
plants I-GENE O
including O O
the O O
S B-GENE B-GENE
- I-GENE I-GENE
receptor I-GENE I-GENE
kinases I-GENE I-GENE
implicated O O
in O O
the O O
rejection O O
of O O
self O O
- O O
pollen O O
in O O
Brassica O O
species O O
and O O
the O O
Pto B-GENE O
gene I-GENE O
product I-GENE O
of I-GENE O
tomato I-GENE O
which O O
confers O O
resistance O O
to O O
a O O
bacterial O O
pathogen O O
. O O

Interestingly O O
, O O
the O O
interaction O O
of O O
ZAP B-GENE O
- I-GENE O
00 I-GENE O
with O O
the O O
motif O O
was O O
dependent O O
on O O
the O O
presence O O
of O O
both O O
ZAP B-GENE O
- I-GENE O
00 I-GENE O
SH0 B-GENE O
domains I-GENE O
and O O
both O O
of O O
the O O
tyrosine O O
residues O O
in O O
the O O
motif O O
, O O
suggesting O O
that O O
ZAP B-GENE O
- I-GENE O
00 I-GENE O
interacts O O
with O O
two O O
phosphotyrosine O O
residues O O
and O O
that O O
the O O
binding O O
of O O
the O O
two O O
SH0 B-GENE O
domains I-GENE O
is O O
cooperative O O
. O O

A O O
cDNA O O
clone O O
corresponding O O
to O O
the O O
putative O O
GA B-GENE O
00 I-GENE O
- O O
oxidase B-GENE O
genomic O O
sequence O O
was O O
constructed O O
with O O
the O O
reverse O O
transcription O O
- O O
PCR O O
method O O
, O O
and O O
the O O
identity O O
of O O
the O O
cDNA O O
clone O O
was O O
confirmed O O
by O O
analyzing O O
the O O
capability O O
of O O
the O O
fusion O B-GENE
protein O I-GENE
expressed O O
in O O
Escherichia O O
coli O O
to O O
convert O O
GA00 B-GENE O
to O O
GA00 B-GENE O
and O O
GA00 B-GENE O
to O O
GA00 B-GENE O
. O O

A O O
full O O
- O O
length O O
cDNA O O
clone O O
isolated O O
from O O
a O O
rat O O
lung O O
library O O
was O O
predicted O O
to O O
encode O O
a O O
00 O O
- O O
kDa O O
protein O O
containing O O
at O O
its O O
amino O O
terminus O O
a O O
targeting O O
domain O O
that O O
binds O O
to O O
the O O
ANP B-GENE B-GENE
- I-GENE I-GENE
receptor I-GENE I-GENE
kinase I-GENE I-GENE
- I-GENE O
like I-GENE O
domain I-GENE O
and O O
containing O O
at O O
its O O
carboxyl O O
terminus O O
a O O
putative O O
protein B-GENE O
- I-GENE O
serine I-GENE O
phosphatase I-GENE O
domain O O
. O O

These O O
data O O
show O O
that O O
PTH B-GENE O
and O O
cAMP O O
can O O
repress O O
collagen B-GENE O
promoter I-GENE O
activity O O
in O O
calvariae O O
from O O
transgenic O O
mice O O
, O O
suggesting O O
that O O
the O O
alpha B-GENE B-GENE
0 I-GENE I-GENE
( I-GENE I-GENE
I I-GENE I-GENE
) I-GENE O
collagen I-GENE O
promoter I-GENE O
may O O
contain O O
cis O O
elements O O
down O O
- O O
stream O O
of O O
- O O
0 O O
. O O
0 O O
kilobases O O
that O O
mediate O O
PTH B-GENE O
and O O
cAMP O O
repression O O
of O O
collagen B-GENE B-GENE
gene I-GENE I-GENE
expression O O
in O O
bone O O
. O O

Refugees O O
living O O
in O O
Lund O O
and O O
repatriated O O
to O O
Chile O O
considered O O
their O O
health O O
as O O
bad O O
in O O
a O O
higher O O
proportion O O
than O O
their O O
Swedish O O
counterparts O O
, O O
with O O
an O O
odds O O
ratio O O
of O O
0 O O
. O O
00 O O
( O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
and O O
0 O O
. O O
00 O O
( O O
0 O O
. O O
0 O O
- O O
00 O O
. O O
00 O O
) O O
respectively O O
. O O

Three O O
mutants O O
( O O
pms0 B-GENE O
, O O
pms0 B-GENE O
and O O
pms0 B-GENE O
) O O
isolated O O
earlier O O
from O O
MW000 O O
- O O
0B O O
were O O
shown O O
to O O
correct O O
in O O
vitro O O
constructed O O
plasmids O O
with O O
defined O O
DNA O O
mismatches O O
( O O
G O O
/ O O
T O O
, O O
A O O
/ O O
C O O
, O O
G O O
/ O O
G O O
, O O
etc O O
. O O
) O O
poorly O O
( O O
Kramer O O
et O O
al O O
. O O
, O O
0000a O O
) O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
We O O
report O O
our O O
experience O O
with O O
seven O O
children O O
with O O
active O O
small O O
bowel O O
Crohn O O
' O O
s O O
disease O O
given O O
a O O
casein B-GENE O
- O O
based O O
, O O
polymeric O O
feed O O
rich O O
in O O
TGF B-GENE O
- I-GENE O
beta I-GENE O
0 I-GENE O
( O O
Specific O O
Polymeric O O
Diet O O
; O O
Nestle O O
- O O
Clintec O O
; O O
Vevey O O
, O O
Switzerland O O
) O O
as O O
complete O O
nutrition O O
for O O
0 O O
weeks O O
. O O

Two O O
mammalian O O
enzymes O O
, O O
the O O
haem B-GENE B-GENE
- I-GENE O
controlled I-GENE O
repressor I-GENE O
( O O
HCR B-GENE O
) O O
and O O
the O O
double B-GENE O
- I-GENE O
stranded I-GENE O
RNA I-GENE O
- I-GENE O
activated I-GENE O
inhibitor I-GENE O
( O O
dsI B-GENE O
) O O
, O O
phosphorylate O O
Ser O O
- O O
00 O O
of O O
the O O
alpha O O
subunit O O
, O O
thereby O O
inhibiting O O
the O O
exchange O O
of O O
bound O O
nucleotides O O
on O O
, O O
and O O
thus O O
the O O
recycling O O
of O O
, O O
eIF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

In O O
the O O
present O O
article O O
, O O
the O O
causes O O
of O O
death O O
or O O
ill O O
- O O
being O O
as O O
found O O
in O O
00 O O
consecutive O O
carcinogenicity O O
studies O O
- O O
- O O
0 O O
studies O O
with O O
0000 O O
OFA O O
( O O
Sprague O O
- O O
Dawley O O
- O O
derived O O
) O O
and O O
Wistar O O
rats O O
and O O
0 O O
studies O O
with O O
0000 O O
OF0 O O
and O O
NMRI O O
mice O O
- O O
- O O
were O O
re O O
- O O
examined O O
. O O

Tryptic O O
cleavage O O
and O O
peptide O O
sequence O O
analysis O O
demonstrated O O
that O O
the O O
00 O B-GENE
- O I-GENE
kD O I-GENE
protein O I-GENE
is O O
identical O O
to O O
a O O
recently O O
cloned O O
protein O O
, O O
special B-GENE O
A I-GENE O
- I-GENE O
T I-GENE I-GENE
- I-GENE I-GENE
rich I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
0 I-GENE I-GENE
( O O
SATB0 B-GENE O
) O O
, O O
that O O
binds O O
selectively O O
to O O
nuclear O O
matrix O O
/ O O
scaffold O O
- O O
associated O O
regions O O
of O O
DNA O O
( O O
MARs O O
/ O O
SARs O O
) O O
. O O

In O O
addition O O
, O O
a O O
microsatellite O O
repeat O O
polymorphism O O
with O O
a O O
heterozygosity O O
of O O
00 O O
% O O
at O O
the O O
RET B-GENE O
locus I-GENE O
and O O
a O O
restriction O O
fragment O O
length O O
polymorphism O O
with O O
a O O
heterozygosity O O
of O O
00 O O
% O O
detected O O
by O O
a O O
lambda O O
clone O O
from O O
the O O
D00S00 B-GENE O
locus I-GENE O
have O O
been O O
developed O O
for O O
high O O
- O O
resolution O O
genetic O O
linkage O O
mapping O O
and O O
predictive O O
diagnostic O O
testing O O
. O O

Here O O
we O O
describe O O
an O O
in O O
vitro O O
assay O O
where O O
the O O
NS0 B-GENE B-GENE
- I-GENE I-GENE
0A I-GENE I-GENE
polyprotein I-GENE O
, O O
NS0 B-GENE O
, O O
the O O
serine B-GENE O
proteinase I-GENE O
domain I-GENE O
( I-GENE O
the I-GENE O
N I-GENE O
- I-GENE O
terminal I-GENE O
000 I-GENE O
residues I-GENE O
of I-GENE O
NS0 I-GENE O
) I-GENE O
, O O
and O O
the O O
NS0A B-GENE O
cofactor I-GENE O
were O O
produced O O
by O O
cell O O
- O O
free O O
translation O O
and O O
tested O O
for O O
trans O O
- O O
processing O O
of O O
radiolabeled O O
substrates O O
. O O

Insertion O O
of O O
short O O
oligonucleotides O O
encoding O O
the O O
basic O O
amino O O
acid O O
motifs O O
000 O O
- O O
GRKRKSP O O
- O O
000 O O
from O O
IE000 B-GENE O
and O O
000 O O
- O O
VRPRKRR O O
- O O
000 O O
from O O
IE000 B-GENE O
into O O
deleted O O
cytoplasmic O O
forms O O
of O O
the O O
two O O
proteins O O
restored O O
the O O
karyophilic O O
phenotype O O
and O O
confirmed O O
that O O
these O O
motifs O O
are O O
both O O
necessary O O
and O O
sufficient O O
for O O
proper O O
nuclear O O
localization O O
. O O

Such O O
an O O
increase O O
in O O
the O O
steady O O
- O O
state O O
testicular B-GENE O
TIMP I-GENE O
- I-GENE O
0 I-GENE O
mRNA I-GENE O
level O O
apparently O O
is O O
not O O
the O O
result O O
of O O
an O O
up O O
- O O
regulation O O
by O O
germ O O
cells O O
because O O
germ O O
cells O O
cocultured O O
with O O
Sertoli O O
cells O O
failed O O
to O O
elicit O O
an O O
increase O O
in O O
the O O
Sertoli O O
cell O O
steady O O
- O O
state O O
TIMP B-GENE O
- I-GENE O
0 I-GENE O
mRNA I-GENE O
level O O
. O O

Striking O O
sequence O O
similarities O O
( O O
00 O O
and O O
00 O O
% O O
) O O
were O O
observed O O
with O O
yeast O O
mitochondrial O O
proteins O O
, O O
SMF0 B-GENE O
and O O
SMF0 B-GENE O
, O O
especially O O
within O O
putative O O
functional O O
domains O O
: O O
exon O O
0 O O
encoding O O
the O O
second O O
transmembrane O O
spanning O O
domain O O
, O O
site O O
of O O
the O O
murine B-GENE O
susceptibility I-GENE O
mutation O O
; O O
and O O
exon O O
00 O O
encoding O O
a O O
conserved O O
transport O O
motif O O
. O O

To O O
determine O O
the O O
signal B-GENE O
recognition I-GENE O
particle I-GENE O
( O O
SRP B-GENE B-GENE
) O I-GENE
- O I-GENE
SRP B-GENE I-GENE
receptor I-GENE I-GENE
( O O
Srb B-GENE O
) O O
system O O
in O O
Bacillus O O
subtilis O O
( O O
Bs O O
) O O
, O O
we O O
cloned O O
the O O
Bs B-GENE B-GENE
srb I-GENE I-GENE
gene I-GENE I-GENE
, O O
which O O
encodes O O
a O O
homologue O O
of O O
the O O
mammalian B-GENE B-GENE
SRP I-GENE I-GENE
receptor I-GENE I-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
subunit I-GENE I-GENE
[ O O
Oguro O O
et O O
al O O
. O O
, O O
DNA O O
Res O O
. O O

Our O O
data O O
demonstrate O O
directly O O
that O O
Rpm0r B-GENE O
is O O
transcribed O O
with O O
its O O
substrates O O
, O O
tRNA B-GENE O
met I-GENE O
f I-GENE O
and O O
tRNAPro B-GENE O
, O O
from O O
a O O
promoter O O
located O O
upstream O O
of O O
the O O
tRNA B-GENE O
met I-GENE O
f I-GENE I-GENE
gene I-GENE I-GENE
and O O
suggest O O
that O O
a O O
portion O O
also O O
originates O O
from O O
a O O
second O O
promoter O O
, O O
located O O
between O O
the O O
tRNA B-GENE O
met I-GENE O
f I-GENE I-GENE
gene I-GENE I-GENE
and O O
RPM0 B-GENE O
. O O

The O O
HiNF B-GENE B-GENE
- I-GENE I-GENE
D I-GENE I-GENE
( O O
CDP B-GENE O
/ O O
cut B-GENE O
) O O
complex O O
with O O
the O O
H0 B-GENE O
promoter I-GENE O
is O O
immunoreactive O O
with O O
antibodies O O
against O O
CDP B-GENE O
/ O O
cut B-GENE O
and O O
pRB B-GENE O
but O O
not O O
p000 B-GENE O
, O O
whereas O O
the O O
CDP B-GENE O
/ O O
cut B-GENE O
complex O O
with O O
a O O
nonhistone O O
promoter O O
( O O
gp00 B-GENE O
- O O
phox B-GENE O
) O O
reacts O O
only O O
with O O
CDP B-GENE O
and O O
p000 B-GENE O
antibodies O O
. O O

How O O
does O O
a O O
nurse O O
go O O
about O O
maintaining O O
her O O
level O O
of O O
competence O O
when O O
she O O
is O O
one O O
of O O
the O O
few O O
local O O
practitioners O O
in O O
her O O
field O O
? O O
Vancouver O O
sex O O
therapist O O
Bianca O O
Rucker O O
is O O
doing O O
it O O
by O O
cultivating O O
a O O
network O O
of O O
colleagues O O
and O O
mentors O O
in O O
related O O
fields O O
both O O
at O O
home O O
and O O
across O O
the O O
continent O O
. O O

Further O O
, O O
the O O
reduction O O
in O O
0 O O
- O O
hydroxytryptophan O O
( O O
0 O O
- O O
HTP O O
) O O
accumulation O O
by O O
LSD O O
showed O O
regional O O
differences O O
in O O
inhibition O O
by O O
methiothepin O O
( O O
hypothalamus O O
greater O O
than O O
cortex O O
greater O O
than O O
striatum O O
) O O
which O O
paralleled O O
the O O
autoreceptor O O
antagonist O O
activity O O
of O O
methiothepin O O
in O O
vitro O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

Atcys0 B-GENE O
, O O
Athyp0 B-GENE O
, O O
AKin00 B-GENE O
and O O
the O O
ORF O O
are O O
very O O
close O O
to O O
each O O
other O O
and O O
organized O O
in O O
the O O
same O O
polarity O O
; O O
hence O O
, O O
the O O
intergenic O O
regions O O
probably O O
contain O O
, O O
within O O
less O O
than O O
0 O O
. O O
0 O O
kb O O
, O O
all O O
the O O
regulatory O O
elements O O
necessary O O
to O O
govern O O
initiation O O
and O O
termination O O
of O O
transcription O O
. O O

Southern O O
blot O O
analysis O O
using O O
probes O O
from O O
the O O
0 O O
' O O
portions O O
of O O
the O O
genomic O O
and O O
B B-GENE O
. I-GENE O
napus I-GENE O
MA I-GENE O
and O O
MB B-GENE O
cDNA I-GENE O
clones O O
showed O O
that O O
MA B-GENE O
type I-GENE O
myrosinases B-GENE O
are O O
encoded O O
by O O
approximately O O
0 O O
genes O O
, O O
while O O
MB B-GENE O
type I-GENE O
myrosinases B-GENE O
are O O
encoded O O
by O O
more O O
than O O
00 O O
genes O O
in O O
B O O
. O O
napus O O
. O O

Mutational O O
analyses O O
have O O
demonstrated O O
the O O
importance O O
of O O
sequences O O
within O O
the O O
000 O O
bp O O
segment O O
that O O
contain O O
a O O
putative O O
cyclic B-GENE O
AMP I-GENE O
responsive I-GENE B-GENE
element I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( O O
CREB B-GENE B-GENE
) O O
binding O O
site O O
for O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
0 I-GENE I-GENE
and O O
PMA O B-GENE
responsiveness O O
and O O
putative O O
PU B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
Sp0 B-GENE O
binding I-GENE O
sites I-GENE O
for O O
basal O B-GENE
promoter O I-GENE
activity O O
. O O

Transcription O O
initiation O O
sites O O
of O O
the O O
rat O B-GENE
II B-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
, I-GENE I-GENE
III I-GENE I-GENE
beta I-GENE I-GENE
, I-GENE O
and I-GENE O
O I-GENE O
beta I-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
genes O I-GENE
were O O
determined O O
to O O
be O O
00 O O
base O O
pairs O O
( O O
bp O O
) O O
0 O O
' O O
- O O
upstream O O
of O O
the O O
translation O B-GENE
initiation O I-GENE
codon O I-GENE
( O O
ATG O B-GENE
) O O
, O O
in O O
each O O
gene O O
by O O
primer O O
extension O O
analysis O O
. O O

Full B-GENE O
- I-GENE O
length I-GENE O
AT I-GENE O
- I-GENE O
PHH0 I-GENE O
, O O
and O O
both O O
AT B-GENE O
- I-GENE O
PHH0 I-GENE O
and O O
AT B-GENE O
- I-GENE O
PHH0 I-GENE O
delta I-GENE O
C I-GENE O
- I-GENE O
000 I-GENE O
( O O
truncated O O
to O O
be O O
approximately O O
the O O
size O O
of O O
microbial B-GENE B-GENE
photolyase I-GENE I-GENE
genes I-GENE I-GENE
) O O
cDNAs O O
, O O
were O O
overexpressed O O
, O O
respectively O O
, O O
in O O
yeast O O
and O O
Escherichia O O
coli O O
mutants O O
hypersensitive O O
to O O
ultraviolet O O
light O O
. O O

Here O O
we O O
report O O
the O O
purification O O
of O O
this O O
larger O O
form O O
as O O
an O O
approximately O O
000 O O
- O O
kDa O O
particle O O
that O O
contains O O
mRNP0 B-GENE O
+ I-GENE O
0 I-GENE O
and O O
nine O O
additional O O
polypeptides O O
, O O
including O O
mRNA O O
- O O
binding O O
polypeptides O O
of O O
00 O O
and O O
00 O O
kDa O O
and O O
a O O
doublet O O
of O O
000 O O
/ O O
000 O O
kDa O O
that O O
proved O O
to O O
be O O
nucleolin B-GENE O
. O O

Using O O
a O O
MOS O O
- O O
Hypersil O O
reversed O O
- O O
phase O O
column O O
with O O
a O O
phosphate O O
buffer O O
- O O
- O O
acetonitrile O O
mobile O O
phase O O
, O O
baseline O O
separation O O
of O O
antipyrine O O
, O O
its O O
metabolites O O
0 O O
- O O
hydroxymethylantipyrine O O
, O O
norantipyrine O O
and O O
0 O O
- O O
hydroxyantipyrine O O
, O O
and O O
the O O
internal O O
standard O O
, O O
phenacetin O O
, O O
was O O
achieved O O
within O O
0 O O
min O O
. O O

A O O
single O O
NMSC O O
was O O
present O O
in O O
00 O O
. O O
0 O O
% O O
, O O
two O O
in O O
00 O O
% O O
, O O
three O O
in O O
0 O O
. O O
0 O O
% O O
, O O
four O O
in O O
0 O O
. O O
0 O O
% O O
, O O
five O O
to O O
nine O O
in O O
0 O O
. O O
0 O O
% O O
, O O
and O O
0 O O
. O O
0 O O
% O O
had O O
ten O O
or O O
more O O
. O O

Transcriptional O O
analysis O O
of O O
a O O
series O O
of O O
deletion O O
mutants O O
of O O
the O O
gene O O
in O O
the O O
nuclear O O
extracts O O
prepared O O
from O O
the O O
middle O O
silk O O
gland O O
of O O
0 O O
- O O
day O O
- O O
old O O
fifth O O
instar O O
larvae O O
revealed O O
the O O
presence O O
of O O
multiple O O
cis O O
- O O
regulatory O O
elements O O
located O O
both O O
upstream O O
and O O
downstream O O
of O O
the O O
initiation O O
site O O
. O O

Its O O
hydropathy O O
profile O O
predicts O O
seven O O
transmembrane O O
spans O O
and O O
a O O
hydrophilic O O
amino O O
terminus O O
of O O
approximately O O
000 O O
residues O O
, O O
and O O
it O O
suggests O O
the O O
presence O O
of O O
an O O
amphiphilic O O
alpha O O
- O O
helix O O
( O O
L O O
- O O
00 O O
to O O
F O O
- O O
00 O O
) O O
in O O
close O O
proximity O O
to O O
the O O
first O O
strongly O O
hydrophobic O O
segment O O
of O O
ProW B-GENE O
. O O

Enterococcus O O
faecium O O
strains O O
with O O
vanA O O
- O O
mediated O O
glycopeptide O O
resistance O O
were O O
isolated O O
by O O
enrichment O O
culture O O
from O O
the O O
intestines O O
and O O
feces O O
of O O
several O O
animal O O
species O O
, O O
mainly O O
horses O O
and O O
dogs O O
( O O
0 O O
% O O
positive O O
) O O
, O O
chickens O O
( O O
0 O O
% O O
positive O O
) O O
, O O
and O O
pigs O O
( O O
0 O O
% O O
positive O O
) O O
. O O

We O O
have O O
characterized O O
a O O
panel O O
of O O
0 O O
monoclonal O O
antibodies O O
raised O O
against O O
human B-GENE O
platelet I-GENE O
talin I-GENE O
by O O
Western O O
blotting O O
, O O
immune O O
precipitation O O
, O O
and O O
immunofluorescence O O
, O O
and O O
shown O O
that O O
antibodies B-GENE O
TA000 I-GENE O
and O O
TD00 B-GENE O
disrupt O O
actin B-GENE O
stress O O
fibers O O
and O O
focal O O
adhesions O O
, O O
and O O
inhibit O O
cell O O
motility O O
when O O
microinjected O O
into O O
human O O
fibroblasts O O
. O O

The O O
interferon B-GENE B-GENE
- O I-GENE
induced O I-GENE
RNA B-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
( O O
PKR B-GENE B-GENE
) O O
is O O
considered O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
cellular O O
defense O O
against O O
viral O O
infection O O
and O O
, O O
in O O
addition O O
, O O
has O O
been O O
suggested O O
to O O
be O O
a O O
tumor O O
suppressor O O
gene O O
because O O
of O O
its O O
growth O O
- O O
suppressive O O
properties O O
. O O

The O O
first O O
identification O O
of O O
the O O
active O O
00LRP B-GENE O
/ O O
p00 B-GENE B-GENE
gene O I-GENE
presented O O
in O O
this O O
study O O
is O O
a O O
critical O O
step O O
toward O O
the O O
isolation O O
of O O
the O O
corresponding O B-GENE
human O I-GENE
gene O I-GENE
and O O
the O O
understanding O O
of O O
the O O
molecular O O
mechanisms O O
involved O O
in O O
the O O
up O O
- O O
regulation O O
of O O
its O O
expression O O
during O O
tumor O O
invasion O O
and O O
metastasis O O
. O O

The O O
nucleotide O O
sequence O O
directly O O
upstream O O
of O O
fimA B-GENE O
contains O O
two O O
open O O
reading O O
frames O O
, O O
ORF0 O O
and O O
ORF0 O B-GENE
, O O
whose O O
deduced O B-GENE
protein O I-GENE
products O O
are O O
homologous O O
to O O
members O O
of O O
a O O
superfamily O O
of O O
ATP B-GENE O
- I-GENE O
binding I-GENE O
cassette I-GENE O
membrane I-GENE O
transport I-GENE O
proteins I-GENE O
, O O
including O O
both O O
prokaryotic O O
and O O
eukaryotic O O
uptake O O
and O O
export O O
systems O O
. O O

In O O
view O O
of O O
the O O
presence O O
of O O
SECIS O O
elements O O
in O O
the O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
of O O
bacterial B-GENE O
selenoproteins I-GENE O
, O O
we O O
examine O O
the O O
effects O O
in O O
the O O
type B-GENE O
0 I-GENE O
deiodinase I-GENE O
of O O
extending O O
the O O
ORF O O
into O O
the O O
SECIS O O
element O O
, O O
and O O
find O O
that O O
this O O
dramatically O O
inhibits O O
SECIS O O
function O O
. O O

TNF B-GENE O
Treatment O O
of O O
cell O O
activated O O
the O O
p00 B-GENE B-GENE
MAP I-GENE I-GENE
kinase I-GENE I-GENE
pathway O O
, O O
as O O
revealed O O
by O O
increased O O
phosphorylation O O
of O O
p00 B-GENE B-GENE
MAP I-GENE O
kinase I-GENE O
itself O O
, O O
activation O O
of O O
the O O
substrate O B-GENE
protein O I-GENE
MAPKAP B-GENE I-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
and O O
culminating O O
in O O
the O O
phosphorylation O O
of O O
the O O
heat B-GENE O
shock I-GENE O
protein I-GENE O
00 I-GENE O
( O O
hsp00 B-GENE O
) O O
. O O

The O O
promoter O O
of O O
the O O
rat B-GENE B-GENE
PGS I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
contains O O
a O O
CAAT B-GENE B-GENE
enhancer I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
consensus I-GENE I-GENE
site I-GENE O
( I-GENE O
CAAT I-GENE O
box I-GENE O
) I-GENE O
which O O
can O O
confer O O
hormone O O
inducibility O O
to O O
a O O
PGS B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O
CAT B-GENE O
reporter O I-GENE
gene O I-GENE
, O O
as O O
well O O
as O O
a O O
putative O O
E O O
- O O
box O O
region O O
. O O

Members O O
of O O
the O O
Ras B-GENE O
subfamily I-GENE O
of O O
small B-GENE O
GTP I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins I-GENE I-GENE
have O O
been O O
shown O O
to O O
be O O
promiscuous O O
towards O O
a O O
variety O O
of O O
putative O O
effector O O
molecules O O
such O O
as O O
the O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
c I-GENE I-GENE
- I-GENE I-GENE
Raf I-GENE I-GENE
and O O
the O O
Ral B-GENE B-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
guanine I-GENE I-GENE
nucleotide I-GENE I-GENE
exchange I-GENE I-GENE
factor I-GENE I-GENE
( O O
Ral B-GENE B-GENE
- I-GENE I-GENE
GEF I-GENE I-GENE
) O O
. O O

We O O
have O O
found O O
that O O
the O O
expression O O
of O O
GTPase B-GENE B-GENE
- O O
deficient O O
mutants O O
of O O
alpha B-GENE B-GENE
00 I-GENE I-GENE
( O I-GENE
alpha B-GENE I-GENE
00Q000L I-GENE I-GENE
) O I-GENE
or O I-GENE
alpha B-GENE I-GENE
00 I-GENE I-GENE
( O I-GENE
alpha B-GENE I-GENE
00Q000L I-GENE I-GENE
) O O
leads O O
to O O
robust O O
activation O O
of O O
the O O
Jun B-GENE B-GENE
kinase I-GENE I-GENE
/ O I-GENE
stress B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
( O O
JNK B-GENE B-GENE
/ O O
SAPK B-GENE O
) O O
pathway O O
. O O

We O O
here O O
demonstrate O O
that O O
a O O
temperature O O
- O O
sensitive O O
fission O O
yeast O O
mutant O O
which O O
has O O
a O O
mutation O O
in O O
a O O
homologous O O
gene O O
, O O
and O O
two O O
of O O
three O O
additional O O
( O O
mtr0 B-GENE B-GENE
/ O O
prp00 B-GENE B-GENE
/ O O
srm0 B-GENE O
) O O
mutants O O
accumulate O O
nuclear O O
poly O O
( O O
A O O
) O O
+ O O
RNA O O
at O O
00 O O
degrees O O
C O O
. O O

The O O
previously O O
described O O
enhanced O O
translation O O
of O O
spinach O O
L00 B-GENE O
mRNA I-GENE O
from O O
its O O
two O O
tandem O O
AUG O O
codons O O
and O O
the O O
two O O
functional O O
rpl00 B-GENE O
genes I-GENE O
in O O
Arabidopsis O O
probably O O
provide O O
two O O
mechanisms O O
for O O
generating O O
the O O
four O O
copies O O
of O O
L00 B-GENE B-GENE
/ I-GENE O
chloroplast I-GENE O
ribosome I-GENE O
, O O
qualitatively O O
different O O
from O O
those O O
attempted O O
in O O
eubacteria O O
. O O

Fibromuscular O O
intimal O O
thickening O O
was O O
seen O O
in O O
the O O
ascending O O
and O O
thoracic O O
aorta O O
of O O
the O O
swine O O
fed O O
00 O O
, O O
000 O O
IU O O
of O O
vitamin O O
D0 O O
/ O O
kg O O
of O O
diet O O
for O O
three O O
months O O
duration O O
; O O
and O O
after O O
0 O O
months O O
of O O
vitamin O O
D0 O O
withdrawal O O
, O O
atherosclerotic O O
lesions O O
were O O
found O O
. O O

Based O O
on O O
peptide O O
map O O
similarities O O
, O O
partial O O
amino O O
- O O
terminal O O
sequence O O
data O O
, O O
and O O
common O O
genetic O O
origin O O
, O O
it O O
is O O
suggested O O
that O O
p00 B-GENE B-GENE
and O O
p00 B-GENE O
have O O
identical O O
amino O O
acid O O
sequences O O
carboxy O O
- O O
terminal O O
to O O
the O O
p00 B-GENE B-GENE
initiator O O
methionine O O
( O O
residue O O
00 O O
of O O
p00 B-GENE B-GENE
) O O
. O O

Although O O
both O O
transfected O O
cell O O
lines O O
contain O O
FGF B-GENE O
- I-GENE O
0 I-GENE O
cell I-GENE O
surface I-GENE O
receptors I-GENE O
as O O
judged O O
by O O
crosslinking O O
studies O O
, O O
the O O
wild O B-GENE
- O I-GENE
type O I-GENE
transfectants O I-GENE
are O O
refractory O O
to O O
exogenous O O
FGF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
whereas O O
the O O
mutant O O
transfectants O O
respond O O
normally O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

The O O
synthetic O O
DNA O O
sequence O O
was O O
constructed O O
to O O
achieve O O
efficient O O
base O O
pairing O O
with O O
Escherichia B-GENE O
coli I-GENE O
00S I-GENE O
ribosomal I-GENE O
RNA I-GENE O
, O O
avoidance O O
of O O
internal O O
secondary O O
structure O O
, O O
and O O
optimal O O
codon O O
usage O O
for O O
high O O
- O O
level O O
protein O O
expression O O
in O O
accord O O
with O O
the O O
known O O
preferences O O
in O O
E O O
. O O
coli O O
. O O

As O O
regards O O
lipid O O
metabolism O O
, O O
the O O
mean O O
values O O
for O O
total O O
triglycerides O O
, O O
cholesterol O O
, O O
LDL B-GENE O
- I-GENE O
cholesterol I-GENE O
and O O
HDL B-GENE O
- I-GENE O
cholesterol I-GENE O
seen O O
at O O
the O O
end O O
of O O
five O O
years O O
of O O
Norplant O O
- O O
0 O O
rod O O
use O O
and O O
six O O
months O O
postremoval O O
were O O
similar O O
to O O
the O O
preinsertion O O
mean O O
. O O

METHODS O O
: O O
Fifty O O
- O O
one O O
healthy O O
eyes O O
, O O
000 O O
ocular O O
hypertensive O O
eyes O O
with O O
normal O O
visual O O
fields O O
, O O
and O O
000 O O
glaucomatous O O
eyes O O
with O O
early O O
visual O O
field O O
defects O O
were O O
evaluated O O
with O O
qualitative O O
and O O
quantitative O O
measures O O
of O O
structural O O
damage O O
to O O
the O O
optic O O
nerve O O
and O O
nerve O O
fiber O O
layer O O
. O O

The O O
DNase B-GENE O
I I-GENE O
footprint O O
extended O O
0 O O
' O O
in O O
the O O
silencer O O
region O O
to O O
include O O
an O O
inverted O O
repeat O O
of O O
a O O
six O O
- O O
nucleotide O O
motif O O
( O O
epsilon O O
- O O
000 O O
to O O
- O O
000 O O
bp O O
) O O
which O O
shares O O
0 O O
of O O
0 O O
bases O O
with O O
the O O
GATA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
consensus I-GENE O
sequence I-GENE O
. O O

Mutations O O
within O O
conserved O O
region O O
0 O O
( O O
CR0 O O
) O O
of O O
E0A B-GENE O
that O O
inhibit O O
the O O
binding O O
of O O
E0A B-GENE O
to O O
the O O
retinoblastoma B-GENE B-GENE
gene I-GENE I-GENE
product I-GENE I-GENE
( O O
pRb B-GENE O
) O O
further O O
enhanced O O
the O O
stimulation O O
of O O
transcription O O
from O O
the O O
PEPCK B-GENE O
promoter I-GENE O
by O O
0 O O
0 O O
- O O
fold O O
compared O O
with O O
wild B-GENE O
type I-GENE O
E0A I-GENE O
. O O

Here O O
we O O
localize O O
a O O
transferable O O
00 O O
- O O
amino O O
acid O O
region O O
within O O
the O O
LBDs B-GENE O
of O O
RXR B-GENE B-GENE
, O O
RAR B-GENE B-GENE
, O O
TR B-GENE B-GENE
, O O
and O O
chicken B-GENE B-GENE
ovalbumin I-GENE I-GENE
upstream I-GENE I-GENE
promoter I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE O
that O O
is O O
critical O O
for O O
determining O O
identity O O
in O O
the O O
heterodimeric O O
interaction O O
and O O
for O O
high O O
- O O
affinity O O
DNA O O
binding O O
. O O

This O O
0 O O
. O O
00 O O
kb O O
cDNA O O
contains O O
an O O
open O O
reading O O
frame O O
( O O
ORF O O
) O O
of O O
000 O O
bp O O
encoding O O
a O O
polypeptide O O
of O O
000 O O
amino O O
acids O O
( O O
aa O O
) O O
which O O
differs O O
at O O
only O O
one O O
position O O
( O O
position O O
00 O O
) O O
from O O
the O O
human B-GENE O
U0 I-GENE B-GENE
- I-GENE I-GENE
C I-GENE I-GENE
protein I-GENE I-GENE
. O O

In O O
co O O
- O O
transfection O O
studies O O
, O O
an O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
but O O
not O O
an O O
Egr B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
expression O O
vector O O
activated O O
VPF B-GENE O
/ O O
VEGF B-GENE O
transcription O O
, O O
thus O O
indicating O O
that O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
protein I-GENE I-GENE
is O O
functionally O O
important O O
in O O
TGF B-GENE B-GENE
alpha I-GENE I-GENE
- O I-GENE
induced O I-GENE
VPF B-GENE I-GENE
/ O I-GENE
VEGF B-GENE I-GENE
gene O I-GENE
expression O O
. O O

Response O O
to O O
treatment O O
was O O
better O O
in O O
patients O O
with O O
less O O
pretreatment O O
( O O
one O O
- O O
two O O
prior O O
treatments O O
) O O
than O O
in O O
heavily O O
pretreated O O
ones O O
( O O
more O O
than O O
three O O
) O O
and O O
this O O
relation O O
was O O
found O O
to O O
be O O
statistically O O
significant O O
( O O
p O O
< O O
0 O O
. O O
00 O O
) O O
. O O

Sterile O O
mutants O O
of O O
Saccharomyces O O
cerevisiae O O
were O O
isolated O O
from O O
alpha O O
* O O
cells O O
having O O
the O O
a B-GENE O
/ I-GENE O
alpha I-GENE I-GENE
aar0 I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
genotype O I-GENE
( O O
exhibiting O O
alpha O O
mating O O
ability O O
and O O
weak O O
a O O
mating O O
ability O O
as O O
a O O
result O O
of O O
a O O
defect O O
in O O
a0 B-GENE O
- I-GENE O
alpha I-GENE O
0 I-GENE O
repression O O
) O O
. O O

The O O
differential O O
investigation O O
of O O
lipoproteins O O
, O O
however O O
, O O
showed O O
that O O
the O O
high B-GENE O
- I-GENE O
density I-GENE O
lipoprotein I-GENE O
( O O
HDL B-GENE O
) O O
fractions O O
are O O
absolutely O O
or O O
relatively O O
decreased O O
with O O
respect O O
to O O
low B-GENE O
- I-GENE O
density I-GENE O
lipoproteins I-GENE O
( O O
LDL B-GENE O
) O O
in O O
cerebral O O
infarcts O O
and O O
in O O
transient O O
ischaemic O O
attacks O O
. O O

Analysis O O
of O O
a O O
set O O
of O O
deletion O O
constructs O O
in O O
transient O O
transfection O O
assays O O
measuring O O
heterologous O B-GENE
reporter O I-GENE
gene O I-GENE
( O O
luciferase B-GENE O
) O O
activity O O
demonstrated O O
that O O
the O O
000 O B-GENE
- O I-GENE
bp O I-GENE
0 O O
' O O
- O O
flanking O O
region O O
provides O O
full O O
promoter O O
activity O O
in O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- O O
stimulated O O
L0 O O
cells O O
. O O

BACKGROUND O O
AND O O
DESIGN O O
: O O
Fifty O O
- O O
nine O O
melanocytic O O
nevi O O
with O O
eccentric O O
foci O O
of O O
hyperpigmentation O O
( O O
" O O
small O O
dark O O
dots O O
" O O
) O O
that O O
measured O O
primarily O O
0 O O
to O O
0 O O
mm O O
in O O
diameter O O
were O O
prospectively O O
examined O O
to O O
determine O O
the O O
histologic O O
correlates O O
of O O
the O O
dark O O
dots O O
. O O

Analysis O O
of O O
the O O
gag B-GENE O
and O O
rev B-GENE O
proteins I-GENE O
in O O
the O O
transfected O O
cells O O
demonstrated O O
that O O
these O O
proteins O O
were O O
not O O
detectable O O
in O O
cells O O
transfected O O
with O O
the O O
tat B-GENE O
mutants I-GENE O
but O O
could O O
be O O
readily O O
detected O O
when O O
the O O
mutations O O
were O O
complemented O O
in O O
trans O O
with O O
a O O
tat B-GENE O
expression O O
vector O O
. O O

Following O O
seizure O O
induction O O
, O O
MABP O O
increased O O
to O O
000 O O
mm O O
Hg O O
and O O
brain O O
pHi O O
fell O O
to O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
within O O
00 O O
min O O
and O O
remained O O
at O O
this O O
level O O
for O O
0 O O
h O O
( O O
P O O
< O O
0 O O
. O O
000 O O
) O O
. O O

The O O
model O O
also O O
predicts O O
that O O
blood O O
flow O O
shunt O O
fraction O O
( O O
Qs O O
/ O O
QT O O
) O O
is O O
directly O O
related O O
to O O
the O O
oxygen O O
sine O O
- O O
wave O O
amplitude O O
perturbations O O
transmitted O O
to O O
end O O
- O O
expired O O
air O O
and O O
arterial O O
and O O
mixed O O
- O O
venous O O
blood O O
through O O
two O O
simple O O
equations O O
. O O

For O O
steers O O
the O O
urinary O O
N O O
values O O
were O O
000 O O
and O O
000 O O
mg O O
/ O O
kg O O
W0 O O
. O O
00 O O
at O O
000 O O
and O O
000 O O
kg O O
live O O
weight O O
respectively O O
and O O
total O O
N O O
excretion O O
including O O
faecal O O
N O O
was O O
000 O O
and O O
000 O O
mg O O
/ O O
kg O O
W0 O O
. O O
00 O O
. O O

The O O
geometric O O
mean O O
hemagglutination O O
- O O
inhibition O O
antibody O O
titers O O
( O O
GMT O O
) O O
of O O
non O O
- O O
immunized O O
, O O
once O O
- O O
immunized O O
, O O
and O O
twice O O
- O O
immunized O O
chickens O O
were O O
compared O O
at O O
0 O O
- O O
week O O
intervals O O
following O O
primary O O
immunization O O
, O O
secondary O O
immunization O O
, O O
and O O
challenge O O
. O O

Six O O
hours O O
after O O
the O O
last O O
administration O O
, O O
uterus O O
of O O
Gf O O
and O O
Cv O O
mice O O
were O O
weight O O
000 O O
. O O
0 O O
mg O O
% O O
and O O
000 O O
. O O
0 O O
mg O O
% O O
respectively O O
, O O
the O O
difference O O
was O O
statistically O O
significant O O
( O O
p O O
less O O
than O O
0 O O
. O O
00 O O
) O O
. O O

That O O
sequence O O
strongly O O
promoted O O
the O O
transcription O O
of O O
the O O
promotorless O B-GENE
chloramphenicol B-GENE I-GENE
acetyltranferase I-GENE I-GENE
( O O
CAT B-GENE B-GENE
) O I-GENE
gene O I-GENE
in O O
cells O O
of O O
pancreatic O O
origin O O
( O O
AR O B-GENE
- O I-GENE
00J O I-GENE
) O O
but O O
not O O
in O O
cells O O
of O O
non O O
- O O
pancreatic O O
origin O O
( O O
Rat O O
0 O O
and O O
IEC O O
0 O O
) O O
. O O

The O O
amino O O
acid O O
sequences O O
of O O
the O O
predicted O O
RfbA B-GENE O
and O O
RfbB B-GENE O
homologs I-GENE O
showed O O
identities O O
of O O
00 O O
. O O
0 O O
% O O
( O O
00 O O
. O O
0 O O
% O O
total O O
similarity O O
) O O
and O O
00 O O
. O O
0 O O
% O O
( O O
00 O O
. O O
0 O O
% O O
total O O
similarity O O
) O O
, O O
respectively O O
. O O

Infant O O
aged O O
0 O O
. O O
0 O O
years O O
presents O O
persistence O O
of O O
primordial O O
vitreous O O
body O O
with O O
crystalline O O
dislocation O O
in O O
the O O
camera O O
aquosa O O
and O O
secondary O O
buphthalmos O O
of O O
the O O
left O O
eye O O
and O O
microphthalmos O O
with O O
dislocation O O
of O O
the O O
crystalline O O
in O O
the O O
vitreous O O
body O O
of O O
the O O
right O O
eye O O
. O O

Specifically O O
, O O
this O O
study O O
determined O O
the O O
influence O O
of O O
: O O
( O O
0 O O
) O O
an O O
awareness O O
strategy O O
, O O
( O O
0 O O
) O O
a O O
non O O
- O O
awareness O O
strategy O O
, O O
( O O
0 O O
) O O
a O O
Five O O
- O O
Step O O
Approach O O
strategy O O
and O O
( O O
0 O O
) O O
a O O
control O O
condition O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
KRAB B-GENE O
domain I-GENE O
present O O
in O O
the O O
non O O
- O O
finger O O
region O O
of O O
many O O
ZFP B-GENE O
genes I-GENE O
quenches O O
transcription O O
possibly O O
due O O
to O O
specific O O
protein O O
- O O
protein O O
interactions O O
between O O
the O O
KRAB B-GENE B-GENE
- I-GENE O
A I-GENE O
domain I-GENE O
and O O
components O O
of O O
the O O
proximal O O
transcriptional O O
apparatus O O
. O O

The O O
revertant O O
TATA O O
boxes O O
accelerated O O
the O O
kinetics O O
of O O
HIV O O
replication O O
when O O
present O O
in O O
the O O
context O O
of O O
an O O
LTR O O
containing O O
a O O
Sp0 B-GENE O
mutation O O
( O O
deletion O O
or O O
site O O
specific O O
) O O
; O O
no O O
effect O O
was O O
observed O O
on O O
the O O
infectivity O O
of O O
wild O O
- O O
type O O
HIV O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
minimal O O
requirements O O
for O O
induction O O
of O O
PEPCK B-GENE O
by O O
PKA B-GENE O
and O O
inhibition O O
by O O
insulin B-GENE O
include O O
: O O
0 O O
) O O
the O O
CREB B-GENE O
activation I-GENE O
domain I-GENE O
, O O
0 O O
) O O
the O O
PEPCK B-GENE O
TATA I-GENE O
sequence I-GENE O
, O O
and O O
0 O O
) O O
insulin B-GENE O
- O O
responsive O O
hepatoma O O
cells O O
. O O

By O O
using O O
the O O
full O O
- O O
length O O
cytoplasmic O O
domain O O
and O O
mutants O O
with O O
progressive O O
carboxy O O
- O O
terminal O O
deletions O O
, O O
internal O O
deletions O O
, O O
or O O
point O O
mutations O O
, O O
we O O
identified O O
the O O
first O O
000 O O
amino O O
acid O O
residues O O
of O O
LIFR B-GENE O
as O O
the O O
minimal O O
region O O
necessary O O
for O O
signaling O O
. O O

Pseudosubstrate O O
( O O
00 O O
- O O
00 O O
) O O
, O O
derived O O
from O O
the O O
C O O
- O O
terminus O O
of O O
Ca B-GENE O
- I-GENE O
dependent I-GENE O
PKC I-GENE O
isotypes I-GENE O
, O O
inhibited O O
beta B-GENE O
- I-GENE O
PKC I-GENE O
but O O
not O O
nPKC B-GENE O
activity O O
using O O
either O O
Histone B-GENE O
IIIS I-GENE O
or O O
peptide O O
( O O
00 O O
- O O
00 O O
) O O
as O O
substrate O O
. O O

Contrary O O
to O O
expectations O O
, O O
we O O
find O O
a O O
relatively O O
high O O
level O O
of O O
variation O O
in O O
the O O
stripe B-GENE O
0 I-GENE O
enhancer O O
region O O
, O O
including O O
point O O
substitutions O O
and O O
insertion O O
/ O O
deletions O O
in O O
binding O O
sites O O
, O O
and O O
a O O
comparable O O
level O O
of O O
variation O O
in O O
the O O
other O O
noncoding O O
regions O O
. O O

Deletion O O
analysis O O
of O O
rOC B-GENE B-GENE
promoter I-GENE I-GENE
- O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
constructs O O
demonstrates O O
that O O
an O O
AML B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- I-GENE O
binding I-GENE O
sequence I-GENE O
within O O
the O O
proximal O B-GENE
promoter O I-GENE
( O O
- O O
000 O O
to O O
- O O
000 O O
nt O O
) O O
contributes O O
to O O
00 O O
% O O
of O O
the O O
level O O
of O O
osteocalcin B-GENE B-GENE
gene I-GENE I-GENE
expression O O
. O O

Individual O O
mutations O O
in O O
motifs O O
III O O
, O O
IV O O
, O O
and O O
V O O
had O O
distinctive O O
effects O O
on O O
the O O
affinity O O
of O O
enzyme O O
for O O
GTP O O
, O O
the O O
rate O O
of O O
covalent O O
catalysis O O
( O O
EpG O O
formation O O
) O O
, O O
or O O
the O O
transfer O O
of O O
GMP O O
from O O
enzyme O O
to O O
RNA O O
. O O

Human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
Tax B-GENE O
activation O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
/ O O
Rel B-GENE O
involves O O
phosphorylation O O
and O O
degradation O O
of O O
I B-GENE O
kappa I-GENE B-GENE
B I-GENE I-GENE
alpha I-GENE I-GENE
and O O
RelA B-GENE B-GENE
( I-GENE O
p00 I-GENE B-GENE
) I-GENE O
- O O
mediated O O
induction O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
rel I-GENE I-GENE
gene I-GENE I-GENE
. O O

Essential O O
features O O
of O O
this O O
model O O
are O O
bending O O
of O O
the O O
DNA O O
double O O
helix O O
and O O
contact O O
of O O
operator O O
sites O O
with O O
repressor O O
domains O O
bearing O O
sequence O O
homologies O O
with O O
the O O
helix O B-GENE
- O I-GENE
turn O I-GENE
- O I-GENE
helix O I-GENE
( O O
HTH O O
) O O
motifs O O
of O O
other O O
DNA O O
- O O
binding O O
proteins O O
. O O

Monospecific O O
antibodies O O
raised O O
against O O
rat B-GENE O
cytochrome I-GENE O
P I-GENE O
- I-GENE O
000 I-GENE O
0A0 I-GENE O
recognized O O
a O O
protein O O
in O O
the O O
hepatic O O
microsomes O O
of O O
the O O
double O B-GENE
- O I-GENE
crested O I-GENE
cormorant O I-GENE
, O O
and O O
also O O
in O O
those O O
of O O
the O O
great O O
blue O O
heron O O
( O O
Ardea O O
herodias O O
) O O
, O O
using O O
immunoblotting O O
. O O

Using O O
autoantibodies O O
from O O
a O O
Sjogren O O
' O O
s O O
syndrome O O
patient O O
, O O
we O O
have O O
previously O O
identified O O
a O O
000 O O
- O O
kDa O O
peripheral O O
membrane O O
protein O O
associated O O
with O O
the O O
cytosolic O O
face O O
of O O
the O O
trans O B-GENE
- O I-GENE
Golgi O I-GENE
( O O
Kooy O O
, O O
J O O
. O O
, O O
Toh O O
, O O
B O O
. O O

Our O O
results O O
confirm O O
the O O
participation O O
of O O
intron O B-GENE
0 O O
in O O
transcriptional O O
regulation O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
myb I-GENE I-GENE
gene I-GENE I-GENE
( O O
in O O
mouse O O
and O O
human O O
) O O
and O O
implicate O O
multiple O O
and O O
complex O O
regulatory O O
mechanisms O O
of O O
activation O O
during O O
myelomonocytic O O
differentiation O O
and O O
leukemic O O
cell O O
growth O O
control O O
. O O

There O O
was O O
a O O
general O O
broadening O O
of O O
proton O O
resonances O O
for O O
a O O
three O O
- O O
nucleotide O O
segment O O
centered O O
about O O
the O O
lesion O O
site O O
which O O
resulted O O
in O O
a O O
tentative O O
assignment O O
for O O
the O O
sugar O O
protons O O
of O O
the O O
C0 O O
residue O O
in O O
the O O
spectrum O O
of O O
the O O
adduct O O
duplex O O
. O O

We O O
have O O
been O O
studying O O
the O O
interaction O O
of O O
the O O
oncogenic O B-GENE
human O I-GENE
polyomavirus O I-GENE
BK O I-GENE
( O O
BKV O O
) O O
with O O
the O O
tumor B-GENE B-GENE
- I-GENE I-GENE
suppressor I-GENE I-GENE
protein I-GENE I-GENE
p00 I-GENE O
to O O
understand O O
the O O
biology O O
of O O
this O O
virus O O
as O O
well O O
as O O
to O O
understand O O
the O O
basic O O
mechanisms O O
of O O
p00 B-GENE B-GENE
transactivation O O
. O O

In O O
vitro O O
interaction O O
studies O O
, O O
using O O
proteins O O
fused O O
to O O
glutathione B-GENE B-GENE
- I-GENE I-GENE
S I-GENE I-GENE
- I-GENE O
transferase I-GENE O
, O O
showed O O
that O O
RBP B-GENE B-GENE
- I-GENE I-GENE
J I-GENE I-GENE
kappa I-GENE I-GENE
and O O
Su B-GENE O
( I-GENE O
H I-GENE O
) I-GENE O
bind O O
directly O O
to O O
the O O
RAM00 B-GENE O
regions I-GENE O
of O O
mouse B-GENE O
Notch0 I-GENE O
and O O
Drosophila B-GENE B-GENE
Notch I-GENE I-GENE
, O O
respectively O O
. O O

There O O
was O O
a O O
significant O O
correlation O O
between O O
tubular O O
diameter O O
and O O
spg O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
P O O
less O O
than O O
0 O O
. O O
000 O O
) O O
suggesting O O
that O O
tubular O O
diameter O O
measurements O O
in O O
histological O O
sections O O
could O O
be O O
used O O
to O O
predict O O
sperm O O
production O O
. O O

The O O
U00 B-GENE O
genes I-GENE O
of O O
mouse O O
as O O
well O O
as O O
rat O O
, O O
hamster O O
, O O
human O O
, O O
Xenopus O O
and O O
trout O O
are O O
encoded O O
within O O
introns O O
of O O
the O O
constitutively O O
expressed O O
00 B-GENE O
- I-GENE O
kDa I-GENE B-GENE
- I-GENE I-GENE
cognate I-GENE I-GENE
- I-GENE I-GENE
heat I-GENE I-GENE
- I-GENE I-GENE
shock I-GENE I-GENE
protein I-GENE I-GENE
gene I-GENE I-GENE
( O O
hsc00 B-GENE O
) O O
. O O

Surprisingly O O
, O O
Northern O O
( O O
RNA O O
) O O
blot O O
analysis O O
and O O
reverse B-GENE O
transcriptase I-GENE O
- O O
PCRs O O
performed O O
after O O
transfection O O
of O O
COS O O
- O O
0 O O
or O O
HeLa O O
cells O O
with O O
these O O
viral O O
RNAs O O
revealed O O
that O O
Y00S B-GENE O
and O O
Y00L B-GENE O
RNAs I-GENE O
replicated O O
at O O
only O O
very O O
low O O
levels O O
. O O

In O O
addition O O
, O O
REP00 O O
plants O O
were O O
resistant O O
to O O
an O O
unusually O O
broad O O
range O O
of O O
tobamoviruses O O
including O O
tomato O O
mosaic O O
virus O O
, O O
tobacco O O
mild O O
green O O
mosaic O O
virus O O
, O O
TMV O O
- O O
U0 O O
, O O
green O O
tomato O O
atypical O O
mosaic O O
virus O O
, O O
and O O
ribgrass O O
mosaic O O
virus O O
. O O

Because O O
of O O
the O O
small O O
number O O
of O O
visceral O O
angiography O O
procedures O O
performed O O
( O O
00 O O
) O O
, O O
no O O
definitive O O
conclusions O O
could O O
be O O
drawn O O
as O O
to O O
the O O
differences O O
between O O
ionic O O
and O O
nonionic O O
agents O O
regarding O O
grade O O
- O O
0 O O
and O O
grade O O
- O O
0 O O
adverse O O
events O O
. O O

Glomerular O O
mesangial O O
cells O O
expressed O O
an O O
abundant O O
0 O O
. O O
0 O O
kb O O
mRNA O O
transcript O O
for O O
Id0 B-GENE O
, O O
but O O
in O O
contrast O O
to O O
other O O
cell O O
types O O
Id0 B-GENE O
mRNA I-GENE O
was O O
expressed O O
in O O
both O O
randomly O O
cycling O O
cells O O
and O O
in O O
serum O O
- O O
deprived O O
, O O
quiescent O O
cultures O O
. O O

A O O
single O O
0 O O
. O O
0 O O
- O O
kb O O
transcript O O
mRNA O O
was O O
detected O O
by O O
Northern O O
( O O
RNA O O
) O O
blot O O
analysis O O
, O O
and O O
its O O
0 O O
' O O
end O O
maps O O
to O O
a O O
position O O
00 O O
bp O O
upstream O O
from O O
the O O
site O O
of O O
initiation O O
of O O
protein O O
synthesis O O
. O O

In O O
the O O
present O O
study O O
, O O
beta O B-GENE
- O I-GENE
funaltrexamine O I-GENE
( O O
beta O B-GENE
- O I-GENE
FNA O I-GENE
) O O
and O O
naltrindole O O
( O O
NTI O O
) O O
( O O
nonequilibrium O O
mu O O
- O O
and O O
delta O O
- O O
antagonist O O
, O O
respectively O O
) O O
were O O
used O O
to O O
precipitate O O
withdrawal O O
in O O
butorphanol O O
- O O
dependent O O
rats O O
. O O

Five O O
- O O
year O O
survivals O O
amounted O O
to O O
000 O O
% O O
, O O
00 O O
. O O
0 O O
% O O
, O O
00 O O
. O O
0 O O
% O O
, O O
00 O O
. O O
0 O O
% O O
, O O
and O O
00 O O
% O O
for O O
stages O O
I O O
, O O
II O O
, O O
III O O
, O O
IVA O O
and O O
IVB O O
respectively O O
. O O

These O O
two O O
repeat O O
motifs O O
are O O
organized O O
in O O
an O O
extremely O O
well O O
- O O
ordered O O
pattern O O
in O O
each O O
domain O O
, O O
which O O
suggests O O
that O O
SbHRGP0 B-GENE O
belongs O O
to O O
a O O
new O O
group O O
of O O
proteins O O
having O O
the O O
repeat O O
motifs O O
of O O
two O O
distinct O O
groups O O
of O O
dicot B-GENE O
extensins I-GENE O
. O O

Finally O O
, O O
antibody O O
binding O O
to O O
site O O
IIIa O O
on O O
the O O
hCG B-GENE B-GENE
- I-GENE I-GENE
ectodomain I-GENE I-GENE
complex I-GENE O
was O O
also O O
hindered O O
by O O
an O O
anti O O
- O O
peptide O O
mAb O O
directed O O
against O O
a O O
peptide O O
encoded O O
by O O
the O O
eighth O O
exon O O
( O O
pE O B-GENE
x O I-GENE
0 O I-GENE
) O O
of O O
the O O
LHR B-GENE O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
isolated O O
and O O
sequenced O O
several O O
p00E B-GENE O
cDNA I-GENE O
gene I-GENE O
fragments I-GENE O
amplified O O
by O O
means O O
of O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
from O O
parental O O
( O O
P000 O O
) O O
and O O
xenogenized O O
( O O
P000 O O
/ O O
DTIC O O
) O O
tumour O O
cells O O
. O O

All O O
ribosomal B-GENE B-GENE
protein I-GENE I-GENE
( O O
rp B-GENE O
) O O
gene O O
promoters O O
from O O
Saccharomyces O O
cerevisiae O O
studied O O
so O O
far O O
contain O O
either O O
( O O
usually O O
two O O
) O O
binding O O
sites O O
for O O
the O O
global O O
gene O O
regulator O O
Rap0p B-GENE O
or O O
one O O
binding O O
site O O
for O O
another O O
global O O
factor O O
, O O
Abf0p B-GENE O
. O O

Southern O O
blot O O
hybridization O O
experiments O O
suggest O O
the O O
presence O O
of O O
one O O
copy O O
of O O
Atcys0 B-GENE O
, O O
Athyp0 B-GENE O
and O O
AKin00 B-GENE O
per O O
haploid O O
genome O O
, O O
and O O
Northern O O
blot O O
analysis O O
demonstrates O O
that O O
the O O
three O O
genes O O
are O O
differentially O O
expressed O O
in O O
roots O O
, O O
shoots O O
and O O
leaves O O
. O O

All O O
other O O
normal O O
and O O
transformed O O
lymphoid O O
and O O
nonlymphoid O O
cell O O
lines O O
and O O
normal O O
tissues O O
were O O
negative O O
for O O
PANG B-GENE O
expression O O
except O O
for O O
the O O
brain O O
, O O
wherein O O
unique O O
0 O O
. O O
0 O O
- O O
and O O
0 O O
. O O
0 O O
- O O
kb O O
transcripts O O
were O O
detected O O
. O O

Stimulation O O
of O O
[ O O
0H O O
] O O
PA O O
production O O
upon O O
CD0 B-GENE O
cross O O
- O O
linking O O
was O O
00 O O
% O O
lower O O
in O O
permeabilized O O
CD00 B-GENE O
- I-GENE O
cells O O
than O O
in O O
CD00 B-GENE O
+ I-GENE O
cells O O
, O O
consistent O O
with O O
the O O
reduced O O
activity O O
of O O
p00fyn B-GENE O
in O O
CD00 B-GENE O
- I-GENE O
cells O O
. O O

We O O
postulate O O
that O O
CaM B-GENE O
binding O O
by O O
HIV B-GENE O
envelope I-GENE O
proteins I-GENE O
is O O
likely O O
to O O
exert O O
diverse O O
modulatory O O
effects O O
, O O
and O O
the O O
mechanism O O
for O O
HIV O O
- O O
induced O O
cytotoxicity O O
may O O
involve O O
, O O
in O O
part O O
, O O
inhibition O O
of O O
CaM B-GENE O
- O O
regulated O O
cellular O O
functions O O
. O O

The O O
lemdr0 B-GENE B-GENE
gene I-GENE I-GENE
was O O
cloned O O
in O O
the O O
expression O O
vector O O
pALTNEO O O
and O O
transfected O O
into O O
wild O O
- O O
type O O
L O O
. O O
enriettii O O
and O O
the O O
resulting O O
transfected O O
cells O O
were O O
resistant O O
to O O
vinblastine O O
but O O
at O O
lower O O
levels O O
than O O
in O O
the O O
selected O O
mutant O O
cells O O
. O O

0 O O
- O O
AP O O
induced O O
marked O O
, O O
steady O O
rises O O
in O O
mRNA O O
accumulation O O
from O O
both O O
transfected O O
and O O
chromosomally O O
integrated O O
HIV O O
- O O
0 O O
constructs O O
but O O
no O O
increases O O
from O O
an O O
endogenous O O
gene O O
encoding O O
gamma B-GENE O
- I-GENE O
actin I-GENE O
or O O
glucose B-GENE O
0 I-GENE O
- I-GENE O
phosphate I-GENE O
dehydrogenase I-GENE O
. O O

A O O
sheep O O
testicular O O
cDNA O O
library O O
constructed O O
in O O
pcDNA0 O O
vector O O
was O O
screened O O
with O O
a O O
probe O O
generated O O
by O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
and O O
corresponding O O
to O O
a O O
0 O O
. O O
0 O O
kb O O
fragment O O
of O O
the O O
rat B-GENE O
luteinizing I-GENE O
hormone I-GENE O
receptor I-GENE O
cDNA I-GENE O
. O O

Therefore O O
, O O
PC B-GENE B-GENE
- I-GENE I-GENE
PLC I-GENE I-GENE
is O O
a O O
component O O
of O O
a O O
signal O O
transduction O O
pathway O O
leading O O
to O O
transcription O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
and O O
junB B-GENE O
that O O
collaborates O O
with O O
c B-GENE B-GENE
- I-GENE I-GENE
myc I-GENE I-GENE
and O O
is O O
independent O O
of O O
PKC B-GENE B-GENE
- I-GENE I-GENE
delta I-GENE I-GENE
and O O
Ras B-GENE O
activation O O
. O O

Further O O
evidence O O
for O O
a O O
clustered O O
organization O O
of O O
FAX B-GENE B-GENE
- O I-GENE
ZFP B-GENE I-GENE
transcription O O
units O O
is O O
provided O O
by O O
Southern O O
blot O O
analysis O O
of O O
large O O
genomic O O
restriction O O
fragments O O
separated O O
by O O
transverse O O
field O O
gel O O
electrophoresis O O
, O O
and O O
by O O
in O O
situ O O
hybridization O O
on O O
intact O O
chromosomes O O
. O O

( O O
ii O O
) O O
opening O O
of O O
KATP O O
attenuates O O
, O O
inhibition O O
of O O
the O O
channel O O
exacerbates O O
functional O O
consequences O O
of O O
coronary O O
occlusion O O
, O O
and O O
( O O
iii O O
) O O
KATP O O
opening O O
attenuates O O
reperfusion O O
- O O
induced O O
VF O O
, O O
but O O
it O O
triggers O O
ischemia O O
- O O
induced O O
VF O O
. O O

This O O
phenomenon O O
did O O
not O O
require O O
DNA O O
binding O O
by O O
the O O
" O O
interfering O O
" O O
receptor O O
but O O
required O O
it O O
to O O
be O O
hormone O O
- O O
bound O O
, O O
indicating O O
that O O
a O O
transcriptionally O O
active O O
form O O
of O O
the O O
interfering O O
receptor O O
is O O
essential O O
for O O
the O O
interfering O O
effect O O
. O O

The O O
Pro O O
- O O
000 O I-GENE
- O I-GENE
- O I-GENE
> O I-GENE
Leu O I-GENE
( O O
P000L O O
) O O
mutation O O
caused O O
constitutive O O
receptor O O
signaling O O
that O O
was O O
equivalent O O
to O O
about O O
00 O O
% O O
of O O
the O O
maximum O O
level O O
observed O O
in O O
wild O O
- O O
type O O
cells O O
stimulated O O
with O O
alpha B-GENE B-GENE
- I-GENE I-GENE
factor I-GENE I-GENE
. O O

The O O
concentrations O O
of O O
vitamin O O
A O O
precursors O O
and O O
vitamin O O
E O O
in O O
the O O
hay O O
were O O
below O O
currently O O
recommended O O
dietary O O
levels O O
for O O
llamas O O
, O O
and O O
alfalfa O O
hay O O
appears O O
to O O
provide O O
an O O
unreliable O O
source O O
of O O
vitamins O O
A O O
and O O
E O O
in O O
this O O
species O O
. O O

The O O
mobility O O
shift O O
assay O O
of O O
the O O
00 O O
bp O O
( O O
- O O
000 O O
/ O O
- O O
000 O O
) O O
fragment O O
with O O
nuclear O O
extract O O
from O O
the O O
dark O O
- O O
adapted O O
sample O O
showed O O
an O O
additional O O
band O O
, O O
not O O
seen O O
with O O
the O O
light O O
- O O
grown O O
sample O O
. O O

The O O
identification O O
of O O
the O O
hepatitis O O
C O O
virus O O
as O O
the O O
major O O
cause O O
of O O
liver O O
disease O O
both O O
in O O
dialysis O O
patients O O
and O O
in O O
transplant O O
patients O O
has O O
focused O O
attention O O
on O O
the O O
epidemiology O O
and O O
the O O
impact O O
of O O
continuing O O
infection O O
in O O
these O O
patient O O
groups O O
. O O

The O O
number O O
of O O
lactotropes O O
, O O
somatotropes O O
, O O
thyrotropes O O
, O O
and O O
gonadotropes O O
was O O
not O O
altered O O
compared O O
with O O
controls O O
, O O
indicating O O
that O O
in O O
the O O
adult O O
pituitary O O
, O O
POMC B-GENE O
products I-GENE O
are O O
not O O
required O O
to O O
maintain O O
the O O
distribution O O
of O O
cell O O
types O O
. O O

The O O
two O O
bases O O
immediately O O
flanking O O
the O O
0 O O
' O O
end O O
of O O
the O O
element O O
proved O O
to O O
be O O
very O O
important O O
to O O
its O O
function O O
as O O
a O O
UAS O O
element O O
as O O
did O O
the O O
two O O
bases O O
immediately O O
0 O O
' O O
of O O
the O O
bHLH O O
core O O
motif O O
. O O

Here O O
we O O
focused O O
on O O
the O O
role O O
of O O
the O O
0 O O
' O O
proximal O O
regulatory O O
cassette O O
( O O
- O O
000 O O
; O O
+ O O
00 O O
bp O O
) O O
of O O
the O O
rat B-GENE O
enkephalin I-GENE O
( O O
rENK B-GENE O
) O O
gene O O
in O O
the O O
developmental O O
regulation O O
of O O
the O O
enkephalin B-GENE O
phenotype O O
. O O

Unexpectedly O O
, O O
all O O
ENK B-GENE O
- I-GENE O
specific I-GENE O
motifs I-GENE O
formed O O
specific O O
and O O
highly O O
abundant O O
protein O O
- O O
DNA O O
complexes O O
when O O
nuclear O O
extracts O O
from O O
the O O
human O O
tumor O O
cell O O
line O O
( O O
HeLa O O
) O O
, O O
which O O
does O O
not O O
express O O
ENK B-GENE O
, O O
were O O
used O O
. O O

Mean O O
growth O O
changes O O
in O O
this O O
Class O O
II O O
sample O O
were O O
comparable O O
to O O
those O O
previously O O
reported O O
for O O
male O O
subjects O O
with O O
Class O O
I O O
malocclusions O O
over O O
the O O
same O O
age O O
period O O
, O O
suggesting O O
a O O
similarity O O
in O O
postpubertal O O
development O O
between O O
these O O
two O O
groups O O
. O O

The O O
study O O
was O O
repeated O O
after O O
administration O O
of O O
oral O O
amiodarone O O
, O O
00 O O
mg O O
/ O O
kg O O
/ O O
day O O
for O O
0 O O
days O O
in O O
0 O O
divided O O
doses O O
( O O
mean O O
dose O O
0 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
g O O
) O O
. O O

Transfection O O
of O O
non O B-GENE
- O O
deleted O O
expression O O
vector O O
into O O
NIH0T0 O O
cells O O
results O O
in O O
acquisition O O
of O O
focus O O
- O O
forming O O
activity O O
while O O
a O O
deleted O O
form O O
of O O
expression O O
vector O O
fails O O
to O O
show O O
this O O
activity O O
even O O
in O O
the O O
presence O O
of O O
basic B-GENE O
FGF I-GENE O
. O O

Removal O O
of O O
the O O
GST B-GENE O
domain I-GENE O
from O O
GST B-GENE O
- O O
Tax B-GENE O
by O O
thrombin B-GENE O
restores O O
Tax B-GENE O
' O O
s O O
ability O O
to O O
assemble O O
a O O
ternary O O
Tax B-GENE O
- O O
CREB B-GENE O
- O O
00 O O
- O O
bp O O
- O O
repeat O O
complex O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

The O O
results O O
indicate O O
that O O
hrpRS B-GENE O
and O O
hrpL B-GENE O
are O O
part O O
of O O
a O O
regulatory O O
cascade O O
in O O
which O O
HrpR B-GENE O
and O O
HrpS B-GENE O
activate O O
expression O O
of O O
hrpL B-GENE B-GENE
and O O
HrpL B-GENE O
, O O
a O O
putative O B-GENE
sigma B-GENE I-GENE
factor I-GENE I-GENE
, O O
induces O O
expression O O
of O O
HrpL B-GENE B-GENE
- I-GENE I-GENE
responsive I-GENE I-GENE
genes I-GENE I-GENE
. O O

Members O O
of O O
the O O
myocyte B-GENE B-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
enhancer I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
factor I-GENE I-GENE
0 I-GENE I-GENE
( O O
MEF0 B-GENE B-GENE
) O O
family O O
of O O
transcription O B-GENE
factors O I-GENE
bind O O
a O O
conserved O O
A O O
/ O O
T O O
- O O
rich O O
sequence O O
in O O
the O O
control O O
regions O O
of O O
numerous O O
muscle O O
- O O
specific O O
genes O O
. O O

Escherichia O O
coli O O
BL00 O O
( O O
DE0 O B-GENE
) O O
plysS O O
, O O
harbouring O O
a O O
recombinant O O
plasmid O O
containing O O
the O O
catalase B-GENE B-GENE
- O I-GENE
peroxidase B-GENE I-GENE
gene O I-GENE
, O O
produced O O
a O O
large O O
amount O O
of O O
proteins O O
that O O
co O O
- O O
migrated O O
on O O
SDS O O
/ O O
PAGE O O
with O O
the O O
native O O
enzyme O O
. O O

An O O
inactive O O
analog O O
of O O
wortmannin O B-GENE
, O O
WM00 O O
, O O
did O O
not O O
affect O O
TCR B-GENE O
/ O O
CD0 B-GENE O
- O O
induced O O
Erk0 B-GENE O
activation O O
, O O
and O O
wortmannin O O
had O O
no O O
effect O O
on O O
the O O
activity O O
of O O
Erk0 B-GENE O
when O O
added O O
directly O O
to O O
the O O
in O O
vitro O O
assays O O
. O O

00 O O
. O O
0 O O
micromol O O
/ O O
0 O O
, O O
p O O
< O O
0 O O
. O O
00 O O
) O O
and O O
area O O
under O O
the O O
plasma O O
concentration O O
- O O
time O O
curve O O
extrapolated O O
to O O
infinity O O
AUC O O
0 O O
( O O
0 O O
- O O
infinity O O
) O O
( O O
000 O O
. O O
0 O O
vs O O
. O O

The O O
most O O
frequent O O
causes O O
of O O
the O O
meningitis O O
was O O
the O O
external O O
ventricular O O
drainage O O
( O O
00 O O
. O O
0 O O
% O O
) O O
, O O
post O O
- O O
neurosurgical O O
( O O
0 O O
. O O
0 O O
% O O
) O O
and O O
head O O
injury O O
( O O
0 O O
. O O
0000 O O
% O O
) O O
. O O

Almost O O
complete O O
sequence O O
identity O O
was O O
found O O
between O O
the O O
0 O O
' O O
end O O
of O O
the O O
DXS0000E B-GENE B-GENE
gene I-GENE I-GENE
and O O
two O O
expressed O O
sequence O O
tags O O
( O O
ESTs O O
) O O
and O O
between O O
the O O
0 O O
' O O
end O O
of O O
the O O
DXS0000E B-GENE B-GENE
gene I-GENE I-GENE
and O O
a O O
third O O
EST O O
. O O

Stable O O
transfection O O
of O O
the O O
BL O O
cell O O
line O O
Raji O O
with O O
constructs O O
containing O O
core O O
promoter O O
mutations O O
confirmed O O
that O O
the O O
proximal O O
Sp0 B-GENE O
site I-GENE O
and O O
the O O
TATA O O
box O O
are O O
essential O O
for O O
the O O
activation O O
of O O
promoter O O
P0 O O
by O O
the O O
Ig B-GENE O
kappa I-GENE O
enhancers I-GENE O
. O O

The O O
alterations O O
in O O
differentiation O O
of O O
osteoprogenitor O O
cells O O
, O O
together O O
with O O
the O O
failure O O
of O O
mineralization O O
, O O
resulted O O
in O O
significantly O O
lower O O
rates O O
of O O
bone O O
formation O O
( O O
as O O
measured O O
by O O
fluorochrome O O
labeling O O
) O O
in O O
the O O
magnesium O O
- O O
deficient O O
rats O O
. O O

Of O O
the O O
000 O O
patients O O
( O O
out O O
of O O
the O O
000 O O
) O O
with O O
serologic O O
evidence O O
of O O
chronic O O
thyroiditis O O
who O O
could O O
be O O
studied O O
, O O
eight O O
( O O
0 O O
% O O
) O O
had O O
hyperthyroidism O O
and O O
00 O O
( O O
00 O O
% O O
) O O
were O O
hypothyroid O O
. O O

A O O
0 B-GENE O
. I-GENE O
0 I-GENE O
- I-GENE O
kb I-GENE O
MAPKAPK I-GENE O
- I-GENE O
0 I-GENE O
message I-GENE O
is O O
expressed O O
throughout O O
development O O
, O O
while O O
two O O
shorter O O
transcripts O O
of O O
0 O O
. O O
0 O O
and O O
0 O O
. O O
0 O O
kb O O
appear O O
to O O
be O O
specifically O O
expressed O O
in O O
the O O
germline O O
. O O

The O O
experimental O O
design O O
represents O O
a O O
0 O O
x O O
0 O O
factorial O O
arrangement O O
of O O
treatments O O
with O O
three O O
dietary O O
levels O O
of O O
incorporation O O
of O O
RSB O O
( O O
0 O O
, O O
00 O O
, O O
and O O
000 O O
% O O
) O O
, O O
and O O
chickens O O
either O O
infected O O
or O O
uninfected O O
. O O

A O O
triple O O
Ser O O
- O O
- O O
> O O
Ala O O
mutant O O
form O O
of O O
yeast O B-GENE
eIF B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
alpha I-GENE I-GENE
was O O
found O O
to O O
be O O
no O O
longer O O
phosphorylated O O
by O O
either O O
of O O
the O O
yeast O O
( O O
or O O
mammalian O O
) O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
activities O O
in O O
vitro O O
. O O

Binding O O
activity O O
in O O
rat O O
liver O O
nuclear O O
extracts O O
includes O O
these O O
orphan O O
receptors O O
as O O
judged O O
from O O
electromobility O O
supershift O O
experiments O O
and O O
from O O
results O O
obtained O O
with O O
expressed O O
receptors O O
, O O
although O O
the O O
element O O
in O O
CYP0C00 B-GENE O
did O O
not O O
bind O O
HNF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

MATERIAL O O
AND O O
METHODS O O
: O O
Of O O
the O O
00 O O
men O O
and O O
00 O O
women O O
, O O
who O O
were O O
00 O O
to O O
00 O O
years O O
of O O
age O O
, O O
00 O O
had O O
hereditary O O
motor O O
and O O
sensory O O
neuropathy O O
type O O
I O O
and O O
0 O O
had O O
acquired O O
demyelinating O O
polyneuropathy O O
. O O

Reconstitution O O
of O O
complexes O O
containing O O
p00 B-GENE B-GENE
and O O
the O O
src B-GENE B-GENE
family I-GENE I-GENE
kinase I-GENE I-GENE
p00fyn B-GENE O
in O O
HeLa O O
cells O O
demonstrated O O
that O O
complex O O
formation O O
resulted O O
in O O
tyrosine O O
phosphorylation O O
of O O
p00 B-GENE B-GENE
and O O
was O O
mediated O O
by O O
both O O
the O O
SH0 B-GENE O
and O O
SH0 B-GENE O
domains I-GENE O
of O O
p00fyn B-GENE O
. O O

A O O
short O O
sequence O O
surrounding O O
the O O
major O O
JNK B-GENE O
phosphorylation O O
site O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
is O O
conserved O O
in O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
and O O
is O O
part O O
of O O
its O O
activation O O
domain O O
, O O
suggesting O O
that O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
may O O
be O O
similarly O O
regulated O O
. O O

Southern O O
analysis O O
on O O
genomic O O
DNA O O
isolated O O
from O O
tissues O O
and O O
cell O O
lines O O
from O O
several O O
mouse O O
strains O O
using O O
mCD00 B-GENE O
cDNA I-GENE O
demonstrated O O
that O O
the O O
Cd00 B-GENE O
locus I-GENE O
encoding O O
mCD00 B-GENE O
is O O
a O O
single O O
copy O O
gene O O
of O O
< O O
or O O
= O O
00 O O
kb O O
. O O

A O O
series O O
of O O
0 O O
' O O
- O O
deletions O O
revealed O O
that O O
the O O
fragment O B-GENE
- O I-GENE
000 O I-GENE
to O O
+ O O
0 O O
from O O
the O O
TSS O O
had O O
the O O
highest O O
promoter O O
activity O O
, O O
nearly O O
0000 O O
- O O
fold O O
greater O O
than O O
the O O
promoterless O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
construct I-GENE O
. O O

The O O
0 O O
' O O
ends O O
of O O
F0R B-GENE O
late O O
transcripts O O
were O O
located O O
to O O
an O O
A O O
within O O
the O O
sequence O O
0 O O
' O O
- O O
TAAAG O O
, O O
00 O O
nt O O
downstream O O
from O O
the O O
early O O
promoter O O
and O O
00 O O
nt O O
upstream O O
from O O
the O O
initiation O O
codon O O
. O O

In O O
these O O
constructs O O
, O O
GUS B-GENE O
expression O O
was O O
driven O O
by O O
promoter O O
regions O O
derived O O
from O O
the O O
Arabidopsis B-GENE O
alcohol I-GENE O
dehydrogenase I-GENE O
( O O
Adh0 B-GENE O
) O O
, O O
maize B-GENE O
ubiquitin I-GENE O
( O O
Ubi0 B-GENE O
) O O
, O O
rice B-GENE O
actin I-GENE O
( O O
Act0 B-GENE O
) O O
and O O
CaMV B-GENE O
00S I-GENE O
genes I-GENE O
. O O

The O O
novel O O
hematopoietic B-GENE O
growth I-GENE O
factor I-GENE O
FLT0 I-GENE O
ligand I-GENE O
( O O
FL B-GENE O
) O O
is O O
the O O
cognate O O
ligand O O
for O O
the O O
FLT0 B-GENE B-GENE
, O O
tyrosine B-GENE B-GENE
kinase I-GENE I-GENE
receptor I-GENE I-GENE
( O O
R B-GENE O
) O O
, O O
also O O
referred O O
to O O
as O O
FLK B-GENE O
- I-GENE O
0 I-GENE O
and O O
STK B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

A O O
study O O
was O O
performed O O
to O O
compare O O
the O O
ONLINE O O
and O O
EMIT O O
II O O
immunoassays O O
with O O
gas O O
chromatographic O O
/ O O
mass O O
spectrometric O O
( O O
GC O O
/ O O
MS O O
) O O
analysis O O
of O O
methaqualone O O
metabolites O O
on O O
urine O O
using O O
samples O O
obtained O O
from O O
a O O
clinical O O
study O O
. O O

Promoter O O
activity O O
was O O
high O O
in O O
cell O O
lines O O
that O O
expressed O O
high O O
levels O O
of O O
endogenous O O
D0 B-GENE O
mRNA I-GENE O
, O O
as O O
indicated O O
by O O
Northern O O
blot O O
analyses O O
, O O
and O O
was O O
significantly O O
reduced O O
when O O
the O O
promoter O O
was O O
truncated O O
to O O
- O O
000 O O
bp O O
. O O

In O O
the O O
same O O
period O O
we O O
pointed O O
out O O
an O O
increase O O
of O O
hematocrit O O
( O O
from O O
00 O O
% O O
to O O
00 O O
% O O
) O O
and O O
of O O
the O O
Hb B-GENE O
( O O
from O O
0 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
g O O
/ O O
dl O O
) O O
. O O

Cytohesin B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
a O O
protein O O
abundant O O
in O O
cells O O
of O O
the O O
immune O O
system O O
, O O
has O O
been O O
proposed O O
to O O
be O O
a O O
human O O
homolog O O
of O O
the O O
Saccharomyces B-GENE B-GENE
cerevisiae I-GENE I-GENE
Sec0 I-GENE I-GENE
gene I-GENE I-GENE
product I-GENE I-GENE
, O O
which O O
is O O
crucial O O
in O O
protein O O
transport O O
. O O

Thus O O
, O O
the O O
tri O B-GENE
- O I-GENE
snRNP O I-GENE
- O I-GENE
specific O I-GENE
00K O I-GENE
protein O I-GENE
could O O
potentially O O
be O O
involved O O
in O O
SR B-GENE B-GENE
protein O I-GENE
- O I-GENE
mediated O I-GENE
protein O I-GENE
/ O I-GENE
protein O I-GENE
interactions O I-GENE
and O O
, O O
additionally O O
, O O
its O O
phosphorylation O O
state O O
could O O
modulate O O
pre O O
- O O
mRNA O O
splicing O O
. O O

The O O
different O O
holoenzyme B-GENE O
RNA I-GENE O
polymerases I-GENE O
generated O O
upon O O
reconstituting O O
these O O
mutants O O
independently O O
with O O
core B-GENE O
RNA I-GENE O
polymerase I-GENE O
( O O
alpha0beta B-GENE O
beta I-GENE O
' I-GENE O
) O O
have O O
shown O O
reduced O O
transcriptional O O
activity O O
in O O
comparison O O
to O O
the O O
enzyme O O
containing O O
wild B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
sigma I-GENE I-GENE
factor I-GENE I-GENE
. O O

While O O
all O O
deletions O O
within O O
the O O
sequence O O
coding O O
for O O
the O O
mature O O
tRNA O O
led O O
to O O
inactivity O O
of O O
the O O
mutated O B-GENE
genes O I-GENE
, O O
substitution O O
of O O
the O O
central O O
portion O O
by O O
concatenated B-GENE O
Hind I-GENE O
III I-GENE O
linkers I-GENE O
produced O O
gene O O
units O O
active O O
in O O
transcription O O
. O O

TG O O
- O O
day O O
and O O
TG O O
- O O
night O O
were O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
% O O
, O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
% O O
, O O
( O O
000 O O
mm0 O O
< O O
T O O
. O O

The O O
LTR O O
- O O
binding O O
activities O O
of O O
VBP B-GENE B-GENE
, O O
a0 B-GENE O
/ I-GENE O
EBP I-GENE O
, O O
and O O
B B-GENE O
- I-GENE O
cell I-GENE O
nuclear I-GENE O
extract I-GENE O
protein I-GENE O
were O O
compared O O
and O O
mapped O O
by O O
gel O O
shift O O
, O O
DNase B-GENE O
I I-GENE O
footprinting O O
, O O
and O O
methylation O O
interference O O
assays O O
. O O

Seven O O
of O O
these O O
had O O
counterparts O O
in O O
the O O
US O O
of O O
herpes O O
simplex O O
type O O
0 O O
( O O
HSV O B-GENE
- O I-GENE
0 O I-GENE
) O O
, O O
pseudorabies O O
virus O O
( O O
PRV O O
) O O
, O O
and O O
equine O O
herpesvirus O O
type O O
0 O O
( O O
EHV O B-GENE
- O I-GENE
0 O I-GENE
) O O
. O O

The O O
following O O
evidence O O
indicates O O
that O O
the O O
00 O B-GENE
- O I-GENE
kD O I-GENE
protein O I-GENE
is O O
a O O
common O O
, O O
rather O O
than O O
a O O
U0 B-GENE B-GENE
- O I-GENE
specific O I-GENE
, O O
protein O O
, O O
possibly O O
associating O O
with O O
the O O
snRNP O B-GENE
core O I-GENE
particles O I-GENE
by O O
protein O B-GENE
- O I-GENE
protein O I-GENE
interaction O O
. O O

The O O
sequence O O
of O O
the O O
HIR0 B-GENE B-GENE
gene I-GENE I-GENE
predicts O O
an O O
00 O O
- O O
kDa O O
protein O O
with O O
three O O
repeats O O
of O O
a O O
motif O O
found O O
in O O
the O O
G B-GENE O
beta I-GENE O
subunit I-GENE O
of O O
retinal B-GENE O
transducin I-GENE O
and O O
in O O
a O O
yeast O O
transcriptional O O
repressor O O
, O O
Tup0 B-GENE O
. O O

The O O
gene O O
encoding O O
the O O
receptor O O
for O O
macrophage B-GENE B-GENE
colony I-GENE I-GENE
- I-GENE I-GENE
stimulating I-GENE I-GENE
factor I-GENE I-GENE
0 I-GENE I-GENE
( O O
CSF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
, O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
fms I-GENE I-GENE
protooncogene I-GENE I-GENE
, O O
is O O
selectively O O
expressed O O
in O O
immature O O
and O O
mature O O
mononuclear O O
phagocytes O O
and O O
trophoblasts O O
. O O

The O O
C O O
/ O O
D O O
ratio O O
was O O
equal O O
to O O
or O O
over O O
0 O O
. O O
0 O O
in O O
0 O O
cases O O
( O O
00 O O
eyes O O
) O O
, O O
and O O
the O O
values O O
were O O
inconsistent O O
between O O
both O O
eyes O O
in O O
00 O O
% O O
of O O
the O O
patients O O
. O O

In O O
the O O
point O O
mutant O O
we O O
observed O O
normal O O
repair O O
of O O
endonuclease B-GENE O
III I-GENE O
site I-GENE O
( O O
i O O
. O O
e O O
. O O
as O O
wild O O
type O O
) O O
, O O
but O O
no O O
removal O O
of O O
CPDs O O
at O O
the O O
MAT B-GENE O
alpha I-GENE O
and O O
HML B-GENE O
alpha I-GENE O
loci I-GENE O
. O O

LY000000 O O
appears O O
to O O
inhibit O O
uPA B-GENE O
promoter I-GENE O
activation O O
by O O
blocking O O
phorbol O O
ester O O
- O O
stimulated O O
binding O O
of O O
nuclear O O
proteins O O
to O O
the O O
uPA B-GENE O
PEA0 B-GENE O
/ O O
00 O O
- O O
0 O O
- O O
tetradecanoylphorbol O O
00 O O
- O O
acetate O O
responsive O O
element O O
( O O
TRE O O
) O O
. O O

IMPLICATIONS O O
: O O
Given O O
the O O
small O O
size O O
of O O
this O O
study O O
and O O
the O O
inconsistency O O
of O O
results O O
among O O
the O O
few O O
prospective O O
studies O O
of O O
ovarian O O
cancer O O
conducted O O
to O O
test O O
these O O
associations O O
, O O
replications O O
of O O
these O O
findings O O
are O O
highly O O
desirable O O
. O O

Recent O O
studies O O
have O O
demonstrated O O
that O O
the O O
U0 B-GENE B-GENE
snRNP I-GENE O
is O O
recruited O O
to O O
the O O
0 O O
' O O
splice O O
site O O
by O O
protein O O
/ O O
protein O O
interactions O O
involving O O
the O O
SR B-GENE O
domains O O
of O O
the O O
U0 B-GENE B-GENE
- I-GENE I-GENE
00K I-GENE I-GENE
protein I-GENE I-GENE
and O O
SF0 B-GENE B-GENE
/ O O
ASF B-GENE O
. O O

The O O
similar O O
phenotypes O O
of O O
bur0 B-GENE O
and O O
bur0 B-GENE O
( O O
mot0 B-GENE O
) O O
mutations O O
suggest O O
that O O
Bur0p B-GENE O
and O O
Mot0p B-GENE O
have O O
related O O
, O O
but O O
not O O
identical O O
, O O
functions O O
in O O
modulating O O
the O O
activity O O
of O O
the O O
general O O
transcription O O
machinery O O
in O O
vivo O O
. O O

The O O
Authors O O
have O O
proposed O O
to O O
develop O O
this O O
research O O
employing O O
a O O
preparation O O
containing O O
exclusively O O
a O O
cortisonic O O
, O O
the O O
desametazone O O
, O O
in O O
order O O
to O O
evaluate O O
the O O
alterations O O
of O O
the O O
dentinogenesis O O
to O O
be O O
attributed O O
to O O
such O O
component O O
. O O

The O O
results O O
indicate O O
that O O
folate O O
compounds O O
decrease O O
formate O O
accumulation O O
after O O
methanol O O
by O O
stimulating O O
formate O O
oxidation O O
or O O
utilization O O
and O O
suggest O O
a O O
possible O O
use O O
for O O
folates O O
in O O
the O O
treatment O O
of O O
certain O O
cases O O
of O O
human O O
methanol O O
poisoning O O
. O O

Peroxisome B-GENE O
proliferator I-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
receptors I-GENE I-GENE
( O O
PPARs B-GENE B-GENE
) O O
and O O
retinoid B-GENE B-GENE
X I-GENE I-GENE
receptors I-GENE I-GENE
( O O
RXRs B-GENE B-GENE
) O O
are O O
nuclear B-GENE O
hormone I-GENE O
receptors I-GENE O
that O O
are O O
activated O O
by O O
fatty O O
acids O O
and O O
0 O O
- O O
cis O O
- O O
retinoic O O
acid O O
, O O
respectively O O
. O O

These O O
incisors O O
were O O
studied O O
by O O
scanning O O
electron O O
microscopy O O
- O O
energy O O
dispersive O O
spectroscopy O O
analysis O O
( O O
SEM O O
- O O
EDS O O
) O O
and O O
light O O
microscopy O O
to O O
examine O O
the O O
calciotraumatic O O
lines O O
of O O
strontium O O
in O O
the O O
rat O O
incisor O O
labial O O
dentin O O
. O O

These O O
results O O
suggest O O
that O O
G B-GENE O
beta I-GENE O
gamma I-GENE O
- O O
stimulated O O
Shc B-GENE O
phosphorylation O O
represents O O
an O O
early O O
step O O
in O O
the O O
pathway O O
leading O O
to O O
p00ras B-GENE O
activation O O
, O O
similar O O
to O O
the O O
mechanism O O
utilized O O
by O O
growth B-GENE O
factor I-GENE O
tyrosine I-GENE O
kinase I-GENE O
receptors I-GENE O
. O O

We O O
demonstrate O O
here O O
that O O
the O O
- O O
DEDDDL O O
sequence O O
stabilizes O O
GDP O O
binding O O
to O O
Ran B-GENE O
, O O
and O O
that O O
the O O
domain O O
is O O
required O O
for O O
high O O
affinity O O
interaction O O
with O O
a O O
Ran B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
, O O
HTF0A B-GENE B-GENE
/ O O
RanBP0 B-GENE O
. O O

However O O
, O O
cotransfection O O
studies O O
indicate O O
that O O
RVR B-GENE O
does O O
not O O
activate O O
transcription O O
when O O
this O O
hormone O O
response O O
element O O
is O O
linked O O
to O O
a O O
reporter O O
gene O O
but O O
rather O O
acts O O
as O O
a O O
potent O O
competitive O O
repressor O O
of O O
ROR B-GENE B-GENE
alpha I-GENE I-GENE
function O O
. O O

In O O
general O O
, O O
the O O
filtration O O
rate O O
in O O
relevant O O
areas O O
appears O O
to O O
be O O
an O O
integrative O O
and O O
easily O O
determined O O
parameter O O
, O O
reflecting O O
hormonal O O
and O O
neurogenic O O
vascular O O
as O O
well O O
as O O
local O O
interstitial O O
control O O
of O O
the O O
Starling O O
forces O O
. O O

In O O
Rat O O
0a O O
cells O O
, O O
m0R B-GENE O
stimulation O O
of O O
phospholipase B-GENE B-GENE
C I-GENE I-GENE
beta I-GENE I-GENE
and O O
the O O
marked O O
rise O O
in O O
intracellular O O
calcium O O
stimulated O O
cyclic O O
AMP O O
( O O
cAMP O O
) O O
synthesis O O
, O O
resulting O O
in O O
the O O
activation O O
of O O
protein B-GENE O
kinase I-GENE O
A I-GENE O
. O O

Restriction O O
analysis O O
and O O
Southern O O
hybridization O O
revealed O O
the O O
presence O O
of O O
Tn0000 B-GENE O
in O O
all O O
the O O
plasmid O O
- O O
mediated O O
cadmium O O
- O O
resistant O O
L O O
. O O
monocytogenes O O
strains O O
tested O O
but O O
not O O
in O O
strains O O
encoding O O
cadmium O O
resistance O O
on O O
the O O
chromosome O O
. O O

Lithium O O
phthalocyanine O O
( O O
LiPc O O
) O O
is O O
a O O
prototype O O
of O O
another O O
generation O O
of O O
synthetic O O
, O O
metallic O B-GENE
- O O
organic O O
, O O
paramagnetic O O
crystallites O O
that O O
appear O O
very O O
useful O O
for O O
in O O
vitro O O
and O O
in O O
vivo O O
electron O O
paramagnetic O O
resonance O O
oximetry O O
. O O

Furthermore O O
, O O
competitor O O
containing O O
the O O
YY0 B-GENE O
consensus I-GENE O
sequence I-GENE O
competed O O
for O O
protein B-GENE O
B I-GENE O
binding O O
, O O
whereas O O
competitor O O
containing O O
a O O
perfect O O
yeast B-GENE O
ABF I-GENE O
- I-GENE O
0 I-GENE O
consensus I-GENE O
sequence I-GENE O
did O O
not O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

Targeted O O
disruption O O
of O O
the O O
OGG0 B-GENE B-GENE
gene I-GENE I-GENE
in O O
yeast O O
revealed O O
a O O
second O O
OG B-GENE O
glycosylase I-GENE O
/ I-GENE O
lyase I-GENE B-GENE
protein I-GENE I-GENE
, O O
tentatively O O
named O O
Ogg0 B-GENE O
, O O
which O O
differs O O
from O O
Ogg0 B-GENE O
in O O
that O O
it O O
preferentially O O
acts O O
on O O
OG O O
: O O
G O O
. O O

Experimental O O
data O O
showed O O
that O O
these O O
abnormal O O
proteins O O
are O O
constitutively O O
localized O O
in O O
the O O
nucleus O O
, O O
have O O
lost O O
the O O
transcriptional O O
repressor O O
functions O O
typical O O
of O O
normal O O
NF B-GENE O
- I-GENE O
kappa I-GENE O
B0p00 I-GENE O
and O O
may O O
be O O
capable O O
of O O
transactivation O O
activity O O
. O O

In O O
silicosis O O
, O O
significant O O
relationships O O
between O O
patients O O
and O O
sons O O
were O O
not O O
seen O O
with O O
respect O O
to O O
arterial O O
blood O O
gas O O
determinations O O
and O O
ventilatory O O
responses O O
except O O
for O O
Paco0 O O
of O O
patients O O
and O O
hypercapnic O O
ventilatory O O
responses O O
of O O
sons O O
. O O

Visual O O
response O O
properties O O
of O O
neurons O O
in O O
four O O
extrastriate O O
visual O O
areas O O
of O O
the O O
owl O O
monkey O O
( O O
Aotus O O
trivirgatus O O
) O O
: O O
a O O
quantitative O O
comparison O O
of O O
medial O O
, O O
dorsomedial O O
, O O
dorsolateral O O
, O O
and O O
middle O O
temporal O O
areas O O
. O O

As O O
expected O O
, O O
the O O
insulin B-GENE O
effect O O
to O O
increase O O
ras B-GENE O
GTP I-GENE O
formation O O
and O O
MAP B-GENE O
kinase I-GENE O
activity O O
was O O
negligible O O
in O O
A O O
/ O O
K0000 O O
cells O O
but O O
normal O O
, O O
or O O
supernormal O O
, O O
in O O
Y O O
/ O O
F0 O O
cells O O
. O O

Since O O
RCC0p B-GENE O
acts O O
as O O
GNRP B-GENE O
for O O
Ran B-GENE O
, O O
a O O
small B-GENE O
nuclear I-GENE O
GTPase I-GENE O
of O O
the O O
ras B-GENE O
superfamily I-GENE O
, O O
we O O
have O O
identified O O
two O O
homologs O O
of O O
Ran B-GENE O
in O O
S O O
. O O
cerevisiae O O
( O O
CNR0 B-GENE O
and O O
CNR0 B-GENE O
) O O
. O O

Identification O O
of O O
mutations O O
in O O
the O O
coding O O
sequence O O
of O O
the O O
proto B-GENE B-GENE
- I-GENE I-GENE
oncogene I-GENE I-GENE
c I-GENE I-GENE
- I-GENE I-GENE
kit I-GENE I-GENE
in O O
a O O
human O O
mast O O
cell O O
leukemia O O
cell O O
line O O
causing O O
ligand O O
- O O
independent O O
activation O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
kit I-GENE I-GENE
product I-GENE I-GENE
. O O

Hybridization O O
signals O O
were O O
also O O
detected O O
with O O
total O O
DNAs O O
of O O
Rhizobium O O
leguminosarum O O
bv O O
. O O
phaseoli O O
, O O
Rhodobacter O O
capsulatus O O
and O O
Escherichia O O
coli O O
, O O
but O O
not O O
those O O
of O O
Xanthomonas O O
campestris O O
pv O O
. O O
campestris O O
and O O
Pseudomonas O O
putida O O
. O O

Molecular O O
cloning O O
and O O
sequencing O O
of O O
a O O
cDNA O O
encoding O O
SR B-GENE O
beta I-GENE O
revealed O O
that O O
SR B-GENE B-GENE
beta I-GENE I-GENE
is O O
a O O
transmembrane O B-GENE
protein O I-GENE
and O O
, O O
like O O
SR B-GENE O
alpha I-GENE O
and O O
SRP00 B-GENE B-GENE
, O O
is O O
a O O
member O O
of O O
the O O
GTPase B-GENE O
superfamily I-GENE O
. O O

To O O
understand O O
the O O
function O O
of O O
receptor B-GENE O
- I-GENE O
linked I-GENE O
tyrosine I-GENE O
phosphatases I-GENE O
in O O
neural O O
development O O
, O O
we O O
sought O O
to O O
identify O O
LAR B-GENE O
isoforms I-GENE O
preferentially O O
expressed O O
in O O
the O O
nervous O O
system O O
and O O
cellular O O
processes O O
regulating O O
LAR B-GENE O
alternative O O
splicing O O
. O O

In O O
acute O O
- O O
phase O O
livers O O
, O O
we O O
observed O O
a O O
dramatic O O
reduction O O
in O O
HNF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
alpha I-GENE I-GENE
expression O O
which O O
correlates O O
with O O
a O O
decrease O O
in O O
the O O
expression O O
of O O
its O O
target O O
gene O O
, O O
the O O
TTR B-GENE B-GENE
gene I-GENE I-GENE
. O O

Moreover O O
, O O
the O O
ability O O
to O O
selectivity O O
arrest O O
elongation O O
by O O
polIII B-GENE O
at O O
defined O O
positions O O
within O O
the O O
tRNA O B-GENE
gene O I-GENE
transcription O O
unit O O
has O O
permitted O O
the O O
identification O O
of O O
discrete O O
functional O O
properties O O
of O O
paused O O
mammalian B-GENE O
polIII I-GENE O
ternary I-GENE O
complexes I-GENE O
. O O

The O O
two O O
ParA B-GENE O
proteins I-GENE O
that O O
are O O
produced O O
as O O
a O O
result O O
of O O
independent O O
translation O O
initiation O O
at O O
two O O
different O O
start O O
codons O O
within O O
the O O
same O O
open O O
reading O O
frame O O
were O O
overexpressed O O
in O O
Escherichia O O
coli O O
and O O
partially O O
purified O O
. O O

This O O
strategy O O
was O O
used O O
to O O
place O O
both O O
the O O
Tn000 B-GENE O
neo I-GENE O
gene I-GENE O
and O O
the O O
Rhodosporidium B-GENE O
toruloides I-GENE O
phenylalanine I-GENE O
ammonia I-GENE O
lyase I-GENE O
( O O
PAL B-GENE O
) O O
- O O
encoding O O
gene O O
under O O
the O O
transcriptional O O
control O O
of O O
pPGK B-GENE O
: O O
: O O
REP0 B-GENE O
. O O

Co O O
- O O
transfection O O
of O O
a O O
tat B-GENE O
expressing O O
plasmid O O
with O O
these O O
viruses O O
containing O O
the O O
tat B-GENE O
ORF I-GENE O
mutations O O
resulted O O
in O O
higher O O
levels O O
of O O
virus O O
production O O
demonstrating O O
that O O
the O O
effects O O
of O O
both O O
mutants O O
are O O
tat B-GENE O
specific O O
. O O

In O O
our O O
studies O O
, O O
we O O
utilized O O
HIV O O
- O O
0 O O
HXB0 B-GENE O
and O O
HIV O O
- O O
0 O O
Z0Z0 B-GENE O
core I-GENE O
enhancers I-GENE O
because O O
the O O
Z0Z0 B-GENE O
strain O O
has O O
a O O
single O O
point O O
mutation O O
flanking O O
the O O
right O O
ETS B-GENE O
- I-GENE O
binding I-GENE O
site I-GENE O
. O O

Praziquantel O O
and O O
Albendazole O O
were O O
found O O
effective O O
in O O
the O O
treatment O O
of O O
neurocysticercosis O O
, O O
but O O
because O O
of O O
serious O O
side O O
effects O O
encountered O O
in O O
some O O
cases O O
, O O
the O O
drugs O O
should O O
be O O
used O O
cautiously O O
in O O
selected O O
cases O O
only O O
. O O

The O O
amino O O
acid O O
sequence O O
alignment O O
of O O
TC B-GENE O
II I-GENE O
with O O
that O O
of O O
other O O
Cbl B-GENE O
binding I-GENE O
proteins I-GENE O
( O O
rat B-GENE B-GENE
intrinsic I-GENE I-GENE
factor I-GENE I-GENE
, O O
human B-GENE O
transcobalamin I-GENE O
I I-GENE O
and O O
porcine B-GENE O
haptocorrin I-GENE O
) O O
revealed O O
only O O
00 O O
% O O
overall O O
homology O O
. O O

The O O
Arabidopsis B-GENE B-GENE
FAD0 I-GENE I-GENE
gene I-GENE I-GENE
encodes O O
a O O
chloroplast B-GENE O
omega I-GENE O
- I-GENE O
0 I-GENE O
fatty I-GENE O
acid I-GENE O
desaturase I-GENE O
that O O
catalyzes O O
the O O
desaturation O O
of O O
lipid O O
- O O
linked O O
dienoic O O
fatty O O
acids O O
( O O
00 O O
: O O
0 O O
and O O
00 O O
: O O
0 O O
) O O
. O O

In O O
contrast O O
to O O
the O O
selective O O
expression O O
of O O
the O O
receptor O B-GENE
, O O
FL B-GENE O
expression O O
was O O
detected O O
in O O
00 O O
- O O
000 O O
% O O
of O O
the O O
various O O
cell O O
types O O
of O O
leukemia O O
cell O O
lines O O
from O O
all O O
hematopoietic O O
cell O O
lineages O O
. O O

Consistent O O
with O O
ErbB B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
being O O
a O O
shared O O
receptor O O
subunit O O
, O O
its O O
tyrosine O O
phosphorylation O O
was O O
increased O O
by O O
both O O
heterologous O O
ligands O O
and O O
it O O
mediated O O
a O O
trans O O
- O O
inhibitory O O
effect O O
of O O
NDF B-GENE O
on O O
EGF B-GENE O
binding O O
. O O

CONCLUSIONS O O
: O O
Our O O
findings O O
suggest O O
that O O
pre O O
- O O
treatment O O
with O O
coenzyme O O
Q00 O O
may O O
play O O
a O O
protective O O
role O O
during O O
routine O O
vascular O O
procedures O O
requiring O O
abdominal O O
aortic O O
cross O O
clamping O O
by O O
attenuating O O
the O O
degree O O
of O O
peroxidative O O
damage O O
. O O

Both O O
verapamil O O
and O O
propranolol O O
can O O
exhibit O O
additive O O
effects O O
with O O
adenosine O O
in O O
prolonging O O
AV O O
nodal O O
conduction O O
time O O
; O O
however O O
, O O
only O O
verapamil O O
can O O
reduce O O
the O O
dose O O
of O O
adenosine O O
required O O
to O O
produce O O
AV O O
nodal O O
block O O
. O O

RVR B-GENE O
' O O
loss O O
of O O
function O O
' O O
studies O O
by O O
constitutive O O
over O O
- O O
expression O O
of O O
a O O
dominant O O
negative O O
RVR B-GENE O
delta I-GENE O
E I-GENE O
resulted O O
in O O
increased O O
levels O O
of O O
p00Cip0 B-GENE O
/ O O
Waf0 B-GENE O
and O O
myogenin B-GENE O
mRNAs I-GENE O
after O O
serum O O
withdrawal O O
. O O

They O O
suggest O O
that O O
decreased O O
steady O O
- O O
state O O
levels O O
of O O
IME0 B-GENE O
and O O
IME0 B-GENE O
mRNA I-GENE O
were O O
not O O
merely O O
the O O
result O O
of O O
non O O
- O O
specific O O
adverse O O
affects O O
on O O
nucleic O O
acid O O
metabolism O O
caused O O
by O O
the O O
yvh0 B-GENE O
disruption O O
. O O

Its O O
transcription O O
product O O
, O O
a O O
0 O O
. O O
0 O O
kb O O
mRNA O O
, O O
is O O
polyadenylated O O
at O O
a O O
site O O
containing O O
consensus O O
eukaryotic O O
polyadenylation O O
signals O O
and O O
mapping O O
00 O O
bp O O
downstream O O
of O O
the O O
translation O O
termination O O
codon O O
for O O
CG00 B-GENE O
. O O

Terbutaline O O
; O O
a O O
beta0 O O
- O O
adrenergic O O
agonist O O
, O O
and O O
aminophyllin O O
, O O
a O O
phosphodiesterase O O
inhibitor O O
, O O
were O O
given O O
separately O O
, O O
or O O
in O O
combination O O
, O O
to O O
rabbit O O
fetuses O O
on O O
the O O
00th O O
day O O
of O O
gestation O O
. O O

A O O
dose O O
- O O
dependent O O
fall O O
in O O
GABA O O
content O O
was O O
observed O O
; O O
GABA O O
decrease O O
was O O
evident O O
00 O O
min O O
after O O
the O O
administration O O
, O O
reached O O
its O O
nadir O O
at O O
00 O O
min O O
and O O
disappeared O O
at O O
000 O O
minutes O O
. O O

We O O
also O O
isolated O O
two O O
alternatively O O
spliced O O
forms O O
of O O
human B-GENE O
CD0 I-GENE O
cDNA I-GENE O
lacking O O
sequences O O
encoding O O
membrane O O
- O O
proximal O O
regions O O
of O O
the O O
cytoplasmic O O
domain O O
which O O
maintain O O
the O O
same O O
reading O O
frame O O
as O O
CD0 B-GENE O
- O O
PB0 B-GENE O
. O O

The O O
normal O O
cell O O
cycle O O
is O O
regulated O O
by O O
several O O
molecules O O
, O O
such O O
as O O
the O O
tumor B-GENE B-GENE
- I-GENE I-GENE
suppressor I-GENE I-GENE
protein I-GENE I-GENE
pRb I-GENE O
, O O
the O O
G0 B-GENE O
cyclins I-GENE O
, O O
the O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinases I-GENE I-GENE
, O O
and O O
their O O
inhibitors O O
. O O

The O O
transport O O
of O O
a O O
genetically O O
engineered O O
chimeric O O
transmembrane O O
protein O O
connected O O
to O O
this O O
ER O O
leader O O
sequence O O
was O O
as O O
efficient O O
as O O
that O O
of O O
the O O
original O O
protein O O
from O O
which O O
the O O
ER O O
sequence O O
has O O
been O O
derived O O
. O O

CONCLUSION O O
: O O
The O O
MTD O O
for O O
CPT O O
- O O
00 O O
administered O O
in O O
a O O
0 O O
consecutive O O
- O O
days O O
- O O
every O O
- O O
0 O O
weeks O O
schedule O O
in O O
this O O
patient O O
population O O
is O O
000 O O
mg O O
/ O O
m0 O O
/ O O
day O O
. O O

Northern O O
analysis O O
of O O
RNA O O
samples O O
isolated O O
from O O
ammonium O O
- O O
grown O O
cultures O O
of O O
the O O
ntcA B-GENE O
mutant I-GENE O
showed O O
reduced O O
amounts O O
of O O
glnA B-GENE O
message I-GENE O
and O O
the O O
absence O O
of O O
a O O
0 O O
. O O
0 O O
- O O
kb O O
transcript O O
. O O

This O O
sequenced O O
region O O
of O O
the O O
V O O
beta O O
locus O O
contains O O
an O O
average O O
number O O
of O O
repetitive O O
DNA O O
elements O O
( O O
00 O O
Alu B-GENE O
, O O
three O O
L0 B-GENE O
, O O
three O O
MER O O
, O O
and O O
three O O
retrovirus O O
- O O
related O O
elements O O
. O O

To O O
get O O
further O O
insights O O
into O O
the O O
molecular O O
mechanisms O O
that O O
control O O
tal B-GENE O
- I-GENE O
0 I-GENE O
expression O O
, O O
we O O
have O O
isolated O O
0 O O
' O O
sequences O O
of O O
the O O
murine O B-GENE
gene O I-GENE
and O O
compared O O
them O O
to O O
their O O
human O O
counterparts O O
. O O

Within O O
the O O
span O O
of O O
attenuator O O
region O O
encoding O O
the O O
three O O
stem O O
- O O
loop O O
structures O O
of O O
mRNA O O
secondary O O
configuration O O
, O O
hot O O
spots O O
of O O
base O O
- O O
residue O O
divergence O O
were O O
localized O O
to O O
looped O O
- O O
out O O
regions O O
. O O

The O O
tyrosine B-GENE B-GENE
hydroxylase I-GENE I-GENE
gene I-GENE I-GENE
( O O
TH B-GENE O
) O O
contains O O
a O O
single O O
copy O O
of O O
a O O
consensus O O
CRE O O
at O O
- O O
00 O O
to O O
- O O
00 O O
base O O
pair O O
( O O
bp O O
) O O
upstream O O
of O O
the O O
transcription O O
initiation O O
site O O
. O O

One O O
complex O O
most O O
likely O O
contained O O
Sp0 B-GENE O
, O O
and O O
another O O
complex O O
showed O O
S O O
- O O
phase O O
- O O
specific O O
binding O O
, O O
suggesting O O
a O O
direct O O
role O O
in O O
the O O
cell O O
- O O
cycle O O
- O O
dependent O O
R0 B-GENE O
gene I-GENE O
expression O O
. O O

IE0 B-GENE O
- O O
IE0 B-GENE O
interactions O O
were O O
mapped O O
to O O
a O O
domain O O
containing O O
a O O
putative O O
helix O O
- O O
turn O O
- O O
helix O O
motif O O
located O O
near O O
the O O
C O O
terminus O O
of O O
IE0 B-GENE O
, O O
between O O
amino O O
acids O O
000 O O
and O O
000 O O
. O O

In O O
the O O
present O O
study O O
we O O
demonstrated O O
a O O
unique O O
mechanism O O
of O O
action O O
of O O
0 O O
- O O
Cl O O
- O O
cAMP O O
in O O
the O O
regulation O O
of O O
these O O
kinase O O
isozymes O O
in O O
HL O O
- O O
00 O O
human O O
promyelocytic O O
leukemia O O
cells O O
. O O

The O O
purpose O O
of O O
the O O
study O O
reported O O
here O O
was O O
to O O
investigate O O
whether O O
differences O O
in O O
T0 O O
and O O
T0 O O
between O O
tumors O O
are O O
mainly O O
a O O
consequence O O
of O O
differences O O
in O O
the O O
fractional O O
volume O O
of O O
the O O
extracellular O O
compartment O O
. O O

The O O
Clb0 B-GENE B-GENE
kinase I-GENE I-GENE
, O O
which O O
promotes O O
S O O
phase O O
, O O
remains O O
active O O
during O O
the O O
G0 O O
- O O
phase O O
arrest O O
of O O
cells O O
of O O
the O O
parental O O
strain O O
, O O
but O O
its O O
activity O O
declines O O
rapidly O O
in O O
sim B-GENE O
mutants I-GENE O
. O O

Mean O O
increase O O
of O O
milk O O
protein O O
yield O O
was O O
00 O O
g O O
/ O O
d O O
with O O
Met O O
plus O O
Lys O O
, O O
and O O
mean O O
increase O O
of O O
true O O
protein O O
content O O
was O O
0 O O
. O O
0 O O
g O O
/ O O
kg O O
of O O
milk O O
. O O

The O O
mechanism O O
involves O O
Gbetagamma B-GENE O
subunit O O
- O O
mediated O O
increases O O
in O O
tyrosine O O
phosphorylation O O
of O O
the O O
Shc B-GENE B-GENE
adapter I-GENE I-GENE
protein I-GENE I-GENE
, O O
Shc B-GENE O
* O O
Grb0 B-GENE O
complex O O
formation O O
, O O
and O O
recruitment O O
of O O
Ras B-GENE O
guanine I-GENE O
nucleotide I-GENE O
exchange I-GENE O
factor I-GENE O
activity O O
. O O

RUSH B-GENE O
- I-GENE O
0 I-GENE O
beta I-GENE O
is O O
a O O
00 O O
- O O
kDa O O
truncated O O
version O O
of O O
RUSH B-GENE O
- I-GENE O
0 I-GENE O
alpha I-GENE O
that O O
results O O
from O O
alternative O O
splicing O O
of O O
a O O
00 O O
- O O
bp O O
exon O O
as O O
confirmed O O
by O O
genomic O O
cloning O O
. O O

In O O
cellular O O
supernatant O O
fraction O O
, O O
SHRSP O O
showed O O
a O O
decrease O O
of O O
magnesium O O
in O O
many O O
tissues O O
and O O
an O O
elevation O O
of O O
the O O
calcium O O
to O O
magnesium O O
ratio O O
when O O
compared O O
to O O
age O O
- O O
matched O O
WKY O O
and O O
SHRSR O O
. O O

Although O O
methods O O
to O O
align O O
the O O
control O O
and O O
activation O O
fMR O O
images O O
may O O
correct O O
for O O
some O O
of O O
this O O
motional O O
error O O
, O O
they O O
will O O
be O O
incomplete O O
in O O
correcting O O
for O O
those O O
that O O
depend O O
on O O
spatial O O
orientation O O
. O O

Cotransfection O O
of O O
Ets B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
p00 B-GENE B-GENE
mitogen B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
( I-GENE O
MAP I-GENE O
) I-GENE O
kinase I-GENE O
expression O O
vectors O O
strongly O O
potentiated O O
HB B-GENE B-GENE
- O I-GENE
EGF B-GENE I-GENE
promoter O I-GENE
activation O O
in O O
response O O
to O O
deltaRaf B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
: O O
ER B-GENE O
. O O

The O O
likelihood O O
that O O
a O O
common O O
region O O
of O O
deletions O O
would O O
contain O O
a O O
tumor O O
suppressor O O
is O O
strongly O O
enhanced O O
by O O
coincidence O O
of O O
that O O
region O O
with O O
a O O
chromosome O O
fragment O O
suppressing O O
tumorigenicity O O
upon O O
introduction O O
in O O
tumor O O
cells O O
. O O

In O O
a O O
recent O O
measles O O
epidemic O O
in O O
El O O
Paso O O
, O O
TX O O
, O O
000 O O
, O O
000 O O
records O O
were O O
screened O O
using O O
these O O
criteria O O
, O O
and O O
as O O
a O O
result O O
00 O O
, O O
000 O O
students O O
were O O
vaccinated O O
. O O

The O O
hormonal O O
response O O
to O O
a O O
standardized O O
bicycle O O
exercise O O
test O O
was O O
studied O O
in O O
00 O O
male O O
cadets O O
exposed O O
to O O
a O O
course O O
of O O
000 O O
h O O
of O O
continuous O O
activity O O
with O O
less O O
than O O
0 O O
h O O
sleep O O
. O O

As O O
a O O
result O O
, O O
beta O B-GENE
- O I-GENE
apo O I-GENE
- O O
0 O O
' O O
- O O
carotenoic O O
acid O O
ethyl O O
ester O O
( O O
apo O O
- O O
EE O O
) O O
was O O
used O O
as O O
a O O
reference O O
standard O O
in O O
Experiments O O
0 O O
to O O
0 O O
. O O

TPBF B-GENE O
has O O
two O O
potential O O
coiled O O
- O O
coil O O
regions O O
, O O
a O O
basic O O
region O O
, O O
a O O
proline O O
- O O
rich O O
region O O
, O O
a O O
histidine O O
- O O
rich O O
N O O
terminus O O
, O O
and O O
a O O
nuclear O O
targeting O O
sequence O O
. O O

The O O
gene O O
product O O
of O O
cotS B-GENE O
was O O
confirmed O O
to O O
be O O
identical O O
to O O
Cot00 B-GENE O
- I-GENE O
0 I-GENE O
by O O
SDS O O
- O O
PAGE O O
and O O
immunoblotting O O
from O O
Escherichia O O
coli O O
transformed O O
with O O
a O O
plasmid O O
containing O O
the O O
cotS B-GENE O
region I-GENE O
. O O

This O O
paper O O
summarises O O
the O O
experimental O O
evidence O O
upon O O
which O O
the O O
clinical O O
trials O O
of O O
aldose B-GENE O
reductase I-GENE O
inhibitors O O
in O O
diabetic O O
patients O O
have O O
been O O
initiated O O
and O O
the O O
results O O
of O O
published O O
drug O O
trials O O
in O O
these O O
patients O O
. O O

Both O O
factors O O
demonstrated O O
significant O O
correlations O O
with O O
rCBF O O
in O O
the O O
medial O O
prefrontal O O
cortex O O
and O O
frontal O O
polar O O
cortex O O
while O O
for O O
each O O
factor O O
there O O
were O O
also O O
unique O O
patterns O O
of O O
correlations O O
with O O
posterior O O
brain O O
regions O O
. O O

The O O
Y O O
. O O
lipolytica O O
genomic O I-GENE
POT0 B-GENE I-GENE
gene O I-GENE
was O O
disrupted O O
by O O
replacing O O
000 O O
bp O O
of O O
its O O
coding O O
sequence O O
with O O
0 O O
. O O
0 O O
kbp O O
of O O
DNA O O
including O O
the O O
Y O O
. O O
lipolytica O O
LEU0 B-GENE O
gene I-GENE O
. O O

Splice O O
variations O O
in O O
genes O O
coding O O
for O O
the O O
transmembrane B-GENE B-GENE
FGF I-GENE I-GENE
receptor I-GENE I-GENE
( O O
FGFR B-GENE B-GENE
) O O
result O O
in O O
isoforms O O
that O O
vary O O
in O O
the O O
ectodomain O O
, O O
intracellular O O
juxtamembrane O O
domain O O
, O O
and O O
the O O
intracellular O B-GENE
kinase O I-GENE
domain O O
. O O

Ras B-GENE O
- I-GENE O
and I-GENE O
ultra I-GENE O
- I-GENE O
violet I-GENE O
- I-GENE O
responsive I-GENE O
protein I-GENE O
kinases I-GENE O
that O O
phosphorylate O B-GENE
c B-GENE I-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
on O O
serine O O
residues O O
at O O
positions O O
00 O O
and O O
00 O O
and O O
stimulate O O
its O O
transcriptional O O
activity O O
have O O
been O O
identified O O
. O O

Topical O O
L O O
- O O
NNA O O
attenuated O O
the O O
hypercapnic O O
increase O O
of O O
CoBF O O
by O O
00 O O
+ O O
/ O O
- O O
0 O O
% O O
and O O
CeBF O O
by O O
00 O O
+ O O
/ O O
- O O
0 O O
% O O
after O O
00 O O
- O O
min O O
exposure O O
. O O

These O O
results O O
demonstrate O O
the O O
existence O O
of O O
different O O
PI B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
isoforms I-GENE O
and O O
define O O
a O O
family O O
of O O
genes O O
encoding O O
distinct O O
PI B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
catalytic I-GENE O
subunits I-GENE O
that O O
can O O
associate O O
with O O
p00 B-GENE B-GENE
. O O

Two O O
putative O O
Rev B-GENE O
proteins I-GENE O
with O O
apparent O O
molecular O O
masses O O
of O O
00 O O
and O O
00 O O
kDa O O
were O O
expressed O O
by O O
p0 B-GENE O
/ I-GENE O
0 I-GENE O
and O O
p000 B-GENE O
, O O
while O O
p00 B-GENE O
expressed O O
only O O
a O O
00 O O
- O O
kDa O O
species O O
. O O

We O O
describe O O
a O O
novel O O
cytoplasmic B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase I-GENE I-GENE
, O O
termed O O
BPK B-GENE O
( O O
B B-GENE O
cell I-GENE I-GENE
progenitor I-GENE I-GENE
kinase I-GENE I-GENE
) O O
, O O
which O O
is O O
expressed O O
in O O
all O O
stages O O
of O O
the O O
B O O
lineage O O
and O O
in O O
myeloid O O
cells O O
. O O

However O O
, O O
L B-GENE B-GENE
- I-GENE I-GENE
plastin I-GENE I-GENE
has O O
been O O
found O O
in O O
many O O
types O O
of O O
malignant O O
human O O
cells O O
of O O
non O O
- O O
hemopoietic O O
origin O O
suggesting O O
that O O
its O O
expression O O
is O O
induced O O
accompanying O O
tumorigenesis O O
in O O
solid O O
tissues O O
. O O

SBF B-GENE O
binds O O
to O O
the O O
promoter O O
prior O O
to O O
the O O
activation O O
of O O
transcription O O
in O O
late O O
G0 O O
, O O
suggesting O O
that O O
Cln B-GENE B-GENE
/ O O
Cdc00 B-GENE B-GENE
kinase O I-GENE
regulates O O
the O O
ability O O
of O O
previously O O
bound O O
SBF B-GENE O
to O O
activate O O
transcription O O
. O O

This O O
region O O
contains O O
a O O
motif O O
with O O
partial O O
identity O O
with O O
the O O
binding O O
site O O
for O O
the O O
ubiquitous O B-GENE
transcription O I-GENE
factor O I-GENE
upstream B-GENE I-GENE
stimulatory I-GENE I-GENE
factor I-GENE I-GENE
( O O
USF B-GENE B-GENE
) O O
, O O
which O O
binds O O
to O O
the O O
human B-GENE B-GENE
insulin I-GENE I-GENE
promoter I-GENE I-GENE
. O O

Cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
Cdk0 B-GENE O
) O O
forms O O
an O O
inactive O O
complex O O
with O O
cyclin B-GENE O
D0 I-GENE O
since O O
Cdk0 B-GENE O
associated O O
with O O
cyclin B-GENE B-GENE
D0 I-GENE I-GENE
is O O
not O O
phosphorylated O O
by O O
Cdk0 B-GENE O
- O O
cyclin B-GENE O
- I-GENE O
H I-GENE O
. O O

Quantitative O O
analysis O O
of O O
plasmid O O
loss O O
rates O O
in O O
cdc00 B-GENE O
- I-GENE O
0N I-GENE O
strains O O
carrying O O
plasmids O O
with O O
multiple O O
replication O O
origins O O
suggests O O
that O O
a O O
defect O O
in O O
initiating O O
DNA O O
replication O O
probably O O
causes O O
this O O
plasmid O O
loss O O
phenotype O O
. O O

Taken O O
together O O
, O O
these O O
observations O O
indicate O O
that O O
the O O
C O O
- O O
terminal O O
00 O O
amino O O
acids O O
are O O
sufficient O O
for O O
NodO B-GENE O
secretion O O
although O O
the O O
region O O
adjacent O O
to O O
this O O
domain O O
appears O O
to O O
affect O O
secretion O O
efficiency O O
. O O

In O O
the O O
absence O O
of O O
E0A000 B-GENE O
, O O
YY0 B-GENE O
represses O O
CRE O O
- O O
dependent O O
transcription O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
by O O
physically O O
interacting O O
with O O
ATF B-GENE B-GENE
/ O O
CREB B-GENE O
proteins O O
bound O O
to O O
the O O
- O O
00 O O
CRE O O
. O O

Transcription O O
factors O O
containing O O
a O O
basic O O
helix O O
- O O
loop O I-GENE
- O I-GENE
helix O I-GENE
( O O
bHLH O O
) O O
motif O O
regulate O O
the O O
expression O O
of O O
tissue O B-GENE
- O I-GENE
specific O I-GENE
genes O I-GENE
in O O
a O O
number O O
of O O
mammalian O O
and O O
insect O O
systems O O
. O O

The O O
leader O O
sequence O O
of O O
the O O
isolated O O
cDNA O O
clone O O
contains O O
several O O
small O O
open O O
reading O O
frames O O
upstream O O
of O O
the O O
initiation O O
codon O O
of O O
the O O
largest O O
open O O
reading O O
frame O O
coding O O
for O O
the O O
homeodomain B-GENE B-GENE
protein I-GENE I-GENE
. O O

Analysis O O
of O O
disassociation O O
rates O O
indicates O O
that O O
the O O
Grf00 B-GENE B-GENE
- O I-GENE
Swi0 B-GENE I-GENE
- O O
DNA O O
complex O O
has O O
a O O
longer O O
half O O
- O O
life O O
than O O
protein O O
- O O
DNA O O
complexes O O
that O O
contain O O
only O O
Swi0 B-GENE O
or O O
Grf00 B-GENE O
. O O

Plasmids O O
were O O
constructed O O
with O O
the O O
mouse O O
promoter O O
region O O
linked O O
to O O
the O O
reporter B-GENE O
gene I-GENE O
chloramphenicol I-GENE O
acetyltransferase I-GENE O
( O O
CAT B-GENE O
) O O
, O O
and O O
transiently O O
and O O
stably O O
transfected O O
in O O
the O O
INS O O
- O O
0 O O
cells O O
. O O

A O O
second O O
important O O
molecule O O
in O O
TCR B-GENE O
signal O O
transduction O O
is O O
the O O
guanine B-GENE O
nucleotide I-GENE O
binding I-GENE O
protein I-GENE O
, O O
p00ras B-GENE B-GENE
, O O
which O O
is O O
coupled O O
to O O
the O O
TCR B-GENE O
by O O
a O O
protein B-GENE O
tyrosine I-GENE O
kinase I-GENE O
dependent O O
mechanism O O
. O O

Mutations O O
in O O
the O O
nuclear B-GENE O
gene I-GENE O
CBP0 I-GENE O
of I-GENE O
Saccharomyces I-GENE O
cerevisiae I-GENE O
result O O
in O O
degradation O O
of O O
mitochondrially B-GENE B-GENE
encoded I-GENE I-GENE
cytochrome I-GENE I-GENE
b I-GENE I-GENE
( O O
cob B-GENE O
) O O
RNA O O
; O O
thus O O
, O O
the O O
cells O O
are O O
unable O O
to O O
respire O O
. O O

Precipitation O O
using O O
GST B-GENE O
fusion I-GENE O
proteins I-GENE O
containing O O
Fyn B-GENE O
SH0 B-GENE O
, O O
SH0 B-GENE B-GENE
, O O
and O O
SH0 B-GENE B-GENE
/ O O
SH0 B-GENE O
domains O O
revealed O O
that O O
PI B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
bound O O
principally O O
to O O
the O O
SH0 B-GENE O
domain I-GENE O
of O O
Fyn B-GENE O
. O O

We O O
conclude O O
that O O
the O O
alpha O O
- O O
subunit O O
of O O
the O O
telomere B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
, O O
like O O
many O O
transcription O B-GENE
factors O I-GENE
, O O
has O O
separable O O
DNA O B-GENE
- O I-GENE
binding O I-GENE
and O O
protein O B-GENE
- O I-GENE
protein O I-GENE
interaction O O
domains O O
. O O

However O O
, O O
while O O
the O O
sequence O O
similarity O O
between O O
the O O
membrane O O
exons O O
of O O
avian B-GENE O
mIgY I-GENE O
and O O
mammalian B-GENE O
mIgG I-GENE O
and I-GENE O
IgE I-GENE O
is O O
striking O O
, O O
the O O
overall O O
similarity O O
with O O
Xenopus B-GENE O
mIgY I-GENE O
is O O
very O O
low O O
. O O

Cloning O O
of O O
individual O O
ZI O O
domains O O
upstream O O
of O O
a O O
minimal O O
promoter O O
demonstrated O O
that O O
the O O
ZIA O O
, O O
ZIC O O
, O O
and O O
ZID O O
domains O O
, O O
but O O
not O O
the O O
ZIB O O
domain O O
, O O
are O O
TPA O O
responsive O O
. O O

However O O
, O O
the O O
action O O
of O O
each O O
cognate O O
ligand O O
and O O
the O O
accessory O O
cellular O O
factors O O
that O O
can O O
differentially O O
regulate O O
the O O
transcriptional O O
responses O O
of O O
a O O
heterodimer O O
- O O
DNA O O
complex O O
are O O
not O O
well O O
understood O O
. O O

In O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
the O O
PERE B-GENE O
formed O O
three O O
major O O
complexes O O
( O O
P0 O O
, O O
P0 O O
and O O
P0 O O
) O O
with O O
proteins O O
in O O
nuclear O O
extracts O O
from O O
HeLa O O
or O O
000 O O
cells O O
. O O

To O O
confirm O O
the O O
GapIII B-GENE B-GENE
protein I-GENE I-GENE
activity O O
, O O
constructs O O
containing O O
different O O
GapIII B-GENE B-GENE
- O I-GENE
GRD B-GENE I-GENE
domains O O
were O O
transformed O O
into O O
iral B-GENE O
mutant O O
yeast O O
to O O
determine O O
their O O
relative O O
ability O O
to O O
replace O O
IRA0 B-GENE O
functionally O O
. O O

By O O
in O O
vitro O O
immunoprecipitations O O
and O O
gel O O
shift O O
assays O O
, O O
we O O
identified O O
two O O
classes O O
of O O
high O O
affinity O O
Engrailed B-GENE O
- I-GENE O
binding I-GENE O
sites I-GENE O
upstream O O
of O O
each O O
of O O
the O O
two O O
polyhomeotic O O
transcription O O
units O O
. O O

Self O O
or O O
foreign O O
cellular O O
proteins O O
provide O O
peptides O O
for O O
presentation O O
by O O
major B-GENE O
histocompatibility I-GENE O
complex I-GENE O
( I-GENE O
MHC I-GENE O
) I-GENE O
class I-GENE O
I I-GENE O
molecules I-GENE O
on O O
the O O
surface O O
of O O
antigen O O
presenting O O
cells O O
( O O
APC O O
) O O
. O O

From O O
sequence O O
alignments O O
with O O
phylogenetically O O
related O O
viruses O O
, O O
including O O
tymoviruses O O
, O O
we O O
predicted O O
that O O
p000 B-GENE O
contained O O
a O O
papain B-GENE O
- I-GENE O
like I-GENE O
proteinase I-GENE O
domain I-GENE O
with O O
a O O
putative O O
catalytic O O
cysteine000 O O
and O O
histidine0000 O O
. O O

In O O
order O O
to O O
define O O
potential O O
candidate O O
genes O O
for O O
inherited O O
disorders O O
characterized O O
by O O
aberrant O B-GENE
gene O I-GENE
expression O O
, O O
we O O
utilized O O
Kruppel B-GENE O
- I-GENE O
related I-GENE O
sequences I-GENE O
to O O
isolate O O
zinc O O
finger O O
- O O
containing O O
cDNAs O O
. O O

A O O
strong O O
trithorax B-GENE O
binding I-GENE O
site I-GENE O
was O O
found O O
at O O
the O O
cytological O O
location O O
of O O
the O O
fork B-GENE B-GENE
head I-GENE I-GENE
gene I-GENE I-GENE
, O O
a O O
region O O
- O O
specific O I-GENE
homeotic B-GENE I-GENE
gene I-GENE I-GENE
not O O
located O O
within O O
a O O
homeotic B-GENE O
complex I-GENE O
. O O

C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
alpha I-GENE I-GENE
also O O
activates O O
the O O
promoter O O
of O O
the O O
rat B-GENE B-GENE
class I-GENE I-GENE
- I-GENE I-GENE
I I-GENE I-GENE
ADH I-GENE I-GENE
gene I-GENE I-GENE
in O O
a O O
sequence O O
- O O
specific O O
manner O O
[ O O
Potter O O
et O O
al O O
. O O
, O O
Arch O O
. O O

C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
alpha I-GENE I-GENE
also O O
activates O O
the O O
promoter O O
of O O
the O O
rat B-GENE B-GENE
class I-GENE I-GENE
- I-GENE I-GENE
I I-GENE I-GENE
ADH I-GENE I-GENE
gene I-GENE I-GENE
in O O
a O O
sequence O O
- O O
specific O O
manner O O
[ O O
Potter O O
et O O
al O O
. O O
, O O
Arch O O
. O O

To O O
determine O O
whether O O
P00 B-GENE O
could O O
activate O O
the O O
00k O O
promoter O O
in O O
the O O
absence O O
of O O
IE0 B-GENE O
, O O
the O O
p00 B-GENE O
open O O
reading O O
frame O O
was O O
cloned O O
under O O
the O O
control O O
of O O
the O O
ie0 B-GENE O
promoter I-GENE O
. O O

We O O
have O O
identified O O
in O O
the O O
0 O O
' O O
untranslated O O
region O O
of O O
the O O
Drosophila B-GENE B-GENE
copia I-GENE I-GENE
retrotransposon I-GENE I-GENE
, O O
0 O O
' O O
to O O
the O O
left O O
LTR O O
, O O
a O O
sequence O O
for O O
transcriptional O O
regulation O O
by O O
homeoproteins O O
. O O

These O O
cell O O
lines O O
, O O
selected O O
for O O
the O O
ability O O
to O O
support O O
the O O
replication O O
of O O
a O O
temperature O O
- O O
sensitive O O
VP0 B-GENE O
mutant I-GENE O
, O O
were O O
used O O
to O O
isolate O O
VP0 B-GENE O
and O O
VP00 B-GENE O
null O O
mutants O O
. O O

This O O
short O O
communication O O
compares O O
a O O
novel O O
fluorimetric O O
microplate O O
enzyme O O
immunoassay O O
( O O
FEIA O O
) O O
with O O
a O O
commercial O O
time O O
- O O
resolved O O
fluoroimmunoassay O O
for O O
the O O
determination O O
of O O
thyrotropin B-GENE O
in O O
dried O O
blood O O
spots O O
. O O

The O O
yeast O B-GENE
gene O I-GENE
that O O
encodes O O
eIF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
designated O O
TIF0 B-GENE O
, O O
has O O
been O O
isolated O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
to O O
yield O O
a O O
catalytically O O
active O O
eIF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
protein I-GENE I-GENE
. O O

The O O
sequence O O
and O O
isolated O O
cDNAs O O
will O O
provide O O
useful O O
reagents O O
for O O
studying O O
the O O
expression O O
of O O
Brca0 B-GENE O
in O O
the O O
mouse O O
, O O
and O O
for O O
testing O O
the O O
importance O O
of O O
the O O
evolutionarily O O
conserved O O
domains O O
. O O

Exposure O O
of O O
peripheral O O
blood O O
T O O
cells O O
from O O
young O O
subjects O O
to O O
PHA B-GENE O
or O O
cross O O
- O O
linked O O
anti B-GENE O
- I-GENE O
CD0 I-GENE O
monoclonal I-GENE O
antibodies I-GENE O
stimulated O O
rapid O O
increases O O
in O O
MAPK B-GENE O
and O O
MEK B-GENE O
enzymatic O O
activity O O
. O O

Substantial O O
evidence O O
supports O O
a O O
critical O O
role O O
for O O
the O O
activation O O
of O O
the O O
Raf B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
/ O O
MEK B-GENE B-GENE
/ O I-GENE
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
pathway O O
in O O
oncogenic O O
Ras B-GENE O
- O O
mediated O O
transformation O O
. O O

Although O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
IFN B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
activated O I-GENE
STAT0 B-GENE I-GENE
alpha I-GENE I-GENE
and O O
STAT0 B-GENE B-GENE
, O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
predominantly O O
activated O O
STAT0 B-GENE O
, O O
while O O
IFN B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
predominantly O O
activated O B-GENE
STAT0 B-GENE I-GENE
alpha I-GENE I-GENE
. O O

Site O O
S O O
- O O
II O O
also O O
spans O O
a O O
00 O O
bp O O
sequence O O
containing O O
two O O
tandem O O
consensus O O
binding O O
sites O O
with O O
three O O
base O O
pair O O
mismatches O O
in O O
each O O
and O O
a O O
one O O
base O O
pair O O
deletion O O
. O O

Chloroplast B-GENE O
mutator I-GENE O
( O O
chm B-GENE O
) O O
of O O
Arabidopsis O O
is O O
a O O
recessive O O
nuclear O O
mutation O O
that O O
causes O O
green O O
and O O
white O O
variegation O O
in O O
leaves O O
and O O
is O O
inherited O O
in O O
a O O
non O O
- O O
Mendelian O O
fashion O O
. O O

Platelet B-GENE O
- I-GENE O
derived I-GENE O
growth I-GENE O
factor I-GENE O
- O O
dependent O O
activation O O
of O O
phosphatidylinositol B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
is O O
regulated O O
by O O
receptor O O
binding O O
of O O
SH0 B-GENE B-GENE
- I-GENE I-GENE
domain I-GENE I-GENE
- I-GENE O
containing I-GENE O
proteins I-GENE O
which O O
influence O O
Ras B-GENE O
activity O O
. O O

These O O
two O O
contigs O O
contain O O
a O O
total O O
of O O
000 O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
in O O
00 O O
- O O
00 O O
putative O O
operons O O
; O O
00 O O
ORFs O O
could O O
be O O
identified O O
with O O
reasonable O O
certainty O O
. O O

Derepression O O
of O O
gene O O
expression O O
mediated O O
by O O
the O O
0 O O
' O O
upstream O O
region O O
of O O
the O O
isocitrate B-GENE B-GENE
lyase I-GENE I-GENE
gene I-GENE I-GENE
of I-GENE O
Candida I-GENE O
tropicalis I-GENE O
is O O
controlled O O
by O O
two O O
distinct O O
regulatory O O
pathways O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

Effects O O
of O O
dopamine O O
and O O
of O O
a O O
dopaminergic O O
blocker O O
, O O
haloperidol O O
, O O
on O O
the O O
responses O O
of O O
carotid O O
body O O
chemoreceptors O O
to O O
hypoxia O O
and O O
hypercapnia O O
were O O
investigated O O
in O O
00 O O
anesthetized O O
cats O O
. O O

Tyrosine O O
phosphorylation O O
of O O
cellular O B-GENE
proteins O O
is O O
the O O
earliest O O
identifiable O O
event O O
following O O
T B-GENE O
- I-GENE O
cell I-GENE O
antigen I-GENE O
receptor I-GENE O
( O O
TCR B-GENE B-GENE
) O O
stimulation O O
and O O
is O O
essential O O
for O O
activating O O
downstream O O
signaling O O
machinery O O
. O O

Appropriate O O
restriction O O
sites O O
allow O O
one O O
to O O
insert O O
virtually O O
any O O
desired O O
cDNA O O
fragment O O
directly O O
behind O O
the O O
epitope O O
- O O
specific O O
sequence O O
and O O
before O O
a O O
long O O
poly O O
( O O
A O O
) O O
tail O O
. O O

The O O
chloramphenicol B-GENE O
- I-GENE O
resistance I-GENE O
transposon I-GENE O
Tn0000 B-GENE O
undergoes O O
precise O O
conjugative O O
deletion O O
from O O
its O O
parent O O
plasmid O O
plP000 O O
in O O
Clostridium O O
perfringens O O
and O O
precise O O
spontaneous O O
excision O O
from O O
multicopy O O
plasmids O O
in O O
Escherichia O O
coli O O
. O O

Analysis O O
of O O
this O O
sequence O O
combined O O
with O O
that O O
previously O O
reported O O
for O O
the O O
0 O O
' O O
- O O
flanking O O
region O O
directly O O
proximal O O
to O O
the O O
start O O
of O O
transcription O O
revealed O O
several O O
putative O O
regulatory O O
sequences O O
. O O

CCAAT B-GENE B-GENE
/ I-GENE O
enhancer I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
isoforms I-GENE I-GENE
beta I-GENE I-GENE
and I-GENE O
delta I-GENE O
are O O
expressed O O
in O O
mammary O O
epithelial O O
cells O O
and O O
bind O O
to O O
multiple O O
sites O O
in O O
the O O
beta B-GENE B-GENE
- I-GENE I-GENE
casein I-GENE I-GENE
gene I-GENE I-GENE
promoter I-GENE I-GENE
. O O

Binding O O
of O O
meAda B-GENE O
is O O
necessary O O
to O O
activate O O
transcription O O
of O O
the O O
adaptive O B-GENE
response O I-GENE
genes O I-GENE
; O O
accordingly O O
, O O
in O O
vitro O O
transcription O O
of O O
aidB B-GENE O
is O O
dependent O O
on O O
the O O
presence O O
of O O
meAda B-GENE O
. O O

Twenty O O
- O O
two O O
consecutive O O
patients O O
with O O
ischaemic O O
ulcers O O
had O O
tcPO0 O O
measured O O
and O O
the O O
ankle O O
/ O O
brachial O O
( O O
ABI O O
) O O
and O O
toe O O
/ O O
brachial O O
( O O
TBI O O
) O O
indices O O
calculated O O
. O O

The O O
PSD0 B-GENE B-GENE
gene I-GENE I-GENE
was O O
heterologously O O
expressed O O
by O O
infection O O
of O O
Sf O B-GENE
- O I-GENE
0 O I-GENE
insect O O
cells O O
with O O
recombinant O O
baculovirus O O
, O O
resulting O O
in O O
a O O
00 O O
- O O
fold O O
increase O O
in O O
PSD B-GENE O
activity O O
. O O

Mutually O O
exclusive O O
interaction O O
of O O
the O O
adenovirus B-GENE B-GENE
E0 I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
/ I-GENE I-GENE
0 I-GENE I-GENE
protein I-GENE I-GENE
and O O
the O O
retinoblastoma B-GENE B-GENE
gene I-GENE I-GENE
product I-GENE O
with O O
internal O O
domains O O
of O O
E0F B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
DP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

These O O
results O O
provide O O
evidence O O
of O O
a O O
bypass O O
of O O
p00 B-GENE B-GENE
- O O
induced O O
Waf0 B-GENE O
/ O O
Cip0 B-GENE O
- O O
mediated O O
cell O O
cycle O O
regulatory O O
pathways O O
by O O
a O O
member O O
of O O
the O O
myb B-GENE B-GENE
oncogene I-GENE I-GENE
family I-GENE I-GENE
. O O

Heparin O O
had O O
no O O
effect O O
on O O
rAC B-GENE O
- I-GENE O
st I-GENE O
myosin I-GENE O
light I-GENE O
chain I-GENE O
phosphatase I-GENE O
activity O O
, O O
while O O
the O O
B O O
subunit O O
- O O
containing O O
forms O O
were O O
stimulated O O
0 O O
- O O
0 O O
- O O
fold O O
. O O

The O O
RFLP O O
patterns O O
of O O
the O O
isolates O O
from O O
six O O
of O O
these O O
patients O O
remained O O
essentially O O
unchanged O O
( O O
two O O
strains O O
showed O O
one O O
additional O O
band O O
) O O
despite O O
the O O
development O O
of O O
drug O O
resistance O O
. O O

Western O O
blotting O O
( O O
immunoblotting O O
) O O
with O O
an O O
antiserum O O
to O O
a O O
partial O O
SOD B-GENE O
expressed O O
in O O
Escherichia O O
coli O O
revealed O O
two O O
proteins O O
with O O
estimated O O
molecular O O
masses O O
of O O
00 O O
and O O
00 O O
kDa O O
. O O

The O O
class B-GENE O
II I-GENE O
Escherichia I-GENE O
coli I-GENE O
alanine I-GENE O
tRNA I-GENE O
synthetase I-GENE O
aminoacylates I-GENE O
RNA I-GENE O
miniduplexes I-GENE O
, O O
which O O
reconstruct O O
the O O
acceptor O O
end O O
of O O
alanine B-GENE O
tRNA I-GENE O
with O O
the O O
critical O O
G0 O O
: O O
U00 O O
base O O
pair O O
. O O

These O O
data O O
are O O
consistent O O
with O O
the O O
idea O O
that O O
the O O
neuron B-GENE B-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
SCG00 I-GENE I-GENE
gene I-GENE I-GENE
evolved O O
by O O
duplication O O
and O O
modification O O
of O O
the O O
more O O
broadly O O
expressed O O
stathmin B-GENE B-GENE
/ O I-GENE
Lap00 B-GENE I-GENE
gene O I-GENE
. O O

NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE O
p00 B-GENE B-GENE
, O O
p00 B-GENE B-GENE
, O O
and O O
Rel B-GENE O
functionally O O
synergize O O
with O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
alpha I-GENE I-GENE
, O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
beta I-GENE I-GENE
, O O
and O O
C B-GENE O
/ I-GENE O
EBP I-GENE O
delta I-GENE O
. O O

All O O
of O O
these O O
data O O
suggest O O
that O O
replication O O
of O O
UV O O
- O O
damaged O O
templates O O
occurs O O
in O O
vitro O O
as O O
it O O
does O O
in O O
vivo O O
and O O
that O O
this O O
replication O O
results O O
in O O
mutation O O
fixation O O
. O O

Weak O O
promoter O O
activity O O
was O O
observed O O
for O O
the O O
promoter O O
of O O
the O O
C0 B-GENE O
and O O
C0 B-GENE O
ORFs O O
( O O
C0 B-GENE B-GENE
- O I-GENE
C0 B-GENE I-GENE
gene O I-GENE
) O O
and O O
for O O
the O O
promoter O O
of O O
the O O
V0 B-GENE O
ORF I-GENE O
. O O

No O O
significant O O
differences O O
existed O O
between O O
the O O
two O O
age O O
groups O O
in O O
baseline O O
characteristics O O
, O O
including O O
treatment O O
protocol O O
, O O
performance O O
status O O
, O O
and O O
serum B-GENE O
lactate I-GENE O
dehydrogenase I-GENE O
( O O
LDH B-GENE O
) O O
level O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
increase O O
in O O
V O O
O0 O O
may O O
have O O
been O O
a O O
consequence O O
of O O
the O O
increase O O
in O O
Q O O
O0 O O
rather O O
than O O
a O O
response O O
to O O
the O O
procedure O O
itself O O
. O O

The O O
cis O O
- O O
acting O O
elements O O
that O O
control O O
promoter O O
activity O O
include O O
binding O O
sites O O
for O O
transcription O O
factors O O
Sp0 B-GENE O
and O O
alphaCbf B-GENE O
, O O
a O O
00 B-GENE O
- I-GENE O
kDa I-GENE O
CCAAT I-GENE O
box I-GENE O
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
. O O

Twelve O O
genomic O O
fragments O O
containing O O
novel O O
response O O
elements O O
are O O
described O O
, O O
and O O
the O O
transcription O O
unit O O
associated O O
with O O
one O O
of O O
them O O
, O O
NN B-GENE O
- I-GENE O
00AG I-GENE O
, O O
was O O
characterized O O
in O O
detail O O
. O O

Two O O
classes O O
of O O
inactive O O
receptors O O
were O O
identified O O
: O O
one O O
in O O
which O O
both O O
transcriptional O O
activation O O
and O O
dimerization O O
were O O
compromised O O
and O O
a O O
second O O
in O O
which O O
only O O
transcriptional O O
activation O O
was O O
abolished O O
. O O

RNase B-GENE O
protection O O
analysis O O
of O O
two O O
rRNA O O
fragments O O
whose O O
genes O O
are O O
adjacent O O
provided O O
evidence O O
for O O
a O O
polycistronic O O
transcript O O
containing O O
sequences O O
from O O
both O O
, O O
as O O
well O O
as O O
separate O O
small O O
RNAs O O
. O O

Leukemia B-GENE B-GENE
- I-GENE I-GENE
inhibitory I-GENE I-GENE
factor I-GENE I-GENE
( O O
LIF B-GENE B-GENE
) O O
is O O
a O O
neuropoietin B-GENE O
able O O
to O O
regulate O O
the O O
differentiation O O
and O O
the O O
survival O O
of O O
many O O
cell O O
types O O
, O O
which O O
include O O
some O O
neuronal O O
populations O O
. O O

Liver O O
transplantation O O
in O O
one O O
patient O O
resolved O O
metabolic O O
complications O O
but O O
did O O
not O O
improve O O
PMN O O
count O O
or O O
the O O
infectious O O
status O O
, O O
while O O
neutropenia O O
was O O
corrected O O
by O O
G B-GENE O
- I-GENE O
CSF I-GENE O
. O O

Phorbol O O
esters O O
stimulated O O
phosphorylation O O
of O O
CSK B-GENE B-GENE
00H I-GENE I-GENE
proteins I-GENE I-GENE
, O O
thus O O
emphasizing O O
that O O
sequences O O
isolated O O
according O O
to O O
PKC B-GENE O
binding O O
activity O O
in O O
vitro O O
are O O
also O O
PKC B-GENE O
substrates O O
in O O
vivo O O
. O O

The O O
ORF0 O O
probe O O
also O O
hybridized O O
to O O
a O O
000 O O
bp O O
transcript O O
consistent O O
with O O
the O O
size O O
of O O
ORF0 O O
alone O O
and O O
supportive O O
of O O
the O O
mutagenesis O O
data O O
of O O
non O O
- O O
linkage O O
. O O

The O O
ectopic O O
expression O O
of O O
Oct B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
/ I-GENE I-GENE
0 I-GENE I-GENE
in O O
hybrid O O
cells O O
under O O
a O O
constitutive O O
promoter O O
is O O
sufficient O O
for O O
transcriptional O O
activation O O
of O O
an O O
octamer O O
- O O
dependent O O
promoter O O
. O O

Insulin B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
IGF B-GENE B-GENE
- I-GENE I-GENE
BP I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
transcription O O
in O O
rat O O
liver O O
varies O O
with O O
developmental O O
age O O
and O O
fasting O O
. O O

Since O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
an O O
important O O
mediator O O
of O O
tumor O O
promoter O O
action O O
, O O
these O O
findings O O
may O O
explain O O
the O O
anti O O
- O O
tumor O O
- O O
promoting O O
activity O O
of O O
phenolic O O
antioxidants O O
. O O

The O O
other O O
two O O
clones O O
, O O
Ash B-GENE O
- I-GENE O
m I-GENE O
and I-GENE O
- I-GENE O
s I-GENE O
, O O
had O O
nucleotide O O
sequences O O
identical O O
with O O
Ash B-GENE O
- I-GENE O
l I-GENE O
cDNA O O
in O O
the O O
amino O O
- O O
terminal O O
region O O
. O O

We O O
found O O
that O O
PML B-GENE O
was O O
expressed O O
at O O
a O O
lower O O
level O O
in O O
S O O
, O O
G0 O O
, O O
and O O
M O O
phases O O
and O O
at O O
a O O
significantly O O
higher O O
level O O
in O O
G0 O O
phase O O
. O O

The O O
first O O
open O O
reading O O
frame O O
of O O
the O O
blueberry O O
scorch O O
carlavirus O O
( O O
BBScV O O
) O O
genome O O
encodes O O
a O O
putative O O
replication O O
- O O
associated O O
protein O O
of O O
000 O O
kDa O O
( O O
p000 B-GENE O
) O O
. O O

The O O
isolated O O
POT0 B-GENE O
clones O O
hybridized O O
to O O
a O O
0 O O
. O O
0 O O
kb O O
RNA O O
species O O
, O O
which O O
was O O
induced O O
approximately O O
00 O O
- O O
fold O O
when O O
oleate O O
was O O
the O O
carbon O O
source O O
. O O

All O O
groups O O
were O O
challenged O O
subsequently O O
with O O
naloxone O O
( O O
0 O O
. O O
0 O O
mg O O
/ O O
kg O O
) O O
in O O
the O O
distinctive O O
environment O O
and O O
then O O
observed O O
for O O
signs O O
of O O
opiate O O
withdrawal O O
. O O

The O O
molecular O O
basis O O
for O O
commitment O O
of O O
progenitors O O
to O O
the O O
eosinophil O O
lineage O O
and O O
mechanisms O O
by O O
which O O
eosinophil O O
- O O
specific O O
genes O O
are O O
expressed O O
and O O
regulated O O
during O O
differentiation O O
is O O
unknown O O
. O O

The O O
000 O O
- O O
to O O
- O O
000 O O
region O O
blocked O O
ADR0 B-GENE O
activity O O
independently O O
of O O
the O O
TAD B-GENE O
present O O
on O O
ADR0 B-GENE O
, O O
ADR0 B-GENE O
DNA O O
binding O O
, O O
and O O
specific O O
ADH0 B-GENE O
promoter I-GENE O
sequences I-GENE O
. O O

ENV B-GENE O
also O O
was O O
secreted O O
from O O
P O O
. O O
pastoris O O
using O O
the O O
S B-GENE O
. I-GENE O
cerevisiae I-GENE O
alpha I-GENE I-GENE
- I-GENE I-GENE
factor I-GENE I-GENE
prepro I-GENE I-GENE
secretion I-GENE I-GENE
leader I-GENE O
and O O
the O O
S B-GENE O
. I-GENE O
cerevisiae I-GENE O
invertase I-GENE O
signal I-GENE O
sequence I-GENE O
. O O

Type O O
II O O
could O O
be O O
divided O O
further O O
into O O
two O O
forms O O
( O O
IIA O O
and O O
IIB O O
) O O
that O O
may O O
represent O O
two O O
underscribed O O
species O O
or O O
developmental O O
stages O O
of O O
the O O
same O O
species O O
. O O

We O O
obtained O O
the O O
prevalence O O
of O O
IgG B-GENE O
antibodies I-GENE O
against O O
Trypanosoma O O
cruzi O O
among O O
0000 O O
blood O O
donors O O
at O O
the O O
Instituto O O
Nacional O O
de O O
Cardiologia O O
" O O
Ignacio O O
Chavez O O
" O O
in O O
Mexico O O
City O O
. O O

However O O
, O O
it O O
remains O O
an O O
open O O
question O O
whether O O
vertebrate B-GENE O
Hox I-GENE O
genes I-GENE O
expressed O O
under O O
the O O
control O O
of O O
Drosophila O O
regulatory O O
sequences O O
can O O
substitute O O
the O O
function O O
of O O
Drosophila B-GENE B-GENE
Hox I-GENE I-GENE
genes I-GENE I-GENE
. O O

We O O
propose O O
that O O
CTS0 B-GENE O
and I-GENE O
CTS0 I-GENE O
of I-GENE O
Ci I-GENE O
are O O
members O O
of O O
two O O
distinct O O
classes O O
of O O
fungal B-GENE O
chitinases I-GENE O
, O O
an O O
observation O O
not O O
previously O O
reported O O
for O O
a O O
single O O
fungus O O
. O O

This O O
spindle O O
defect O O
of O O
pds0 B-GENE O
mutants I-GENE O
results O O
from O O
a O O
temperature O O
- O O
sensitive O O
step O O
that O O
occurs O O
around O O
the O O
G0 O O
/ O O
S O O
boundary O O
about O O
the O O
time O O
of O O
spindle O O
assembly O O
. O O

However O O
, O O
for O O
the O O
evaluable O O
cases O O
, O O
the O O
performances O O
of O O
the O O
CD0000 O O
and O O
the O O
STKS O O
were O O
broadly O O
similar O O
and O O
generally O O
correlated O O
well O O
with O O
the O O
manual O O
reference O O
procedure O O
. O O

A O O
chimeric O O
VP00 B-GENE O
- O O
Tat B-GENE O
construct O O
containing O O
the O O
leucine O O
mutations O O
showed O O
no O O
increased O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
responsiveness O O
in O O
comparison O O
with O O
that O O
of O O
the O O
VP00 B-GENE O
activation I-GENE O
domain I-GENE O
alone O O
. O O

In O O
both O O
settings O O
, O O
it O O
can O O
be O O
phosphorylated O O
by O O
cyclin B-GENE O
D I-GENE O
- I-GENE O
dependent I-GENE O
kinases I-GENE O
, O O
suggesting O O
that O O
its O O
transcriptional O O
activity O O
may O O
normally O O
be O O
regulated O O
through O O
such O O
mechanisms O O
. O O

The O O
ERH B-GENE O
expression O O
profile O O
is O O
similar O O
, O O
to O O
that O O
of O O
An0 B-GENE O
, O O
which O O
localizes O O
to O O
the O O
animal O O
hemisphere O O
of O O
oocytes O O
and O O
is O O
abundantly O O
expressed O O
in O O
the O O
embryo O O
. O O

BCL B-GENE O
- I-GENE O
0 I-GENE O
, O O
an O O
inhibitor O O
of O O
apoptosis O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
, O O
has O O
been O O
reported O O
to O O
prevent O O
oxidative O O
stress O O
- O O
induced O O
cell O O
death O O
. O O

Apart O O
from O O
iron O O
regulation O O
, O O
sodA B-GENE O
expression O O
was O O
affected O O
by O O
changes O O
in O O
DNA O O
topology O O
induced O O
by O O
coumermycin O O
A O O
but O O
not O O
by O O
the O O
global O O
virulence O O
regulatory O O
Bvg B-GENE O
system I-GENE O
. O O

Movement O O
time O O
and O O
kinematic O O
characteristics O O
were O O
analyzed O O
together O O
with O O
the O O
magnitude O O
of O O
cerebral O O
blood O O
flow O O
to O O
identify O O
areas O O
of O O
brain O O
activity O O
proportionate O O
to O O
task O O
and O O
movement O O
variables O O
. O O

The O O
foregoing O O
results O O
show O O
that O O
CXD O O
has O O
high O O
efficacy O O
and O O
safety O O
and O O
it O O
can O O
be O O
said O O
that O O
it O O
is O O
a O O
drug O O
required O O
in O O
the O O
pediatric O O
field O O
. O O

The O O
new O O
semi O O
- O O
synthetic O O
oral O O
cephalosporin O O
, O O
CGP O O
0 O O
, O O
000 O O
, O O
has O O
been O O
evaluated O O
in O O
a O O
large O O
number O O
of O O
hospitalized O O
patients O O
with O O
urinary O O
infections O O
. O O

In O O
this O O
paper O O
we O O
report O O
that O O
ligand O O
binding O O
induced O O
tyrosine O O
phosphorylation O O
in O O
BaF0 O O
cells O O
engineered O O
to O O
express O O
the O O
murine B-GENE B-GENE
Mpl I-GENE I-GENE
receptor I-GENE I-GENE
( O O
BaF0 O B-GENE
/ O I-GENE
mMpl B-GENE I-GENE
) O O
. O O

Piperacillin O O
- O O
tazobactam O O
can O O
be O O
used O O
for O O
the O O
treatment O O
of O O
infections O O
caused O O
by O O
gram O O
- O O
negative O O
, O O
gram O O
- O O
positive O O
, O O
aerobic O O
, O O
and O O
anaerobic O O
bacteria O O
. O O

Comparison O O
of O O
0 O O
. O O
0 O O
Tesla O O
and O O
0 O O
. O O
00 O O
Tesla O O
field O O
strength O O
magnetic O O
resonance O O
imaging O O
scans O O
in O O
the O O
morphometric O O
evaluation O O
of O O
the O O
lumbar O O
intervertebral O O
foramina O O
. O O

In O O
contrast O O
, O O
over O O
- O O
expression O O
of O O
RAR B-GENE B-GENE
beta I-GENE I-GENE
only O O
poorly O O
restored O O
differentiation O O
, O O
although O O
it O O
could O O
replace O O
RAR B-GENE O
gamma I-GENE O
for O O
the O O
activation O O
of O O
target O O
genes O O
. O O

The O O
0 O O
' O O
- O O
terminus O O
of O O
the O O
p B-GENE B-GENE
- I-GENE I-GENE
gvpF I-GENE I-GENE
- I-GENE I-GENE
M I-GENE I-GENE
mRNA I-GENE I-GENE
was O O
located O O
000 O O
nucleotides O O
upstream O O
of O O
p B-GENE O
- I-GENE O
gvpF I-GENE O
within O O
p B-GENE O
- I-GENE O
gvpE I-GENE O
. O O

As O O
in O O
Tb O O
, O O
U0 B-GENE O
is O O
a O O
single O O
- O O
copy O I-GENE
gene O I-GENE
and O O
two O O
tRNA O O
genes O O
, O O
tRNAGln B-GENE O
and O O
tRNAIle B-GENE O
, O O
are O O
found O O
upstream O O
to O O
the O O
gene O O
. O O

Moreover O O
, O O
the O O
hypoxia O O
- O O
induced O O
expression O O
of O O
the O O
endogenous O B-GENE
Epo B-GENE I-GENE
gene I-GENE I-GENE
was O O
significantly O O
inhibited O O
in O O
Hep0B O O
cells O O
stably O O
transfected O O
with O O
HNF B-GENE O
- I-GENE O
0 I-GENE O
delta I-GENE O
C I-GENE O
. O O

The O O
resulting O O
integrated O O
physical O O
, O O
genetic O O
, O O
and O O
cytogenetic O O
map O O
constitutes O O
a O O
resource O O
for O O
the O O
characterization O O
of O O
genes O O
that O O
may O O
be O O
involved O O
in O O
the O O
WAGR O O
syndrome O O
. O O

The O O
git0 B-GENE B-GENE
, O O
git0 B-GENE O
, O O
git0 B-GENE B-GENE
, O O
git0 B-GENE B-GENE
, O O
git0 B-GENE O
and O O
git00 B-GENE O
genes I-GENE O
act O O
upstream O O
of O O
adenylate B-GENE O
cyclase I-GENE O
, O O
presumably O O
encoding O O
an O O
adenylate B-GENE O
cyclase I-GENE O
activation O O
pathway O O
. O O

However O O
, O O
by O O
an O O
NS00 B-GENE O
- I-GENE O
specific I-GENE O
RNA I-GENE O
capture O O
assay O O
, O O
the O O
multimers O O
were O O
shown O O
to O O
possess O O
the O O
RNA O B-GENE
- O I-GENE
binding O I-GENE
activity O O
previously O O
demonstrated O O
for O O
NS00 B-GENE O
. O O

To O O
identify O O
the O O
precise O O
location O O
of O O
the O O
phosphorylation O O
site O O
on O O
the O O
00 O O
- O O
kDa O O
protein O O
, O O
a O O
step O O
- O O
by O O
- O O
step O O
mutagenesis O O
procedures O O
was O O
followed O O
. O O

The O O
Stryker O O
frame O O
modification O O
to O O
the O O
standard O O
Dornier O O
HM0 O O
lithotriptor O O
allows O O
for O O
improved O O
visualization O O
and O O
easier O O
localization O O
of O O
distal O O
ureteral O O
calculi O O
compared O O
to O O
the O O
standard O O
gantry O O
. O O

The O O
E0 B-GENE O
nuclear I-GENE O
transport I-GENE O
motif I-GENE O
is O O
highly O O
conserved O O
in O O
the O O
animal O O
and O O
human O O
papillomaviruses O O
and O O
is O O
encoded O O
in O O
a O O
similar O O
region O O
in O O
the O O
related O O
E0 B-GENE O
genes I-GENE O
. O O

Mutations O O
at O O
the O O
extreme O O
C O O
- O O
terminus O O
of O O
EIAV B-GENE O
Tat I-GENE O
impaired O O
both O O
RNA O O
binding O O
and O O
activation O O
domain O O
functions O O
, O O
suggesting O O
effects O O
on O O
secondary O O
or O O
tertiary O O
structure O O
. O O

A O O
region O O
approximately O O
000 O O
bp O O
upstream O O
from O O
the O O
transcription O O
start O O
point O O
of O O
virB B-GENE O
was O O
identified O O
as O O
being O O
necessary O O
for O O
full O O
activation O O
of O O
this O O
promoter O O
by O O
VirF B-GENE O
. O O

This O O
may O O
account O O
, O O
at O O
least O O
in O O
part O O
, O O
for O O
the O O
ability O O
of O O
excess O O
wt B-GENE O
p00 I-GENE O
to O O
inhibit O O
cell O O
proliferation O O
and O O
to O O
interfere O O
with O O
neoplastic O O
processes O O
. O O

Since O O
the O O
regulation O O
of O O
SWI0 B-GENE O
is O O
required O O
for O O
normal O O
cell O O
cycle O O
progression O O
, O O
we O O
have O O
characterized O O
cis O O
- O O
and O O
trans O O
- O O
acting O O
regulators O O
of O O
SWI0 B-GENE O
transcription O O
. O O

Patient O O
characteristics O O
associated O O
with O O
deep O O
wounds O O
as O O
well O O
as O O
patient O O
and O O
wound O O
characteristics O O
predictive O O
of O O
the O O
extent O O
of O O
healing O O
and O O
time O O
required O O
for O O
healing O O
were O O
identified O O
. O O

Yeast O O
mutants O O
lacking O O
a O O
functional O O
NOP0 B-GENE O
gene I-GENE O
can O O
be O O
complemented O O
by O O
human B-GENE O
fibrillarin I-GENE O
but O O
are O O
temperature O O
sensitive O O
for O O
growth O O
and O O
impaired O O
in O O
pre O O
- O O
rRNA O O
processing O O
. O O

Both O O
immunophilins B-GENE O
may O O
have O O
important O O
roles O O
in O O
receptor O O
assembly O O
and O O
may O O
represent O O
a O O
new O O
category O O
of O O
ligand O O
- O O
and O O
calcium O O
- O O
dependent O O
modulators O O
of O O
protein O O
function O O
. O O

Human B-GENE O
LAF I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
readily O O
hybridized O O
with O O
genes O O
in O O
mouse O O
and O O
chicken O O
, O O
thus O O
showing O O
that O O
this O O
gene O O
family O O
has O O
been O O
highly O O
conserved O O
during O O
vertebrate O O
evolution O O
. O O

We O O
observed O O
abundant O O
levels O O
of O O
Rev B-GENE B-GENE
- O I-GENE
erbA B-GENE I-GENE
alpha I-GENE I-GENE
mRNA O O
in O O
dividing O O
C0C00 O O
myoblasts O O
, O O
which O O
were O O
suppressed O O
when O O
the O O
cells O O
differentiated O O
into O O
postmitotic O O
multinucleated O O
myotubes O O
. O O

Using O O
immunogold O O
electron O O
microscopy O O
, O O
we O O
found O O
that O O
p00 B-GENE B-GENE
/ O O
p00 B-GENE B-GENE
and O O
p00 B-GENE B-GENE
are O O
localized O O
on O O
both O O
sides O O
of O O
the O O
nuclear O O
pore O O
complex O O
, O O
like O O
p00 B-GENE O
. O O

The O O
elevations O O
achieved O O
by O O
LDEE O O
given O O
s O O
. O O
c O O
. O O
were O O
higher O O
than O O
those O O
achieved O O
after O O
i O O
. O O
p O O
. O O
administration O O
and O O
lasted O O
for O O
longer O O
periods O O
. O O

These O O
data O O
are O O
consistent O O
with O O
a O O
model O O
in O O
which O O
GATA B-GENE O
- I-GENE O
0 I-GENE O
performs O O
a O O
unique O O
temporally O O
and O O
spatially O O
restricted O O
function O O
in O O
the O O
embryonic O O
heart O O
and O O
lung O O
. O O

The O O
atp B-GENE O
0 I-GENE O
and O O
atp B-GENE O
0 I-GENE O
types O O
of O O
cDNA O O
sequences O O
were O O
the O O
most O O
redundant O O
among O O
the O O
00 O O
different O O
isoperoxidases B-GENE O
identified O O
among O O
about O O
000 O O
peroxidase B-GENE O
encoding I-GENE O
ESTs I-GENE O
. O O

Moreover O O
, O O
Lck B-GENE O
was O O
reversibly O O
co O O
- O O
immunoprecipitated O O
with O O
p00Vav B-GENE O
, O O
and O O
the O O
stoichiometry O O
of O O
binding O O
increased O O
in O O
anti B-GENE O
- I-GENE O
CD0 I-GENE O
- O O
treated O O
Jurkat O O
cells O O
. O O

Interleukin B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
is O O
a O O
potent O O
inflammatory O O
mediator O O
that O O
belongs O O
to O O
the O O
family O O
of O O
C B-GENE B-GENE
- I-GENE I-GENE
X I-GENE I-GENE
- I-GENE I-GENE
C I-GENE I-GENE
chemokines I-GENE O
. O O

A O O
general O O
model O O
for O O
ARE O O
- O O
mediated O O
mRNA O O
degradation O O
involving O O
a O O
potential O O
role O O
for O O
certain O O
heterogeneous O O
nuclear O O
ribonucleoproteins O O
and O O
ARE B-GENE O
- I-GENE O
binding I-GENE O
proteins I-GENE O
is O O
proposed O O
. O O

These O O
observations O O
lead O O
to O O
the O O
proposal O O
that O O
the O O
RNAP B-GENE O
II I-GENE O
CTD I-GENE O
might O O
be O O
an O O
in O O
vivo O O
target O O
for O O
the O O
activated O O
p00mapk B-GENE O
and O O
p00mapk B-GENE O
MAP I-GENE O
kinases I-GENE O
. O O

Diffuse O O
white O O
matter O O
injury O O
can O O
be O O
attributed O O
to O O
radiation O O
and O O
associated O O
with O O
neurological O O
deficits O O
, O O
but O O
leukoencephalopathy O O
is O O
rarely O O
observed O O
in O O
the O O
absence O O
of O O
chemotherapy O O
. O O

By O O
contrast O O
, O O
all O O
proteins O O
initiated O O
with O O
a O O
methionine O O
placed O O
one O O
residue O O
upstream O O
of O O
the O O
natural O O
N O O
terminus O O
of O O
PR B-GENE O
failed O O
to O O
show O O
specific O O
proteolysis O O
. O O

In O O
000 O O
cells O O
, O O
expression O O
of O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
inhibitor O I-GENE
, O O
I B-GENE O
kappa I-GENE B-GENE
B I-GENE I-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
, O O
reduced O O
the O O
stimulatory O O
activity O O
of O O
LMP B-GENE O
. O O

The O O
NarX B-GENE O
and O O
NarQ B-GENE O
proteins I-GENE O
with O O
amino O O
acid O O
substitutions O O
at O O
the O O
first O O
conserved O O
histidine O O
position O O
were O O
also O O
unable O O
to O O
dephosphorylate O O
NarL B-GENE O
- O O
phosphate O O
in O O
vitro O O
. O O

Transcript O O
analysis O O
reveals O O
that O O
lethal O O
B B-GENE O
block I-GENE O
substitutions O O
reduce O O
U0 B-GENE O
RNA I-GENE O
synthesis O O
at O O
least O O
00 O O
- O O
fold O O
in O O
vivo O O
and O O
00 O O
- O O
fold O O
in O O
vitro O O
. O O

Lung O O
function O O
tests O O
( O O
EFR O O
) O O
were O O
performed O O
on O O
these O O
patients O O
for O O
a O O
period O O
of O O
00 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
months O O
. O O

Coronary O O
vasoconstriction O O
caused O O
by O O
endothelin B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
enhanced O O
by O O
ischemia O O
- O O
reperfusion O O
and O O
by O O
norepinephrine O O
present O O
in O O
concentrations O O
typically O O
observed O O
after O O
neonatal O O
cardiopulmonary O O
bypass O O
. O O

Similarly O O
, O O
in O O
mammalian O O
cells O O
PBP00 B-GENE O
is O O
synthesized O O
as O O
a O O
pre O O
- O O
protein O O
that O O
requires O O
membrane O O
potential O O
- O O
dependent O O
import O O
into O O
mitochondria O O
for O O
its O O
maturation O O
. O O

Homozygous O O
null O O
embryos O O
also O O
displayed O O
abnormalities O O
in O O
heart O O
development O O
, O O
consistent O O
with O O
the O O
conclusion O O
that O O
Tek B-GENE O
is O O
necessary O O
for O O
endocardial O O
/ O O
myocardial O O
interactions O O
during O O
development O O
. O O

A O O
high O O
- O O
resolution O O
restriction O O
map O O
of O O
over O O
000 O O
kb O O
of O O
contiguous O O
DNA O O
containing O O
N B-GENE O
- I-GENE O
myc I-GENE O
has O O
been O O
generated O O
by O O
subcloning O O
YACs O O
into O O
cosmids O O
. O O

Women O O
' O O
s O O
opportunities O O
for O O
paid O O
work O O
outside O O
the O O
home O O
are O O
constrained O O
by O O
their O O
role O O
as O O
primary O O
carer O O
within O O
the O O
family O O
, O O
writes O O
Trudy O O
Wynne O O
. O O

Pentazocine O O
analgesia O O
: O O
is O O
there O O
a O O
niche O O
for O O
Talwin O O
Nx O O
? O O
Pentazocine O O
can O O
be O O
a O O
useful O O
analgesic O O
agent O O
for O O
the O O
management O O
of O O
acute O O
dental O O
pain O O
. O O

This O O
study O O
underlines O O
the O O
importance O O
of O O
terminal O O
SC0b B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
complement I-GENE O
complex I-GENE O
as O O
a O O
suitable O O
marker O O
in O O
the O O
evaluation O O
of O O
complement O O
activation O O
during O O
cardiopulmonary O O
bypass O O
. O O

The O O
gene O O
was O O
uniquely O O
mapped O O
with O O
odds O O
> O O
0 O O
, O O
000 O O
: O O
0 O O
on O O
chromosome O O
0p O O
in O O
Centre O O
d O O
' O O
Etude O O
du O O
Polymorphisme O O
Humain O O
pedigrees O O
. O O

A O O
cis O O
- O O
acting O O
DNA O O
element O O
located O O
between O O
TATA O O
box O O
and O O
transcription O O
initiation O O
site O O
is O O
critical O O
in O O
response O O
to O O
regulatory O O
sequences O O
in O O
human O O
angiotensinogen B-GENE O
gene I-GENE O
. O O

Sequence O O
analysis O O
of O O
the O O
isolated O O
genomic O O
clone O O
revealed O O
that O O
the O O
DNA O O
binding O O
domain O O
of O O
this O O
orphan O O
receptor O O
is O O
most O O
homologous O O
to O O
the O O
human B-GENE B-GENE
TR0 I-GENE I-GENE
receptor I-GENE I-GENE
. O O

Feline O O
leukemia O O
viruses O O
( O O
FeLVs O O
) O O
, O O
which O O
are O O
replication O O
- O O
competent O O
oncoretroviruses O O
of O O
the O O
domestic O O
cat O O
species O O
, O O
are O O
contagiously O O
transmitted O O
in O O
natural O O
environments O O
. O O

These O O
results O O
were O O
corroborated O O
in O O
a O O
subsequent O O
study O O
in O O
which O O
00 O O
hypogonadal O O
men O O
were O O
supplemented O O
with O O
SLT O O
0 O O
mg O O
three O O
times O O
daily O O
for O O
0 O O
months O O
. O O

Unlike O O
wild B-GENE O
- I-GENE O
type I-GENE O
p00 I-GENE O
, O O
the O O
delta B-GENE O
proAE I-GENE O
mutant I-GENE O
cDNA I-GENE O
can O O
be O O
stably O O
expressed O O
in O O
tumor O O
derived O O
cell O O
lines O O
with O O
few O O
immediate O O
detrimental O O
effects O O
. O O

A O O
genetic O O
screen O O
applied O O
to O O
mutants O O
in O O
the O O
branch O O
site O O
region O O
shows O O
that O O
all O O
positions O O
in O O
the O O
conserved O O
TACTAAC O O
sequence O O
are O O
important O O
for O O
intron O O
recognition O O
. O O

Effects O O
of O O
methiothepin O O
and O O
lysergic O O
acid O O
diethylamide O O
on O O
serotonin O O
release O O
in O O
vitro O O
and O O
serotonin O O
synthesis O O
in O O
vivo O O
: O O
possible O O
relation O O
to O O
serotonin B-GENE O
autoreceptor I-GENE O
function O O
. O O

The O O
hypertension O O
with O O
elevated O O
PRA O O
, O O
however O O
, O O
was O O
resistant O O
to O O
the O O
angiotensin B-GENE B-GENE
II I-GENE I-GENE
( O O
AII B-GENE O
) O O
analog O O
[ O O
Sar0 O O
, O O
Ile0 O O
] O O
ALL O O
. O O

Over O O
a O O
period O O
of O O
00 O O
days O O
00 O O
% O O
of O O
the O O
dose O O
administered O O
was O O
excreted O O
with O O
faeces O O
and O O
0 O O
. O O
0 O O
% O O
in O O
the O O
urine O O
. O O

Mutational O O
analysis O O
of O O
mRNA B-GENE O
capping I-GENE O
enzyme I-GENE O
identifies O O
amino O O
acids O O
involved O O
in O O
GTP O O
binding O O
, O O
enzyme O O
- O O
guanylate O O
formation O O
, O O
and O O
GMP O O
transfer O O
to O O
RNA O O
. O O

We O O
have O O
isolated O O
a O O
Drosophila O O
melanogaster O O
( O O
Dm O O
) O O
cDNA O O
encoding O O
a O O
polypeptide O O
that O O
has O O
extensive O O
sequence O O
similarity O O
to O O
the O O
mammalian B-GENE B-GENE
MAPKAPK I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

This O O
apparently O O
anomalous O O
structure O O
/ O O
activity O O
relationship O O
raises O O
important O O
issues O O
for O O
understanding O O
the O O
evolution O O
of O O
regulatory O O
peptides O O
and O O
the O O
mechanisms O O
that O O
control O O
their O O
expression O O
. O O

Using O O
mutagenesis O O
, O O
we O O
have O O
identified O O
two O O
mutations O O
of O O
the O O
second O O
actin B-GENE O
- I-GENE O
binding I-GENE O
domain I-GENE O
that O O
can O O
also O O
suppress O O
the O O
act0 B-GENE O
mutations O O
of O O
interest O O
. O O

A O O
polymorphic O O
bipartite O O
motif O O
signals O O
nuclear O O
targeting O O
of O O
early O O
auxin O B-GENE
- O I-GENE
inducible O I-GENE
proteins O I-GENE
related O O
to O O
PS B-GENE B-GENE
- I-GENE I-GENE
IAA0 I-GENE I-GENE
from I-GENE O
pea I-GENE O
( I-GENE O
Pisum I-GENE O
sativum I-GENE O
) I-GENE O
. O O

The O O
CVA00 B-GENE O
. I-GENE O
0 I-GENE O
proteolipid I-GENE O
transcript I-GENE O
is O O
the O O
most O O
prevalent O O
of O O
the O O
two O O
proteolipid O O
messages O O
in O O
expanding O O
ovules O O
harvested O O
00 O O
d O O
post O O
- O O
anthesis O O
. O O

We O O
conclude O O
that O O
, O O
in O O
comparison O O
to O O
reports O O
from O O
other O O
regions O O
, O O
Scandinavian O O
renal O O
transplant O O
recipients O O
are O O
at O O
high O O
risk O O
of O O
dying O O
of O O
IHD O O
. O O

No O O
significant O O
differences O O
were O O
identified O O
between O O
groups O O
for O O
pH O O
, O O
PaCO0 O O
, O O
intracranial O O
pressure O O
, O O
heart O O
rate O O
, O O
brain O O
temperature O O
, O O
or O O
glucose O O
levels O O
. O O

Serum O O
induction O O
of O O
a O O
MEF0 B-GENE B-GENE
reporter I-GENE I-GENE
gene I-GENE I-GENE
was O O
not O O
observed O O
in O O
a O O
line O O
of O O
NIH O O
0T0 O O
cells O O
which O O
contain O O
low O O
MEF0 B-GENE O
site I-GENE O
binding O O
activity O O
. O O

000 O O
students O O
had O O
a O O
count O O
of O O
less O O
than O O
00 O O
eggs O O
/ O O
00 O O
ml O O
. O O
urine O O
and O O
00 O O
had O O
more O O
than O O
00 O O
eggs O O
/ O O
00ml O O
. O O

The O O
transverse O O
magnetization O O
decays O O
mentioned O O
above O O
exhibited O O
two O O
components O O
, O O
a O O
T0 O O
fast O O
( O O
T0f O O
) O O
and O O
a O O
T0 O O
slow O O
( O O
T0s O O
) O O
component O O
. O O

Segments O O
with O O
more O O
reduced O O
BMIPP O O
uptake O O
than O O
MIBI O O
uptake O O
( O O
mismatching O O
) O O
showed O O
either O O
normal O O
wall O O
motion O O
or O O
demonstrated O O
inotropic O O
reserve O O
during O O
dobutamine O O
stimulation O O
. O O

No O O
drop O O
in O O
oxygen O O
saturation O O
( O O
SaO0 O O
) O O
or O O
visual O O
evidence O O
of O O
transient O O
electroencephalographic O O
( O O
EEG O O
) O O
arousals O O
can O O
be O O
found O O
at O O
repeat O O
polysomnography O O
. O O

Certain O O
spt00 B-GENE O
spontaneous O O
alleles O O
are O O
good O O
suppressors O O
but O O
have O O
a O O
normal O O
growth O O
rate O O
, O O
suggesting O O
that O O
the O O
SPT00 B-GENE O
protein I-GENE O
may O O
have O O
two O O
distinct O O
functions O O
. O O

Structure O O
and O O
expression O O
of O O
the O O
alternative O B-GENE
sigma B-GENE I-GENE
factor I-GENE I-GENE
, O O
RpoN B-GENE O
, O O
in O O
Rhodobacter O O
capsulatus O O
; O O
physiological O O
relevance O O
of O O
an O O
autoactivated O O
nifU0 B-GENE O
- O O
rpoN B-GENE O
superoperon O O
. O O

These O O
findings O O
suggest O O
a O O
functional O O
cross O O
- O O
talk O O
between O O
RB B-GENE O
protein I-GENE O
and O O
p00ras B-GENE O
, O O
which O O
balances O O
the O O
cell O O
phenotype O O
between O O
normal O O
and O O
transformed O O
states O O
. O O

Consistent O O
with O O
the O O
hypothesis O O
that O O
it O O
acts O O
as O O
transcriptional O O
regulator O O
, O O
wild B-GENE O
- I-GENE O
type I-GENE O
p00 I-GENE O
protein I-GENE O
binds O O
DNA O O
and O O
activates O O
transcription O O
of O O
several O O
promoters O O
. O O

Finally O O
, O O
we O O
present O O
evidence O O
that O O
fimbrin B-GENE O
is O O
a O O
third O O
distinct O O
plastin B-GENE O
isoform I-GENE O
which O O
is O O
specifically O O
expressed O O
at O O
high O O
levels O O
in O O
the O O
small O O
intestine O O
. O O

Finger B-GENE O
associated I-GENE O
box I-GENE B-GENE
- I-GENE I-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
proteins I-GENE I-GENE
( O O
FAX B-GENE B-GENE
- I-GENE I-GENE
ZFPs I-GENE I-GENE
) O O
constitute O O
a O O
subfamily O O
of O O
the O O
many O O
C0H0 B-GENE O
type I-GENE O
ZFPs I-GENE O
in O O
Xenopus O O
laevis O O
. O O

The O O
patients O O
were O O
divided O O
into O O
ischaemia O O
and O O
non O O
- O O
ischaemia O O
groups O O
on O O
the O O
basis O O
of O O
the O O
change O O
in O O
lactate O O
extraction O O
ratio O O
during O O
balloon O O
inflation O O
. O O

A O O
mutant B-GENE O
areA I-GENE O
product I-GENE O
truncated O O
immediately O O
after O O
the O O
last O O
residue O O
of O O
the O O
highly O O
conserved O O
GATA B-GENE O
( I-GENE O
DNA I-GENE O
- I-GENE O
binding I-GENE O
) I-GENE O
domain I-GENE O
retains O O
partial O O
function O O
. O O

Its O O
organization O O
and O O
regulation O O
indicate O O
that O O
the O O
S B-GENE O
. I-GENE O
pombe I-GENE I-GENE
URA0 I-GENE I-GENE
gene I-GENE I-GENE
product I-GENE O
appears O O
very O O
similar O O
to O O
the O O
S B-GENE O
. I-GENE O
cerevisiae I-GENE I-GENE
URA0 I-GENE I-GENE
gene I-GENE I-GENE
product I-GENE O
. O O

Furthermore O O
, O O
strains O O
with O O
mutant B-GENE O
RPM0 I-GENE O
genes I-GENE O
also O O
accumulate O O
precursor B-GENE O
Rpm0r I-GENE O
, O O
suggesting O O
that O O
mutations O O
in O O
either O O
gene O O
can O O
lead O O
to O O
similar O O
biogenesis O O
defects O O
. O O

Many O O
human O O
viruses O O
are O O
able O O
to O O
develop O O
suitable O O
strategies O O
for O O
modifying O O
apoptosis O O
in O O
virus O O
- O O
infected O O
cells O O
and O O
in O O
virus O O
- O O
primed O O
T O O
cells O O
. O O

Eight O O
- O O
four O O
ACOAs O O
were O O
tested O O
in O O
order O O
to O O
examine O O
the O O
fit O O
of O O
the O O
model O O
to O O
the O O
data O O
by O O
path O O
analysis O O
with O O
LISREL O O
VII O O
. O O

Paracrine O O
activation O O
of O O
the O O
HIV B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
LTR I-GENE I-GENE
promoter I-GENE I-GENE
by O O
the O O
viral B-GENE B-GENE
Tat I-GENE I-GENE
protein I-GENE I-GENE
is O O
mechanistically O O
similar O O
to O O
trans O B-GENE
- O O
activation O O
within O O
a O O
cell O O
. O O

When O O
the O O
degree O O
of O O
exercise O O
was O O
maximal O O
, O O
mPAP O O
was O O
maintained O O
, O O
SVI O O
decreased O O
, O O
HR O O
was O O
unchanged O O
, O O
and O O
CO O O
and O O
VO0 O O
decreased O O
. O O

This O O
establishes O O
Rad0 B-GENE O
/ O O
Mec0 B-GENE O
as O O
the O O
only O O
conserved O O
protein O O
which O O
is O O
required O O
for O O
all O O
the O O
DNA O O
structure O O
checkpoints O O
in O O
both O O
yeast O O
model O O
systems O O
. O O

There O O
is O O
now O O
a O O
significative O O
difference O O
between O O
age O O
group O O
0 O O
- O O
0 O O
and O O
the O O
others O O
( O O
p O O
Less O O
Than O O
0 O O
, O O
00 O O
) O O
. O O

Factor B-GENE O
VIII I-GENE O
procoagulant O O
activity O O
, O O
antigen O O
concentration O O
and O O
von B-GENE O
Willebrand I-GENE O
activity O O
as O O
ristocetin B-GENE O
cofactor I-GENE O
were O O
determined O O
several O O
times O O
in O O
00 O O
patients O O
with O O
DIC O O
. O O

In O O
vitro O O
penetration O O
tests O O
of O O
human O O
sperm O O
into O O
cervical O O
mucus O O
were O O
introduced O O
in O O
order O O
to O O
study O O
the O O
interaction O O
between O O
sperm O O
and O O
cervical O O
mucus O O
. O O

This O O
relatively O O
simple O O
and O O
easily O O
performed O O
technique O O
of O O
measuring O O
deep O O
muscle O O
temperature O O
appears O O
to O O
be O O
a O O
useful O O
adjunct O O
in O O
choosing O O
the O O
amputation O O
level O O
. O O

A O O
particularly O O
striking O O
HpaII B-GENE O
tiny O O
fragment O O
island O O
, O O
extending O O
over O O
nearly O O
0 O O
, O O
000 O O
base O O
pairs O O
, O O
surrounds O O
the O O
USF0 B-GENE O
translation I-GENE O
initiation I-GENE O
site I-GENE O
. O O

A O O
chicken B-GENE O
paxillin I-GENE O
cDNA I-GENE O
was O O
also O O
cloned O O
and O O
is O O
predicted O O
to O O
encode O O
a O O
protein O O
approximately O O
00 O O
% O O
identical O O
to O O
human B-GENE O
paxil I-GENE O
- I-GENE O
lin I-GENE O
. O O

SL0 B-GENE O
trans O O
- O O
splicing O O
specified O O
by O O
AU O O
- O O
rich O O
synthetic O O
RNA O O
inserted O O
at O O
the O O
0 O O
' O O
end O O
of O O
Caenorhabditis O O
elegans O O
pre O O
- O O
mRNA O O
. O O

These O O
results O O
are O O
very O O
useful O O
for O O
deciding O O
on O O
the O O
doses O O
of O O
hormones O O
and O O
the O O
expected O O
serum O O
estradiol O O
level O O
in O O
HRT O O
for O O
Japanese O O
women O O
. O O

Using O O
gel O O
retardation O O
assays O O
with O O
HepG0 O O
nuclear O O
extract O O
, O O
we O O
demonstrated O O
the O O
presence O O
of O O
a O O
specific O O
protein O O
which O O
bound O O
to O O
the O O
NRE O O
fragment O O
. O O

These O O
results O O
demonstrate O O
that O O
a O O
diverse O O
set O O
of O O
carboxyl O O
- O O
terminal O O
sequence O O
motifs O O
and O O
posttranslational O O
modifications O O
lead O O
to O O
functional O O
Ras B-GENE O
proteins I-GENE O
in O O
yeast O O
. O O

Binding O O
of O O
U0 B-GENE O
small I-GENE O
nuclear I-GENE O
ribonucleoprotein I-GENE O
( O O
snRNP O O
) O O
to O O
the O O
pre O B-GENE
- O I-GENE
mRNA O I-GENE
is O O
an O O
early O O
and O O
important O O
step O O
in O O
spliceosome O O
assembly O O
. O O

Significant O O
alterations O O
in O O
CBC O O
results O O
and O O
serum B-GENE O
CRP I-GENE O
concentration O O
, O O
compared O O
with O O
baseline O O
values O O
, O O
were O O
lacking O O
in O O
dogs O O
of O O
the O O
control O O
group O O
. O O

In O O
the O O
case O O
of O O
congenital O O
protein B-GENE O
C I-GENE O
deficiency O O
, O O
vitamin O O
K O O
antagonists O O
must O O
be O O
started O O
cautiously O O
due O O
to O O
the O O
risk O O
of O O
skin O O
necrosis O O
. O O

In O O
addition O O
, O O
we O O
observe O O
that O O
the O O
hUBF B-GENE B-GENE
- I-GENE I-GENE
promoter I-GENE I-GENE
interaction O O
is O O
highly O O
sensitive O O
to O O
the O O
antagonistic O O
effects O O
of O O
cisplatin O O
- O O
DNA O O
adducts O O
. O O

The O O
bioavailability O O
of O O
etodolac O O
from O O
capsules O O
exposed O O
to O O
stressed O O
conditions O O
was O O
compared O O
in O O
both O O
dogs O O
and O O
humans O O
to O O
capsules O O
stored O O
at O O
RT O O
conditions O O
. O O

To O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
case O O
in O O
which O O
a O O
probable O O
association O O
between O O
cholelithiasis O O
and O O
Wildervanck O O
' O O
s O O
syndrome O O
has O O
been O O
recorded O O
. O O

Addition O O
of O O
phalloidin O B-GENE
- O I-GENE
stabilized O I-GENE
F B-GENE I-GENE
- I-GENE I-GENE
actin I-GENE I-GENE
nuclei O O
and O O
phalloidin O O
restored O O
L000D O O
actin B-GENE O
' O O
s O O
ability O O
to O O
polymerize O O
at O O
0 O O
degrees O O
C O O
. O O

The O O
rate O O
of O O
enzymic O O
stimulation O O
induced O O
by O O
a O O
given O O
nitrate O O
correlates O O
closely O O
with O O
the O O
rate O O
of O O
measured O O
NO O O
production O O
from O O
the O O
nitrate O O
molecule O O
. O O

Oligonucleotide O O
competitors O O
were O O
used O O
to O O
evaluate O O
the O O
accessibility O O
of O O
the O O
TATA O O
- O O
binding O O
site O O
in O O
TIF B-GENE O
- I-GENE O
IB I-GENE O
, O O
TFIID B-GENE O
, O O
and O O
TFIIIB B-GENE O
. O O

The O O
activity O O
of O O
the O O
coat B-GENE B-GENE
protein I-GENE I-GENE
promoter I-GENE O
of O O
chloris O O
striate O O
mosaic O O
virus O O
is O O
enhanced O O
by O O
its O O
own O O
and O O
C0 B-GENE B-GENE
- O I-GENE
C0 B-GENE I-GENE
gene O I-GENE
products O O
. O O

Pokeweed B-GENE O
mitogen I-GENE O
( O O
PWM B-GENE O
) O O
or O O
anti B-GENE O
- I-GENE O
CD0 I-GENE O
significantly O O
increases O O
c B-GENE B-GENE
- I-GENE I-GENE
jun I-GENE I-GENE
messenger I-GENE I-GENE
RNA I-GENE I-GENE
( I-GENE O
mRNA I-GENE O
) I-GENE O
levels O O
in O O
T O O
cells O O
. O O

Northern O O
blot O O
analysis O O
of O O
total O O
cellular O O
RNA O O
indicated O O
that O O
xylP B-GENE O
encodes O O
a O O
0 O O
. O O
0 O O
- O O
kb O O
transcript O O
which O O
is O O
induced O O
by O O
xylan O O
. O O

A O O
human O O
cytoplasmic O O
signaling O O
protein O O
has O O
been O O
cloned O O
that O O
possesses O O
the O O
same O O
structural O O
arrangement O O
of O O
SH0 B-GENE B-GENE
- O I-GENE
SH0 B-GENE I-GENE
- O O
SH0 B-GENE O
domains O O
as O O
Grb0 B-GENE O
. O O

Also O O
like O O
the O O
thrombin B-GENE B-GENE
receptor I-GENE I-GENE
, O O
PAR0 B-GENE O
can O O
be O O
activated O O
by O O
the O O
hexapeptide O O
corresponding O O
to O O
its O O
tethered O O
ligand O O
sequence O O
independent O O
of O O
receptor O O
cleavage O O
. O O

Tristetraprolin B-GENE O
( O O
TTP B-GENE O
) O O
is O O
the O O
prototype O O
of O O
a O O
group O O
of O O
potential O O
transcription O O
factors O O
that O O
contain O O
two O O
or O O
more O O
unusual O O
CCCH O O
zinc O O
fingers O O
. O O

OKA O O
and O O
calyculin O O
A O O
do O O
not O O
decrease O O
OCFRE B-GENE O
DNA O O
- O O
protein O O
interactions O O
, O O
suggesting O O
that O O
important O O
protein O B-GENE
- O I-GENE
protein O I-GENE
interactions O I-GENE
are O O
phosphatase O O
regulated O O
. O O

We O O
have O O
performed O O
toeprinting O O
analyses O O
on O O
repA B-GENE O
mRNA I-GENE O
of O O
plasmid O O
R0 O O
, O O
both O O
free O O
and O O
in O O
duplex O O
with O O
the O O
antisense O O
RNA O O
, O O
CopA B-GENE O
. O O

The O O
STAT B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
signaling O O
pathway O O
provides O O
at O O
least O O
one O O
mechanism O O
for O O
activation O O
of O O
the O O
CAEV B-GENE O
LTR I-GENE O
by O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma I-GENE I-GENE
in O O
monocytes O O
. O O

During O O
skeletal O O
muscle O O
development O O
, O O
different O O
types O O
of O O
muscle O O
fibers O O
are O O
generated O O
, O O
which O O
express O O
different O O
combinations O O
of O O
muscle O O
- O O
specific O O
gene O O
products O O
. O O

The O O
recombinant O B-GENE
protein O I-GENE
was O O
purified O O
to O O
homogeneity O O
by O O
( O O
NH0 O O
) O O
0SO0 O O
- O O
precipitation O O
and O O
affinity O O
chromatography O O
on O O
0 O O
' O O
AMP O O
- O O
Sepharose O O
. O O

The O O
carboxyl O O
- O O
terminal O O
CCCC O O
module O O
is O O
structurally O O
related O O
to O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
the O O
erythroid B-GENE B-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
GATA I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

Serum O O
lipids O O
and O O
lipoproteins O O
of O O
00 O O
insulin B-GENE O
dependent O O
diabetic O O
children O O
have O O
been O O
determined O O
and O O
related O O
to O O
the O O
metabolic O O
status O O
of O O
the O O
patients O O
. O O

All O O
samples O O
exhibited O O
a O O
decline O O
in O O
ethanol O O
concentration O O
, O O
with O O
most O O
losses O O
falling O O
within O O
the O O
expected O O
00 O O
to O O
00 O O
mg O O
% O O
range O O
. O O

One O O
of O O
these O O
is O O
surrounded O O
by O O
an O O
adenine O O
- O O
uridine O O
rich O O
region O O
that O O
can O O
form O O
an O O
00 O O
- O O
base O O
pair O O
stem O O
structure O O
. O O

Remarkably O O
, O O
U00 B-GENE O
contains O O
a O O
long O O
stretch O O
( O O
00 O O
nt O O
. O O
) O O
of O O
complementarity O O
to O O
a O O
highly O O
conserved O O
sequence O O
in O O
00S B-GENE O
rRNA I-GENE O
. O O

Deletion O O
studies O O
identified O O
a O O
distal O O
response O O
element O O
that O O
is O O
responsible O O
for O O
the O O
cytokine O O
response O O
and O O
has O O
properties O O
of O O
an O O
inducible O O
transcriptional O O
enhancer O O
. O O

These O O
results O O
suggest O O
that O O
leader O O
- O O
mRNA O O
fusion O O
in O O
coronavirus O O
transcription O O
does O O
not O O
require O O
direct O O
RNA O O
- O O
RNA O O
interaction O O
between O O
complementary O O
sequences O O
. O O

These O O
results O O
suggest O O
that O O
leader O O
- O O
mRNA O O
fusion O O
in O O
coronavirus O O
transcription O O
does O O
not O O
require O O
direct O O
RNA O O
- O O
RNA O O
interaction O O
between O O
complementary O O
sequences O O
. O O

However O O
, O O
tyrA B-GENE O
can O O
be O O
expressed O O
efficiently O O
from O O
an O O
internal O O
promoter O O
which O O
appears O O
to O O
lie O O
within O O
the O O
0 O O
' O O
portion O O
of O O
aroF B-GENE O
. O O

Previous O O
studies O O
showed O O
that O O
mutations O O
in O O
the O O
0K O O
protein O O
led O O
to O O
the O O
slow O O
release O O
of O O
aberrant O O
, O O
multi O O
- O O
cored O O
infectious O O
virions O O
. O O

A O O
segment O O
of O O
mRNA O O
encoding O O
the O O
leader O O
peptide O O
of O O
the O O
CPA0 B-GENE B-GENE
gene I-GENE I-GENE
confers O I-GENE
repression O O
by O O
arginine O O
on O O
a O O
heterologous O O
yeast O O
gene O O
transcript O O
. O O

Mapping O O
of O O
intracellular O O
localization O O
domains O O
and O O
evidence O O
for O O
colocalization O O
interactions O O
between O O
the O O
IE000 B-GENE O
and O O
IE000 B-GENE O
nuclear O O
transactivator O O
proteins O O
of O O
herpes O O
simplex O O
virus O O
. O O

A O O
second O O
study O O
group O O
, O O
with O O
intact O O
cardiac O O
innervation O O
, O O
consisted O O
of O O
00 O O
patients O O
with O O
stable O O
angina O O
pectoris O O
class O O
I O O
to O O
III O O
. O O

PRL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
able O O
to O O
dephosphorylate O O
phosphotyrosine O O
substrates O O
, O O
and O O
mutation O O
of O O
the O O
active O O
- O O
site O O
cysteine O O
residue O O
abolishes O O
this O O
activity O O
. O O

The O O
pyrR B-GENE O
and O O
pyrP B-GENE O
genes I-GENE O
encoded O O
polypeptides O O
with O O
calculated O O
molecular O O
masses O O
of O O
00 O O
. O O
0 O O
and O O
00 O O
. O O
0 O O
kDa O O
, O O
respectively O O
. O O

SIN O O
- O O
0 O O
had O O
no O O
influence O O
on O O
either O O
the O O
ischemic O O
parameters O O
in O O
the O O
surface O O
electrocardiogram O O
( O O
ECG O O
) O O
or O O
the O O
intracoronary O O
ECG O O
. O O

Two O O
patients O O
were O O
treated O O
successfully O O
with O O
a O O
combination O O
of O O
metronidazole O O
( O O
a O O
tissue O O
amoebicide O O
) O O
and O O
diloxanide O O
( O O
a O O
lumenal O O
amoebicide O O
) O O
. O O

TGF B-GENE B-GENE
beta I-GENE I-GENE
0 I-GENE I-GENE
expression O O
is O O
largely O O
governed O O
by O O
three O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
binding I-GENE O
sites I-GENE O
located O O
in O O
two O O
different O O
promoters O O
of O O
this O O
gene O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
structures O O
of O O
the O O
b O O
- O O
Zip O O
domain O O
are O O
well O O
conserved O O
among O O
these O O
Maf B-GENE O
- I-GENE O
related I-GENE O
proteins I-GENE O
. O O

Consistent O O
with O O
the O O
hepatic O O
and O O
epidermal O O
expression O O
of O O
histidase B-GENE O
, O O
this O O
finding O O
suggests O O
that O O
histidase B-GENE O
transcription O O
may O O
be O O
regulated O O
by O O
these O O
factors O O
. O O

We O O
found O O
that O O
000 O O
bp O O
of O O
the O O
enhancer O O
' O O
s O O
transcriptional O O
core O O
becomes O O
DNase B-GENE O
I I-GENE O
hypersensitive O O
early O O
in O O
B O O
- O O
cell O O
development O O
. O O

Heme B-GENE O
oxygenase I-GENE O
0 I-GENE O
is O O
an O O
essential O O
enzyme O O
in O O
heme O O
catabolism O O
that O O
cleaves O O
heme O O
to O O
form O O
biliverdin O O
, O O
iron O O
, O O
and O O
carbon O O
monoxide O O
. O O

In O O
a O O
screen O O
for O O
genes O O
with O O
oncogenic O O
potential O O
expressed O O
by O O
the O O
murine O O
B0SUtA0 O O
myeloid O O
progenitor O O
cell O O
line O O
, O O
we O O
isolated O O
a O O
0 O O
. O O

This O O
brief O O
review O O
analyses O O
these O O
interactions O O
and O O
defines O O
clinical O O
settings O O
where O O
antibiotic O O
- O O
induced O O
endotoxin O O
release O O
may O O
prove O O
to O O
be O O
clinically O O
relevant O O
. O O

Transcriptional O O
activity O O
was O O
measured O O
by O O
slot O O
- O O
blot O O
hybridization O O
with O O
steady O O
- O O
state O O
RNA O O
isolated O O
from O O
lacZ B-GENE O
+ I-GENE O
M I-GENE O
. I-GENE O
smegmatis I-GENE O
clones O O
. O O

The O O
Rlm0 B-GENE B-GENE
protein I-GENE I-GENE
, O O
a O O
member O O
of O O
the O O
MADS B-GENE O
box I-GENE O
family I-GENE O
of O O
transcription O B-GENE
factors O I-GENE
, O O
functions O O
downstream O O
of O O
Mpk0 B-GENE O
in O O
the O O
pathway O O
. O O

After O O
a O O
year O O
of O O
planning O O
in O O
the O O
Laboratory O O
Assistants O O
' O O
School O O
in O O
Stockholm O O
: O O
new O O
education O O
for O O
laboratory O O
assistants O O
is O O
now O O
arranged O O

Ulcer O O
appeared O O
on O O
the O O
angulus O O
of O O
the O O
stomach O O
at O O
the O O
00th O O
week O O
and O O
resulted O O
in O O
ulcer O O
scar O O
at O O
the O O
00nd O O
week O O
. O O

Mutations O O
in O O
the O O
VPS00 B-GENE B-GENE
gene I-GENE I-GENE
, O O
a O O
SEC0 B-GENE O
homologue O O
, O O
result O O
in O O
vacuolar O O
protein O O
sorting O O
defects O O
and O O
accumulation O O
of O O
membrane O O
vesicles O O
. O O

Inclusion O O
in O O
this O O
family O O
of O O
proteins O O
suggests O O
that O O
FliQ B-GENE O
and O O
FliR B-GENE O
may O O
participate O O
in O O
an O O
export O O
pathway O O
required O O
for O O
flagellum O O
assembly O O
. O O

A O O
major O O
task O O
for O O
sports O O
scientists O O
may O O
be O O
to O O
verify O O
empirically O O
the O O
nature O O
of O O
an O O
integrated O O
model O O
of O O
the O O
sport O O
performer O O
. O O

Like O O
Epo B-GENE O
, O O
HNF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
expressed O O
in O O
kidney O O
, O O
liver O O
, O O
and O O
Hep0B O O
cells O O
but O O
not O O
in O O
HeLa O O
cells O O
. O O

There O O
was O O
no O O
apparent O O
effect O O
of O O
growth O O
temperature O O
on O O
the O O
steady O O
- O O
state O O
levels O O
of O O
fad0 B-GENE O
mRNA I-GENE O
in O O
wild O O
type O O
plants O O
. O O

The O O
E0 B-GENE O
replication I-GENE O
protein I-GENE O
of O O
bovine O B-GENE
papillomavirus O I-GENE
type O I-GENE
0 O O
contains O O
an O O
extended O O
nuclear O O
localization O O
signal O O
that O O
includes O O
a O O
p00cdc0 B-GENE O
phosphorylation O O
site O O
. O O

This O O
observation O O
suggests O O
that O O
the O O
methyl O O
- O O
directed O O
repair O O
system O O
utilizes O O
the O O
proximal O O
d O O
( O O
GATC O O
) O O
sequence O O
to O O
direct O O
correction O O
. O O

The O O
use O O
of O O
this O O
model O O
for O O
investigating O O
pathophysiologically O O
significant O O
issues O O
in O O
denervating O O
diseases O O
is O O
illustrated O O
with O O
five O O
different O O
sets O O
of O O
parameters O O
. O O

Examination O O
of O O
the O O
immediate O O
sequence O O
0 O O
' O O
to O O
the O O
mRNA O O
start O O
site O O
reveals O O
no O O
TATA O O
box O O
and O O
multiple O O
known O O
enhancer O O
sequences O O
. O O

Unlike O O
ARF B-GENE O
, O O
the O O
ARP B-GENE O
immunoreactivity O O
was O O
detected O O
in O O
plasma O O
membranes O O
but O O
not O O
in O O
cytosol O O
of O O
fractionated O O
0T0 O O
- O O
L0 O O
cells O O
. O O

The O O
XS0 B-GENE B-GENE
gene I-GENE I-GENE
down O O
- O O
regulates O O
but O O
does O O
not O O
abolish O O
expression O O
of O O
LU B-GENE B-GENE
genes I-GENE I-GENE
and O O
does O O
not O O
affect O O
expression O O
of O O
CD00 B-GENE O
. O O

Conversely O O
, O O
when O O
VDR B-GENE O
is O O
overexpressed O O
, O O
vitamin O O
D0 O O
attenuates O O
0 O O
- O O
cis O O
RA O O
induction O O
from O O
an O O
RXR B-GENE O
- O O
responsive O O
element O O
. O O

Sp0 B-GENE O
binds O O
two O O
sites O O
in O O
the O O
CD00c B-GENE O
promoter I-GENE O
in O O
vivo O O
specifically O O
in O O
myeloid O O
cells O O
and O O
cooperates O O
with O O
AP0 B-GENE O
to O O
activate O O
transcription O O
. O O

Oncogenic O O
activation O O
of O O
the O O
tyrosine B-GENE O
kinase I-GENE O
domain I-GENE O
of O O
the O O
human B-GENE B-GENE
trk I-GENE I-GENE
proto I-GENE I-GENE
- I-GENE I-GENE
oncogene I-GENE I-GENE
by O O
fusion O O
to O O
a O O
cell O O
adhesion O O
molecule O O
. O O

In O O
this O O
regard O O
, O O
it O O
differs O O
from O O
a O O
recently O O
reported O O
BFA O O
- O O
sensitive O O
ARF B-GENE O
- O O
GEP B-GENE O
that O O
contains O O
a O O
Sec0 B-GENE O
domain I-GENE O
. O O

At O O
an O O
ambient O O
temperature O O
of O O
00 O O
degrees O O
C O O
, O O
the O O
responses O O
to O O
spinal O O
cooling O O
are O O
reduced O O
during O O
the O O
dark O O
phase O O
. O O

Hematopoietic B-GENE O
growth I-GENE O
factors I-GENE O
are O O
being O O
used O O
to O O
accelerate O O
the O O
recovery O O
of O O
myelopoiesis O O
following O O
high O O
- O O
dose O O
chemotherapy O O
in O O
cancer O O
patients O O
. O O

The O O
integrity O O
of O O
the O O
cDNA O O
sequence O O
was O O
confirmed O O
by O O
analysis O O
of O O
several O O
overlapping O O
genomic O O
clones O O
that O O
span O O
the O O
GAR0 B-GENE B-GENE
gene I-GENE I-GENE
. O O

Additionally O O
, O O
the O O
enzyme O O
shows O O
activity O O
towards O O
triglycerides O O
such O O
as O O
olive O O
oil O O
and O O
tributyrin O O
and O O
towards O O
egg O O
- O O
yolk O O
emulsions O O
. O O

A O O
new O O
non O O
- O O
LTR O O
retrotransposon O O
provides O O
evidence O O
for O O
multiple O O
distinct O O
site O O
- O O
specific O O
elements O O
in O O
Crithidia O O
fasciculata O O
miniexon O O
arrays O O
. O O

Structure O O
and O O
regulation O O
of O O
the O O
gene O O
encoding O O
the O O
neuron O B-GENE
- O I-GENE
specific O I-GENE
protein B-GENE I-GENE
kinase I-GENE I-GENE
C I-GENE I-GENE
substrate O I-GENE
neurogranin B-GENE I-GENE
( O O
RC0 B-GENE B-GENE
protein I-GENE I-GENE
) O O
. O O

Protein B-GENE O
cHMGI I-GENE O
binds O O
preferentially O O
to O O
AT O O
- O O
rich O O
DNA O O
with O O
a O O
half O O
- O O
saturation O O
value O O
of O O
0 O O
. O O
0 O O
nM O O
. O O

The O O
novel O O
Notch B-GENE O
homologue I-GENE O
mouse B-GENE O
Notch I-GENE O
0 I-GENE O
lacks O O
specific O O
epidermal B-GENE O
growth I-GENE O
factor I-GENE O
- I-GENE O
repeats I-GENE O
and O O
is O O
expressed O O
in O O
proliferating O O
neuroepithelium O O
. O O

Immunoreactive O O
AR B-GENE O
content O O
in O O
transfected O O
COS O O
- O O
0 O O
cells O O
was O O
not O O
influenced O O
by O O
exposure O O
to O O
0 O O
- O O
Br O O
- O O
cAMP O O
. O O

Internal O O
biliary O O
drainage O O
, O O
unlike O O
external O O
drainage O O
, O O
does O O
not O O
suppress O O
the O O
regeneration O O
of O O
cholestatic O O
rat O O
liver O O
after O O
partial O O
hepatectomy O O
. O O

These O O
RZR B-GENE O
subtypes O O
represent O O
members O O
of O O
a O O
new O O
family O O
of O O
orphan B-GENE O
nuclear I-GENE O
receptors I-GENE O
that O O
most O O
likely O O
regulate O O
specific O O
gene O O
expression O O
. O O

There O O
were O O
0 O O
patients O O
in O O
NYHA O O
class O O
III O O
and O O
0 O O
in O O
class O O
IV O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
000 O O
WORDS O O
) O O

A O O
recent O O
index O O
( O O
Fluorosis O O
Risk O O
Index O O
) O O
developed O O
by O O
Pendrys O O
( O O
0000 O O
) O O
is O O
also O O
included O O
in O O
this O O
review O O
. O O

Thus O O
, O O
YMIP B-GENE O
is O O
a O O
functional O O
homolog O O
of O O
RMIP B-GENE O
and O O
represents O O
a O O
new O O
component O O
of O O
the O O
yeast O O
mitochondrial O O
import O O
machinery O O
. O O

The O O
0 O O
- O O
day O O
treatment O O
resulted O O
in O O
a O O
decrease O O
in O O
mitochondrial O O
uptake O O
of O O
Rh000 O O
and O O
an O O
increase O O
in O O
NAO O O
uptake O O
. O O

Northern O O
( O O
RNA O O
) O O
analysis O O
demonstrated O O
expression O O
of O O
human O B-GENE
PI B-GENE I-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
in O O
all O O
tissues O O
and O O
cell O O
lines O O
tested O O
. O O

The O O
equivalent O O
of O O
the O O
third O O
ligand O O
, O O
H O O
- O O
00 O O
, O O
is O O
T O O
- O O
00 O O
in O O
the O O
PSTAIRE O O
sequence O O
motif O O
. O O

Identification O O
of O O
a O O
consensus O O
cyclin B-GENE O
- I-GENE O
dependent I-GENE O
kinase I-GENE O
phosphorylation I-GENE O
site I-GENE O
unique O O
to O O
the O O
nuclear O O
form O O
of O O
human B-GENE O
deoxyuridine I-GENE O
triphosphate I-GENE O
nucleotidohydrolase I-GENE O
. O O

In O O
the O O
SPK O O
and O O
PTA O O
category O O
, O O
anti O O
- O O
T O O
- O O
cell O O
therapy O O
significantly O O
lowered O O
the O O
risk O O
of O O
graft O O
loss O O
. O O

A O O
subset O O
of O O
these O O
DMP0 B-GENE O
recognition I-GENE O
sequences I-GENE O
containing O O
a O O
GGA O O
trinucleotide O O
core O O
can O O
also O O
function O O
as O O
Ets B-GENE O
- I-GENE O
responsive I-GENE O
elements I-GENE O
. O O

000 O O
and O O
000 O O
protocols O O
of O O
postmortem O O
examinations O O
from O O
Moscow O O
hospitals O O
N O O
00 O O
and O O
00 O O
, O O
respectively O O
, O O
were O O
evaluated O O
statistically O O
. O O

We O O
have O O
measured O O
the O O
MBF O O
on O O
incisors O O
and O O
its O O
direction O O
in O O
three O O
dimensions O O
for O O
different O O
jaw O O
openings O O
in O O
ten O O
subjects O O
. O O

Areas O O
with O O
significantly O O
greater O O
rCBF O O
for O O
targeting O O
were O O
the O O
left O O
motor O O
cortex O O
, O O
left O O
intraparietal O O
sulcus O O
, O O
and O O
left O O
caudate O O
. O O

An O O
aromatic O O
stacking O O
interaction O O
between O O
subunits O O
helps O O
mediate O O
DNA O O
sequence O O
specificity O O
: O O
operator O O
site O O
discrimination O O
by O O
phage B-GENE O
lambda I-GENE O
cI I-GENE O
repressor I-GENE O
. O O

The O O
AD O O
components O O
were O O
markedly O O
more O O
dependent O O
on O O
the O O
affective O O
state O O
of O O
the O O
rat O O
then O O
was O O
the O O
V0 O O
component O O
. O O

Circulating O O
platelets O O
may O O
be O O
activated O O
by O O
exposed O O
triple O O
- O O
helical O O
collagen B-GENE O
in O O
atherosclerotic O O
lesions O O
in O O
Mg O O
- O O
deficient O O
ruminants O O
. O O

Fluorometric O O
methods O O
can O O
also O O
provide O O
information O O
about O O
porphyrin O O
binding O O
sites O O
that O O
is O O
useful O O
in O O
understanding O O
porphyrin O O
transport O O
and O O
clearance O O
. O O

The O O
uncomplicated O O
cases O O
of O O
typhoid O O
fever O O
were O O
found O O
to O O
have O O
an O O
intact O O
CMIR O O
as O O
compared O O
to O O
the O O
complicated O O
cases O O
. O O

In O O
the O O
past O O
, O O
immunology O O
in O O
Singapore O O
was O O
mainly O O
confined O O
to O O
serology O O
for O O
the O O
diagnosis O O
of O O
certain O O
infectious O O
diseases O O
. O O

Results O O
of O O
the O O
recognition O O
task O O
revealed O O
significant O O
effects O O
of O O
consonant O O
voicing O O
, O O
position O O
and O O
vowel O O
context O O
on O O
syllable O O
recognition O O
. O O

Changes O O
in O O
immunologic O O
reactivity O O
in O O
subjects O O
receiving O O
transfer B-GENE O
factor I-GENE O
could O O
not O O
be O O
distinguished O O
from O O
those O O
in O O
subjects O O
receiving O O
placebo O O
. O O

Mechanism O O
of O O
enhancement O O
of O O
DNA O O
expression O O
consequent O O
to O O
cointernalization O O
of O O
a O O
replication O O
- O O
deficient O O
adenovirus O O
and O O
unmodified O O
plasmid O O
DNA O O
. O O

One O O
of O O
these O O
factors O O
, O O
HRF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
recognizes O O
a O O
cis O O
element O O
consisting O O
of O O
an O O
inverted O O
palindromic O O
motif O O
. O O

Regulation O O
of O O
Gax B-GENE B-GENE
homeobox B-GENE I-GENE
gene I-GENE I-GENE
transcription O O
by O O
a O O
combination O O
of O O
positive O O
factors O O
including O O
myocyte B-GENE B-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
enhancer I-GENE I-GENE
factor I-GENE I-GENE
0 I-GENE O
. O O

The O O
presence O O
of O O
the O O
RV O O
0 O O
' O O
( O O
+ O O
) O O
SL O O
sequence O O
had O O
the O O
primary O O
enhancing O O
effect O O
on O O
translation O O
. O O

The O O
Ng B-GENE B-GENE
/ I-GENE O
RC0 I-GENE O
and O O
PKC B-GENE B-GENE
- I-GENE I-GENE
gamma I-GENE I-GENE
genes I-GENE O
have O O
a O O
similar O O
expression O O
pattern O O
in O O
the O O
brain O O
during O O
development O O
. O O

Small B-GENE O
Maf I-GENE O
proteins I-GENE O
heterodimerize O O
with O O
Fos B-GENE O
and O O
may O O
act O O
as O O
competitive O O
repressors O O
of O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
E0 I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
. O O

ORF O O
0 O O
potentially O O
encoded O O
a O O
hydrophobic O O
protein O O
of O O
00 O O
, O O
000 O O
Da O O
with O O
six O O
potential O O
membrane O O
- O O
spanning O O
regions O O
. O O

Interestingly O O
, O O
these O O
response O O
elements O O
display O O
dramatically O O
reduced O O
affinity O O
for O O
retinoic B-GENE O
acid I-GENE O
receptor I-GENE O
- O O
retinoid B-GENE B-GENE
- I-GENE I-GENE
X I-GENE I-GENE
receptor I-GENE I-GENE
heterodimers O O
. O O

The O O
present O O
data O O
also O O
indicate O O
that O O
patients O O
with O O
TGBM O O
nephropathy O O
often O O
have O O
concomitant O O
IgA B-GENE O
nephropathy O O
and O O
mesangial O O
proliferative O O
glomerulonephritis O O
. O O

c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
transcriptional O O
activity O O
stimulated O O
by O O
H B-GENE B-GENE
- I-GENE I-GENE
Ras I-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
distinct O O
from O O
JNK B-GENE O
and O O
ERK B-GENE O
. O O

Fenoldopam O O
, O O
a O O
dopamine B-GENE O
receptor I-GENE O
agonist O O
, O O
has O O
been O O
shown O O
, O O
in O O
animal O O
experiments O O
, O O
to O O
improve O O
renal O O
perfusion O O
. O O

Thus O O
, O O
we O O
have O O
separated O O
the O O
signal O O
function O O
from O O
the O O
anchor O O
function O O
of O O
the O O
0 O O
. O O
0K O O
SA O O
domain O O
. O O

OBJECTIVE O O
: O O
Our O O
purpose O O
was O O
to O O
determine O O
the O O
simultaneous O O
concentrations O O
of O O
serum O O
cotinine O O
in O O
both O O
fetal O O
and O O
maternal O O
blood O O
. O O

Upstream O O
of O O
- O O
00 O O
, O O
the O O
0 O O
' O O
untranslated O O
sequences O O
of O O
the O O
isolates O O
differ O O
in O O
both O O
length O O
and O O
sequence O O
. O O

( O O
0000 O O
) O O
, O O
which O O
is O O
identical O O
to O O
the O O
SSC0 B-GENE B-GENE
gene I-GENE I-GENE
( O O
Smith O O
et O O
al O O
. O O
, O O
0000 O O
) O O
. O O

This O O
region O O
also O O
contains O O
a O O
gene O O
specifying O O
a O O
Leu B-GENE B-GENE
- I-GENE I-GENE
tRNA I-GENE I-GENE
precursor I-GENE I-GENE
and O O
a O O
remnant O O
of O O
a O O
tau O O
element O O
. O O

In O O
conclusion O O
, O O
IgM B-GENE O
class O O
CIC O O
is O O
the O O
predominant O O
CIC O O
in O O
acute O O
hepatitis O O
A O O
and O O
correlated O O
with O O
disease O O
activity O O
. O O

They O O
were O O
found O O
to O O
stimulate O O
at O O
nanomolar O O
concentrations O O
the O O
turnover O O
of O O
biosynthetically O O
labeled O O
ceramide O O
, O O
glucosylceramide O O
, O O
and O O
lactosylceramide O O
. O O

VDR B-GENE O
/ O O
RXR B-GENE O
bound O O
well O O
to O O
the O O
VDREs O O
and O O
to O O
DR0 O O
and O O
DR0 O O
using O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

Isolation O O
by O O
PCR O O
of O O
a O O
cDNA O O
clone O O
from O O
pea O O
petals O O
with O O
similarity O O
to O O
petunia O O
and O O
wheat B-GENE O
zinc I-GENE O
finger I-GENE O
proteins I-GENE O
. O O

Furthermore O O
, O O
we O O
have O O
identified O O
a O O
00 O O
- O O
bp O O
region O O
of O O
the O O
00p0 B-GENE B-GENE
promoter I-GENE I-GENE
required O O
for O O
the O O
Dex O O
responsiveness O O
. O O

Blood O O
GSH B-GENE O
- I-GENE O
Px I-GENE O
activity O O
was O O
measured O O
with O O
a O O
spectrophotometer O O
, O O
using O O
a O O
modification O O
of O O
a O O
previously O O
described O O
assay O O
. O O

The O O
cDNA O O
encoded O O
a O O
mature O O
protein O O
of O O
000 O O
amino O O
acids O O
, O O
including O O
a O O
00 O O
- O O
amino O O
acid O O
signal O O
sequence O O
. O O

The O O
effect O O
of O O
ligustrazine O O
hydrochloride O O
( O O
LTH O O
) O O
on O O
depressing O O
pulmonary O O
artery O O
hypertension O O
has O O
been O O
proved O O
in O O
recent O O
studies O O
. O O

Discrimination O O
between O O
HIV O O
- O O
0 O O
and O O
HIV O O
- O O
0 O O
showed O O
evidence O O
for O O
the O O
presence O O
of O O
HIV O B-GENE
- O I-GENE
0 O I-GENE
only O O
. O O

RESULTS O O
: O O
The O O
age O O
distribution O O
was O O
00 O O
to O O
00 O O
years O O
old O O
( O O
mean O O
was O O
00 O O
. O O
0 O O
years O O
) O O
. O O

Twenty O O
- O O
one O O
percent O O
of O O
these O O
patients O O
had O O
neurologic O O
disease O O
that O O
appeared O O
to O O
be O O
responsible O O
for O O
the O O
tinnitus O O
. O O

The O O
resulting O O
R B-GENE O
protein I-GENE O
terminates O O
five O O
codons O O
downstream O O
of O O
the O O
frameshift O O
site O O
at O O
the O O
V B-GENE O
protein I-GENE O
stop O O
codon O O
. O O

The O O
median O O
post O O
- O O
treatment O O
, O O
pre O B-GENE
- O I-GENE
operative O I-GENE
serum B-GENE I-GENE
PSA I-GENE I-GENE
was O O
0 O O
. O O
0 O O
ng O O
/ O O
ml O O
. O O

In O O
vivo O O
association O O
between O O
Shb B-GENE B-GENE
- O O
SH0 B-GENE O
domain O O
proteins O O
v B-GENE O
- I-GENE O
Src I-GENE O
and O O
Eps0 B-GENE O
was O O
detected O O
by O O
coimmunoprecipitation O O
. O O

Reverse B-GENE O
transcriptase I-GENE O
and O O
protease O O
activities O O
of O O
avian O O
leukosis O O
virus O O
Gag B-GENE O
- O O
Pol B-GENE O
fusion O O
proteins O O
expressed O O
in O O
insect O O
cells O O
. O O

Serial O O
followup O O
strength O O
data O O
for O O
0 O O
patients O O
were O O
compared O O
to O O
change O O
in O O
creatinine B-GENE O
kinase I-GENE O
( O O
CK B-GENE O
) O O
levels O O
. O O

A O O
secondary O O
phosphorylation O O
of O O
CREB000 B-GENE O
at O O
Ser000 O O
is O O
required O O
for O O
the O O
cAMP O O
- O O
mediated O O
control O O
of O O
gene O O
expression O O
. O O

Specific O O
binding O O
was O O
not O O
observed O O
with O O
either O O
the O O
orthologous O O
rat O O
or O O
mouse O O
fragments O O
using O O
human O O
or O O
rodent O O
extracts O O
. O O

These O O
observations O O
indicate O O
that O O
there O O
are O O
multiple O O
mechanisms O O
by O O
which O O
an O O
individual O O
transcript O O
can O O
be O O
degraded O O
following O O
deadenylation O O
. O O

Expression O O
of O O
a O O
dominant B-GENE O
- I-GENE O
negative I-GENE O
ras I-GENE O
gene I-GENE O
also O O
blocks O O
TIS00 B-GENE O
/ O O
PGS0 B-GENE O
induction O O
by O O
v B-GENE B-GENE
- I-GENE I-GENE
src I-GENE I-GENE
. O O

Upon O O
differentiation O O
with O O
retinoic O O
acid O O
( O O
RA O O
) O O
, O O
transcription O O
of O O
the O O
Rex B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
decreases O O
rapidly O O
. O O

The O O
sequence O O
similarity O O
has O O
suggested O O
that O O
SCG00 B-GENE O
and O O
stathmin B-GENE O
have O O
been O O
derived O O
from O O
structurally O O
and O O
evolutionarily O O
related O O
genes O O
. O O

Defects O O
of O O
fibrillin B-GENE B-GENE
( O O
FBN0 B-GENE O
) O O
, O O
a O O
glycoprotein O O
component O O
of O O
the O O
extracellular O O
microfibril O O
, O O
cause O O
Marfan O O
syndrome O O
. O O

It O O
also O O
suggests O O
that O O
there O O
is O O
another O O
pathway O O
which O O
can O O
activate O O
SWI0 B-GENE O
transcription O O
in O O
the O O
absence O O
of O O
SWI0 B-GENE O
. O O

I O O
report O O
here O O
that O O
induction O O
of O O
HSP00 B-GENE O
is O O
regulated O O
by O O
the O O
early O O
meiotic O O
IME0 B-GENE O
- O O
IME0 B-GENE O
transcriptional O O
cascade O O
. O O

Furthermore O O
, O O
we O O
have O O
identified O O
a O O
soluble O O
form O O
of O O
ERp00 B-GENE O
/ O O
GRP00 B-GENE O
by O O
Western O O
blotting O O
and O O
biosynthetic O O
labeling O O
. O O

Defects O O
in O O
the O O
Schizosaccharomyces O O
pombe O O
( O O
Sp O O
) O O
cell O O
cycle O O
- O O
controlling O O
genes O O
prevent O O
the O O
cell O O
cycle O O
progression O O
. O O

One O O
complex O O
containing O O
a O O
00 O O
D O O
protein O O
was O O
found O O
to O O
be O O
associated O O
specifically O O
with O O
transcriptionally O O
active O O
leukemia O O
cells O O
. O O

Genomic O O
DNA O O
hybridization O O
suggests O O
that O O
SpSHR0 B-GENE O
is O O
a O O
single O O
- O O
copy O O
gene O O
in O O
the O O
S O O
. O O
purpuratus O O
genome O O
. O O

In O O
rlf0 B-GENE O
mutants I-GENE O
, O O
telomeric O B-GENE
chromatin O I-GENE
is O O
perturbed O O
: O O
Telomeric O O
silencing O O
is O O
reduced O O
and O O
Rap0p B-GENE O
localization O O
is O O
altered O O
. O O

The O O
reduced O O
NO O O
production O O
in O O
these O O
cells O O
was O O
associated O O
with O O
low O O
levels O O
of O O
mRNA O O
of O O
inducible B-GENE O
NO I-GENE O
synthetase I-GENE O
. O O

Secretory B-GENE O
IgA I-GENE O
and O O
serum B-GENE O
immunoglobulins I-GENE O
as O O
indices O O
of O O
the O O
local O O
immunity O O
of O O
the O O
intestinal O O
mucosa O O
in O O
acute O O
leukemias O O

A O O
mutant O O
( O O
residues O O
0 O O
- O O
000 O O
) O O
showed O O
complete O O
Ca0 O O
+ O O
/ O O
CaM B-GENE O
- O O
dependent O O
activity O O
. O O

The O O
carboxyl O O
- O O
terminal O O
transactivation O O
domain O O
of O O
heat B-GENE B-GENE
shock I-GENE I-GENE
factor I-GENE I-GENE
0 I-GENE O
is O O
negatively O O
regulated O O
and O O
stress O O
responsive O O
. O O

Prostate B-GENE O
specific I-GENE O
antigen I-GENE O
shows O O
the O O
metastatic O O
cases O O
better O O
[ O O
correction O O
of O O
worse O O
] O O
than O O
prostatic B-GENE O
acid I-GENE O
phosphatase I-GENE O
. O O

Each O O
dietary O O
treatment O O
was O O
fed O O
to O O
six O O
pen O O
replicates O O
of O O
five O O
chicks O O
per O O
pen O O
for O O
00 O O
d O O
. O O

The O O
second O O
complex O O
, O O
when O O
purified O O
, O O
contained O O
four O O
protein O O
components O O
including O O
the O O
00 O O
- O O
kDa O O
protein O O
. O O

Simultaneous O O
, O O
bilateral O O
and O O
permanent O O
ventilation O O
with O O
a O O
diaphragm O O
pacing O O
in O O
childhood O O
: O O
the O O
implantation O O
technique O O
and O O
indications O O

One O O
of O O
these O O
elements O O
, O O
the O O
homeodomain B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
element I-GENE I-GENE
, O O
was O O
identified O O
to O O
mediate O O
negative O O
regulation O O
. O O

Release O O
of O O
this O O
selective O O
pressure O O
, O O
however O O
, O O
gave O O
way O O
to O O
homologous O O
resolution O O
of O O
the O O
cointegrate O O
structures O O
. O O

Instead O O
, O O
mRNA O O
of O O
0 O O
. O O
0 O O
and O O
0 O O
. O O
0 O O
kb O O
are O O
detected O O
in O O
varying O O
abundance O O
. O O

The O O
evaluation O O
was O O
performed O O
using O O
a O O
retrospective O O
study O O
design O O
with O O
newborn O O
blood O O
samples O O
from O O
three O O
screening O O
centres O O
. O O

Limited O O
role O O
for O O
PCR O O
- O O
based O O
diagnosis O O
of O O
Whipple O O
' O O
s O O
disease O O
from O O
peripheral O O
blood O O
mononuclear O O
cells O O
. O O

Previous O O
work O O
showed O O
that O O
repA B-GENE O
( O O
initiator O B-GENE
protein O I-GENE
) O O
expression O O
requires O O
tap B-GENE O
( O O
leader O O
peptide O O
) O O
translation O O
. O O

Glycemic O O
response O O
to O O
malted O O
, O O
popped O O
and O O
roller O O
dried O O
wheat O O
- O O
legume O O
based O O
foods O O
in O O
normal O O
subjects O O
. O O

The O O
role O O
of O O
DNA O O
rearrangement O O
and O O
alternative O O
RNA O O
processing O O
in O O
the O O
expression O O
of O O
immunoglobulin B-GENE B-GENE
delta I-GENE I-GENE
genes I-GENE I-GENE
. O O

Evoked O O
potential O O
and O O
single O O
unit O O
responses O O
to O O
olfactory O O
nerve O O
volleys O O
in O O
the O O
isolated O O
turtle O O
olfactory O O
bulb O O
. O O

Hepatitis B-GENE O
B I-GENE O
surface I-GENE O
antigen I-GENE O
was O O
detected O O
in O O
0 O O
patients O O
, O O
with O O
negative O O
hepatitis B-GENE O
C I-GENE O
virus I-GENE O
antibody I-GENE O
. O O

METHODS O O
: O O
rHb0 B-GENE O
. I-GENE O
0 I-GENE O
or O O
human B-GENE O
serum I-GENE O
albumin I-GENE O
was O O
administered O O
intravenously O O
to O O
fasting O O
male O O
volunteers O O
. O O

Staphylococcal B-GENE O
enterotoxin I-GENE O
A I-GENE O
involvement O O
in O O
the O O
illness O O
of O O
a O O
00 O O
- O O
month O O
- O O
old O O
burn O O
patient O O
. O O

The O O
RAT0 B-GENE B-GENE
gene I-GENE I-GENE
encodes O O
an O O
0000 O O
- O O
amino O O
acid O O
protein O O
without O O
similarity O O
to O O
other O O
known O O
proteins O O
. O O

Mutagenesis O O
of O O
IM0 B-GENE O
enhances O O
the O O
ability O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
to O O
activate O O
an O O
AP0 B-GENE O
bearing I-GENE O
promoter I-GENE O
. O O

Polymyxin O O
B O O
was O O
given O O
intravenously O O
for O O
0 O O
week O O
postburn O O
in O O
doses O O
designed O O
to O O
neutralize O O
circulating O O
endotoxemia O O
. O O

Xylose O O
- O O
and O O
arabinose O O
- O O
containing O O
polymers O O
were O O
better O O
digested O O
than O O
was O O
cellulose O O
for O O
both O O
breads O O
. O O

Certain O O
transcript O O
patterns O O
in O O
Epifagus O O
plastids O O
are O O
highly O O
complex O O
and O O
similar O O
to O O
those O O
of O O
tobacco O O
operons O O
. O O

This O O
approach O O
places O O
gHoxb B-GENE O
- I-GENE O
0 I-GENE O
into O O
the O O
normal O O
embryonic O O
spatiotemporal O O
context O O
in O O
which O O
lab O O
acts O O
. O O

Several O O
of O O
the O O
exon O O
boundaries O O
correspond O O
to O O
the O O
boundaries O O
of O O
functional O O
domains O O
in O O
the O O
p00 B-GENE B-GENE
protein I-GENE I-GENE
. O O

Moreover O O
, O O
the O O
same O O
mutations O O
alter O O
the O O
structure O O
of O O
junB B-GENE O
0 O O
' O O
flanking O O
DNA O O
within O O
chromatin O O
. O O

Both O O
groups O O
were O O
subjected O O
to O O
tests O O
of O O
delayed O O
hypersensitivity O O
with O O
Candidin B-GENE O
, O O
Trycophytin B-GENE O
and O O
Tuberculin B-GENE O
. O O

For O O
monocytes O O
, O O
as O O
measured O O
on O O
the O O
Hematrak O O
, O O
it O O
was O O
00 O O
. O O
0 O O
% O O
. O O

Survival O O
was O O
calculated O O
both O O
from O O
the O O
date O O
of O O
onset O O
and O O
from O O
the O O
date O O
of O O
diagnosis O O
. O O

With O O
Sair O O
and O O
So0 O O
, O O
mean O O
vital O O
capacity O O
was O O
reduced O O
by O O
00 O O
% O O
from O O
control O O
. O O

The O O
optimal O O
care O O
of O O
CHF O O
patient O O
includes O O
the O O
recognition O O
and O O
management O O
of O O
these O O
electrolyte O O
disturbances O O
. O O

EsaR B-GENE O
can O O
repress O O
its O O
own O O
expression O O
but O O
seems O O
not O O
to O O
regulate O O
the O O
expression O O
of O O
esaI B-GENE O
. O O

Staphylococcus O O
aureus O O
and O O
CNS O O
showed O O
high O O
or O O
moderate O O
resistance O O
rates O O
to O O
methicillin O O
( O O
DMPPC O O
) O O
. O O

The O O
roxithromycin O O
doses O O
that O O
were O O
chosen O O
for O O
these O O
studies O O
were O O
less O O
than O O
achievable O O
blood O O
levels O O
. O O

Between O O
the O O
subgroups O O
of O O
dementia O O
disorders O O
there O O
were O O
no O O
significant O O
differences O O
in O O
basal O O
cortisol O O
levels O O
. O O

The O O
mRNAs O O
of O O
the O O
GRF B-GENE B-GENE
genes I-GENE I-GENE
are O O
encoded O O
by O O
six O O
exons O O
interrupted O O
by O O
five O O
introns O O
. O O

The O O
mutant O O
allele O O
of O O
the O O
alpha B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
tubulin I-GENE I-GENE
gene I-GENE I-GENE
was O O
designated O O
tua0 B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

Genomic O O
DNA O O
clones O O
containing O O
the O O
T B-GENE O
- I-GENE O
cell I-GENE O
- I-GENE O
specific I-GENE O
human I-GENE O
MAL I-GENE I-GENE
gene I-GENE I-GENE
were O O
isolated O O
. O O

The O O
therapeutic O O
action O O
of O O
cyclosporin O O
A O O
( O O
Sandimmun O O
) O O
: O O
its O O
application O O
in O O
rheumatoid O O
arthritis O O
. O O

It O O
could O O
be O O
detected O O
exclusively O O
in O O
the O O
culture O O
medium O O
of O O
cDNA O O
- O O
transfected O O
COS O O
cells O O
. O O

The O O
transverse O O
relaxation O O
time O O
( O O
T0 O O
) O O
and O O
apparent O O
diffusion O O
coefficient O O
of O O
water O O
were O O
determined O O
. O O

The O O
other O O
transmembrane O O
regions O O
as O O
well O O
as O O
the O O
nucleoplasmic O O
domain O O
are O O
not O O
required O O
for O O
sorting O O
. O O

0 O O
micrograms O O
/ O O
l O O
was O O
detected O O
in O O
urine O O
from O O
some O O
non O O
- O O
occupationally O O
exposed O O
persons O O
. O O

Multiple O O
SWI0 B-GENE O
- O O
dependent O O
cis O O
- O O
acting O O
elements O O
control O O
SWI0 B-GENE O
transcription O O
through O O
the O O
cell O O
cycle O O
. O O

Occupational O O
exposure O O
to O O
hepatitis O O
B O O
virus O O
and O O
human O O
immunodeficiency O O
virus O O
: O O
a O O
comparative O O
risk O O
analysis O O
. O O

The O O
protein O O
folds O O
correctly O O
with O O
two O O
disulfide O O
bonds O O
and O O
a O O
free O O
thiol O O
group O O
at O O
Cys00 O O
. O O

Selective O O
translation O O
initiation O O
by O O
ribosome O O
jumping O O
in O O
adenovirus O O
- O O
infected O O
and O O
heat O O
- O O
shocked O O
cells O O
. O O

The O O
experience O O
of O O
the O O
lateral O O
rhinotomy O O
approach O O
in O O
transsphenoidal O O
surgery O O
of O O
acromegaly O O
has O O
been O O
favourable O O
. O O

Tonsillectomy O O
is O O
an O O
effective O O
means O O
of O O
prophylaxis O O
for O O
upper O O
respiratory O O
infection O O
in O O
habitual O O
angina O O
patients O O
. O O

However O O
, O O
an O O
intrinsic O O
DNA O O
- O O
binding O O
subunit O O
for O O
HiNF B-GENE O
- I-GENE O
D I-GENE O
was O O
not O O
identified O O
. O O

Parasitological O O
and O O
pathological O O
findings O O
in O O
capuchin O O
monkeys O O
infected O O
with O O
Schistosoma O O
japonicum O O
or O O
Schistosoma O O
mansoni O O
. O O

A O O
water O O
- O O
vapour O O
giga O O
- O O
maser O O
in O O
the O O
active O O
galaxy O O
TXFS0000 O O
- O O
000 O O
. O O

These O O
results O O
indicate O O
that O O
the O O
PCNA B-GENE B-GENE
gene I-GENE I-GENE
is O O
a O O
likely O O
target O O
gene O O
of O O
E0F B-GENE O
. O O

Of O O
these O O
carriers O O
000 O O
were O O
diagnosed O O
to O O
be O O
asymptomatic O O
clinically O O
, O O
biochemically O O
and O O
echographically O O
. O O

Muscle B-GENE O
GSH I-GENE O
- I-GENE O
Px I-GENE O
activity O O
after O O
prolonged O O
exercise O O
, O O
training O O
, O O
and O O
selenium O O
supplementation O O
. O O

A O O
role O O
for O O
glycogen B-GENE B-GENE
synthase I-GENE I-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
in O O
the O O
control O O
of O O
gene O O
expression O O
. O O

TcPO0 O O
measurement O O
appears O O
to O O
be O O
a O O
reliable O O
technique O O
that O O
can O O
influence O O
ischaemic O O
ulcer O O
management O O
. O O

Naval O O
personnel O O
who O O
exceed O O
standards O O
for O O
% O O
BF O O
can O O
be O O
separated O O
from O O
active O O
duty O O
. O O

An O O
infectious O O
origin O O
should O O
always O O
be O O
excluded O O
since O O
specific O O
etiologic O O
therapy O O
may O O
be O O
implemented O O
. O O

Diabetes O O
care O O
: O O
a O O
guideline O O
to O O
the O O
facilities O O
needed O O
to O O
support O O
internationally O O
endorsed O O
standards O O
. O O

Pseudomembranous O O
conjunctivitis O O
following O O
bone O O
marrow O O
transplantation O O
: O O
immunopathological O O
and O O
ultrastructural O O
study O O
of O O
one O O
case O O
. O O

The O O
structure O O
of O O
these O O
genes O O
suggests O O
a O O
common O O
ancestor O O
for O O
all O O
viperid B-GENE O
PLA0 I-GENE O
genes I-GENE O
. O O

The O O
ewes O O
were O O
returned O O
to O O
normoxia O O
, O O
and O O
monitoring O O
was O O
continued O O
for O O
0 O O
h O O
. O O

These O O
changes O O
in O O
virus O O
entry O O
features O O
may O O
result O O
in O O
coronaviruses O O
with O O
novel O O
pathogenic O O
properties O O
. O O

Implication O O
of O O
PAF B-GENE B-GENE
and O O
acetylhydrolase B-GENE B-GENE
( O O
PAF B-GENE B-GENE
- I-GENE I-GENE
AH I-GENE I-GENE
) O O
activity O O
in O O
periodontal O O
disease O O
. O O

Similar O O
observations O O
were O O
made O O
with O O
unilateral O O
pneumothorax O O
of O O
00 O O
cmH0O O O
for O O
00 O O
min O O
. O O

Specific O O
IgE B-GENE O
levels O O
decreased O O
slightly O O
, O O
but O O
always O O
remained O O
within O O
the O O
pathological O O
range O O
. O O

Electron O O
microscopic O O
picture O O
of O O
the O O
cerebral O O
cortex O O
in O O
rats O O
cooled O O
to O O
00 O O
degrees O O
C O O

Prevention O O
of O O
transfusion O O
reactions O O
by O O
the O O
use O O
of O O
saline O O
washed O O
red O O
blood O O
cells O O
. O O

Weak O O
allergenicity O O
of O O
recombinant B-GENE O
hirudin I-GENE O
CGP I-GENE O
00000 I-GENE O
( O O
REVASC O O
) O O
in O O
immunocompetent O O
volunteers O O
. O O

Expression O O
of O O
the O O
dibasic O O
proprotein O O
processing O O
enzyme O O
furin B-GENE O
is O O
directed O O
by O O
multiple O O
promoters O O
. O O

These O O
lesions O O
were O O
asymptomatic O O
, O O
but O O
both O O
were O O
characterized O O
clinically O O
by O O
central O O
ulceration O O
. O O

The O O
Functional O O
Independence O O
Measure O O
: O O
a O O
comparative O O
study O O
of O O
clinician O O
and O O
self O O
ratings O O
. O O

There O O
are O O
, O O
however O O
, O O
several O O
differences O O
between O O
the O O
two O O
new O O
ars O O
sequences O O
. O O

A O O
developmentally O O
modulated O O
chromatin O O
structure O O
at O O
the O O
mouse B-GENE O
immunoglobulin I-GENE O
kappa I-GENE O
0 I-GENE O
' I-GENE O
enhancer I-GENE O
. O O

The O O
total O O
number O O
of O O
specimens O O
was O O
000 O O
with O O
00 O O
nonsmokers O O
and O O
00 O O
smokers O O
. O O

Three O O
women O O
have O O
had O O
abnormal O O
endocervical O O
follow O O
up O O
cytology O O
suggestive O O
of O O
residual O O
disease O O
. O O

Overexpression O O
of O O
wild B-GENE O
- I-GENE O
type I-GENE O
p00 I-GENE O
also O O
induces O O
apoptosis O O
in O O
an O O
LCL O O
. O O

A O O
new O O
vector O O
, O O
pHBK000 O O
, O O
was O O
designed O O
to O O
facilitate O O
this O O
analysis O O
. O O

Chrispeels O O
[ O O
0000 O O
] O O
EMBO O O
J O O
00 O O
: O O
0000 O O
- O O
0000 O O
) O O
. O O

The O O
p00 B-GENE B-GENE
- O O
depleted O O
nuclei O O
remained O O
largely O O
competent O O
for O O
nuclear O O
protein O O
import O O
. O O

Calcification O O
of O O
a O O
cariogenic O O
Streptococcus O O
and O O
of O O
Corynebacterium O O
( O O
Bacterionema O O
) O O
matruchotii O O
. O O

Eight O O
cats O O
infected O O
with O O
H O O
. O O
pylori O O
were O O
used O O
in O O
the O O
study O O
. O O

Using O O
anchored O O
PCR O O
, O O
a O O
VL B-GENE O
element I-GENE O
rearranged O O
to O O
CL0 B-GENE O
was O O
isolated O O
. O O

The O O
effect O O
of O O
six O O
arginine O O
mutations O O
of O O
oxidative O O
phosphorylation O O
and O O
AAC B-GENE O
expression O O
. O O

Serotonin O O
concentration O O
in O O
the O O
blood O O
of O O
patients O O
with O O
hemorrhagic O O
fever O O
with O O
renal O O
syndrome O O

Clinically O O
meaningful O O
decreases O O
due O O
to O O
alkalinization O O
alone O O
within O O
00 O O
minutes O O
are O O
unlikely O O
. O O

This O O
site O O
is O O
upstream O O
from O O
the O O
TATA O O
box O O
used O O
in O O
somatic O O
cells O O
. O O

HBB O O
concentration O O
in O O
the O O
fetuses O O
indicated O O
little O O
, O O
if O O
any O O
accumulation O O
. O O

Detection O O
of O O
exercise O O
- O O
induced O O
asynergy O O
by O O
M O O
- O O
mode O O
echocardiography O O
. O O

Differential O O
sensitivity O O
of O O
the O O
MMPI O B-GENE
- O I-GENE
0 O I-GENE
depression O I-GENE
scales O I-GENE
and O O
subscales O O
. O O

Negative O O
- O O
staining O O
, O O
refractile O O
mycobacteria O O
in O O
Romanowsky O O
- O O
stained O O
smears O O
. O O

However O O
, O O
the O O
relative O O
binding O O
affinity O O
for O O
the O O
motifs O O
is O O
different O O
. O O

L O O
. O O
, O O
Greer O O
, O O
J O O
. O O
& O O
Carter O O
, O O
G O O
. O O

The O O
mutations O O
did O O
not O O
affect O O
the O O
repression O O
of O O
CPA0 B-GENE O
by O O
arginine O O
. O O

Exposure O O
to O O
higher O O
TPA O O
concentrations O O
decreased O O
the O O
content O O
of O O
these O O
transcripts O O
. O O

Effects O O
of O O
repeated O O
exposures O O
of O O
hydrogen O O
sulphide O O
on O O
rat O O
hippocampal O O
EEG O O
. O O

SETTING O O
- O O
- O O
Delhi O O
, O O
urban O O
India O O
, O O
0000 O O
- O O
0 O O
. O O

Aggravating O O
process O O
induced O O
by O O
indomethacin O O
on O O
chronic O O
gastric O O
lesion O O
in O O
rat O O
. O O

There O O
are O O
four O O
polyglutamine O O
motifs O O
interspersed O O
with O O
histidine O O
- O O
rich O O
regions O O
. O O

Effect O O
of O O
Azadirachta O O
indica O O
hydroalcoholic O O
leaf O O
extract O O
on O O
the O O
cardiovascular O O
system O O
. O O

A O O
note O O
on O O
some O O
consequences O O
of O O
UV O O
vision O O
in O O
birds O O
. O O

The O O
alpha O B-GENE
- O I-GENE
subunit O I-GENE
by O O
itself O O
binds O O
to O O
telomeric O O
DNA O O
. O O

Cdk0 B-GENE O
formed O O
a O O
complex O O
with O O
cyclin B-GENE O
D0 I-GENE O
in O O
this O O
system O O
. O O

Several O O
artifacts O O
occurred O O
that O O
interfered O O
with O O
visualization O O
of O O
the O O
diaphragm O O
. O O

Control O O
examination O O
was O O
performed O O
at O O
the O O
end O O
of O O
each O O
period O O
. O O

Correlation O O
between O O
intraocular O O
involvement O O
and O O
systemic O O
outcome O O
was O O
poor O O
. O O

Vibrio O O
fluvialis O O
( O O
group O O
F O O
vibrio O O
) O O
in O O
Maharashtra O O
. O O

Autoradiographic O O
localisation O O
of O O
its O O
cellular O O
distribution O O
in O O
the O O
kidney O O
. O O

Imaging O O
features O O
of O O
splenic O O
epidermoid O O
cyst O O
with O O
pathologic O O
correlation O O
. O O

Increase O O
in O O
urinary O O
calcium O O
and O O
oxalate O O
after O O
fructose O O
infusion O O
. O O

Ketamine O O
in O O
the O O
treatment O O
of O O
bronchospasm O O
during O O
mechanical O O
ventilation O O
. O O

00 O O
kDa O O
and O O
000 O O
- O O
000 O O
kDa O O
were O O
detected O O
. O O

A O O
Dictyostelium O O
transformant O O
overexpressing O O
DdPTPa B-GENE O
does O O
not O O
develop O O
normally O O
. O O

SvO0 O O
can O O
be O O
determined O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Sequence O O
analysis O O
and O O
identification O O
of O O
two O O
hyp B-GENE O
regulatory I-GENE O
mutants I-GENE O
. O O

Stylohyoid O O
chain O O
ossification O O
: O O
choice O O
of O O
the O O
surgical O O
approach O O
. O O

Possible O O
relationship O O
between O O
hyperinsulinemia O O
and O O
glomerular O O
hypertrophy O O
in O O
nephrosclerosis O O
. O O

Rifabutin O O
has O O
substantial O O
efficacy O O
when O O
combined O O
with O O
other O O
agents O O
. O O

Pilot O O
study O O
of O O
blood O O
coagulation O O
in O O
gout O O
patients O O
. O O

TEMTU O O
and O O
DPTU O O
were O O
the O O
most O O
potent O O
teratogens O O
. O O

Diagnosis O O
of O O
phenylalanine B-GENE O
hydroxylase I-GENE O
deficiency O O
( O O
phenylketonuria O O
) O O
. O O

A O O
unified O O
approach O O
to O O
the O O
standardization O O
of O O
allergens O O
. O O

Current O O
status O O
of O O
chemotherapy O O
for O O
Hodgkin O O
' O O
s O O
disease O O

000 O O
more O O
than O O
in O O
the O O
summer O O
coat O O
) O O
. O O

The O O
plant O O
hormone O I-GENE
auxin O I-GENE
transcriptionally O I-GENE
activates O I-GENE
early B-GENE O
genes I-GENE O
. O O

Experimental O O
adhesion O O
prophylaxis O O
with O O
recombinant B-GENE O
tissue I-GENE O
plasminogen I-GENE O
activator I-GENE O
. O O

Botulinum B-GENE O
toxin I-GENE O
: O O
preferred O O
treatment O O
for O O
hemifacial O O
spasm O O
. O O

All O O
three O O
NR B-GENE O
isoforms I-GENE O
are O O
expressed O O
in O O
cv O O
. O O

All O O
three O O
NR B-GENE O
isoforms O O
are O O
expressed O O
in O O
cv O O
. O O

Unaided O O
attempts O O
to O O
quit O O
smoking O O
are O O
generally O O
unsuccessful O O
. O O

Serotonin B-GENE O
receptors I-GENE O
in O O
suicide O O
victims O O
with O O
major O O
depression O O
. O O

The O O
hyperacute O O
phase O O
of O O
posterolateral O O
myocardial O O
infarction O O
. O O

The O O
" O O
cracked O O
- O O
tooth O O
" O O
syndrome O O
. O O

Two O O
new O O
artifacts O O
in O O
automated O O
coagulation O O
testing O O
. O O

Thrombotic O O
thrombocytopenic O O
purpura O O
in O O
systemic O O
lupus O O
erythematosus O O
. O O

Efficacy O O
of O O
cervical O O
spine O O
immobilization O O
methods O O
. O O

Modification O O
of O O
enteral O O
resorption O O
by O O
cytostatic O O
therapy O O

Retinal O O
changes O O
in O O
pigmentary O O
retinopathy O O
in O O
children O O

Microscopic O O
anatomy O O
and O O
cell O O
population O O
dynamics O O
. O O

000 O O
, O O
0000 O O
- O O
0000 O O
) O O
. O O

Cycles O O
were O O
repeated O O
every O O
0 O O
weeks O O
. O O

Merlie O O
, O O
Cold O O
Spring O O
Harbor O O
Symp O O
. O O

Analysis O O
of O O
an O O
autopsy O O
population O O
. O O

Histopathological O O
features O O
of O O
relapsed O O
leprosy O O
. O O

Veterinary O O
certification O O
for O O
livestock O O
export O O
. O O

Marine O O
oils O O
and O O
cardiovascular O O
reactivity O O
. O O

The O O
newly O O
recognised O O
skeletogenital O O
syndrome O O
. O O

Mitochondrial B-GENE O
Mas00p I-GENE O
signal I-GENE O
anchor I-GENE O
sequence I-GENE O
. O O

Bullous O O
angiolymphoid O O
hyperplasia O O
with O O
eosinophilia O O

Charcoal O O
- O O
facilitated O O
dialysis O O
. O O

The O O
Babcock O O
Surgical O O
Clinic O O
. O O

( O O
0000 O O
) O O
J O O
. O O

BSE O O
and O O
farmworkers O O
. O O

Joys O O
and O O
F O O
. O O

Otte O O
, O O
Mol O O
. O O

The O O
electrocardiogram O O
. O O

0 O O
. O O

0 O O
. O O

0 O O
. O O

Biol O O
. O O

Biol O O
. O O

Umweltchem O O
. O O

Biol O O
. O O

Physiol O O
. O O

RESULTS O O
: O O
Factors O O
associated O O
with O O
significantly O O
( O O
P O O
< O O
. O O
00 O O
) O O
increased O O
risk O O
of O O
treatment O O
failure O O
in O O
a O O
Cox O O
multivariate O O
analysis O O
included O O
age O O
older O O
than O O
00 O O
years O O
( O O
relative O O
hazard O O
, O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
, O O
Karnofsky O O
performance O O
score O O
less O O
than O O
00 O O
% O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
, O O
absence O O
of O O
hormone O O
receptors O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
, O O
prior O O
use O O
of O O
adjuvant O O
chemotherapy O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
, O O
initial O O
disease O O
- O O
free O O
survival O O
interval O O
after O O
adjuvant O O
treatment O O
of O O
no O O
more O O
than O O
00 O O
months O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
, O O
metastases O O
in O O
the O O
liver O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
or O O
central O O
nervous O O
system O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
[ O O
approaches O O
significance O O
] O O
) O O
vs O O
soft O O
tissue O O
, O O
bone O O
, O O
or O O
lung O O
, O O
0 O O
or O O
more O O
sites O O
of O O
metastatic O O
disease O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
, O O
and O O
incomplete O O
response O O
vs O O
complete O O
response O O
to O O
standard O O
- O O
dose O O
chemotherapy O O
( O O
0 O O
. O O
00 O O
; O O
00 O O
% O O
CI O O
, O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
) O O
. O O

Wild B-GENE O
- I-GENE O
type I-GENE O
AT0A I-GENE O
receptors I-GENE O
, O O
expressed O O
in O O
Chinese O O
hamster O O
ovary O O
cells O O
, O O
rapidly O O
internalized O O
after O O
Ang B-GENE O
II I-GENE O
stimulation O O
[ O O
t0 O O
/ O O
0 O O
0 O O
. O O
0 O O
min O O
; O O
maximal O O
level O O
of O O
internalization O O
( O O
Ymax O O
) O O
00 O O
. O O
0 O O
% O O
] O O
, O O
as O O
did O O
mutant O O
receptors O O
carrying O O
single O O
acidic O O
substitutions O O
( O O
T000E O O
, O O
t0 O O
/ O O
0 O O
0 O O
. O O
0 O O
min O O
, O O
Ymax O O
00 O O
. O O
0 O O
% O O
; O O
S000D O O
, O O
t0 O O
/ O O
0 O O
0 O O
. O O
0 O O
min O O
, O O
Ymax O O
00 O O
. O O
0 O O
% O O
; O O
T000E O O
, O O
t0 O O
/ O O
0 O O
0 O O
. O O
0 O O
min O O
, O O
Ymax O O
00 O O
. O O
0 O O
% O O
; O O
S000D O O
, O O
t0 O O
/ O O
0 O O
0 O O
. O O
0 O O
min O O
, O O
Ymax O O
00 O O
. O O
0 O O
% O O
) O O
. O O

In O O
the O O
clinical O O
study O O
, O O
the O O
defect O O
size O O
shown O O
by O O
BMIPP O O
imaging O O
was O O
greater O O
in O O
anterior O O
than O O
in O O
inferior O O
infarcts O O
( O O
p O O
< O O
0 O O
. O O
000 O O
) O O
and O O
correlated O O
well O O
with O O
the O O
risk O O
area O O
revealed O O
by O O
contrast O O
ventriculography O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
p O O
< O O
0 O O
. O O
0000 O O
) O O
CONCLUSION O O
: O O
The O O
above O O
preliminary O O
data O O
, O O
admittedly O O
from O O
a O O
small O O
group O O
of O O
patients O O
, O O
suggest O O
that O O
tomographic O O
BMIPP O O
imaging O O
provides O O
an O O
accurate O O
quantification O O
of O O
defect O O
size O O
by O O
means O O
of O O
a O O
simple O O
threshold O O
technique O O
and O O
, O O
in O O
the O O
subacute O O
phase O O
, O O
permits O O
determination O O
of O O
the O O
amount O O
of O O
myocardium O O
at O O
risk O O
after O O
acute O O
myocardial O O
infarction O O
. O O

In O O
conclusion O O
: O O
( O O
i O O
) O O
TECRA O O
kit O O
is O O
suggested O O
to O O
be O O
used O O
for O O
screening O O
SE O O
producing O O
strains O O
; O O
( O O
ii O O
) O O
SET O O
- O O
RPLA O O
and O O
RIDASCREEN O O
kits O O
are O O
suitable O O
for O O
epidemiological O O
investigation O O
of O O
SE O O
types O O
, O O
but O O
the O O
lack O O
of O O
ability O O
for O O
detecting O O
SEE O O
, O O
long O O
time O O
required O O
for O O
testing O O
with O O
SET O O
- O O
RPLA O O
kit O O
and O O
high O O
background O O
when O O
using O O
RIDASCREEN O O
kit O O
must O O
be O O
overcome O O
; O O
and O O
( O O
iii O O
) O O
because O O
of O O
the O O
complicated O O
test O O
procedures O O
and O O
the O O
lack O O
of O O
ability O O
for O O
detecting O O
SEE O O
, O O
the O O
practicality O O
of O O
SET O O
- O O
EIA O O
kit O O
in O O
screening O O
and O O
epidemiological O O
research O O
purposes O O
is O O
low O O
. O O

Topics O O
reviewed O O
here O O
include O O
: O O
data O O
supporting O O
the O O
association O O
of O O
myositis O O
with O O
cancer O O
and O O
the O O
appropriate O O
evaluations O O
for O O
malignancy O O
in O O
a O O
myositis O O
patient O O
; O O
an O O
approach O O
to O O
the O O
assessment O O
of O O
patients O O
with O O
dermatomyositis O O
sine O O
myositis O O
; O O
the O O
usefulness O O
of O O
the O O
clinicopathological O O
and O O
serological O O
classifications O O
; O O
a O O
discussion O O
of O O
whether O O
childhood O O
and O O
adult O O
myositis O O
are O O
the O O
same O O
or O O
different O O
entities O O
; O O
a O O
review O O
of O O
those O O
prognostic O O
factors O O
to O O
consider O O
in O O
the O O
clinical O O
management O O
of O O
myositis O O
patients O O
; O O
current O O
approaches O O
and O O
their O O
limitations O O
for O O
assessing O O
disease O O
activity O O
and O O
damage O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
Lung O O
elastance O O
( O O
EL O O
) O O
and O O
resistance O O
( O O
RL O O
) O O
were O O
calculated O O
from O O
measurements O O
of O O
airway O O
pressure O O
, O O
esophageal O O
pressure O O
, O O
and O O
airway O O
flow O O
in O O
five O O
anesthetized O O
, O O
paralyzed O O
dogs O O
during O O
sinusoidal O O
forcing O O
at O O
a O O
constant O O
mean O O
airway O O
pressure O O
of O O
00 O O
cmH0O O O
in O O
a O O
wide O O
range O O
of O O
breathing O O
frequencies O O
( O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
Hz O O
in O O
intervals O O
of O O
0 O O
. O O
0 O O
) O O
and O O
tidal O O
volumes O O
( O O
00 O O
, O O
000 O O
, O O
000 O O
, O O
and O O
to O O
000 O O
mL O O
) O O
. O O

The O O
recovery O O
rates O O
for O O
the O O
MB O O
/ O O
BacT O O
, O O
MGIT O O
000 O O
, O O
and O O
solid O O
media O O
were O O
00 O O
. O O
0 O O
, O O
00 O O
. O O
0 O O
, O O
and O O
00 O O
. O O
0 O O
% O O
, O O
respectively O O
, O O
for O O
all O O
mycobacteria O O
; O O
the O O
recovery O O
rates O O
were O O
00 O O
. O O
0 O O
, O O
00 O O
. O O
0 O O
, O O
and O O
00 O O
. O O
0 O O
% O O
, O O
respectively O O
, O O
for O O
M O O
. O O
tuberculosis O O
complex O O
alone O O
, O O
and O O
00 O O
. O O
0 O O
, O O
00 O O
. O O
0 O O
, O O
and O O
00 O O
. O O
0 O O
% O O
, O O
respectively O O
, O O
for O O
all O O
nontuberculous O O
mycobacteria O O
. O O

In O O
canrenoate O O
- O O
treated O O
rats O O
, O O
ANP B-GENE O
infusion O O
caused O O
greater O O
increases O O
in O O
sodium O O
excretion O O
( O O
FENA O O
from O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
% O O
; O O
P O O
< O O
0 O O
. O O
00 O O
; O O
n O O
= O O
0 O O
) O O
than O O
saline O O
infusion O O
( O O
FENA O O
from O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
% O O
; O O
n O O
= O O
0 O O
) O O
, O O
despite O O
the O O
hypocapnia O O
. O O

CONCLUSIONS O O
: O O
XCoe0 B-GENE O
may O O
play O O
a O O
pivotal O O
role O O
in O O
the O O
transcriptional O O
cascade O O
that O O
specifies O O
primary O O
neurons O O
in O O
Xenopus O O
embryos O O
: O O
by O O
maintaining O O
Delta B-GENE O
- O O
Notch B-GENE O
signalling O O
, O O
XCoe0 B-GENE O
stabilises O O
the O O
higher O O
neural O O
potential O O
of O O
selected O O
progenitor O O
cells O O
that O O
express O O
X B-GENE B-GENE
- I-GENE I-GENE
ngnr I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
ensuring O O
the O O
transition O O
between O O
neural O O
competence O O
and O O
irreversible O O
commitment O O
to O O
a O O
neural O O
fate O O
; O O
and O O
it O O
promotes O O
neuronal O O
differentiation O O
by O O
activating O O
XNeuroD B-GENE O
expression O O
, O O
directly O O
or O O
indirectly O O
. O O

RESULTS O O
: O O
Patients O O
in O O
Group O O
A O O
had O O
a O O
higher O O
incidence O O
of O O
posterolateral O O
wall O O
motion O O
abnormalities O O
( O O
p O O
< O O
0 O O
. O O
000 O O
) O O
on O O
radionuclide O O
ventriculography O O
, O O
a O O
larger O O
infarct O O
area O O
( O O
as O O
evidenced O O
by O O
higher O O
peak O O
creatine B-GENE O
kinase I-GENE O
levels O O
) O O
( O O
p O O
< O O
0 O O
. O O
00 O O
) O O
and O O
a O O
lower O O
left O O
ventricular O O
ejection O O
fraction O O
( O O
LVEF O O
) O O
at O O
hospital O O
discharge O O
( O O
p O O
< O O
0 O O
. O O
000 O O
) O O
than O O
those O O
in O O
Group O O
B O O
. O O

CONCLUSION O O
: O O
Our O O
study O O
shows O O
that O O
( O O
0 O O
) O O
total O O
body O O
BMD O O
and O O
femoral O O
neck O O
BMD O O
were O O
significantly O O
higher O O
in O O
the O O
study O O
group O O
that O O
performed O O
weight O O
- O O
bearing O O
exercises O O
than O O
in O O
control O O
subjects O O
, O O
( O O
0 O O
) O O
swimming O O
exercise O O
had O O
no O O
effect O O
on O O
BMD O O
, O O
and O O
( O O
0 O O
) O O
although O O
swimming O O
is O O
not O O
a O O
bone O O
- O O
building O O
exercise O O
, O O
it O O
can O O
significantly O O
improve O O
shoulder O O
, O O
back O O
, O O
and O O
grip O O
muscle O O
strength O O
. O O

D0 B-GENE O
/ I-GENE O
D0 I-GENE O
( I-GENE O
CT I-GENE O
) I-GENE O
or O O
D0 B-GENE O
/ I-GENE O
D0D I-GENE O
( I-GENE O
CT I-GENE O
) I-GENE O
tail O O
substitution O O
mutants O O
displayed O O
a O O
rank O O
order O O
of O O
potency O O
and O O
agonist O O
affinities O O
virtually O O
mimicking O O
wild B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
( I-GENE O
wt I-GENE O
) I-GENE O
D0 I-GENE O
receptors I-GENE O
, O O
as O O
indexed O O
by O O
both O O
ligand O O
binding O O
and O O
dopamine O O
- O O
stimulated O O
cAMP O O
accumulation O O
assays O O
, O O
and O O
, O O
similar O O
to O O
wt O O
D0 B-GENE O
receptors I-GENE O
, O O
did O O
not O O
exhibit O O
receptor O O
constitutive O O
activity O O
or O O
responsiveness O O
to O O
inverse O O
agonists O O
. O O

Two O O
- O O
dimensional O O
gel O O
electrophoresis O O
of O O
anti B-GENE B-GENE
- I-GENE O
p00fyn I-GENE O
immunoprecipitates O O
obtained O O
from O O
non O O
- O O
transformed O O
resting O O
human O O
T O O
lymphocytes O O
resulted O O
in O O
the O O
identification O O
of O O
an O O
oligomeric O O
protein O O
complex O O
which O O
is O O
constitutively O O
formed O O
between O O
Fyn B-GENE O
and O O
several O O
additional O O
phosphoproteins O O
( O O
pp00 B-GENE B-GENE
, O O
pp00 B-GENE B-GENE
, O O
pp00 B-GENE B-GENE
, O O
the O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase I-GENE I-GENE
Pyk0 B-GENE O
, O O
as O O
well O O
as O O
the O O
two O O
recently O O
cloned O O
adaptor O O
proteins O O
, O O
SKAP00 B-GENE O
and O O
SLAP B-GENE B-GENE
- I-GENE I-GENE
000 I-GENE I-GENE
) O O
. O O

Furthermore O O
, O O
deletion O O
and O O
mutation O O
analyses O O
of O O
the O O
VCAM B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter I-GENE I-GENE
performed O O
with O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
constructs I-GENE O
revealed O O
that O O
Tax B-GENE O
was O O
trans O O
activating O O
the O O
VCAM B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter I-GENE I-GENE
via O O
two O O
NF B-GENE O
- I-GENE O
kappaB I-GENE O
sites I-GENE O
present O O
at O O
bp O O
- O O
00 O O
and O O
- O O
00 O O
in O O
the O O
VCAM B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
promoter I-GENE O
, O O
with O O
both O O
of O O
them O O
being O O
required O O
for O O
the O O
Tax B-GENE O
- O O
induced O O
expression O O
of O O
this O O
adhesion O O
molecule O O
. O O

Experiments O O
on O O
narcotized O O
cats O O
demonstrated O O
that O O
the O O
derivatives O O
of O O
0 O O
- O O
mercaptobenzimidazole O O
possessing O O
the O O
properties O O
of O O
specific O O
bradycardic O O
agents O O
and O O
coded O O
as O O
CM O O
- O O
000 O O
, O O
CM O O
- O O
000 O O
, O O
and O O
CM O O
- O O
000 O O
, O O
reduce O O
the O O
mean O O
rise O O
of O O
segment O O
ST O O
on O O
numerous O O
leads O O
of O O
the O O
epicardial O O
electrogram O O
during O O
0 O O
- O O
min O O
occlusion O O
of O O
the O O
anterior O O
descending O O
branch O O
of O O
the O O
left O O
coronary O O
artery O O
. O O

The O O
major O O
transcription O O
factors O O
controlling O O
arginine O O
metabolism O O
in O O
Escherichia O O
coli O O
and O O
Bacillus O O
subtilis O O
, O O
ArgR B-GENE O
and O O
AhrC B-GENE B-GENE
, O O
respectively O O
, O O
are O O
homologous O O
multimeric O O
proteins O O
that O O
form O O
l O O
- O O
arginine O O
- O O
dependent O O
DNA O O
- O O
binding O O
complexes O O
capable O O
of O O
repressing O O
transcription O O
of O O
the O O
biosynthetic O B-GENE
genes O I-GENE
( O O
both O O
) O O
, O O
activating O O
transcription O O
of O O
catabolic O B-GENE
genes O I-GENE
( O O
AhrC B-GENE O
only O O
) O O
or O O
facilitating O O
plasmid O O
dimer O O
resolution O O
( O O
both O O
) O O
. O O

Significantly O O
, O O
two O O
proximal O O
GATA B-GENE O
- I-GENE O
0 I-GENE O
- I-GENE O
binding I-GENE O
sites I-GENE O
( O O
- O O
000 O O
/ O O
- O O
000 O O
and O O
- O O
00 O O
/ O O
- O O
00 O O
) O O
and O O
a O O
region O O
located O O
within O O
- O O
000 O O
to O O
- O O
000bp O O
of O O
the O O
mouse B-GENE B-GENE
ALAS0 I-GENE I-GENE
promoter I-GENE I-GENE
were O O
essential O O
for O O
transcriptional O O
activation O O
during O O
chemically O O
induced O O
differentiation O O
of O O
MEL O O
cells O O
, O O
implying O O
their O O
importance O O
in O O
conferring O O
erythroid O O
specificity O O
to O O
the O O
ALAS0 B-GENE O
transcriptional O O
activation O O
. O O

These O O
results O O
suggest O O
that O O
UBP00 B-GENE O
may O O
play O O
an O O
important O O
role O O
in O O
the O O
recycling O O
of O O
ubiquitin B-GENE O
by O O
hydrolysis O O
of O O
branched B-GENE O
poly I-GENE O
- I-GENE O
ubiquitin I-GENE O
chains I-GENE O
generated O O
by O O
the O O
action O O
of O O
00 B-GENE O
S I-GENE O
proteasome I-GENE O
on O O
poly O O
- O O
ubiquitinated O O
protein O O
substrates O O
, O O
as O O
well O O
as O O
in O O
the O O
production O O
of O O
free O O
ubiquitin B-GENE O
from O O
linear B-GENE O
poly I-GENE O
- I-GENE O
ubiquitin I-GENE O
chains I-GENE O
and O O
of O O
certain O O
ribosomal O O
proteins O O
from O O
ubiquitin B-GENE O
fusion I-GENE O
proteins I-GENE O
. O O

A O O
reciprocal O O
binding O O
assay O O
using O O
IM O B-GENE
- O I-GENE
0 O I-GENE
cells O O
as O O
a O O
source O O
of O O
SHP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
SHP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
revealed O O
specific O O
association O O
of O O
SHP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
but O O
not O O
SHP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
with O O
a O O
glutathione B-GENE O
S I-GENE O
- I-GENE O
transferase I-GENE O
fusion I-GENE O
incorporating O O
GHR B-GENE O
cytoplasmic I-GENE O
domain I-GENE O
residues I-GENE O
000 I-GENE O
- I-GENE O
000 I-GENE O
, O O
but O O
only O O
if O O
the O O
fusion O O
was O O
first O O
rendered O O
tyrosine O O
- O O
phosphorylated O O
. O O

In O O
HCMV O O
( O O
Towne O O
) O O
- O O
infected O O
HF O O
cells O O
at O O
00 O O
to O O
00 O O
h O O
, O O
IE0 B-GENE O
also O O
accumulated O O
in O O
newly O O
formed O O
viral O O
DNA O O
replication O O
compartments O O
containing O O
the O O
polymerase B-GENE B-GENE
processivity I-GENE I-GENE
factor I-GENE I-GENE
( O O
UL00 B-GENE O
) O O
, O O
the O O
single B-GENE O
- I-GENE O
stranded I-GENE O
DNA I-GENE O
binding I-GENE O
protein I-GENE O
( O O
SSB B-GENE O
; O O
UL00 B-GENE O
) O O
, O O
the O O
UL000 B-GENE B-GENE
- I-GENE I-GENE
000 I-GENE I-GENE
accessory I-GENE I-GENE
protein I-GENE I-GENE
, O O
and O O
newly O O
incorporated O O
bromodeoxyuridine O O
( O O
BrdU O O
) O O
. O O

These O O
data O O
show O O
that O O
the O O
alpha O B-GENE
- O I-GENE
helix O I-GENE
domain O I-GENE
of O O
p00 B-GENE B-GENE
( O O
Kip0 B-GENE B-GENE
) O O
, O O
which O O
is O O
conserved O O
in O O
the O O
Cip B-GENE B-GENE
/ O I-GENE
Kip B-GENE I-GENE
proteins O I-GENE
, O O
is O O
implicated O O
in O O
protein O B-GENE
- O I-GENE
protein O I-GENE
interaction O O
and O O
confers O O
a O O
specific O O
regulatory O O
mechanism O O
, O O
outside O O
of O O
their O O
Cdk B-GENE B-GENE
- O I-GENE
inhibitory O I-GENE
activity O O
, O O
by O O
which O O
the O O
p00 B-GENE B-GENE
( O O
Kip0 B-GENE O
) O O
family O O
members O O
positively O O
act O O
on O O
myogenic O O
differentiation O O
. O O

We O O
were O O
able O O
to O O
detect O O
significant O O
differences O O
in O O
functional O O
residual O O
capacity O O
adjusted O O
for O O
weight O O
or O O
height O O
, O O
and O O
compliance O O
of O O
the O O
respiratory O O
system O O
adjusted O O
for O O
weight O O
or O O
lung O O
volume O O
in O O
the O O
ILD O O
infants O O
compared O O
to O O
the O O
healthy O O
controls O O
or O O
infants O O
who O O
had O O
PPHN O O
, O O
indicating O O
that O O
these O O
PFTs O O
were O O
sensitive O O
enough O O
to O O
determine O O
abnormal O O
lung O O
function O O
in O O
this O O
age O O
group O O
. O O

SCOB O O
testing O O
of O O
food O O
- O O
restricted O O
animals O O
, O O
using O O
a O O
multiple O O
fixed O O
ratio O O
( O O
FR O O
) O O
/ O O
fixed O O
interval O O
( O O
FI O O
) O O
schedule O O
( O O
FR00 O O
: O O
FI000 O O
) O O
, O O
was O O
conducted O O
prior O O
to O O
each O O
exposure O O
to O O
maintain O O
the O O
operant O O
behavior O O
; O O
the O O
data O O
from O O
Weeks O O
- O O
0 O O
, O O
0 O O
, O O
0 O O
, O O
and O O
00 O O
were O O
evaluated O O
for O O
evidence O O
of O O
neurotoxicity O O
. O O

The O O
objectives O O
of O O
the O O
present O O
study O O
were O O
to O O
evaluate O O
the O O
effects O O
of O O
adding O O
Equex O O
to O O
a O O
TRIS O O
- O O
extender O O
, O O
diluting O O
the O O
semen O O
in O O
0 O O
or O O
0 O O
steps O O
, O O
freezing O O
according O O
to O O
0 O O
methods O O
, O O
thawing O O
at O O
0 O O
rates O O
, O O
and O O
the O O
interactions O O
between O O
these O O
treatments O O
, O O
on O O
the O O
post O O
- O O
thaw O O
survival O O
of O O
dog O O
spermatozoa O O
at O O
00 O O
degrees O O
C O O
. O O

Null O O
mutations O O
in O O
daf B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
suppress O O
mutations O O
in O O
genes O O
encoding O O
this O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
signal O O
, O O
its O O
receptors O O
, O O
and O O
associated O O
Smad B-GENE O
signal I-GENE O
transduction I-GENE O
proteins I-GENE O
. O O
daf B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
encodes O I-GENE
a O O
Smad B-GENE B-GENE
protein I-GENE I-GENE
that O O
is O O
most O O
closely O O
related O O
to O O
mammalian B-GENE O
DPC0 I-GENE O
, O O
and O O
is O O
expressed O O
throughout O O
development O O
in O O
many O O
of O O
the O O
tissues O O
that O O
are O O
remodeled O O
during O O
dauer O O
development O O
. O O

SCID O O
V B-GENE O
( O O
D B-GENE O
) O O
J B-GENE O
recombination O O
can O O
be O O
partly O O
rescued O O
in O O
T O O
- O O
lymphocytes O O
by O O
either O O
DNA O O
- O O
damaging O O
agents O O
( O O
gamma O O
- O O
irradiation O O
and O O
bieomycin O O
) O O
or O O
a O O
null O O
mutation O O
of O O
the O O
p00 B-GENE B-GENE
gene I-GENE I-GENE
, O O
possibly O O
because O O
of O O
transiently O O
elevated O O
DNA O O
repair O O
activity O O
in O O
response O O
to O O
DNA O O
damage O O
or O O
to O O
delayed O O
apoptosis O O
in O O
the O O
absence O O
of O O
p00 B-GENE O
. O O

Leukocyte O O
cultures O O
, O O
prepared O O
from O O
blood O O
drawn O O
from O O
these O O
00 O O
children O O
at O O
0 O O
months O O
of O O
age O O
, O O
produced O O
lower O O
yields O O
of O O
IFN B-GENE O
than O O
those O O
of O O
the O O
remaining O O
00 O O
children O O
, O O
when O O
stimulated O O
with O O
adenovirus O O
( O O
P O O
< O O
0 O O
. O O
000 O O
) O O
, O O
coronavirus O O
( O O
P O O
< O O
0 O O
. O O
000 O O
) O O
or O O
rhinovirus O O
( O O
P O O
= O O
0 O O
. O O
000 O O
) O O
. O O

By O O
progressive O O
0 O O
' O O
- O O
deletion O O
studies O O
, O O
we O O
have O O
identified O O
a O O
000 O O
- O O
bp O O
DNA O O
fragment O O
( O O
- O O
0000 O O
to O O
- O O
000 O O
, O O
relative O O
to O O
the O O
translation O O
start O O
site O O
) O O
at O O
the O O
0 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
human B-GENE O
GnRHR I-GENE I-GENE
gene I-GENE I-GENE
that O O
is O O
responsible O O
for O O
the O O
GnRHa O O
- O O
mediated O O
down O O
- O O
regulation O O
of O O
human B-GENE O
GnRHR I-GENE O
promoter I-GENE O
activity O O
. O O

Badcock O O
and O O
Westheimer O O
( O O
Spatial O O
Vision O O
0 O O
( O O
0 O O
) O O
, O O
0 O O
- O O
00 O O
, O O
0000 O O
) O O
showed O O
that O O
a O O
thin O O
vertical O O
line O O
induces O O
nearby O O
zones O O
of O O
attraction O O
and O O
repulsion O O
; O O
this O O
study O O
extends O O
those O O
results O O
by O O
more O O
closely O O
examining O O
the O O
horizontal O O
and O O
vertical O O
extents O O
of O O
the O O
repulsion O O
zone O O
and O O
by O O
using O O
an O O
illusory O O
contour O O
to O O
induce O O
repulsion O O
. O O

The O O
0 O O
' O O
flanking O O
region O O
contains O O
potential O O
binding O O
sites O O
for O O
TATA B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
, O O
Sp0 B-GENE B-GENE
, O O
nuclear B-GENE B-GENE
factor I-GENE I-GENE
0 I-GENE I-GENE
( O O
NF0 B-GENE B-GENE
) O O
, O O
CAAT B-GENE B-GENE
- I-GENE I-GENE
box I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
) O O
, O O
hepatocyte B-GENE B-GENE
nuclear I-GENE I-GENE
factors I-GENE I-GENE
0 I-GENE I-GENE
and I-GENE O
0 I-GENE O
( O O
HNF0 B-GENE O
, O O
HNF0 B-GENE B-GENE
) O O
and O O
activator B-GENE B-GENE
proteins I-GENE I-GENE
0 I-GENE O
and I-GENE O
0 I-GENE O
( O O
AP0 B-GENE O
, O O
AP0 B-GENE O
) O O
. O O

The O O
fatigue O O
exercise O O
showed O O
relatively O O
high O O
blood O O
lactate O O
concentration O O
[ O O
00 O O
. O O
0 O O
( O O
SD O O
0 O O
. O O
0 O O
) O O
mmol O O
x O O
l O O
( O O
- O O
0 O O
) O O
] O O
and O O
an O O
increase O O
of O O
serum B-GENE O
creatine I-GENE O
kinase I-GENE O
( O O
CK B-GENE O
) O O
activity O O
delayed O O
by O O
0 O O
days O O
[ O O
000 O O
( O O
SD O O
000 O O
) O O
U O O
x O O
l O O
( O O
- O O
0 O O
) O O
] O O
. O O

Serum B-GENE O
insulin I-GENE O
- I-GENE O
like I-GENE O
growth I-GENE O
factor I-GENE O
I I-GENE O
( O O
IGF B-GENE O
- I-GENE O
I I-GENE O
) O O
SD O O
score O O
increased O O
from O O
- O O
0 O O
. O O
0 O O
and O O
- O O
0 O O
. O O
0 O O
in O O
men O O
and O O
women O O
, O O
respectively O O
, O O
to O O
0 O O
. O O
0 O O
and O O
- O O
0 O O
. O O
0 O O
at O O
0 O O
months O O
and O O
0 O O
. O O
0 O O
and O O
- O O
0 O O
. O O
0 O O
at O O
00 O O
months O O
. O O

Alternatively O O
, O O
PC00 O B-GENE
- O O
E0 O O
cells O O
were O O
submitted O O
to O O
treatment O O
with O O
antibodies O O
to O O
the O O
fibroblast B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
( I-GENE O
FGF I-GENE O
) I-GENE O
receptor I-GENE O
, O O
inhibitors O O
of O O
the O O
nonreceptor B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase I-GENE I-GENE
p00 B-GENE I-GENE
( O O
fyn B-GENE O
) O O
, O O
PLC B-GENE O
, O O
PKC B-GENE O
and O O
MEK B-GENE O
and O O
an O O
activator O O
of O O
PKC B-GENE O
, O O
phorbol O O
- O O
00 O O
- O O
myristate O O
- O O
00 O O
- O O
acetate O O
( O O
PMA O O
) O O
. O O

TSA O O
treatment O O
, O O
however O O
, O O
did O O
not O O
detectably O O
alter O O
enhancer O O
factor O O
binding O O
or O O
the O O
positioning O O
of O O
nuc B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
on O O
the O O
majority O O
of O O
the O O
chromatin O O
templates O O
indicating O O
that O O
protein O O
acetylation O O
and O O
chromatin O O
remodeling O O
may O O
be O O
limiting O O
steps O O
that O O
occur O O
only O O
on O O
transcriptionally O O
competent O O
templates O O
, O O
or O O
that O O
remodeling O O
of O O
nuc B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
requires O O
additional O O
factors O O
. O O

Based O O
on O O
the O O
current O O
literature O O
, O O
the O O
mechanisms O O
involved O O
in O O
the O O
toxicity O O
of O O
OA B-GENE O
indicate O O
three O O
major O O
effects O O
: O O
( O O
0 O O
) O O
inhibition O O
of O O
mitochondrial O O
respiration O O
correlated O O
with O O
a O O
depletion O O
of O O
ATP O O
; O O
( O O
0 O O
) O O
inhibition O O
of O O
tRNA B-GENE O
- I-GENE O
synthetase I-GENE O
accompanied O O
by O O
a O O
reduced O O
protein O O
synthesis O O
; O O
and O O
( O O
0 O O
) O O
enhanced O O
lipid O O
peroxidation O O
. O O

Previous O O
work O O
has O O
shown O O
that O O
spleen B-GENE O
necrosis I-GENE O
virus I-GENE O
( I-GENE O
SNV I-GENE O
) I-GENE O
long I-GENE O
terminal I-GENE O
repeats I-GENE O
( O O
LTRs O O
) O O
are O O
associated O O
with O O
Rex B-GENE B-GENE
/ O O
Rex B-GENE O
- O O
responsive O O
element O O
- O O
independent O O
expression O O
of O O
bovine O O
leukemia O O
virus O O
RNA O O
and O O
supports O O
the O O
hypothesis O O
that O O
SNV O O
RNA O O
contains O O
a O O
cis O O
- O O
acting O O
element O O
that O O
interacts O O
with O O
cellular B-GENE O
Rex I-GENE O
- I-GENE O
like I-GENE O
proteins I-GENE O
. O O

Aryl B-GENE O
hydrocarbon I-GENE O
receptor I-GENE O
nuclear I-GENE O
translocator I-GENE O
( O O
ARNT B-GENE B-GENE
) O O
is O O
a O O
component O O
of O O
the O O
transcription O B-GENE
factors O I-GENE
, O O
aryl B-GENE B-GENE
hydrocarbon I-GENE I-GENE
receptor I-GENE I-GENE
( O O
AhR B-GENE B-GENE
) O O
and O O
hypoxia B-GENE B-GENE
- I-GENE I-GENE
inducible I-GENE I-GENE
factor I-GENE I-GENE
0 I-GENE I-GENE
, O O
which O O
transactivate O O
their O O
target O O
genes O O
, O O
such O O
as O O
CYP0A0 B-GENE O
and O O
erythropoietin B-GENE O
, O O
in O O
response O O
to O O
xenobiotic O O
aromatic O O
hydrocarbons O O
and O O
to O O
low O O
O0 O O
concentration O O
, O O
respectively O O
. O O

Although O O
RAD00 B-GENE O
, O O
RAD00 B-GENE O
and O O
MEC0 B-GENE O
are O O
not O O
required O O
for O O
cell O O
cycle O O
arrest O O
when O O
S O O
phase O O
is O O
inhibited O O
by O O
hydroxyurea O O
( O O
HU O O
) O O
, O O
they O O
do O O
contribute O O
to O O
the O O
viability O O
of O O
yeast O O
cells O O
grown O O
in O O
the O O
presence O O
of O O
HU O O
, O O
possibly O O
because O O
they O O
are O O
required O O
for O O
the O O
repair O O
of O O
HU O O
- O O
induced O O
DNA O O
damage O O
. O O

Here O O
we O O
have O O
examined O O
the O O
ability O O
of O O
the O O
cellular O B-GENE
protein O I-GENE
YB B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
to O O
modulate O O
transcription O O
of O O
the O O
HIV B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter I-GENE I-GENE
in O O
a O O
human O O
astrocytic O O
cell O O
line O O
( O O
U O B-GENE
- O I-GENE
00MG O I-GENE
) O O
, O O
a O O
neuronal O O
cell O O
line O O
( O O
SK O B-GENE
- O I-GENE
N O I-GENE
- O I-GENE
MC O I-GENE
) O O
and O O
lymphoid O O
cells O O
( O O
Jurkat O O
) O O
by O O
transfection O O
assay O O
. O O

Sp0 B-GENE O
can O O
activate O O
transcription O O
through O O
immunoglobulin B-GENE B-GENE
kappa I-GENE I-GENE
- I-GENE I-GENE
chain I-GENE I-GENE
enhancer I-GENE I-GENE
or O O
P B-GENE B-GENE
- I-GENE I-GENE
selectin I-GENE I-GENE
promoter I-GENE O
NF B-GENE O
- I-GENE O
kappaB I-GENE O
sites I-GENE O
. O O
p00 B-GENE B-GENE
homodimers I-GENE O
replace O O
Sp0 B-GENE O
from O O
the O O
P B-GENE B-GENE
- I-GENE I-GENE
selectin I-GENE I-GENE
promoter I-GENE O
by O O
binding O O
site O O
competition O O
and O O
thereby O O
either O O
inhibit O O
basal O O
Sp0 B-GENE O
- O O
driven O O
expression O O
or O O
, O O
in O O
concert O O
with O O
Bcl B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
stimulate O O
expression O O
. O O

INTERVENTIONS O O
: O O
Study O O
patients O O
were O O
randomly O O
divided O O
into O O
four O O
parallel O O
groups O O
to O O
receive O O
either O O
terbinafine O O
000 O O
mg O O
a O O
day O O
for O O
00 O O
or O O
00 O O
weeks O O
( O O
groups O O
T00 O O
and O O
T00 O O
) O O
or O O
itraconazole O O
000 O O
mg O O
a O O
day O O
for O O
0 O O
week O O
in O O
every O O
0 O O
weeks O O
for O O
00 O O
or O O
00 O O
weeks O O
( O O
groups O O
I0 O O
and O O
I0 O O
) O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
risk O O
factors O O
for O O
background O O
diabetic O O
retinopathy O O
( O O
BDR O O
) O O
and O O
PDR O O
by O O
following O O
000 O O
Japanese O O
patients O O
with O O
early O O
- O O
onset O O
type O O
0 O O
diabetes O O
diagnosed O O
before O O
00 O O
years O O
of O O
age O O
( O O
mean O O
age O O
00 O O
, O O
mean O O
blood O O
pressure O O
at O O
entry O O
000 O O
/ O O
00 O O
mm O O
Hg O O
) O O
. O O

0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
mmol O O
/ O O
l O O
, O O
P O O
< O O
0 O O
. O O
00 O O
) O O
, O O
and O O
systolic O O
BP O O
responses O O
to O O
intravenous O O
norepinephrine O O
and O O
angiotensin B-GENE O
II I-GENE O
were O O
significantly O O
higher O O
on O O
glibenclamide O O
than O O
on O O
metformin O O
( O O
P O O
< O O
0 O O
. O O
00 O O
and O O
P O O
< O O
0 O O
. O O
00 O O
, O O
respectively O O
) O O
. O O

Agonist O O
- O O
induced O O
receptor O O
internalization O O
, O O
determined O O
as O O
the O O
percent O O
of O O
total O O
[ O O
000I O O
] O O
Tyr0 B-GENE O
- I-GENE O
oCRF I-GENE O
bound O O
located O O
in O O
the O O
acid O O
- O O
resistant O O
fraction O O
of O O
transfected O O
Cos O O
0 O O
cells O O
, O O
increased O O
with O O
time O O
( O O
0 O O
- O O
00 O O
min O O
at O O
00 O O
degrees O O
C O O
) O O
for O O
both O O
wild O O
- O O
type O O
and O O
variant O O
oCRF0 B-GENE O
. O O

In O O
order O O
to O O
examine O O
the O O
potential O O
role O O
of O O
transcriptional O O
silencing O O
during O O
productive O O
HSV O O
- O O
0 O O
infection O O
, O O
recombinant O O
viruses O O
were O O
generated O O
in O O
which O O
wild B-GENE O
- I-GENE O
type I-GENE O
or I-GENE O
mutant I-GENE O
ICP00 I-GENE O
. I-GENE O
0 I-GENE O
promoters I-GENE O
controlling O O
the O O
expression O O
of O O
a O O
chloramphenicol B-GENE O
acetyltransferase I-GENE O
reporter I-GENE O
gene I-GENE O
were O O
inserted O O
into O O
the O O
thymidine B-GENE O
kinase I-GENE O
gene I-GENE O
of O O
the O O
viral O O
genome O O
. O O

MEKs B-GENE O
and O O
ERKs B-GENE O
inhibited O O
IL B-GENE O
- I-GENE O
0 I-GENE O
activation O O
of O O
Stat0 B-GENE B-GENE
harboring O I-GENE
a O O
mutation O O
at O O
serine O O
- O O
000 O O
, O O
the O O
major O O
site O O
for O O
serine O O
phosphorylation O O
, O O
similar O O
to O O
inhibition O O
of O O
wild B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
Stat0 I-GENE I-GENE
, O O
and O O
inhibited O O
Janus B-GENE O
kinases I-GENE O
Jak0 B-GENE O
and O O
Jak0 B-GENE O
upstream O O
of O O
Stat0 B-GENE O
in O O
the O O
Jak B-GENE B-GENE
- O O
STAT B-GENE O
- O O
signaling O O
pathway O O
. O O

( O O
0 O O
) O O
Erythroid O O
00D O O
Epo0 B-GENE O
cells O O
showed O O
a O O
lower O O
level O O
of O O
bulk O O
PKC B-GENE O
catalytic O O
activity O O
, O O
lacked O O
the O O
expression O O
of O O
epsilon B-GENE O
and I-GENE O
eta I-GENE O
PKC I-GENE O
isoforms I-GENE O
, O O
and O O
showed O O
a O O
weak O O
or O O
absent O O
upregulation O O
of O O
the O O
remaining O O
isoforms O O
, O O
except O O
betaI B-GENE O
, O O
upon O O
readdition O O
of O O
Epo B-GENE O
to O O
growth O O
factor O O
- O O
starved O O
cells O O
. O O

Polypyrimidine O O
and O O
ssDNA O O
binding O O
by O O
the O O
isolated O O
VH B-GENE O
domain I-GENE O
of O O
immunization O B-GENE
- O I-GENE
induced O I-GENE
anti O I-GENE
- O I-GENE
Z O I-GENE
- O O
DNA O O
Ab O O
resembles O O
the O O
activity O O
of O O
natural O O
autoantibodies O O
and O O
suggests O O
that O O
VH B-GENE B-GENE
- O O
dependent O O
binding O O
to O O
a O O
ligand O O
mimicked O O
by O O
polypyrimidines O O
may O O
play O O
a O O
role O O
in O O
B O O
cell O O
selection O O
before O O
immunization O O
with O O
Z O O
- O O
DNA O O
. O O

While O O
determination O O
of O O
the O O
protein O O
content O O
of O O
the O O
formulae O O
gave O O
no O O
valid O O
information O O
, O O
RAST O O
/ O O
EAST O O
inhibition O O
was O O
highest O O
for O O
cow O O
' O O
s O O
milk O O
, O O
followed O O
by O O
the O O
partially O O
hydrolysed O O
whey O O
formula O O
, O O
partially O O
hydrolysed O O
whey O O
/ O O
casein B-GENE O
formula O O
, O O
soy B-GENE O
/ I-GENE O
pork I-GENE O
collagen I-GENE O
formula O O
, O O
and O O
the O O
amino O O
acid O O
formula O O
. O O

These O O
results O O
further O O
support O O
an O O
important O O
role O O
for O O
CBF0 B-GENE O
in O O
mediating O O
EBNA0 B-GENE O
transactivation O O
; O O
they O O
identify O O
the O O
hnRNP B-GENE B-GENE
protein I-GENE I-GENE
AUF0 I-GENE O
as O O
a O O
major O O
component O O
of O O
CBF0 B-GENE B-GENE
and O O
are O O
also O O
the O O
first O O
evidence O O
of O O
a O O
cis O O
- O O
acting O O
sequence O O
other O O
than O O
a O O
CBF0 B-GENE O
binding I-GENE O
element I-GENE O
that O O
is O O
able O O
to O O
confer O O
responsiveness O O
to O O
EBNA0 B-GENE O
. O O

RT O O
- O O
PCR O O
indicated O O
that O O
p00 B-GENE O
mRNA I-GENE O
was O O
induced O O
0 O O
. O O
0 O O
- O O
, O O
0 O O
. O O
0 O O
- O O
, O O
and O O
0 O O
. O O
0 O O
- O O
fold O O
in O O
the O O
0 O O
- O O
day O O
neonatal O O
, O O
0 O O
- O O
day O O
neonatal O O
, O O
and O O
adult O O
stages O O
, O O
respectively O O
, O O
compared O O
to O O
the O O
00 O O
- O O
day O O
fetal O O
stage O O
. O O

Malaria O O
had O O
diminished O O
significantly O O
by O O
the O O
early O O
0000s O O
, O O
and O O
this O O
paper O O
queries O O
whether O O
that O O
reduction O O
was O O
due O O
to O O
the O O
control O O
projects O O
of O O
the O O
thirties O O
, O O
and O O
, O O
if O O
so O O
, O O
whether O O
such O O
projects O O
should O O
be O O
a O O
model O O
for O O
the O O
current O O
developing O O
world O O
, O O
where O O
malaria O O
is O O
a O O
growing O O
problem O O
today O O
. O O

The O O
present O O
investigation O O
conducted O O
in O O
a O O
population O O
of O O
000 O O
dentally O O
aware O O
individuals O O
in O O
the O O
age O O
range O O
00 O O
- O O
00 O O
years O O
, O O
was O O
initiated O O
to O O
elucidate O O
the O O
relationship O O
between O O
tobacco O O
smoking O O
and O O
supragingival O O
calculus O O
, O O
taking O O
into O O
account O O
possible O O
confounding O O
factors O O
such O O
as O O
age O O
, O O
gender O O
, O O
oral O O
hygiene O O
and O O
gingival O O
inflammation O O
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
evaluate O O
the O O
level O O
of O O
oxidative O O
stress O O
in O O
healthy O O
controls O O
( O O
CTL O O
) O O
compared O O
with O O
CRF O O
and O O
HD O O
patients O O
before O O
( O O
pre O O
- O O
HD O O
) O O
and O O
after O O
( O O
post O O
- O O
HD O O
) O O
the O O
dialysis O O
session O O
, O O
carried O O
out O O
on O O
a O O
high O O
biocompatible O O
polyacrylonitrile O O
membrane O O
AN00 O O
. O O

The O O
Drosophila B-GENE O
melanogaster I-GENE O
suppressor I-GENE O
of I-GENE O
sable I-GENE B-GENE
gene I-GENE I-GENE
, O O
su B-GENE O
( I-GENE O
s I-GENE O
) I-GENE O
, O O
encodes O O
a O O
novel O O
, O O
000 O B-GENE
- O I-GENE
kDa O I-GENE
nuclear O I-GENE
RNA O I-GENE
binding O I-GENE
protein O I-GENE
, O O
SU B-GENE B-GENE
( I-GENE O
S I-GENE O
) I-GENE O
, O O
that O O
negatively O O
regulates O O
RNA O O
accumulation O O
from O O
mutant O O
alleles O O
of O O
other O O
genes O O
that O O
have O O
transposon O O
insertions O O
in O O
the O O
0 O O
' O O
transcribed O O
region O O
. O O

RESULTS O O
: O O
The O O
main O O
effect O O
of O O
muscle O O
pain O O
, O O
compared O O
to O O
non O O
- O O
painful O O
stimulation O O
, O O
was O O
a O O
significant O O
and O O
long O O
- O O
lasting O O
increase O O
of O O
delta O O
( O O
0 O O
- O O
0 O O
Hz O O
) O O
power O O
and O O
an O O
alpha O O
- O O
0 O O
( O O
0 O O
- O O
00 O O
Hz O O
) O O
power O O
increase O O
over O O
the O O
contralateral O O
parietal O O
locus O O
. O O

Using O O
mouse O O
- O O
human O O
somatic O O
hybrids O O
and O O
FISH O O
analysis O O
, O O
the O O
PE B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
is O O
localized O O
to O O
human O O
chromosome O O
00q00 O O
. O O
0 O O
, O O
a O O
region O O
involved O O
in O O
translocations O O
and O O
deletions O O
in O O
leukemias O O
and O O
several O O
solid O O
tumors O O
, O O
suggesting O O
that O O
this O O
novel O O
ETS B-GENE O
factor I-GENE O
may O O
play O O
a O O
role O O
in O O
carcinogenesis O O
. O O

The O O
RNA O B-GENE
- O I-GENE
binding O I-GENE
and O O
RNA B-GENE O
- I-GENE O
DNA I-GENE O
helicase I-GENE O
activities O O
of O O
the O O
Escherichia B-GENE B-GENE
coli I-GENE I-GENE
transcription I-GENE I-GENE
termination I-GENE I-GENE
factor I-GENE I-GENE
rho I-GENE O
have O O
been O O
investigated O O
using O O
natural O O
RNA O O
molecules O O
that O O
are O O
000 O O
and O O
000 O O
nucleotide O O
residues O O
in O O
length O O
and O O
that O O
contain O O
the O O
trp B-GENE O
t I-GENE O
' I-GENE O
rho I-GENE O
- I-GENE O
dependent I-GENE O
termination I-GENE O
sequence I-GENE O
of O O
E O O
. O O
coli O O
. O O

The O O
purpose O O
of O O
this O O
article O O
is O O
to O O
discuss O O
the O O
factors O O
involved O O
in O O
the O O
selection O O
of O O
antibodies O O
, O O
radionuclides O O
and O O
labeling O O
methods O O
in O O
the O O
development O O
of O O
radioimmunotherapy O O
( O O
RIT O O
) O O
for O O
non O O
- O O
Hodgkin O O
' O O
s O O
lymphoma O O
( O O
NHL O O
) O O
from O O
a O O
single O O
clinical O O
study O O
site O O
through O O
multicenter O O
trials O O
and O O
commercialization O O
. O O

We O O
have O O
previously O O
demonstrated O O
that O O
expression O O
of O O
the O O
gene O O
for O O
the O O
reproductive O O
neuropeptide O O
, O O
GnRH B-GENE B-GENE
, O O
is O O
repressed O O
by O O
the O O
glutamate O B-GENE
/ O I-GENE
NO O I-GENE
/ O O
cyclic O B-GENE
GMP O I-GENE
( O O
cGMP O O
) O O
signal O O
transduction O O
pathway O O
through O O
cGMP B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
in O O
the O O
hypothalamic O O
GnRH B-GENE O
- O O
secreting O O
neuronal O O
cell O O
line O O
GT0 O O
- O I-GENE
0 O I-GENE
. O O

Extracellular B-GENE B-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
kinase I-GENE I-GENE
( O O
ERK B-GENE O
) O O
activation O O
and O O
molecular O O
coupling O O
of O O
the O O
adaptor O B-GENE
proteins O I-GENE
p000 B-GENE I-GENE
Crk B-GENE I-GENE
- I-GENE I-GENE
associated I-GENE I-GENE
substrate I-GENE I-GENE
( O O
CAS B-GENE O
) O O
and O O
c B-GENE B-GENE
- I-GENE I-GENE
CrkII I-GENE I-GENE
( O O
Crk B-GENE O
) O O
represent O O
two O O
distinct O O
pathways O O
that O O
induce O O
cell O O
invasion O O
and O O
protect O O
cells O O
from O O
apoptosis O O
in O O
a O O
three O O
- O O
dimensional O O
collagen B-GENE O
matrix O O
. O O

However O O
, O O
mean O O
food O O
intake O O
in O O
the O O
00 O O
% O O
group O O
was O O
half O O
that O O
of O O
the O O
ACT O O
group O O
( O O
p O O
< O O
0 O O
. O O
000 O O
) O O
and O O
significantly O O
less O O
( O O
p O O
< O O
0 O O
. O O
00 O O
) O O
than O O
the O O
SEP O O
group O O
, O O
which O O
consumed O O
amounts O O
equivalent O O
to O O
00 O O
% O O
of O O
daily O O
requirement O O
. O O

In O O
a O O
heterologous O O
transcriptional O O
system O O
in O O
which O O
the O O
upstream O O
regions O O
of O O
oIFNtau B-GENE O
were O O
inserted O O
in O O
front O O
of O O
simian B-GENE O
virus I-GENE O
00 I-GENE O
( I-GENE O
SV00 I-GENE O
) I-GENE O
promoter I-GENE O
, O O
the O O
regions O O
between O O
bases O O
- O O
000 O O
and O O
- O O
000 O O
were O O
determined O O
as O O
being O O
the O O
enhancer O O
region O O
required O O
for O O
oIFNtau B-GENE O
- O O
SV00 O O
- O O
CAT B-GENE O
transactivation O O
. O O

During O O
treatment O O
, O O
the O O
phosphorylation O O
state O O
of O O
Rb B-GENE O
shifted O O
to O O
a O O
hypophosphorylated O O
form O O
. O O
mRNA O O
for O O
the O O
HPV O B-GENE
E0 B-GENE I-GENE
/ O I-GENE
E0 B-GENE I-GENE
genes O I-GENE
decreased O O
; O O
however O O
, O O
significant O O
changes O O
in O O
the O O
E0 B-GENE O
protein I-GENE O
were O O
not O O
observed O O
, O O
while O O
increased O O
levels O O
of O O
Rb B-GENE O
immunoprecipitated O O
with O O
anti B-GENE O
- I-GENE O
E0 I-GENE O
antibodies I-GENE O
were O O
observed O O
. O O

Analysis O O
of O O
Standard O O
Reference O O
Material O O
0000 O O
, O O
Infant O O
Formula O O
, O O
gave O O
a O O
mean O O
value O O
of O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
000 O O
mg O O
vitamin O O
K O O
/ O O
kg O O
( O O
K O O
or O O
K0 O O
? O O
) O O
( O O
n O O
= O O
00 O O
) O O
with O O
a O O
coefficient O O
of O O
variation O O
of O O
0 O O
. O O
00 O O
. O O

We O O
describe O O
the O O
identification O O
and O O
initial O O
characterization O O
of O O
neurobeachin B-GENE B-GENE
, O O
a O O
neuron O O
- O O
specific O O
multidomain O O
protein O O
of O O
000 O O
kDa O O
with O O
a O O
high O O
- O O
affinity O O
binding O O
site O O
( O O
K O O
( O O
d O O
) O O
, O O
00 O O
nm O O
) O O
for O O
the O O
type B-GENE O
II I-GENE O
regulatory I-GENE O
subunit I-GENE O
of I-GENE O
protein I-GENE B-GENE
kinase I-GENE I-GENE
A I-GENE I-GENE
( O O
PKA B-GENE O
RII I-GENE O
) O O
. O O

RESULTS O O
: O O
Surprisingly O O
, O O
PAF B-GENE O
blockade O O
increased O O
mortality O O
after O O
trauma O O
( O O
0 O O
of O O
00 O O
WEB O O
- O O
0000 O O
animals O O
versus O O
0 O O
of O O
0 O O
vehicle O O
animals O O
; O O
p O O
= O O
0 O O
. O O
00 O O
) O O
and O O
depressed O O
cardiac O O
index O O
and O O
O0 O O
delivery O O
at O O
00 O O
hours O O
( O O
p O O
< O O
0 O O
. O O
00 O O
) O O
. O O

Using O O
a O O
conditional O O
- O O
lethal O O
mutant O O
allele O O
of O O
SUP00 B-GENE B-GENE
( O O
sup00 B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
and O O
a O O
combination O O
of O O
in O O
vivo O O
and O O
in O O
vitro O O
approaches O O
, O O
we O O
demonstrate O O
that O O
the O O
product O O
of O O
the O O
SUP00 B-GENE B-GENE
gene I-GENE I-GENE
( O O
Sup00p B-GENE O
or O O
eRF0 B-GENE O
) O O
is O O
a O O
factor O O
required O O
for O O
translation O O
termination O O
in O O
yeast O O
. O O

CONCLUSIONS O O
: O O
Valproate O O
appears O O
to O O
inhibit O O
the O O
glucuronidation O O
of O O
carbamazepine O O
- O O
00 O O
, O O
00 O O
- O O
trans O O
- O O
diol O O
, O O
and O O
probably O O
also O O
inhibits O O
the O O
conversion O O
of O O
carbamazepine O O
- O O
00 O O
, O O
00 O O
- O O
epoxide O O
to O O
this O O
trans O O
- O O
diol O O
derivative O O
, O O
rather O O
than O O
simply O O
inhibiting O O
the O O
latter O O
reaction O O
only O O
. O O

First O O
, O O
two O O
MCTs O O
using O O
a O O
long O O
electrode O O
, O O
0 O O
cm O O
in O O
size O O
, O O
were O O
performed O O
in O O
the O O
central O O
area O O
of O O
the O O
tumor O O
, O O
and O O
eight O O
MCTs O O
by O O
a O O
short O O
electrode O O
, O O
0 O O
cm O O
in O O
size O O
, O O
were O O
done O O
in O O
the O O
peripheral O O
and O O
surrounding O O
area O O
of O O
the O O
tumor O O
. O O

Systematic O O
functional O O
analysis O O
of O O
V0a B-GENE B-GENE
/ I-GENE O
V0 I-GENE O
hybrid I-GENE O
receptors I-GENE O
showed O O
that O O
the O O
second O O
intracellular O O
loop O O
of O O
the O O
V0a B-GENE B-GENE
receptor I-GENE I-GENE
is O O
required O O
and O O
sufficient O O
for O O
efficient O O
coupling O O
to O O
Gq B-GENE O
/ I-GENE O
00 I-GENE O
, O O
whereas O O
the O O
third O O
intracellular O O
loop O O
of O O
the O O
V0 B-GENE B-GENE
receptor I-GENE I-GENE
is O O
required O O
and O O
sufficient O O
for O O
coupling O O
to O O
Gs B-GENE O
. O O

This O O
report O O
describes O O
a O O
patient O O
with O O
a O O
previous O O
inferior O O
acute O O
myocardial O O
infarction O O
who O O
developed O O
right O O
ventricular O O
infarction O O
with O O
significant O O
anterior O O
lead O O
ST O O
segment O O
elevation O O
( O O
V0 O O
- O O
V0 O O
) O O
caused O O
by O O
the O O
loss O O
of O O
two O O
large O O
right O O
ventricular O O
branches O O
during O O
a O O
coronary O O
angioplasty O O
of O O
the O O
right O O
coronary O O
artery O O
. O O

While O O
mutations O O
in O O
K B-GENE O
- I-GENE O
Rev I-GENE O
that O O
inactivate O O
any O O
one O O
of O O
these O O
properties O O
also O O
blocked O O
K B-GENE O
- I-GENE O
Rev I-GENE O
- O O
dependent O O
nuclear O O
RNA O O
export O O
, O O
several O O
K B-GENE O
- I-GENE O
Rev I-GENE O
mutants I-GENE O
were O O
comparable O O
to O O
wild O O
type O O
when O O
assayed O O
for O O
any O O
of O O
these O O
individual O O
activities O O
yet O O
nevertheless O O
defective O O
for O O
RNA O O
export O O
. O O

The O O
overall O O
results O O
of O O
this O O
paper O O
are O O
consistent O O
with O O
the O O
conclusion O O
that O O
the O O
carboxyl O O
- O O
terminal O O
LBD O O
is O O
not O O
sufficient O O
for O O
mediating O O
PR B-GENE O
dimerization O O
and O O
that O O
multiple O O
regions O O
, O O
including O O
the O O
hinge O O
and O O
amino O O
- O O
terminal O O
sequences O O
, O O
contribute O O
either O O
directly O O
or O O
indirectly O O
to O O
homodimerization O O
of O O
PR B-GENE O
. O O

Previously O O
, O O
we O O
reported O O
that O O
scanthrough O O
translation O O
, O O
where O O
the O O
initiating O O
AUG O O
of O O
a O O
primary O O
open O O
reading O O
frame O O
is O O
bypassed O O
, O O
is O O
most O O
likely O O
to O O
account O O
for O O
the O O
presentation O O
of O O
cryptic O O
epitopes O O
from O O
alternative O O
reading O O
frames O O
within O O
the O O
influenza B-GENE O
A I-GENE O
PR I-GENE O
/ I-GENE O
0 I-GENE O
/ I-GENE O
00 I-GENE O
nucleoprotein I-GENE O
gene I-GENE O
. O O

The O O
RAS B-GENE B-GENE
- O I-GENE
cyclic B-GENE I-GENE
AMP I-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
cAPK B-GENE O
pathway O O
prevents O O
the O O
UAS O O
activity O O
of O O
IREu B-GENE O
in O O
the O O
presence O O
of O O
glucose O O
as O O
the O O
sole O O
carbon O O
source O O
, O O
while O O
the O O
transcriptional O O
activators O O
Msn0p B-GENE O
and O O
Msn0p B-GENE O
promote O O
the O O
UAS O O
activity O O
of O O
this O O
repeat O O
in O O
the O O
presence O O
of O O
acetate O O
. O O

EMSA O O
with O O
crude O O
nuclear O O
extracts O O
demonstrated O O
that O O
stimulation O O
with O O
CD00L B-GENE O
results O O
in O O
the O O
induction O O
of O O
NF B-GENE O
- I-GENE O
kappaB I-GENE O
complexes I-GENE O
that O O
bind O O
to O O
each O O
of O O
the O O
three O O
NF B-GENE O
- I-GENE O
kappaB I-GENE O
sites I-GENE O
and O O
are O O
composed O O
mainly O O
of O O
p00 B-GENE B-GENE
and O O
RelB B-GENE O
, O O
but O O
also O O
include O O
c B-GENE O
- I-GENE O
Rel I-GENE O
and O O
p00 B-GENE B-GENE
. O O

Although O O
the O O
OC B-GENE B-GENE
promoter I-GENE I-GENE
is O O
activated O O
in O O
a O O
C O O
terminus O O
dependent O O
manner O O
, O O
the O O
MDR B-GENE O
, O O
LTR O O
and O O
BSP B-GENE O
promoters I-GENE O
are O O
repressed O O
by O O
three O O
distinct O O
mechanisms O O
, O O
either O O
independent O O
of O O
or O O
involving O O
the O O
AML B-GENE O
C I-GENE O
terminus I-GENE O
, O O
or O O
requiring O O
only O O
the O O
conserved O O
C O O
- O O
terminal O O
pentapeptide O O
VWRPY O O
. O O

We O O
now O O
demonstrate O O
that O O
CCAAT B-GENE B-GENE
/ I-GENE O
enhancer I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( I-GENE O
C I-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
) I-GENE O
delta I-GENE O
is O O
a O O
major O O
component O O
of O O
a O O
PGE0 O B-GENE
- O I-GENE
stimulated O I-GENE
DNA O I-GENE
- O I-GENE
protein O I-GENE
complex O O
involving O O
HS0D B-GENE O
and O O
find O O
that O O
C B-GENE B-GENE
/ I-GENE O
EBPdelta I-GENE O
transactivates O O
IGF B-GENE O
- I-GENE O
I I-GENE O
promoter I-GENE O
0 I-GENE O
through O O
this O O
site O O
. O O

UDP B-GENE O
- I-GENE O
GlcNAc I-GENE O
: O O
alpha B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
D I-GENE I-GENE
- I-GENE I-GENE
mannoside I-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, I-GENE O
0 I-GENE O
- I-GENE O
N I-GENE O
- I-GENE O
acetylglucosaminyltransferase I-GENE O
II I-GENE O
( O O
GnT B-GENE O
II I-GENE O
; O O
EC B-GENE O
0 I-GENE O
. I-GENE O
0 I-GENE O
. I-GENE O
0 I-GENE O
. I-GENE O
000 I-GENE O
) O O
is O O
essential O O
for O O
the O O
normal O O
assembly O O
of O O
complex O O
Asn O O
- O O
linked O O
glycans O O
. O O

This O O
sequence O O
, O O
Thr O B-GENE
- O I-GENE
Gly O I-GENE
- O I-GENE
X O I-GENE
- O I-GENE
X O I-GENE
- O I-GENE
Gly O I-GENE
- O I-GENE
Asp O I-GENE
- O I-GENE
Gly O I-GENE
- O O
Lys O O
- O O
Ile O O
- O O
Phe O O
, O O
forms O O
part O O
of O O
the O O
B O B-GENE
- O I-GENE
loop O I-GENE
and O O
is O O
conserved O O
in O O
a O O
wide O O
variety O O
of O O
organisms O O
that O O
include O O
bacteria O O
, O O
algae O O
and O O
archeabacteria O O
. O O

Comparison O O
with O O
the O O
bHLH B-GENE B-GENE
/ O O
PAS B-GENE O
family O O
genes O O
revealed O O
that O O
the O O
intron O B-GENE
/ O O
exon O O
splice O O
pattern O O
of O O
mBMAL0 B-GENE O
most O O
closely O O
matches O O
that O O
of O O
the O O
mAhr B-GENE O
, O O
which O O
suggests O O
that O O
BMAL0 B-GENE O
and O O
Ahr B-GENE O
belong O O
to O O
the O O
same O O
subclass O O
and O O
may O O
be O O
derived O O
from O O
a O O
common O O
primordial O O
gene O O
. O O

The O O
data O O
indicate O O
that O O
etr B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
essential O O
for O O
muscle O O
development O O
in O O
C O O
. O O
elegans O O
, O O
perhaps O O
by O O
playing O O
a O O
role O O
in O O
post O O
- O O
transcriptional O O
processing O O
of O O
some O O
muscle O O
component O O
, O O
and O O
thus O O
suggesting O O
a O O
possible O O
conservation O O
of O O
gene O O
function O O
with O O
human B-GENE O
CUG I-GENE O
- I-GENE O
bp I-GENE O
. O O

The O O
central O O
( O O
R O O
) O O
domain O O
is O O
responsible O O
for O O
receptor O O
- O O
binding O O
activity O O
whereas O O
the O O
N O B-GENE
- O I-GENE
terminal O I-GENE
( O O
T O O
) O O
domain O O
mediates O O
translocation O O
, O O
the O O
process O O
by O O
which O O
the O O
C O O
- O O
terminal O O
cytotoxic O O
domain O O
is O O
transported O O
from O O
the O O
receptor O O
to O O
the O O
site O O
of O O
its O O
cytotoxicity O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
revealed O O
that O O
Sp0 B-GENE O
binds O O
to O O
two O O
different O O
regions O O
in O O
the O O
proximal O O
promoter O O
, O O
a O O
typical O O
Sp0 B-GENE O
site I-GENE O
located O O
at O O
( O O
- O O
00 O O
; O O
- O O
00 O O
) O O
and O O
a O O
G O O
/ O O
C O O
- O O
rich O O
region O O
between O O
( O O
- O O
00 O O
; O O
- O O
00 O O
) O O
. O O

Retroviral O O
transduction O O
of O O
T B-GENE O
/ I-GENE O
T I-GENE O
( I-GENE O
L I-GENE O
) I-GENE O
causes O O
a O O
rapidly O O
fatal O O
myeloproliferative O O
disease O O
in O O
a O O
murine O O
bone O O
marrow O O
transplant O O
( O O
BMT O O
) O O
model O O
, O O
whereas O O
T B-GENE O
/ I-GENE O
T I-GENE O
( I-GENE O
F I-GENE O
) I-GENE O
causes O O
a O O
long O O
- O O
latency O O
, O O
pre O O
- O O
B O O
- O O
cell O O
lymphoblastic O O
lymphoma O O
. O O

Toward O O
this O O
end O O
, O O
we O O
prepared O O
synthetic O O
proteins O O
with O O
either O O
the O O
catalytic O O
domain O O
of O O
FAP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( I-GENE O
C I-GENE O
- I-GENE O
terminal I-GENE O
000 I-GENE O
amino I-GENE O
acids I-GENE O
) I-GENE O
or O O
its O O
inactive O O
form O O
( O O
Cys0000 O B-GENE
- O I-GENE
- O I-GENE
> O I-GENE
Ser O O
) O O
fused O O
to O O
glutathione B-GENE B-GENE
- I-GENE I-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase I-GENE I-GENE
( O O
GST B-GENE O
) O O
. O O

However O O
, O O
serial O O
passages O O
of O O
fetal O O
lamb O O
kidney O O
( O O
FLK O O
) O O
cells O O
, O O
which O O
are O O
sensitive O O
to O O
infection O O
with O O
BLV O O
, O O
after O O
transient O O
transfection O O
revealed O O
that O O
mutation O O
of O O
a O O
second O O
tyrosine O O
residue O O
in O O
the O O
N O O
- O O
terminal O O
motif O O
completely O O
prevented O O
the O O
propagation O O
of O O
the O O
virus O O
. O O

Gel O O
filtration O O
, O O
sedimentation O O
velocity O O
, O O
and O O
immunoprecipitation O O
experiments O O
revealed O O
that O O
beta0 O O
is O O
a O O
component O O
of O O
a O O
multisubunit O O
complex O O
( O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
that O O
also O O
contains O O
the O O
sigma0 O O
polypeptide O O
and O O
two O O
additional O O
adaptor O O
subunit O O
homologs O O
named O O
mu0 O O
( O O
mu O B-GENE
- O I-GENE
ARP0 O I-GENE
) O O
and O O
epsilon O O
. O O

The O O
arrangement O O
of O O
these O O
cutoff O O
- O O
levels O O
leads O O
to O O
a O O
sensitivity O O
of O O
00 O O
% O O
at O O
a O O
specificity O O
of O O
00 O O
% O O
for O O
Protein B-GENE O
S000 I-GENE O
when O O
measured O O
by O O
RIA O O
, O O
and O O
to O O
a O O
sensitivity O O
of O O
00 O O
% O O
at O O
a O O
specificity O O
of O O
00 O O
% O O
when O O
measured O O
by O O
LIA O O
. O O

Statins B-GENE O
: O O
lower O O
lipids O O
and O O
better O O
bones O O
? O O
Although O O
statins O O
are O O
widely O O
used O O
as O O
cholesterol O O
- O O
lowering O O
drugs O O
, O O
a O O
recent O O
study O O
suggests O O
that O O
these O O
compounds O O
have O O
anabolic O O
effects O O
on O O
bone O O
and O O
could O O
be O O
developed O O
into O O
new O O
treatments O O
for O O
common O O
metabolic O O
bone O O
diseases O O
such O O
as O O
osteoporosis O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
The O O
sexually O O
transmitted O O
diseases O O
( O O
STD O O
) O O
control O O
program O O
for O O
female O O
sex O O
workers O O
( O O
FSW O O
) O O
in O O
Lima O O
, O O
Peru O O
, O O
provided O O
periodic O O
serological O O
tests O O
for O O
syphilis O O
and O O
cervical O O
smears O O
for O O
gonococci O O
, O O
but O O
not O O
medication O O
for O O
STD O O
or O O
condoms O O
. O O

RESULTS O O
: O O
The O O
binding O O
of O O
00mTc O O
d O O
, O O
0 O O
- O O
HMPAO O O
to O O
human O O
placenta O O
ranged O O
from O O
0 O O
. O O
00 O O
% O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
% O O
to O O
0 O O
. O O
00 O O
% O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
% O O
per O O
0 O O
ml O O
standard O O
solution O O
. O O

Sequence O O
analysis O O
suggests O O
that O O
TtrA B-GENE O
contains O O
a O O
molybdopterin O O
guanine O O
dinucleotide O O
cofactor O O
and O O
a O O
[ O O
0Fe O O
- O O
0S O O
] O O
cluster O O
, O O
that O O
TtrB B-GENE O
binds O O
four O O
[ O O
0Fe O O
- O O
0S O O
] O O
clusters O O
, O O
and O O
that O O
TtrC B-GENE O
is O O
an O O
integral O O
membrane O O
protein O O
containing O O
a O O
quinol O O
oxidation O O
site O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
spontaneous O O
reports O O
of O O
suspected O O
adverse O O
drug O O
reactions O O
, O O
observed O O
in O O
elderly O O
patients O O
( O O
over O O
00 O O
years O O
of O O
age O O
) O O
in O O
Sicily O O
( O O
Italy O O
) O O
during O O
the O O
period O O
from O O
0 O O
January O O
0000 O O
to O O
00 O O
December O O
0000 O O
. O O

The O O
recruitment O O
of O O
constitutively O O
phosphorylated O O
p000 B-GENE O
( O O
neu B-GENE O
) O O
and O O
the O O
activated O B-GENE
mitogenic O I-GENE
pathway O I-GENE
proteins O I-GENE
to O O
this O O
membrane O O
- O O
microfilament O O
interaction O O
site O O
provides O O
a O O
physical O O
model O O
for O O
integrating O O
the O O
assembly O O
of O O
the O O
mitogenic O O
pathway O O
with O O
the O O
transmission O O
of O O
growth O O
factor O O
signal O O
to O O
the O O
cytoskeleton O O
. O O

CONCLUSIONS O O
: O O
In O O
addition O O
to O O
the O O
superiority O O
of O O
octafluoropropane O O
- O O
filled O O
microspheres O O
to O O
air O O
- O O
filled O O
microspheres O O
for O O
LV O O
opacification O O
, O O
the O O
efficacy O O
of O O
OCTA O O
is O O
relatively O O
unaffected O O
by O O
impaired O O
LV O O
function O O
and O O
is O O
less O O
susceptible O O
to O O
the O O
effects O O
of O O
poor O O
echogenicity O O
than O O
AIR O O
. O O

The O O
delta B-GENE O
srb00 I-GENE O
mutation I-GENE O
also O O
influenced O O
on O O
the O O
transcript O O
levels O O
of O O
meiosis O B-GENE
- O I-GENE
inducing O I-GENE
genes O I-GENE
called O O
IME0 B-GENE O
and O O
IME0 B-GENE O
: O O
the O O
mutation O O
elevated O O
the O O
transcript O O
level O O
of O O
IME0 B-GENE O
but O O
reduced O O
that O O
of O O
IME0 B-GENE O
, O O
resulting O O
in O O
partial O O
defects O O
in O O
premeiotic O O
DNA O O
synthesis O O
and O O
meiosis O O
. O O

Effects O O
of O O
spatial O O
and O O
temporal O O
smoothing O O
on O O
stimulated O O
brillouin O O
scattering O O
in O O
the O O
independent O O
- O O
hot O O
- O O
spot O O
model O O
limit O O
The O O
influence O O
of O O
laser O O
beam O O
smoothing O O
on O O
stimulated O O
Brillouin O O
backscattering O O
( O O
SBBS O O
) O O
is O O
studied O O
analytically O O
in O O
the O O
limit O O
of O O
the O O
independent O O
hot O O
spot O O
model O O
. O O

Area O O
under O O
the O O
drug O O
concentration O O
- O O
time O O
curves O O
( O O
AUC0 O O
- O O
00 O O
hr O O
) O O
for O O
MTX O O
were O O
0000 O O
and O O
0000 O O
ng O O
* O O
hr O O
/ O O
ml O O
from O O
PG O B-GENE
- O I-GENE
0 O I-GENE
. O O
0 O O
% O O
Azone O O
and O O
PG O B-GENE
- O I-GENE
0 O I-GENE
. O O
0 O O
% O O
Azone O O
systems O O
respectively O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
silymarin O O
may O O
exert O O
a O O
strong O O
anticarcinogenic O O
effect O O
against O O
PCA O O
and O O
that O O
this O O
effect O O
is O O
likely O O
to O O
involve O O
impairment O O
of O O
erbB0 B-GENE B-GENE
- O I-GENE
SHC B-GENE I-GENE
- O O
mediated O O
signaling O O
pathway O O
, O O
induction O O
of O O
CDKIs B-GENE O
, O O
and O O
a O O
resultant O O
G0 O O
arrest O O
. O O

These O O
results O O
suggest O O
that O O
, O O
for O O
the O O
HML B-GENE O
ARS O O
cluster O O
( O O
ARS000 B-GENE O
, O O
ARS000 B-GENE O
, O O
and O O
ARS000 B-GENE O
) O O
, O O
inactivity O O
of O O
origins O O
is O O
independent O O
of O O
local O O
transcriptional O O
silencing O O
, O O
even O O
though O O
origins O O
and O O
silencers O O
share O O
key O O
cis O O
- O O
and O O
trans O O
- O O
acting O O
components O O
. O O

For O O
EPV O O
0 O O
, O O
00 O O
, O O
or O O
00 O O
, O O
the O O
bias O O
exceeded O O
00 O O
% O O
for O O
0 O O
, O O
0 O O
, O O
and O O
0 O O
in O O
the O O
0 O O
- O O
predictor O O
model O O
respectively O O
, O O
when O O
a O O
conventional O O
selection O O
criterion O O
was O O
used O O
( O O
alpha O O
= O O
0 O O
. O O
00 O O
) O O
. O O

Previously O O
, O O
we O O
showed O O
that O O
the O O
APRE O B-GENE
is O O
a O O
cytokine O O
[ O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
( O O
TNFalpha B-GENE B-GENE
) O O
] O O
- O O
inducible O O
enhancer O O
by O O
binding O O
the O O
heterodimeric B-GENE B-GENE
nuclear I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
kappaB I-GENE I-GENE
( O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB I-GENE I-GENE
) O O
complex O O
Rel B-GENE O
A I-GENE O
x O O
NF B-GENE O
- I-GENE O
kappaB0 I-GENE O
. O O

We O O
concluded O O
that O O
activation O O
of O O
c B-GENE B-GENE
- I-GENE O
fosER I-GENE O
mediated O O
transcriptional O O
inhibition O O
of O O
p00 B-GENE B-GENE
( O O
Cip0 B-GENE B-GENE
/ O O
WAF0 B-GENE B-GENE
) O O
through O O
a O O
previously O O
uncharacterized O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
site I-GENE O
, O O
revealing O O
an O O
important O O
role O O
for O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
in O O
negative O O
control O O
of O O
cell O O
cycle O O
regulatory O O
genes O O
. O O

Type O O
I O O
position O O
- O O
vestibular O O
- O O
pause O O
( O O
PVP O O
I O O
) O O
and O O
vestibular O O
- O O
only O O
( O O
V O O
I O O
) O O
neurons O O
, O O
as O O
well O O
as O O
a O O
smaller O O
number O O
of O O
other O O
type O O
I O O
and O O
type O O
II O O
eye O O
- O O
plus O O
- O O
vestibular O O
neurons O O
were O O
studied O O
. O O

We O O
also O O
provide O O
evidence O O
that O O
gar0 B-GENE O
is O O
phosphorylated O O
in O O
vitro O O
by O O
a O O
p00 B-GENE B-GENE
( O O
suc0 B-GENE B-GENE
) O O
- O O
Sepharose O O
- O O
bound O O
kinase O O
from O O
Schizosaccharomyces O O
pombe O O
extracts O O
that O O
displays O O
cell O O
cycle O O
- O O
regulated O O
activity O O
similar O O
to O O
that O O
of O O
the O O
p00 B-GENE B-GENE
( O O
cdc0 B-GENE O
( O O
kinase O O
. O O

We O O
have O O
separated O O
a O O
dermatan O O
sulfate O O
proteoglycan O O
, O O
epiphycan O O
, O O
from O O
decorin B-GENE O
and O O
biglycan O O
by O O
using O O
dissociative O O
extraction O O
of O O
bovine O O
fetal O O
epiphyseal O O
cartilage O O
, O O
followed O O
by O O
sequential O O
ion O O
- O O
exchange O O
, O O
gel O O
permeation O O
, O O
hydrophobic O O
, O O
and O O
Zn0 O O
+ O O
chelate O O
chromatographic O O
steps O O
. O O

These O O
cells O O
fail O O
to O O
generate O O
the O O
signals O O
to O O
phosphorylate O O
CREB B-GENE O
and O O
produce O O
significantly O O
less O O
of O O
the O O
cytokine O B-GENE
Interleukin B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
in O O
response O O
to O O
agents O O
that O O
either O O
increase O O
intracellular O O
Ca0 O O
+ O O
and O O
/ O O
or O O
activate O B-GENE
protein B-GENE I-GENE
kinase I-GENE I-GENE
C I-GENE O
. O O

Both O O
of O O
these O O
dogs O O
had O O
low O O
serum O O
IgG B-GENE O
( O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
mg O O
/ O O
ml O O
) O O
and O O
the O O
second O O
littermate O O
also O O
had O O
reduced O O
serum O O
IgA B-GENE O
( O O
< O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
00 O O
mg O O
/ O O
ml O O
) O O
. O O

Here O O
, O O
we O O
present O O
evidence O O
that O O
exposure O O
of O O
DT00 O O
lymphoma O O
B O O
cells O O
to O O
low O O
energy O O
electromagnetic O O
field O O
( O O
EMF O O
) O O
results O O
in O O
a O O
tyrosine B-GENE O
kinase I-GENE O
- O O
dependent O O
activation O O
of O O
phospholipase B-GENE B-GENE
Cgamma0 I-GENE I-GENE
( O O
PLC B-GENE B-GENE
- I-GENE I-GENE
gamma0 I-GENE I-GENE
) O O
leading O O
to O O
increased O O
inositol O O
phospholipid O O
turnover O O
. O O

The O O
ability O O
to O O
maintain O O
expression O O
of O O
FAS0 B-GENE O
in O O
nmt0 B-GENE O
- O O
000Dino0 B-GENE O
Delta O O
cells O O
suggests O O
the O O
existence O O
of O O
another O O
transcription O B-GENE
factor O I-GENE
, O O
or O O
factors O O
, O O
whose O O
expression O O
/ O O
activity O O
is O O
inversely O O
related O O
to O O
overall O O
levels O O
of O O
cellular O B-GENE
protein O I-GENE
N O I-GENE
- O I-GENE
myristoy O I-GENE
- O O
lation O O
. O O

In O O
the O O
budding O O
yeast O O
, O O
Saccharomyces O O
cerevisiae O O
, O O
replicators O O
can O O
function O O
outside O O
the O O
chromosome O O
as O O
autonomously O O
replicating O O
sequence O O
( O O
ARS O O
) O O
elements O O
; O O
however O O
, O O
within O O
chromosome O O
III O O
, O O
certain O O
ARSs O O
near O O
the O O
transcriptionally O O
silent O O
HML B-GENE O
locus I-GENE O
show O O
no O O
replication O O
origin O O
activity O O
. O O

Cytokine O O
- O O
induced O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE O
DNA O O
binding O O
activity O O
, O O
RelA B-GENE B-GENE
nuclear O I-GENE
translocation O I-GENE
, O O
I B-GENE O
kappa I-GENE B-GENE
B I-GENE I-GENE
alpha I-GENE I-GENE
degradation O I-GENE
, O O
I B-GENE O
kappa I-GENE O
B I-GENE O
serine O O
00 O O
phosphorylation O O
, O O
and O O
I B-GENE O
kappa I-GENE B-GENE
B I-GENE I-GENE
kinase I-GENE I-GENE
( O O
IKK B-GENE O
) O O
activity O O
were O O
blocked O O
by O O
curcumin O O
treatment O O
. O O

Several O O
genes O O
or O O
transcriptional O O
units O O
were O O
identified O O
, O O
including O O
the O O
0 O O
' O O
end O O
of O O
ribosomal B-GENE B-GENE
s0 I-GENE I-GENE
kinase I-GENE I-GENE
( O O
Rsk0 B-GENE B-GENE
) O O
; O O
two O O
apparently O O
intronless O O
and O O
ORF O B-GENE
- O I-GENE
less O I-GENE
genes O I-GENE
; O O
and O O
Gpr00 B-GENE O
, O O
an O O
intronless O O
, O O
putative O B-GENE
G B-GENE I-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
coupled I-GENE O
receptor I-GENE O
. O O

Me O O
( O O
0 O O
) O O
SO O O
- O O
induced O O
neuronal O O
differentiation O O
of O O
N0E O B-GENE
- O O
000 O O
neuroblastoma O O
cells O O
increased O O
both O O
the O O
expression O O
of O O
the O O
endogenous B-GENE B-GENE
Ntr I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
and O O
reporter O O
genes O O
driven O O
by O O
NTR B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter I-GENE O
sequences I-GENE O
by O O
0 O O
- O O
0 O O
- O O
fold O O
. O O

RT O O
- O O
PCR O O
and O O
in O O
situ O O
hybridization O O
analyses O O
of O O
a O O
time O O
course O O
of O O
juvenile O O
testis O O
development O O
indicate O O
that O O
Spo00 B-GENE O
expression O O
begins O O
in O O
early O O
meiotic O O
Prophase O O
I O O
, O O
prior O O
to O O
the O O
pachytene O O
stage O O
, O O
with O O
increasing O O
accumulation O O
of O O
mRNA O O
through O O
the O O
pachytene O O
stage O O
. O O

Two O O
US O O
commercial O O
cultivars O O
( O O
Tehama O O
and O O
Vina O O
) O O
, O O
three O O
European O O
commercial O O
cultivars O O
( O O
Esterhazy O O
, O O
000 O O
, O O
G000 O O
) O O
and O O
five O O
New O O
Zealand O O
selections O O
( O O
Rex O O
, O O
Dublin O O
' O O
s O O
Glory O O
, O O
Meyric O O
, O O
McKinster O O
, O O
Stanley O O
) O O
were O O
evaluated O O
. O O

Intra O O
- O O
operative O O
ultrasound O O
( O O
IOUS O O
) O O
has O O
been O O
widely O O
used O O
in O O
an O O
attempt O O
to O O
overcome O O
these O O
difficulties O O
, O O
but O O
is O O
limited O O
by O O
its O O
two O O
- O O
dimensional O O
nature O O
, O O
inter O O
- O O
user O O
variability O O
, O O
and O O
image O O
obliteration O O
with O O
ablative O O
or O O
resectional O O
techniques O O
. O O

The O O
effect O O
of O O
acute O O
, O O
mid O O
- O O
cervical O O
spinal O O
cord O O
lesions O O
on O O
neuronal O O
and O O
reflex O O
activity O O
evoked O O
by O O
the O O
noxious O O
visceral O O
stimulus O O
, O O
colorectal O O
distension O O
( O O
CRD O O
; O O
00 O O
mmHg O O
, O O
00 O O
s O O
) O O
, O O
was O O
determined O O
in O O
halothane O O
- O O
anesthetized O O
rats O O
. O O

A O O
0 O O
kb O O
transcript O O
was O O
isolated O O
from O O
brain O O
that O O
encodes O O
a O O
approximately O O
00 O O
kDa O O
protein O O
; O O
the O O
predicted O O
protein O O
contains O O
the O O
known O O
N B-GENE O
- I-GENE O
terminal I-GENE O
Ets I-GENE O
domain I-GENE O
of O O
PE0 B-GENE O
and O O
a O O
novel O O
C O O
- O O
terminal O O
domain O O
with O O
signficant O O
homology O O
to O O
murine B-GENE O
ERF I-GENE O
. O O

Altogether O O
these O O
results O O
suggest O O
that O O
, O O
in O O
KG0a O O
cells O O
, O O
TNFalpha B-GENE O
can O O
stimulate O O
in O O
parallel O O
PC B-GENE B-GENE
- I-GENE I-GENE
PLC I-GENE I-GENE
and O O
PLD B-GENE O
, O O
whose O O
lipid O B-GENE
products O I-GENE
activate O I-GENE
in O O
turn O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
( O O
MAP B-GENE B-GENE
kinase I-GENE I-GENE
) O O
and O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB I-GENE I-GENE
signalling O O
respectively O O
. O O

CONCLUSION O O
: O O
Patients O O
wit O O
clinically O O
palpable O O
neck O O
disease O O
( O O
N0 O O
- O O
0 O O
) O O
, O O
histological O O
evidence O O
of O O
metastatic O O
nodal O O
disease O O
, O O
extracapsular O O
spread O O
, O O
and O O
three O O
or O O
more O O
positive O O
lymph O O
nodes O O
are O O
at O O
greater O O
risk O O
of O O
developing O O
failure O O
at O O
distant O O
sites O O
. O O

The O O
recognition O O
specificity O O
of O O
the O O
p00 B-GENE B-GENE
PDZ B-GENE I-GENE
domain I-GENE O
appears O O
to O O
be O O
unique O O
, O O
since O O
the O O
three O O
PDZ B-GENE O
domains I-GENE O
of O O
hDlg B-GENE O
( O O
human O O
lymphocyte O O
homologue O O
of O O
the O O
Drosophila B-GENE O
discs I-GENE O
large I-GENE O
tumor I-GENE O
suppressor I-GENE O
) O O
do O O
not O O
bind O O
the O O
cytoplasmic O O
domain O O
of O O
glycophorin B-GENE O
C I-GENE O
. O O

We O O
recommend O O
that O O
paracervical O O
block O O
with O O
lignocaine O O
should O O
be O O
used O O
in O O
conjunction O O
with O O
i O O
. O O
v O O
. O O
sedation O O
/ O O
analgesia O O
during O O
egg O O
collection O O
performed O O
through O O
the O O
transvaginal O O
route O O
under O O
ultrasound O O
guidance O O
( O O
TUGOR O O
) O O
to O O
reduce O O
the O O
pain O O
of O O
the O O
procedure O O
. O O

Based O O
on O O
a O O
type O O
I O O
error O O
of O O
0 O O
. O O
00 O O
, O O
our O O
study O O
had O O
a O O
power O O
greater O O
than O O
or O O
equal O O
to O O
00 O O
% O O
to O O
detect O O
group O O
differences O O
in O O
treatment O O
effect O O
of O O
greater O O
than O O
or O O
equal O O
to O O
00 O O
% O O
to O O
00 O O
% O O
. O O

Mucosal O O
application O O
of O O
NCX O O
- O O
0000 O O
, O O
however O O
, O O
did O O
not O O
cause O O
PD O O
reduction O O
and O O
luminal O O
H O O
+ O O
loss O O
, O O
but O O
produced O O
a O O
marked O O
hyperemia O O
, O O
resulting O O
in O O
no O O
damage O O
in O O
the O O
stomach O O
of O O
both O O
normal O O
and O O
STZ O O
- O O
diabetic O O
rats O O
. O O

This O O
dynamic O O
response O O
strongly O O
suggests O O
that O O
the O O
p00 B-GENE B-GENE
and O O
Rb B-GENE O
tumor O O
suppressor O O
pathways O O
are O O
intact O O
in O O
HeLa O O
cells O O
and O O
that O O
repression O O
of O O
HPV B-GENE O
E0 I-GENE O
and O O
E0 B-GENE O
mobilizes O O
these O O
pathways O O
in O O
an O O
orderly O O
fashion O O
to O O
deliver O O
growth O O
inhibitory O O
signals O O
to O O
the O O
cells O O
. O O

The O O
frequency O O
of O O
positive O O
anti B-GENE O
- I-GENE O
GM0 I-GENE O
antibody I-GENE O
titers O O
in O O
the O O
Guillain O O
- O O
Barre O O
syndrome O O
patients O O
with O O
PEN O O
00 O O
isolates O O
was O O
higher O O
than O O
that O O
in O O
the O O
Guillain O O
- O O
Barre O O
syndrome O O
and O O
Fisher O O
' O O
s O O
syndrome O O
patients O O
without O O
PEN O O
00 O O
isolates O O
. O O

Neither O O
of O O
these O O
proteins O O
, O O
individually O O
or O O
as O O
a O O
pair O O
, O O
can O O
bind O O
the O O
alpha B-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
0 I-GENE O
' I-GENE O
UTR I-GENE O
unless O O
they O O
are O O
complexed O O
with O O
the O O
remaining O O
non O O
- O O
poly O O
( O O
C O O
) O O
binding O O
proteins O O
of O O
the O O
alpha B-GENE B-GENE
- I-GENE I-GENE
complex I-GENE I-GENE
. O O

Although O O
previous O O
data O O
have O O
suggested O O
that O O
Rev B-GENE O
uses O O
the O O
same O O
export O O
pathway O O
as O O
uracil O O
- O O
rich O O
small O O
nuclear O O
RNAs O O
and O O
0S B-GENE O
ribosomal I-GENE O
RNA I-GENE O
, O O
the O O
CTE O O
seems O O
to O O
interact O O
with O O
evolutionarily O O
conserved O O
factors O O
that O O
are O O
essential O O
for O O
cellular O O
mRNA O O
export O O
. O O

Consistent O O
with O O
previous O O
reports O O
, O O
addition O O
of O O
a O O
myristoylation O O
signal O O
to O O
mSos0 B-GENE O
( O O
MyrSos0 B-GENE O
) O O
rendered O O
it O O
transforming O O
for O O
NIH O O
0T0 O O
cells O O
and O O
deletion O O
of O O
the O O
mSos B-GENE B-GENE
C I-GENE I-GENE
terminus I-GENE I-GENE
( O O
MyrSos0 B-GENE B-GENE
- I-GENE I-GENE
deltaC I-GENE I-GENE
) O O
did O O
not O O
interfere O O
with O O
this O O
activity O O
. O O

RESULTS O O
: O O
Using O O
information O O
in O O
the O O
dbEST O O
database O O
of O O
expressed O O
sequence O O
tags O O
, O O
we O O
isolated O O
an O O
Arabidopsis O B-GENE
thaliana O I-GENE
gene O I-GENE
( O O
GCR0 B-GENE O
) O O
that O O
encodes O O
a O O
protein O O
with O O
seven O O
predicted O O
membrane O O
- O O
spanning O O
domains O O
and O O
other O O
features O O
characteristic O O
of O O
0TM B-GENE O
receptors I-GENE O
. O O

Collectively O O
, O O
this O O
study O O
emphasizes O O
a O O
critical O O
role O O
of O O
Phox0a B-GENE O
as O O
well O O
as O O
its O O
functional O O
synergism O O
with O O
other O O
transcription O O
factors O O
( O O
e O O
. O O
g O O
. O O
, O O
CREB B-GENE O
, O O
AP0 B-GENE O
, O O
and O O
Sp0 B-GENE O
) O O
in O O
transcriptional O O
activation O O
of O O
the O O
DBH B-GENE B-GENE
gene I-GENE I-GENE
. O O

Sequence O O
comparisons O O
strongly O O
suggest O O
that O O
the O O
S00a B-GENE O
and O O
the O O
ubiquitin B-GENE O
coding O O
sequences O O
found O O
in O O
the O O
genome O O
of O O
CP O O
Rit O O
were O O
both O O
derived O O
from O O
a O O
bovine O O
mRNA O O
encoding O O
a O O
hybrid O O
protein O O
with O O
the O O
structure O O
NH0 O O
- O O
ubiquitin B-GENE O
- O O
S00a B-GENE O
- O O
COOH O O
. O O

In O O
co O O
- O O
transfection O O
studies O O
, O O
the O O
expression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
plus O O
c B-GENE O
- I-GENE O
Fos I-GENE O
enhanced O O
the O O
transactivation O O
of O O
oIFNtau B-GENE B-GENE
- O O
CAT B-GENE O
but O O
the O O
expression O O
of O O
GATA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
GATA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
or O O
GATA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
did O O
not O O
. O O

Taken O O
together O O
, O O
these O O
results O O
demonstrate O O
that O O
the O O
RP B-GENE O
, O O
like O O
the O O
00S B-GENE O
proteasome I-GENE O
, O O
is O O
functionally O O
and O O
structurally O O
conserved O O
among O O
eukaryotes O O
and O O
indicate O O
that O O
the O O
plant B-GENE O
RPT I-GENE O
subunits I-GENE O
, O O
like O O
their O O
yeast O O
counterparts O O
, O O
have O O
non O O
- O O
redundant O O
functions O O
. O O

The O O
MXR B-GENE B-GENE
gene I-GENE I-GENE
encodes O O
a O O
half O O
- O O
transporter O O
and O O
the O O
absence O O
of O O
cytogenetic O O
evidence O O
of O O
coamplification O O
of O O
other O O
regions O O
suggests O O
that O O
a O O
partner O O
may O O
not O O
be O O
overexpressed O O
, O O
and O O
instead O O
the O O
MXR B-GENE O
half I-GENE O
- I-GENE O
transporter I-GENE O
homodimerizes O O
to O O
mediate O O
drug O O
transport O O
. O O

Because O O
the O O
Pit B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
sites I-GENE O
in O O
the O O
hGH B-GENE B-GENE
- I-GENE I-GENE
N I-GENE I-GENE
gene I-GENE I-GENE
promoter I-GENE O
are O O
insufficient O O
for O O
such O O
gene O O
activation O O
in O O
vivo O O
, O O
these O O
data O O
suggested O O
a O O
unique O O
chromatin O O
- O O
mediated O O
developmental O O
role O O
for O O
Pit B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
in O O
the O O
hGH B-GENE O
LCR I-GENE O
. O O

The O O
0 O O
cDNAs O O
differed O O
in O O
the O O
length O O
of O O
their O O
respective O O
0 O O
' O O
untranslated O O
regions O O
, O O
of O O
000 O O
bp O O
in O O
Cp B-GENE O
. I-GENE O
F0 I-GENE O
and O O
00 O O
bp O O
in O O
Cp B-GENE O
. I-GENE O
F00 I-GENE O
, O O
in O O
both O O
of O O
which O O
a O O
putative O O
polyadenylation O O
signal O O
was O O
identified O O
. O O

In O O
addition O O
, O O
a O O
noncanonical O O
C B-GENE O
/ I-GENE O
EBP I-GENE O
- I-GENE O
binding I-GENE O
site I-GENE O
within O O
the O O
Gadd00gamma B-GENE B-GENE
promoter I-GENE I-GENE
where O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBPbeta I-GENE I-GENE
and O O
C B-GENE B-GENE
/ I-GENE O
EBPdelta I-GENE O
could O O
bind O O
, O O
was O O
identified O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
and O O
reporter O O
gene O O
analysis O O
. O O

We O O
had O O
previously O O
analyzed O O
repair O O
rates O O
of O O
cyclobutane O O
pyrimidine O O
dimers O O
at O O
nucleotide O O
resolution O O
along O O
the O O
human B-GENE B-GENE
JUN I-GENE I-GENE
gene I-GENE I-GENE
in O O
normal O O
fibroblasts O O
and O O
found O O
very O O
efficient O O
repair O O
of O O
sequences O O
near O O
the O O
transcription O O
initiation O O
site O O
but O O
slow O O
repair O O
along O O
the O O
promoter O O
. O O

The O O
interaction O O
between O O
piroxicam O O
and O O
poloxamer O O
was O O
studied O O
by O O
x O O
- O O
ray O O
diffractometry O O
( O O
XRD O O
) O O
, O O
infrared O O
( O O
IR O O
) O O
spectroscopy O O
and O O
differential O O
thermal O O
analysis O O
( O O
DTA O O
) O O
with O O
a O O
solid O O
dispersion O O
, O O
coprecipitate O O
, O O
or O O
physical O O
mixture O O
. O O

Using O O
Southern O O
blot O O
analysis O O
and O O
restriction O O
mapping O O
of O O
genomic O B-GENE
YAC O I-GENE
( O O
yeast O O
artificial O O
chromosome O O
) O O
and O O
cosmid O O
clones O O
, O O
we O O
located O O
the O O
human B-GENE O
RIL I-GENE O
gene I-GENE O
000 O O
- O O
000 O O
kb O O
telomeric O O
to O O
the O O
IRF0 B-GENE B-GENE
gene I-GENE I-GENE
and O O
characterized O O
its O O
genomic O O
structure O O
. O O

Echinostomiasis O O
is O O
aggravated O O
by O O
socioeconomic O O
factors O O
such O O
as O O
poverty O O
, O O
malnutrition O O
, O O
an O O
explosively O O
growing O O
free O O
- O O
food O O
market O O
, O O
a O O
lack O O
of O O
supervised O O
food O O
inspection O O
, O O
poor O O
or O O
insufficient O O
sanitation O O
, O O
other O O
helminthiases O O
, O O
and O O
declining O O
economic O O
conditions O O
. O O

The O O
localization O O
of O O
ZAP B-GENE O
- I-GENE O
00 I-GENE O
to O O
the O O
cell O O
cortex O O
is O O
, O O
therefore O O
, O O
regulated O O
by O O
the O O
activity O O
of O O
SRC B-GENE B-GENE
- I-GENE I-GENE
family I-GENE I-GENE
kinases I-GENE I-GENE
, O O
independently O O
of O O
their O O
ability O O
to O O
phosphorylate O O
immunoreceptor O O
tyrosine O O
- O O
based O O
activation O O
motifs O O
of O O
the O O
TCR B-GENE O
. O O

Tensile O O
bond O O
strengths O O
between O O
resin O O
composite O O
and O O
bovine O O
dentin O O
using O O
dentin O O
adhesive O O
systems O O
( O O
Clearfil O O
Liner O O
Bond O O
II O O
: O O
LB O O
II O O
; O O
Scotchbond O O
Multi O O
- O O
Purpose O O
: O O
MP O O
) O O
bonding O O
systems O O
showed O O
a O O
large O O
scatter O O
among O O
students O O
and O O
dentists O O
. O O

Downregulation O O
of O O
FUS B-GENE O
expression O O
in O O
BCR B-GENE O
/ O O
ABL B-GENE O
- O O
expressing O O
00Dcl0 O O
cells O O
was O O
associated O O
with O O
suppression O O
of O O
growth O O
factor O O
- O O
independent O O
colony O O
formation O O
, O O
restoration O O
of O O
G B-GENE B-GENE
- I-GENE I-GENE
CSF I-GENE I-GENE
- O O
induced O O
granulocytic O O
differentiation O O
and O O
reduced O O
tumorigenic O O
potential O O
in O O
vivo O O
. O O

Therefore O O
, O O
in O O
order O O
to O O
search O O
for O O
the O O
latent O O
genes O O
, O O
we O O
used O O
allotype O O
- O O
specific O O
oligonucleotides O O
for O O
b0 O O
, O O
b0 O O
and O O
b0 O O
to O O
probe O O
DNAs O O
from O O
both O O
normal O O
and O O
T O O
. O O
brucei O O
- O O
infected O O
rabbits O O
by O O
Southern O O
blotting O O
. O O

The O O
algorithm O O
also O O
limited O O
TG O O
to O O
00 O O
and O O
00 O O
% O O
, O O
apoB B-GENE O
to O O
0 O O
and O O
00 O O
% O O
, O O
and O O
Lp B-GENE O
( I-GENE O
a I-GENE O
) I-GENE O
to O O
00 O O
and O O
00 O O
% O O
, O O
of O O
low O O
- O O
and O O
high O O
- O O
risk O O
groups O O
, O O
respectively O O
. O O

The O O
enhanced O O
binding O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Abl I-GENE I-GENE
to O O
DNA O O
containing O O
0 O O
- O O
methylcytosine O O
residues O O
may O O
result O O
from O O
an O O
increased O O
propensity O O
of O O
the O O
double O O
helix O O
to O O
denature O O
locally O O
coupled O O
with O O
a O O
protein O O
- O O
induced O O
reduction O O
in O O
the O O
base O O
stacking O O
interaction O O
. O O

The O O
potency O O
of O O
the O O
effect O O
of O O
Nim O O
( O O
0 O O
. O O
0 O O
mg O O
. O O
kg O O
- O O
0 O O
i O O
. O O
p O O
. O O
) O O
was O O
similar O O
to O O
that O O
of O O
NBP O O
( O O
00 O O
mg O O
. O O
kg O O
- O O
0 O O
i O O
. O O
p O O
. O O
) O O
. O O

The O O
genome O O
organization O O
of O O
the O O
mite O O
- O O
transmitted O O
wheat O O
streak O O
mosaic O O
virus O O
( O O
WSMV O O
) O O
appears O O
to O O
parallel O O
that O O
of O O
members O O
of O O
the O O
Potyviridae O O
with O O
monopartite O O
genomes O O
, O O
but O O
there O O
are O O
substantial O O
amino O O
acid O O
dissimilarities O O
with O O
other O O
potyviral O O
polyproteins O O
. O O

The O O
AtERF B-GENE O
genes I-GENE O
were O O
differentially O O
regulated O O
by O O
ethylene O O
and O O
by O O
abiotic O O
stress O O
conditions O O
, O O
such O O
as O O
wounding O O
, O O
cold O O
, O O
high O O
salinity O O
, O O
or O O
drought O O
, O O
via O O
ETHYLENE B-GENE O
- I-GENE O
INSENSITIVE0 I-GENE O
( O O
EIN0 B-GENE O
) O O
- O O
dependent O O
or O O
- O O
independent O O
pathways O O
. O O

CONCLUSIONS O O
: O O
There O O
is O O
a O O
relation O O
in O O
the O O
topography O O
of O O
some O O
visual O O
field O O
areas O O
assessed O O
by O O
SWAP O O
and O O
the O O
inferotemporal O O
neuroretinal O O
rim O O
area O O
, O O
which O O
may O O
play O O
a O O
role O O
in O O
the O O
diagnosis O O
and O O
follow O O
- O O
up O O
of O O
suspected O O
glaucoma O O
. O O

Activation O O
of O O
PKA B-GENE O
by O O
0 O O
- O O
bromo O O
- O O
cyclic O O
AMP O O
or O O
forskolin O O
, O O
and O O
inhibition O O
of O O
PKC B-GENE O
by O O
calphostin O O
C O O
, O O
resulted O O
in O O
a O O
significant O O
decrease O O
in O O
0TP B-GENE O
activity O O
as O O
well O O
as O O
in O O
vitro O O
ERK B-GENE O
kinase I-GENE O
activity O O
in O O
CRAC O O
. O O

In O O
patients O O
with O O
type O O
II O O
tumors O O
, O O
the O O
pattern O O
of O O
lymphatic O O
spread O O
was O O
primarily O O
directed O O
toward O O
the O O
paracardial O O
, O O
lesser O O
curvature O O
, O O
and O O
left O O
gastric O O
artery O O
nodes O O
; O O
esophagectomy O O
offered O O
no O O
survival O O
benefit O O
over O O
extended O O
gastrectomy O O
in O O
these O O
patients O O
. O O

These O O
probable O O
border O O
sequences O O
are O O
closely O O
related O O
to O O
those O O
of O O
other O O
known O O
T O O
- O O
regions O O
and O O
define O O
a O O
second O O
T O O
- O O
region O O
of O O
pTiChry0 O O
, O O
called O O
T O O
- O O
right O O
( O O
TR O O
) O O
, O O
that O O
confers O O
production O O
of O O
the O O
Amadoriopines O O
. O O

CONCLUSION O O
: O O
Our O O
results O O
suggest O O
that O O
AIF O O
peak O O
saturation O O
leads O O
to O O
a O O
significant O O
systematic O O
error O O
in O O
the O O
determination O O
of O O
CBV O O
and O O
CBF O O
values O O
and O O
has O O
necessarily O O
to O O
be O O
taken O O
into O O
account O O
for O O
dynamic O O
contrast O O
- O O
enhanced O O
MR O O
perfusion O O
studies O O
. O O

It O O
is O O
present O O
in O O
the O O
nucleus O O
of O O
the O O
cells O O
in O O
which O O
it O O
is O O
expressed O O
and O O
can O O
phosphorylate O O
and O O
activate O O
the O O
cyclic B-GENE O
AMP I-GENE O
response I-GENE O
element I-GENE O
binding I-GENE O
proteins I-GENE O
CREB B-GENE O
and O O
CREM B-GENE O
tau I-GENE O
in O O
a O O
manner O O
analogous O O
to O O
protein B-GENE O
kinase I-GENE O
A I-GENE O
. O O

Restriction O O
enzyme O O
mapping O O
, O O
subcloning O O
, O O
and O O
DNA O O
sequencing O O
analysis O O
of O O
recombinant O O
phage O O
lambda O O
and O O
P0 O O
clones O O
revealed O O
that O O
exons O O
encoding O O
the O O
0 O O
. O O
0 O O
- O O
kb O O
mouse B-GENE O
TS I-GENE O
mRNA I-GENE O
are O O
dispersed O O
over O O
> O O
000 O O
kb O O
genomic O O
DNA O O
. O O

Protein B-GENE O
C I-GENE O
deficiency O O
or O O
protein B-GENE O
S I-GENE O
deficiency O O
was O O
the O O
only O O
identified O O
risk O O
factor O O
for O O
0 O O
. O O
0 O O
% O O
( O O
0 O O
patients O O
) O O
and O O
00 O O
. O O
0 O O
% O O
( O O
0 O O
patients O O
) O O
, O O
respectively O O
, O O
of O O
these O O
00 O O
children O O
. O O

Alternative O O
splicing O O
of O O
fibroblast B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
0 I-GENE I-GENE
( O O
FGF B-GENE B-GENE
- I-GENE I-GENE
R0 I-GENE I-GENE
) O O
is O O
an O O
example O O
of O O
highly O O
regulated O O
alternative O O
splicing O O
in O O
which O O
exons O O
IIIb O O
and O O
IIIc O O
are O O
utilized O O
in O O
a O O
mutually O O
exclusive O O
manner O O
in O O
different O O
cell O O
types O O
. O O

The O O
divergence O O
in O O
primary O O
structure O O
between O O
the O O
sheep O O
CRF0 B-GENE O
and O O
the O O
other O O
mammalian B-GENE O
CRF0s I-GENE O
is O O
primarily O O
localized O O
to O O
the O O
extracellular O O
amino O O
terminal O O
domain O O
of O O
the O O
receptor O O
( O O
00 O O
of O O
00 O O
divergent O O
residues O O
, O O
ovine O O
vs O O
human B-GENE O
CRF0 I-GENE O
) O O
. O O

Moreover O O
, O O
this O O
enhancement O O
of O O
transcriptional O O
activation O O
by O O
COUP B-GENE O
- I-GENE O
TFI I-GENE O
requires O O
specifically O O
the O O
AF O B-GENE
- O I-GENE
0 O I-GENE
transactivation O O
function O O
of O O
ER B-GENE O
and O O
can O O
be O O
observed O O
in O O
the O O
presence O O
of O O
E0 O O
or O O
0 O O
- O O
hydroxytamoxifen O O
but O O
not O O
ICI O O
000000 O O
. O O

Pokeweed B-GENE O
antiviral I-GENE O
protein I-GENE O
( O O
PAP B-GENE O
) O O
from O O
Phytolacca O O
americana O O
is O O
a O O
highly O O
specific O O
N B-GENE O
- I-GENE O
glycosidase I-GENE O
removing O O
adenine O O
residues O O
( O O
A0000 O O
in O O
00S B-GENE O
rRNA I-GENE O
and O O
A0000 O O
in O O
00S B-GENE O
rRNA I-GENE O
) O O
from O O
intact O O
ribosomes O O
of O O
both O O
eukaryotes O O
and O O
prokaryotes O O
. O O

Conformational O O
studies O O
combining O O
secondary O O
structure O O
predictions O O
, O O
CD O O
and O O
NMR O O
spectroscopy O O
together O O
with O O
ELISA O O
assays O O
, O O
showed O O
that O O
the O O
greater O O
is O O
the O O
propensity O O
of O O
the O O
epitope O O
for O O
helix O O
formation O O
the O O
higher O O
is O O
the O O
recognition O O
by O O
anti B-GENE O
- I-GENE O
K000 I-GENE O
. O O

Bacteria O O
can O O
also O O
cause O O
a O O
labyrinthitis O O
acting O O
directly O O
on O O
the O O
inner O O
ear O O
: O O
among O O
these O O
, O O
Treponemas O O
Pallidum O O
, O O
a O O
spirochaete O O
which O O
causes O O
syphilis O O
and O O
Borrelia O O
Burgdorferi O O
, O O
a O O
spirochaete O O
that O O
causes O O
Lyme O O
Disease O O
, O O
must O O
be O O
mentioned O O
. O O

We O O
further O O
demonstrate O O
that O O
the O O
Stress B-GENE O
- I-GENE O
Activated I-GENE B-GENE
- I-GENE I-GENE
Protein I-GENE I-GENE
- I-GENE I-GENE
Kinase I-GENE I-GENE
( O O
SAPK B-GENE O
) O O
target O O
sites O O
of O O
ATF0 B-GENE B-GENE
, O O
Thr00 O B-GENE
and O O
Thr00 O O
are O O
not O O
required O O
for O O
the O O
formation O O
of O O
the O O
p000 B-GENE B-GENE
/ O O
CBP B-GENE B-GENE
- O I-GENE
ATF0 B-GENE I-GENE
multiprotein O I-GENE
complex O O
. O O

We O O
have O O
shown O O
previously O O
that O O
in O O
contrast O O
to O O
other O O
extracellular O B-GENE
matrix O I-GENE
molecules O I-GENE
pepsin B-GENE I-GENE
- O I-GENE
solubilized O I-GENE
collagen B-GENE I-GENE
VI I-GENE O
( O O
CVI B-GENE O
) O O
can O O
stimulate O O
DNA O O
synthesis O O
of O O
various O O
mesenchymal O O
cell O O
types O O
, O O
apparently O O
independent O O
of O O
integrin B-GENE B-GENE
- O O
mediated O O
signal O O
transduction O O
. O O

METHODS O O
: O O
The O O
former O O
group O O
included O O
patients O O
who O O
had O O
been O O
treated O O
with O O
at O O
least O O
four O O
PGE0 O O
alpha O O
- O O
ciclodestrina O O
, O O
short O O
- O O
term O O
treatment O O
cycles O O
per O O
year O O
while O O
the O O
latter O O
was O O
a O O
historical O O
reference O O
group O O
managed O O
without O O
prostaglandins O O
. O O

Because O O
the O O
mutant O O
defective O O
in O O
DNA O O
binding O O
also O O
fails O O
to O O
stimulate O O
Abf0 B-GENE O
ARS0 O O
DNA O O
- O O
binding O O
activity O O
, O O
our O O
results O O
suggest O O
that O O
Cdc0 B-GENE O
DNA O O
- O O
binding O O
activity O O
may O O
play O O
a O O
pivotal O O
role O O
in O O
the O O
initiation O O
of O O
DNA O O
replication O O
. O O

Resistance O O
ratios O O
for O O
the O O
other O O
field O O
strains O O
obtained O O
by O O
comparison O O
with O O
the O O
R0 O O
strain O O
ranged O O
from O O
00 O O
. O O
0 O O
to O O
000 O O
for O O
topical O O
application O O
and O O
from O O
0 O O
. O O
0 O O
to O O
0 O O
. O O
0 O O
for O O
the O O
glass O O
jar O O
method O O
. O O

Based O O
on O O
00S B-GENE O
rRNA I-GENE O
gene I-GENE O
sequence I-GENE O
analysis O O
, O O
the O O
00 O O
species O O
having O O
two O O
tuf B-GENE O
genes I-GENE O
all O O
have O O
a O O
common O O
ancestor O O
, O O
while O O
the O O
six O O
species O O
having O O
only O O
one O O
copy O O
diverged O O
from O O
the O O
enterococcal O O
lineage O O
before O O
that O O
common O O
ancestor O O
. O O

A O O
xylE B-GENE O
transcriptional I-GENE O
fusion I-GENE O
to O O
the O O
putative O O
mxbD B-GENE O
promoter I-GENE O
showed O O
low O O
- O O
level O O
expression O O
in O O
wild O O
- O O
type O O
cells O O
grown O O
on O O
one O O
- O O
carbon O O
( O O
C0 O O
) O O
compounds O O
and O O
no O O
detectable O O
expression O O
in O O
cells O O
grown O O
on O O
succinate O O
. O O

In O O
adherent O O
macrophages O O
, O O
absence O O
of O O
CD00 B-GENE O
led O O
to O O
the O O
hyperphosphorylation O O
and O O
hyperactivation O O
of O O
p00 B-GENE B-GENE
/ I-GENE O
00 I-GENE O
( O O
hck B-GENE O
) O O
and O O
p00 B-GENE B-GENE
/ I-GENE O
00 I-GENE O
( O O
lyn B-GENE O
) O O
, O O
but O O
not O O
of O O
p00 B-GENE B-GENE
( O O
c B-GENE B-GENE
- I-GENE I-GENE
fgr I-GENE I-GENE
) O O
. O O

In O O
contrast O O
to O O
the O O
wild O B-GENE
- O I-GENE
type O I-GENE
protein O I-GENE
, O O
expression O O
of O O
p00 B-GENE B-GENE
NF B-GENE I-GENE
- I-GENE I-GENE
E0 I-GENE I-GENE
lacking O O
this O O
activation O O
domain O O
in O O
an O O
NF B-GENE O
- I-GENE O
E0 I-GENE O
null O O
cell O O
line O O
fails O O
to O O
support O O
enhancer O O
- O O
dependent O O
transcription O O
in O O
transient O O
assays O O
. O O

In O O
the O O
United O O
States O O
high O O
- O O
MW O O
HES O O
000 O O
which O O
is O O
difficult O O
to O O
degrade O O
is O O
most O O
frequently O O
used O O
and O O
results O O
in O O
a O O
larger O O
in O O
vivo O O
MW O O
and O O
subsequent O O
decrease O O
in O O
factor B-GENE O
VIII I-GENE O
/ O O
von B-GENE O
Willebrand I-GENE O
factor I-GENE O
levels O O
. O O

Furthermore O O
, O O
a O O
minor O O
start O O
site O O
was O O
localized O O
000 O O
bp O O
upstream O O
of O O
the O O
major O O
site O O
using O O
reverse B-GENE O
transcriptase I-GENE O
- O O
polymerase O O
chain O O
reaction O O
with O O
various O O
P0 O O
primers O O
( O O
primer O O
walking O O
) O O
, O O
primer O O
extension O O
, O O
and O O
cDNA O O
cloning O O
. O O

Combined O O
expression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
and O O
p00 B-GENE B-GENE
induced O O
vigorous O O
transcription O O
of O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter O I-GENE
- O O
and O O
CD00RE B-GENE O
- I-GENE O
driven I-GENE O
reporter I-GENE O
constructs I-GENE O
in O O
both O O
LFA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- O O
and O O
B0 B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- O O
costimulated O O
Jurkat O O
cells O O
. O O

RT O O
- O O
PCR O O
analysis O O
showed O O
that O O
PLP B-GENE O
- I-GENE O
H I-GENE O
as O O
well O O
as O O
PLP B-GENE O
- I-GENE O
C I-GENE O
and O O
PLP B-GENE O
- I-GENE O
D I-GENE O
are O O
expressed O O
in O O
all O O
rat O O
strains O O
examined O O
, O O
confirming O O
that O O
PLP B-GENE O
diversity O O
is O O
not O O
due O O
to O O
strain O O
differences O O
. O O

In O O
ischemic O O
and O O
hypoxic O O
hypoxia O O
, O O
a O O
strong O O
correlation O O
was O O
found O O
between O O
cyt O O
a O O
, O O
a0 O O
oxidation O O
level O O
and O O
VO0 O O
in O O
both O O
ischemic O O
and O O
hypoxic O O
hypoxia O O
( O O
r0 O O
= O O
. O O
00 O O
and O O
. O O
00 O O
, O O
respectively O O
) O O
. O O

O B-GENE O
. I-GENE O
novo I-GENE O
- I-GENE O
ulmi I-GENE I-GENE
RNA I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
previously O O
believed O O
to O O
be O O
a O O
satellite O O
- O O
like O O
RNA O O
, O O
is O O
shown O O
to O O
be O O
a O O
defective O O
RNA O O
, O O
derived O O
from O O
OnuMV0 B-GENE O
- I-GENE O
Ld I-GENE O
RNA I-GENE O
by O O
multiple O O
internal O O
deletions O O
. O O

The O O
immune O O
system O O
is O O
closely O O
integrated O O
with O O
the O O
neuroendocrine O O
system O O
, O O
and O O
infection O O
- O O
induced O O
increases O O
in O O
cytokines O O
such O O
as O O
IL B-GENE O
- I-GENE O
0 I-GENE O
, O O
IL B-GENE O
- I-GENE O
0 I-GENE O
and O O
TNF B-GENE O
have O O
numerous O O
effects O O
on O O
the O O
central O O
nervous O O
system O O
. O O

Using O O
PRL B-GENE B-GENE
- I-GENE O
R I-GENE O
tagged O O
both O O
in O O
the O O
N O O
- O O
terminal O O
or O O
C O O
- O O
terminal O O
regions O O
of O O
the O O
mature O B-GENE
receptor O I-GENE
excludes O O
the O O
possibility O O
of O O
a O O
cleaved O O
fragment O O
which O O
could O O
have O O
been O O
subsequently O O
imported O O
into O O
the O O
nucleus O O
. O O

Five O O
cell O O
strains O O
of O O
human O O
dermal O O
fibroblasts O O
were O O
each O O
treated O O
with O O
three O O
samples O O
of O O
burn O O
blister O O
fluid O O
and O O
the O O
effect O O
compared O O
with O O
the O O
rate O O
of O O
contraction O O
of O O
free O O
floating O O
fibroblast O O
populated O O
collagen B-GENE O
lattices O O
( O O
FPCL O O
) O O
. O O

During O O
the O O
CR O O
/ O O
PP O O
diet O O
only O O
the O O
HS O O
subjects O O
did O O
not O O
show O O
the O O
stress O O
- O O
induced O O
rise O O
in O O
depression O O
, O O
decline O O
in O O
vigour O O
and O O
cortisol O O
elevation O O
that O O
they O O
showed O O
after O O
the O O
PR O O
/ O O
CP O O
diet O O
. O O

AMY B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
was O O
localized O O
in O O
the O O
cytoplasm O O
in O O
cells O O
expressing O O
c B-GENE O
- I-GENE O
myc I-GENE O
at O O
low O O
levels O O
, O O
but O O
in O O
the O O
nucleus O O
in O O
the O O
cells O O
of O O
a O O
high O O
c B-GENE O
- I-GENE O
myc I-GENE O
expression O O
in O O
transiently O O
transfected O O
cells O O
. O O

Examination O O
of O O
DNA O O
: O O
protein O O
binding O O
complexes O O
by O O
gel O O
- O O
shift O O
analysis O O
indicated O O
that O O
nuclear O O
factors O O
from O O
both O O
proliferative O O
and O O
growth O O
- O O
arrested O O
cells O O
bound O O
to O O
the O O
DNA O O
fragment O O
spanning O O
- O O
000 O O
- O O
- O O
000 O O
bp O O
. O O

Competitive O O
mobility O O
shift O O
assays O O
using O O
either O O
alphaT0 O O
- O O
0 O O
nuclear O O
extract O O
or O O
recombinant B-GENE B-GENE
SF I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
protein I-GENE I-GENE
clearly O O
indicated O O
that O O
SF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
able O O
to O O
interact O O
specifically O O
with O O
this O O
GSE B-GENE O
element I-GENE O
positioned O O
at O O
- O O
000 O O
. O O

FISH O O
using O O
a O O
whole O O
chromosome O O
0 O O
paint O O
demonstrated O O
multiple O O
rearrangements O O
involving O O
chromosome O O
0 O O
in O O
MCF O O
- O O
0 O O
AdVp0000 O O
and O O
MCF O B-GENE
- O I-GENE
0 O I-GENE
MX O O
, O O
while O O
S0 O O
- O O
M0 O O
- O O
00 O O
contained O O
only O O
a O O
simple O O
reciprocal O O
translocation O O
. O O

Forty O O
0 O O
- O O
month O O
old O O
SD O O
female O O
rats O O
were O O
randomly O O
divided O O
into O O
four O O
groups O O
, O O
namely O O
sham O O
operation O O
, O O
bilateral O O
ovariectomy O O
, O O
ovariectomy O O
plus O O
supplementary O O
ethinyl O O
estradiol O O
( O O
0 O O
. O O
0 O O
microgram O O
/ O O
000 O O
g O O
B O O
. O O

Abrogation O O
of O O
p00 B-GENE O
function O O
by O O
E0 B-GENE O
resulted O O
in O O
an O O
increase O O
in O O
the O O
spontaneous O O
mutation O O
frequencies O O
at O O
the O O
heterozygous O B-GENE
thymidine B-GENE I-GENE
kinase I-GENE I-GENE
( O O
TK B-GENE O
) O O
locus O O
but O O
not O O
at O O
the O O
hemizygous O O
hypoxanthine B-GENE O
phosphoribosyl I-GENE O
transferase I-GENE O
( O O
HPRT B-GENE O
) O O
locus O O
. O O

Plectin B-GENE O
and O O
desmoplakin B-GENE O
have O O
GSR O O
- O O
containing O O
domains O O
at O O
their O O
C O O
- O O
termini O O
and O O
we O O
further O O
demonstrate O O
that O O
the O O
GSR O O
- O O
containing O O
domain O O
of O O
plectin B-GENE B-GENE
, O O
but O O
not O O
desmoplakin B-GENE O
, O O
can O O
bind O O
to O O
MTs O O
in O O
vivo O O
. O O

Children O O
' O O
s O O
temperament O O
and O O
maternal O O
socialization O O
at O O
Time O O
0 O O
( O O
n O O
= O O
000 O O
, O O
aged O O
0 O O
- O O
0 O O
years O O
) O O
were O O
considered O O
predictors O O
of O O
future O O
conscience O O
, O O
assessed O O
using O O
new O O
observational O O
and O O
narrative O O
measures O O
. O O

Thus O O
, O O
an O O
increase O O
in O O
plasma B-GENE O
TBG I-GENE O
and O O
a O O
shift O O
from O O
adrenal O O
androgen O O
and O O
mineralocorticoid O O
steroid O O
secretion O O
towards O O
cortisol O O
secretion O O
may O O
be O O
endocrine O O
markers O O
for O O
progression O O
of O O
the O O
disease O O
in O O
patients O O
with O O
HIV O O
- O O
infection O O
. O O

Genes O O
for O O
ocs B-GENE B-GENE
element I-GENE I-GENE
binding I-GENE I-GENE
factors I-GENE I-GENE
( O O
OBFs B-GENE B-GENE
) O O
, O O
belonging O O
to O O
a O O
specific O O
class O O
of O O
basic B-GENE B-GENE
- I-GENE I-GENE
region I-GENE I-GENE
leucine I-GENE I-GENE
zipper I-GENE I-GENE
( I-GENE O
bZIP I-GENE B-GENE
) I-GENE O
transcription I-GENE O
factors I-GENE O
, O O
have O O
been O O
isolated O O
in O O
a O O
number O O
of O O
plants O O
. O O

Thus O O
E00 O O
. O O
0TG0B0 O O
is O O
a O O
useful O O
ES O O
cell O O
line O O
for O O
modifying O O
the O O
mouse O O
genome O O
using O O
the O O
HPRT B-GENE B-GENE
gene I-GENE I-GENE
as O O
a O O
selection O O
marker O O
and O O
for O O
transmission O O
at O O
a O O
high O O
frequency O O
into O O
the O O
mouse O O
germ O O
line O O
. O O

One O O
RNA O O
construct O O
which O O
consisted O O
of O O
000 O O
nucleotides O O
( O O
nt O O
) O O
from O O
nt O O
000 O O
to O O
nt O O
000 O O
formed O O
a O O
heterodimeric O O
complex O O
with O O
the O O
RNA O O
which O O
consisted O O
of O O
000 O O
nucleotides O O
from O O
nt O O
000 O O
to O O
nt O O
000 O O
. O O

NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
/ O O
Rel B-GENE O
transcription O O
factors O O
participate O O
in O O
the O O
activation O O
of O O
numerous O O
genes O O
involved O O
in O O
immune O O
regulation O O
/ O O
inflammation O O
including O O
cytokines O O
, O O
cell O O
surface O O
receptors O O
, O O
adhesion O O
molecules O O
, O O
and O O
acute O O
phase O O
proteins O O
. O O

Consistent O O
with O O
this O O
model O O
, O O
a O O
synthetic O O
construct O O
containing O O
three O O
tandem O O
copies O O
of O O
the O O
native O O
LDL B-GENE O
receptor I-GENE O
SREBP B-GENE O
site O O
linked O O
to O O
a O O
single O O
Sp0 B-GENE O
site I-GENE O
was O O
also O O
significantly O O
activated O O
in O O
a O O
buttonhead B-GENE O
- O O
independent O O
fashion O O
. O O

These O O
discoloration O O
' O O
s O O
can O O
be O O
treated O O
in O O
several O O
ways O O
but O O
up O O
to O O
lately O O
tooth O O
structure O O
had O O
to O O
be O O
removed O O
in O O
an O O
irreversible O O
manner O O
in O O
order O O
to O O
provide O O
sufficient O O
bulk O O
for O O
the O O
new O O
restorative O O
material O O
. O O

[ O O
Pulmonary O O
vascular O O
resistance O O
( O O
PVR O O
) O O
during O O
00 O O
% O O
O0 O O
- O O
PVR O O
during O O
00 O O
% O O
O0 O O
/ O O
PVR O O
during O O
00 O O
% O O
O0 O O
] O O
x O O
000 O O
was O O
termed O O
as O O
hypoxic O O
pulmonary O O
vasoconstriction O O
( O O
HPV O O
) O O
. O O

The O O
pel B-GENE B-GENE
gene I-GENE I-GENE
from O O
an O O
Amycolata O O
sp O O
. O O
encoding O O
a O O
pectate B-GENE O
lyase I-GENE O
( O O
EC B-GENE O
0 I-GENE O
. I-GENE O
0 I-GENE O
. I-GENE O
0 I-GENE O
. I-GENE O
0 I-GENE O
) O O
was O O
isolated O O
by O O
activity O O
screening O O
a O O
genomic O O
DNA O O
library O O
in O O
Streptomyces O O
lividans O O
TK00 O O
. O O

The O O
identified O O
isolates O O
of O O
CSF O O
( O O
00 O O
of O O
00 O O
) O O
were O O
: O O
ECHO O O
00 O O
( O O
0 O O
) O O
, O O
ECHO O O
00 O O
( O O
0 O O
) O O
, O O
ECHO O O
0 O O
( O O
0 O O
) O O
and O O
ECHO O O
0 O O
( O O
0 O O
) O O
. O O

To O O
better O O
understand O O
the O O
role O O
of O O
Ets B-GENE O
proteins I-GENE O
in O O
Ras B-GENE O
transformation O O
, O O
we O O
have O O
now O O
analyzed O O
the O O
effects O O
of O O
stably O O
expressing O O
a O O
variety O O
of O O
Ets0 B-GENE O
constructs I-GENE O
in O O
Ras B-GENE O
- O O
transformed O O
NIH0T0 O O
( O O
DT O O
) O O
cells O O
. O O

TBP B-GENE O
can O O
be O O
phosphorylated O O
in O O
vitro O O
by O O
extracts O O
of O O
U000 O O
cells O O
or O O
by O O
bacterially O O
expressed O O
activated O O
ERK0 B-GENE O
; O O
the O O
phosphorylation O O
sites O O
were O O
mapped O O
to O O
ERK B-GENE O
kinase I-GENE O
consensus I-GENE O
sites I-GENE O
in O O
the O O
TBP B-GENE O
amino I-GENE O
- I-GENE O
terminal I-GENE O
domain I-GENE O
. O O

Peroxisome B-GENE O
proliferator I-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
receptors I-GENE I-GENE
( O O
PPAR B-GENE O
) O O
modulate O O
transcription O O
by O O
binding O O
to O O
specific O O
peroxisome O O
proliferator O O
- O O
response O O
elements O O
( O O
PPRE O O
) O O
through O O
heterodimerization O O
with O O
the O O
0 B-GENE B-GENE
- I-GENE I-GENE
cis I-GENE I-GENE
retinoic I-GENE I-GENE
acid I-GENE I-GENE
receptor I-GENE I-GENE
( O O
RXR B-GENE O
) O O
. O O

Several O O
mutations O O
disrupted O O
the O O
endonuclease O O
and O O
helicase B-GENE O
activities O O
; O O
however O O
, O O
only O O
one O O
amino B-GENE O
- I-GENE O
terminal I-GENE O
- I-GENE O
charge I-GENE O
cluster I-GENE O
mutant I-GENE O
protein I-GENE O
( O O
D00A O B-GENE
- O I-GENE
D00A O I-GENE
- O I-GENE
D00A O I-GENE
) O O
completely O O
lost O O
AAV O O
hairpin O O
DNA O O
binding O O
activity O O
. O O

It O O
was O O
demonstrated O O
that O O
the O O
processing O O
signals O O
in O O
the O O
transcript O O
, O O
i O O
. O O
e O O
. O O
both O O
donor O O
splice O O
sites O O
and O O
the O O
polyadenylation O O
site O O
located O O
in O O
the O O
muscle O O
- O O
specific O O
intron O O
, O O
have O O
to O O
be O O
weak O O
. O O

Sequence O O
analysis O O
revealed O O
that O O
the O O
MEMA B-GENE B-GENE
protein I-GENE I-GENE
is O O
identical O O
with O O
a O O
000 B-GENE O
kDa I-GENE O
nuclear I-GENE O
' I-GENE O
domain I-GENE O
rich I-GENE O
in I-GENE O
serines I-GENE O
' I-GENE O
( I-GENE O
DRS I-GENE O
) I-GENE O
protein I-GENE O
occurring O O
free O O
in O O
the O O
nucleoplasm O O
and O O
in O O
U0 B-GENE O
- I-GENE O
ribonucleoprotein I-GENE O
structures I-GENE O
. O O

Twenty O O
eligible O O
patients O O
with O O
cirrhosis O O
were O O
randomized O O
into O O
two O O
groups O O
: O O
00 O O
patients O O
treated O O
with O O
0 O O
million O O
units O O
of O O
natural O O
IFN B-GENE O
- I-GENE O
beta I-GENE O
twice O O
a O O
week O O
for O O
00 O O
months O O
and O O
00 O O
patients O O
without O O
IFN B-GENE O
therapy O O
. O O

Splicing O O
of O O
the O O
K B-GENE O
- I-GENE O
SAM I-GENE O
alternative O O
exon O O
of O O
the O O
fibroblast B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
is O O
heavily O O
dependent O O
on O O
the O O
U O O
- O O
rich O O
sequence O O
IAS0 B-GENE O
lying O O
immediately O O
downstream O O
from O O
its O O
0 O O
' O O
splice O O
site O O
. O O

Cytogenetic O O
analysis O O
of O O
LOH O O
mutants O O
by O O
chromosome O O
painting O O
indicated O O
a O O
mosaic O O
of O O
chromosomal O O
aberrations O O
involving O O
chromosome O O
00 O O
, O O
in O O
which O O
partial O O
chromosome O O
deletions O O
, O O
amplifications O O
, O O
and O O
multiple O O
translocations O O
appeared O O
heterogeneously O O
in O O
a O O
single O O
mutant O O
. O O

These O O
six O O
amino O O
acids O O
are O O
part O O
of O O
an O O
amphipathic O O
helix O O
that O O
is O O
highly O O
conserved O O
among O O
nuclear B-GENE O
hormone I-GENE O
receptors I-GENE O
and O O
contains O O
the O O
core O O
domain O O
of O O
the O O
ligand O O
- O O
dependent O O
transactivation O O
function O O
, O O
AF O B-GENE
- O I-GENE
0 O I-GENE
. O O

Alternative O O
splicing O O
of O O
ClC B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
a O O
member O O
of O O
the O O
CIC B-GENE B-GENE
chloride I-GENE I-GENE
- I-GENE I-GENE
channel I-GENE I-GENE
family I-GENE I-GENE
) O O
transcripts O O
generates O O
three O O
truncated O O
isoforms O O
one O O
of O O
which O O
, O O
ClC B-GENE B-GENE
- I-GENE I-GENE
0c I-GENE I-GENE
, O O
is O O
kidney O O
- O O
specific O O
. O O

Y00000 B-GENE O
( O O
Surf B-GENE O
- I-GENE O
0 I-GENE O
, O O
Surf B-GENE O
- I-GENE O
0 I-GENE O
) O O
, O O
Y00000 B-GENE O
( O O
Surf B-GENE O
- I-GENE O
0 I-GENE O
, O O
Surf B-GENE O
- I-GENE O
0 I-GENE O
, O O
Surf B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
, O O
and O O
Y00000 B-GENE O
( O O
Surf B-GENE O
- I-GENE O
0 I-GENE O
. O O
) O O
] O O

During O O
organogenesis O O
, O O
HFH B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
expression O O
is O O
found O O
in O O
the O O
splanchnic O O
mesoderm O O
in O O
close O O
apposition O O
of O O
the O O
gut O O
endoderm O O
, O O
suggesting O O
a O O
role O O
in O O
mesenchymal O O
- O O
epithelial O O
induction O O
of O O
lung O O
and O O
gut O O
morphogenesis O O
. O O

TRAF0 B-GENE O
is O O
known O O
to O O
associate O O
with O O
TRADD B-GENE O
, O O
and O O
expression O O
of O O
a O O
dominant O O
- O O
negative O O
N O O
- O O
terminal O O
deletion O O
TRAF0 B-GENE O
mutant I-GENE O
was O O
found O O
to O O
partially O O
inhibit O O
LMP0 B-GENE O
- O O
induced O O
JNK B-GENE O
activation O O
in O O
000 O O
cells O O
. O O

This O O
construct O O
, O O
termed O O
pDeltaCREC B-GENE O
/ O O
EBP B-GENE O
, O O
binds O O
C B-GENE O
/ I-GENE O
EBPalpha I-GENE B-GENE
and I-GENE O
beta I-GENE O
but O O
not O O
CREB B-GENE O
, O O
yet O O
it O O
confers O O
a O O
nearly O O
complete O O
glucocorticoid O O
response O O
when O O
transiently O O
transfected O O
into O O
H0IIE O O
rat O O
hepatoma O O
cells O O
. O O

Analysis O O
of O O
the O O
protein O O
sequences O O
of O O
these O O
two O O
replicases B-GENE O
, O O
together O O
with O O
previously O O
characterized O O
H B-GENE O
. I-GENE O
pylori I-GENE O
plasmid I-GENE O
replication I-GENE O
proteins I-GENE O
, O O
supports O O
the O O
formation O O
of O O
a O O
distinct O O
class O O
of O O
H B-GENE O
. I-GENE O
pylori I-GENE O
plasmid I-GENE O
proteins I-GENE O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
show O O
that O O
SRm000 B-GENE O
/ I-GENE O
000 I-GENE O
is O O
required O O
for O O
a O O
purine O O
- O O
rich O O
ESE B-GENE O
to O O
promote O O
the O O
splicing O O
of O O
a O O
pre O O
- O O
mRNA O O
derived O O
from O O
the O O
Drosophila B-GENE B-GENE
doublesex I-GENE I-GENE
gene I-GENE I-GENE
. O O

Using O O
sequence O O
information O O
from O O
human B-GENE O
BMAL0 I-GENE O
( O O
hBMAL0 B-GENE O
) O O
cDNAs O O
previously O O
reported O O
by O O
our O O
laboratory O O
, O O
we O O
have O O
isolated O O
and O O
characterized O O
cDNAs O O
encoding O O
three O O
splice O O
variants O O
of O O
the O O
mouse B-GENE B-GENE
BMAL0 I-GENE I-GENE
( O O
mBMAL0 B-GENE B-GENE
) O I-GENE
gene O I-GENE
. O O

PURPOSE O O
: O O
Previous O O
WR O O
- O O
0000 O O
human O O
pharmacokinetic O O
studies O O
were O O
limited O O
to O O
plasma O O
levels O O
in O O
patients O O
receiving O O
platinum O O
- O O
based O O
compounds O O
, O O
and O O
none O O
includes O O
the O O
effects O O
of O O
WR O O
- O O
0000 O O
on O O
endogenous O O
thiols O O
. O O

Arhythmacanthus O O
Yamaguti O O
, O O
0000 O O
is O O
maintained O O
as O O
a O O
synonym O O
of O O
Heterosentis O O
because O O
the O O
distinction O O
between O O
two O O
and O O
three O O
hook O O
types O O
is O O
made O O
equivocal O O
when O O
the O O
transition O O
between O O
the O O
apical O O
and O O
subapical O O
hooks O O
is O O
gradual O O
. O O

Following O O
EPI O O
- O O
C0000 O O
, O O
but O O
not O O
saline O O
or O O
DepoFoam O O
vehicle O O
, O O
there O O
were O O
transient O O
( O O
< O O
00 O O
hr O O
) O O
decreases O O
in O O
food O O
consumption O O
, O O
arousal O O
, O O
hindlimb O O
muscle O O
tone O O
, O O
and O O
body O O
temperature O O
. O O

Taken O O
together O O
, O O
these O O
observations O O
indicate O O
that O O
inhibition O O
of O O
p00 B-GENE B-GENE
( O O
KIP0 B-GENE B-GENE
) O O
transcription O O
through O O
PI0K B-GENE O
- O O
induced O O
FKHR B-GENE O
- I-GENE O
L0 I-GENE O
phosphorylation O O
provides O O
a O O
novel O O
mechanism O O
of O O
regulating O O
cytokine O O
- O O
mediated O O
survival O O
and O O
proliferation O O
. O O

However O O
, O O
by O O
immobilized O O
metal O O
affinity O O
chromatography O O
assay O O
, O O
self O O
- O O
association O O
of O O
PR B-GENE B-GENE
- I-GENE I-GENE
A I-GENE I-GENE
was O O
0 O O
. O O
0 O O
- O O
fold O O
more O O
efficient O O
than O O
that O O
of O O
either O O
the O O
DhLBD O O
or O O
hLBD O O
constructs O O
. O O

The O O
m0GpppN O O
cap O O
structure O O
of O O
eukaryotic O B-GENE
mRNA O I-GENE
is O O
formed O O
cotranscriptionally O O
by O O
the O O
sequential O O
action O O
of O O
three O O
enzymes O O
: O O
RNA B-GENE O
triphosphatase I-GENE O
, O O
RNA B-GENE O
guanylyltransferase I-GENE O
, O O
and O O
RNA B-GENE O
( I-GENE O
guanine I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) I-GENE O
- I-GENE O
methyltransferase I-GENE O
. O O

Polarised O O
expression O O
of O O
human O B-GENE
intestinal O I-GENE
N B-GENE I-GENE
- I-GENE I-GENE
benzoyl I-GENE I-GENE
- I-GENE I-GENE
L I-GENE I-GENE
- I-GENE I-GENE
tyrosyl I-GENE I-GENE
- I-GENE I-GENE
p I-GENE I-GENE
- I-GENE I-GENE
aminobenzoic I-GENE I-GENE
acid I-GENE I-GENE
hydrolase I-GENE I-GENE
( O O
human B-GENE B-GENE
meprin I-GENE I-GENE
) O I-GENE
alpha O I-GENE
and O O
beta O O
subunits O O
in O O
Madin O O
- O O
Darby O O
canine O O
kidney O O
cells O O
. O O

No O O
difference O O
in O O
telomere O O
length O O
was O O
seen O O
in O O
mutants O O
affected O O
in O O
the O O
regulation O O
of O O
Cdc0 B-GENE O
, O O
whereas O O
some O O
of O O
the O O
DNA O O
repair O O
mutants O O
examined O O
had O O
slightly O O
longer O O
telomeres O O
than O O
did O O
the O O
wild O O
type O O
. O O

Moreover O O
, O O
it O O
is O O
the O O
assumptions O O
behind O O
steady O O
- O O
state O O
O0 O O
uptake O O
that O O
do O O
not O O
permit O O
proper O O
interpretation O O
of O O
energy O O
expenditure O O
during O O
EPOC O O
; O O
0 O O
l O O
O0 O O
not O O
= O O
00 O O
. O O
0 O O
kJ O O
. O O

Whole O O
- O O
mount O O
in O O
situ O O
hybridization O O
to O O
early O O
mouse O O
embryos O O
of O O
0 O O
. O O
0 O O
- O O
00 O O
. O O
0 O O
days O O
indicated O O
a O O
complex O O
pattern O O
of O O
Arp0 B-GENE O
expression O O
spatially O O
overlapping O O
with O O
the O O
expression O O
of O O
All0 B-GENE O
. O O

Our O O
observations O O
suggest O O
that O O
members O O
of O O
the O O
HMG B-GENE B-GENE
- I-GENE I-GENE
I I-GENE I-GENE
family I-GENE I-GENE
play O O
an O O
important O O
role O O
in O O
SRF B-GENE O
- O O
dependent O O
transcription O O
and O O
that O O
their O O
effect O O
is O O
mediated O O
primarily O O
by O O
a O O
protein O B-GENE
- O I-GENE
protein O I-GENE
interaction O O
. O O

Another O O
stem O O
- O O
loop O O
called O O
structure O O
III O O
near O O
the O O
0 O O
' O O
- O O
end O O
of O O
repY B-GENE O
sequesters O O
both O O
the O O
0 O O
' O O
- O O
rCGCC O O
- O O
0 O O
' O O
sequence O O
and O O
the O O
repZ B-GENE O
ribosome I-GENE O
- I-GENE O
binding I-GENE O
site I-GENE O
. O O

However O O
, O O
mandibular O O
position O O
( O O
S O O
- O O
N O O
- O O
B O O
and O O
S O O
- O O
N O O
- O O
Pog O O
) O O
was O O
found O O
to O O
be O O
significantly O O
more O O
retrusive O O
in O O
Class O O
II O O
when O O
compared O O
with O O
Class O O
I O O
subjects O O
. O O

Quantitative O O
evaluation O O
of O O
the O O
steady O O
state O O
kinetics O O
of O O
MEK B-GENE O
inhibition O O
by O O
these O O
compounds O O
reveals O O
that O O
U0000 O O
has O O
approximately O O
000 O O
- O O
fold O O
higher O O
affinity O O
for O O
deltaN0 B-GENE O
- I-GENE O
S000E I-GENE O
/ I-GENE O
S000D I-GENE O
MEK I-GENE O
than O O
does O O
PD000000 O O
. O O

The O O
binding O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
ATp I-GENE I-GENE
, O O
although O O
not O O
NF B-GENE B-GENE
- I-GENE I-GENE
AT0 I-GENE I-GENE
, O O
to O O
this O O
enhancer O O
also O O
occurs O O
along O O
with O O
HTLV O B-GENE
- O I-GENE
I O I-GENE
- O O
mediated O O
infection O O
of O O
human O O
peripheral O O
blood O O
T O O
- O O
cells O O
. O O

Whereas O O
, O O
in O O
the O O
single O O
- O O
chambered O O
body O O
box O O
, O O
PenH O O
units O O
( O O
Enhanced O O
Pause O O
) O O
reflect O O
" O O
effort O O
of O O
breathing O O
. O O
" O O
This O O
is O O
measured O O
as O O
the O O
pause O O
between O O
inspiration O O
and O O
expiration O O
. O O

This O O
domain O O
, O O
although O O
adjacent O O
to O O
the O O
0 O O
' O O
edge O O
of O O
the O O
SD O O
sequence O O
, O O
does O O
not O O
inhibit O O
ribosome O O
binding O O
as O O
long O O
as O O
the O O
single O O
- O O
stranded O O
region O O
of O O
domain O O
0 O O
is O O
present O O
. O O

NF B-GENE O
- I-GENE O
kappaB I-GENE O
, O O
which O O
is O O
probably O O
important O O
for O O
basal O O
activity O O
of O O
the O O
human B-GENE B-GENE
NOS I-GENE I-GENE
II I-GENE I-GENE
promoter I-GENE I-GENE
, O O
is O O
unlikely O O
to O O
function O O
as O O
a O O
major O O
effector O O
of O O
CM O O
in O O
DLD O O
- O O
0 O O
cells O O
. O O

These O O
data O O
further O O
define O O
a O O
role O O
for O O
TRADD B-GENE O
and O O
TRAF0 B-GENE O
in O O
JNK B-GENE O
activation O O
and O O
confirm O O
that O O
LMP0 B-GENE O
utilizes O O
signalling O O
mechanisms O O
used O O
by O O
the O O
TNF B-GENE B-GENE
receptor I-GENE I-GENE
/ O O
CD00 B-GENE O
family O O
to O O
elicit O O
its O O
pleiotropic O O
activities O O
. O O

In O O
contrast O O
, O O
transiently O O
transfected O O
cells O O
expressing O O
EBNA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
revealed O O
a O O
sixfold O O
increase O O
in O O
EBNA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
protein I-GENE I-GENE
expression O O
from O O
the O O
genomic O B-GENE
EBNA B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
compared O O
to O O
EBNA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
cDNA I-GENE O
. O O

We O O
used O O
expression O O
cloning O O
to O O
identify O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
as O O
one O O
factor O O
that O O
suppressed O O
growth O O
of O O
a O O
pre O O
- O O
B O O
- O O
cell O O
variant O O
line O O
, O O
0A0 O O
- O O
M O O
. O O

Nevertheless O O
cryopreservation O O
of O O
spermatozoa O O
in O O
a O O
medium O O
containing O O
neither O O
SP O O
nor O O
biological O O
substances O O
could O O
offer O O
an O O
acceptable O O
cryoprotection O O
of O O
spermatozoa O O
to O O
be O O
used O O
in O O
assisted O O
fertilization O O
procedures O O
, O O
especially O O
for O O
intracytoplasmic O O
sperm O O
injection O O
. O O

The O O
results O O
suggest O O
that O O
GATA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
may O O
have O O
specific O O
downstream O O
targets O O
and O O
that O O
GATA B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, I-GENE O
- I-GENE O
0 I-GENE O
, I-GENE O
and I-GENE O
- I-GENE O
0 I-GENE O
can O O
only O O
partially O O
substitute O O
for O O
each O O
other O O
in O O
cardiogenesis O O
. O O

Phosphatidylinositol B-GENE O
0 I-GENE O
- I-GENE O
kinase I-GENE O
requirement O O
in O O
activation O O
of O O
the O O
ras B-GENE B-GENE
/ O O
C B-GENE B-GENE
- I-GENE I-GENE
raf I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
/ O O
MEK B-GENE B-GENE
/ O O
ERK B-GENE O
and O O
p00 B-GENE B-GENE
( O O
s0k B-GENE O
) O O
signaling O O
cascade O O
by O O
the O O
insulinomimetic O O
agent O O
vanadyl O O
sulfate O O
. O O

The O O
two O O
- O O
hybrid O O
assay O O
was O O
then O O
performed O O
using O O
full O O
- O O
length O O
genes O O
of O O
CI B-GENE O
, O O
HC B-GENE B-GENE
- I-GENE I-GENE
Pro I-GENE I-GENE
, O O
P0 B-GENE O
, O O
P0 B-GENE O
, O O
and O O
CP B-GENE O
, O O
but O O
no O O
heterologous O O
interactions O O
were O O
detected O O
. O O

The O O
expression O O
of O O
the O O
yam0 B-GENE B-GENE
( I-GENE O
+ I-GENE O
) I-GENE O
cDNA I-GENE O
in O O
the O O
mid0 B-GENE O
mutant I-GENE O
cells O O
partially O O
remediated O O
the O O
mid O O
phenotype O O
and O O
resulted O O
in O O
a O O
slight O O
increase O O
in O O
Ca O O
( O O
0 O O
+ O O
) O O
uptake O O
activity O O
. O O

CONCLUSION O O
: O O
Treatment O O
of O O
sepsis O O
with O O
the O O
platelet B-GENE B-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
factor I-GENE O
antagonist O O
BB O O
- O O
000 O O
offers O O
no O O
advantage O O
over O O
placebo O O
on O O
survival O O
, O O
hemodynamic O O
status O O
, O O
respiratory O O
function O O
, O O
or O O
organ O O
failure O O
scores O O
. O O

The O O
results O O
suggest O O
that O O
the O O
role O O
of O O
S O O
. O O
argyrostoma O O
in O O
the O O
dissemination O O
of O O
Trichinella O O
larvae O O
in O O
nature O O
is O O
limited O O
in O O
comparison O O
to O O
the O O
role O O
played O O
by O O
mammals O O
with O O
scavenger O O
and O O
cannibalistic O O
behavior O O
. O O

The O O
Spo0F B-GENE O
residues I-GENE O
making O O
up O O
the O O
hydrophobic O O
patch O O
are O O
very O O
similar O O
in O O
all O O
response O O
regulators O O
suggesting O O
that O O
the O O
binding O O
is O O
initiated O O
through O O
the O O
same O O
residues O O
in O O
all O O
interacting O O
response O O
regulator O O
- O O
kinase O O
pairs O O
. O O

Overexpression O O
of O O
Trdpm0 B-GENE O
in O O
a O O
dpm0 B-GENE O
( I-GENE O
+ I-GENE O
) I-GENE O
: O O
: O O
his0 B-GENE O
/ I-GENE O
dpm0 I-GENE O
( I-GENE O
+ I-GENE O
) I-GENE O
S O O
. O O
pombe O O
diploid O O
resulted O O
in O O
a O O
0 O O
- O O
fold O O
increase O O
in O O
specific O O
DPM B-GENE O
synthase I-GENE O
activity O O
. O O

Unlike O O
the O O
mammalian O B-GENE
proteins O I-GENE
, O O
XFGF0 B-GENE O
is O O
efficiently O O
secreted O O
as O O
a O O
Mr O O
00 O O
, O O
000 O O
glycoprotein O O
, O O
gp00 B-GENE O
, O O
which O O
undergoes O O
proteolytic O O
cleavage O O
to O O
produce O O
an O O
NH0 O O
- O O
terminally O O
truncated O O
product O O
, O O
gp00 B-GENE O
. O O

0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
0 O O
, O O
P O O
< O O
0 O O
. O O
0000 O O
) O O
, O O
large O O
accelerations O O
/ O O
00 O O
min O O
( O O
0 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
00 O O
vs O O
. O O

Though O O
the O O
BACTEC O O
0000 O O
MB O O
system O O
is O O
recommended O O
for O O
respiratory O O
specimens O O
, O O
we O O
demonstrated O O
that O O
it O O
can O O
be O O
successfully O O
used O O
also O O
for O O
recovery O O
of O O
mycobacteria O O
from O O
clinical O O
specimens O O
from O O
various O O
extrapulmonary O O
sites O O
. O O

The O O
COOH O O
- O O
terminal O O
region O O
of O O
the O O
transcripts O O
contained O O
fifteen O O
triplet O O
repeats O O
( O O
GCT O O
; O O
alanine O O
) O O
at O O
nucleotide O O
000 O O
to O O
000 O O
, O O
which O O
is O O
significantly O O
expanded O O
compared O O
to O O
the O O
rat B-GENE O
RL00 I-GENE O
. O O

The O O
predicted O O
domain O O
structures O O
of O O
FkbB B-GENE O
and O O
FkbC B-GENE O
are O O
analogous O O
to O O
that O O
of O O
FkbA B-GENE O
and O O
comprise O O
00 O O
fatty B-GENE O
- I-GENE O
acid I-GENE O
- I-GENE O
synthase I-GENE O
( O O
FAS B-GENE O
) O O
- O O
like O O
domains O O
arranged O O
in O O
0 O O
modules O O
. O O

The O O
various O O
available O O
data O O
strongly O O
suggesting O O
an O O
environmental O O
toxic O O
origin O O
for O O
the O O
" O O
sperm O O
fall O O
" O O
will O O
be O O
presented O O
as O O
well O O
as O O
the O O
most O O
frequently O O
suspected O O
class O O
of O O
substances O O
, O O
the O O
xenoestrogens O O
. O O

Proteins O O
known O O
to O O
bind O O
the O O
PEPCK B-GENE O
CRE O O
include O O
the O O
CRE B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( O O
CREB B-GENE B-GENE
) O O
and O O
members O O
of O O
the O O
CCAAT B-GENE B-GENE
/ I-GENE I-GENE
enhancer I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
) O O
family O O
. O O

To O O
identify O O
additional O O
non O O
- O O
Sir B-GENE O
factors I-GENE O
that O O
affect O O
rDNA O O
silencing O O
, O O
we O O
performed O O
a O O
genetic O O
screen O O
designed O O
to O O
isolate O O
mutations O O
which O O
alter O O
the O O
expression O O
of O O
reporter O O
genes O O
integrated O O
within O O
the O O
rDNA O O
. O O

The O O
enzyme O O
displays O O
optimal O O
activity O O
at O O
about O O
0 O O
. O O
0 O O
mM O O
pantoate O O
( O O
k O O
( O O
cat O O
) O O
0 O O
. O O
00 O O
s O O
( O O
- O O
0 O O
) O O
) O O
and O O
at O O
pH O O
0 O O
. O O
0 O O
. O O

Angiotensin B-GENE O
II I-GENE O
induces O B-GENE
nuclear B-GENE I-GENE
factor I-GENE I-GENE
( I-GENE O
NF I-GENE B-GENE
) I-GENE I-GENE
- I-GENE I-GENE
kappaB0 I-GENE I-GENE
isoforms I-GENE O
to O O
bind O O
the O O
angiotensinogen B-GENE B-GENE
gene I-GENE I-GENE
acute O I-GENE
- O O
phase O O
response O O
element O O
: O O
a O O
stimulus O O
- O O
specific O O
pathway O O
for O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB I-GENE I-GENE
activation O O
. O O

The O O
requirement O O
of O O
0 O O
' O O
complementarity O O
for O O
a O O
ligation O O
reaction O O
is O O
reaffirmed O O
by O O
results O O
from O O
0 O O
nt O O
insertions O O
on O O
either O O
the O O
0 O O
' O O
- O O
or O O
0 O O
' O O
- O O
side O O
of O O
the O O
nick O O
. O O

Scanning O O
mutations O O
throughout O O
the O O
AC O O
element O O
interfered O O
with O O
induction O O
but O O
allowed O O
us O O
to O O
define O O
five O O
overlapping O O
sites O O
for O O
regulatory O O
factors O O
in O O
AC O O
and O O
to O O
design O O
probes O O
binding O O
just O O
one O O
or O O
two O O
factors O O
. O O

We O O
also O O
found O O
that O O
environmental O O
conditions O O
for O O
meiosis O O
finely O O
regulate O O
the O O
transcript O O
levels O O
of O O
KIN00 B-GENE O
and O O
CCL0 B-GENE O
, O O
such O O
that O O
nitrogen O O
starvation O O
first O O
elevates O O
them O O
but O O
subsequent O O
alkalization O O
of O O
medium O O
decreases O O
them O O
. O O

We O O
have O O
shown O O
that O O
the O O
epidural O O
( O O
EPI O O
) O O
delivery O O
of O O
morphine O O
encapsulated O O
in O O
multivesicular O O
liposomes O O
( O O
DepoFoam O O
drug O O
delivery O O
system O O
) O O
produces O O
a O O
sustained O O
clearance O O
of O O
morphine O O
and O O
a O O
prolonged O O
analgesia O O
. O O

It O O
contains O O
00 O O
exons O O
coding O O
for O O
a O O
0 O O
. O O
0kb O O
transcript O O
including O O
large O O
0 O O
' O O
- O O
and O O
0 O O
' O O
- O O
( O O
0000bp O O
and O O
000bp O O
, O O
respectively O O
) O O
untranslated O O
regions O O
( O O
UTRs O O
) O O
. O O

Vasoactive B-GENE O
intestinal I-GENE O
peptide I-GENE O
and O O
pituitary B-GENE O
adenylate I-GENE O
cyclase I-GENE B-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
polypeptide I-GENE I-GENE
inhibit O I-GENE
nuclear B-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
gene I-GENE I-GENE
activation O O
at O O
multiple O O
levels O O
in O O
the O O
human O O
monocytic O O
cell O O
line O O
THP O B-GENE
- O I-GENE
0 O I-GENE
. O O

Pure O O
T0 O O
and O O
dual O O
- O O
T0 O O
images O O
were O O
visually O O
evaluated O O
for O O
image O O
quality O O
( O O
IQ O O
) O O
on O O
a O O
five O O
- O O
point O O
scale O O
( O O
0 O O
= O O
unacceptable O O
to O O
0 O O
= O O
excellent O O
) O O
. O O

In O O
our O O
previous O O
studies O O
, O O
transcriptional O O
activation O O
was O O
shown O O
to O O
correlate O O
with O O
IEP00 B-GENE O
binding O O
to O O
both O O
the O O
TATA B-GENE B-GENE
- I-GENE I-GENE
box I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( O O
TBP B-GENE B-GENE
) O O
and O O
the O O
transcription O O
factor O O
bound O O
upstream O O
. O O

These O O
observations O O
provide O O
strong O O
support O O
for O O
the O O
idea O O
that O O
expression O O
of O O
mutant O O
tRNA O O
can O O
confer O O
a O O
mutator O O
phenotype O O
, O O
including O O
the O O
UVM O B-GENE
- O O
constitutive O O
phenotype O O
observed O O
in O O
mutA B-GENE O
and O O
mutC B-GENE O
cells O O
. O O

In O O
all O O
cells O O
, O O
the O O
accumulation O O
of O O
high O O
Dsg B-GENE O
protein I-GENE O
levels O O
required O O
calcium O O
and O O
was O O
not O O
observed O O
in O O
low O O
calcium O O
( O O
0 O O
. O O
00 O O
- O O
0 O O
. O O
00 O O
mM O O
) O O
media O O
. O O

In O O
a O O
gntR B-GENE O
deletion I-GENE O
mutant I-GENE O
, O O
the O O
expression O O
of O O
a O O
chromosomal O O
gntT B-GENE O
: O O
: O O
lacZ B-GENE O
fusion O O
is O O
both O O
high O O
and O O
constitutive O O
, O O
confirming O O
that O O
GntR B-GENE O
is O O
the O O
negative O O
regulator O O
of O O
gntT B-GENE O
. O O

Induction O O
of O O
anaesthesia O O
was O O
standardised O O
: O O
fentanyl O O
( O O
0 O O
micrograms O O
/ O O
kg O O
) O O
, O O
thiopentone O O
( O O
0 O O
mg O O
/ O O
kg O O
) O O
, O O
atracurium O O
( O O
0 O O
. O O
0 O O
mg O O
/ O O
kg O O
) O O
. O O

Among O O
these O O
000 O O
ZFPs B-GENE O
, O O
a O O
novel O O
ZFP B-GENE O
cDNA I-GENE O
named O O
HFHZ B-GENE O
( O O
human B-GENE O
fetal I-GENE O
heart I-GENE O
ZFP I-GENE O
) O O
with O O
sequence O O
homology O O
to O O
a O O
Kruppel B-GENE O
- I-GENE O
associated I-GENE O
box I-GENE O
( O O
KRAB B-GENE O
) O O
was O O
identified O O
. O O

In O O
light O O
of O O
the O O
importance O O
of O O
GnRHR B-GENE O
, O O
the O O
molecular O O
mechanisms O O
underlying O O
the O O
transcriptional O O
regulation O O
of O O
the O O
human B-GENE B-GENE
GnRHR I-GENE I-GENE
( O I-GENE
hGnRHR B-GENE I-GENE
) O I-GENE
gene O I-GENE
become O O
a O O
key O O
issue O O
in O O
understanding O O
human O O
reproduction O O
. O O

The O O
high B-GENE O
density I-GENE O
lipoprotein I-GENE O
( I-GENE O
HDL I-GENE B-GENE
) I-GENE O
receptor I-GENE O
mediates O O
the O O
uptake O O
of O O
cholesterol O O
and O O
cholesteryl O O
esters O O
, O O
substrates O O
for O O
steroidogenesis O O
, O O
from O O
an O O
HDL B-GENE O
particle O O
in O O
the O O
adrenal O O
gland O O
and O O
gonads O O
. O O

Null O O
alleles O O
of O O
SAS0 B-GENE B-GENE
and O O
SAS0 B-GENE O
bypassed O O
the O O
role O O
of O O
the O O
Abf0p B-GENE O
binding I-GENE O
site I-GENE O
of O O
the O O
HMR B-GENE B-GENE
- I-GENE I-GENE
E I-GENE I-GENE
silencer I-GENE O
but O O
not O O
the O O
role O O
of O O
the O O
ACS B-GENE O
or O O
Rap0p B-GENE O
binding I-GENE O
site I-GENE O
. O O

The O O
GPI O O
anchor O O
moiety O O
is O O
either O O
absent O O
or O O
present O O
at O O
a O O
very O O
low O O
level O O
in O O
the O O
polypeptide O O
expressed O O
from O O
the O O
cDNA O O
that O O
contained O O
both O O
the O O
signal O O
peptide O O
and O O
GPI O O
signal O O
sequences O O
. O O

An O O
amino O O
- O O
acid O O
sequence O O
comparison O O
revealed O O
that O O
Bacillus B-GENE O
YM00 I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
aspartase I-GENE O
shared O O
00 O O
% O O
homology O O
with O O
Bacillus B-GENE O
subtilis I-GENE O
aspartase I-GENE O
and O O
00 O O
% O O
with O O
Escherichia O O
coli O O
and O O
Pseudomonas B-GENE O
fluorescens I-GENE O
aspartases I-GENE O
. O O

As O O
assessed O O
by O O
a O O
genetic O O
assay O O
that O O
measures O O
AAI O O
- O O
dependent O O
DNA O O
binding O O
, O O
TraM B-GENE O
inhibited O O
TraR B-GENE O
function O O
before O O
and O O
after O O
the O O
transcription O O
factor O O
had O O
bound O O
to O O
its O O
DNA O O
recognition O O
site O O
. O O

Collectively O O
, O O
the O O
results O O
suggest O O
that O O
ARF B-GENE O
binding O O
to O O
Mdm0 B-GENE O
induces O O
a O O
conformational O O
change O O
that O O
facilitates O O
nucleolar O O
import O O
of O O
the O O
ARF B-GENE B-GENE
- O I-GENE
Mdm0 B-GENE I-GENE
complex O O
and O O
p00 B-GENE B-GENE
- O O
dependent O O
cell O O
cycle O O
arrest O O
. O O

To O O
understand O O
whether O O
Shc B-GENE O
localization O O
in O O
membrane O O
rafts O O
is O O
sufficient O O
to O O
regulate O O
Shc B-GENE O
function O O
, O O
we O O
constructed O O
a O O
Shc B-GENE O
chimera I-GENE O
containing O O
the O O
Ras B-GENE O
membrane I-GENE O
localization I-GENE O
motif I-GENE O
at O O
the O O
C O O
- O O
terminus O O
. O O

In O O
hemodialyzed O O
patients O O
( O O
Epo B-GENE O
and O O
Non O O
- O O
Epo B-GENE O
group O O
) O O
leptin B-GENE O
levels O O
were O O
significantly O O
higher O O
when O O
compared O O
to O O
CAPD O O
patients O O
( O O
Epo B-GENE O
and O O
Non O O
- O O
Epo B-GENE O
group O O
, O O
respectively O O
) O O
. O O

This O O
enabled O O
the O O
formation O O
of O O
stem O O
- O O
loop O O
templates O O
with O O
the O O
fusion O O
point O O
of O O
the O O
chimeric O O
transcript O O
in O O
the O O
loop O O
and O O
the O O
use O O
of O O
MLL B-GENE O
primers O O
in O O
two O O
- O O
sided O O
PCR O O
. O O

RESULTS O O
: O O
Glaucoma O O
suspects O O
were O O
divided O O
into O O
two O O
groups O O
according O O
to O O
their O O
SWAP O O
results O O
: O O
high O O
risk O O
( O O
with O O
SWAP O O
abnormalities O O
) O O
and O O
low O O
risk O O
( O O
with O O
normal O O
SWAP O O
result O O
) O O
. O O

Nuclease O O
probing O O
and O O
structure O O
- O O
directed O O
mutagenesis O O
revealed O O
that O O
the O O
000 O B-GENE
- O I-GENE
nt O I-GENE
TE O O
( O O
TE000 O O
) O O
forms O O
a O O
cruciform O O
secondary O O
structure O O
containing O O
four O O
helices O O
connected O O
by O O
single O O
- O O
stranded O O
regions O O
. O O

The O O
C O B-GENE
- O I-GENE
LIP O I-GENE
also O O
was O O
compared O O
with O O
transcather O O
arterial O O
embolization O O
( O O
TAE O O
; O O
C O O
- O O
LIP O O
followed O O
by O O
gelatin O O
sponge O O
) O O
and O O
percutaneous O O
ethanol O O
injection O O
therapy O O
( O O
PEIT O O
) O O
. O O

Selected O O
parameters O O
: O O
heart O O
rate O O
( O O
HR O O
) O O
, O O
arterial O O
blood O O
pressure O O
( O O
ABP O O
) O O
and O O
arterial O O
O0 O O
saturation O O
( O O
SaO0 O O
) O O
monitored O O
by O O
pulsoximetry O O
were O O
measured O O
during O O
the O O
procedure O O
. O O

The O O
mean O O
times O O
to O O
detection O O
of O O
all O O
mycobacteria O O
with O O
BACTEC O O
0000 O O
MB O O
and O O
BACTEC O O
000 O O
TB O O
were O O
similar O O
( O O
00 O O
. O O
0 O O
and O O
00 O O
. O O
0 O O
days O O
, O O
respectively O O
) O O
. O O

Because O O
the O O
biosynthetic O O
pathway O O
to O O
the O O
vacuole O O
intersects O O
with O O
the O O
endocytic O O
pathway O O
, O O
internalization O O
of O O
a O O
bulk O O
membrane O O
endocytic O O
marker O O
FM O O
0 O O
- O O
00 O O
was O O
assayed O O
in O O
the O O
sop B-GENE O
mutants I-GENE O
. O O

The O O
promoter O O
region O O
showed O O
no O O
consensus O O
TATA O O
box O O
but O O
it O O
contains O O
CCAAT O O
and O O
CreA B-GENE O
boxes O O
known O O
to O O
be O O
involved O O
in O O
both O O
stress O O
and O O
carbon O O
- O O
catabolite O O
regulation O O
of O O
fungal O O
promoters O O
. O O

Attenuation O O
from O O
the O O
vit B-GENE O
A0 I-GENE O
consensus O O
ERE O O
is O O
not O O
necessarily O O
dependent O O
on O O
DNA O O
binding O O
as O O
the O O
TR B-GENE B-GENE
alpha I-GENE I-GENE
DNA O O
binding O O
mutant O O
was O O
still O O
able O O
to O O
inhibit O O
E O O
- O O
dependent O O
transactivation O O
. O O

The O O
AGM B-GENE O
and I-GENE O
NIH I-GENE O
/ I-GENE O
Swiss I-GENE O
mouse I-GENE O
CCR0 I-GENE O
proteins I-GENE O
are O O
00 O O
. O O
0 O O
to O O
00 O O
. O O
0 O O
% O O
and O O
00 O O
. O O
0 O O
% O O
identical O O
to O O
the O O
human O B-GENE
protein O I-GENE
, O O
respectively O O
. O O

These O O
results O O
implicate O O
a O O
precursor O O
- O O
specific O O
base O O
- O O
paired O O
structure O O
involving O O
sequences O O
on O O
both O O
sides O O
of O O
the O O
mature O O
cleavage O O
site O O
in O O
the O O
0 O O
' O O
processing O O
of O O
human B-GENE O
U0 I-GENE O
RNA I-GENE O
. O O

Southern O O
blot O O
analysis O O
of O O
endonuclease O B-GENE
- O I-GENE
digested O I-GENE
genomic O O
DNA O O
from O O
primary O O
chick O O
embryo O O
fibroblasts O O
( O O
CEF O O
) O O
suggested O O
that O O
MEK0 B-GENE O
is O O
a O O
single O O
- O O
copy O O
gene O O
in O O
this O O
vertebrate O O
species O O
. O O

In O O
patients O O
with O O
type O O
IA O O
maple O O
syrup O O
urine O O
disease O O
, O O
the O O
E0alpha B-GENE O
subunit I-GENE O
is O O
affected O O
, O O
resulting O O
in O O
the O O
loss O O
of O O
E0 B-GENE O
and O O
branched B-GENE O
- I-GENE O
chain I-GENE O
ketoacid I-GENE O
dehydrogenase I-GENE O
catalytic O O
activities O O
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
performed O O
with O O
the O O
HNF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
X O I-GENE
and O O
Y O O
sites O O
demonstrated O O
that O O
both O O
sites O O
are O O
capable O O
of O O
binding O O
HNF B-GENE O
- I-GENE O
0alpha I-GENE O
and O O
HNF B-GENE B-GENE
- I-GENE I-GENE
0beta I-GENE I-GENE
. O O

Interaction O O
of O O
HRI B-GENE O
with O O
Hsc00 B-GENE O
was O O
required O O
for O O
the O O
transformation O O
of O O
HRI B-GENE O
, O O
as O O
the O O
Hsc00 B-GENE O
antagonist O O
clofibric O O
acid O O
inhibited O O
the O O
folding O O
of O O
HRI B-GENE O
into O O
a O O
mature O O
- O O
competent O O
conformation O O
. O O

The O O
proteasome O O
is O O
a O O
large O O
complex O O
consisting O O
of O O
two O O
multisubunit O O
structures O O
, O O
the O O
00S B-GENE O
and O O
00S B-GENE O
( O O
PA000 B-GENE O
) O O
or O O
P00 B-GENE O
complexes I-GENE O
, O O
that O O
combine O O
to O O
form O O
the O O
00S B-GENE O
particles I-GENE O
. O O

Approximately O O
00 O O
% O O
of O O
ALCLs O O
that O O
express O O
ALK B-GENE O
do O O
not O O
contain O O
the O O
t O O
( O O
0 O O
; O O
0 O O
) O O
, O O
suggesting O O
that O O
other O O
genetic O O
abnormalities O O
can O O
result O O
in O O
aberrant O O
ALK B-GENE O
expression O O
. O O

Here O O
we O O
describe O O
the O O
cloning O O
, O O
tissue O O
- O O
specific O O
expression O O
pattern O O
, O O
and O O
functional O O
characterization O O
of O O
two O O
novel O O
TEF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
isoforms I-GENE I-GENE
, O O
TEF B-GENE B-GENE
- I-GENE I-GENE
0beta I-GENE I-GENE
and O O
TEF B-GENE B-GENE
- I-GENE I-GENE
0gamma I-GENE I-GENE
. O O

Preliminary O O
use O O
of O O
the O O
Nottingham O O
Eczema O O
Severity O O
Score O O
would O O
support O O
further O O
development O O
as O O
a O O
research O O
tool O O
for O O
a O O
simple O O
assessment O O
of O O
disease O O
severity O O
that O O
could O O
be O O
used O O
in O O
epidemiological O O
studies O O
. O O

SELECTION O O
CRITERIA O O
: O O
All O O
controlled O O
trials O O
where O O
adults O O
with O O
schizophrenia O O
or O O
similar O O
illnesses O O
were O O
randomised O O
to O O
quetiapine O O
, O O
placebo O O
or O O
other O O
neuroleptic O O
drugs O O
and O O
where O O
clinically O O
relevant O O
outcomes O O
were O O
reported O O
. O O

This O O
compound O O
is O O
the O O
main O O
bioactive O O
metabolite O O
of O O
trimebutine O O
II O O
( O O
Debridat O O
, O O
CAS O O
00000 O O
- O O
00 O O
- O O
0 O O
) O O
, O O
an O O
antispasmodic O O
widely O O
used O O
for O O
intestinal O O
diseases O O
since O O
0000 O O
. O O

The O O
amino O O
acid O O
sequence O O
of O O
matrilysin B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
also O O
contains O O
a O O
threonine O O
residue O O
adjacent O O
to O O
the O O
Zn O B-GENE
- O O
binding O O
site O O
that O O
has O O
been O O
defined O O
as O O
a O O
specific O O
feature O O
of O O
matrilysin B-GENE O
. O O

This O O
transcriptional O O
regulation O O
occurs O O
through O O
modulation O O
of O O
the O O
forkhead B-GENE B-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
FKHR B-GENE I-GENE
- I-GENE I-GENE
L0 I-GENE I-GENE
, O O
and O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
inhibited O I-GENE
FKHR B-GENE I-GENE
- I-GENE I-GENE
L0 I-GENE I-GENE
activity O O
in O O
a O O
PI0K B-GENE O
- O O
dependent O O
manner O O
. O O

Furthermore O O
, O O
transfection O O
of O O
cells O O
with O O
the O O
spacer O O
- O O
RING O O
domain O O
alone O O
suppressed O O
the O O
antiapoptotic O O
function O O
of O O
the O O
N O O
- O O
terminal O O
BIR B-GENE O
domain O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
IAP0 I-GENE I-GENE
and O O
induced O O
apoptosis O O
. O O

Surprisingly O O
, O O
the O O
RXR B-GENE B-GENE
- O I-GENE
specific O I-GENE
ligand O I-GENE
0 O I-GENE
- O I-GENE
cis O I-GENE
- O O
retinoic O O
acid O O
induced O O
binding O O
of O O
SRC B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
to O O
the O O
RXR B-GENE O
component I-GENE O
of O O
the O O
TRE O B-GENE
- O I-GENE
bound O I-GENE
heterodimer O I-GENE
. O O

Liquid O O
chromatographic O O
method O O
for O O
analysis O O
of O O
all O O
- O O
rac O O
- O O
alpha O O
- O O
tocopheryl O O
acetate O O
and O O
retinyl O O
palmitate O O
in O O
milk O O
- O O
based O O
infant O O
formula O O
using O O
matrix O O
solid O O
- O O
phase O O
dispersion O O
. O O

Binding O O
affinities O O
of O O
different O O
nucleotide O O
mono O O
- O O
, O O
di O O
- O O
and O O
triphosphates O O
and O O
non O O
- O O
hydrolyzable O O
analogs O O
indicate O O
that O O
the O O
beta O B-GENE
- O I-GENE
phosphate O I-GENE
moiety O O
is O O
required O O
for O O
substrate O O
binding O O
. O O

The O O
activity O O
of O O
the O O
minimal O B-GENE
promoter O I-GENE
was O O
found O O
to O O
be O O
controlled O O
by O O
a O O
combination O O
of O O
the O O
activities O O
of O O
the O O
transcription O O
factors O O
Sp0 B-GENE O
, O O
Sp0 B-GENE O
, O O
and O O
NF B-GENE O
- I-GENE O
Y I-GENE O
. O O

Ethylene O O
is O O
involved O O
in O O
endosperm O O
rupture O O
and O O
high O O
- O O
level O O
betaGLU B-GENE O
I I-GENE O
expression O O
; O O
but O O
, O O
it O O
does O O
not O O
affect O O
the O O
spatial O O
and O O
temporal O O
pattern O O
of O O
betaGLU B-GENE O
I I-GENE O
expression O O
. O O

This O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
activity O O
is O O
inhibited O O
by O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
, O O
another O O
protooncoprotein O O
that O O
can O O
dimerize O O
with O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
to O O
form O O
the O O
transcription O O
factor O O
AP B-GENE O
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

To O O
search O O
for O O
transcriptional O O
regulators O O
, O O
we O O
used O O
a O O
fragment O O
of O O
the O O
SpHE B-GENE O
promoter I-GENE O
containing O O
several O O
individual O O
elements O O
instead O O
of O O
the O O
conventional O O
bait O O
that O O
contains O O
a O O
multimerized O O
cis O O
element O O
. O O

Here O O
we O O
describe O O
the O O
identification O O
and O O
characterization O O
of O O
several O O
Sp000 B-GENE O
splice I-GENE O
variant I-GENE O
proteins I-GENE O
and O O
support O O
their O O
existence O O
by O O
elucidation O O
of O O
the O O
0 O O
' O O
- O O
end O O
of O O
the O O
Sp000 B-GENE B-GENE
gene I-GENE I-GENE
. O O

These O O
results O O
indicate O O
that O O
ATF B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
plays O O
a O O
central O O
role O O
in O O
TGF B-GENE O
- I-GENE O
beta I-GENE O
signaling O O
by O O
acting O O
as O O
a O O
common O O
nuclear O O
target O O
of O O
both O O
Smad B-GENE O
and O O
TAK0 B-GENE O
pathways O O
. O O

Schwab O O
and O O
England O O
ADL O O
scores O O
in O O
the O O
" O O
off O O
" O O
state O O
were O O
improved O O
by O O
00 O O
% O O
and O O
in O O
the O O
" O O
on O O
" O O
state O O
the O O
scores O O
declined O O
by O O
0 O O
% O O
. O O

00 O O
- O O
OH O O
- O O
D0 O O
did O O
not O O
adversely O O
affect O O
animal O O
health O O
at O O
the O O
proposed O O
use O O
level O O
of O O
00 O O
micrograms O O
/ O O
kg O O
feed O O
when O O
replacing O O
vitamin O O
D0 O O
in O O
turkey O O
rations O O
. O O

In O O
the O O
cell O O
- O O
free O O
import O O
assay O O
, O O
beta B-GENE B-GENE
- I-GENE I-GENE
catenin I-GENE I-GENE
rapidly O O
migrates O O
into O O
the O O
nucleus O O
without O O
the O O
exogenous O O
addition O O
of O O
cytosol O O
, O O
Ran B-GENE O
, O O
or O O
ATP O O
/ O O
GTP O O
. O O

We O O
calculated O O
differences O O
in O O
late O O
occlusion O O
rates O O
by O O
the O O
chi0 O O
( O O
chi O O
- O O
square O O
) O O
test O O
, O O
and O O
found O O
these O O
differences O O
were O O
significant O O
( O O
P O O
= O O
. O O
00 O O
) O O
. O O

Repair O O
of O O
double O O
- O O
strand O O
breaks O O
( O O
DSBs O O
) O O
in O O
chromosomal O O
DNA O O
by O O
nonhomologous O O
end O O
- O O
joining O O
( O O
NHEJ O O
) O O
is O O
not O O
well O O
characterized O O
in O O
the O O
yeast O O
Saccharomyces O O
cerevisiae O O
. O O

From O O
February O O
0000 O O
to O O
August O O
0000 O O
, O O
000 O O
patients O O
with O O
endometrial O O
carcinoma O O
were O O
treated O O
postoperatively O O
with O O
high O O
- O O
dose O O
- O O
rate O O
vaginal O O
vault O O
brachytherapy O O
as O O
the O O
only O O
adjuvant O O
treatment O O
. O O

Sequence O O
analysis O O
of O O
the O O
promoter O O
region O O
showed O O
no O O
TATA O O
box O O
but O O
identified O O
consensus O O
binding O O
motifs O O
for O O
Sp0 B-GENE O
, O O
CREB B-GENE O
, O O
and O O
half O O
sites O O
of O O
the O O
estrogen B-GENE B-GENE
receptor I-GENE I-GENE
binding I-GENE O
site I-GENE O
. O O

Upon O O
tyrosine O O
phosphorylation O O
at O O
the O O
ITIMs O O
, O O
these O O
molecules O O
recruit O O
SH0 B-GENE O
domain O O
- O O
containing O O
phosphatases O O
such O O
as O O
SH0 B-GENE O
- O O
containing O O
tyrosine B-GENE O
phosphatase I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
negatively O O
regulate O O
cell O O
activity O O
. O O

Molecular O O
cloning O O
of O O
a O O
novel O O
human B-GENE O
I I-GENE O
- I-GENE O
mfa I-GENE O
domain I-GENE O
- I-GENE O
containing I-GENE O
protein I-GENE O
that O O
differently O O
regulates O O
human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
and O O
HIV O B-GENE
- O I-GENE
0 O I-GENE
expression O O
. O O

Eight O O
patients O O
received O O
0 O O
. O O
0 O O
mg O O
of O O
adefovir O O
dipivoxil O O
per O O
kg O O
of O O
body O O
weight O O
, O O
and O O
six O O
patients O O
received O O
0 O O
. O O
0 O O
mg O O
of O O
adefovir O O
dipivoxil O O
per O O
kg O O
. O O

The O O
evolution O O
of O O
the O O
CCR0 B-GENE O
cis I-GENE O
- I-GENE O
regulatory I-GENE O
region I-GENE O
versus O O
the O O
open O O
reading O O
frame O O
as O O
well O O
as O O
among O O
different O O
domains O O
of O O
the O O
open O O
reading O O
frame O O
differed O O
from O O
one O O
another O O
. O O

The O O
structural O O
study O O
of O O
peptides O O
belonging O O
to O O
the O O
terminal O O
domains O O
of O O
histone B-GENE O
H0 I-GENE O
can O O
be O O
considered O O
as O O
a O O
step O O
toward O O
the O O
understanding O O
of O O
the O O
function O O
of O O
H0 B-GENE O
in O O
chromatin O O
. O O

In O O
contrast O O
to O O
the O O
morphological O O
criteria O O
, O O
the O O
few O O
data O O
available O O
from O O
recent O O
studies O O
at O O
the O O
genetic O O
level O O
have O O
suggested O O
that O O
EPVs O O
infecting O O
different O O
insect O O
orders O O
are O O
phylogenetically O O
distant O O
. O O

Viruses O O
were O O
isolated O O
from O O
0 O O
lungs O O
: O O
0 O O
with O O
PI O O
- O O
0V O O
, O O
0 O O
with O O
NCP O O
BVDV O O
type O O
0 O O
, O O
and O O
0 O O
with O O
both O O
BVHV O O
- O O
0 O O
and O O
BVDV O O
. O O

An O O
unusual O O
cysteine O O
triplet O O
conserved O O
in O O
the O O
sequences O O
of O O
TB B-GENE O
domains I-GENE O
is O O
localized O O
to O O
the O O
hydrophobic O O
core O O
, O O
at O O
the O O
C O O
- O O
terminus O O
of O O
an O O
alpha O B-GENE
- O I-GENE
helix O I-GENE
. O O

The O O
results O O
confirm O O
that O O
a O O
single O O
base O O
change O O
in O O
the O O
branchpoint O O
consensus O O
sequence O O
of O O
an O O
intron O O
can O O
cause O O
human O O
disease O O
although O O
this O O
sequence O O
is O O
poorly O O
conserved O O
in O O
mammals O O
. O O

The O O
second O O
patient O O
had O O
received O O
pituitary B-GENE O
- I-GENE O
derived I-GENE O
growth I-GENE O
hormone I-GENE O
for O O
treatment O O
of O O
growth B-GENE O
hormone I-GENE O
deficiency O O
, O O
secondary O O
to O O
a O O
third O O
ventricle O O
teratoma O O
, O O
exised O O
00 O O
yr O O
earlier O O
. O O

A O O
0 O O
. O O
0 O O
- O O
kb O O
transcript O O
detected O O
by O O
the O O
differential O O
display O O
amplicon O O
0G0 O O
was O O
found O O
to O O
correlate O O
strongly O O
with O O
RAG0 B-GENE O
mRNA I-GENE O
expression O O
in O O
various O O
human O O
cell O O
lines O O
. O O

The O O
cwg0 B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
mutation I-GENE O
was O O
identified O O
as O O
a O O
guanine O O
to O O
adenine O O
substitution O O
at O O
nucleotide O O
000 O O
of O O
the O O
coding O O
region O O
, O O
originating O O
the O O
change O O
A000T O O
in O O
the O O
cwg0p B-GENE O
. O O

RESULTS O O
: O O
An O O
herpetic O O
seroconversion O O
is O O
observed O O
with O O
presence O O
of O O
type O O
I O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
I O O
) O O
nucleic O O
acids O O
in O O
the O O
recipient O O
' O O
s O O
aqueous O O
humor O O
. O O

Conventionally O O
, O O
four O O
nominal O O
allotypic O O
variants O O
, O O
b0 O O
, O O
b0 O O
, O O
b0 O O
and O O
b0 O O
have O O
been O O
shown O O
to O O
be O O
co O O
- O O
dominantly O O
expressed O O
at O O
the O O
Ckappa0 B-GENE B-GENE
gene I-GENE I-GENE
locus I-GENE O
. O O

As O O
expected O O
for O O
a O O
positive O O
SpHE B-GENE O
transcriptional I-GENE O
regulator I-GENE O
, O O
the O O
timing O O
of O O
SpEts0 B-GENE O
gene I-GENE O
expression O O
precedes O O
the O O
transient O O
expression O O
of O O
SpHE B-GENE O
in O O
the O O
very O O
early O O
sea O O
urchin O O
blastula O O
. O O

The O O
0 O O
. O O
0 O O
- O O
fold O O
higher O O
expression O O
in O O
the O O
fetal O O
heart O O
than O O
in O O
the O O
adult O O
heart O O
suggests O O
that O O
HFHZ B-GENE O
mRNA I-GENE O
is O O
downregulated O O
in O O
the O O
process O O
of O O
development O O
. O O

The O O
relatively O O
mild O O
defects O O
observed O O
in O O
Rpd0 B-GENE O
mutants I-GENE O
suggest O O
that O O
the O O
recently O O
identified O O
Groucho B-GENE O
and O O
dCtBP B-GENE O
corepressor I-GENE O
proteins I-GENE O
do O O
not O O
function O O
solely O O
through O O
the O O
recruitment O O
of O O
histone B-GENE O
deacetylases I-GENE O
. O O

Hrs B-GENE O
has O O
a O O
FYVE O O
double O O
zinc O O
finger O O
domain O O
, O O
which O O
specifically O O
binds O O
phosphatidylinositol O O
( O O
0 O O
) O O
- O O
phosphate O O
and O O
is O O
conserved O O
in O O
several O O
proteins O O
involved O O
in O O
vesicular O O
traffic O O
. O O

This O O
study O O
was O O
designed O O
to O O
compare O O
the O O
efficacy O O
of O O
efegatran O O
plus O O
streptokinase B-GENE O
versus O O
heparin O O
plus O O
accelerated O O
tissue B-GENE O
plasminogen I-GENE O
activator I-GENE O
( O O
TPA B-GENE O
) O O
in O O
coronary O O
reperfusion O O
in O O
acute O O
MI O O
. O O

We O O
have O O
cloned O O
cDNA O O
and O O
genomic O O
DNA O O
for O O
a O O
mouse O O
gene O O
encoding O O
a O O
protein O O
with O O
significant O O
sequence O O
similarity O O
to O O
conserved O O
domains O O
found O O
in O O
proteins O O
of O O
the O O
Spo00p B-GENE O
family I-GENE O
. O O

There O O
was O O
a O O
trend O O
toward O O
an O O
association O O
between O O
IENF O O
and O O
sural O O
nerve O O
unmyelinated O O
fiber O O
densities O O
( O O
r O O
= O O
0 O O
. O O
00 O O
, O O
p O O
= O O
0 O O
. O O
000 O O
) O O
. O O

In O O
addition O O
, O O
expected O O
decreases O O
in O O
ATIC B-GENE O
enzymatic O O
function O O
in O O
ATIC B-GENE O
- O O
ALK B-GENE O
- O O
containing O O
lymphomas O O
may O O
render O O
these O O
tumors O O
more O O
sensitive O O
to O O
antifolate O O
drugs O O
such O O
as O O
methotrexate O O
. O O

Advanced O O
adenoma O O
was O O
defined O O
as O O
an O O
adenoma O O
larger O O
than O O
00 O O
mm O O
or O O
an O O
adenoma O O
of O O
any O O
size O O
with O O
villous O O
component O O
, O O
high O O
- O O
grade O O
dysplasia O O
or O O
invasive O O
carcinoma O O
. O O

CONCLUSIONS O O
: O O
This O O
randomized O O
study O O
shows O O
that O O
Vivostat O O
fibrin B-GENE O
sealant O O
is O O
effective O O
in O O
preventing O O
air O O
leakage O O
after O O
small O O
lung O O
resections O O
in O O
pigs O O
, O O
even O O
at O O
high O O
inspiratory O O
pressures O O
. O O

Modeling O O
also O O
revealed O O
a O O
very O O
hydrophobic O O
surface O O
due O O
to O O
the O O
absence O O
of O O
H00 O O
, O O
exposing O O
residues O O
from O O
H0 O O
, O O
loop O O
0 O O
- O O
0 O O
, O O
H0 O O
, O O
and O O
H00 O O
. O O

ID O O
- O O
PaGIA O O
diphtheria B-GENE O
toxin I-GENE O
polymer O O
particle O O
diagnostic O O
agent O O
manufactured O O
by O O
DiaMed O O
AG O O
, O O
Switzerland O O
, O O
was O O
tried O O
at O O
bacteriological O O
laboratory O O
of O O
Institute O O
of O O
Childhood O O
Infections O O
in O O
St O O
. O O

The O O
detector O O
has O O
the O O
advantage O O
of O O
finding O O
both O O
ST O O
segment O O
deviations O O
and O O
entire O O
ST O O
- O O
T O O
complex O O
changes O O
thereby O O
providing O O
a O O
wider O O
characterization O O
of O O
the O O
potential O O
ischemic O O
events O O
. O O

As O O
a O O
result O O
, O O
we O O
have O O
defined O O
two O O
arginine O B-GENE
- O I-GENE
rich O I-GENE
motifs O O
( O O
ARM0 O O
and O O
ARM0 O O
) O O
that O O
mediate O O
the O O
RNA O O
binding O O
activity O O
of O O
SU B-GENE O
( I-GENE O
S I-GENE O
) I-GENE O
. O O

Expression O O
of O O
a O O
hybrid O O
protein O O
containing O O
the O O
cytoplasmic O O
C O O
- O O
terminal O O
half O O
of O O
UhpB B-GENE O
fused O O
to O O
glutathione B-GENE B-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase I-GENE I-GENE
( O O
GST B-GENE O
) O O
also O O
interfered O O
with O O
Uhp B-GENE O
signaling O O
. O O

We O O
have O O
used O O
mutation O O
- O O
directed O O
chemical O O
cross O O
- O O
linking O O
with O O
bis O O
( O O
sulfosuccinimidyl O O
) O O
suberate O O
( O O
BS0 O O
) O O
to O O
investigate O O
the O O
architecture O O
of O O
the O O
gp00 B-GENE O
oligomer I-GENE O
. O O

Levels O O
of O O
the O O
MEK B-GENE O
inhibitor O O
PD00000 O O
that O O
block O O
EGF B-GENE O
- O O
induced O O
mitogenesis O O
and O O
MAP B-GENE O
kinase I-GENE O
phosphorylation O O
also O O
abrogate O O
EGF B-GENE O
- O O
induced O O
focal O O
adhesion O O
disassembly O O
and O O
cell O O
motility O O
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
m B-GENE B-GENE
- I-GENE I-GENE
Staf I-GENE I-GENE
is O O
highly O O
homologous O O
to O O
that O O
of O O
Staf B-GENE B-GENE
, O O
another O O
selenocysteine B-GENE B-GENE
tRNA I-GENE I-GENE
gene I-GENE I-GENE
transcription I-GENE O
activating I-GENE O
factor I-GENE O
of O O
Xenopus O O
laevis O O
. O O

Indeed O O
, O O
it O O
is O O
shown O O
that O O
it O O
mediates O O
the O O
formation O O
of O O
disulfide O B-GENE
- O O
linked O O
homodimers O O
and O O
that O O
the O O
formation O O
of O O
homo O B-GENE
- O I-GENE
and O O
heterodimers O O
are O O
mutually O O
excluded O O
. O O

The O O
results O O
raise O O
the O O
possibility O O
that O O
pH O O
induced O O
post O O
- O O
translational O O
modifications O O
of O O
DdRPA B-GENE O
are O O
involved O O
in O O
events O O
that O O
halt O O
cell O O
proliferation O O
and O O
induce O O
differentiation O O
in O O
Dictyostelium O O
. O O

This O O
model O O
is O O
supported O O
by O O
experiments O O
showing O O
that O O
Cdr0 B-GENE O
associates O O
with O O
the O O
N B-GENE O
- I-GENE O
terminal I-GENE O
regulatory I-GENE O
domain I-GENE O
of I-GENE O
Wee0 I-GENE O
in O O
cell O O
lysates O O
and O O
phosphorylates O O
Wee0 B-GENE O
in O O
vitro O O
. O O

Expression O O
of O O
the O O
second O O
gene O O
( O O
XT0 B-GENE O
) O O
was O O
found O O
to O O
be O O
conserved O O
in O O
human O O
kidney O O
, O O
and O O
partial O O
sequence O O
was O O
obtained O O
from O O
a O O
human O O
cDNA O O
library O O
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
hormone O O
receptor O O
status O O
between O O
the O O
cases O O
without O O
lymph O O
node O O
metastases O O
and O O
with O O
lymph O O
node O O
metastases O O
, O O
' O O
clandestine O O
' O O
or O O
macrometastases O O
. O O

The O O
binding O O
of O O
PH B-GENE O
domains I-GENE O
to O O
Gbetagamma B-GENE O
was O O
inhibited O O
by O O
preincubation O O
of O O
Gbetagamma B-GENE O
with O O
the O O
GDP O O
- O O
bound O O
but O O
not O O
the O O
GTP O O
- O O
bound O O
form O O
of O O
Gialpha B-GENE O
. O O

Classical O O
ligand O O
- O O
activated O O
nuclear O O
receptors O O
( O O
e O O
. O O
g O O
. O O
thyroid B-GENE O
hormone I-GENE O
receptor I-GENE O
, O O
retinoic B-GENE B-GENE
acid I-GENE I-GENE
receptor I-GENE I-GENE
) O O
, O O
orphan B-GENE O
nuclear I-GENE O
receptors I-GENE O
( O O
e O O
. O O
g O O
. O O

Although O O
the O O
Src B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase I-GENE I-GENE
induces O O
constitutive O O
Stat0 B-GENE O
phosphorylation O O
on O O
tyrosine O O
, O O
activation O O
of O O
Stat0 B-GENE B-GENE
- O I-GENE
mediated O I-GENE
gene O I-GENE
regulation O O
requires O O
both O O
tyrosine O O
and O O
serine O O
phosphorylation O O
of O O
Stat0 B-GENE O
. O O

Animals O O
were O O
put O O
to O O
death O O
0 O O
weeks O O
later O O
and O O
the O O
grafts O O
were O O
sterilely O O
explanted O O
and O O
analyzed O O
via O O
microbiologic O O
culture O O
and O O
standard O O
histologic O O
procedures O O
for O O
evidence O O
of O O
infection O O
. O O

We O O
also O O
show O O
that O O
activation O O
of O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
A I-GENE I-GENE
( O O
PKA B-GENE B-GENE
) O O
signaling O O
is O O
sufficient O O
to O O
down O O
- O O
regulate O O
caveolin B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
protein I-GENE I-GENE
expression O O
and O O
promoter O O
activity O O
. O O

However O O
, O O
reoperation O O
for O O
bulky O O
cervical O O
disease O O
( O O
group O O
0 O O
) O O
rarely O O
results O O
in O O
normal O O
calcitonin B-GENE O
levels O O
and O O
is O O
associated O O
with O O
a O O
high O O
incidence O O
of O O
permanent O O
hypoparathyroidism O O
. O O

Several O O
0SL B-GENE O
RNA I-GENE O
- I-GENE O
encoding I-GENE O
sequences I-GENE O
and O O
various O O
intergenic O O
spacers O O
were O O
amplified O O
from O O
the O O
individual O O
HindIII B-GENE O
fragments I-GENE O
of O O
about O O
0 O O
. O O
0 O O
and O O
0 O O
. O O
0 O O
kb O O
. O O

For O O
this O O
purpose O O
, O O
we O O
used O O
a O O
series O O
of O O
plasmid O O
constructs O O
encoding O O
different O O
forms O O
of O O
the O O
envelope B-GENE O
glycoprotein I-GENE O
E I-GENE O
of I-GENE O
the I-GENE O
flavivirus I-GENE O
tick I-GENE O
- I-GENE O
borne I-GENE O
encephalitis I-GENE O
virus I-GENE O
. O O

Expression O O
in O O
early O O
postnatal O O
pituitary O O
and O O
in O O
pre O O
- O O
somatotrophic O O
cells O O
suggests O O
that O O
Zn B-GENE O
- I-GENE O
00 I-GENE O
could O O
play O O
a O O
role O O
in O O
pituitary O O
development O O
prior O O
to O O
somatotroph O O
differentiation O O
. O O

In O O
an O O
attempt O O
to O O
understand O O
Wee0 B-GENE O
regulation O O
during O O
cell O O
cycle O O
, O O
yeast O O
two O O
- O O
hybrid O O
screening O O
was O O
used O O
to O O
identify O O
Wee0 B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( I-GENE O
s I-GENE O
) I-GENE O
. O O

Transcriptional O O
regulation O O
of O O
the O O
mouse B-GENE B-GENE
cytosolic I-GENE I-GENE
chaperonin I-GENE I-GENE
subunit I-GENE I-GENE
gene I-GENE I-GENE
Ccta B-GENE I-GENE
/ I-GENE O
t I-GENE B-GENE
- I-GENE I-GENE
complex I-GENE I-GENE
polypeptide I-GENE I-GENE
0 I-GENE O
by O O
selenocysteine B-GENE B-GENE
tRNA I-GENE I-GENE
gene I-GENE I-GENE
transcription I-GENE I-GENE
activating I-GENE I-GENE
factor I-GENE I-GENE
family I-GENE I-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
proteins I-GENE I-GENE
. O O

Intracellular O O
localization O O
studies O O
using O O
the O O
mDAP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
/ O O
EGFP B-GENE O
fusion O O
protein O O
, O O
cell O O
fractionation O O
and O O
protease O O
protection O O
experiments O O
localized O O
mDAP B-GENE O
- I-GENE O
0 I-GENE O
to O O
the O O
mitochondrial O O
matrix O O
. O O

They O O
also O O
negatively O O
modulate O O
the O O
PI B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
catalytic O I-GENE
activity O O
but O O
to O O
different O O
extents O O
, O O
dependent O O
on O O
the O O
unique O O
N O O
- O O
terminal O O
structure O O
of O O
each O O
isoform O O
. O O

Molecular O O
cloning O O
and O O
expression O O
of O O
human B-GENE O
UDP I-GENE B-GENE
- I-GENE I-GENE
d I-GENE I-GENE
- I-GENE I-GENE
Xylose I-GENE I-GENE
: I-GENE O
proteoglycan I-GENE O
core I-GENE O
protein I-GENE O
beta B-GENE O
- I-GENE O
d I-GENE O
- I-GENE O
xylosyltransferase I-GENE O
and O O
its O O
first O O
isoform B-GENE O
XT I-GENE O
- I-GENE O
II I-GENE O
. O O

Transfection O O
experiments O O
using O O
preformed O O
triplexes O O
with O O
a O O
reporter O O
plasmid O O
containing O O
the O O
collagen B-GENE O
promoter I-GENE O
sequence I-GENE O
showed O O
significant O O
inhibition O O
of O O
transcription O O
when O O
compared O O
with O O
a O O
control O O
phosphorothioate O O
ODN O O
. O O

These O O
mutations O O
create O O
stop O O
codons O O
in O O
exon O O
0 O O
and O O
0 O O
, O O
respectively O O
, O O
and O O
probably O O
result O O
in O O
truncated O O
proteins O O
lacking O O
HLH O O
- O O
Zip O O
or O O
Zip O O
structure O O
. O O

Also O O
, O O
transient O O
overexpression O O
of O O
this O O
protein O O
in O O
C0C00 O O
cells O O
reduced O O
the O O
transcription O O
of O O
a O O
CAT B-GENE O
- O O
reporter O O
regulated O O
by O O
an O O
E00 B-GENE O
/ O O
MyoD B-GENE O
driven O O
enhancer O O
. O O

By O O
deletion O O
analysis O O
of O O
the O O
MLS0 B-GENE O
control O O
region O O
, O O
we O O
identified O O
two O O
sites O O
, O O
UAS0 O O
and O O
UAS0 O O
, O O
as O O
important O O
for O O
efficient O O
derepression O O
of O O
the O O
gene O O
. O O

Transfection O O
analyses O O
indicated O O
that O O
the O O
expression O O
of O O
Tbxas0 B-GENE O
is O O
controlled O O
by O O
a O O
short O O
( O O
00 O O
- O O
bp O O
) O O
positive O O
regulatory O O
sequence O O
and O O
several O O
upstream O O
repressive O O
elements O O
. O O

It O O
bound O O
to O O
vitamin B-GENE O
D I-GENE O
receptor I-GENE O
( O O
VDR B-GENE O
) O O
but O O
not O O
retinoic B-GENE O
acid I-GENE O
Xalpha I-GENE O
receptor I-GENE O
( O O
RXRalpha B-GENE O
) O O
in O O
the O O
human O O
T O O
cell O O
line O O
MT0 O O
cells O O
. O O

The O O
general O B-GENE
transcription B-GENE I-GENE
factor I-GENE I-GENE
IIA I-GENE I-GENE
( O O
TFIIA B-GENE B-GENE
) O O
interacts O O
with O O
the O O
TATA B-GENE B-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
( O O
TBP B-GENE B-GENE
) O O
and O O
promoter O O
DNA O O
to O O
mediate O O
transcription O O
activation O O
in O O
vitro O O
. O O

Sp0 B-GENE O
and O O
two O O
Sp0 B-GENE O
isoforms I-GENE O
were O O
detected O O
as O O
the O O
primary O O
cellular O O
constituents O O
of O O
DNA O B-GENE
- O I-GENE
protein O I-GENE
complexes O O
formed O O
with O O
the O O
NF B-GENE B-GENE
- I-GENE O
kappaB I-GENE O
- I-GENE O
proximal I-GENE O
site I-GENE O
. O O

Ligand O O
- O O
independent O O
activation O O
of O O
platelet B-GENE B-GENE
- I-GENE I-GENE
derived I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
is O O
a O O
necessary O O
intermediate O O
in O O
lysophosphatidic O O
, O O
acid O O
- O O
stimulated O O
mitogenic O O
activity O O
in O O
L O O
cells O O
. O O

Dopamine B-GENE O
beta I-GENE B-GENE
- I-GENE I-GENE
hydroxylase I-GENE I-GENE
( O O
DBH B-GENE O
) O O
catalyzes O O
the O O
conversion O O
of O O
dopamine O O
to O O
noradrenaline O O
and O O
is O O
selectively O O
expressed O O
in O O
noradrenergic O O
and O O
adrenergic O O
neurons O O
and O O
neuroendocrine O O
cells O O
. O O

By O O
DNase B-GENE O
I I-GENE O
footprint O O
analysis O O
of O O
the O O
PNR O O
element O O
, O O
a O O
palindrome O O
of O O
two O O
high O O
- O O
affinity O O
Ets B-GENE O
- I-GENE O
binding I-GENE O
sites I-GENE O
( O O
CTTCCCTGGAAG O O
) O O
was O O
identified O O
. O O

Epstein B-GENE O
- I-GENE O
Barr I-GENE O
virus I-GENE O
- I-GENE I-GENE
encoded I-GENE I-GENE
latent I-GENE I-GENE
membrane I-GENE I-GENE
protein I-GENE I-GENE
0 I-GENE O
activates O O
the O O
JNK B-GENE O
pathway O O
through O O
its O O
extreme O O
C O O
terminus O O
via O O
a O O
mechanism O O
involving O O
TRADD B-GENE O
and O O
TRAF0 B-GENE O
. O O

This O O
region O O
of O O
hsp00 B-GENE O
mediates O O
ATP O O
- O O
independent O O
chaperone O O
activity O O
, O O
overlaps O O
the O O
hsp00 B-GENE O
dimerization I-GENE O
domain I-GENE O
, O O
and O O
includes O O
structural O O
elements O O
important O O
for O O
steroid B-GENE B-GENE
receptor I-GENE I-GENE
interaction O O
. O O

Each O O
of O O
these O O
genes O O
contains O O
a O O
putative O O
upstream O O
ORF O O
, O O
while O O
STA0 B-GENE O
has O O
two O O
additional O O
in O O
- O O
frame O O
AUG O O
codons O O
0 O O
' O O
to O O
the O O
major O O
cistron O O
. O O

We O O
describe O O
a O O
genetic O O
system O O
for O O
further O O
characterizing O O
the O O
role O O
of O O
the O O
extreme O O
C O O
- O O
terminus O O
of O O
the O O
beta O O
subunit O O
of O O
E B-GENE O
. I-GENE O
coli I-GENE O
RNA I-GENE O
polymerase I-GENE O
. O O

To O O
estimate O O
the O O
locations O O
of O O
sources O O
with O O
the O O
TF O O
- O O
MUSIC O O
algorithm O O
, O O
we O O
first O O
set O O
the O O
target O O
region O O
on O O
the O O
spectrogram O O
of O O
the O O
somatosensory O O
responses O O
. O O

We O O
present O O
a O O
case O O
of O O
carcinoma O O
of O O
the O O
breast O O
presenting O O
concurrently O O
with O O
SSc O O
that O O
subsequently O O
progressed O O
to O O
dialysis O O
- O O
dependent O O
renal O O
failure O O
in O O
just O O
0 O O
month O O
. O O

By O O
an O O
induced O O
- O O
fit O O
mechanism O O
, O O
contacts O O
with O O
the O O
anticodon O O
can O O
activate O O
formation O O
of O O
a O O
robust O O
transition O O
state O O
at O O
a O O
site O O
over O O
00 O O
A O O
away O O
. O O

We O O
describe O O
a O O
case O O
of O O
acetaminophen O O
overdose O O
that O O
was O O
treated O O
with O O
both O O
hemodialysis O O
( O O
HD O O
) O O
and O O
NAC O O
due O O
to O O
severe O O
intoxication O O
and O O
slow O O
drug O O
clearance O O
. O O

As O O
no O O
complete O O
PPARgamma B-GENE O
antagonists O O
have O O
been O O
described O O
hitherto O O
, O O
we O O
have O O
constructed O O
a O O
dominant O O
- O O
negative O O
mutant O O
receptor O O
to O O
inhibit O O
wild O O
- O O
type O O
PPARgamma B-GENE O
action O O
. O O

IgM B-GENE O
and O O
IgG B-GENE O
anti I-GENE O
A I-GENE O
and O O
anti B-GENE O
B I-GENE O
antibody I-GENE O
status O O
of O O
000 O O
antenatal O O
O O O
group O O
mothers O O
( O O
who O O
had O O
non O O
O O O
group O O
husbands O O
) O O
were O O
studied O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
trials O O
comparing O O
children O O
undergoing O O
systematic O O
therapy O O
focusing O O
on O O
the O O
family O O
in O O
conjunction O O
with O O
asthma O O
medication O O
, O O
with O O
children O O
taking O O
asthma O O
medication O O
only O O
. O O

Using O O
adenoviral O O
transfer O O
of O O
IkappaBalpha B-GENE O
( O O
IkappaBalpha B-GENE O
overexpression O O
) O O
, O O
the O O
production O O
of O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
induced O O
by O O
whole O O
GBS O O
was O O
inhibited O O
by O O
only O O
00 O O
% O O
. O O

Double O O
mutant O O
analysis O O
suggests O O
that O O
Rad00p B-GENE O
and O O
Mus00p B-GENE O
act O O
in O O
one O O
pathway O O
for O O
the O O
repair O O
of O O
, O O
or O O
tolerance O O
to O O
, O O
UV O O
- O O
induced O O
DNA O O
damage O O
. O O

Here O O
, O O
we O O
identified O O
three O O
cis O O
- O O
elements O O
required O O
for O O
replication O O
within O O
the O O
000 O B-GENE
bp O I-GENE
promoter O I-GENE
, O O
using O O
autonomously O O
replicating O O
plasmids O O
carrying O O
various O O
mutations O O
and O O
deletions O O
. O O

MS O O
characteristics O O
of O O
coumarins O O
, O O
psoralens O O
and O O
polymethoxylated O O
flavones O O
with O O
different O O
substitution O O
patterns O O
were O O
determined O O
on O O
the O O
basis O O
of O O
the O O
response O O
obtained O O
with O O
the O O
APcI O O
interface O O
. O O

SRE O O
activity O O
is O O
dependent O O
upon O O
the O O
activation O O
by O O
phosphorylation O O
of O O
a O O
ternary O O
complex O O
factor O O
; O O
included O O
among O O
the O O
ternary O O
complex O O
factors O O
is O O
Elk B-GENE O
- I-GENE O
0 I-GENE O
. O O

Transcription O O
of O O
these O O
genes O O
was O O
also O O
elevated O O
in O O
gut O O
and O O
lung O O
during O O
freezing O O
, O O
but O O
mRNA O O
levels O O
in O O
these O O
tissues O O
were O O
lower O O
than O O
in O O
liver O O
. O O

However O O
, O O
we O O
could O O
not O O
find O O
the O O
homologous O O
regions O O
with O O
guanine B-GENE O
nucleotide I-GENE O
exchange I-GENE O
factors I-GENE O
or O O
GTPase B-GENE B-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
proteins I-GENE O
in O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
cbl I-GENE I-GENE
gene I-GENE I-GENE
. O O

S0F B-GENE O
, O O
a O O
leaf O O
- O O
specific O O
trans O B-GENE
- O I-GENE
acting O I-GENE
factor O I-GENE
, O O
binds O O
to O O
a O O
novel O O
cis O O
- O O
acting O O
element O O
and O O
differentially O B-GENE
activates O I-GENE
the O O
RPL00 B-GENE B-GENE
gene I-GENE I-GENE
. O O

We O O
also O O
show O O
by O O
immunogold O O
electron O O
microscopy O O
immunocytochemistry O O
that O O
amphiphysin B-GENE O
I I-GENE O
is O O
localized O O
in O O
the O O
nerve O O
terminal O O
cytomatrix O O
and O O
is O O
partially O O
associated O O
with O O
endocytic O O
intermediates O O
. O O

The O O
existence O O
of O O
these O O
two O O
categories O O
of O O
strains O O
offers O O
a O O
new O O
genetic O O
system O O
in O O
which O O
the O O
properties O O
of O O
a O O
potential O O
invertebrate O O
retrovirus O O
can O O
be O O
tested O O
. O O

Localization O O
of O O
00 O O
exons O O
on O O
a O O
YAC O O
contig O O
spanning O O
0 O O
. O O
0 O O
Mb O O
around O O
the O O
multidrug B-GENE O
resistance I-GENE O
gene I-GENE O
region I-GENE O
of O O
human O O
chromosome O O
0q00 O O
. O O
0 O O
. O O

Thus O O
, O O
included O O
in O O
the O O
KG0a O O
EST O O
dataset O O
are O O
candidates O O
for O O
new O O
human O O
genes O O
that O O
may O O
play O O
roles O O
in O O
hematopoietic O O
differentiative O O
progression O O
and O O
lineage O O
commitment O O
. O O

Fowlpox O O
virus O O
encodes O O
nonessential O O
homologs O O
of O O
cellular B-GENE B-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
SNAP I-GENE I-GENE
, O O
PC B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
and O O
an O O
orphan O O
human O O
homolog O O
of O O
a O O
secreted O B-GENE
nematode O I-GENE
protein O I-GENE
. O O

BACKGROUND O O
: O O
The O O
c B-GENE B-GENE
- I-GENE I-GENE
myc I-GENE I-GENE
proto I-GENE I-GENE
- I-GENE I-GENE
oncogene I-GENE I-GENE
has O O
been O O
suggested O O
to O O
play O O
key O O
roles O O
in O O
cell O O
proliferation O O
, O O
differentiation O O
, O O
transformation O O
and O O
apoptosis O O
. O O

The O O
highly O O
amyloidogenic O O
00 O O
- O O
residue O O
form O O
of O O
Abeta B-GENE O
( O O
Abeta00 B-GENE O
) O O
is O O
the O O
first O O
species O O
to O O
be O O
deposited O O
in O O
both O O
sporadic O O
and O O
familial O O
AD O O
. O O

Also O O
, O O
the O O
amplitude O O
of O O
the O O
oscillatory O O
potentials O O
( O O
O0 O B-GENE
+ O I-GENE
O0 O I-GENE
+ O I-GENE
O0 O I-GENE
+ O I-GENE
O0 O I-GENE
) O O
was O O
significantly O O
reduced O O
in O O
the O O
early O O
postoperative O O
period O O
. O O

In O O
contrast O O
, O O
an O O
amino O O
- O O
terminal O O
fragment O O
containing O O
the O O
C O B-GENE
/ O I-GENE
H0 O I-GENE
domain O O
was O O
sufficient O O
for O O
coactivation O O
of O O
Zta B-GENE O
transcription O O
and O O
viral O O
reactivation O O
function O O
. O O

Two O O
patients O O
with O O
recurrent O O
tumors O O
had O O
high O O
S O O
- O O
phase O O
fractions O O
both O O
on O O
the O O
first O O
resected O O
specimens O O
and O O
at O O
the O O
time O O
of O O
the O O
second O O
operation O O
. O O

Mutations O O
of O O
the O O
RET B-GENE B-GENE
gene I-GENE I-GENE
, O O
encoding O B-GENE
a O I-GENE
receptor B-GENE I-GENE
tyrosine I-GENE I-GENE
kinase I-GENE I-GENE
, O O
have O O
been O O
associated O O
with O O
the O O
inherited O O
cancer O O
syndromes O O
MEN O O
0A O O
and O O
MEN O O
0B O O
. O O

During O O
both O O
encephalopathy O O
episodes O O
, O O
CSF O B-GENE
protein O I-GENE
and O O
immunoglobulin B-GENE B-GENE
G I-GENE I-GENE
( O O
IgG B-GENE O
) O O
levels O O
were O O
elevated O O
without O O
an O O
increased O O
IgG B-GENE O
index O O
or O O
IgG B-GENE O
synthesis O O
rate O O
. O O

Oseltamivir O O
( O O
GS0000 O O
) O O
, O O
which O O
can O O
be O O
administered O O
orally O O
, O O
is O O
the O O
prodrug O O
of O O
GS0000 O O
, O O
a O O
potent O O
and O O
selective O O
inhibitor O O
of O O
influenzavirus B-GENE O
neuraminidases I-GENE O
. O O

For O O
example O O
, O O
introduction O O
of O O
immunogenic O O
and O O
purification O O
tag O O
sequences O O
into O O
the O O
C O O
- O O
terminal O O
coding O O
region O O
significantly O O
decreased O O
bop B-GENE O
gene I-GENE O
mRNA I-GENE O
and O O
protein O O
accumulation O O
. O O

Mouse B-GENE O
growth I-GENE O
hormone I-GENE O
transcription I-GENE O
factor I-GENE O
Zn I-GENE O
- I-GENE O
00 I-GENE O
: O O
unique O O
bipartite O O
structure O O
containing O O
tandemly O O
repeated O O
zinc O O
finger O O
domains O O
not O O
reported O O
in O O
rat B-GENE O
Zn I-GENE O
- I-GENE O
00 I-GENE O
. O O

The O O
early O O
dg O O
. O O
of O O
rejection O O
and O O
especially O O
acute O O
rejection O O
, O O
it O O
' O O
s O O
adequate O O
management O O
, O O
decreased O O
risk O O
for O O
the O O
future O O
chronic O O
rejection O O
nephropathy O O
. O O

We O O
also O O
show O O
that O O
p00 B-GENE O
binds O O
to O O
these O O
targets O O
with O O
almost O O
equal O O
affinity O O
and O O
that O O
different O O
residues O O
have O O
variable O O
roles O O
in O O
binding O O
different O O
kappaB B-GENE O
targets I-GENE O
. O O

Taken O O
together O O
, O O
these O O
results O O
indicate O O
that O O
MAP B-GENE O
kinase I-GENE O
stimulates O O
the O O
hPL B-GENE B-GENE
- I-GENE I-GENE
B I-GENE I-GENE
enhancer I-GENE O
by O O
an O O
NF B-GENE B-GENE
- I-GENE I-GENE
IL I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- O O
dependent O O
pathway O O
. O O

The O O
equilibrium O O
dissociation O O
binding O O
constant O O
for O O
the O O
interaction O O
of O O
TnrA B-GENE O
with O O
the O O
nrgAB B-GENE O
promoter I-GENE O
fragment I-GENE O
was O O
0 O O
. O O
0 O O
nM O O
under O O
the O O
conditions O O
used O O
here O O
. O O

It O O
is O O
now O O
well O O
accepted O O
that O O
the O O
p00 B-GENE B-GENE
C I-GENE I-GENE
- I-GENE I-GENE
terminus I-GENE I-GENE
plays O O
a O O
central O O
role O O
in O O
controlling O O
the O O
activity O O
of O O
the O O
wild O O
- O O
type O O
molecule O O
. O O

The O O
transcription O B-GENE
factor O I-GENE
Jun B-GENE I-GENE
( O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
) O O
functions O O
as O O
a O O
recipient O O
of O O
extracellular O O
growth O O
signals O O
and O O
converts O O
them O O
into O O
patterns O O
of O O
gene O O
expression O O
. O O

On O O
long O O
- O O
term O O
follow O O
- O O
up O O
, O O
there O O
was O O
no O O
significant O O
difference O O
in O O
the O O
incidence O O
of O O
hospitalizations O O
( O O
0 O O
per O O
0 O O
. O O
0 O O
vs O O
. O O

We O O
conclude O O
that O O
c B-GENE O
- I-GENE O
Myb I-GENE O
regulates O O
the O O
RAG B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
promoter I-GENE I-GENE
in O O
T O O
cells O O
by O O
binding O O
to O O
this O O
consensus B-GENE O
c I-GENE O
- I-GENE O
Myb I-GENE O
binding I-GENE O
site I-GENE O
. O O

Oncogenic O O
signalling O O
by O O
E0F0 B-GENE O
has O O
recently O O
been O O
linked O O
to O O
stabilization O O
and O O
activation O O
of O O
the O O
tumour O O
suppressor O O
p00 B-GENE O
( O O
refs O O
0 O O
, O O
0 O O
, O O
0 O O
) O O
. O O

We O O
have O O
tested O O
this O O
proposal O O
by O O
carrying O O
out O O
circular O O
dichroism O O
( O O
CD O O
) O O
and O O
NMR O O
experiments O O
on O O
the O O
Skn B-GENE O
domain I-GENE O
and O O
five O O
truncated O O
proteins O O
. O O

This O O
regulation O O
requires O O
two O O
HMG B-GENE B-GENE
- I-GENE I-GENE
box I-GENE I-GENE
proteins I-GENE I-GENE
: O O
the O O
ubiquitous O O
Ste00 B-GENE O
transcription I-GENE O
factor I-GENE O
and O O
the O O
M O O
cell O O
- O O
controlling O O
protein O O
Mat0 B-GENE O
- I-GENE O
Mc I-GENE O
. O O

It O O
is O O
thus O O
one O O
of O O
the O O
key O O
enzymes O O
involved O O
in O O
the O O
triiodothyronine O O
- O O
mediated O O
control O O
of O O
growth O O
, O O
differentiation O O
and O O
basal O O
metabolism O O
in O O
vertebrates O O
. O O

We O O
have O O
overexpressed O O
, O O
purified O O
, O O
characterized O O
, O O
and O O
crystallized O O
the O O
BTB B-GENE O
/ O O
POZ O O
domain O O
from O O
PLZF B-GENE O
( O O
PLZF B-GENE B-GENE
- O I-GENE
BTB B-GENE I-GENE
/ O O
POZ O O
) O O
. O O

Tumor B-GENE O
necrosis I-GENE O
factor I-GENE O
signaling O O
to O O
stress B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
( O O
SAPK B-GENE B-GENE
) O O
/ O O
Jun B-GENE O
NH0 I-GENE B-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase I-GENE I-GENE
( O O
JNK B-GENE O
) O O
and O O
p00 B-GENE B-GENE
. O O

Furthermore O O
, O O
we O O
demonstrated O O
that O O
Galpha00 B-GENE O
Q000L I-GENE O
stimulated O O
Src B-GENE B-GENE
family I-GENE I-GENE
kinase O I-GENE
activity O O
and O O
induced O O
tyrosine O O
phosphorylation O O
of O O
several O O
proteins O O
in O O
HEK O O
- O O
000 O O
cells O O
. O O

Expression O O
of O O
constitutively O O
active O O
MEK0 B-GENE O
, O O
the O O
kinase O O
that O O
activates O O
ERKs B-GENE O
, O O
or O O
overexpression O O
of O O
ERK0 B-GENE B-GENE
, O O
but O O
not O O
JNK0 B-GENE O
, O O
inhibited O O
Stat0 B-GENE O
activation O O
. O O

P B-GENE O
- I-GENE O
CIP0 I-GENE O
, O O
a O O
novel O O
protein O O
that O O
interacts O O
with O O
the O O
cytosolic O O
domain O O
of O O
peptidylglycine B-GENE B-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
amidating I-GENE I-GENE
monooxygenase I-GENE I-GENE
, O O
is O O
associated O O
with O O
endosomes O O
. O O

However O O
, O O
there O O
has O O
not O O
been O O
any O O
evidence O O
of O O
A O O
. O O
salmonicida O O
infections O O
, O O
specifically O O
furunculosis O O
, O O
associated O O
with O O
the O O
fish O O
in O O
this O O
loch O O
. O O

The O O
H O O
- O O
reflex O O
recovery O O
curve O O
was O O
obtained O O
after O O
stimulation O O
of O O
the O O
median O O
nerve O O
at O O
the O O
elbow O O
and O O
recording O O
from O O
the O O
flexor O O
carpi O O
radialis O O
. O O

The O O
hybrid O O
viruses O O
were O O
found O O
to O O
accumulate O O
to O O
high O O
levels O O
in O O
infected O O
plants O O
, O O
to O O
form O O
stable O O
virions O O
, O O
and O O
to O O
be O O
mechanically O O
transmissible O O
. O O

CONCLUSIONS O O
: O O
Turbutest O O
is O O
a O O
valuable O O
tool O O
in O O
asthmatic O O
patients O O
' O O
training O O
, O O
allowing O O
identification O O
and O O
improvement O O
of O O
an O O
inadequate O O
inhalation O O
technique O O
with O O
Turbuhaler O O
. O O

We O O
report O O
the O O
construction O O
of O O
an O O
approximately O O
0 O O
. O O
0 O O
- O O
Mb O O
sequence O O
- O O
ready O O
YAC O O
/ O O
BAC O O
clone O O
contig O O
of O O
0p00 O O
- O O
p00 O O
. O O

These O O
results O O
suggest O O
that O O
VP0 B-GENE O
was O O
efficiently O O
transported O O
to O O
the O O
nucleus O O
and O O
localized O O
in O O
the O O
discrete O O
subnuclear O O
regions O O
, O O
possibly O O
with O O
VP0 B-GENE O
and O O
VP0 B-GENE O
. O O

A O O
total O O
of O O
000 O O
STSs O O
map O O
to O O
this O O
interval O O
of O O
0 O O
Mb O O
, O O
giving O O
an O O
average O O
marker O O
resolution O O
of O O
approximately O O
one O O
per O O
00 O O
kb O O
. O O

These O O
results O O
suggest O O
that O O
Cdc00p B-GENE O
is O O
in O O
fact O O
required O O
for O O
pheromone O O
response O O
and O O
that O O
interaction O O
with O O
the O O
PAK B-GENE O
Ste00p B-GENE O
is O O
critical O O
for O O
that O O
role O O
. O O

Another O O
cis O O
- O O
acting O O
element O O
, O O
exonic O O
splicing O O
suppressor O O
0 O O
( O O
ESS0 O O
) O O
, O O
represses O O
use O O
of O O
the O O
nt O O
0000 O O
0 O O
' O O
splice O O
site O O
. O O

Characterization O O
of O O
the O O
microtubule O O
binding O O
domain O O
of O O
microtubule B-GENE B-GENE
actin I-GENE I-GENE
crosslinking I-GENE I-GENE
factor I-GENE I-GENE
( O O
MACF B-GENE O
) O O
: O O
identification O O
of O O
a O O
novel O O
group O O
of O O
microtubule B-GENE O
associated I-GENE O
proteins I-GENE O
. O O

In O O
addition O O
, O O
we O O
identified O O
two O O
mutations O O
, O O
Delta O O
M0000 O O
and O O
IVS00 O O
+ O O
0G O O
- O O
- O O
> O O
A O O
, O O
in O O
a O O
German O O
USH0 B-GENE O
patient O O
. O O

One O O
P0 O O
genomic O O
clone O O
and O O
six O O
subsequent O O
plasmid O O
subclones O O
were O O
isolated O O
and O O
analyzed O O
for O O
the O O
exon O O
- O O
intron O O
organization O O
of O O
the O O
Ctpct B-GENE B-GENE
gene I-GENE I-GENE
. O O

Latanoprost O O
produces O O
an O O
additional O O
reduction O O
of O O
intraocular O O
pressure O O
( O O
IOP O O
) O O
when O O
used O O
in O O
combination O O
with O O
timolol O O
, O O
pilocarpine O O
, O O
acetazolamide O O
and O O
dipivefrin O O
. O O

Transient O O
overexpression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
induced O O
tenascin B-GENE O
- I-GENE O
C I-GENE O
expression O O
in O O
primary O O
REF O O
and O O
in O O
FR0T0 O O
, O O
an O O
established O O
fibroblast O O
cell O O
line O O
. O O

In O O
support O O
of O O
this O O
interpretation O O
we O O
demonstrate O O
that O O
MQ0b B-GENE O
binds O O
strongly O O
0 O O
of O O
00 O O
motif O O
- O O
positive O O
, O O
pathogen O O
- O O
derived O O
synthetic O O
peptides O O
. O O

The O O
malate B-GENE B-GENE
synthase I-GENE I-GENE
gene I-GENE I-GENE
, O O
MLS0 B-GENE O
, O O
of O O
the O O
yeast O O
Saccharomyces O O
cerevisiae O O
is O O
transcriptionally O O
regulated O O
by O O
the O O
carbon O O
source O O
in O O
the O O
growth O O
medium O O
. O O

Electromobility O O
shift O O
and O O
cotransfection O O
assays O O
demonstrated O O
that O O
HNF0alpha B-GENE O
, O O
but O O
not O O
HNF0 B-GENE O
, O O
bound O O
to O O
its O O
cognate O O
site O O
and O O
transactivated O B-GENE
G0Pase B-GENE I-GENE
gene I-GENE I-GENE
expression O O
. O O

SNAC O O
or O O
PBS O O
was O O
infused O O
for O O
0 O O
. O O
0 O O
h O O
, O O
beginning O O
00 O O
min O O
before O O
ischemia O O
and O O
continuing O O
throughout O O
the O O
duration O O
of O O
reperfusion O O
. O O

Deleting O O
SNF0 B-GENE O
repressed O O
meiosis O O
at O O
the O O
same O O
three O O
steps O O
that O O
were O O
inhibited O O
by O O
glucose O O
, O O
suggesting O O
that O O
glucose O O
blocks O O
meiosis O O
by O O
inhibiting O O
Snf0 B-GENE O
. O O

Our O O
results O O
show O O
that O O
, O O
from O O
a O O
thermodynamical O O
standpoint O O
, O O
melatonin O O
may O O
directly O O
scavenge O O
hydroxyl O O
radicals O O
both O O
in O O
vacuum O O
and O O
in O O
aqueous O O
solution O O
. O O

Previous O O
genetic O O
studies O O
led O O
to O O
the O O
conclusion O O
that O O
nitrate O O
and O O
nitrite O O
induction O O
of O O
nasF B-GENE B-GENE
operon I-GENE I-GENE
expression O O
is O O
determined O O
by O O
a O O
transcriptional O O
antitermination O O
mechanism O O
. O O

RESULTS O O
: O O
The O O
cardiac O O
index O O
significantly O O
changed O O
with O O
varying O O
PaCO0 O O
levels O O
( O O
hypocapnia O O
, O O
- O O
0 O O
% O O
; O O
hypercapnia O O
, O O
00 O O
% O O
) O O
. O O

Molecular O O
cloning O O
and O O
characterization O O
of O O
a O O
new O O
member O O
of O O
the O O
rat B-GENE B-GENE
placental I-GENE I-GENE
prolactin I-GENE I-GENE
( O O
PRL B-GENE B-GENE
) O O
family O O
, O O
PRL B-GENE B-GENE
- O I-GENE
like O I-GENE
protein B-GENE I-GENE
H I-GENE O
. O O

Thus O O
, O O
we O O
have O O
identified O O
an O O
activation O O
target O O
of O O
a O O
human O O
activator O O
, O O
Oct B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
, O O
within O O
its O O
cognate O O
basal O O
transcription O O
complex O O
. O O

Both O O
NUP00 B-GENE O
- O O
HOXA0 B-GENE O
chimeras O O
transformed O O
NIH O O
0T0 O O
fibroblasts O O
, O O
and O O
this O O
transformation O O
required O O
the O O
HOXA0 B-GENE O
domains I-GENE O
for O O
DNA O O
binding O O
and O O
PBX B-GENE O
interaction O O
. O O

A O O
motif O O
( O O
TGATGTCA O O
) O O
which O O
matches O O
a O O
CREB B-GENE O
site I-GENE O
and O O
is O O
similar O O
to O O
an O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
site I-GENE O
is O O
embedded O O
within O O
ER0 B-GENE O
. O O

The O O
induced O O
respiratory O O
burst O O
was O O
investigated O O
by O O
the O O
intracellular O O
oxidative O O
transformation O O
of O O
dihydrorhodamine O O
000 O O
to O O
the O O
fluorescent O O
dye O O
rhodamine O O
000 O O
via O O
flow O O
cytometry O O
. O O

The O O
studied O O
protein O O
fragments O O
consist O O
of O O
residues O O
Arg000 O O
- O O
His000 O O
of O O
the O O
human B-GENE O
ER I-GENE O
and O O
residues O O
Lys000 O O
- O O
Gln000 O O
of O O
the O O
rat O O
GR B-GENE O
. O O

Thus O O
, O O
elongin B-GENE O
C I-GENE O
is O O
found O O
to O O
oligomerize O O
in O O
solution O O
and O O
to O O
undergo O O
significant O O
structural O O
rearrangements O O
upon O O
binding O O
of O O
two O O
different O O
partner O O
proteins O O
. O O

MSSPs B-GENE O
are O O
believed O O
to O O
regulate O O
DNA O O
replication O O
, O O
transcription O O
, O O
apopotosis O O
and O O
cell O O
cycle O O
progression O O
by O O
interacting O O
with O O
the O O
C B-GENE B-GENE
- I-GENE I-GENE
MYC I-GENE I-GENE
protein I-GENE I-GENE
. O O

In O O
vivo O O
dimethyl O O
sulfate O O
footprinting O O
of O O
the O O
cyclin B-GENE B-GENE
E I-GENE O
promoter I-GENE O
revealed O O
several O O
regions O O
of O O
protection O O
and O O
hypersensitivity O O
that O O
were O O
unique O O
to O O
infected O O
cells O O
. O O

Symptoms O O
, O O
however O O
, O O
appear O O
to O O
correlate O O
poorly O O
with O O
oesophagitis O O
; O O
hence O O
, O O
severe O O
symptoms O O
do O O
not O O
indicate O O
there O O
is O O
greater O O
oesophageal O O
damage O O
. O O

Fecal O O
samples O O
were O O
collected O O
at O O
the O O
beginning O O
and O O
end O O
of O O
each O O
trial O O
period O O
and O O
were O O
analyzed O O
for O O
gastrointestinal O O
nematode O O
eggs O O
and O O
Giardia O O
cyst O O
. O O

Is O O
leishmaniasis O O
endemic O O
on O O
the O O
island O O
of O O
Minorca O O
( O O
Spain O O
) O O
? O O
A O O
human O O
visceral O O
case O O
after O O
living O O
00 O O
years O O
in O O
Minorca O O
. O O

Congruent O O
with O O
empirical O O
predictions O O
, O O
the O O
most O O
homesick O O
children O O
perceived O O
low O O
control O O
over O O
homesickness O O
and O O
separation O O
, O O
and O O
coped O O
by O O
relinquishing O O
control O O
. O O

The O O
serum O O
levels O O
of O O
beta B-GENE B-GENE
- I-GENE I-GENE
human I-GENE I-GENE
chorionic I-GENE I-GENE
gonadotropin I-GENE I-GENE
( O O
HCG B-GENE O
) O O
and O O
placental B-GENE B-GENE
alkaline I-GENE I-GENE
phosphatase I-GENE I-GENE
( O O
PLAP B-GENE O
) O O
were O O
not O O
elevated O O
. O O

Differential O O
regulation O O
of O O
the O O
pre B-GENE B-GENE
- I-GENE I-GENE
C I-GENE I-GENE
and O O
pregenomic O O
promoters O O
of O O
human O O
hepatitis O O
B O O
virus O O
by O O
members O O
of O O
the O O
nuclear B-GENE B-GENE
receptor I-GENE I-GENE
superfamily I-GENE O
. O O

The O O
promoter O O
for O O
HMG B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
synthase I-GENE O
contains O O
two O O
binding O O
sites O O
for O O
the O O
sterol B-GENE O
regulatory I-GENE O
element I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins I-GENE I-GENE
( O O
SREBPs B-GENE O
) O O
. O O

Members O O
of O O
the O O
meis0 B-GENE B-GENE
and O O
pbx B-GENE B-GENE
homeodomain I-GENE I-GENE
protein I-GENE I-GENE
families I-GENE O
cooperatively O O
bind O O
a O O
cAMP O O
- O O
responsive O O
sequence O O
( O O
CRS0 O O
) O O
from O O
bovine B-GENE O
CYP00 I-GENE O
. O O

A O O
large O O
deletion O O
in O O
the O O
CTD B-GENE O
- I-GENE O
binding I-GENE O
motif I-GENE O
blocks O O
down O O
- O O
regulation O O
but O O
does O O
not O O
affect O O
the O O
essential O O
function O O
of O O
Nrd0 B-GENE O
. O O

Genome O O
plasticity O O
in O O
the O O
distal O O
tail O O
fiber O O
locus O O
of O O
the O O
T O O
- O O
even O O
bacteriophage O O
: O O
recombination O O
between O O
conserved O O
motifs O O
swaps O O
adhesin B-GENE O
specificity O O
. O O

Expression O O
of O O
lacZ B-GENE O
from O O
the O O
promoter O O
of O O
the O O
Escherichia B-GENE O
coli I-GENE O
spc I-GENE O
operon I-GENE O
cloned O O
into O O
vectors O O
carrying O O
the O O
W000 O O
trp B-GENE O
- O O
lac B-GENE O
fusion O O
. O O

CONTEXT O O
: O O
ThinPrep O O
, O O
AutoPap O O
, O O
and O O
Papnet O O
are O O
0 O O
new O O
technologies O O
that O O
increase O O
the O O
sensitivity O O
and O O
cost O O
of O O
cervical O O
cancer O O
screening O O
. O O

Dominant O O
negative O O
Sos B-GENE O
did O O
not O O
affect O O
carbachol O O
stimulation O O
of O O
HA B-GENE O
- O O
ERK0 B-GENE O
but O O
inhibited O O
the O O
stimulatory O O
effect O O
of O O
EGF B-GENE O
by O O
00 O O
% O O
. O O

Protein B-GENE O
kinase I-GENE O
A I-GENE O
- I-GENE O
Ialpha I-GENE O
subunit O O
- O O
directed O O
antisense O O
inhibition O O
of O O
ovarian O O
cancer O O
cell O O
growth O O
: O O
crosstalk O O
with O O
tyrosine B-GENE O
kinase I-GENE O
signaling O O
pathway O O
. O O

They O O
self O O
- O O
completed O O
the O O
SF O O
- O O
00 O O
questionnaire O O
and O O
their O O
QoL O O
was O O
described O O
and O O
retrospectively O O
compared O O
to O O
that O O
of O O
historical O O
controls O O
. O O

The O O
HMG B-GENE O
domain I-GENE O
of O O
both O O
HMG00 B-GENE O
proteins I-GENE O
is O O
most O O
similar O O
to O O
that O O
of O O
yeast B-GENE O
NHP0A I-GENE O
( O O
00 O O
% O O
to O O
00 O O
% O O
) O O
. O O

Our O O
results O O
suggest O O
that O O
proteasome O O
inhibition O O
leads O O
to O O
upregulation O O
of O O
specific O O
members O O
of O O
transcription O O
factor O O
families O O
controlling O O
cellular O O
stress O O
response O O
and O O
proliferation O O
. O O

The O O
Cili B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
sequences I-GENE O
possess O O
similarity O O
to O O
the O O
RNaseH B-GENE O
domain I-GENE O
of O O
Lian B-GENE B-GENE
- O I-GENE
Aa0 B-GENE I-GENE
, O O
a O O
mosquito B-GENE O
non I-GENE O
- I-GENE O
LTR I-GENE O
retrotransposon I-GENE O
. O O

Pax B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
a O O
paired B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
homeobox I-GENE I-GENE
gene I-GENE I-GENE
that O O
is O O
specifically O O
expressed O O
in O O
the O O
dorsal O O
and O O
posterior O O
neural O O
tube O O
. O O

The O O
used O O
expression O O
system O O
could O O
allow O O
to O O
produce O O
mutated O O
forms O O
of O O
SsEF B-GENE O
- I-GENE O
0 I-GENE O
obtained O O
by O O
mutagenesis O O
of O O
the O O
corresponding O B-GENE
gene O I-GENE
. O O

These O O
findings O O
suggest O O
one O O
potential O O
mechanism O O
for O O
direct O O
recruitment O O
of O O
distal O O
regulatory O O
regions O O
of O O
the O O
globin B-GENE O
loci I-GENE O
to O O
the O O
individual O O
promoters O O
. O O

Recently O O
, O O
roles O O
also O O
have O O
been O O
suggested O O
for O O
the O O
nuclear O O
trans O B-GENE
- O I-GENE
factor O I-GENE
GATA B-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
in O O
regulating O O
progenitor O O
cell O O
proliferation O O
. O O

( O O
ii O O
) O O
An O O
AF O O
G B-GENE O
- I-GENE O
CSF I-GENE O
level O O
> O O
0000 O O
pg O O
/ O O
ml O O
is O O
a O O
strong O O
positive O O
predictor O O
of O O
CAM O O
. O O

Control O O
of O O
fatty O O
liver O O
syndrome O O
in O O
a O O
Jersey O O
herd O O
by O O
a O O
change O O
of O O
diet O O
and O O
the O O
use O O
of O O
recombinant O O
bovine O O
somatotrophin B-GENE O
. O O

M B-GENE O
- I-GENE O
00 I-GENE O
identified O O
the O O
00 O O
- O O
kDa O O
protein O O
in O O
another O O
MMTV O O
bearing O O
T O O
- O O
cell O O
lymphoma O O
, O O
EL O O
- O O
0 O O
. O O

U00 B-GENE O
contains O O
C O O
, O O
D O O
and O O
D O O
' O O
boxes O O
and O O
a O O
00 O O
- O O
nucleotide O O
antisense O O
complementarity O O
to O O
the O O
00S B-GENE O
ribosomal I-GENE O
RNA I-GENE O
. O O

Manipulation O O
of O O
the O O
checkpoint O O
regulators O O
involved O O
in O O
cell O O
cycle O O
arrest O O
and O O
apoptosis O O
may O O
thus O O
provide O O
a O O
novel O O
strategy O O
to O O
cancer O O
therapy O O
. O O

We O O
propose O O
a O O
model O O
in O O
which O O
Sro0 B-GENE O
function O O
is O O
involved O O
in O O
the O O
targeting O O
of O O
the O O
myosin B-GENE O
proteins I-GENE O
to O O
their O O
intrinsic O O
pathways O O
. O O

In O O
experiments O O
with O O
the O O
D0 O O
antagonist O O
SCH O O
00000 O O
, O O
buprenorphine O O
- O O
induced O O
depression O O
was O O
consistently O O
blocked O O
, O O
but O O
facilitation O O
was O O
unaffected O O
. O O

This O O
suggests O O
that O O
while O O
underpredictions O O
of O O
pain O O
do O O
not O O
hurt O O
more O O
, O O
disruption O O
on O O
primary O O
tasks O O
and O O
physiological O O
impact O O
are O O
higher O O
. O O

Furthermore O O
, O O
LB0 B-GENE B-GENE
gene I-GENE I-GENE
mapped O O
to O O
chromosome O O
00q00 O O
, O O
a O O
region O O
that O O
has O O
been O O
involved O O
as O O
a O O
chromosomal O O
breakpoint O O
in O O
DLBL O O
. O O

Antidepressant O O
- O O
like O O
properties O O
of O O
some O O
serotonin B-GENE O
receptor I-GENE O
ligands O O
and O O
calcium O O
channel O O
antagonists O O
measured O O
with O O
the O O
forced O O
swimming O O
test O O
in O O
mice O O
. O O

Comparisons O O
with O O
other O O
known O O
germins B-GENE O
and O O
germin B-GENE B-GENE
- I-GENE I-GENE
like I-GENE O
proteins I-GENE O
indicate O O
that O O
these O O
Arabidopsis O O
GLP B-GENE O
subfamilies O O
are O O
unique O O
from O O
wheat O O
germin B-GENE O
. O O

The O O
RNA B-GENE O
polymerase I-GENE O
III I-GENE O
- I-GENE O
recruiting I-GENE O
factor I-GENE O
TFIIIB I-GENE O
induces O O
a O O
DNA O O
bend O O
between O O
the O O
TATA O O
box O O
and O O
the O O
transcriptional O O
start O O
site O O
. O O

These O O
data O O
suggest O O
that O O
other O O
Ras B-GENE O
effectors I-GENE O
can O O
collaborate O O
with O O
PI B-GENE B-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
and O O
with O O
each O O
other O O
to O O
activate O O
Pak B-GENE O
. O O

The O O
Lp B-GENE O
mouse I-GENE O
mutant I-GENE O
provides O O
a O O
model O O
for O O
the O O
severe O O
human O O
neural O O
tube O O
defect O O
( O O
NTD O O
) O O
, O O
cranio O O
- O O
rachischisis O O
. O O

Independent O O
splicing O O
events O O
involve O O
three O O
previously O O
described O O
cassette O O
exons O O
, O O
which O O
are O O
predicted O O
to O O
encode O O
most O O
of O O
the O O
second O O
transmembrane O O
domain O O
. O O

Macroscopic O O
researches O O
on O O
heart O O
vascularization O O
have O O
indicated O O
that O O
the O O
angioarchitecture O O
of O O
the O O
conducting O O
system O O
differs O O
from O O
that O O
of O O
the O O
normal O O
myocardium O O
. O O

Analysis O O
of O O
its O O
genomic O O
region O O
revealed O O
that O O
the O O
00 O B-GENE
- O I-GENE
kb O I-GENE
Cdc0 B-GENE I-GENE
gene I-GENE I-GENE
is O O
divided O O
into O O
00 O O
exons O O
by O O
00 O O
introns O O
. O O

In O O
the O O
BF O O
ECT O O
group O O
the O O
- O O
age O O
based O O
dose O O
would O O
have O O
been O O
similarly O O
dependent O O
on O O
the O O
initial O O
seizure O O
threshold O O
level O O
. O O

Zebrafish O O
cyclops B-GENE O
( O O
cyc B-GENE O
) O O
encodes O O
a O O
Transforming B-GENE B-GENE
Growth I-GENE I-GENE
Factor I-GENE I-GENE
beta I-GENE I-GENE
( O O
TGFbeta B-GENE O
) O O
signaling O O
factor O O
closely O O
related O O
to O O
mouse O O
Nodal B-GENE O
. O O

Diverse O O
endogenous O O
light O O
chains O O
contribute O O
to O O
basement O O
membrane O O
reactivity O O
in O O
nonautoimmune O O
mice O O
transgenic O O
for O O
an O O
anti B-GENE O
- I-GENE O
laminin I-GENE O
Ig B-GENE O
heavy I-GENE O
chain I-GENE O
. O O

The O O
CCAAT O O
core O O
sequence O O
mutants O O
in O O
which O O
both O O
CIII O O
and O O
CI O B-GENE
/ O O
CII O O
were O O
abolished O O
, O O
also O O
increased O O
the O O
promoter O O
activity O O
. O O

Bites O O
by O O
two O O
species O O
of O O
adders O O
( O O
Vipera O O
aspis O O
and O O
Vipera O O
berus O O
) O O
can O O
lead O O
to O O
extensive O O
swelling O O
with O O
multiorgan O O
failure O O
. O O

Kaposi O O
' O O
s O O
sarcoma O O
- O O
associated O O
herpesvirus O O
viral B-GENE O
interferon I-GENE O
regulatory I-GENE O
factor I-GENE O
confers O O
resistance O O
to O O
the O O
antiproliferative O O
effect O O
of O O
interferon B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
. O O

Platelet O O
counts O O
and O O
function O O
as O O
well O O
as O O
fibrinogen B-GENE O
and O O
von B-GENE B-GENE
Willebrand I-GENE I-GENE
factor I-GENE I-GENE
( O O
vWF B-GENE O
) O O
levels O O
were O O
determined O O
in O O
each O O
sample O O
. O O

DNase B-GENE O
I I-GENE O
genomic O O
footprinting O O
revealed O O
that O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
Myb I-GENE I-GENE
site I-GENE O
is O O
occupied O O
in O O
a O O
tissue O O
- O O
specific O O
fashion O O
in O O
vivo O O
. O O

Differential O O
association O O
of O O
products O O
of O O
alternative O O
transcripts O O
of O O
the O O
candidate O O
tumor B-GENE O
suppressor I-GENE O
ING0 I-GENE O
with O O
the O O
mSin0 B-GENE B-GENE
/ O O
HDAC0 B-GENE O
transcriptional O O
corepressor O O
complex O O
. O O

Instead O O
, O O
they O O
contained O O
dendritic O O
cells O O
that O O
express O O
melanogenic O O
marker O O
proteins O O
such O O
as O O
tyrosinase B-GENE O
and O O
tyrosinase B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
protein I-GENE I-GENE
0 I-GENE O
. O O

Analysis O O
of O O
the O O
0 O O
' O O
flanking O O
region O O
of O O
the O O
gene O O
also O O
revealed O O
the O O
presence O O
of O O
multiple O O
TATA O O
and O O
CAAT O O
sequences O O
. O O

Analysis O O
of O O
the O O
0 O O
' O O
flanking O O
region O O
of O O
the O O
gene O O
also O O
revealed O O
the O O
presence O O
of O O
multiple O O
TATA O O
and O O
CAAT O O
sequences O O
. O O

Thus O O
, O O
dpp B-GENE O
and O O
omb B-GENE O
promote O O
both O O
dorsal O O
leg O O
cell O O
fate O O
as O O
well O O
as O O
transdetermination O O
- O O
competent O O
leg O O
disc O O
cells O O
. O O

However O O
, O O
laparoscopy O O
failed O O
to O O
establish O O
inoperability O O
in O O
any O O
cases O O
of O O
carcinoma O O
spread O O
to O O
areas O O
not O O
accessible O O
to O O
laparoscopic O O
visualization O O
. O O

Recent O O
studies O O
have O O
revealed O O
unconventional O O
myosin B-GENE O
V I-GENE O
to O O
be O O
an O O
important O O
actin B-GENE O
- O O
based O O
molecular O O
motor O O
involved O O
in O O
vesicular O O
movement O O
. O O

Therefore O O
, O O
we O O
conclude O O
that O O
DnaA B-GENE O
may O O
contact O O
the O O
beta O O
subunit O O
of O O
RNA B-GENE O
polymerase I-GENE O
during O O
activation O O
of O O
the O O
pR B-GENE B-GENE
promoter I-GENE I-GENE
. O O

The O O
diagnostic O O
accuracy O O
of O O
serum O O
PE B-GENE O
- I-GENE O
0 I-GENE O
was O O
0 O O
. O O
00 O O
, O O
and O O
that O O
of O O
amylase B-GENE O
0 O O
. O O
00 O O
. O O

Evidence O O
for O O
a O O
novel O O
MAPKKK B-GENE O
- O O
independent O O
pathway O O
controlling O O
the O O
stress O O
activated O O
Sty0 B-GENE O
/ O O
Spc0 B-GENE B-GENE
MAP O I-GENE
kinase O I-GENE
in O O
fission O O
yeast O O
. O O

Genomic O O
locus O O
of O O
chCTCF B-GENE O
contains O O
a O O
GC O O
- O O
rich O O
untranslated O O
exon O O
separated O O
from O O
seven O O
coding O O
exons O O
by O O
a O O
long O O
intron O O
. O O

These O O
results O O
indicate O O
that O O
the O O
total O O
number O O
of O O
subunit O O
c O O
in O O
F0 B-GENE O
should O O
be O O
a O O
multiple O O
of O O
0 O O
and O O
0 O O
. O O

In O O
this O O
study O O
we O O
provide O O
evidence O O
that O O
B B-GENE O
- I-GENE O
Myb I-GENE O
is O O
a O O
direct O O
physiological O O
target O O
for O O
cyclin B-GENE O
A I-GENE O
/ O O
Cdk0 B-GENE O
. O O

In O O
addition O O
, O O
a O O
potent O O
splicing O O
enhancer O O
sequence O O
isolated O O
in O O
the O O
selection O O
specifically O O
binds O O
a O O
00 B-GENE O
- I-GENE O
kDa I-GENE O
SR I-GENE O
protein I-GENE O
. O O

The O O
coefficient O O
of O O
determination O O
, O O
r0 O O
, O O
of O O
the O O
other O O
scores O O
ranged O O
from O O
0 O O
. O O
00 O O
to O O
0 O O
. O O
00 O O
. O O

ECG O O
- O O
gated O O
myocardial O O
Technetium O O
- O O
00m O O
sestamibi O O
SPECT O O
is O O
a O O
useful O O
technique O O
to O O
measure O O
myocardial O O
perfusion O O
and O O
function O O
simultaneously O O
. O O

The O O
level O O
of O O
serum B-GENE O
creatine I-GENE O
kinase I-GENE O
was O O
significantly O O
high O O
0 O O
days O O
after O O
ESWIB O O
, O O
but O O
it O O
recovered O O
in O O
a O O
week O O
. O O

This O O
revealed O O
a O O
minimum O O
of O O
six O O
novel O O
OSBP B-GENE O
- I-GENE O
related I-GENE O
proteins I-GENE O
, O O
designated O O
ORP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
to O O
ORP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

We O O
examine O O
current O O
models O O
of O O
the O O
effects O O
of O O
aging O O
on O O
mean O O
response O O
time O O
and O O
show O O
how O O
they O O
might O O
be O O
reinterpreted O O
. O O

Mucin B-GENE O
gene I-GENE O
expression O O
has O O
been O O
shown O O
to O O
be O O
altered O O
in O O
many O O
intestinal O O
diseases O O
and O O
especially O O
cancers O O
of O O
the O O
gastrointestinal O O
tract O O
. O O

The O O
first O O
symptoms O O
of O O
enzootic O O
calcinosis O O
were O O
noted O O
in O O
March O O
0000 O O
, O O
when O O
some O O
of O O
the O O
cows O O
developed O O
locomotor O O
abnormalities O O
. O O

Screening O O
, O O
counseling O O
, O O
and O O
treatment O O
for O O
alcohol O O
and O O
illicit O O
drug O O
use O O
should O O
be O O
essential O O
components O O
in O O
comprehensive O O
HBP O O
care O O
. O O

The O O
N O O
- O O
terminal O O
small O O
segment O O
of O O
yeast B-GENE B-GENE
TAF000 I-GENE I-GENE
( O O
yTAF000 B-GENE O
) O O
binds O O
to O O
TBP B-GENE O
and O O
thereby O O
inhibits O O
TBP B-GENE O
function O O
. O O

Antimicrobial O O
Susceptibility O O
of O O
Klebsiella O O
pneumoniae O O
Producing O O
Extended B-GENE O
- I-GENE O
Spectrum I-GENE O
beta I-GENE O
- I-GENE O
lactamase I-GENE O
( O O
ESBL B-GENE O
) O O
Isolated O O
in O O
Hospitals O O
in O O
Brazil O O
. O O

Adjuvant O O
therapy O O
for O O
colon O O
cancer O O
] O O
Surgery O O
alone O O
may O O
fail O O
to O O
cure O O
a O O
considerable O O
number O O
of O O
locally O O
advanced O O
colon O O
cancers O O
. O O

NF B-GENE O
kappa I-GENE O
B I-GENE O
was O O
activated O O
to O O
a O O
much O O
greater O O
extent O O
by O O
roscovitine O O
in O O
the O O
WT O O
cells O O
than O O
in O O
Y0 O O
cells O O
. O O

This O O
conformer O O
features O O
a O O
Type O O
I O O
beta O O
- O O
turn O O
and O O
has O O
extensive O O
hydrophobic O O
contacts O O
with O O
the O O
FKBP00 B-GENE O
binding O O
surface O O
. O O

Crosstalk O O
among O O
the O O
pathways O O
may O O
explain O O
how O O
some O O
forms O O
of O O
stress O O
can O O
contribute O O
to O O
the O O
development O O
of O O
a O O
malignancy O O
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
the O O
gene O O
has O O
significant O O
homology O O
to O O
the O O
interferon B-GENE B-GENE
regulatory I-GENE I-GENE
factors I-GENE I-GENE
( O O
IRFs B-GENE O
) O O
. O O

Analysis O O
of O O
promoter O O
and O O
androgen O O
regulatory O O
sequences O O
required O O
for O O
optimal O O
transcription O O
of O O
the O O
rat O B-GENE
androgen B-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
gene O I-GENE
. O O

Expression O O
of O O
Bcl B-GENE O
- I-GENE O
XL I-GENE O
inhibited O O
the O O
association O O
of O O
Apaf B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
with O O
caspase B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
in O O
mammalian O O
cells O O
. O O

The O O
micturition O O
pressure O O
was O O
significantly O O
decreased O O
only O O
after O O
injection O O
with O O
BUP O O
- O O
0 O O
in O O
both O O
normal O O
and O O
obstructed O O
rats O O
. O O

Consistent O O
with O O
these O O
findings O O
, O O
relatively O O
weak O O
transcriptional O O
silencing O O
by O O
the O O
native O O
VDR B-GENE O
was O O
observed O O
using O O
the O O
osteopontin B-GENE O
VDRE O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
signal O O
transduction O O
pathways O O
that O O
are O O
involved O O
in O O
OM B-GENE O
- O O
induced O O
LDLR B-GENE O
transcription O O
. O O

Online O O
LATCH O O
demonstrates O O
a O O
shift O O
in O O
identification O O
of O O
the O O
library O O
as O O
an O O
isolated O O
unit O O
to O O
an O O
interactive O O
resource O O
center O O
. O O

CONCLUSION O O
: O O
NBP O O
pre O O
- O O
treatment O O
or O O
post O O
- O O
treatment O O
markedly O O
enhanced O O
the O O
rCBF O O
to O O
striatum O O
in O O
RMCAO O O
rats O O
. O O

Gel O O
filtration O O
and O O
co O O
- O O
immunoprecipitation O O
analyses O O
reveal O O
that O O
Mad0p B-GENE O
tightly O O
associates O O
with O O
another O O
spindle O O
checkpoint O O
component O O
, O O
Mad0p B-GENE O
. O O

Immunohistochemical O O
staining O O
with O O
MIB B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
p00 B-GENE B-GENE
antibodies I-GENE O
showed O O
low O O
( O O
< O O
0 O O
% O O
) O O
and O O
negative O O
reaction O O
. O O

Twelve O O
patients O O
had O O
stage O O
IBG0 O O
, O O
00 O O
had O O
ICG0 O O
, O O
0 O O
had O O
ICG0 O O
, O O
and O O
0 O O
had O O
ICG0 O O
disease O O
. O O

All O O
clones O O
and O O
strains O O
produced O O
have O O
been O O
deposited O O
in O O
the O O
EUROFAN O O
genetic O O
stock O O
centre O O
( O O
EUROSCARF O O
, O O
Frankfurt O O
) O O
. O O

Hailey O O
- O O
Hailey O O
disease O O
is O O
caused O O
by O O
mutations O O
in O O
ATP0C0 B-GENE O
encoding O O
a O O
novel O O
Ca O O
( O O
0 O O
+ O O
) O O
pump O O
. O O

Reliability O O
of O O
cervical O O
range O O
of O O
motion O O
using O O
the O O
OSI O O
CA O O
0000 O O
spine O O
motion O O
analyser O O
on O O
asymptomatic O O
and O O
symptomatic O O
subjects O O
. O O

Six O O
distinct O O
Ets B-GENE O
mRNAs I-GENE O
were O O
identified O O
: O O
Ets0 B-GENE O
, O O
Fli0 B-GENE O
, O O
GABPalpha B-GENE O
, O O
SAP0 B-GENE O
, O O
Elk0 B-GENE O
, O O
and O O
PE0 B-GENE O
. O O

The O O
limit O O
between O O
the O O
cecum O O
and O O
the O O
ascending O O
colon O O
was O O
externally O O
marked O O
by O O
the O O
sulcus O O
cecocolicus O O
dorsalis O O
and O O
ventralis O O
. O O

These O O
results O O
support O O
a O O
model O O
in O O
which O O
p00 B-GENE O
protein I-GENE O
contributes O O
to O O
the O O
maintenance O O
of O O
genomic O O
integrity O O
through O O
recombinational O O
repair O O
. O O

It O O
is O O
now O O
estimated O O
that O O
inactivation O O
mutants O O
of O O
PTEN B-GENE O
exist O O
in O O
00 O O
% O O
of O O
all O O
forms O O
of O O
solid O O
tumors O O
. O O

From O O
two O O
inhibitor O O
scaffolds O O
, O O
we O O
have O O
identified O O
potent O O
and O O
selective O O
inhibitors O O
for O O
sensitized O O
kinases O O
from O O
five O O
distinct O O
subfamilies O O
. O O

Reporter O O
gene O O
expression O O
analyses O O
indicate O O
that O O
both O O
WASP B-GENE O
promoters I-GENE O
show O O
high O O
levels O O
of O O
expression O O
in O O
different O O
hematopoietic O O
cell O O
lines O O
. O O

0 O O
' O O
- O O
RACE O O
analysis O O
suggested O O
a O O
single O O
transcription O O
initiation O O
site O O
000 O O
bp O O
upstream O O
from O O
the O O
translational O O
start O O
site O O
. O O

Thromboelastography O O
is O O
a O O
test O O
that O O
could O O
potentially O O
correlate O O
with O O
the O O
degree O O
of O O
anticoagulation O O
produced O O
by O O
low O O
molecular O O
weight O O
heparin O O
. O O

Association O O
of O O
stress O O
during O O
delivery O O
with O O
increased O O
numbers O O
of O O
nucleated O O
cells O O
and O O
hematopoietic O O
progenitor O O
cells O O
in O O
umbilical O O
cord O O
blood O O
. O O

She O O
was O O
able O O
to O O
stand O O
unaided O O
by O O
0 O O
years O O
of O O
age O O
with O O
then O O
progressive O O
worsening O O
of O O
motor O O
abilities O O
. O O

Merosin B-GENE O
positive O O
congenital O O
muscular O O
dystrophy O O
with O O
mental O O
deficiency O O
, O O
epilepsy O O
and O O
MRI O O
changes O O
in O O
the O O
cerebral O O
white O O
matter O O
. O O

Secretion O O
in O O
milk O O
and O O
transplacental O O
transfer O O
of O O
two O O
iodized O O
oils O O
, O O
Lipiodol O O
UF O O
and O O
Oriodol O O
, O O
in O O
rabbits O O
. O O

There O O
were O O
differences O O
between O O
males O O
( O O
p O O
< O O
0 O O
. O O
00 O O
) O O
for O O
most O O
of O O
the O O
characteristics O O
studied O O
. O O

The O O
mean O O
values O O
of O O
the O O
first O O
three O O
components O O
were O O
not O O
significantly O O
different O O
in O O
ARVD O O
patients O O
and O O
control O O
subjects O O
. O O

Surprisingly O O
, O O
the O O
COOH O O
- O O
terminal O O
domain O O
of O O
RanGAP0 B-GENE B-GENE
was O O
also O O
found O O
to O O
harbor O O
a O O
nuclear O O
localization O O
signal O O
. O O

Cytoskeletal O O
polarization O O
of O O
T O O
cells O O
is O O
regulated O O
by O O
an O O
immunoreceptor O O
tyrosine O O
- O O
based O O
activation O O
motif O O
- O O
dependent O O
mechanism O O
. O O

Substrates O O
for O O
p000 B-GENE O
( O O
bcr B-GENE B-GENE
- O I-GENE
abl B-GENE I-GENE
) O O
are O O
likely O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
CML O O
. O O

E0A B-GENE O
represses O O
apolipoprotein B-GENE O
AI I-GENE O
enhancer I-GENE O
activity O O
in O O
liver O O
cells O O
through O O
a O O
pRb B-GENE O
- O O
and O O
CBP B-GENE O
- O O
independent O O
pathway O O
. O O

Acute O O
idiopathic O O
thrombocytopenic O O
purpura O O
presenting O O
a O O
high O O
serum O O
level O O
of O O
immunoglobulin B-GENE O
E I-GENE O
and O O
eosinophilia O O
in O O
an O O
elderly O O
patient O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
GluR0 B-GENE B-GENE
gene I-GENE I-GENE
: O O
neural O O
- O O
specific O O
expression O O
, O O
multiple O O
promoters O O
, O O
and O O
regulatory O O
elements O O
. O O

Thus O O
, O O
TRAF0 B-GENE O
initiates O O
SAPK B-GENE O
and O O
p00 B-GENE B-GENE
activation O O
by O O
binding O O
two O O
proximal O O
protein O O
kinases O O
: O O
GCK B-GENE O
and O O
RIP B-GENE O
. O O

000 O O
+ O O
/ O O
- O O
000 O O
aggregates O O
/ O O
ml O O
at O O
0 O O
rpm O O
; O O
P O O
< O O
0 O O
. O O
000 O O
) O O
. O O

CD0 B-GENE O
lymphocyte O O
and O O
viral O O
load O O
levels O O
suggested O O
an O O
optimal O O
response O O
to O O
ARV O O
therapy O O
at O O
the O O
time O O
LD O O
developed O O
. O O

Chirality O O
- O O
glass O O
and O O
spin O O
- O O
glass O O
correlations O O
in O O
the O O
two O O
- O O
dimensional O O
random O O
- O O
bond O O
XY O O
model O O
. O O

Analysis O O
of O O
lacZ B-GENE O
transcriptional I-GENE O
fusions I-GENE O
shows O O
that O O
the O O
KdgR B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
sites I-GENE O
negatively O O
affect O O
the O O
expression O O
of O O
rsmB B-GENE O
. O O

Each O O
recombinant O O
product O O
was O O
a O O
fusion O O
protein O O
with O O
a O O
B O O
domain O O
of O O
Staphylococcal B-GENE B-GENE
protein I-GENE I-GENE
A I-GENE O
( O O
SPA B-GENE O
) O O
. O O

The O O
gene O O
structure O O
of O O
Elk0 B-GENE O
spans O O
00 O O
. O O
0 O O
kb O O
and O O
consists O O
of O O
seven O O
exons O O
and O O
six O O
introns O O
. O O

Three O O
subgenomes O O
also O O
comprised O O
00 O O
to O O
00 O O
nucleotides O O
derived O O
from O O
the O O
0 O O
' O O
part O O
of O O
the O O
NS0 B-GENE O
gene I-GENE O
. O O

Ozagrel O O
, O O
ifenprodil O O
, O O
cinnarizine O O
and O O
dilazep O O
were O O
more O O
effective O O
than O O
pentoxifylline O O
in O O
increasing O O
rCBF O O
at O O
the O O
HPC O O
. O O

Phosphorylation O O
of O O
myosin B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
subunit I-GENE I-GENE
( O O
MBS B-GENE O
) O O
of O O
myosin B-GENE O
phosphatase I-GENE O
by O O
Rho B-GENE B-GENE
- I-GENE I-GENE
kinase I-GENE I-GENE
in O O
vivo O O
. O O

The O O
case O O
for O O
completing O O
the O O
lymphadenectomy O O
when O O
positive O O
lymph O O
nodes O O
are O O
found O O
during O O
radical O O
hysterectomy O O
for O O
cervical O O
carcinoma O O
. O O

Manganese O O
ions O O
were O O
found O O
to O O
be O O
essential O O
for O O
autophosphorylation O O
of O O
BGLF0 B-GENE O
, O O
and O O
magnesium O O
can O O
stimulate O O
the O O
activity O O
. O O

The O O
comparison O O
of O O
the O O
expression O O
patterns O O
of O O
the O O
known O O
Kv0 B-GENE O
family I-GENE O
members I-GENE O
shows O O
subtype O O
specificity O O
with O O
significant O O
overlaps O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
and O O
possibly O O
randomised O O
trials O O
using O O
acupuncture O O
to O O
treat O O
asthma O O
and O O
asthma O O
- O O
like O O
symptoms O O
. O O

Therefore O O
, O O
analogs O O
of O O
vitamin O O
D0 O O
have O O
been O O
investigated O O
in O O
a O O
number O O
of O O
trials O O
showing O O
improvement O O
of O O
psoriasis O O
. O O

Five O O
of O O
the O O
Aeromonas O O
strains O O
and O O
one O O
of O O
V O O
cholerae O O
non O O
- O O
O0 O O
were O O
positive O O
for O O
enterotoxin O O
activity O O
. O O

To O O
begin O O
to O O
understand O O
this O O
role O O
, O O
we O O
overexpressed O O
ATF B-GENE O
- I-GENE O
0 I-GENE O
in O O
a O O
human O O
cancer O O
cell O O
line O O
. O O

NH0 O O
- O O
terminal O O
trimming O O
of O O
Xenopus O O
and O O
mammalian B-GENE O
FGF0s I-GENE O
may O O
therefore O O
be O O
a O O
prerequisite O O
of O O
optimal O O
biological O O
activity O O
. O O

We O O
also O O
review O O
the O O
role O O
of O O
grains O O
in O O
the O O
formation O O
of O O
complex O O
molecules O O
in O O
interstellar O O
molecular O O
clouds O O
. O O

We O O
also O O
demonstrate O O
that O O
preformed O O
triplexes O O
are O O
quite O O
stable O O
when O O
precipitated O O
with O O
ethanol O O
and O O
resuspended O O
in O O
water O O
. O O

Naltrexone O O
has O O
been O O
recently O O
approved O O
by O O
the O O
Food O O
and O O
Drug O O
Administration O O
for O O
the O O
treatment O O
of O O
alcohol O O
dependence O O
. O O

Overexpression O O
of O O
BAG B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
also O O
protected O O
certain O O
cell O O
lines O O
from O O
heat O O
shock O O
- O O
induced O O
cell O O
death O O
. O O

Prior O O
to O O
meals O O
0 O O
to O O
0 O O
times O O
daily O O
, O O
0 O O
- O O
0 O O
tablespoons O O
of O O
Alzoon O O
are O O
recommended O O
. O O

Protein O O
phosphatases O O
play O O
a O O
critical O O
role O O
in O O
the O O
regulation O O
of O O
the O O
eukaryotic O O
cell O O
cycle O O
and O O
signal O O
transduction O O
. O O

The O O
mouse B-GENE B-GENE
M I-GENE I-GENE
- I-GENE I-GENE
lysozyme I-GENE I-GENE
downstream I-GENE I-GENE
enhancer I-GENE I-GENE
has O O
been O O
previously O O
characterized O O
on O O
several O O
levels O O
of O O
gene O O
regulation O O
. O O

Recombinant B-GENE O
HRMT0L0 I-GENE O
protein I-GENE O
encoded O O
by O O
the O O
most O O
common O O
0 O O
' O O
- O O
variant O O
exhibited O O
methyltransferase O O
activity O O
in O O
vitro O O
. O O

The O O
effect O O
of O O
nitric B-GENE O
oxide I-GENE O
synthase I-GENE O
inhibitor O O
on O O
reperfusion O O
injury O O
of O O
the O O
brain O O
under O O
hypothermic O O
circulatory O O
arrest O O
. O O

However O O
, O O
little O O
is O O
known O O
regarding O O
the O O
genomic O O
organization O O
and O O
developmental O O
expression O O
of O O
the O O
caveolin B-GENE B-GENE
gene I-GENE I-GENE
family I-GENE I-GENE
. O O

The O O
only O O
abundant O O
viral O O
transcript O O
expressed O O
during O O
latency O O
is O O
the O O
latency B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
( O O
LR B-GENE O
) O O
RNA O O
. O O

GH B-GENE O
failed O O
to O O
stimulate O O
phosphorylation O O
or O O
activation O O
of O O
Jun B-GENE O
N I-GENE O
- I-GENE O
terminal I-GENE O
kinase I-GENE O
under O O
the O O
conditions O O
used O O
. O O

RESULTS O O
: O O
Significant O O
changes O O
from O O
pretreatment O O
to O O
posttreatment O O
were O O
observed O O
( O O
p O O
< O O
0 O O
. O O
000 O O
) O O
. O O

The O O
tip O O
of O O
the O O
button O O
caused O O
a O O
perforation O O
of O O
the O O
posterior O O
stomach O O
wall O O
, O O
leading O O
to O O
death O O
. O O

These O O
results O O
suggest O O
that O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
met I-GENE I-GENE
gene I-GENE I-GENE
is O O
also O O
a O O
target O O
of O O
p00 B-GENE B-GENE
gene I-GENE I-GENE
regulation O O
. O O

Factors O O
influencing O O
direct O O
- O O
immersion O O
( O O
DI O O
) O O
- O O
SPME O O
process O O
were O O
also O O
checked O O
and O O
chosen O O
experimentally O O
. O O

In O O
the O O
brain O O
, O O
muscarinic B-GENE O
receptors I-GENE O
mediate O O
motor O O
and O O
memory O O
function O O
by O O
interaction O O
with O O
their O O
ligand O O
acetylcholine O O
. O O

In O O
this O O
study O O
, O O
we O O
elucidate O O
signaling O O
pathways O O
induced O O
by O O
photodynamic O O
therapy O O
( O O
PDT O O
) O O
with O O
hypericin O O
. O O

Isolation O O
of O O
cDNAs B-GENE O
encoding I-GENE O
gibbon I-GENE O
and I-GENE O
monkey I-GENE O
platelet I-GENE O
and I-GENE O
T I-GENE O
cell I-GENE O
activation I-GENE O
antigen I-GENE O
0 I-GENE O
( O O
PTA0 B-GENE O
) O O
. O O

Actins B-GENE O
show O O
two O O
different O O
forms O O
of O O
N O O
- O O
terminal O O
processing O O
dependent O O
on O O
their O O
N O O
- O O
terminal O O
sequence O O
. O O

TIP00 B-GENE O
has O O
an O O
intrinsic O O
kinase O O
activity O O
required O O
for O O
up O O
- O O
regulation O O
of O O
a O O
subset O O
of O O
apoptotic O B-GENE
genes O I-GENE
. O O

Unique O O
to O O
this O O
system O O
, O O
the O O
activity O O
of O O
TraR B-GENE O
is O O
negatively O O
modulated O O
by O O
an O O
antiactivator O O
called O O
TraM B-GENE O
. O O

The O O
models O O
were O O
tested O O
by O O
studying O O
their O O
response O O
to O O
disturbances O O
of O O
the O O
afferent O O
signal O O
from O O
the O O
bladder O O
. O O

Biologically O O
significant O O
amounts O O
of O O
platelet B-GENE O
activating I-GENE O
factor I-GENE O
were O O
eluted O O
from O O
the O O
sorbent O O
during O O
the O O
entire O O
treatment O O
time O O
. O O

Phd B-GENE O
antibody O O
- O O
immunoreactive O O
peptides O O
are O O
seen O O
in O O
light O O
- O O
adapted O O
mouse O O
retinal O O
cytosolic O O
and O O
nuclear O O
extracts O O
. O O

The O O
outer O O
diameter O O
and O O
the O O
thickness O O
of O O
the O O
rotor O O
are O O
00 O O
mm O O
and O O
0 O O
mm O O
, O O
respectively O O
. O O

The O O
results O O
indicate O O
that O O
the O O
relationship O O
between O O
comprehension O O
and O O
production O O
is O O
different O O
at O O
different O O
stages O O
in O O
development O O
. O O

Polysome O O
and O O
00S B-GENE O
ribosome I-GENE O
fractions O O
were O O
severely O O
decreased O O
in O O
the O O
krr0 B-GENE O
mutant I-GENE O
and O O
Kri0p B-GENE O
- O O
depleted O O
cells O O
. O O

Botulinum B-GENE O
toxin I-GENE O
A I-GENE O
in O O
the O O
treatment O O
of O O
hemiplegic O O
spastic O O
foot O O
drop O O
- O O
- O O
clinical O O
and O O
functional O O
outcomes O O
. O O

As O O
hypothesized O O
, O O
believers O O
showed O O
relatively O O
higher O O
right O O
hemispheric O O
activation O O
and O O
reduced O O
hemispheric O O
asymmetry O O
of O O
functional O O
complexity O O
. O O

Nucleotide O O
sequence O O
, O O
genome O O
organization O O
and O O
phylogenetic O O
analysis O O
of O O
pineapple O O
mealybug O O
wilt O O
- O O
associated O O
virus O O
- O I-GENE
0 O I-GENE
. O O

This O O
finding O O
is O O
the O O
first O O
example O O
of O O
utilization O O
of O O
noncomplementary O O
dinucleotide O O
primer O O
by O O
an O O
RNA B-GENE O
polymerase I-GENE O
. O O

The O O
most O O
important O O
one O O
among O O
them O O
is O O
Cyclosporin O O
A O O
, O O
which O O
is O O
a O O
selective O O
immunosuppressive O O
drug O O
. O O

Sequence O O
divergence O O
is O O
observed O O
in O O
untranslated O O
regions O O
which O O
allows O O
the O O
definition O O
of O O
gene O O
- O O
specific O O
probes O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
was O O
designed O O
to O O
analyze O O
the O O
common O O
cause O O
of O O
asthenopia O O
, O O
mixed O O
astigmatism O O
. O O

The O O
pheromone O O
response O O
pathway O O
activates O O
transcription O O
of O O
Ty0 B-GENE O
retrotransposons I-GENE O
located O O
within O O
silent O O
chromatin O O
of O O
Saccharomyces O O
cerevisiae O O
. O O

Bitter O O
cassava O O
contains O O
cyanogenic O O
glycosides O O
; O O
processing O O
breaks O O
them O O
down O O
to O O
acetone O O
cyanohydrin O O
and O O
hydrogen O O
cyanide O O
. O O

The O O
prescription O O
for O O
apoplexy O O
includes O O
C0 O B-GENE
- O I-GENE
0 O I-GENE
, O O
T0 O B-GENE
- O I-GENE
0 O I-GENE
and O O
L0 O B-GENE
- O I-GENE
0 O I-GENE
. O O

To O O
identify O O
nuclear O O
regulatory O O
factors O O
, O O
we O O
have O O
located O O
and O O
functionally O O
characterized O O
the O O
CCR0 B-GENE B-GENE
gene I-GENE I-GENE
promoter I-GENE I-GENE
. O O

A O O
point O O
mutation O O
in O O
Galphao B-GENE O
and O O
Galphai0 B-GENE O
blocks O O
interaction O O
with O O
regulator O O
of O O
G B-GENE O
protein I-GENE O
signaling O O
proteins O O
. O O

All O O
patients O O
diagnosed O O
of O O
H O O
. O O
influenza O O
type O O
b O O
meningitis O O
were O O
less O O
than O O
0 O O
years O O
old O O
. O O

Further O O
, O O
Ser O O
/ O O
Thr O O
phosphorylation O O
of O O
downstream O O
molecules O O
Akt B-GENE O
and O O
p00 B-GENE B-GENE
S0 I-GENE I-GENE
kinase I-GENE I-GENE
was O O
inhibited O O
. O O

We O O
demonstrate O O
that O O
Ddc0p B-GENE O
interacts O O
physically O O
in O O
vivo O O
with O O
Mec0p B-GENE O
, O O
and O O
this O O
interaction O O
requires O O
Rad00p B-GENE O
. O O

Small B-GENE O
GTPases I-GENE O
of O O
the O O
Ypt B-GENE B-GENE
/ O O
Rab B-GENE O
family O O
are O O
involved O O
in O O
the O O
regulation O O
of O O
vesicular O O
transport O O
. O O

The O O
activated O O
glucocorticoid B-GENE O
receptor I-GENE O
forms O O
a O O
complex O O
with O O
Stat0 B-GENE O
and O O
enhances O O
Stat0 B-GENE O
- O O
mediated O O
transcriptional O O
induction O O
. O O

Sequencing O O
of O O
a O O
00 O O
- O O
kb O O
DNA O O
segment O O
of O O
the O O
FK000 O B-GENE
gene O I-GENE
cluster O O
from O O
Streptomyces O O
sp O O
. O O

Handling O O
on O O
PND O O
0 O O
did O O
not O O
result O O
in O O
elevated O O
CORT O O
levels O O
in O O
any O O
of O O
the O O
groups O O
. O O

As O O
such O O
the O O
findings O O
support O O
existing O O
studies O O
that O O
have O O
identified O O
given O O
social O O
characteristics O O
of O O
drink O O
drivers O O
. O O

Initial O O
control O O
of O O
bleeding O O
is O O
similar O O
, O O
but O O
eradication O O
is O O
achieved O O
in O O
fewer O O
sessions O O
with O O
EVL O O
. O O

RESULTS O O
: O O
000 O O
Periods O O
of O O
TTP O O
or O O
PUNP O O
were O O
reported O O
by O O
men O O
and O O
000 O O
by O O
women O O
. O O

Slap B-GENE O
negatively O O
regulates O O
Src B-GENE O
mitogenic O O
function O O
but O O
does O O
not O O
revert O O
Src B-GENE O
- O O
induced O O
cell O O
morphology O O
changes O O
. O O

E0F B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
is O O
a O O
transcription O O
factor O O
that O O
regulates O O
cell O O
cycle O O
progression O O
into O O
S O O
- O O
phase O O
. O O

Indirect O O
plasma O O
parameters O O
such O O
as O O
vitamin O O
E O O
, O O
thiol O O
and O O
uric O O
acid O O
levels O O
were O O
also O O
quantified O O
. O O

Effects O O
of O O
Trypanosoma O O
vivax O O
on O O
pregnancy O O
of O O
Yankasa O O
sheep O O
and O O
the O O
results O O
of O O
homidum O O
chloride O O
chemotherapy O O
. O O

A O O
prospective O O
observational O O
study O O
was O O
conducted O O
to O O
identify O O
early O O
indicators O O
of O O
acute O O
dengue O O
virus O O
infection O O
. O O

Lysine B-GENE O
- I-GENE O
ketoglutarate I-GENE O
reductase I-GENE O
and O O
saccharopine B-GENE O
dehydrogenase I-GENE O
from O O
Arabidopsis O O
thaliana O O
: O O
nucleotide O O
sequence O O
and O O
characterization O O
. O O

For O O
the O O
0HT0A B-GENE O
receptor I-GENE O
the O O
addition O O
of O O
yohimbine O O
resulted O O
in O O
a O O
similar O O
but O O
smaller O O
effect O O
. O O

Immunohistochemically O O
, O O
anticytokeratin B-GENE O
00 I-GENE O
antibody I-GENE O
revealed O O
strong O O
staining O O
in O O
both O O
epithelial O O
and O O
sarcomatous O O
MPM O O
tissues O O
. O O

The O O
hBRAG B-GENE B-GENE
gene I-GENE I-GENE
was O O
localized O O
to O O
the O O
long O O
arm O O
of O O
chromosome O O
00 O O
( O O
00q00 O O
) O O
. O O

Conserved O O
and O O
distinct O O
roles O O
of O O
kreisler B-GENE O
in O O
regulation O O
of O O
the O O
paralogous O B-GENE
Hoxa0 B-GENE I-GENE
and O O
Hoxb0 B-GENE B-GENE
genes I-GENE I-GENE
. O O

We O O
show O O
that O O
the O O
mouse O O
genome O O
contains O O
four O O
copies O O
of O O
the O O
ubc B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
. O O

Primary O O
and O O
secondary O O
structural O O
elements O O
required O O
for O O
synthesis O O
of O O
barley O O
yellow O O
dwarf O O
virus O O
subgenomic O O
RNA0 O O
. O O

Both O O
carbachol O O
( O O
000 O O
microM O O
) O O
and O O
EGF B-GENE O
( O O
00 O O
nM O O
) O O
induced O O
Ras B-GENE O
activation O O
. O O

Structure O O
and O O
expression O O
of O O
the O O
mouse B-GENE B-GENE
growth I-GENE I-GENE
hormone I-GENE I-GENE
receptor I-GENE I-GENE
/ O I-GENE
growth B-GENE I-GENE
hormone I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
gene I-GENE I-GENE
. O O

Differential O O
expression O O
was O O
confirmed O O
by O O
Northern O O
blot O O
analysis O O
employing O O
multiple O O
normal O O
and O O
tumor O O
cell O O
lines O O
. O O

Finally O O
, O O
the O O
mechanism O O
of O O
ASK0 B-GENE O
activation O O
involves O O
, O O
in O O
part O O
, O O
homo O O
- O O
oligomerization O O
. O O

The O O
variations O O
were O O
caused O O
by O O
opposite O O
shifts O O
in O O
TSH B-GENE O
frequency O O
distribution O O
in O O
mothers O O
and O O
neonates O O
. O O

However O O
, O O
such O O
a O O
mechanism O O
was O O
not O O
detected O O
in O O
preliminary O O
observations O O
on O O
M O O
. O O
synoviae O O
. O O

Recently O O
, O O
a O O
mutation O O
in O O
the O O
amino O O
- O O
terminus O O
of O O
IB0 B-GENE O
was O O
associated O O
with O O
diabetes O O
. O O

The O O
codon O O
usage O O
is O O
particularly O O
marked O O
for O O
the O O
gag B-GENE O
, O O
pol B-GENE O
, O O
and O O
env B-GENE O
genes I-GENE O
. O O

To O O
illustrate O O
its O O
performance O O
, O O
measurements O O
of O O
photoluminescence O O
in O O
GaAs O O
/ O O
AlGaAs O O
heterostructures O O
are O O
presented O O
. O O

We O O
have O O
demonstrated O O
that O O
the O O
activity O O
of O O
ILK B-GENE B-GENE
is O O
constitutively O O
elevated O O
in O O
PTEN B-GENE O
mutant I-GENE O
cells O O
. O O

Re O O
: O O
" O O
Assessing O O
the O O
direction O O
of O O
causality O O
in O O
cross O O
- O O
sectional O O
studies O O
" O O
. O O

However O O
, O O
the O O
signaling O O
cascade O O
utilized O O
by O O
the O O
urokinase B-GENE B-GENE
receptor I-GENE I-GENE
is O O
only O O
incompletely O O
understood O O
. O O

Identification O O
and O O
characterization O O
of O O
two O O
putative O O
human B-GENE O
arginine I-GENE O
methyltransferases I-GENE O
( O O
HRMT0L0 B-GENE O
and O O
HRMT0L0 B-GENE O
) O O
. O O

CPDs O O
at O O
these O O
three O O
sites O O
may O O
partially O O
displace O O
TFIIIA B-GENE O
, O O
thereby O O
enabling O O
rapid O O
repair O O
. O O

Detection O O
of O O
poisoning O O
by O O
Impila O O
( O O
Callilepis O O
laureola O O
) O O
in O O
a O O
mother O O
and O O
child O O
. O O

Mycoplasma O O
hominis O O
infections O O
are O O
easily O O
missed O O
because O O
conventional O O
methods O O
for O O
bacterial O O
detection O O
may O O
fail O O
. O O

Following O O
conditioning O O
, O O
a O O
single O O
coat O O
of O O
adhesive O O
was O O
applied O O
and O O
light O O
- O O
cured O O
. O O

Regarding O O
" O O
the O O
relation O O
between O O
sexual O O
orientation O O
and O O
penile O O
size O O
, O O
" O O
by O O
A O O
. O O

The O O
U00 B-GENE B-GENE
/ O O
U00 B-GENE O
and O O
the O O
U00 B-GENE B-GENE
+ I-GENE I-GENE
gene I-GENE I-GENE
products I-GENE O
transactivated O O
the O O
HIV B-GENE O
LTR I-GENE O
. O O

Transformation O O
of O O
the O O
sconC0 B-GENE O
mutant I-GENE O
with O O
sconB B-GENE O
+ I-GENE O
restores O O
the O O
wild O O
- O O
type O O
phenotype O O
. O O

Additionally O O
, O O
MIP B-GENE O
- I-GENE O
0A I-GENE O
antagonizes O O
cell O O
growth O O
regulatory O O
role O O
of O O
MBP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

The O O
interaction O O
between O O
DDB B-GENE O
and O O
E0F0 B-GENE O
can O O
also O O
be O O
detected O O
by O O
coimmunoprecipitation O O
experiments O O
. O O

Demonstration O O
of O O
tissue O O
lesions O O
after O O
intramuscular O O
injection O O
by O O
determination O O
of O O
creatine B-GENE O
kinase I-GENE O
in O O
blood O O

The O O
possible O O
roles O O
of O O
HRMT0L0 B-GENE O
and O O
HRMT0L0 B-GENE O
in O O
human O O
disease O O
are O O
currently O O
unknown O O
. O O

However O O
, O O
no O O
genetic O O
alteration O O
was O O
detected O O
in O O
any O O
of O O
the O O
cancers O O
examined O O
. O O

The O O
network O O
evolution O O
was O O
interpreted O O
by O O
an O O
approach O O
based O O
on O O
the O O
Flory O O
model O O
. O O

The O O
variable O O
phenotype O O
of O O
the O O
allotetraploids O O
could O O
not O O
be O O
explained O O
by O O
cytological O O
abnormalities O O
. O O

A O O
pre O O
- O O
boutonniere O O
deformity O O
was O O
simulated O O
by O O
dividing O O
the O O
central O O
slip O O
. O O

PATIENTS O O
AND O O
METHOD O O
: O O
Since O O
0000 O O
, O O
00 O O
patients O O
were O O
irradiated O O
stereotactically O O
. O O

Creatine B-GENE O
kinase I-GENE O
release O O
after O O
hepatic O O
artery O O
embolization O O
in O O
patients O O
with O O
carcinoid O O
tumors O O
. O O

In O O
connective O O
tissue O O
, O O
cell O O
structure O O
contributes O O
to O O
type B-GENE O
I I-GENE O
collagen I-GENE O
expression O O
. O O

There O O
was O O
no O O
evidence O O
of O O
any O O
persistent O O
oscillation O O
within O O
the O O
ULF O O
band O O
. O O

Identical O O
c B-GENE O
- I-GENE O
erbB0 I-GENE O
transcripts I-GENE O
are O O
expressed O O
in O O
normal O O
human O O
placental O O
tissues O O
. O O

The O O
GEF B-GENE O
and O O
GAP B-GENE O
activities O O
for O O
Ypt0p B-GENE O
localize O O
to O O
particulate O O
cellular O O
fractions O O
. O O

T O O
. O O
, O O
Mahasneh O O
, O O
A O O
. O O
, O O
and O O
Cote O O
, O O
G O O
. O O

CM O O
reduced O O
the O O
nuclear O O
binding O O
activity O O
of O O
transcription B-GENE B-GENE
factor I-GENE I-GENE
AP I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
. O O

Mechanisms O O
of O O
visible O O
- O O
light O O
emission O O
from O O
electro O O
- O O
oxidized O O
porous O O
silicon O O
. O O

These O O
kinases O O
belong O O
to O O
a O O
new O O
subfamily O O
related O O
to O O
the O O
Trk B-GENE O
subfamily I-GENE O
. O O

Recombinant B-GENE O
prenylcysteine I-GENE O
lyase I-GENE O
was O O
produced O O
in O O
a O O
baculovirus O O
- O O
Sf0 O O
expression O O
system O O
. O O

Comparison O O
of O O
immunoassay O O
kits O O
for O O
detection O O
of O O
staphylococcal B-GENE O
enterotoxins I-GENE O
produced O O
by O O
Staphylococcus O O
aureus O O

High O O
resolution O O
computed O O
tomography O O
of O O
the O O
lungs O O
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
. O O

All O O
four O O
domains O O
were O O
linked O O
via O O
proline O O
- O O
threonine O O
- O O
rich O O
peptides O O
. O O

RegA B-GENE O
is O O
a O O
positive O O
yet O O
nonessential O O
regulator O O
of O O
tol B-GENE O
- O O
oprL B-GENE O
expression O O
. O O

Mutation O O
analysis O O
demonstrates O O
that O O
the O O
motif O O
TCCCCT O O
is O O
critical O O
for O O
PyRo0 B-GENE O
interaction O O
. O O

Mus00p B-GENE O
also O O
shares O O
homology O O
with O O
motifs O O
found O O
in O O
the O O
XPF B-GENE O
endonuclease I-GENE O
superfamily I-GENE O
. O O

The O O
tumor B-GENE B-GENE
- I-GENE I-GENE
suppressor I-GENE I-GENE
protein I-GENE I-GENE
p00 I-GENE I-GENE
is O O
involved O O
in O O
maintaining O O
genomic O O
stability O O
. O O

Primary O O
adrenal O O
hypersensitivity O O
to O O
ACTH B-GENE O
drive O O
in O O
obesity O O
has O O
also O O
been O O
suggested O O
. O O

RESULTS O O
: O O
Average O O
age O O
at O O
symptom O O
onset O O
was O O
00 O O
. O O
0 O O
years O O
. O O

Colorectal O O
carcinoma O O
: O O
therapeutic O O
approach O O
in O O
patients O O
already O O
treated O O
with O O
metastasis O O
resection O O

We O O
recently O O
characterized O O
a O O
single O O
yeast B-GENE O
hnRNP I-GENE O
methyltransferase I-GENE O
( O O
HMT0 B-GENE O
) O O
. O O

We O O
recently O O
characterized O O
a O O
single O O
yeast B-GENE O
hnRNP I-GENE O
methyltransferase I-GENE O
( O O
HMT0 B-GENE O
) O O
. O O

EGFR B-GENE O
levels O O
were O O
found O O
to O O
be O O
elevated O O
0 O O
- O O
, O O
0 O O
. O O

Recombinant B-GENE O
Ffh I-GENE O
has O O
a O O
melting O O
point O O
of O O
tm O O
= O O
00 O O
degreesC O O
. O O

Airflow O O
through O O
the O O
dust O O
trap O O
was O O
controlled O O
with O O
a O O
vacuum O O
pump O O
. O O

New O O
Langevin O O
equations O O
for O O
a O O
translating O O
and O O
simultaneously O O
rotating O O
asymmetric O O
top O O
. O O

Therefore O O
, O O
high O O
set O O
- O O
up O O
accuracy O O
and O O
reproducibility O O
are O O
mandatory O O
. O O

Most O O
likely O O
they O O
might O O
represent O O
regulatory O O
RNAs O O
or O O
transcribed O O
transposable O O
elements O O
. O O

The O O
effects O O
of O O
these O O
mutations O O
on O O
protein O O
function O O
require O O
further O O
examination O O
. O O

AMDA O O
white O O
paper O O
identifies O O
ways O O
to O O
improve O O
pharmaceutical O O
care O O
in O O
SNFs O O
. O O

ACE B-GENE O
- I-GENE O
0 I-GENE O
has O O
a O O
hydrophobic O O
C O O
terminus O O
of O O
H O O
type O O
. O O

The O O
muskox O O
is O O
a O O
new O O
host O O
record O O
for O O
T O O
. O O
gondii O O
. O O

( O O
0000a O O
) O O
Biochemistry O O
00 O O
, O O
0000 O O
- O O
0000 O O
] O O
. O O

Neither O O
mutant O O
exhibited O O
derepression O O
of O O
the O O
silent B-GENE O
mating I-GENE O
type I-GENE O
loci I-GENE O
. O O

Ganciclovir O O
and O O
foscarnet O O
efficacy O O
in O O
AIDS O O
- O O
related O O
CMV O O
polyradiculopathy O O
. O O

Analysis O O
of O O
hematopoietic B-GENE O
growth I-GENE O
factor I-GENE O
prescriptions O O
in O O
00 O O
french O O
cancer O O
centers O O

Dopaminergic O O
modulation O O
of O O
transcallosal O O
activity O O
of O O
cat O O
motor O O
cortical O O
neurons O O
. O O

The O O
paramyxovirus B-GENE O
fusion I-GENE O
( I-GENE O
F I-GENE O
) I-GENE O
protein I-GENE O
mediates O O
membrane O O
fusion O O
. O O

Haycocknema O O
perplexum O O
n O O
. O O
g O O
. O O
, O O
n O O
. O O
sp O O
. O O

These O O
cells O O
produced O O
P0Y B-GENE O
( I-GENE O
00 I-GENE O
) I-GENE O
mRNA I-GENE O
during O O
culture O O
. O O

Interleukin B-GENE O
- I-GENE O
0 I-GENE O
levels O O
remained O O
low O O
throughout O O
the O O
course O O
. O O

[ O O
Treatment O O
of O O
early O O
T0 O O
small O O
T0N O O
breast O O
cancers O O
. O O

Molecular O O
cloning O O
and O O
functional O O
characterization O O
of O O
murine B-GENE B-GENE
sphingosine I-GENE I-GENE
kinase I-GENE I-GENE
. O O

There O O
was O O
a O O
trend O O
in O O
all O O
studies O O
favouring O O
PVI O O
. O O

The O O
controversy O O
of O O
significance O O
testing O O
: O O
misconceptions O O
and O O
alternatives O O
. O O

Treatment O O
of O O
unstable O O
angina O O
: O O
role O O
of O O
antithrombotic O O
therapy O O
. O O

Hypothermia O O
After O O
Cardiac O O
Arrest O O
( O O
HACA O O
) O O
Study O O
Group O O
. O O

The O O
somatoform O O
conundrum O O
: O O
a O O
question O O
of O O
nosological O O
valves O O
. O O

Plasma O O
CCK B-GENE O
levels O O
were O O
determined O O
at O O
regular O O
intervals O O
. O O

Optically O O
detected O O
librons O O
and O O
phonons O O
in O O
crystalline O O
C00 O O
. O O

Solution O O
structure O O
and O O
mechanism O O
of O O
the O O
MutT B-GENE O
pyrophosphohydrolase I-GENE O
. O O

Grade O O
0 O O
mucositis O O
was O O
reported O O
in O O
0 O O
patient O O
. O O

Microcirculatory O O
oxygenation O O
and O O
shunting O O
in O O
sepsis O O
and O O
shock O O
. O O

Mechanisms O O
of O O
tachyphylaxis O O
in O O
regional O O
anesthesia O O
of O O
long O O
duration O O

A O O
cause O O
of O O
increase O O
of O O
alkaline B-GENE O
phosphatase I-GENE O
in O O
children O O

Prevention O O
, O O
differential O O
diagnosis O O
and O O
therapy O O
of O O
travel O O
diarrhea O O

Neural O O
blockade O O
in O O
chronic O O
and O O
cancer O O
pain O O
. O O

N O O
. O O
, O O
and O O
Fanning O O
, O O
E O O
. O O

No O O
mutations O O
were O O
found O O
in O O
follicular O O
adenomas O O
. O O

Echo O O
modulation O O
in O O
Pr0 O O
+ O O
: O O
YAlO0 O O
. O O

FASEB O O
Federal O O
Funding O O
Consensus O O
Conference O O
FY O O
0000 O O
. O O

Canalith O O
repositioning O O
is O O
the O O
mainstay O O
of O O
treatment O O
. O O

Sak B-GENE O
kinase I-GENE O
gene O O
structure O O
and O O
transcriptional O O
regulation O O
. O O

The O O
regurgitation O O
of O O
large O O
vitreous O O
injections O O
. O O

Improving O O
the O O
evidence O O
base O O
for O O
anaesthesia O O
. O O

JCAHO O O
asks O O
for O O
hospitals O O
' O O
patience O O
. O O

Proteinuria O O
in O O
a O O
young O O
man O O
. O O

Internal O O
modes O O
of O O
a O O
soliton O O
. O O

Two O O
other O O
patients O O
underwent O O
PRFR O O
. O O

Dermatology O O
is O O
no O O
exception O O
. O O

Flavonoids O O
from O O
Brosimum O O
acutifolium O O
. O O

Copyright O O
0000 O O
Academic O O
Press O O
. O O

Training O O
for O O
audit O O
. O O

desmethyltrimebutine O O
was O O
inactive O O
. O O

Schlegel O O
, O O
J O O
. O O

Pressure O O
ulcers O O
. O O

John O O
leonard O O
dawson O O

0 O O
. O O

J O O
. O O

Chem O O
. O O

Biol O O
. O O

In O O
such O O
conditions O O
, O O
the O O
following O O
kinetic O O
reactions O O
have O O
been O O
studied O O
: O O
N0 O O
( O O
A O O
) O O
+ O O
N0 O O
( O O
A O O
) O O
- O O
- O O
> O O
N0 O O
( O O
C O O
, O O
B O O
, O O
V O O
' O O
) O O
+ O O
N0 O O
( O O
X O O
) O O
, O O
N0 O O
( O O
A O O
) O O
+ O O
N0 O O
( O O
X O O
, O O
V O O
> O O
0 O O
) O O
- O O
- O O
> O O
N0 O O
( O O
X O O
) O O
+ O O
N0 O O
( O O
B O O
, O O
V O O
' O O
) O O
in O O
pure O O
N0 O O
post O O
- O O
discharges O O
and O O
N0 O O
( O O
A O O
) O O
+ O O
CH0 O O
- O O
- O O
> O O
products O O
, O O
C O O
+ O O
N O O
+ O O
M0 O O
- O O
- O O
> O O
CN O O
( O O
B O O
, O O
V O O
' O O
) O O
+ O O
M0 O O
, O O
N0 O O
( O O
X O O
, O O
V O O
> O O
0 O O
) O O
+ O O
CN O O
- O O
- O O
> O O
N0 O O
( O O
X O O
) O O
+ O O
CN O O
( O O
B O O
, O O
A O O
, O O
V O O
' O O
) O O
, O O
in O O
N0 O O
- O O
0 O O
% O O
CH0 O O
post O O
- O O
discharges O O
. O O

Five O O
modalities O O
of O O
nonpharmacologic O O
approaches O O
are O O
recommended O O
at O O
present O O
for O O
lifestyle O O
modification O O
and O O
control O O
of O O
arterial O O
blood O O
pressure O O
elevation O O
: O O
0 O O
) O O
weight O O
reduction O O
to O O
ideal O O
body O O
weight O O
, O O
since O O
it O O
reduces O O
risk O O
of O O
hypertension O O
as O O
well O O
as O O
overall O O
cardiovascular O O
morbidity O O
and O O
mortality O O
; O O
0 O O
) O O
dietary O O
sodium O O
restriction O O
to O O
less O O
than O O
0 O O
g O O
a O O
day O O
, O O
without O O
assurance O O
that O O
it O O
will O O
normalize O O
arterial O O
pressure O O
although O O
it O O
may O O
help O O
reduce O O
dosage O O
and O O
numbers O O
of O O
prescribed O O
antihypertensive O O
drugs O O
; O O
0 O O
) O O
moderation O O
of O O
alcohol O O
consumption O O
to O O
less O O
than O O
0 O O
ounce O O
a O O
day O O
; O O
0 O O
) O O
a O O
regular O O
isotonic O O
exercise O O
program O O
; O O
and O O
0 O O
) O O
cessation O O
of O O
tobacco O O
consumption O O
. O O

The O O
severity O O
of O O
clinical O O
course O O
was O O
expressed O O
by O O
means O O
of O O
SOFA O O
score O O
( O O
group O O
A O O
0 O O
. O O
0 O O
- O O
0 O O
- O O
0 O O
. O O
0 O O
point O O
, O O
group O O
B O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
point O O
, O O
group O O
C O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
point O O
) O O
and O O
APACHE O O
II O O
score O O
( O O
group O O
A O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
- O O
0 O O
. O O
0 O O
point O O
, O O
group O O
B O O
0 O O
. O O
0 O O
- O O
00 O O
. O O
0 O O
- O O
00 O O
. O O
0 O O
point O O
, O O
group O O
C O O
00 O O
. O O
0 O O
- O O
00 O O
. O O
0 O O
- O O
00 O O
. O O
0 O O
point O O
) O O
. O O

The O O
observed O O
phenotypes O O
may O O
be O O
explained O O
by O O
( O O
i O O
) O O
a O O
selective O O
disruption O O
of O O
very B-GENE O
- I-GENE O
low I-GENE O
- I-GENE O
density I-GENE O
lipoprotein I-GENE O
secretion O O
due O O
to O O
decreased O O
expression O O
of O O
genes O O
encoding O O
apolipoprotein B-GENE O
B I-GENE O
and O O
microsomal B-GENE O
triglyceride I-GENE O
transfer I-GENE O
protein I-GENE O
, O O
( O O
ii O O
) O O
an O O
increase O O
in O O
hepatic O O
cholesterol O O
uptake O O
due O O
to O O
increased O O
expression O O
of O O
the O O
major O O
high B-GENE O
- I-GENE O
density I-GENE O
lipoprotein I-GENE O
receptor I-GENE O
, O O
scavenger B-GENE O
receptor I-GENE O
BI I-GENE O
, O O
and O O
( O O
iii O O
) O O
a O O
decrease O O
in O O
bile O O
acid O O
uptake O O
to O O
the O O
liver O O
due O O
to O O
down O O
- O O
regulation O O
of O O
the O O
major O O
basolateral B-GENE O
bile I-GENE O
acid I-GENE O
transporters I-GENE O
sodium I-GENE I-GENE
taurocholate I-GENE I-GENE
cotransporter I-GENE I-GENE
protein I-GENE I-GENE
and O O
organic B-GENE B-GENE
anion I-GENE I-GENE
transporter I-GENE I-GENE
protein I-GENE I-GENE
0 I-GENE O
. O O

We O O
used O O
stored O O
plasma O O
samples O O
from O O
000 O O
patients O O
in O O
the O O
National O O
Institute O O
of O O
Neurological O O
Diseases O O
and O O
Stroke O O
( O O
NINDS O O
) O O
tissue B-GENE O
plasminogen I-GENE O
activator I-GENE O
( O O
t B-GENE O
- I-GENE O
PA I-GENE O
) O O
Stroke O O
Trial O O
to O O
examine O O
the O O
relationship O O
between O O
an O O
apolipoprotein B-GENE O
( I-GENE O
Apo I-GENE O
) I-GENE O
E0 I-GENE O
or O O
an O O
Apo B-GENE O
E0 I-GENE O
phenotype O O
and O O
a O O
favorable O O
outcome O O
0 O O
months O O
after O O
stroke O O
, O O
the O O
risk O O
of O O
intracerebral O O
hemorrhage O O
, O O
and O O
the O O
response O O
to O O
intravenous O O
t B-GENE O
- I-GENE O
PA I-GENE O
therapy O O
. O O

We O O
previously O O
showed O O
that O O
this O O
proteolysis O O
0 O O
) O O
can O O
be O O
acutely O O
promoted O O
by O O
the O O
phorbol O O
ester O O
phorbol O O
00 O O
- O O
myristate O O
00 O O
- O O
acetate O O
( O O
PMA O O
) O O
, O O
0 O O
) O O
requires O O
a O O
metalloprotease B-GENE O
activity O O
, O O
0 O O
) O O
generates O O
both O O
shed O O
GHBP B-GENE O
and O O
a O O
membrane B-GENE O
- I-GENE O
associated I-GENE O
GHR I-GENE O
transmembrane I-GENE O
/ I-GENE O
cytoplasmic I-GENE O
domain I-GENE O
remnant O O
, O O
and O O
0 O O
) O O
results O O
in O O
down O O
- O O
regulation O O
of O O
GHR B-GENE O
abundance O O
and O O
GH B-GENE O
signaling O O
. O O

Because O O
results O O
of O O
recent O O
randomized O O
trials O O
indicate O O
minimal O O
efficacy O O
of O O
continuing O O
MAC O O
prophylaxis O O
in O O
patients O O
who O O
respond O O
to O O
potent O O
combination O O
antiretroviral O O
therapy O O
, O O
the O O
observed O O
high O O
incidence O O
of O O
macrolide O O
- O O
resistant O O
bacterial O O
colonization O O
of O O
the O O
respiratory O O
tract O O
in O O
this O O
trial O O
supports O O
the O O
discontinuation O O
of O O
macrolide O O
prophylaxis O O
in O O
all O O
AIDS O O
patients O O
whose O O
CD0 B-GENE O
counts O O
have O O
risen O O
above O O
000 O O
cells O O
/ O O
microL O O
. O O

Inactivity O O
of O O
the O O
human B-GENE B-GENE
cytomegalovirus I-GENE I-GENE
( I-GENE I-GENE
HCMV I-GENE I-GENE
) I-GENE O
major I-GENE O
immediate I-GENE O
- I-GENE O
early I-GENE O
regulatory I-GENE O
region I-GENE O
( O O
MIERR B-GENE O
) O O
, O O
which O O
is O O
composed O O
of O O
promoter O O
, O O
enhancer O O
, O O
unique O O
region O O
, O O
and O O
modulator O O
, O O
is O O
linked O O
to O O
lack O O
of O O
HCMV O O
replication O O
in O O
latently O O
infected O O
cells O O
and O O
in O O
other O O
nonpermissive O O
cell O O
types O O
, O O
including O O
human O O
embryonal O O
NTera0 O O
carcinoma O O
( O O
NT0 O O
) O O
cells O O
. O O

Sequence O O
analysis O O
revealed O O
significant O O
differences O O
between O O
the O O
0 O O
' O O
region O O
of O O
the O O
beta O B-GENE
subunit O I-GENE
gene O I-GENE
and O O
the O O
corresponding O O
regions O O
of O O
the O O
homologous B-GENE B-GENE
GlyR I-GENE I-GENE
alpha I-GENE I-GENE
subunit I-GENE I-GENE
genes I-GENE I-GENE
; O O
it O O
also O O
identified O O
a O O
novel O O
exon O O
( O O
exon O O
0 O O
) O O
that O O
encodes O O
most O O
of O O
the O O
0 O O
' O O
- O O
untranslated O O
portion O O
of O O
the O O
GlyR B-GENE B-GENE
beta I-GENE I-GENE
mRNA I-GENE I-GENE
. O O

TaqMan O O
analysis O O
of O O
gene O O
expression O O
following O O
chronic O O
FA O O
treatment O O
showed O O
neither O O
a O O
decrease O O
in O O
the O O
amount O O
of O O
leptin B-GENE B-GENE
receptor I-GENE I-GENE
( O O
Ob B-GENE B-GENE
- I-GENE I-GENE
R I-GENE I-GENE
) O O
mRNA O O
, O O
nor O O
an O O
increase O O
in O O
the O O
negative O O
regulators O O
of O O
STAT B-GENE O
signalling O O
, O O
SOCS0 B-GENE O
( O O
suppressors B-GENE O
of I-GENE O
cytokine I-GENE O
signalling I-GENE O
) O O
or O O
cytokine B-GENE O
inducible I-GENE O
sequence I-GENE O
( O O
CIS B-GENE O
) O O
. O O

In O O
sterilized O O
milk O O
there O O
was O O
a O O
slight O O
decrease O O
of O O
linoleic O O
acid O O
( O O
C00 O O
: O O
0n0 O O
; O O
- O O
0 O O
. O O
0 O O
% O O
vs O O
. O O
fresh O O
; O O
P O O
= O O
0 O O
. O O
000 O O
) O O
and O O
arachidonic O O
acid O O
( O O
C00 O O
: O O
0n0 O O
; O O
- O O
0 O O
. O O
0 O O
% O O
; O O
P O O
= O O
0 O O
. O O
000 O O
) O O
. O O

Adjacent O O
to O O
those O O
lesions O O
, O O
and O O
in O O
homologous O O
contralateral O O
structures O O
, O O
FMZ O O
binding O O
was O O
analysed O O
in O O
four O O
pairs O O
of O O
cortical O O
0 O O
x O O
0 O O
- O O
mm O O
regions O O
of O O
interest O O
( O O
ROIs O O
) O O
placed O O
on O O
transaxial O O
and O O
coronal O O
slices O O
, O O
respectively O O
, O O
as O O
well O O
as O O
in O O
the O O
lesion O O
volume O O
and O O
its O O
mirror O O
region O O
. O O

Is O O
clopidogrel O O
superior O O
to O O
aspirin O O
in O O
secondary O O
prevention O O
of O O
vascular O O
disease O O
? O O
The O O
cornerstone O O
in O O
clinical O O
evidence O O
of O O
the O O
relative O O
efficacy O O
of O O
thienopyridines O O
( O O
clopidogrel O O
, O O
ticlopidine O O
) O O
versus O O
aspirin O O
in O O
the O O
secondary O O
prevention O O
of O O
vascular O O
disease O O
is O O
the O O
Clopidogrel O O
versus O O
Aspirin O O
in O O
Patients O O
at O O
Risk O O
of O O
Ischaemic O O
Events O O
trial O O
. O O

CONCLUSIONS O O
: O O
ChromaFlo O O
- O O
enhanced O O
IVUS O O
demonstrates O O
colorized O O
blood O O
flow O O
inside O O
the O O
vessel O O
lumen O O
, O O
which O O
is O O
helpful O O
in O O
distinguishing O O
echolucent O O
disease O O
from O O
luminal O O
blood O O
flow O O
and O O
can O O
also O O
be O O
used O O
to O O
perform O O
peripheral O O
interventions O O
in O O
patients O O
with O O
renal O O
failure O O
or O O
allergy O O
, O O
avoiding O O
the O O
use O O
of O O
contrast O O
media O O
. O O

Energy O O
expenditure O O
was O O
obtained O O
using O O
a O O
primed O O
, O O
0 O O
- O O
hour O O
infusion O O
of O O
NaH O O
( O O
00 O O
) O O
CO O O
( O O
0 O O
' O O
) O O
, O O
breath O O
( O O
00 O O
) O O
CO O O
( O O
0 O O
) O O
enrichment O O
determination O O
by O O
isotope O O
ratio O O
mass O O
spectroscopy O O
, O O
and O O
the O O
application O O
of O O
a O O
standard O O
regression O O
equation O O
. O O

Age O O
was O O
categorized O O
into O O
four O O
groups O O
: O O
00 O O
- O O
00 O O
, O O
00 O O
- O O
00 O O
, O O
00 O O
- O O
00 O O
, O O
and O O
00 O O
+ O O
. O O
RESULTS O O
: O O
At O O
the O O
initiation O O
of O O
dialysis O O
PD O O
patients O O
were O O
approximately O O
0 O O
years O O
younger O O
( O O
P O O
< O O
0 O O
. O O
0000 O O
) O O
than O O
HD O O
patients O O
. O O

She O O
has O O
since O O
developed O O
a O O
positive O O
anti B-GENE O
- I-GENE O
cardiolipin I-GENE O
antibody I-GENE O
but O O
does O O
not O O
meet O O
diagnostic O O
criteria O O
for O O
systemic O O
lupus O O
erythematosis O O
. O O
CONCLUSION O O
: O O
The O O
presence O O
of O O
known O O
autoimmune O O
disease O O
in O O
a O O
woman O O
with O O
POF O O
should O O
not O O
dissuade O O
the O O
clinician O O
from O O
evaluating O O
for O O
a O O
potential O O
genetic O O
cause O O
. O O

Cells O O
containing O O
alpha O O
subunits O O
that O O
lacked O O
a O O
distal O O
domain O O
( O O
term O B-GENE
- O I-GENE
0 O I-GENE
) O O
or O O
had O O
the O O
alternatively O B-GENE
spliced O I-GENE
alpha O I-GENE
- O I-GENE
0 O I-GENE
distal O I-GENE
domain O O
showed O O
markedly O O
decreased O O
ability O O
to O O
support O O
tyrosine O O
phosphorylation O O
of O O
Jak B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
and O O
its O O
substrates O O
or O O
to O O
up O O
- O O
regulate O O
CD00 B-GENE O
. O O

The O O
application O O
of O O
the O O
biotechnology O O
at O O
the O O
plants O O
for O O
treatment O O
of O O
the O O
surface O O
storm O O
waters O O
from O O
the O O
industrial O O
zone O O
Telychka O O
of O O
the O O
city O O
of O O
Kyiv O O
has O O
allowed O O
the O O
content O O
of O O
petroleum O O
in O O
water O O
dropped O O
to O O
the O O
Dnieper O O
to O O
be O O
constantly O O
reduced O O
00 O O
- O O
000 O O
times O O
. O O

We O O
hypothesize O O
that O O
proprioception O O
may O O
be O O
used O O
to O O
calibrate O O
the O O
efference O O
copy O O
during O O
development O O
and O O
in O O
response O O
to O O
perturbations O O
by O O
signaling O O
potential O O
mismatches O O
between O O
eye O O
movement O O
information O O
derived O O
from O O
the O O
efferent O O
command O O
and O O
the O O
actual O O
motion O O
of O O
the O O
eye O O
transduced O O
by O O
the O O
proprioceptive O O
organs O O
. O O

Recent O O
studies O O
using O O
isolated O O
rat O O
adipocytes O O
and O O
chemically O O
synthesized O O
PIG O O
compounds O O
point O O
to O O
IRS0 B-GENE O
/ I-GENE O
0 I-GENE O
tyrosine O O
phosphorylation O O
by O O
p00Lyn B-GENE O
kinase I-GENE O
as O O
the O O
site O O
of O O
cross O O
- O O
talk O O
, O O
the O O
negative O O
regulation O O
of O O
which O O
by O O
interaction O O
with O O
caveolin B-GENE O
is O O
apparently O O
abrogated O O
by O O
PIG O O
. O O

Analysis O O
of O O
regulatory O O
regions O O
in O O
the O O
promoter O O
of O O
the O O
ctr0 B-GENE B-GENE
( I-GENE I-GENE
+ I-GENE I-GENE
) I-GENE O
copper I-GENE O
transporter I-GENE I-GENE
gene I-GENE I-GENE
in O O
fission O O
yeast O O
Schizosaccharomyces O O
pombe O O
reveals O O
the O O
identity O O
of O O
a O O
conserved O O
copper O O
- O I-GENE
signaling O I-GENE
element O I-GENE
( O O
CuSE O O
) O O
, O O
which O O
is O O
recognized O O
by O O
the O O
transcription B-GENE O
factor I-GENE O
Cuf0 I-GENE O
. O O

Our O O
results O O
suggest O O
that O O
the O O
C O O
- O O
terminal O O
region O O
of O O
Crk B-GENE O
contains O O
negative O O
regulatory O O
elements O O
important O O
for O O
both O O
Abl B-GENE O
and O O
FAK B-GENE O
dependent O O
signal O O
pathways O O
, O O
and O O
offers O O
a O O
paradigm O O
for O O
an O O
autoinhibitory O O
region O O
in O O
the O O
SH0 B-GENE O
linker O O
/ O O
C O O
- O O
terminal O O
SH0 B-GENE O
domain O O
. O O

RANTES B-GENE O
( O O
regulated B-GENE O
upon I-GENE O
activation I-GENE O
, I-GENE O
normally I-GENE O
T I-GENE O
- I-GENE O
cell I-GENE O
expressed I-GENE O
and I-GENE O
presumably I-GENE O
secreted I-GENE O
) O O
is O O
a O O
CC O O
chemokine O O
which O O
recruits O O
and O O
activates O O
monocytes O O
, O O
lymphocytes O O
, O O
and O O
eosinophils O O
, O O
all O O
cell O O
types O O
present O O
in O O
the O O
lung O O
inflammatory O O
infiltrate O O
induced O O
by O O
RSV O O
infection O O
. O O

Behavioural O O
tests O O
with O O
000 O O
specimen O O
of O O
the O O
roman O O
garden O O
snail O O
Helix O O
pomatia O O
L O O
. O O
were O O
performed O O
in O O
order O O
to O O
clarify O O
whether O O
the O O
thermopreferendum O O
of O O
this O O
pulmonate O O
is O O
influenced O O
not O O
only O O
by O O
the O O
temperature O O
of O O
the O O
substratum O O
but O O
also O O
by O O
air O O
temperature O O
. O O

Data O O
from O O
in O O
vitro O O
splicing O O
assays O O
, O O
UV O O
crosslinking O O
and O O
RNA O O
- O O
binding O O
competition O O
experiments O O
indicates O O
a O O
strong O O
correlation O O
between O O
the O O
binding O O
affinities O O
of O O
PSI B-GENE O
for O O
the O O
SELEX O O
sequences O O
and O O
their O O
ability O O
to O O
modulate O O
splicing O O
of O O
P B-GENE O
element I-GENE O
IVS0 B-GENE O
in O O
vitro O O
. O O

The O O
corresponding O O
orifice O O
voltages O O
for O O
the O O
three O O
instruments O O
were O O
00 O O
/ O O
00 O O
/ O O
00 O O
V O O
( O O
API O O
000 O O
) O O
, O O
00 O O
/ O O
00 O O
/ O O
000 O O
V O O
( O O
API O O
0000 O O
) O O
and O O
00 O O
/ O O
00 O O
/ O O
000 O O
V O O
( O O
API O O
0000 O O
) O O
. O O

Furthermore O O
, O O
stable O O
expression O O
of O O
a O O
constitutively O O
active O O
form O O
of O O
chicken O O
Notch0 B-GENE O
or O O
Notch0 B-GENE O
in O O
a O O
B O O
cell O O
line O O
results O O
in O O
a O O
down O O
- O O
regulation O O
of O O
surface O O
IgM B-GENE O
expression O O
, O O
which O O
is O O
accompanied O O
by O O
the O O
reduction O O
of O O
IgH B-GENE B-GENE
gene I-GENE I-GENE
transcripts I-GENE O
. O O

METHODS O O
: O O
000 O O
consecutive O O
patients O O
with O O
BS O O
and O O
000 O O
patients O O
with O O
other O O
rheumatological O O
conditions O O
were O O
surveyed O O
for O O
the O O
presence O O
or O O
absence O O
of O O
the O O
features O O
of O O
BS O O
by O O
means O O
of O O
a O O
standard O O
form O O
which O O
had O O
been O O
prepared O O
according O O
to O O
ISG O O
criteria O O
. O O

We O O
mapped O O
the O O
DGCR0 B-GENE B-GENE
gene I-GENE I-GENE
to O O
chromosome O O
00q00 O O
within O O
a O O
low O O
copy O O
repeat O O
, O O
termed O O
sc00 O O
. O O
0a O O
, O O
and O O
identified O O
a O O
second O O
copy O O
of O O
the O O
gene O O
, O O
DGCR0L B-GENE O
, O O
within O O
the O O
duplicate O O
locus O O
, O O
termed O O
sc00 O O
. O O
0b O O
. O O

In O O
contrast O O
, O O
exogenous B-GENE O
PTHrP0 I-GENE O
- I-GENE O
00 I-GENE O
and I-GENE O
0 I-GENE O
- I-GENE O
00 I-GENE O
peptides I-GENE O
did O O
not O O
significantly O O
affect O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
production O O
; O O
moreover O O
, O O
PTHrP B-GENE O
- I-GENE O
neutralizing I-GENE O
antibodies I-GENE O
did O O
not O O
inhibit O O
the O O
production O O
of O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
by O O
transfected O O
PTHrP B-GENE O
. O O

Modality O O
- O O
specific O O
areas O O
( O O
e O O
. O O
g O O
. O O
, O O
right O O
Wernicke O O
, O O
left O O
fusiform O O
gyrus O O
, O O
Broca O O
BA00 O O
, O O
supramarginal O O
gyrus O O
) O O
, O O
appear O O
to O O
cope O O
with O O
the O O
computations O O
relevant O O
to O O
making O O
contact O O
with O O
these O O
more O O
abstract O O
dimensions O O
. O O

The O O
prevalence O O
of O O
tobacco O O
dependence O O
diagnosed O O
according O O
to O O
the O O
ICD O O
- O O
00 O O
criteria O O
was O O
higher O O
in O O
alcohol O O
- O O
dependent O O
individuals O O
( O O
00 O O
. O O
0 O O
% O O
) O O
than O O
in O O
nondrinkers O O
or O O
social O O
drinkers O O
( O O
00 O O
. O O
0 O O
% O O
) O O
. O O

This O O
paper O O
describes O O
the O O
results O O
of O O
an O O
initial O O
study O O
on O O
the O O
application O O
of O O
linear O O
solvation O O
energy O O
relationships O O
( O O
LSERs O O
) O O
to O O
the O O
prediction O O
of O O
internal O O
standard O O
compounds O O
in O O
reversed O O
- O O
phase O O
liquid O O
chromatographic O O
( O O
RPLC O O
) O O
method O O
development O O
. O O

The O O
most O O
important O O
risk O O
factors O O
are O O
: O O
0 O O
) O O
genetic O O
; O O
0 O O
) O O
Epstein O O
- O O
Barr O O
virus O O
( O O
infectious O O
mononucleosis O O
) O O
; O O
0 O O
) O O
congenital O O
and O O
acquired O O
immunodeficiency O O
; O O
0 O O
) O O
occupational O O
exposure O O
( O O
the O O
wood O O
industry O O
) O O
. O O

Because O O
a O O
close O O
correlation O O
between O O
regional O O
decreases O O
in O O
FMZ O O
binding O O
and O O
spiking O O
activity O O
was O O
recently O O
demonstrated O O
in O O
neocortical O O
epilepsies O O
, O O
abnormal O O
peri O O
- O O
lesional O O
FMZ O O
binding O O
may O O
bear O O
some O O
relation O O
to O O
the O O
mechanisms O O
of O O
epileptogenesis O O
in O O
symptomatic O O
epilepsies O O
. O O

In O O
this O O
study O O
we O O
wanted O O
to O O
assess O O
the O O
DR O O
using O O
the O O
' O O
combined O O
test O O
' O O
in O O
an O O
unselected O O
population O O
of O O
self O O
- O O
referred O O
pregnant O O
women O O
at O O
a O O
false O O
- O O
positive O O
rate O O
( O O
FPR O O
) O O
of O O
about O O
0 O O
% O O
. O O

The O O
continuing O O
development O O
of O O
ligands O O
that O O
function O O
as O O
selective O O
estrogens O O
or O O
antiestrogens O O
for O O
ERalpha B-GENE O
or O O
ERbeta B-GENE O
should O O
allow O O
optimized O O
tissue O O
selectivity O O
of O O
these O O
agents O O
for O O
menopausal O O
hormone O O
replacement O O
therapy O O
and O O
the O O
treatment O O
and O O
prevention O O
of O O
breast O O
cancer O O
. O O

The O O
telomerase B-GENE B-GENE
RNA I-GENE I-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
complex I-GENE O
responsible O O
for O O
maintenance O O
of O O
telomeric O O
DNA O O
at O O
chromosome O O
ends O O
, O O
is O O
usually O O
inactive O O
in O O
most O O
primary O O
somatic O O
human O O
cells O O
, O O
but O O
is O O
specifically O O
activated O O
with O O
in O O
vitro O O
immortalization O O
and O O
during O O
tumorigenesis O O
. O O

Both O O
toxins O O
in O O
a O O
dose O O
00 O O
- O O
fold O O
surpassing O O
the O O
maximum O O
permissible O O
concentration O O
increased O O
activity O O
of O O
glutathione B-GENE O
peroxidase I-GENE O
in O O
brain O O
tissue O O
; O O
moreover O O
, O O
toluene O O
increased O O
chemiluminescence O O
intensity O O
, O O
which O O
attested O O
to O O
activation O O
of O O
free O O
radical O O
processes O O
. O O

The O O
results O O
are O O
discussed O O
in O O
relation O O
to O O
acoustical O O
models O O
of O O
sound O O
propagation O O
and O O
physiology O O
, O O
and O O
it O O
is O O
suggested O O
that O O
height O O
- O O
dependent O O
degradation O O
within O O
a O O
forest O O
is O O
an O O
important O O
selection O O
pressure O O
for O O
transmissibility O O
in O O
avian O O
communication O O
. O O

We O O
found O O
three O O
out O O
of O O
four O O
original O O
( O O
Volkan O O
' O O
s O O
) O O
groups O O
of O O
linking O O
objects O O
, O O
but O O
also O O
an O O
additional O O
one O O
, O O
hitherto O O
undescribed O O
, O O
comprising O O
objects O O
used O O
for O O
designing O O
a O O
memorial O O
shrine O O
to O O
the O O
deceased O O
. O O

Analysis O O
of O O
the O O
promoter O O
sequence O O
revealed O O
the O O
presence O O
of O O
a O O
major O O
transcriptional O O
start O O
site O O
, O O
a O O
canonical O O
TATA O O
box O O
and O O
putative O O
cis O O
regulatory O O
elements O O
for O O
pituitary O O
specific O O
expression O O
as O O
well O O
as O O
an O O
E O O
- O O
responsive O O
element O O
. O O

Single O O
amino O O
acid O O
substitutions O O
at O O
the O O
acyl O B-GENE
- O I-GENE
CoA O I-GENE
- O O
binding O O
domain O O
interrupt O O
00 O O
[ O O
C O O
] O O
palmitoyl O O
- O O
CoA O O
binding O O
of O O
ACBP0 B-GENE O
, O O
an O O
Arabidopsis O O
acyl B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
with O O
ankyrin B-GENE O
repeats O O
. O O

We O O
show O O
here O O
that O O
the O O
in O O
vitro O O
transcription O O
extract O O
contains O O
a O O
binding O O
activity O O
that O O
is O O
specific O O
for O O
the O O
initiator O O
element O O
and O O
thus O O
may O O
participate O O
in O O
recruiting O O
RNA B-GENE O
polymerase I-GENE O
II I-GENE O
to O O
the O O
SL O B-GENE
RNA O I-GENE
gene O I-GENE
promoter O I-GENE
. O O

These O O
data O O
suggest O O
that O O
ADAM B-GENE B-GENE
- I-GENE O
TS00 I-GENE O
may O O
play O O
roles O O
in O O
pulmonary O O
cells O O
during O O
fetal O O
development O O
or O O
in O O
tumor O O
processes O O
through O O
its O O
proteolytic O O
activity O O
or O O
as O O
a O O
molecule O O
potentially O O
involved O O
in O O
regulation O O
of O O
cell O O
adhesion O O
. O O

To O O
this O O
end O O
, O O
an O O
expression O O
cassette O O
consisting O O
of O O
the O O
gene O O
for O O
a O O
green B-GENE O
fluorescent I-GENE B-GENE
protein I-GENE I-GENE
( O O
GFP B-GENE O
) O O
flanked O O
at O O
its O O
0 O O
' O O
end O O
by O O
EAV O O
- O O
specific O O
transcription O O
- O O
regulating O O
sequences O O
was O O
constructed O O
. O O

PURPOSE O O
: O O
The O O
objective O O
of O O
this O O
study O O
was O O
to O O
assess O O
first O O
embryo O O
cleavage O O
( O O
FEC O O
) O O
00 O O
- O O
00 O O
h O O
after O O
intracytoplasmic O O
sperm O O
injection O O
( O O
ICSI O O
) O O
as O O
a O O
parameter O O
for O O
the O O
embryo O O
selection O O
process O O
. O O

The O O
regulation O O
of O O
PGHS B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
mRNA I-GENE I-GENE
and O O
protein O O
was O O
studied O O
in O O
primary O O
cultures O O
of O O
bovine O O
uterine O O
stromal O O
cells O O
stimulated O O
with O O
phorbol O O
00 O O
- O O
myristate O O
00 O O
- O O
acetate O O
( O O
PMA O O
; O O
000 O O
nM O O
) O O
. O O

As O O
an O O
oral O O
, O O
nontoxic O O
compound O O
with O O
a O O
mechanism O O
of O O
action O O
distinct O O
from O O
that O O
of O O
ABL B-GENE O
tyrosine I-GENE O
kinase I-GENE O
inhibition O O
, O O
FTI O O
SCH00000 O O
shows O O
promise O O
for O O
the O O
treatment O O
of O O
BCR B-GENE O
/ O O
ABL B-GENE O
- O O
induced O O
leukemia O O
. O O

Here O O
we O O
present O O
evidence O O
that O O
the O O
distal O O
half O O
( O O
Stem O O
0 O O
) O O
of O O
the O O
conserved O O
base O O
- O O
paired O O
stem O O
structure O O
found O O
in O O
all O O
hY B-GENE O
RNAs I-GENE O
also O O
plays O O
a O O
critical O O
role O O
in O O
the O O
export O O
process O O
. O O

A O O
00 O O
- O O
base O O
pair O O
oligonucleotide O O
containing O O
this O O
nonamer O O
confers O O
up O O
- O O
regulation O O
by O O
hypoxia O O
and O O
inhibition O O
by O O
unsaturated O O
fatty O O
acids O O
when O O
placed O O
upstream O O
of O O
a O O
heterologous O O
promoter O O
in O O
a O O
lacZ B-GENE O
reporter I-GENE O
construct I-GENE O
. O O

Finally O O
a O O
00 O O
- O O
nucleotide O O
region O O
flanking O O
the O O
exon O B-GENE
0 O I-GENE
protein O I-GENE
- O I-GENE
binding O I-GENE
site O O
is O O
homologous O O
to O O
instability O O
elements O O
within O O
five O O
other O O
transcripts O O
, O O
suggesting O O
that O O
a O O
common O O
coding O O
region O O
determinant O O
may O O
exist O O
. O O

Pitx0 B-GENE O
rescues O O
the O O
GABAergic O O
differentiation O O
defect O O
and O O
partially O O
rescues O O
the O O
axon O O
guidance O O
and O O
behavioral O O
phenotypes O O
of O O
unc B-GENE O
- I-GENE O
00 I-GENE O
mutants I-GENE O
, O O
indicating O O
a O O
high O O
degree O O
of O O
functional O O
conservation O O
between O O
these O O
evolutionarily O O
related O O
genes O O
. O O

A O O
proposal O O
of O O
00 O O
performance O O
indicators O O
divided O O
into O O
five O O
different O O
groups O O
is O O
presented O O
here O O
, O O
namely O O
structural O O
indicators O O
, O O
operational O O
indicators O O
, O O
water O O
and O O
service O O
quality O O
indicators O O
, O O
personnel O O
indicators O O
and O O
economic O O
indicators O O
. O O

The O O
small O O
copepod O O
Pseudonychocamptus O O
proximus O O
progressively O O
replaced O O
the O O
large O O
Tisbe O O
furcata O O
in O O
sand O O
filters O O
during O O
the O O
fall O O
of O O
0000 O O
and O O
was O O
responsible O O
for O O
the O O
large O O
increase O O
in O O
meiofaunal O O
biomass O O
observed O O
after O O
spring O O
0000 O O
. O O

Colorectal O O
cancer O O
was O O
shown O O
to O O
disproportionately O O
overburden O O
Ashkenazi O O
Jews O O
, O O
who O O
may O O
also O O
be O O
at O O
increased O O
risk O O
for O O
ovarian O O
, O O
pancreatic O O
and O O
stomach O O
cancer O O
, O O
and O O
non O O
- O O
Hodgkin O O
' O O
s O O
lymphoma O O
. O O

A O O
computer O O
program O O
, O O
ACCESS O O
- O O
IAQ O O
, O O
is O O
developed O O
to O O
simulate O O
the O O
airflow O O
pattern O O
, O O
the O O
time O O
history O O
of O O
the O O
contaminant O O
concentrations O O
in O O
the O O
occupied O O
zone O O
, O O
and O O
the O O
inhalation O O
exposures O O
. O O

Interestingly O O
, O O
continuation O O
of O O
the O O
interferon B-GENE O
therapy O O
in O O
the O O
presence O O
of O O
a O O
mild O O
- O O
to O O
- O O
moderate O O
exacerbation O O
of O O
sarcoidosis O O
may O O
be O O
safe O O
in O O
a O O
minority O O
of O O
patients O O
with O O
noncritical O O
organ O O
involvement O O
. O O

Our O O
results O O
show O O
that O O
CVN B-GENE O
specifically O O
recognizes O O
with O O
nanomolar O O
affinity O O
Man O O
( O O
0 O O
) O O
GlcNAc O O
( O O
0 O O
) O O
and O O
the O O
D0D0 O O
isomer O O
of O O
Man O O
( O O
0 O O
) O O
GlcNAc O O
( O O
0 O O
) O O
. O O

The O O
novel O O
approach O O
to O O
insulin B-GENE O
administration O O
known O O
as O O
chronic O O
intermittent O O
intravenous O O
insulin B-GENE O
therapy O O
( O O
CIIIT O O
) O O
delivers O O
insulin B-GENE O
in O O
a O O
pulsatile O O
fashion O O
and O O
achieves O O
physiological O O
insulin B-GENE O
concentration O O
in O O
the O O
portal O O
vein O O
. O O

EXAFS O O
measurements O O
around O O
the O O
Ge O O
- O O
K O O
edge O O
have O O
been O O
carried O O
out O O
for O O
liquid O O
Ge O O
- O O
Si O O
alloys O O
for O O
the O O
first O O
time O O
to O O
investigate O O
the O O
local O O
structure O O
around O O
a O O
Ge O O
atom O O
. O O

We O O
have O O
previously O O
shown O O
that O O
the O O
adenoviral B-GENE O
00S I-GENE O
E0A I-GENE O
protein I-GENE O
modulates O O
the O O
phosphorylation O O
status O O
of O O
p000 B-GENE B-GENE
and O O
p000 B-GENE O
without O O
apparent O O
changes O O
in O O
the O O
cell O O
cycle O O
dependent O O
phosphorylation O O
of O O
the O O
retinoblastoma B-GENE B-GENE
protein I-GENE I-GENE
. O O

Classification O O
according O O
to O O
the O O
ILAR O O
criteria O O
was O O
possible O O
in O O
000 O O
patients O O
; O O
000 O O
patients O O
had O O
a O O
disease O O
duration O O
> O O
or O O
= O O
0 O O
months O O
and O O
were O O
classified O O
according O O
to O O
the O O
EULAR O O
criteria O O
. O O

Because O O
the O O
DPPD B-GENE B-GENE
gene I-GENE I-GENE
is O O
not O O
present O O
in O O
non O O
- O O
tuberculous O O
bacilli O O
, O O
these O O
results O O
suggest O O
that O O
this O O
molecule O O
can O O
be O O
an O O
additional O O
tool O O
for O O
a O O
more O O
specific O O
diagnosis O O
of O O
tuberculosis O O
. O O

As O O
well O O
, O O
mixtures O O
of O O
( O O
LA O O
) O O
( O O
00 O O
) O O
with O O
the O O
longer O O
chain O O
PEs O O
exhibit O O
unusual O O
biomodal O O
enthalpy O O
variations O O
, O O
suggesting O O
peptide O O
immiscibility O O
in O O
thicker O O
gel O O
state O O
bilayers O O
. O O

The O O
human B-GENE O
cytomegalovirus I-GENE O
( I-GENE O
HCMV I-GENE O
) I-GENE O
major I-GENE O
immediate I-GENE O
- I-GENE O
early I-GENE O
protein I-GENE O
IE0 I-GENE O
is O O
a O O
nuclear O O
phosphoprotein O O
that O O
is O O
believed O O
to O O
be O O
a O O
key O O
regulator O O
in O O
both O O
lytic O O
and O O
latent O O
infections O O
. O O

In O O
addition O O
, O O
another O O
derivative O O
of O O
pCMVJS00 O O
( O O
pCMVJS00DeltaGP O O
) O O
in O O
which O O
the O O
gag B-GENE O
, O O
pol B-GENE O
( O O
and O O
orf B-GENE B-GENE
- I-GENE I-GENE
x I-GENE I-GENE
) O O
coding O O
sequences O O
were O O
deleted O O
also O O
gave O O
transformed O O
foci O O
. O O

The O O
JHRLSS O O
has O O
been O O
used O O
in O O
prior O O
studies O O
to O O
assess O O
RLS O O
severity O O
, O O
but O O
has O O
not O O
previously O O
been O O
validated O O
in O O
relation O O
to O O
direct O O
measures O O
of O O
the O O
morbidity O O
associated O O
with O O
RLS O O
. O O

Hormonal O O
regulation O O
of O O
multiple O O
promoters O O
of O O
the O O
rat B-GENE B-GENE
mitochondrial I-GENE I-GENE
glycerol I-GENE I-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
- I-GENE I-GENE
phosphate I-GENE I-GENE
dehydrogenase I-GENE I-GENE
gene I-GENE I-GENE
: O O
identification O O
of O O
a O O
complex O O
hormone O O
- O O
response O O
element O O
in O O
the O O
ubiquitous O O
promoter O O
B O O
. O O

CONCLUSION O O
: O O
There O O
are O O
no O O
differences O O
in O O
the O O
measurement O O
data O O
derived O O
from O O
this O O
method O O
and O O
actual O O
measurement O O
data O O
from O O
an O O
object O O
created O O
by O O
the O O
computer O O
- O O
aided O O
dental O O
design O O
program O O
. O O

The O O
human B-GENE B-GENE
ABCG0 I-GENE I-GENE
gene I-GENE I-GENE
encodes O O
a O O
member O O
of O O
the O O
ATP B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
cassette I-GENE I-GENE
( O O
ABC B-GENE O
) O O
superfamily O O
of O O
transporter B-GENE B-GENE
proteins I-GENE I-GENE
and O O
is O O
highly O O
induced O O
when O O
macrophages O O
are O O
incubated O O
with O O
oxysterols O O
. O O

The O O
performance O O
of O O
pH O O
- O O
sensitive O O
particles O O
is O O
attributed O O
to O O
their O O
ability O O
to O O
release O O
the O O
drug O O
selectively O O
in O O
the O O
upper O O
part O O
of O O
the O O
intestine O O
in O O
a O O
molecular O O
or O O
amorphous O O
form O O
. O O

Sural O O
nerve O O
biopsy O O
showed O O
mild O O
thickening O O
of O O
the O O
perineurium O O
, O O
vascular O O
alterations O O
with O O
inflammatory O O
cell O O
infiltration O O
in O O
the O O
perineurium O O
, O O
and O O
remarkable O O
loss O O
of O O
large O O
and O O
small O O
myelinated O O
fibers O O
. O O

The O O
images O O
showed O O
rapid O O
, O O
predominantly O O
urinary O O
excretion O O
of O O
00mTc O O
ciprofloxacin O O
, O O
with O O
low O O
to O O
absent O O
brain O O
, O O
lung O O
and O O
bone O O
marrow O O
uptake O O
and O O
low O O
liver O O
uptake O O
and O O
excretion O O
. O O

Our O O
results O O
demonstrated O O
that O O
00 O O
% O O
of O O
the O O
hepatic O O
artery O O
- O O
alone O O
ALT O O
graft O O
showed O O
almost O O
normal O O
structure O O
histologically O O
at O O
0 O O
month O O
after O O
grafting O O
, O O
with O O
bile O O
secretion O O
preserved O O
. O O

In O O
patients O O
who O O
respond O O
to O O
quetiapine O O
, O O
therapy O O
should O O
be O O
continued O O
at O O
the O O
optimal O O
dose O O
that O O
maintains O O
remission O O
, O O
within O O
the O O
range O O
of O O
000 O O
to O O
000 O O
mg O O
/ O O
d O O
. O O

Transactivation O O
of O O
oIFNtau B-GENE O
enhancer O O
- O O
reporter O O
constructs O O
was O O
primarily O O
regulated O O
by O O
three O O
regions O O
containing O O
AP B-GENE O
- I-GENE O
0 I-GENE O
site I-GENE O
, O O
GATA B-GENE O
like I-GENE O
sequence I-GENE O
and O O
site O O
( O O
s O O
) O O
unidentified O O
. O O

These O O
data O O
reveal O O
a O O
complex O O
network O O
of O O
interactions O O
between O O
GTPases B-GENE O
in O O
the O O
ARF B-GENE O
family I-GENE O
and O O
their O O
effectors O O
and O O
reveal O O
a O O
potential O O
for O O
cross O O
- O O
talk O O
not O O
demonstrated O O
previously O O
. O O

These O O
disorders O O
include O O
low O O
- O O
back O O
pain O O
, O O
saddle O O
anesthesia O O
, O O
bilateral O O
sciatica O O
, O O
then O O
motor O O
weakness O O
of O O
the O O
lower O O
extremities O O
or O O
chronic O O
paraplegia O O
and O O
, O O
bladder O O
dysfunction O O
. O O

Many O O
factors O O
do O O
influence O O
the O O
educational O O
outcome O O
in O O
students O O
and O O
large O O
statistical O O
power O O
( O O
such O O
as O O
meta O O
analysis O O
) O O
should O O
be O O
helpful O O
to O O
eliminate O O
many O O
sources O O
of O O
error O O
. O O

Although O O
metabolized O O
by O O
the O O
cytochrome B-GENE B-GENE
P I-GENE I-GENE
- I-GENE I-GENE
000 I-GENE I-GENE
( O O
CYP B-GENE O
) O O
system O O
, O O
venlafaxine O O
inhibits O O
CYP B-GENE O
0D0 I-GENE O
and I-GENE O
0A0 I-GENE O
to O O
a O O
far O O
lesser O O
extent O O
than O O
do O O
the O O
SSRIs O O
. O O

Six O O
of O O
the O O
gstC B-GENE O
' I-GENE O
mutants I-GENE O
, O O
primarily O O
in O O
the O O
C O O
- O O
terminal O O
half O O
of O O
C B-GENE O
' I-GENE O
, O O
exhibited O O
a O O
defect O O
in O O
the O O
ability O O
to O O
bind O O
L B-GENE O
protein I-GENE O
. O O

Northern O O
blot O O
analysis O O
with O O
one O O
of O O
the O O
PARNAs B-GENE O
revealed O O
a O O
highly O O
abundant O O
signal O O
of O O
approximately O O
0 O O
. O O
0 O O
kilobases O O
( O O
kb O O
) O O
present O O
in O O
all O O
cell O O
lines O O
tested O O
. O O

Our O O
results O O
suggest O O
that O O
WASP B-GENE O
activates O O
transcription O O
following O O
TCR B-GENE O
stimulation O O
in O O
a O O
manner O O
that O O
is O O
independent O O
of O O
its O O
role O O
in O O
Arp0 B-GENE O
/ I-GENE O
0 I-GENE O
- O O
directed O O
actin B-GENE O
polymerization O O
. O O

The O O
LA O O
00s O O
derived O O
from O O
this O O
combined O O
data O O
when O O
compared O O
with O O
our O O
earlier O O
series O O
from O O
0000 O O
to O O
0000 O O
also O O
did O O
not O O
show O O
a O O
significant O O
change O O
in O O
mortality O O
. O O

These O O
results O O
were O O
compared O O
with O O
the O O
estimates O O
of O O
penetration O O
from O O
steady O O
- O O
state O O
calculations O O
, O O
square O O
root O O
of O O
time O O
calculations O O
, O O
and O O
a O O
biologically O O
based O O
mathematical O O
model O O
. O O

We O O
found O O
no O O
correlation O O
between O O
plasma O O
COP O O
and O O
body O O
weight O O
at O O
the O O
same O O
age O O
( O O
r0 O O
= O O
0 O O
. O O
00 O O
, O O
P O O
= O O
0 O O
. O O
000 O O
) O O
. O O

Therefore O O
, O O
this O O
study O O
has O O
demonstrated O O
that O O
prenatal O O
disturbance O O
can O O
induce O O
a O O
lasting O O
change O O
in O O
cytokine O O
biology O O
, O O
which O O
persists O O
well O O
beyond O O
the O O
fetal O O
and O O
infant O O
stage O O
. O O

Derivation O O
and O O
initial O O
characterization O O
of O O
a O O
mouse O O
mammary O O
tumor O O
cell O O
line O O
carrying O O
the O O
polyomavirus B-GENE O
middle I-GENE O
T I-GENE O
antigen I-GENE O
: O O
utility O O
in O O
the O O
development O O
of O O
novel O O
cancer O O
therapeutics O O
. O O

For O O
immunological O O
methods O O
, O O
identification O O
of O O
such O O
antigens O O
with O O
intermolecular O O
variability O O
, O O
e O O
. O O
g O O
. O O
, O O
the O O
structural O O
aescin O O
analogs O O
, O O
is O O
of O O
unknown O O
validity O O
. O O

The O O
000 B-GENE O
bp I-GENE O
EcoRI I-GENE O
fragment I-GENE O
, O O
which O O
was O O
detected O O
by O O
Southern O O
hybridization O O
, O O
reveals O O
an O O
open O O
reading O O
frame O O
which O O
encodes O O
a O O
protein O O
of O O
000 O O
amino O O
acids O O
. O O

A O O
mutation O O
in O O
the O O
C O O
domain O O
of O O
Rb B-GENE O
, O O
L000Q O O
, O O
has O O
been O O
identified O O
that O O
completely O O
abolishes O O
cdk0 B-GENE O
/ O O
D0 B-GENE O
phosphorylation O O
of O O
the O O
isolated O O
C O O
domain O O
. O O

The O O
mechanism O O
of O O
the O O
induction O O
of O O
0beta B-GENE B-GENE
- I-GENE I-GENE
HSD I-GENE I-GENE
type I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
expression O O
was O O
further O O
characterized O O
in O O
ZR O O
- O O
00 O O
- O O
0 O O
human O O
breast O O
cancer O O
cells O O
. O O

C B-GENE O
/ I-GENE O
EBPbeta I-GENE O
LIP I-GENE O
overexpressing O O
HC00 O O
cells O O
did O O
not O O
express O O
beta B-GENE B-GENE
- I-GENE I-GENE
casein I-GENE I-GENE
mRNA I-GENE I-GENE
( O O
mammary O O
epithelial O O
cell O O
differentiation O O
marker O O
) O O
in O O
response O O
to O O
lactogenic O O
hormones O O
. O O

The O O
hatcher O O
incubators O O
of O O
both O O
companies O O
were O O
also O O
persistently O O
contaminated O O
with O O
Salmonella O O
livingstone O O
and O O
Salmonella O O
thomasville O O
in O O
company O O
A O O
and O O
with O O
Salmonella O O
senftenberg O O
in O O
company O O
B O O
. O O

The O O
probability O O
of O O
treatment O O
with O O
lamotrigine O O
being O O
maintained O O
for O O
six O O
months O O
was O O
00 O O
% O O
, O O
for O O
twelve O O
months O O
00 O O
% O O
and O O
for O O
three O O
years O O
00 O O
% O O
. O O

Deletion O O
analyses O O
implicate O O
the O O
N O O
- O O
terminal O O
000 O O
amino O O
acids O O
of O O
Grb00 B-GENE O
and O O
ankyrin B-GENE O
repeats O O
00 O O
- O O
00 O O
of O O
tankyrase B-GENE O
0 I-GENE O
in O O
mediating O O
this O O
interaction O O
. O O

Treadmill O O
training O O
at O O
least O O
for O O
0 O O
weeks O O
can O O
reduce O O
the O O
infarction O O
size O O
and O O
edema O O
caused O O
by O O
MCA O O
occlusion O O
( O O
P O O
< O O
0 O O
. O O
00 O O
) O O
. O O

The O O
electrodes O O
themselves O O
do O O
not O O
need O O
to O O
be O O
polished O O
prior O O
to O O
their O O
use O O
but O O
are O O
observed O O
to O O
be O O
slightly O O
recessed O O
from O O
the O O
surrounding O O
insulating O O
surface O O
. O O

Blood O O
from O O
dams O O
was O O
collected O O
prior O O
to O O
inoculation O O
and O O
at O O
time O O
of O O
necropsy O O
for O O
measurement O O
of O O
IgM B-GENE O
and O O
IgG B-GENE O
antibodies I-GENE O
to O O
M O O
. O O
pulmonis O O
. O O

We O O
conclude O O
that O O
RPMS B-GENE O
acts O O
as O O
a O O
negative O O
regulator O O
of O O
EBNA0 B-GENE O
and O O
Notch B-GENE O
activity O O
through O O
its O O
interactions O O
with O O
the O O
CBF0 B-GENE B-GENE
- I-GENE O
associated I-GENE O
corepressor I-GENE O
complex I-GENE O
. O O

Furthermore O O
, O O
this O O
kinase O O
- O O
deficient O O
mutant O O
inhibited O O
0 O O
- O O
MeSADP O O
- O O
induced O O
caspase B-GENE O
- I-GENE O
0 I-GENE O
stimulation O O
and O O
the O O
associated O O
decrease O O
in O O
cell O O
number O O
. O O

These O O
data O O
define O O
a O O
conserved O O
pathway O O
wherein O O
sequential O O
histone B-GENE O
modifications O O
establish O O
a O O
" O O
histone B-GENE O
code O O
" O O
essential O O
for O O
the O O
epigenetic O O
inheritance O O
of O O
heterochromatin O O
assembly O O
. O O

Linear O O
eight O O
- O O
or O O
nine O O
- O O
residue O O
D O O
- O O
peptides O O
derived O O
from O O
the O O
pocket O O
- O O
binding O O
domain O O
of O O
the O O
cyclic O O
molecules O O
also O O
bind O O
specifically O O
. O O

Molecular O O
analysis O O
of O O
the O O
pRA0 O O
partitioning O O
region O O
: O O
ParB B-GENE O
autoregulates O O
parAB B-GENE O
transcription O O
and O O
forms O O
a O O
nucleoprotein O O
complex O O
with O O
the O O
plasmid O O
partition O O
site O O
, O O
parS B-GENE O
. O O

SERS O O
spectra O O
were O O
obtained O O
by O O
vacuum O O
evaporation O O
and O O
casting O O
of O O
p O O
- O O
NTP O O
onto O O
silver O O
island O O
films O O
, O O
and O O
also O O
from O O
colloidal O O
silver O O
solutions O O
. O O

Diffuse O O
myalgias O O
were O O
more O O
frequent O O
in O O
patients O O
with O O
than O O
without O O
an O O
MMF O O
lesion O O
at O O
deltoid O O
muscle O O
biopsy O O
( O O
P O O
< O O
0 O O
. O O
0000 O O
) O O
. O O

She O O
drank O O
alcohol O O
once O O
or O O
twice O O
a O O
week O O
and O O
regularly O O
took O O
an O O
analgesic O O
preparation O O
, O O
containing O O
aspirin O O
and O O
acetaminophen O O
, O O
for O O
alleviation O O
of O O
headaches O O
. O O

Patients O O
with O O
a O O
secondary O O
cardiac O O
event O O
had O O
more O O
common O O
Type O O
A O O
behavior O O
patterns O O
and O O
higher O O
Bortner O O
scores O O
than O O
patients O O
without O O
a O O
secondary O O
cardiac O O
event O O
. O O

The O O
utility O O
of O O
such O O
analyses O O
in O O
the O O
design O O
of O O
ceramic O O
/ O O
substrate O O
bilayer O O
systems O O
for O O
optimal O O
resistance O O
to O O
lifetime O O
- O O
threatening O O
damage O O
is O O
discussed O O
. O O

We O O
have O O
now O O
tested O O
all O O
known O O
mammalian B-GENE O
Groucho I-GENE O
family I-GENE O
members I-GENE O
for O O
their O O
ability O O
to O O
interact O O
specifically O O
with O O
individual O O
Tcf B-GENE O
/ O O
Lef B-GENE O
family O O
members O O
. O O

CONCLUSIONS O O
: O O
Using O O
icodextrin O O
- O O
based O O
instead O O
of O O
glucose O O
- O O
based O O
PD O O
fluids O O
can O O
largely O O
reduce O O
the O O
formation O O
of O O
Amadori O O
albumin B-GENE O
and O O
AGEs O O
. O O

Expression O O
of O O
human B-GENE O
RACK0 I-GENE O
efficiently O O
relieves O O
E0A B-GENE O
- O O
mediated O O
growth O O
inhibition O O
in O O
HF0c O O
and O O
protects O O
human O O
tumor O O
cells O O
from O O
E0A B-GENE O
- O O
induced O O
apoptosis O O
. O O

Effects O O
of O O
aerosol O O
- O O
vapor O O
JP O O
- O O
0 O O
jet O O
fuel O O
on O O
the O O
functional O O
observational O O
battery O O
, O O
and O O
learning O O
and O O
memory O O
in O O
the O O
rat O O
. O O

Comparison O O
of O O
remnant O B-GENE
- O O
like O O
lipoprotein O O
particles O O
in O O
postmenopausal O O
women O O
with O O
and O O
without O O
coronary O O
artery O O
disease O O
and O O
in O O
men O O
with O O
coronary O O
artery O O
disease O O
. O O

Based O O
on O O
analytic O O
precisions O O
, O O
a O O
+ O O
/ O O
- O O
0 O O
% O O
urine O O
- O O
plasma O O
difference O O
was O O
set O O
as O O
the O O
cut O O
- O O
off O O
value O O
. O O

Southern O O
blot O O
analysis O O
of O O
genomic O O
DNA O O
from O O
somatic O O
cell O O
hybrids O O
showed O O
that O O
endothelial B-GENE O
- I-GENE O
TACC I-GENE O
- I-GENE O
related I-GENE O
cDNA I-GENE O
maps O O
to O O
chromosome O O
00 O O
. O O

The O O
presence O O
of O O
truncated O B-GENE
receptor O I-GENE
isoforms O O
in O O
diverse O O
species O O
suggests O O
that O O
these O O
proteins O O
may O O
have O O
important O O
functional O O
roles O O
in O O
regulating O O
EGFR B-GENE O
activity O O
. O O

The O O
bovine B-GENE O
PGHS I-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
cDNA I-GENE O
was O O
cloned O O
by O O
a O O
combination O O
of O O
reverse O O
transcription O O
- O O
polymerase O O
chain O O
reaction O O
and O O
cDNA O O
library O O
screening O O
. O O

Fans O O
in O O
tunnels O O
and O O
open O O
windows O O
at O O
aboveground O O
locations O O
appeared O O
to O O
greatly O O
reduce O O
the O O
likelihood O O
of O O
high O O
PH0 O O
concentrations O O
in O O
enclosed O O
areas O O
. O O

Mutation O O
of O O
the O O
octamer O O
element O O
also O O
significantly O O
reduced O O
the O O
ability O O
of O O
HDAC0 B-GENE O
to O O
confer O O
repression O O
of O O
inducible O B-GENE
HLA B-GENE I-GENE
- I-GENE I-GENE
DRA I-GENE I-GENE
promoter I-GENE I-GENE
activation O O
. O O

OBJECTIVES O O
: O O
The O O
objective O O
of O O
this O O
review O O
was O O
to O O
assess O O
the O O
effects O O
of O O
prophylactic O O
prostaglandin O O
use O O
in O O
the O O
third O O
stage O O
of O O
labour O O
. O O

Finally O O
, O O
there O O
are O O
a O O
growing O O
number O O
of O O
arguments O O
favouring O O
the O O
use O O
of O O
ACE B-GENE O
inhibitors O O
very O O
early O O
in O O
patients O O
with O O
diabetes O O
mellitus O O
. O O

Recruitment O O
of O O
an O O
RNA B-GENE O
polymerase I-GENE O
II I-GENE O
complex I-GENE O
is O O
mediated O O
by O O
the O O
constitutive O O
activation O O
domain O O
in O O
CREB B-GENE O
, O O
independently O O
of O O
CREB B-GENE O
phosphorylation O O
. O O

Immunofluorescence O O
studies O O
in O O
C0C00 O O
myotubes O O
show O O
that O O
Smad0 B-GENE O
and O O
MEF0A B-GENE O
co O O
- O O
localise O O
in O O
the O O
nucleus O O
of O O
multinuclear O O
myotubes O O
during O O
differentiation O O
. O O

The O O
expression O O
of O O
alpha B-GENE B-GENE
- I-GENE I-GENE
amylase I-GENE I-GENE
can O O
be O O
transactivated O O
by O O
the O O
transcription O O
factor O O
GAMyb B-GENE O
, O O
which O O
is O O
itself O O
induced O O
by O O
GA O O
. O O

Anecdotal O O
observations O O
scattered O O
throughout O O
the O O
literature O O
have O O
often O O
provided O O
clues O O
to O O
underlying O O
variations O O
in O O
humans O O
' O O
ability O O
to O O
handle O O
dietary O O
chemicals O O
. O O

When O O
this O O
CCAAT O O
box O O
was O O
inserted O O
into O O
a O O
heterologous O O
promoter O O
construct O O
, O O
OA O O
induction O O
was O O
dependent O O
on O O
an O O
intact O O
CCAAT O O
box O O
. O O

The O O
Van O O
der O O
Hoeve O O
' O O
s O O
syndrome O O
lesions O O
as O O
poorly O O
mineralized O O
, O O
with O O
low O O
calcium O O
salt O O
and O O
apparent O O
increase O O
of O O
phosphates O O
. O O

Cytosolic B-GENE O
acetyl I-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
synthetase I-GENE I-GENE
( O O
AceCS0 B-GENE O
) O O
activates O O
acetate O O
to O O
supply O O
the O O
cells O O
with O O
acetyl O O
- O O
CoA O O
for O O
lipid O O
synthesis O O
. O O

The O O
effects O O
of O O
the O O
transfected O O
receptors O O
were O O
associated O O
with O O
antagonism O O
of O O
activator B-GENE B-GENE
protein I-GENE I-GENE
0 I-GENE I-GENE
( O O
AP B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
) O O
activity O O
. O O

PABP B-GENE O
is O O
a O O
modular O O
protein O O
, O O
with O O
four O O
N O O
- O O
terminal O O
RNA O O
- O O
binding O O
domains O O
and O O
an O O
extensive O O
C O O
terminus O O
. O O

Here O O
we O O
provide O O
the O O
first O O
evidence O O
for O O
the O O
involvement O O
of O O
GCN0 B-GENE B-GENE
- O O
GCN0 B-GENE O
interaction O O
in O O
activation O O
of O O
GCN0 B-GENE O
per O O
se O O
. O O

In O O
00 O O
of O O
those O O
patients O O
DD O O
was O O
measured O O
also O O
with O O
microlatex O O
tests O O
- O O
- O O
Tinaquant O O
and O O
BC O O
d O O
- O O
dimer O O
. O O

The O O
present O O
chemotherapy O O
of O O
AE O O
is O O
based O O
on O O
the O O
administration O O
of O O
benzimidazole O O
carbamate O O
derivatives O O
, O O
such O O
as O O
mebendazole O O
and O O
albendazole O O
. O O

NF B-GENE O
- I-GENE O
kappaB I-GENE O
is O O
involved O O
in O O
the O O
regulation O O
of O O
CD000 B-GENE B-GENE
( O O
CD00 B-GENE O
ligand I-GENE O
) O O
expression O O
in O O
primary O O
human O O
T O O
cells O O
. O O

In O O
contrast O O
, O O
neither O O
I O O
. O O
argentina O O
nor O O
I O O
. O O
theezans O O
exerted O O
any O O
effect O O
on O O
BF O O
or O O
intestinal O O
propulsion O O
. O O

The O O
MSL B-GENE O
complex I-GENE O
is O O
specifically O O
localized O O
on O O
the O O
male O O
X O O
chromosome O O
to O O
increase O O
its O O
expression O O
approximately O O
0 O O
- O O
fold O O
. O O

With O O
such O O
analysis O O
, O O
one O O
can O O
test O O
hypotheses O O
about O O
the O O
structure O O
of O O
latent O O
variability O O
within O O
a O O
given O O
data O O
set O O
. O O

Increased O O
erythropoietin B-GENE O
synthesis O O
in O O
patients O O
with O O
COLD O O
or O O
left O O
heart O O
failure O O
is O O
related O O
to O O
alterations O O
in O O
renal O O
haemodynamics O O
. O O

Using O O
immunochemical O O
co O O
- O O
precipitation O O
methods O O
, O O
we O O
also O O
found O O
that O O
the O O
two O O
proteins O O
are O O
bound O O
in O O
vivo O O
. O O

Fluorimetric O O
determination O O
of O O
methylmercury O O
as O O
an O O
ion O O
- O O
association O O
complex O O
with O O
rhodamine O O
B O O
in O O
the O O
presence O O
of O O
iodide O O
. O O

The O O
activity O O
of O O
Rac0 B-GENE O
leads O O
to O O
STAT0 B-GENE O
translocation O O
to O O
the O O
nucleus O O
coincident O O
with O O
STAT0 B-GENE B-GENE
- O I-GENE
dependent O I-GENE
gene O I-GENE
expression O O
. O O

Novel O O
intronic O O
promoter O O
in O O
the O O
rat B-GENE B-GENE
ER I-GENE I-GENE
alpha I-GENE I-GENE
gene I-GENE I-GENE
responsible O O
for O O
the O O
transient O O
transcription O O
of O O
a O O
variant O O
receptor O O
. O O

Additionally O O
, O O
a O O
CaCO0 O O
- O O
CO0 O O
/ O O
N0 O O
buffered O O
solution O O
was O O
necessary O O
to O O
maintain O O
a O O
pH O O
of O O
0 O O
. O O

Under O O
our O O
conditions O O
, O O
the O O
combination O O
O0 O O
/ O O
UV O O
did O O
not O O
improve O O
the O O
degradation O O
rate O O
obtained O O
by O O
ozonation O O
. O O

Naltrexone O O
hydrochloride O O
is O O
a O O
synthetic O O
opioid B-GENE O
receptor I-GENE O
antagonist O O
recently O O
used O O
in O O
efforts O O
to O O
provide O O
rapid O O
opioid O O
detoxification O O
. O O

The O O
Delta0CCI O O
virus O O
was O O
extremely O O
attenuated O O
in O O
replication O O
capacity O O
yet O O
retained O O
infectiousness O O
for O O
CEMx000 O O
and O O
MT0 O O
cells O O
. O O

This O O
unique O O
location O O
of O O
cavernous O O
malformation O O
is O O
associated O O
with O O
a O O
risk O O
of O O
permanent O O
loss O O
of O O
the O O
vision O O
. O O

Here O O
, O O
we O O
identify O O
Rsc0 B-GENE O
and O O
Rsc00 B-GENE O
as O O
novel O O
components O O
of O O
the O O
essential O O
yeast B-GENE O
remodeler I-GENE O
RSC I-GENE O
complex I-GENE O
. O O

In O O
addition O O
, O O
severe O O
vision O O
loss O O
can O O
be O O
seen O O
with O O
interferon B-GENE O
alfa I-GENE O
- I-GENE O
0b I-GENE O
- O O
associated O O
retinopathy O O
. O O

A O O
0 O O
- O O
month O O
- O O
old O O
infant O O
with O O
persistent O O
congenital O O
stridor O O
and O O
acute O O
respiratory O O
distress O O
is O O
presented O O
. O O

Topological O O
and O O
mutational O O
analysis O O
of O O
Saccharomyces B-GENE O
cerevisiae I-GENE O
Ste00p I-GENE O
, O O
founding O O
member O O
of O O
the O O
isoprenylcysteine B-GENE B-GENE
carboxyl I-GENE I-GENE
methyltransferase I-GENE I-GENE
family I-GENE O
. O O

At O O
both O O
companies O O
sites O O
Salmonella O O
enteritidis O O
and O O
Salmonella O O
typhimurium O O
Tr000 O O
were O O
also O O
isolated O O
occasionally O O
from O O
various O O
locations O O
. O O

Tele O O
- O O
Talk O O
has O O
the O O
extra O O
capability O O
of O O
operating O O
in O O
live O O
conference O O
situations O O
using O O
microphone O O
input O O
. O O

Only O O
nine O O
patients O O
were O O
offered O O
surgery O O
( O O
six O O
were O O
resected O O
and O O
three O O
were O O
found O O
inoperable O O
) O O
. O O

Early O O
indicators O O
of O O
the O O
effect O O
of O O
a O O
breast O O
cancer O O
screening O O
program O O
for O O
low O O
- O O
income O O
women O O
. O O

Tolerance O O
in O O
renal O O
transplantation O O
after O O
allogeneic O O
bone O O
marrow O O
transplantation O O
- O O
0 O O
- O O
year O O
follow O O
- O O
up O O
. O O

On O O
the O O
other O O
hand O O
, O O
hepatic O O
arterial O O
infusion O O
therapy O O
prolongs O O
the O O
survival O O
of O O
H0 O O
patients O O
only O O
. O O

Schistosoma O O
mansoni O O
schistosomiasis O O
] O O
Schistosomosis O O
are O O
parasitic O O
diseases O O
caused O O
by O O
blood O O
flukes O O
of O O
the O O
Schistosoma O O
genus O O
. O O

Anti B-GENE O
- I-GENE O
nucleolin I-GENE O
mAb I-GENE O
was O O
used O O
to O O
confirm O O
the O O
antigenic O O
properties O O
of O O
this O O
p00 B-GENE O
component I-GENE O
. O O

WRN B-GENE O
helicase I-GENE O
resolves O O
alternate O O
DNA O O
structures O O
including O O
tetraplex O O
and O O
triplex O O
DNA O O
, O O
and O O
Holliday O O
junctions O O
. O O

A O O
patient O O
is O O
described O O
with O O
skin O O
lesions O O
resembling O O
Kaposi O O
' O O
s O O
sarcoma O O
( O O
KS O O
) O O
. O O

The O O
first O O
case O O
of O O
HCV O O
seroconversion O O
in O O
Portugal O O
after O O
the O O
introduction O O
of O O
HCV O O
NAT O O
screening O O
. O O

Ga O O
- O O
00 O O
and O O
Tl O O
- O O
000 O O
scintigraphy O O
in O O
extramedullary O O
plasmacytoma O O
: O O
a O O
case O O
report O O
. O O

Both O O
Z B-GENE O
and O O
R B-GENE O
expression O O
resulted O O
in O O
PML O O
dispersion O O
in O O
EBV O O
- O O
positive O O
cells O O
. O O

In O O
Saccharomyces O O
cerevisiae O O
, O O
eIF0 B-GENE O
is O O
encoded O O
by O O
a O O
single O O
- O O
copy O O
essential O O
gene O O
. O O

These O O
corrections O O
do O O
not O O
involve O O
sequences O O
predicted O O
to O O
function O O
as O O
transcription O O
factor O O
binding O O
sites O O
. O O

Mss0 B-GENE O
also O O
acts O O
as O O
a O O
relatively O O
inefficient O O
guanine B-GENE O
nucleotide I-GENE O
exchange I-GENE O
factor I-GENE O
( O O
GEF B-GENE O
) O O
. O O

A O O
peculiar O O
people O O
: O O
" O O
the O O
physiological O O
aspects O O
of O O
Mormonism O O
0000 O O
- O O
0000 O O
. O O
" O O

We O O
conducted O O
a O O
clinical O O
and O O
pathologic O O
review O O
of O O
nine O O
patients O O
with O O
immature O O
ovarian O O
teratoma O O
. O O

Perfusion O O
technique O O
for O O
perfusion O O
- O O
assisted O O
direct O O
coronary O O
artery O O
bypass O O
( O O
PADCAB O O
) O O
. O O

The O O
blood O O
levels O O
of O O
lactate O O
, O O
pyruvate O O
and O O
amino O O
acids O O
were O O
not O O
elevated O O
. O O

OBJECTIVE O O
: O O
To O O
determine O O
whether O O
RSTD O O
predicts O O
coronary O O
anatomy O O
during O O
acute O O
coronary O O
occlusion O O
. O O

Consistent O O
effects O O
on O O
pVHL B-GENE O
function O O
were O O
observed O O
for O O
all O O
mutations O O
within O O
each O O
subclass O O
. O O

E0F0 B-GENE O
- O O
mediated O O
transcriptional O O
inhibition O O
of O O
the O O
plasminogen B-GENE B-GENE
activator I-GENE I-GENE
inhibitor I-GENE I-GENE
type I-GENE I-GENE
0 I-GENE I-GENE
gene I-GENE I-GENE
. O O

ICAM B-GENE O
- I-GENE O
0 I-GENE O
has O O
been O O
suggested O O
a O O
predictor O O
of O O
the O O
onset O O
of O O
GO O O
. O O

There O O
was O O
no O O
difference O O
in O O
apnea O O
duration O O
between O O
the O O
supine O O
and O O
prone O O
positions O O
. O O

As O O
expected O O
, O O
homologous B-GENE O
loxP I-GENE O
sequences I-GENE O
efficiently O O
underwent O O
Cre B-GENE O
- O O
mediated O O
recombination O O
. O O

TNFalpha B-GENE O
and O O
IL B-GENE B-GENE
- I-GENE I-GENE
0 I-GENE I-GENE
levels O O
were O O
determined O O
in O O
the O O
culture O O
supernatants O O
. O O

An O O
additional O O
0 O O
patients O O
achieved O O
normal O O
levels O O
with O O
adjunctive O O
drug O O
therapy O O
. O O

Hypomorphic O O
dSLBP B-GENE O
alleles I-GENE O
support O O
zygotic O O
development O O
but O O
cause O O
female O O
sterility O O
. O O

The O O
observed O O
triplexes O O
depend O O
on O O
the O O
length O O
of O O
the O O
repeat O O
. O O

Arterial O O
blood O O
gas O O
tensions O O
were O O
similar O O
across O O
all O O
ventilation O O
modes O O
. O O

Copyright O O
0000 O O
John O O
Wiley O O
& O O
Sons O O
, O O
Ltd O O
. O O

Adjuvant O O
and O O
neoadjuvant O O
treatment O O
of O O
breast O O
cancer O O
. O O

Treatment O O
of O O
ischemic O O
heart O O
disease O O
in O O
the O O
elderly O O

Workload O O
, O O
UAPs O O
, O O
and O O
you O O
. O O

One O O
CKD O O
patient O O
' O O
s O O
journey O O
. O O

Emphysematous O O
cholecystitis O O
: O O
sonographic O O
findings O O
. O O

Copyright O O
0000 O O
Academic O O
Press O O
. O O

Zhu O O
, O O
V O O
. O O

Copyright O O
0000 O O
S O O
. O O

Foreigners O O
return O O
. O O

Biol O O
. O O
